<SEC-DOCUMENT>0001694665-21-000111.txt : 20210729
<SEC-HEADER>0001694665-21-000111.hdr.sgml : 20210729
<ACCEPTANCE-DATETIME>20210729072850
ACCESSION NUMBER:		0001694665-21-000111
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		69
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210729
DATE AS OF CHANGE:		20210729

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evelo Biosciences, Inc.
		CENTRAL INDEX KEY:			0001694665
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				465594527
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38473
		FILM NUMBER:		211124824

	BUSINESS ADDRESS:	
		STREET 1:		620 MEMORIAL DRIVE
		STREET 2:		SUITE 200 WEST
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617 870 8281

	MAIL ADDRESS:	
		STREET 1:		620 MEMORIAL DRIVE
		STREET 2:		SUITE 200 WEST
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>evlo-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:aae86b17-43ea-4a10-aac9-9e83e0002ea1,g:814caf2c-83ae-43b0-8a9b-a2d97aa90ba1,d:e2e49401044149ec86a5cefe42299a79--><html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:evlo="http://evelobio.com/20210630" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>evlo-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80L2ZyYWc6ODhiNGQ3YzU5YzkwNDgzNDllYzUxNzUxNTdkNGU4NjkvdGFibGU6OWQ5OWNkZWQ3NDYwNDEzN2FkN2EzNTc3MThmMmQ1ZDgvdGFibGVyYW5nZTo5ZDk5Y2RlZDc0NjA0MTM3YWQ3YTM1NzcxOGYyZDVkOF8xLTEtMS0xLTA_3b0acea1-ba32-41ff-ac5d-79706451ecd9">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80L2ZyYWc6ODhiNGQ3YzU5YzkwNDgzNDllYzUxNzUxNTdkNGU4NjkvdGFibGU6OWQ5OWNkZWQ3NDYwNDEzN2FkN2EzNTc3MThmMmQ1ZDgvdGFibGVyYW5nZTo5ZDk5Y2RlZDc0NjA0MTM3YWQ3YTM1NzcxOGYyZDVkOF8yLTEtMS0xLTA_ba18a2ee-5110-4ccc-a7d3-2d202e0c2927">2021</ix:nonNumeric><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80L2ZyYWc6ODhiNGQ3YzU5YzkwNDgzNDllYzUxNzUxNTdkNGU4NjkvdGFibGU6OWQ5OWNkZWQ3NDYwNDEzN2FkN2EzNTc3MThmMmQ1ZDgvdGFibGVyYW5nZTo5ZDk5Y2RlZDc0NjA0MTM3YWQ3YTM1NzcxOGYyZDVkOF8zLTEtMS0xLTA_516025ef-21f5-48d0-a25d-efc87e10bc37">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80L2ZyYWc6ODhiNGQ3YzU5YzkwNDgzNDllYzUxNzUxNTdkNGU4NjkvdGFibGU6OWQ5OWNkZWQ3NDYwNDEzN2FkN2EzNTc3MThmMmQ1ZDgvdGFibGVyYW5nZTo5ZDk5Y2RlZDc0NjA0MTM3YWQ3YTM1NzcxOGYyZDVkOF80LTEtMS0xLTA_65598105-9395-4dfa-b98a-a5b65564e40e">0001694665</ix:nonNumeric><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80L2ZyYWc6ODhiNGQ3YzU5YzkwNDgzNDllYzUxNzUxNTdkNGU4NjkvdGFibGU6OWQ5OWNkZWQ3NDYwNDEzN2FkN2EzNTc3MThmMmQ1ZDgvdGFibGVyYW5nZTo5ZDk5Y2RlZDc0NjA0MTM3YWQ3YTM1NzcxOGYyZDVkOF81LTEtMS0xLTA_2e8cb2f9-532e-470f-ae5f-7960e7a3edd5">December 31</ix:nonNumeric><ix:nonNumeric contextRef="i92aa56851c3d4aa1842d25b81d3cf9b9_D20190701-20190731" name="evlo:CollaborativeArrangementPeriodOfInactiveManufacturingServices" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81OC9mcmFnOjFiNWI1ZTU0NjljZDRiOGJhMmY2ZWIwNTYwMmY0OTI4L3RleHRyZWdpb246MWI1YjVlNTQ2OWNkNGI4YmEyZjZlYjA1NjAyZjQ5MjhfNjgz_325d5ea5-b4c5-433d-9fed-b5f892efb0bc">P6M</ix:nonNumeric><ix:nonNumeric contextRef="i9f9dcd078cc74893ab6e630a095c99b4_D20180508-20180508" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjIwMw_7adb7c68-f638-4357-9bd2-eeb01a3b009e">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i4760145ee72249da980779ab7e2946dc_D20150101-20151231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMzYzNw_fddafaeb-2db2-49ee-b233-bca37709f790">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="evlo-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i5f6db314b99346ebbead6e9d841d0f45_I20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i21310fe58f274896a1e3326b4c181e8a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1047ebbdeebc4d77b8061fc1199a9403_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i496f247ca1974d999a4a692af25a7310_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia903db629d1f42498076678919475602_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1ad19fa9e57493cbbb0ec828961188a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0082109a8164d348f4eb2e8bce5f920_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c148be66be64d989af7e78bf5f7e8d7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i665d710a2f79419090640d7ff83c1e4f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f497cc4181641a9b457299d6d76b330_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5474d339e8b4928a498360c356f0674_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c423f72409a4144b91ea6e7fba1bc55_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42d970e789bb4ed69e098925d5c8a0c3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c8dbcdf157a4b2b85173162a11cd155_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i075b5732e8484f448eed30f1294e7346_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24f9bb3e88f14426994ec8102cb6c5a1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a9c8fdb6a934f87b09daf63f58245ad_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68735d053ae34d3daf17984648ece5c5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65392f8598ed436ebc29041d16bf2d07_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff63c5d4e86b4a5ca1fe0b493c057332_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i060d039adfbb4d8ab83d6aa4f7896176_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic10cbcf9e0f3462b97277a8c1acc0b01_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i910bfcb82bce48de9eda4ec378464e1d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0ef059b44c043199b23fba40659d54b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib269a5f35e344a0b841bce34774788d6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i968563ce77b0413db17b14b0756a3fc0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba4439be2d484dedb8b5567da52d763e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cb30a9294094ef39b668ef2a3b5440d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71fefa044970467da0b5615dbc48bb75_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i454196204dfa4d2ea9e26fd433432149_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c4bac8c6185474aa56292423c6a0d41_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86b33bf63e00425ab9a0a9ae9659ec7b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b34c1b61faf48b9bb62d38f5e3f1dbf_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47ff8e84f8d84df58cf0940f1bc78215_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i058de24e899b4c6da6e959fc62c7250f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73c5206c27a94431b96f27c4ffdc0c14_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife2588c54a3d47cab5b870f2e150b48c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i472afffea565444284f0fbc04891b4e7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35ec3f05885c4394ad39da1354b18446_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic09b152b78114532b0d0a72a5d0cb108_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96b3bb04ea99475da5fa00256059d7c5_I20190603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:RegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98b9be65b14c4e408ab7e4e90ae4e487_D20190603-20190603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:RegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-03</xbrli:startDate><xbrli:endDate>2019-06-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie55b778fc78c4838bd7596f7406fc60a_I20190603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i010bde50e313426284f4a5003a97bcf6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76cffaf0b6414a3a83a13544db4cb9c8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f65daef97744a4e9f23fb6fc142b479_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:AtTheMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8fd128806d244458684e149d6ba270a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:AtTheMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97a49e3e6ef940f7bd323a42dee5db4e_D20210202-20210202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-02</xbrli:startDate><xbrli:endDate>2021-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i919df7faea17493d83eded85125492f6_I20210202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie79b06c6d089457580ee83ab0fc4178c_D20210202-20210202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-02</xbrli:startDate><xbrli:endDate>2021-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i035578f695544ed4b1cd5c6d23c4dec9_D20210202-20210202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-02</xbrli:startDate><xbrli:endDate>2021-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2be50d786c924771a879f8ead446e51e_I20210202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>evlo:segment</xbrli:measure></xbrli:unit><xbrli:context id="ib0beb087c81f498590a475a3ae51c18c_D20210317-20210317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MeddistCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-17</xbrli:startDate><xbrli:endDate>2021-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaee624f24ba426fa56b1769371f486f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MeddistCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i39b550ef2206421ab7236b2a064fb4bd_I20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i244f5424f2ec4fca8f67abaebe241481_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if77f269a0e0f4ac4ba3ac6fabe81d5f7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia81c752f261c4005a844833c47dd60a5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f28cecd7ac744ffa9db9eccbde588cf_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffae4009f9494e7a838aac21210c8f97_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i757a3246f9b845c897fa5b6fbdb51641_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77ada78732004e3bb019864a37b2c2a1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i197c24816d1b446ca101f657ac31cb79_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9451b4b98a6a4654890a9b2dafd8be53_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3ba13fe044647afa24e9ed23ec77aec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44a958aa41b64d44abd88f59e0828525_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecbdbafb5b334e01b4cb6165e4b047c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia80c368b20a040ebac30679ad7b3f3bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i924d154f1d224e19b69e08a1f7497b5f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6edb25555144d479ada5f406941de92_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icacd72f8312b40c2bfd30c623da239e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i623a78eb6d4049dcad99dc88c1d3a291_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a72f314a6f1407f9083b56e679da505_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a81873e97c845b084025eedbb21adbc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc33321abf024a529d8629c6428a7a86_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc6cc6e7c6414c369c9ac7674119f897_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">evlo:ComputersAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40ecdaafb89540fdbb9ad851b26912d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">evlo:ComputersAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ee77ba9c28c44fe8fb28f1d573090d2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i169ecd01600544e1b2bef1b7ee506185_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83f266dfe3fb4f89a36d8d7e81051de3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id22668e852ea4c39a1f0366200d33039_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8395b938be7d40d5a8124dea1975de06_I20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>evlo:tranche</xbrli:measure></xbrli:unit><xbrli:context id="ia9d83da110a8438d9278f2c13f4fc35d_I20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="evlo:DebtInstrumentTrancheAxis">evlo:SecurityAndLoanAgreementTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06308d75bfe6481f9b1dc21e9c8b5b6e_I20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="evlo:DebtInstrumentTrancheAxis">evlo:SecurityAndLoanAgreementTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b79658da2214b768872e3db030721a9_I20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="evlo:DebtInstrumentTrancheAxis">evlo:SecurityAndLoanAgreementTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia79249ea576049a0a0ea2eee88767eca_I20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="evlo:DebtInstrumentTrancheAxis">evlo:SecurityAndLoanAgreementTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16a46e8e0f914f659f755b6f361a3246_I20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="evlo:DebtInstrumentTrancheAxis">evlo:SecurityAndLoanAgreementTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:AmendedCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0b39aa3345f4829bedab97e315cd1cc_D20190719-20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-19</xbrli:startDate><xbrli:endDate>2019-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d8499bfe37347e19717295b49f69b19_D20190719-20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-19</xbrli:startDate><xbrli:endDate>2019-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3212be8361644f79ddbc0fc27e74c3d_I20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:AmendedCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e37c8565f494644922932f469c3748e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie40915ff285a4e0ca8014dd9b85400f9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f257f1155f0451fa58717d6399f50e0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic49bab0cb25344b6bfe44ce28d21e862_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id28c87a274884b02ba4528a21cc51ba2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e3286835f544983bf8e9e5ef60645a8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd82a12aaa9b4540a734fd0196a83792_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36ffcd3447c14d9996b5b94964c58bc7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:AmendedCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a4ed55838494b35ab23f220a76b8c3b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a5c6f6b678f44e49e72b10e4ab0fa04_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70765e47bdc740f0bad65affe0499791_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4b11afcb9454eceac785c36df755e25_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifea6f295155b467cbdb20351f1ee7713_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie543e908236043ba8be6cd894642aa5a_D20170806-20170806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MayoClinicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-06</xbrli:startDate><xbrli:endDate>2017-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if17724f9bb3d4db2ba6331a7cac91d1a_D20170806-20170806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MayoClinicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-06</xbrli:startDate><xbrli:endDate>2017-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b9e276c407a458f9f69449a649920dc_D20210630-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MayoClinicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-30</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7427f0ed143e4184939402103a418a1a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MayoClinicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86362fee842547b9bde5128b9b9d7696_D20160310-20160310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:UniversityOfChicagoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-10</xbrli:startDate><xbrli:endDate>2016-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i941118753f0c4ff3a809cf847fa3cc04_D20160310-20160310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:UniversityOfChicagoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-10</xbrli:startDate><xbrli:endDate>2016-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i365ea6e18e0541caa57a11096b3a89a2_D20210630-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:UniversityOfChicagoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-30</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83fa1bd396e94b03ba1d3567b925edf7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:UniversityOfChicagoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92aa56851c3d4aa1842d25b81d3cf9b9_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:SaccoS.r.l.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i0d31ed85dd8b45629814b83f4f060752_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:SaccoS.r.l.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i164ea06cf00343df9b0f2f326af8a9e6_D20190701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:SaccoS.r.l.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb6d09c7800f4db9a1cac4fda45089ce_I20210527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndTwentyOneStockInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id28aed25ea8f4f7a93a8c6b2b8ce0a14_D20210527-20210527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndTwentyOneStockInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-27</xbrli:startDate><xbrli:endDate>2021-05-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20e8a93172c24d2e8206286eb8d49a61_D20210630-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndTwentyOneStockInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-30</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07d88ed7511c4fb488a9c834ac2afc00_D20210630-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndTwentyOneStockInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-30</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66585702ee8849e499356a9f4a40d9e0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndTwentyOneStockInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a806946e01c43c7ab029fa63c0a7c9c_I20180508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61004b706937441f80332b86f6a1bd00_D20180508-20180508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-08</xbrli:startDate><xbrli:endDate>2018-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15a5020b711f4d87bba0d1d0b69566cd_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic350846ea0d2431d965b88729486c075_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4d990381fac4ad886d7990c63587b3a_D20180508-20180508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-08</xbrli:startDate><xbrli:endDate>2018-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f9dcd078cc74893ab6e630a095c99b4_D20180508-20180508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-08</xbrli:startDate><xbrli:endDate>2018-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccf9f430cf7d4c31a2c537f0e85686ac_D20180508-20180508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-08</xbrli:startDate><xbrli:endDate>2018-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i224b3142ac434b7d8db8a216dec30657_D20180508-20180508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-08</xbrli:startDate><xbrli:endDate>2018-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib090cc4aa98c45f4b479a5057e7bfe0a_D20210630-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-30</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14af8565540e4dc6b3cb3fd98d163fef_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8244e41e2b0347a1ad64c9419ce3ec00_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4760145ee72249da980779ab7e2946dc_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i633b84c50c4f4e7b81b89cb2a278bdee_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a92391ffc2e4c5ea7bcfabcb58614d5_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b4b46cb61e94103b6de3a962ed2a13b_I20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib60b517f490f4972bfa2ed9e3b09a3c0_D20150101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9c74ef2f71c45ad87a3378e98258fc9_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e11f538a920421ba186e7c8b1a99dd5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a6ab7adc80d4824b666be8b229cb0b6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ac84e56b51542e4a5d75700b09622de_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46432b66afa646449b4065dc8c030013_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1b9cbd25a6b46d6a7303f0144b6f001_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic45337ae21d448d582c46b1700091d22_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fdc9caf00ee42449ae612c261252ddf_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4ffafae80f64bc194e822d4073442a5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ba9feb93d764efd96698e68714de654_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2e1988c04664ea584a4c41ef9af23cc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20fc0d52b2a44c50902a857e8d3130d5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bc4ea56ed944d86bdc1c166dd4863c8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i262999f64df4419982435b7d11f2b955_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i729515b40c8f4158b6586a7ae12ab66e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i264242fbfa064d8fbc4066b8f369a883_D20180508-20180508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-08</xbrli:startDate><xbrli:endDate>2018-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13be462485cb4baebb145fda3b01ca07_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57ce7e89580e42e29ea075112fdd665b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i237329bf49a34a118ff127ea889dd7d9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72fbaf5f78e84aa9be31492a6dfcfb3b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28b06266364d412583cb80ca61576389_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id41c0cbe7c784fe3aab81511b93b8580_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6fcef2a6164499a8a9a7fbb1013a8a9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia30b6f5d35ce44e69d65001940192f50_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evlo:UnvestedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i498626a92f9c490982d76300e711e00a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evlo:UnvestedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a7d195f002343acae14514f10c6c103_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82ff1a0e1f834c328bc95de6abf47cac_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9858c60d7bed47b2814be6df654dc03d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id961f8a7a6d54ba294cfdd02a79a2129_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39c0f1b46d6e4e668982c302cb6394a9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0a9f46458db4036b7b2307aa079dda5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff32a529f86d4871a555686343203169_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i410f08d8ccf041caa3ee3b193f8c60ce_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53f72d5181794c719cc51cf350c7bdf5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:WeatherdenLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6b40b59cd064a4ca4af131a12d171b8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:WeatherdenLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8c74a5ad01f474d8d0477af135c17fb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:WeatherdenLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31d0e9fb79cb425e871db75394a9796b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:WeatherdenLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aeea52635454325a295ece2390835bd_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:VL46Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie19faf0f5e0c4db3b2f52a5594e2b9af_D20210409-20210409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evlo:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-09</xbrli:startDate><xbrli:endDate>2021-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a42be16340a41089a1cd8a571d2ff8e_D20190916-20190916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evlo:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-16</xbrli:startDate><xbrli:endDate>2019-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>evlo:installment</xbrli:measure></xbrli:unit><xbrli:context id="ia236d54dd6634fc7a8f1bf3a6bc3d785_I20201015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evlo:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia16626e077c84f1a8616489f51dfdabb_D20201015-20201015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evlo:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-15</xbrli:startDate><xbrli:endDate>2020-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6986f547b61f46cb9e428885d5c4f66a_D20201011-20201011"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evlo:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-11</xbrli:startDate><xbrli:endDate>2020-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f75681a4eb440c497ad40de810da08d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf794c74c50e4917b5636aa96a990418_D20210630-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001694665</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evlo:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-30</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie2e49401044149ec86a5cefe42299a79_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:80%">_______________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:80%">FORM <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18yMTk5MDIzMjU3Njk3_7182a06e-fbaa-437e-9334-1e704341451b">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:80%">_______________</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:24.75pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6OWZjZWEzNjQyY2Q5NDA0MGIzOWUzMzlhZmNlMjk1MWUvdGFibGVyYW5nZTo5ZmNlYTM2NDJjZDk0MDQwYjM5ZTMzOWFmY2UyOTUxZV8wLTAtMS0xLTA_bf0a7f2b-bd9f-48da-a3ce-0e214f00f637">x</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18xMjE_9d582d2c-53d9-492e-b7b1-09f74546c7c9">June 30, 2021</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6MmRjMzFhYmI1NzU3NDllMGI1MDViYTgwOGE4OWJjZTMvdGFibGVyYW5nZToyZGMzMWFiYjU3NTc0OWUwYjUwNWJhODA4YTg5YmNlM18wLTAtMS0xLTA_4e0efa52-7368-4b3c-b916-ed4b8bfe4102">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18yMDI1_97ab6a8f-7701-4bac-bb66-29bfdee8f290">001-38473</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18yMDI2_8539206e-b7a3-4fda-8c6e-2872d10b0ef0">Evelo Biosciences, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6MGYxYzE1NWFhZWI2NGQ4MmE3NzY5MmQyNjJjZjBhMzEvdGFibGVyYW5nZTowZjFjMTU1YWFlYjY0ZDgyYTc3NjkyZDI2MmNmMGEzMV8wLTAtMS0xLTA_3331ab58-0bee-44a8-b1f3-197f0c6411fc">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6MGYxYzE1NWFhZWI2NGQ4MmE3NzY5MmQyNjJjZjBhMzEvdGFibGVyYW5nZTowZjFjMTU1YWFlYjY0ZDgyYTc3NjkyZDI2MmNmMGEzMV8wLTItMS0xLTA_fd3f2971-3df5-4676-98f5-b79547bee653">46-5594527</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6MGYxYzE1NWFhZWI2NGQ4MmE3NzY5MmQyNjJjZjBhMzEvdGFibGVyYW5nZTowZjFjMTU1YWFlYjY0ZDgyYTc3NjkyZDI2MmNmMGEzMV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoxMDk1YjRiODQyOTA0MmM5OWQ4YzFmNjMwODg5ODVlMV80_2483dfa9-8c90-46a9-ae27-00e928a14379">620 Memorial Drive</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6MGYxYzE1NWFhZWI2NGQ4MmE3NzY5MmQyNjJjZjBhMzEvdGFibGVyYW5nZTowZjFjMTU1YWFlYjY0ZDgyYTc3NjkyZDI2MmNmMGEzMV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoxMDk1YjRiODQyOTA0MmM5OWQ4YzFmNjMwODg5ODVlMV83_62977f2c-0a1f-4ff7-90d8-2541c90b2580">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6MGYxYzE1NWFhZWI2NGQ4MmE3NzY5MmQyNjJjZjBhMzEvdGFibGVyYW5nZTowZjFjMTU1YWFlYjY0ZDgyYTc3NjkyZDI2MmNmMGEzMV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoxMDk1YjRiODQyOTA0MmM5OWQ4YzFmNjMwODg5ODVlMV8xMQ_c927e46a-1db7-4377-8daa-58201b59e365">Massachusetts</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6MGYxYzE1NWFhZWI2NGQ4MmE3NzY5MmQyNjJjZjBhMzEvdGFibGVyYW5nZTowZjFjMTU1YWFlYjY0ZDgyYTc3NjkyZDI2MmNmMGEzMV8zLTItMS0xLTA_37fc9723-c5e0-4cc1-98e1-64c4e7eafde8">02139</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18yMDI3_f47723dc-fc75-43ed-bf42-ed807c1802f8">(617)</ix:nonNumeric> <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18yMDI4_2c82b4ea-adf8-4d0d-968e-55837f7e977b">577-0300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:32.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6YTcyMzBhYjU1NDRiNGM1M2EyYjJlNGVkMWFlZWU1MTQvdGFibGVyYW5nZTphNzIzMGFiNTU0NGI0YzUzYTJiMmU0ZWQxYWVlZTUxNF8yLTAtMS0xLTA_9d0e31a9-8b9c-40bf-a2c5-08f87badbc5a"><div style="margin-bottom:0.5pt;margin-top:2.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock,</span></div><div style="margin-bottom:0.5pt;margin-top:2.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.001 par value per share</span></div></ix:nonNumeric></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6YTcyMzBhYjU1NDRiNGM1M2EyYjJlNGVkMWFlZWU1MTQvdGFibGVyYW5nZTphNzIzMGFiNTU0NGI0YzUzYTJiMmU0ZWQxYWVlZTUxNF8yLTItMS0xLTA_c3ab9d7d-7c6f-4445-b0a3-e7c540da04bb">EVLO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6YTcyMzBhYjU1NDRiNGM1M2EyYjJlNGVkMWFlZWU1MTQvdGFibGVyYW5nZTphNzIzMGFiNTU0NGI0YzUzYTJiMmU0ZWQxYWVlZTUxNF8yLTQtMS0xLTA_f792338c-d06a-4cc1-93ce-e13734fa3665">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18yMDI5_3fcd2ffa-293b-42f6-ac8c-29ec303445b5">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18yMDMw_455b5bec-abd0-479f-be11-5c5cd0bd8218">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:23.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6ZTg5ZWE5MGIzZjdmNGE4ZjhlZTNlY2FhODRiMTI2ZWIvdGFibGVyYW5nZTplODllYTkwYjNmN2Y0YThmOGVlM2VjYWE4NGIxMjZlYl8yLTAtMS0xLTA_fcace697-e0de-4b2b-a2f9-a93b055c07d0">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6ZTg5ZWE5MGIzZjdmNGE4ZjhlZTNlY2FhODRiMTI2ZWIvdGFibGVyYW5nZTplODllYTkwYjNmN2Y0YThmOGVlM2VjYWE4NGIxMjZlYl8yLTYtMS0xLTA_c8fb7638-7fe5-4a2e-bacb-b277c3a80e66">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6ZTg5ZWE5MGIzZjdmNGE4ZjhlZTNlY2FhODRiMTI2ZWIvdGFibGVyYW5nZTplODllYTkwYjNmN2Y0YThmOGVlM2VjYWE4NGIxMjZlYl80LTYtMS0xLTA_6108f659-525f-4d5c-a28d-d8b349184d3c">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18yMDIz_a0c18e15-1693-4b58-90ad-07f837eb20e7">&#9744;</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18yMDI0_4f0d105f-84d9-4a7e-b868-fa09127fdcca">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July 26, 2021, the registrant had <ix:nonFraction unitRef="shares" contextRef="i5f6db314b99346ebbead6e9d841d0f45_I20210726" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18xNDI5MzY1MTE2NDA1Mg_d661b22d-9acb-42b1-94d2-71216222f369">53,398,292</ix:nonFraction>  shares of common stock, $0.001 par value per share, outstanding.</span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie2e49401044149ec86a5cefe42299a79_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements including those contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including without limitation statements regarding our future results of operations and financial position, the anticipated impact of the COVID-19 pandemic on our business, business strategy, prospective products, product approvals, research and development costs, timing and plans for clinical trials, expected timing of the release of clinical trial data, new formulations and product candidates, the scalability of manufacturing for EDP1815, activities related to strategic collaborations  and anticipated revenue therefrom, plans and objectives of management for future operations and future results of anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described under Part I, Item 2. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and Part II, Item 1A. &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q. These forward-looking statements are subject to numerous risks, including, without limitation, the following:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our status as a development-stage company and our expectation to incur losses in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding our expenses, future revenues, anticipated future capital requirements and our need to raise additional funds;</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to build a pipeline of product candidates and develop and commercialize drugs;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our unproven approach to therapeutic intervention;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enroll patients and volunteers in clinical trials, timely and successfully complete those trials and receive necessary regulatory approvals;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish our own manufacturing facilities and to receive or manufacture sufficient quantities of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our operations, including our preclinical studies and clinical trials, and the continuity of our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce our intellectual property rights;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal, state, and foreign regulatory requirements, including regulation of our product candidates by the U.S. Food and Drug Administration (the "FDA");</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of clinical trials and the likelihood of regulatory filings and approvals;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and retain key executives and attract and retain qualified personnel; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully manage our growth.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not occur or be achieved, and actual results could differ materially from those projected in the forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements. Except as required by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable law, we do not plan and expressly disclaim any obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUMMARY RISK FACTORS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks and uncertainties, including those described in Part II, Item 1A. &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q. You should carefully consider these risks and uncertainties when investing in our common stock. Principal risks and uncertainties affecting our business include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We are a development-stage company and have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability. Moreover, our limited operating history may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We will need additional funding in order to complete development of our product candidates and commercialize our products, if approved. If we are unable to raise capital when needed, we could be forced to delay, reduce or discontinue our product development programs or commercialization efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Our product candidates are based on targeting SINTAX&#8482;, the small intestinal axis, which is an unproven approach to therapeutic intervention</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We are dependent on the success of our product candidates. If the product candidates do not successfully complete clinical development or receive regulatory approval, our business may be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;The regulatory approval process is lengthy, expensive and uncertain, and we may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements of the United States and internationally. The denial or delay of any such approval would delay commercialization of our product candidates and adversely impact our ability to generate revenue, our business and our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We rely, and will continue to rely, on third parties to conduct our clinical trials for our product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We do not have our own manufacturing capabilities and will rely on third parties to produce additional clinical supplies, if needed, and commercial supplies of our product candidates. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;If we are unable to establish our own sales, marketing and distribution capabilities, or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if and when they are approved, and we may not be able to generate any revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue clinical trials, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;If we are unable to adequately protect our proprietary technology, or obtain and maintain issued patents which are sufficient to protect our product candidates, other companies could compete against us more directly, which would have a material adverse impact on our business, results of operations, financial condition and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;The COVID-19 pandemic has adversely impacted and may continue to adversely impact, our business, including our preclinical studies and clinical trials, results of operations and financial condition.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie2e49401044149ec86a5cefe42299a79_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evelo Biosciences, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 10-Q for the Quarterly Period Ended June 30, 2021 </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_13">PART I: FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_16">Item 1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_19">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_19">June 30</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_19">, 2021 and December&#160;31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_19">1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_22">Condensed Consolidated Statements of Operations for the three </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_22">and six </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_22">months ended </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_22">June 30</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_22">, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_22">2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_25">Condensed Consolidated Statements of Stockholders' Equity for the three </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_25">and six </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_25">months ended </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_25">June 30</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_25">, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_25">3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_28">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_28">six</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_28"> months ended </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_28">June 30</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_28">, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_28">4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_31">Notes to the Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_31">6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_76">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_76">23</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_79">Item 3. Quantitative and Qualitative Disclosure About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_79">37</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_82">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_82">37</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_85">PART II: OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_88">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_85">38</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_91">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_91">38</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_94">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_94">81</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_97">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_97">81</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_100">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_100">81</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_103">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_103">81</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_106">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_106">82</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_109">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_109">84</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie2e49401044149ec86a5cefe42299a79_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="ie2e49401044149ec86a5cefe42299a79_16"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="ie2e49401044149ec86a5cefe42299a79_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evelo Biosciences, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in&#160;thousands, except per share and share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:66.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.399%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMy0yLTEtMS0w_dda79b86-f70f-4891-bcbf-ec9b2421fbee">123,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMy00LTEtMS0w_d2a3a5f5-fddd-4b34-ad6a-2ab0ae2ce711">68,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfNC0yLTEtMS0w_0dd175d1-174d-48ca-a8d5-4ccf91330cb4">3,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfNC00LTEtMS0w_024ebe4e-410c-4c91-8f2b-b954d037564e">2,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfNi0yLTEtMS0w_d2969df0-6c9e-4a76-8d5e-749deb894907">126,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfNi00LTEtMS0w_d7ff23ca-5bcc-461d-bd21-a2a082679e55">70,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfNy0yLTEtMS0w_88842991-607a-4ecc-a725-4a7ca46526cc">7,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfNy00LTEtMS0w_765a13c2-738c-4f32-b22a-3b9b194e78c8">7,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset - operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfOC0yLTEtMS0w_e4099355-ed3b-4903-a245-fa38d6d14101">9,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfOC00LTEtMS0w_e101c4b3-1a80-4aaf-8d16-131aafe64b86">10,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfOS0yLTEtMS0w_096e0aa5-04f1-4e35-987f-e8306a4ce820">1,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfOS00LTEtMS0w_f18f5371-38a2-4533-b84e-f3d04183e7ef">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTAtMi0xLTEtMA_8b777aac-800e-4c89-8372-298d5812d11e">145,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTAtNC0xLTEtMA_ebde4d00-d544-4bff-b7aa-5c42036cdc4d">90,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTMtMi0xLTEtMA_37c74168-aa33-46f2-9ce0-3fe02546854e">2,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTMtNC0xLTEtMA_d6beb803-1ddf-473c-b0ee-535dba92eced">1,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTQtMi0xLTEtMA_80b762e1-80cf-4582-8626-524b58717a82">15,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTQtNC0xLTEtMA_70db11ee-b00d-410c-acf4-e0b6eef3bdd3">16,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTUtMi0xLTEtMA_c2b2ac62-67f3-4b87-9fe8-e0d53b4f6f37">1,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTUtNC0xLTEtMA_fc3bd21b-5756-493f-979e-d3e831108ffa">1,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTctMi0xLTEtMA_26b45fb9-dc67-43e2-85a7-942e03822da9">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTctNC0xLTEtMA_243970f9-8b6c-44c6-b865-f6ab05596188">463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTgtMi0xLTEtMA_0929ffd7-9ed1-4438-837d-7e692401ae79">19,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTgtNC0xLTEtMA_5e69bf12-57cc-4074-9f90-71c0f1274ea3">19,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjAtMi0xLTEtMA_db12ae54-68af-49d2-8880-09c9808146d7">46,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjAtNC0xLTEtMA_f14a730d-5229-4973-a47e-ae97db5c511c">30,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjEtMi0xLTEtMA_7f2dd450-cb0d-4a93-881b-cc41cc38575d">8,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjEtNC0xLTEtMA_223e7f22-5a0b-49a5-a5d4-55136f380254">9,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjItMi0xLTEtMA_4f433e18-489d-4a63-8007-ccbdd363d2d6">7,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjItNC0xLTEtMA_e7a752c1-2207-4102-81d8-2a6cc31ecf52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjMtMi0xLTEtMA_f0cef2ca-82bd-4e51-a8c8-a9b7acb40ef5">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjMtNC0xLTEtMA_54620b03-b337-4c06-93ad-3f3250144d57">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjQtMi0xLTEtMA_d50311da-8a06-4b93-88d7-0cb45614ccf1">82,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjQtNC0xLTEtMA_a0511074-d86e-4c0c-b047-75d99e9497eb">60,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjUtMi0xLTEtMA_ad29c89d-b0c0-4dae-9502-0745fb2f8238"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjUtNC0xLTEtMA_7cff6040-ba04-49df-9808-c2facb3b5928"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholder&#8217;s equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjY1ZDNjNjZhZjdiZjRmNTc4ZmM0MmU3Nzk0YWJkNzc2XzIx_0d2b42ea-27f4-431b-b795-9e77430d3fc2"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjY1ZDNjNjZhZjdiZjRmNTc4ZmM0MmU3Nzk0YWJkNzc2XzIx_5cb8b1d2-e04c-4b3d-a338-ed3d4443b182">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjY1ZDNjNjZhZjdiZjRmNTc4ZmM0MmU3Nzk0YWJkNzc2XzM1_35696a61-a6fc-46bd-8a21-da175728e297"><ix:nonFraction unitRef="shares" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjY1ZDNjNjZhZjdiZjRmNTc4ZmM0MmU3Nzk0YWJkNzc2XzM1_3e2bbe71-6245-440b-938e-9ac7ba0f6b52">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjY1ZDNjNjZhZjdiZjRmNTc4ZmM0MmU3Nzk0YWJkNzc2XzU3_043f1a67-0d0d-46f4-a52c-c6783695a310"><ix:nonFraction unitRef="shares" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjY1ZDNjNjZhZjdiZjRmNTc4ZmM0MmU3Nzk0YWJkNzc2XzU3_4ef630fe-0b04-4e3e-9552-b345ace38b65"><ix:nonFraction unitRef="shares" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjY1ZDNjNjZhZjdiZjRmNTc4ZmM0MmU3Nzk0YWJkNzc2XzU3_5f3765f1-048b-4782-adfd-b3fe0de2bfa3"><ix:nonFraction unitRef="shares" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjY1ZDNjNjZhZjdiZjRmNTc4ZmM0MmU3Nzk0YWJkNzc2XzU3_a3051940-8f28-457c-80e2-b37a50b4311f">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of June 30, 2021 and December 31, 2020, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctMi0xLTEtMA_dd66bfd9-5b33-4204-8979-9b973be7430e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctNC0xLTEtMA_4ece9b7e-9559-4ca5-9726-201af86fc97e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmVmYWMwZGQwZTAwYTQ0ZTRiMzU2MGYxMGJmY2Q1MTM4XzE4_3bd5b857-a586-4cb4-a2c7-00eb47647f8f"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmVmYWMwZGQwZTAwYTQ0ZTRiMzU2MGYxMGJmY2Q1MTM4XzE4_e7a2f3c8-9a6a-4053-b9f3-18cd63ac48b0">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmVmYWMwZGQwZTAwYTQ0ZTRiMzU2MGYxMGJmY2Q1MTM4XzMy_70412eaa-17e6-4584-b3e4-77fdb1348d73"><ix:nonFraction unitRef="shares" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmVmYWMwZGQwZTAwYTQ0ZTRiMzU2MGYxMGJmY2Q1MTM4XzMy_8aa88247-7f4c-42c2-a7e0-7c876a1f9e66">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmVmYWMwZGQwZTAwYTQ0ZTRiMzU2MGYxMGJmY2Q1MTM4XzU0_736d8ff4-0b7e-4d43-b84f-57eda06492ed">53,416,657</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmVmYWMwZGQwZTAwYTQ0ZTRiMzU2MGYxMGJmY2Q1MTM4XzYx_c0701d55-deb7-4263-8714-c82ccffbbe91">47,488,505</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmVmYWMwZGQwZTAwYTQ0ZTRiMzU2MGYxMGJmY2Q1MTM4Xzgy_ef98fec4-a987-4aff-97b1-80011223e557">53,398,271</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmVmYWMwZGQwZTAwYTQ0ZTRiMzU2MGYxMGJmY2Q1MTM4Xzg5_f2c39827-38bc-4760-aa08-9d9f30101839">47,470,119</ix:nonFraction> shares outstanding as of June 30, 2021 and December 31, 2020, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtMi0xLTEtMA_dcea001f-ff7e-4a07-9572-41aa177be348">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtNC0xLTEtMA_f1cc6077-c2e9-4495-a7f5-4de12b7f5d03">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjktMi0xLTEtMA_9bd8294a-da1f-4b1c-a572-e2a17764f789">414,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjktNC0xLTEtMA_a17e4aeb-6c7a-4f50-921b-883d54457525">322,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMzAtMi0xLTEtMA_4f41017f-1232-4699-8f95-0ab9883565bd">352,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMzAtNC0xLTEtMA_3adb8c88-bc98-4251-a1b2-c85ec55c7199">292,519</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMzEtMi0xLTEtMA_12d30343-2d1a-48ba-8600-25a5289797e7">62,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMzEtNC0xLTEtMA_3cce9be7-864e-46c2-9a88-dcaa8b656dd1">30,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMzItMi0xLTEtMA_2bba43dd-bae2-4b99-a1f0-283d3e0fcfe6">145,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMzItNC0xLTEtMA_1998d953-b229-489f-ac55-2dae895355e9">90,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ie2e49401044149ec86a5cefe42299a79_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evelo Biosciences, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:37.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMy0yLTEtMS0w_a47220fb-b320-4930-8842-c4e181a9aa94">20,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMy00LTEtMS0w_045e5ca0-fa88-4cdf-b13e-af5aa14d20b4">15,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMy02LTEtMS05Mg_27e1be46-3ee4-4fb8-8abd-74f2086c6394">42,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMy04LTEtMS05Mg_150dd201-a47a-4932-84fa-492c2d44cbc5">32,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNC0yLTEtMS0w_1fc4e3d2-def6-4b04-a58d-7f8a1b95c4f2">7,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNC00LTEtMS0w_640b2856-aa5b-4f28-8b3e-4dc35a17f2d8">5,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNC02LTEtMS05Mg_cdbdd19f-43f4-4749-8cba-69d16d68071e">12,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNC04LTEtMS05Mg_7e293495-dbb3-4dee-90d4-79b3ef6210da">10,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNS0yLTEtMS0w_d6a21f03-34c8-4ac0-85de-4573b55caa0e">27,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNS00LTEtMS0w_6d807f8a-e0e4-4cea-8781-ef4d37847b28">20,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNS02LTEtMS05Mg_2fc7172b-58d3-4f10-bb42-e70b4bec8e7f">55,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNS04LTEtMS05Mg_894b4d3a-67ea-4fee-b639-b7abc5d9bf00">43,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNi0yLTEtMS0w_07f615eb-2373-400a-933a-02ca3b223359">27,656</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNi00LTEtMS0w_1eb2319f-5058-4a0e-a683-2ad685466a1a">20,245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNi02LTEtMS05Mg_db18447f-9aee-4ed6-b612-ec6e44868867">55,127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNi04LTEtMS05Mg_f7ce4f6d-eafb-46d4-a286-670d29fed2fe">43,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOC0yLTEtMS0w_90a48300-8729-45ef-a448-cd7cb4017165">814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOC00LTEtMS0w_6d57c8e1-17f2-4328-af99-8c4ad13cd091">458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOC02LTEtMS05Mg_7ede3d98-0d3a-4940-b583-7e92d53e8616">1,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOC04LTEtMS05Mg_d2dd1c92-2d58-4e9c-8600-8a800ae14c2b">639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOS0yLTEtMS0xNDgz_4bf95a20-ae21-4534-9021-2db0080192e0">3,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOS00LTEtMS0xNDgz_c0239658-f8ab-4261-b04b-ebe220d0d1ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOS02LTEtMS0xNDgz_a7236d53-3f47-446d-a522-45d08379f880">3,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOS04LTEtMS0xNDgz_32a1d8b3-3cec-423b-8fbc-dae1378438f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOS0yLTEtMS0w_5a1585c9-8526-4c8f-87e5-78e40e0d8236">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOS00LTEtMS0w_549cb445-532b-4ee0-af12-604a3d6a02b6">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOS02LTEtMS05Mg_3316674f-d1e6-4b93-b9a2-5d24edf7a587">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOS04LTEtMS05Mg_43443a7e-c197-4903-a9b9-38cc4ddac287">606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTAtMi0xLTEtMA_abd77e25-0841-49cd-996a-02da25601742">3,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTAtNC0xLTEtMA_e6257006-aa1f-493a-9f0c-98ab5e466027">318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTAtNi0xLTEtOTI_5fd3decd-4762-4b99-97ad-90722f39c67d">4,492</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTAtOC0xLTEtOTI_b20ffd15-223e-49d7-b765-d08630b900df">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTEtMi0xLTEtMA_ffbe2ad8-18b8-48f7-8476-7ec21047ee50">31,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTEtNC0xLTEtMA_06fb3abb-46ac-4561-b85f-d7b88b974285">20,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTEtNi0xLTEtOTI_2dd0af40-3486-4c35-aa7b-e3503d897283">59,619</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTEtOC0xLTEtOTI_1a7b335b-62b4-43e1-a620-8d265c86a603">43,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTItMi0xLTEtMA_eabdeba6-5a63-42af-a772-458c82f8dbeb">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTItNC0xLTEtMA_5a15679f-150d-4202-b3dd-07d1882f3599">89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTItNi0xLTEtOTI_fa145e2f-62c4-46e7-b8f8-678d70dfca7e">175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTItOC0xLTEtOTI_bb6be2ed-01c4-40ca-a898-aae7d9f15b86">154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTMtMi0xLTEtMA_4fab678f-eacb-4537-b52f-57ae3bb55cf0">31,598</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTMtNC0xLTEtMA_cdae8442-5842-4209-8af6-b038000c1ff0">20,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTQtNi0xLTEtOTI_da3388f6-aa2c-4dff-a533-79ba920b6504">59,794</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTQtOC0xLTEtOTI_c95df018-4943-4f05-81fa-a2dd83b3e373">43,693</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTUtMi0xLTEtMA_48dfeff7-88dc-422a-b1fd-66d871509f70"><ix:nonFraction unitRef="usdPerShare" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTUtMi0xLTEtMA_f5b62f25-b08d-41d8-ba37-868ba3070f46">0.59</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTUtNC0xLTEtMA_3a6e8721-e919-49d9-8ce5-c505b6afd2fd"><ix:nonFraction unitRef="usdPerShare" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTUtNC0xLTEtMA_8db5f595-785b-42e4-837c-2d6fe44350ef">0.63</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTUtNi0xLTEtOTk_666b9601-a218-4d63-a033-d9ddff296f70"><ix:nonFraction unitRef="usdPerShare" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTUtNi0xLTEtOTk_bd70bc65-65e8-48cd-b765-d6ec4dfeb50a">1.14</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTUtOC0xLTEtOTk_3215b07b-f47a-4210-a516-5cdbdb0dd802"><ix:nonFraction unitRef="usdPerShare" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTUtOC0xLTEtOTk_d880a7a7-5153-4e68-ad1a-85daeb7def9a">1.35</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTYtMi0xLTEtMA_83e15df6-7071-4306-8fe6-93dcec901256"><ix:nonFraction unitRef="shares" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTYtMi0xLTEtMA_bd460c1b-a45b-46b4-b3c7-2ce676d1df26">53,379,415</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTYtNC0xLTEtMA_4f4e186c-e1a0-433d-9d90-b8cb761a699d"><ix:nonFraction unitRef="shares" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTYtNC0xLTEtMA_be17a49e-e0ae-4433-83b5-d87b471a06f8">32,634,468</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTYtNi0xLTEtOTk_6591539c-037d-4a25-8e8f-79bf4220371f"><ix:nonFraction unitRef="shares" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTYtNi0xLTEtOTk_740526f1-7b8f-45c7-b4d6-f24c9b859e0d">52,340,608</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTYtOC0xLTEtOTk_e1e3ac14-f738-4ed4-b5be-cf207a66f9eb"><ix:nonFraction unitRef="shares" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTYtOC0xLTEtOTk_f702251e-15f3-44ff-9577-2859b67f8f37">32,442,259</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ie2e49401044149ec86a5cefe42299a79_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evelo Biosciences, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in&#160;thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Month Periods Ended June 30, 2021</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance-December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1047ebbdeebc4d77b8061fc1199a9403_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMi0yLTEtMS0w_c21d36fb-a40e-43d5-8ad0-c82da7cc0071">47,470,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1047ebbdeebc4d77b8061fc1199a9403_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMi00LTEtMS0w_929c77d7-3baa-4e24-b70d-cd3999ff4341">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i496f247ca1974d999a4a692af25a7310_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMi02LTEtMS0w_e58e1aca-ebe6-4972-988f-80683cdac05d">322,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia903db629d1f42498076678919475602_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMi04LTEtMS0w_9e89eb5f-62e6-4f9c-8d30-126cd119dfcb">292,519</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMi0xMC0xLTEtMA_f3964e7c-e4f3-44de-8d2a-ca74fc9c3b27">30,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1ad19fa9e57493cbbb0ec828961188a_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMy0yLTEtMS0w_384f5994-5cf0-419d-bb9c-b65a04c894a4">5,814,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1ad19fa9e57493cbbb0ec828961188a_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMy00LTEtMS0w_dcb5fc8e-df08-4f82-813d-0cc451907b64">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0082109a8164d348f4eb2e8bce5f920_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMy02LTEtMS0w_4cd288cd-722b-4cad-887c-c28a67ab7121">81,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c148be66be64d989af7e78bf5f7e8d7_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMy0xMC0xLTEtMA_86c94ea9-0b95-4b9a-ba01-5842ca7f8701">81,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1ad19fa9e57493cbbb0ec828961188a_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNC0yLTEtMS0w_e8092f56-747e-47ee-9cf1-cf885625b9a4">27,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0082109a8164d348f4eb2e8bce5f920_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNC02LTEtMS0w_6b945170-aa31-4b3b-b469-579f25cb2b6a">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c148be66be64d989af7e78bf5f7e8d7_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNC0xMC0xLTEtMA_8427cac9-4c76-4ac4-905b-f758fe22f581">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1ad19fa9e57493cbbb0ec828961188a_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNS0yLTEtMS0w_338c3b9b-52b0-46ed-8709-91a7a2231048">45,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0082109a8164d348f4eb2e8bce5f920_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNS02LTEtMS0w_2abce18d-5679-430d-a493-e73f10e158b8">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c148be66be64d989af7e78bf5f7e8d7_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNS0xMC0xLTEtMA_bbea3707-4368-44be-82a4-1beee49f08cb">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0082109a8164d348f4eb2e8bce5f920_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNi02LTEtMS0w_287e83f8-2b00-4d51-baf4-9c76c53ce50a">3,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c148be66be64d989af7e78bf5f7e8d7_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNi0xMC0xLTEtMA_6d5cb69d-a03d-457e-9b70-60333cb28e9d">3,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i665d710a2f79419090640d7ff83c1e4f_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNy04LTEtMS0w_50f28a50-181b-423d-90d7-1e65b6734463">28,196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c148be66be64d989af7e78bf5f7e8d7_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNy0xMC0xLTEtMA_2622920c-19df-4afb-aab0-6943c1d4f21b">28,196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance-March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f497cc4181641a9b457299d6d76b330_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfOC0yLTEtMS0w_9d943b99-b99d-4551-97be-9036aa0c22e9">53,357,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f497cc4181641a9b457299d6d76b330_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfOC00LTEtMS0w_2f6be337-50df-459d-8a2f-c24f081bb012">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5474d339e8b4928a498360c356f0674_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfOC02LTEtMS0w_5c6ab738-c79f-4035-bd57-87abd2816838">408,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c423f72409a4144b91ea6e7fba1bc55_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfOC04LTEtMS0w_53684aad-1040-4841-bb1b-340b4978801f">320,715</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42d970e789bb4ed69e098925d5c8a0c3_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfOC0xMC0xLTEtMA_dba0543a-55e6-46ca-8fae-08cee70a7f0d">87,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c8dbcdf157a4b2b85173162a11cd155_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTEtMi0xLTEtMjIx_7e5a6eb9-92ce-4e12-b1a7-dcd82539a4bd">40,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i075b5732e8484f448eed30f1294e7346_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTEtNi0xLTEtMjI3_4c2a8f5b-d911-4f0d-8d44-b39de3d48529">330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTEtMTAtMS0xLTM4OA_6d7a404a-8955-4dc4-9cfd-ea9530e2d3d7">330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i075b5732e8484f448eed30f1294e7346_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTItNi0xLTEtMjI3_764c7e59-ac3e-4f65-a265-a79c53429665">3,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTItMTAtMS0xLTM4OA_8560ad4d-dd37-4ae0-9de3-397d4725a9c6">3,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i075b5732e8484f448eed30f1294e7346_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTMtNi0xLTEtMjQzNA_805c571e-c260-4151-916e-6a26035df38b">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTMtMTAtMS0xLTI0Mzc_4321701e-bed3-4fdb-b63b-062811175abf">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f9bb3e88f14426994ec8102cb6c5a1_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTMtOC0xLTEtMjM3_dc13c160-381b-4d41-a773-e41b030f29bb">31,598</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTMtMTAtMS0xLTM4OA_b0c78886-cf5f-4bc1-9722-013e3b10bc3f">31,598</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance-June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a9c8fdb6a934f87b09daf63f58245ad_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTQtMi0xLTEtMzc5_50ce78c1-2fb3-4758-a5db-73753f3c2689">53,398,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a9c8fdb6a934f87b09daf63f58245ad_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTQtNC0xLTEtMzgx_564ab4f3-272d-4940-8714-176d19038240">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68735d053ae34d3daf17984648ece5c5_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTQtNi0xLTEtMzgz_2549218d-5a14-4d7b-ac95-dd69680ebc45">414,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65392f8598ed436ebc29041d16bf2d07_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTQtOC0xLTEtMzkw_8c65af5c-efdf-40c7-9dd4-88cf4aa1bb33">352,313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTQtMTAtMS0xLTM4OA_829c973c-446c-4884-9acf-db6bf881e3b1">62,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evelo Biosciences, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in&#160;thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Month Periods Ended June 2020</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance-December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff63c5d4e86b4a5ca1fe0b493c057332_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMi0yLTEtMS0w_e768f66b-4aed-4e49-a2e4-15f58bec2e01">32,170,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff63c5d4e86b4a5ca1fe0b493c057332_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMi00LTEtMS0w_9a4980b2-8f4d-4e59-8956-862c8706f0c5">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i060d039adfbb4d8ab83d6aa4f7896176_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMi02LTEtMS0w_0bedf787-1573-40ea-b9e0-438b4f434e00">259,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic10cbcf9e0f3462b97277a8c1acc0b01_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMi04LTEtMS0w_953f863d-8dd7-454f-abaf-e3416553d2c0">198,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i910bfcb82bce48de9eda4ec378464e1d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMi0xMC0xLTEtMA_3afb9e74-38ce-4ac4-9605-e1cae9b02031">60,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0ef059b44c043199b23fba40659d54b_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMy0yLTEtMS0w_99e19a12-6065-41a1-899a-bba74ced741b">13,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib269a5f35e344a0b841bce34774788d6_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMy02LTEtMS0w_52dbc699-bc51-4567-b891-e84c9a486e95">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i968563ce77b0413db17b14b0756a3fc0_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMy0xMC0xLTEtMA_005e5af9-cd8d-43f9-9bdd-30e9f2dc0e15">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0ef059b44c043199b23fba40659d54b_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNC0yLTEtMS0w_7e0ffa44-8dbf-43f2-8735-341f88d8c071">137,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib269a5f35e344a0b841bce34774788d6_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNC02LTEtMS0w_474c52f8-df59-4564-90a1-3a014ba3e763">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i968563ce77b0413db17b14b0756a3fc0_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNC0xMC0xLTEtMA_a4a750fb-5e42-4656-bba6-4eea16f78b7c">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib269a5f35e344a0b841bce34774788d6_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNS02LTEtMS0w_e38daa10-73eb-4d98-ae8f-e75d317ba692">1,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i968563ce77b0413db17b14b0756a3fc0_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNS0xMC0xLTEtMA_6d49a99e-e5ef-4572-bcfb-c7b56b057b17">1,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba4439be2d484dedb8b5567da52d763e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNi04LTEtMS0w_28eaaac7-ad27-4a29-9c26-a23c52e0eeab">23,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i968563ce77b0413db17b14b0756a3fc0_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNi0xMC0xLTEtMA_b2e91bbe-09c9-4d7b-b2cb-c448b3d04f9e">23,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance-March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cb30a9294094ef39b668ef2a3b5440d_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNy0yLTEtMS0w_d4d5b04b-620b-409f-8a64-ee0c0047438c">32,321,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb30a9294094ef39b668ef2a3b5440d_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNy00LTEtMS0w_f44fd61a-4145-4139-b70c-105ae70e213f">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71fefa044970467da0b5615dbc48bb75_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNy02LTEtMS0w_a5ab14f8-287f-46e7-87af-b7cdb52aa825">261,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i454196204dfa4d2ea9e26fd433432149_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNy04LTEtMS0w_b581e529-97a2-45de-96b9-63308c0ddcf7">221,894</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c4bac8c6185474aa56292423c6a0d41_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNy0xMC0xLTEtMA_f6993f9c-87f0-46eb-9127-cea8bb687940">39,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in public offering, net of fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86b33bf63e00425ab9a0a9ae9659ec7b_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfOC0yLTEtMS0xNzg_92b86400-0300-4ebd-a9f9-b3f2349b4a01">13,800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b33bf63e00425ab9a0a9ae9659ec7b_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfOC00LTEtMS0xNzg_e371ecb9-6620-4f55-b400-ec83b9fee649">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b34c1b61faf48b9bb62d38f5e3f1dbf_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfOC02LTEtMS0xOTQ_63d1bc91-b4db-49bb-b7da-74faf3fa074a">48,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfOC0xMC0xLTEtMzk1_7015b93d-bf32-4fc8-a085-2f0b02239225">48,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b34c1b61faf48b9bb62d38f5e3f1dbf_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTAtNi0xLTEtMjU0MQ_f7325997-a79d-4374-8baf-5c22cbcb7afc">2,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTAtMTAtMS0xLTI1NDE_74788ca6-274f-43c7-9bc0-881b72e6bdc9">2,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86b33bf63e00425ab9a0a9ae9659ec7b_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfOS0yLTEtMS0xNzg_3ce39250-3128-4ae4-bca9-8e45f28b0ec0">11,491</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b34c1b61faf48b9bb62d38f5e3f1dbf_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfOS02LTEtMS0xOTQ_e4bf739d-3edf-4cd7-b847-4d230118560d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfOS0xMC0xLTEtMzk1_3bbd88fa-08f0-469b-94a1-7d462cb1f66c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86b33bf63e00425ab9a0a9ae9659ec7b_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTAtMi0xLTEtMTc4_3db79d7d-2cbe-4969-b4d8-d21563e5bf95">3,944</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b34c1b61faf48b9bb62d38f5e3f1dbf_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTAtNi0xLTEtMTk0_28e07c38-0d0e-4ef9-8817-f5c354dc4d46">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTAtMTAtMS0xLTM5NQ_909207d5-8ca0-4f57-99d3-1602e5aba179">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47ff8e84f8d84df58cf0940f1bc78215_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTEtOC0xLTEtMjAy_f9166618-0077-46c3-9ab5-c81fe6beaf28">20,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTEtMTAtMS0xLTM5NQ_1a570277-b5e7-4f52-9f42-dd3d42a5f117">20,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance-June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i058de24e899b4c6da6e959fc62c7250f_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTItMi0xLTEtNDAw_53a45b86-bc23-44d8-9885-0a74d02c7b08">46,136,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i058de24e899b4c6da6e959fc62c7250f_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTItNC0xLTEtNDAy_c73ccab3-6a69-45c2-a836-17e8ef1f8433">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c5206c27a94431b96f27c4ffdc0c14_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTItNi0xLTEtNDA0_c22626bf-a084-4a14-b417-7caa0458ad1b">311,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife2588c54a3d47cab5b870f2e150b48c_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTItOC0xLTEtMzk4_ab12bd08-cb59-41b8-95a2-2f24092484d4">242,546</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i472afffea565444284f0fbc04891b4e7_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTItMTAtMS0xLTM5NQ_5acacc82-98ef-4946-b518-42d21cdf791d">69,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div id="ie2e49401044149ec86a5cefe42299a79_28"></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evelo Biosciences, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in&#160;thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:73.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMy0yLTEtMS0w_7f47b167-4507-4ef8-8042-d030e0d741d9">59,794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMy00LTEtMS0w_d3884518-ea4a-4e32-a547-8d0c585b7f04">43,693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfNS0yLTEtMS0w_a355891c-4c7a-4485-b6df-8ddc51872d17">7,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfNS00LTEtMS0w_5fe63b41-a4bf-4962-a516-d1ea38350bd8">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfNi0yLTEtMS0w_7aef8870-41c3-4eb6-bf6b-4dabe1915409">1,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfNi00LTEtMS0w_04cd6d1e-6602-4bad-8dfa-e0ae48fa56a1">1,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" name="evlo:NonCashInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfNy0yLTEtMS0w_c970d594-49fa-44e5-8151-bcf9c29d9484">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" name="evlo:NonCashInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfNy00LTEtMS0w_5586f7af-f3f1-4823-9f12-5fd90c16a9b3">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" name="evlo:NonCashOperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfOC0yLTEtMS0w_ffd8e563-b2d2-49c5-8323-db1ec2cfe23a">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evlo:NonCashOperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfOC00LTEtMS0w_1ead29bb-e59c-464c-b25a-58a66d0cc9e3">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfOS0yLTEtMS0xNTE2_580bed6c-9d32-4b9b-a895-d78f6890b10f">3,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfOS00LTEtMS0yMDc2_70f07e7b-454c-4f4a-988a-8910af4f869a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of fixed assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfOS0yLTEtMS0w_9d875bd9-2fcd-4e93-b09f-1e2a701ac525">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfOS00LTEtMS0w_5b0fe05f-f8ed-485a-8944-f43d553df5be">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTEtMi0xLTEtMA_6d0d5649-a3e1-4c05-a32d-6ab51867340a">789</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTEtNC0xLTEtMA_97b4e145-b1c3-41bf-b54e-b26f57431860">632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTMtMi0xLTEtMA_cba525fb-563e-4c07-8d87-7b325bbed903">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTMtNC0xLTEtMA_ef9d408a-13a2-4c14-9ce6-9fe1f64bd342">2,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTQtMi0xLTEtMA_e560f35b-76a2-46f0-a16b-e8eb50c2273a">987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTQtNC0xLTEtMA_be65b610-4060-474e-a8f8-88d215f9d516">1,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTUtMi0xLTEtMA_41892e0f-e3be-4f7e-a8cb-c4c57e823c17">927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTUtNC0xLTEtMA_4fb069a7-cc34-4916-b525-1a8919389dc7">1,111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTYtMi0xLTEtMA_eebb369c-edc8-420e-b5bb-d3511b8508bc">7,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTYtNC0xLTEtMA_f7953200-8bad-4d67-8db4-621e5f6d47a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTctMi0xLTEtMA_47761e28-20fa-4f50-8165-8eab4cd6494a">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTctNC0xLTEtMA_a19e050e-1612-4c4e-8acf-9965f26c96bd">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTgtMi0xLTEtMA_7f560417-f709-4324-b800-3c8a08af163b">41,712</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTgtNC0xLTEtMA_44c9440e-ad27-4a98-918f-77455809286a">35,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjAtMi0xLTEtMA_f61a30dc-8c1b-47f0-ab5a-91f1c58a0c0d">1,151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjAtNC0xLTEtMA_fa905716-2a87-48a8-a199-e8e2ba145582">651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of fixed assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjEtMi0xLTEtMA_a8c92b41-a77f-4fd9-95ae-e1529745b874">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjEtNC0xLTEtMA_503bc5c0-00f0-43d7-a454-2a4230f855d9">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in  investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjItMi0xLTEtMA_0c6df94c-e688-4afc-acac-7408f190e65a">1,147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjItNC0xLTEtMA_eafbb861-ad9f-4694-af8a-15d3436eea5d">645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of issuance cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjQtMi0xLTEtMA_e97d2641-00c3-4913-93f0-8c400c61ee79">81,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjQtNC0xLTEtMA_521b815e-f279-4ab5-a5ac-7c3f4e2d8d40">48,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the issuance of long-term debt, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjUtMi0xLTEtMTUyMQ_ab56c97f-c42b-4d05-b051-372eeefd0f40">14,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjUtNC0xLTEtMjA3OA_858c4801-f7a6-4259-9fc1-bb400f230150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under employee stock purchase plan and exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjUtMi0xLTEtMA_638dd8bb-bdcc-48d5-87b3-f64e51e6f550">655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjUtNC0xLTEtMA_ba224c34-d1d4-4fdb-8cbb-e2fc4476710e">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjYtMi0xLTEtMA_24ea5e18-c23a-457f-b33a-46293290087d">97,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjYtNC0xLTEtMA_bd1a6890-4671-4908-9098-0ccb9e554d02">48,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjctMi0xLTEtMA_6fc721cf-39f1-48a1-8c4d-b29f7ad33619">54,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjctNC0xLTEtMA_1b8fb50d-4253-4463-b745-0a2c0641c38c">12,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash &#8211; beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjgtMi0xLTEtMA_5790e1b3-bce5-440f-aeb0-9d0ec48e88b1">70,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i910bfcb82bce48de9eda4ec378464e1d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjgtNC0xLTEtMA_3292c253-3b82-42fd-b5ab-a66734ee0f60">79,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash &#8211; end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjktMi0xLTEtMA_2a90d6cd-7ec0-42e6-bf71-48506a324464">124,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i472afffea565444284f0fbc04891b4e7_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjktNC0xLTEtMA_c0337e92-3006-47e3-a4ce-b7fef33ccfbc">91,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzEtMi0xLTEtMA_54610842-b0c1-4678-ac28-4605be187717">1,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzEtNC0xLTEtMA_55a9fce3-6e96-469b-8e05-681beffc726c">875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for Tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzItMi0xLTEtNDEy_236c79b9-6bd7-4570-a253-6e873c5c006d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzItNC0xLTEtMjU0_e25ea245-47ee-4217-9bb0-e0f4a150de61">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing and public offering costs in accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="evlo:DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzUtMi0xLTEtNDE2_16214373-703f-4c3c-8f1e-e6a5c699553e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" name="evlo:DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzUtNC0xLTEtMjYy_f5c236f0-5f60-4f5f-8d94-3bf8df8a2d79">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public offering cost in accrued expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" name="evlo:PublicOfferingCostInAccruedExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzYtMi0xLTEtMzgxMw_87747366-f243-4743-8555-05da4d88a51d">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="evlo:PublicOfferingCostInAccruedExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzYtNC0xLTEtMzgxNQ_90d732eb-c453-49ad-9412-ada3c7b764c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment additions in accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzQtMi0xLTEtMA_c9dcf9d2-3510-4dc1-b54d-d6b8b5f03800">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzQtNC0xLTEtMA_0ff61f74-d4d0-4d77-9c94-b11436990329">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ec3f05885c4394ad39da1354b18446_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzctMi0xLTEtMzMxMQ_f6c733ea-326f-4ad5-8320-b4f92f8a928b">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic09b152b78114532b0d0a72a5d0cb108_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzctNC0xLTEtMzMxMw_e2b25aa7-cfbf-4659-abd1-25cb384589e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ie2e49401044149ec86a5cefe42299a79_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVELO BIOSCIENCES, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div id="ie2e49401044149ec86a5cefe42299a79_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfNDcwOA_b76bd144-9e4f-405f-adad-6008eafb2641" continuedAt="i6414edf077304803a862194978a8e5fb" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i6414edf077304803a862194978a8e5fb"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evelo Biosciences, Inc. ("Evelo" or the "Company&#8221;) is a biotechnology company which was incorporated in Delaware on May 6, 2014. The Company is discovering and developing a new class of oral biologics that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. The Company is advancing these oral biologics with the aim of treating a broad range of immune mediated diseases with an initial focus on inflammatory diseases and oncology. The Company is headquartered in Cambridge, Massachusetts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has devoted substantially all of its efforts to research and development and raising capital. The Company has not generated any revenue related to its primary business purpose to date. The Company is subject to a number of risks similar to those of other development stage companies, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, and the need to obtain adequate additional financing to fund the development of its products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has financed operations primarily with the proceeds from the issuance of common stock combined with proceeds from previous sales of convertible preferred stock to equity investors and debt financing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2019, the Company filed a Registration Statement on Form S-3 (File No. 333-231911) (the &#8220;Shelf&#8221;) with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof in the aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="i96b3bb04ea99475da5fa00256059d7c5_I20190603" decimals="INF" format="ixt:numdotdecimal" name="evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMTYwNQ_acd4af90-d091-4bce-852f-082fd5d1d258">200.0</ix:nonFraction> million for a period of up to <ix:nonNumeric contextRef="i98b9be65b14c4e408ab7e4e90ae4e487_D20190603-20190603" format="ixt-sec:durwordsen" name="evlo:SaleOfStockConsiderationReceivedTerm" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMTYzMA_964abc37-5493-4d46-b984-e7b15e3f2f40">three years</ix:nonNumeric> from the date of its effectiveness on June 6, 2019. The Company also simultaneously entered into a sales agreement (the "ATM") with Cowen and Company, LLC, as sales agent, providing for the offering, issuance and sale by the Company of up to an aggregate $<ix:nonFraction unitRef="usd" contextRef="ie55b778fc78c4838bd7596f7406fc60a_I20190603" decimals="INF" format="ixt:numdotdecimal" name="evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMTg4OA_b79b62cc-425d-47ce-9738-b789b0fda106">50.0</ix:nonFraction>&#160;million of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf. For the three and six months ended June 30, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i010bde50e313426284f4a5003a97bcf6_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjAyMw_77c44e54-6225-4df9-8bef-30aa5d6dedd5">no</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i76cffaf0b6414a3a83a13544db4cb9c8_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMTA5OTUxMTYzMjYzNA_4966a3ff-4b18-4654-abea-1ca72a3eeb1b">139,734</ix:nonFraction> shares, respectively, under the ATM with offering prices ranging between $<ix:nonFraction unitRef="usdPerShare" contextRef="i0f65daef97744a4e9f23fb6fc142b479_I20210630" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjA5MQ_f913adb4-7415-47a4-899b-3cd3170c0da3">12.54</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ia8fd128806d244458684e149d6ba270a_I20210630" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjA5OA_ed92506e-9b85-499c-be81-01283e661a5c">13.17</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i76cffaf0b6414a3a83a13544db4cb9c8_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="evlo:SaleOfStockGrossConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMTA5OTUxMTYzMjYzOQ_3a0fb1e2-b736-49c9-a0ec-dd6d67271554"><ix:nonFraction unitRef="usd" contextRef="i010bde50e313426284f4a5003a97bcf6_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="evlo:SaleOfStockGrossConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMTA5OTUxMTYzMjYzOQ_641f667a-786b-4ce2-a6ce-ab86d93fa7a2">1.8</ix:nonFraction></ix:nonFraction> million, and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i010bde50e313426284f4a5003a97bcf6_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMTA5OTUxMTYzMjY0Ng_a3ecae17-0ce3-492f-918a-f149e6e09bc2"><ix:nonFraction unitRef="usd" contextRef="i76cffaf0b6414a3a83a13544db4cb9c8_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMTA5OTUxMTYzMjY0Ng_c068a902-49fb-4919-aa78-685ab493b6da">1.7</ix:nonFraction></ix:nonFraction> million, after deducting commission and other offering expenses payable by the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i97a49e3e6ef940f7bd323a42dee5db4e_D20210202-20210202" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjc0ODc3OTA4MTcwMA_0190997f-000d-4f53-afc2-b28d8f41308f">5,175,000</ix:nonFraction> shares of its common stock in an underwritten public offering at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i919df7faea17493d83eded85125492f6_I20210202" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjc0ODc3OTA4MTcxMQ_7b1c8c94-a33f-486a-bf54-b582bdabc12e">15.00</ix:nonFraction> per share, including the underwriters' exercise of their option to purchase <ix:nonFraction unitRef="shares" contextRef="ie79b06c6d089457580ee83ab0fc4178c_D20210202-20210202" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjc0ODc3OTA4MTcxOQ_9334c621-6dfa-4497-9240-037ec6e2cf6e">675,000</ix:nonFraction> shares to cover over-allotment, generating gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i97a49e3e6ef940f7bd323a42dee5db4e_D20210202-20210202" decimals="-5" format="ixt:numdotdecimal" name="evlo:SaleOfStockGrossConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjc0ODc3OTA4MTcyOA_2556e575-b2a5-4b70-9ae3-5a0bfdf676fe">77.6</ix:nonFraction>&#160;million and net proceeds of underwriting discounts and commission of $<ix:nonFraction unitRef="usd" contextRef="i97a49e3e6ef940f7bd323a42dee5db4e_D20210202-20210202" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjc0ODc3OTA4MTc0Mw_9ebf8f49-83f4-4739-a822-11442caa423b">72.7</ix:nonFraction>&#160;million, after deducting underwriting discounts and commission and other offering expenses paid by the Company. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2021, the Company entered into a stock purchase agreement with ALJ Health Care &amp; Life Science Company Limited ("ALJ Health Care"), pursuant to which on February 2, 2021, ALJ Health Care purchased $<ix:nonFraction unitRef="usd" contextRef="i035578f695544ed4b1cd5c6d23c4dec9_D20210202-20210202" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjc0ODc3OTA4MTc1OA_15c4b850-6165-4900-b2f4-c853c3250dc5">7.5</ix:nonFraction>&#160;million of our common stock in a private placement at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2be50d786c924771a879f8ead446e51e_I20210202" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjc0ODc3OTA4MTc3Mg_4b908f89-12ca-486b-9a60-013ea18a265b">15.00</ix:nonFraction> per share, equal to the public offering price per share at which our common stock was sold to the public as referred above. The sale of such shares was not registered under the Securities Act.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses since inception and expects such losses and negative operating cash flows to continue for the foreseeable future. The Company historically has funded its operations from the issuance of convertible notes, convertible preferred stock and common stock, and through debt financings. As of June 30, 2021, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMzU0Mg_a22d8ebd-bcdc-48f0-8488-a7199bc6ee3a">123.3</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMzU3NQ_125d8901-2e05-449c-8d89-ee8fdb280691">352.3</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects that its cash and cash equivalents as of June 30, 2021 will be sufficient to fund the operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these unaudited condensed consolidated financial statements. The future viability of the Company beyond one year from the date of issuance of these unaudited condensed consolidated financial statements is dependent on its ability to raise additional capital to finance its operations. The Company's inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ie2e49401044149ec86a5cefe42299a79_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1OTg_64b09849-d61b-4fa8-862e-f40412bf4198" continuedAt="ic67b936dfe7c4163b4e28c4dbe59ebab" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ic67b936dfe7c4163b4e28c4dbe59ebab" continuedAt="i138df7ef383e4ca290fc6949bfb6c469"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1OTk_fdbc732f-d050-402a-851f-d0ac9f5c5bca" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and ASU of the FASB. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations.&#160;Accordingly, these financial statements should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and notes thereto.&#160;The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments which are necessary to present fairly the Company&#8217;s financial position as of June 30, 2021, the results of its operations and stockholders' equity for the three and six months ended June 30, 2021 and 2020 and cash flows for the six months ended June 30, 2021 and 2020. Such adjustments are of a normal and recurring nature. The results for the three and six months ended June 30, 2021 are not necessarily indicative of the results for the year ending December 31, 2021, or for any future period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1ODc_5be25984-9cf0-40ca-bccf-960d0b884058" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, estimates related to the application of ASC 606 to our collaboration agreement, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1ODg_6a312a07-bfa5-4e30-bd9d-2edaf6ed2161" continuedAt="i97084196428d4b6f874257ff7dc7a5c0" escape="true">Principles of Consolidation</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i97084196428d4b6f874257ff7dc7a5c0">The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</ix:continuation> </span></div><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="evlo:EmergingGrowthCompanyStatusPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1ODk_a032c0b4-4a1d-4b59-98b2-cbc014702b55" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evelo is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Evelo may take advantage of these exemptions until it is no longer an emerging growth company. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. Evelo has elected to use the extended transition period for complying with new or revised accounting standards, and, as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. Evelo may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its IPO or such earlier time that it is no longer an emerging growth company. Evelo would cease to be an emerging growth company if it has more than $1.07 billion in annual revenue, it has more than $700.0 million in market value of its stock held by non-affiliates (and has been a public company for at least 12&#160;months and has filed one annual report on Form&#160;10-K), or it has issued more than $1.0 billion of non-convertible debt securities over a three-year period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1OTM_6f1a3c66-2175-42ce-bfaa-8ca1d8f0db6a" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Income or Loss</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) consists of net income (loss) and changes in equity during a period from transactions and other equity and circumstances generated from non-owner sources. The Company&#8217;s net loss equals comprehensive loss for all periods presented.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><ix:continuation id="i138df7ef383e4ca290fc6949bfb6c469" continuedAt="i3810ad2568084f9ca717c882a34a431a"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1OTA_e6898dfa-950d-42f2-b796-3b8178f8ea99" continuedAt="i2161543fa6b14a9e87b37f94265658df" escape="true">Cash, Cash Equivalents, and Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2161543fa6b14a9e87b37f94265658df">Cash equivalents are comprised of highly liquid investments that are readily convertible into cash with original maturities of three months or less. Cash and cash equivalents include cash held in banks and amounts held in money market funds. Cash equivalents are stated at cost, which approximates market value. The Company&#8217;s restricted cash consists of restricted cash in connection with building leases for the Company&#8217;s office and laboratory premises and deposits held in relation to the company's credit card facility.</ix:continuation> As of June 30, 2021 and December 31, 2020 the Company had $<ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfNDkzNQ_648c4bce-055a-4a9d-92bd-80a956b7ffc2"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfNDkzNQ_ca2270ee-0e53-434e-b798-f6fb20bf14b9">0.3</ix:nonFraction></ix:nonFraction>&#160;million in current restricted cash within prepaid expenses and other current assets and $<ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfNTAxOA_a30aa693-d350-4288-a8d6-74241856bb52"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfNTAxOA_f6abfc33-d700-4b0c-8587-ac9730445f03">1.3</ix:nonFraction></ix:nonFraction>&#160;million in noncurrent restricted cash which were included within other assets in the unaudited condensed consolidated balance sheets. <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1ODQ_4424d345-5f41-47b3-908f-b6821d27c777" continuedAt="i9f1b672952904036b5b29d09fa552a05" escape="true"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ2MDE_6c904fd4-db2d-4384-ac70-57b6b05692f4" continuedAt="i904d71c615194bfaaafdb84375808e95" escape="true">The following reconciles cash, cash equivalents and restricted cash as of June 30, 2021 and December 31, 2020, as presented on the Company's statements of cash flows, to its related balance sheet accounts (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><ix:continuation id="i9f1b672952904036b5b29d09fa552a05"><ix:continuation id="i904d71c615194bfaaafdb84375808e95"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:55.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.056%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.058%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfMi0yLTEtMS0w_22d2d34f-f521-4a4d-bcc3-6f2e15cd0377">2,964</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfMi00LTEtMS0w_d5758a25-b38b-445a-b123-b5daad68d1a8">4,487</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfMy0yLTEtMS0w_8725527a-3cc2-45dd-88c9-dd1384aae45d">120,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfMy00LTEtMS0w_9f1d945c-bb16-42ae-86f5-492958f6339d">64,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfNC0yLTEtMS0w_0ca30d89-dc3d-49a8-be2c-68ca7df16f87">123,333</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfNC00LTEtMS0w_baee30fc-2b73-449b-9027-c54254852abd">68,857</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfNS0yLTEtMS0w_08431979-d817-42eb-a5b6-c2fc43ae751d">1,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfNS00LTEtMS0w_f019a79a-2e0d-4021-b8f8-82c13a2d5f20">1,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfNi0yLTEtMS0w_c5a9d64a-1656-42b1-ab91-bdf4f37eccac">124,896</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfNi00LTEtMS0w_f42593d2-a11a-4cb5-b987-4c792c100466">70,420</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ2MDI_5e4fb1f0-4740-4193-8334-ff982aa6701f" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820,&#160;Fair Value Measurement&#160;(&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 inputs are inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly; and</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings. The Company did not elect to measure any additional financial instruments or other items at fair value.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><ix:continuation id="i3810ad2568084f9ca717c882a34a431a" continuedAt="i438c3364b1c74779bd112f5c146263a4"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1OTQ_800170da-7a89-4676-91d9-ec2979802f37" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreements </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,  Collaborative Arrangements ("ASC 808") to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and its collaboration partner are within the scope of other accounting literature, including ASC 606, Revenue from Contracts with Customers ("ASC 606"). If it is concluded that some or all aspects of the arrangement represent a transaction with a customer, the Company will account for those aspects of the arrangement within the scope of ASC 606. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 808 provides guidance for the presentation and disclosure of transactions in collaborative arrangements, but it does not provide recognition or measurement guidance. Therefore, if the Company concludes a counterparty to a transaction is not a customer or otherwise not within the scope of ASC 606, the Company considers the guidance in other accounting literature, including the guidance in ASC 606, as applicable or by analogy to account for such transaction. The classification of transactions under the Company&#8217;s arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1OTE_8048e1ba-b1ca-44d9-be6f-a8192e7411bc" continuedAt="i60af4b2b653b4bf0b5ef4a12645ca0a7" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of Accounting Standards Codification ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities.  If the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC 606.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, it performs the following steps: (i) identify the contract(s) with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) each performance obligation is satisfied. ASC 606 requires significant judgment and estimates and results in changes to, but not limited to: (i) the determination of the transaction price, including estimates of variable consideration, (ii) the allocation of the transaction price, including the determination of estimated selling price, and (iii) the pattern of recognition, including the application of proportional performance as a measure of progress on service-related promises and application of point-in-time recognition for supply-related promises. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised good or services in the Company&#8217;s arrangement may consist of license rights to the Company&#8217;s intellectual property or research and development services. The Company also may have optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price may be comprised of fixed payments, often an upfront payment due at contract inception, or other types of variable consideration in the form of payments for the Company&#8217;s services and materials and milestone payments due upon the achievement of specified events. Other payments the Company could be entitled to include tiered royalties earned when customers recognize net sales of licensed products. The Company considers the existence of any significant financing component within its arrangements to the extent there is a significant difference between the timing of payment and the transfer of control of the performance obligations.  In making that determination, the Company considers whether substantive business purposes exist to support the payment structure other than to provide a significant benefit of financing. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><ix:continuation id="i438c3364b1c74779bd112f5c146263a4" continuedAt="idcf277c06a9d47a9a0b6070c38329f11"><ix:continuation id="i60af4b2b653b4bf0b5ef4a12645ca0a7"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">promised goods and/or services to the customer. The Company utilizes either the expected value method or the most likely amount method to estimate the amount of variable consideration, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. With respect to arrangements that include payments for a development or regulatory milestone payment, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the Company&#8217;s or the licensee&#8217;s control, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company re-evaluates the probability of achievement of each milestone and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, wherein the license is deemed to be the sole or predominant item to which the payments relate, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements with more than one performance obligation, the Company generally allocates the transaction price to each performance obligation based on a relative standalone selling price basis. The Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated research and development costs. However, in certain instances, the Company may allocate variable consideration entirely to one or more performance obligation if the terms of the variable consideration relate to the satisfaction of the respective performance obligation and the amount allocated is consistent with the amount the Company would expect to receive for the satisfaction of the respective performance obligation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. For performance obligations that are satisfied at a point in time, the Company recognizes revenue when control of the goods and/or services is transferred to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer.  With respect to arrangements containing a license to its intellectual property that is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from amounts allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Liabilities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a contract liability, classified as deferred revenue on its condensed consolidated balance sheet, when it has received payment but has not yet satisfied the related performance obligations. In the event of an early termination of a contract with a customer, any contract liabilities would be recognized in the period in which all Company obligations under the agreement have been fulfilled.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><ix:continuation id="idcf277c06a9d47a9a0b6070c38329f11" continuedAt="i00d1aa69321d4544beecdfd3d15d1af9"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1OTI_f3ec125d-b1e7-4f05-b889-57a64db96f7f" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period incurred. Research and development expenses consist of both internal and external costs such as payroll, consulting, and manufacturing costs associated with the development of the Company&#8217;s product candidates. Costs for certain development activities, such as clinical trials and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the unaudited condensed consolidated balance sheets as prepaid or accrued research and development expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire licenses, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects. Any milestone payments made for Intellectual Property after regulatory approval, or that have alternative future use, are capitalized and amortized.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1ODU_dcc25942-fe9b-4050-9fce-7bdd194dff8a" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records stock-based compensation for equity awards granted to employees and directors based on the grant date fair value of awards issued. The expense is recorded over the requisite service period, which is the vesting period, on a straight-line basis. The Company uses the Black-Scholes option-pricing model to determine the fair value of options. The determination of the fair value of options on the date of grant using an option-pricing model is affected by the Company&#8217;s common stock price, as well as a number of other assumptions. The Company records forfeitures as they occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation arrangements with&#160;non-employees&#160;based upon the fair value of the consideration received or the equity instruments issued, whichever is more reliably measurable. The measurement date for&#160;non-employee&#160;awards is generally the date performance of services required from the&#160;non-employee&#160;is complete. Stock-based compensation costs for&#160;non-employee&#160;awards are recognized as services are provided, which is generally the vesting period, on a straight-line basis.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1OTY_d353fa66-e274-479b-bcc2-389a17fda036" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="segment" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjE0MDc_71e707c7-cea3-49c2-8531-9729075b4601">one</ix:nonFraction> operating segment. The Company's chief operating decision maker, its Chief Executive Officer, manages the Company's operations on a consolidated basis for the purposes of allocating resources.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1ODY_88561f44-e078-4be1-a7fc-5ce3b4e653ae" continuedAt="i03bbf7eabeb04939b5af5e7e944d1a48" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019 -12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new standard was effective for the Company on January 1, 2021 and it includes several provisions which simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The Company adopted ASU No. 2019-12 on January 1, 2021 and has concluded the adoption did not have a material impact on its unaudited condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements Issued and Not Adopted as of June 30, 2021</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Instruments - Credit Losses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326)&#8212;Measurement of Credit Losses on Financial Instruments, which has been subsequently amended by ASU No. 2018-19, ASU No. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><ix:continuation id="i00d1aa69321d4544beecdfd3d15d1af9"><ix:continuation id="i03bbf7eabeb04939b5af5e7e944d1a48"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019-04, ASU No. 2019-05, ASU No. 2019-10, ASU No. 2019-11 and ASU No. 2020-03 (&#8220;ASU 2016-13&#8221;). The provisions of ASU 2016-13 modify the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology and require a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 is effective for the Company on January 1, 2023, with early adoption permitted. The Company is currently evaluating the potential impact that this standard may have on its financial position and results of operations, as well as the timing of its adoption of this standard.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Debt with Conversion and Other Options</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2020, the FASB issued ASU No. 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU-2020-06&#8221;), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models in ASC 470-20 that require separate accounting for embedded conversion features from convertible instruments. As a result, after adopting the ASU&#8217;s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Additionally, the guidance simplifies the evaluation of whether a contract in the issuer&#8217;s own equity can be classified in equity or an embedded feature qualifies for the derivative scope exception. Although the guidance is not effective until 2022, early adoption of ASU 2020-06 is permitted for all entities for fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of this new guidance on the Company&#8217;s condensed consolidated financial statements and related disclosures.</span></div></ix:continuation></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="ie2e49401044149ec86a5cefe42299a79_40"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80MC9mcmFnOmUyYjFlNzM2MWMyMDRmNzBiMzNjN2E2YTdlZDAxMTUyL3RleHRyZWdpb246ZTJiMWU3MzYxYzIwNGY3MGIzM2M3YTZhN2VkMDExNTJfMjg0Mw_4eef2ae2-3b37-4ec2-88be-fd8508c210c8" continuedAt="if63f8ecc91da4cc6bca411cb1c1b2c78" escape="true">ALJ Commercialization and License Agreement</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="if63f8ecc91da4cc6bca411cb1c1b2c78" continuedAt="ia7ec65ea2bc945778e7a9ab298554359"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, the Company entered into a commercialization and license agreement (the &#8220;ALJ Agreement&#8221;) with ALJ. Pursuant to the ALJ Agreement, the Company granted to ALJ an exclusive, non-transferable, sublicensable license to the Company&#8217;s product candidate, EDP1815 (together with any replacement or second products of the Company described below, the &#8220;Products&#8221;) solely (i) to conduct development activities relating to the Products allocated to ALJ in a development plan agreed with the Company, (ii) to conduct manufacturing activities relating to the Products in all therapeutic uses in humans (the &#8220;Field&#8221;) throughout the world, subject to certain conditions and requirements, and (iii) to commercialize the Products in the Field in all countries of Africa and the Middle East-Turkey, excluding certain restricted countries (the &#8220;Territory&#8221;). If the Company ceases development of EDP1815 prior to receipt of regulatory approval required for commercialization of EDP1815 in any one of the United States, the United Kingdom, France, Germany, Spain, Italy, China or Japan, then ALJ will have the right to designate another product candidate of the Company as a replacement to EDP1815 or terminate the ALJ Agreement, subject to certain conditions and requirements. Further, for the first <ix:nonNumeric contextRef="ib0beb087c81f498590a475a3ae51c18c_D20210317-20210317" format="ixt-sec:durwordsen" name="evlo:CollaborativeArrangementSecondProductCandidateNegotiationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80MC9mcmFnOmUyYjFlNzM2MWMyMDRmNzBiMzNjN2E2YTdlZDAxMTUyL3RleHRyZWdpb246ZTJiMWU3MzYxYzIwNGY3MGIzM2M3YTZhN2VkMDExNTJfMTM1MA_1ed04078-5bab-4f5a-b73a-b7950201ec5c">two years</ix:nonNumeric> of the term, ALJ has the option to negotiate with the Company to add a second product candidate of the Company subject to certain conditions and requirements, for an additional license fee not to exceed $<ix:nonFraction unitRef="usd" contextRef="ib0beb087c81f498590a475a3ae51c18c_D20210317-20210317" decimals="-5" format="ixt:numdotdecimal" name="evlo:CollaborativeArrangementSecondProductCandidateFeeMaximum" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80MC9mcmFnOmUyYjFlNzM2MWMyMDRmNzBiMzNjN2E2YTdlZDAxMTUyL3RleHRyZWdpb246ZTJiMWU3MzYxYzIwNGY3MGIzM2M3YTZhN2VkMDExNTJfMTU1Ng_c230d33b-d5ac-4163-a02a-138e38d4525c">7.5</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the rights the Company granted under the ALJ Agreement, ALJ obligated to pay to the Company a one-time, non-refundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="idaee624f24ba426fa56b1769371f486f_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80MC9mcmFnOmUyYjFlNzM2MWMyMDRmNzBiMzNjN2E2YTdlZDAxMTUyL3RleHRyZWdpb246ZTJiMWU3MzYxYzIwNGY3MGIzM2M3YTZhN2VkMDExNTJfMTcyMA_68f2f048-f3c9-4a7b-92e4-cd795542c2e8">7.5</ix:nonFraction>&#160;million. The parties will also share the future operating profits and losses for all Products in the Territory equally (<ix:nonFraction unitRef="number" contextRef="ib0beb087c81f498590a475a3ae51c18c_D20210317-20210317" decimals="INF" name="evlo:CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80MC9mcmFnOmUyYjFlNzM2MWMyMDRmNzBiMzNjN2E2YTdlZDAxMTUyL3RleHRyZWdpb246ZTJiMWU3MzYxYzIwNGY3MGIzM2M3YTZhN2VkMDExNTJfMTgzNQ_f5362841-bcef-4605-b7ec-44988ae72926">50</ix:nonFraction>:50) as well as certain development, regulatory and commercialization costs. The Company concluded that the delivery of the license to ALJ, should be accounted for under ASC 606. The development, regulatory and commercialization activities within the Territory will be accounted for under ASC 808.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not recognized any revenue under the ALJ Agreement to date as they have not completed any performance obligation within the agreement. As of June 30, 2021, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="idaee624f24ba426fa56b1769371f486f_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80MC9mcmFnOmUyYjFlNzM2MWMyMDRmNzBiMzNjN2E2YTdlZDAxMTUyL3RleHRyZWdpb246ZTJiMWU3MzYxYzIwNGY3MGIzM2M3YTZhN2VkMDExNTJfMjMyNA_68f2f048-f3c9-4a7b-92e4-cd795542c2e8">7.5</ix:nonFraction>&#160;million of deferred revenue, which is classified as a non-current liability in the accompanying unaudited condensed consolidated balance sheets as the performance obligation is not expected to be completed within the next twelve months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates that payments under the costs share or profit and loss sharing arrangements, will be classified in the statement of operations consistent with the guidance in ASC 808. To date, the Company has not received or made any costs sharing or profit and loss payments. </span></div></ix:continuation><div id="ie2e49401044149ec86a5cefe42299a79_43"></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfMTI4OA_596188f7-2e49-48a6-b806-4faa5eb8a86f" continuedAt="i5eb8dbf744674828a7bde47c880e8255" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i5eb8dbf744674828a7bde47c880e8255"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company entered into an&#160;operating sublease arrangement to lease approximately <ix:nonFraction unitRef="sqft" contextRef="i39b550ef2206421ab7236b2a064fb4bd_I20180131" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfLand" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfMTE0_30027265-b7dc-4182-ac8a-f5533f637bc9">40,765</ix:nonFraction> square feet for its office and research development space at 620 Memorial Drive, Cambridge, MA 02139 from February 2018 to September 2025. The Company maintained an additional separate operating lease for office and laboratory space that expired in May 2020. The leases require security deposits, which the Company has primarily met with letters of credit from a financial institution that is secured with cash on deposit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into a sublease arrangement with a third party to lease space subject to an operating lease that expired in April 2020. The minimum rental payments received under this agreement totaled $<ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfNzYw_167c2f4a-3a59-4525-88b7-a7a2f647ee3c">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfMTA5OTUxMTYyOTIwNA_b7159c0d-0a11-4193-8444-dbd0c3264dd6">0.2</ix:nonFraction>&#160;million, respectively, for the three months and six months ended June 30, 2020 and were equivalent to the minimum payments due from the Company to the landlord.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months and six months ended June 30, 2021,  the Company recorded rent expense of $<ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfOTQ3_230c2adc-906f-49be-8eff-d09b3c1aa215">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfMTY0OTI2NzQ0MzQxOA_ccbbd3c5-b410-4d06-9c14-26fe4fd281f1">1.5</ix:nonFraction> million, respectively. For the three months and six months ended June 30, 2020,  the Company recorded rent expense of $<ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfMTQyOTM2NTExNjMxMTc_52e22525-c326-4b54-9736-3aff19bf134f">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfMTQyOTM2NTExNjMxMzE_e9d199b7-db1b-4c05-823c-bdd5a665e187">1.4</ix:nonFraction>&#160;million, respectively.There was <ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SubleaseIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfOTYx_c7e0cd18-09f2-4982-b6e8-e3ff5941f613"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SubleaseIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfOTYx_e547bceb-821d-47e1-935c-27223d7116d5">no</ix:nonFraction></ix:nonFraction> sublease rental income for the three months and six months ended June 30, 2021. For the three months and six months ended June 30, 2020, the Company recorded rent expense net of sublease rental income of $<ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfMTY0OTI2NzQ0MzQ1OA_7c8d408b-2bb6-4448-9ed1-f834ed3e00df">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfMTY0OTI2NzQ0MzQ2OA_6bbe3d64-fefe-45e6-8e6f-48b52cce1730">0.3</ix:nonFraction>&#160;million, respectively. Sublease rental income is inclusive of rental payments, taxes and operating expenses.</span></div><div style="margin-top:12pt;text-align:justify"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfMTI4OQ_f90ed4dd-b2e9-4fd7-8701-f37e02e0d4cd" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum aggregate future lease commitments at June 30, 2021, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.814%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2021 (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">excluding amounts paid or in Accounts Payable as of 6/30/2021)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfMS0yLTEtMS0w_5f1ab918-b5dd-4143-8412-1893ce469c70">1,252</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfMi0yLTEtMS0w_62e336f0-a4f5-44c2-baf4-daf8a40759fd">3,062</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfMy0yLTEtMS0w_6de00370-8706-4c84-9f08-b13f6601f45b">3,154</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfNC0yLTEtMS0w_d986fd8f-5eef-48c2-b1ce-b659d4730331">3,249</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfNS0yLTEtMS0w_c264f210-d80f-48ad-b303-1953f25dbc61">2,491</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfNi0yLTEtMS0w_4b1dd91f-ad4b-46c7-9b38-f165d5b859f4">13,208</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfNy0yLTEtMS0w_9b6fd16b-0c15-48a8-b241-9bc0f0d880ed">2,472</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfOC0yLTEtMS0w_7fc230eb-3a25-4789-821a-10f57206eae6">10,736</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used for operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfMTEtMi0xLTEtMA_3bcb4d3e-9f77-4e31-bdcf-8451797dca5e">1,230</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfMTItMi0xLTEtMA_5c9e1175-f2c9-4244-8803-018a6d8d6259">4.25</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfMTMtMi0xLTEtMA_2fbdfd2c-3f07-47d0-9903-703a2cded49a">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:8pt"><span><br/></span></div><div id="ie2e49401044149ec86a5cefe42299a79_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RleHRyZWdpb246ZTc2OWZhOTU2YTY4NDc5NThlZTI0MTZhZWQ3YTgxMzVfNTI5_7da50e74-6cd5-4924-a0d2-60657b1dac41" continuedAt="i882dbf5206114d638fcf99bb507e9cab" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i882dbf5206114d638fcf99bb507e9cab" continuedAt="i22c0148ad4c84c20b2b02980fde9ebec"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RleHRyZWdpb246ZTc2OWZhOTU2YTY4NDc5NThlZTI0MTZhZWQ3YTgxMzVfNTMw_c57a3e85-f214-4ef5-811c-59441ba4a0bb" continuedAt="i57e61043d8084a0392f365386d90aa05" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities that have been measured at fair value as of June 30, 2021 and December 31, 2020 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds included within cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i244f5424f2ec4fca8f67abaebe241481_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmIwNTFiMzU2MWI2ZjRkMjM4Y2EwOTM1MjY1MjMyNzI5L3RhYmxlcmFuZ2U6YjA1MWIzNTYxYjZmNGQyMzhjYTA5MzUyNjUyMzI3MjlfMi0yLTEtMS0w_f7fbb752-1c2f-45b2-8314-e4cbbad95a0b">120,369</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if77f269a0e0f4ac4ba3ac6fabe81d5f7_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmIwNTFiMzU2MWI2ZjRkMjM4Y2EwOTM1MjY1MjMyNzI5L3RhYmxlcmFuZ2U6YjA1MWIzNTYxYjZmNGQyMzhjYTA5MzUyNjUyMzI3MjlfMi00LTEtMS0w_c1eada2d-a69e-4a12-946f-2fa658c9113a">120,369</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia81c752f261c4005a844833c47dd60a5_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmIwNTFiMzU2MWI2ZjRkMjM4Y2EwOTM1MjY1MjMyNzI5L3RhYmxlcmFuZ2U6YjA1MWIzNTYxYjZmNGQyMzhjYTA5MzUyNjUyMzI3MjlfMi02LTEtMS0w_cb78b726-d1a9-4098-8e75-d06179761660">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f28cecd7ac744ffa9db9eccbde588cf_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmIwNTFiMzU2MWI2ZjRkMjM4Y2EwOTM1MjY1MjMyNzI5L3RhYmxlcmFuZ2U6YjA1MWIzNTYxYjZmNGQyMzhjYTA5MzUyNjUyMzI3MjlfMi04LTEtMS0w_b9060c16-efbf-4677-b371-b8985ad4569b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmIwNTFiMzU2MWI2ZjRkMjM4Y2EwOTM1MjY1MjMyNzI5L3RhYmxlcmFuZ2U6YjA1MWIzNTYxYjZmNGQyMzhjYTA5MzUyNjUyMzI3MjlfMy0yLTEtMS0w_7548c804-d49b-4ce4-8832-0fd8f14d02da">120,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffae4009f9494e7a838aac21210c8f97_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmIwNTFiMzU2MWI2ZjRkMjM4Y2EwOTM1MjY1MjMyNzI5L3RhYmxlcmFuZ2U6YjA1MWIzNTYxYjZmNGQyMzhjYTA5MzUyNjUyMzI3MjlfMy00LTEtMS0w_d8bfbab6-b6ad-4176-a7c4-1569563c4854">120,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i757a3246f9b845c897fa5b6fbdb51641_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmIwNTFiMzU2MWI2ZjRkMjM4Y2EwOTM1MjY1MjMyNzI5L3RhYmxlcmFuZ2U6YjA1MWIzNTYxYjZmNGQyMzhjYTA5MzUyNjUyMzI3MjlfMy02LTEtMS0w_4a6e7e47-7f64-48c9-8896-e3b431b542ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ada78732004e3bb019864a37b2c2a1_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmIwNTFiMzU2MWI2ZjRkMjM4Y2EwOTM1MjY1MjMyNzI5L3RhYmxlcmFuZ2U6YjA1MWIzNTYxYjZmNGQyMzhjYTA5MzUyNjUyMzI3MjlfMy04LTEtMS0w_0328a56a-fa6d-4c37-9a5f-cc41692f7712">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><ix:continuation id="i22c0148ad4c84c20b2b02980fde9ebec"><div style="margin-top:12pt;text-align:justify"><ix:continuation id="i57e61043d8084a0392f365386d90aa05"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds included within cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197c24816d1b446ca101f657ac31cb79_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmU4ODBjZTRjNmM5MzRkYmZiNDY3MmFkZTU1MDg3YmI0L3RhYmxlcmFuZ2U6ZTg4MGNlNGM2YzkzNGRiZmI0NjcyYWRlNTUwODdiYjRfMi0yLTEtMS0w_dd46601a-d153-4eff-917c-c9094077021d">64,370</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9451b4b98a6a4654890a9b2dafd8be53_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmU4ODBjZTRjNmM5MzRkYmZiNDY3MmFkZTU1MDg3YmI0L3RhYmxlcmFuZ2U6ZTg4MGNlNGM2YzkzNGRiZmI0NjcyYWRlNTUwODdiYjRfMi00LTEtMS0w_a1edd7ca-1b35-4966-9493-943a2fa6a682">64,370</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ba13fe044647afa24e9ed23ec77aec_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmU4ODBjZTRjNmM5MzRkYmZiNDY3MmFkZTU1MDg3YmI0L3RhYmxlcmFuZ2U6ZTg4MGNlNGM2YzkzNGRiZmI0NjcyYWRlNTUwODdiYjRfMi02LTEtMS0w_ab01bf04-6ee8-4ec4-b85f-02052f2c2e3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44a958aa41b64d44abd88f59e0828525_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmU4ODBjZTRjNmM5MzRkYmZiNDY3MmFkZTU1MDg3YmI0L3RhYmxlcmFuZ2U6ZTg4MGNlNGM2YzkzNGRiZmI0NjcyYWRlNTUwODdiYjRfMi04LTEtMS0w_ecef389f-30ce-470e-a98f-5356dd7ec03e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmU4ODBjZTRjNmM5MzRkYmZiNDY3MmFkZTU1MDg3YmI0L3RhYmxlcmFuZ2U6ZTg4MGNlNGM2YzkzNGRiZmI0NjcyYWRlNTUwODdiYjRfMy0yLTEtMS0w_75f4d7c2-8cd4-4c9e-b858-571c95e167ee">64,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecbdbafb5b334e01b4cb6165e4b047c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmU4ODBjZTRjNmM5MzRkYmZiNDY3MmFkZTU1MDg3YmI0L3RhYmxlcmFuZ2U6ZTg4MGNlNGM2YzkzNGRiZmI0NjcyYWRlNTUwODdiYjRfMy00LTEtMS0w_e906d7cb-7846-4f11-8abc-ae4ed7333abb">64,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80c368b20a040ebac30679ad7b3f3bb_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmU4ODBjZTRjNmM5MzRkYmZiNDY3MmFkZTU1MDg3YmI0L3RhYmxlcmFuZ2U6ZTg4MGNlNGM2YzkzNGRiZmI0NjcyYWRlNTUwODdiYjRfMy02LTEtMS0w_5b086e0e-af7a-4a4f-963e-6f6f5d3dd657">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924d154f1d224e19b69e08a1f7497b5f_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmU4ODBjZTRjNmM5MzRkYmZiNDY3MmFkZTU1MDg3YmI0L3RhYmxlcmFuZ2U6ZTg4MGNlNGM2YzkzNGRiZmI0NjcyYWRlNTUwODdiYjRfMy04LTEtMS0w_65a3c0be-9a73-453c-b621-92d1f427b5cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;June 30, 2021&#160;and&#160;December 31, 2020, the Company's cash equivalents have been initially valued at the transaction price and subsequently valued utilizing a third party pricing service. The Company validates the prices provided by its third-party pricing service by understanding the models used and obtaining market values from other pricing sources.</span></div></ix:continuation><div id="ie2e49401044149ec86a5cefe42299a79_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RleHRyZWdpb246YTRmMzcyYTRlOWU1NGUwOGJkNzhlZjkwMzQzNjE5NzJfMTg1_2e39be78-6579-4cb7-a12d-8439c887209a" continuedAt="if523040155154a4fbef6b80e40da2486" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="if523040155154a4fbef6b80e40da2486"><div style="margin-top:12pt"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RleHRyZWdpb246YTRmMzcyYTRlOWU1NGUwOGJkNzhlZjkwMzQzNjE5NzJfMTg2_99d38f53-8cd0-4487-bbf2-ca5cf8733027" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"></td><td style="width:57.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6edb25555144d479ada5f406941de92_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfMi0yLTEtMS0w_8c644692-8c03-4157-97c8-bcac8902f9f9">9,744</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacd72f8312b40c2bfd30c623da239e6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfMi00LTEtMS0w_6b285628-ebd6-42e8-9408-4622605aad50">8,831</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i623a78eb6d4049dcad99dc88c1d3a291_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfMy0yLTEtMS0w_99e90411-70d8-4c96-b1cc-3c323a65a179">2,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a72f314a6f1407f9083b56e679da505_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfMy00LTEtMS0w_7125b6a4-eb0b-4270-b53e-cbd97ec9c6fa">2,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a81873e97c845b084025eedbb21adbc_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfNC0yLTEtMS0w_32b7a294-0f17-4cdb-9164-751abf1a2274">822</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc33321abf024a529d8629c6428a7a86_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfNC00LTEtMS0w_ffc0bd36-007c-47c2-b683-d55b6a33a60c">822</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc6cc6e7c6414c369c9ac7674119f897_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfNS0yLTEtMS0w_64fb45e9-416a-4485-8b6f-5078ce4b1ec2">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40ecdaafb89540fdbb9ad851b26912d4_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfNS00LTEtMS0w_23672155-345a-46e0-a602-ffebf594f377">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ee77ba9c28c44fe8fb28f1d573090d2_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfNi0yLTEtMS0w_305073bf-86eb-43a3-ad46-8f477f54b5a3">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169ecd01600544e1b2bef1b7ee506185_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfNi00LTEtMS0w_190aee2c-9e53-40c4-909f-53a989ec7868">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83f266dfe3fb4f89a36d8d7e81051de3_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfNy0yLTEtMS0w_7987b957-9b56-4e24-9e0b-0250c587b9e8">1,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22668e852ea4c39a1f0366200d33039_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfNy00LTEtMS0w_012e6598-4418-48d0-b200-bdfbd3339e3d">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfOC0yLTEtMS0w_492c652e-dfad-49a4-9b52-96b90dbccd90">14,239</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfOC00LTEtMS0w_e0707443-40ff-43de-8b33-616dcfed5fc4">13,121</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfOS0yLTEtMS0w_3b212433-bab9-4f58-9e1f-fdb8e3364b4c">6,719</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfOS00LTEtMS0w_998c8eab-3ade-4129-afe0-80efb0be0da0">5,643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfMTAtMi0xLTEtMA_387a300b-4c49-45be-baee-b5a5d6ee6926">7,520</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfMTAtNC0xLTEtMA_7b1ec2ad-f963-49fa-b22f-dde64c5a9bc9">7,478</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RleHRyZWdpb246YTRmMzcyYTRlOWU1NGUwOGJkNzhlZjkwMzQzNjE5NzJfMTI1_8b0b212f-dff2-4bc7-bb7c-2b7028f1c356">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RleHRyZWdpb246YTRmMzcyYTRlOWU1NGUwOGJkNzhlZjkwMzQzNjE5NzJfMTA5OTUxMTYyNzk5Nw_27ac4422-bf5e-4be7-9457-1d9cd58ca81b">1.1</ix:nonFraction>&#160;million of depreciation expense for the three and six months ended June 30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RleHRyZWdpb246YTRmMzcyYTRlOWU1NGUwOGJkNzhlZjkwMzQzNjE5NzJfMTA5OTUxMTYyODA5OQ_3740b55a-267f-48a3-ac2e-e0bd2d95fe9d">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RleHRyZWdpb246YTRmMzcyYTRlOWU1NGUwOGJkNzhlZjkwMzQzNjE5NzJfMTA5OTUxMTYyODEwNw_e6a87555-1fc2-4ef3-9108-8da22068ca54">1.0</ix:nonFraction> million of depreciation expense for the three and six months ended June 30, 2020, respectively.</span></div></ix:continuation><div id="ie2e49401044149ec86a5cefe42299a79_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMzAzNg_3c831350-19f1-4b07-a0b9-2bed5ba6f967" continuedAt="i276e13d53f904d5fbfff58316f54599a" escape="true">Loan and Security Agreements</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i276e13d53f904d5fbfff58316f54599a" continuedAt="i7c7f96319d4e4d549121d977f9d4c4c4"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2019, the Company entered into a loan and security agreement&#160;(as amended, the "2019 Credit Facility") with K2 HealthVentures LLC and others (collectively, "K2HV") pursuant to which the K2HV agreed to make term loans in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i8395b938be7d40d5a8124dea1975de06_I20190719" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMzA3_2e26cd5f-c6bd-4617-a9ae-2caf8a200f05">45.0</ix:nonFraction> million available to the Company in <ix:nonFraction unitRef="tranche" contextRef="i8395b938be7d40d5a8124dea1975de06_I20190719" decimals="INF" format="ixt-sec:numwordsen" name="evlo:SecurityAndLoanAgreementNumberOfTranches" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMzM4_57e632b2-f70c-40b6-848b-554c48ab7e6e">three</ix:nonFraction> tranches. The initial tranche of $<ix:nonFraction unitRef="usd" contextRef="ia9d83da110a8438d9278f2c13f4fc35d_I20190719" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMzc0_8d7f85d6-4dfc-4ea5-bc94-5222064a537b">20.0</ix:nonFraction> million was funded upon closing on July 19, 2019. As amended on May 15, 2020, the second tranche of $<ix:nonFraction unitRef="usd" contextRef="i06308d75bfe6481f9b1dc21e9c8b5b6e_I20190719" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfNDY5_08b9532e-f6b3-4948-a3ee-7416f49cdefd">10.0</ix:nonFraction> million was available to be funded between December 1, 2019 and July 15, 2020 and was drawn down on July 14, 2020. The availability of the third tranche of $<ix:nonFraction unitRef="usd" contextRef="i2b79658da2214b768872e3db030721a9_I20190719" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfNjAw_beed73ed-ab25-4f70-af2e-16ef1259cee5">15.0</ix:nonFraction> million expired on January 15, 2021. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021 (the "Amended Credit Facility Effective Date"), the parties further amended the 2019 Credit Facility (as so amended, the &#8220;Amended Credit Facility&#8221;) to, among other things, replace and supersede the existing $<ix:nonFraction unitRef="usd" contextRef="ia79249ea576049a0a0ea2eee88767eca_I20210616" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMTI2NDQzODM3NTA2NDU_13c45106-0cc9-4835-bbeb-925f759eefaa">15.0</ix:nonFraction>&#160;million third tranche commitment with a new $<ix:nonFraction unitRef="usd" contextRef="i16a46e8e0f914f659f755b6f361a3246_I20210616" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMTI2NDQzODM3NTA2NjI_c10adb78-39e4-4dcb-9839-585db6ade8b0">15.0</ix:nonFraction>&#160;million fourth tranche commitment, which the Company drew down on June 16, 2021. In connection with the Amended Credit Facility, the Company issued to K2 HealthVentures Equity Trust LLC, an affiliate of K2HV a warrant to purchase up to <ix:nonFraction unitRef="shares" contextRef="ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTg1NA_a0c7060f-527f-4ca8-bd42-85c8cbfa9798">139,770</ix:nonFraction> shares of the Company&#8217;s common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTg2Mw_15159086-4ced-4cae-b00c-048898beacb1">13.30</ix:nonFraction> per share, subject to customary per share adjustments that are within the Company's control (&#8220;the Warrant&#8221;).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Amended Credit Facility, K2HV has the option, exercisable at any time, to convert up to $<ix:nonFraction unitRef="usd" contextRef="ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTg3MQ_cc5af828-dd0c-41ee-916d-13700f85dcee">5.0</ix:nonFraction>&#160;million of principal outstanding into shares of the Company&#8217;s common stock at a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTg4NQ_634e49e8-5ae2-4b57-bea0-07414225c843">13.30</ix:nonFraction> per share, subject to customary per share adjustments within the Company's control (the "Conversion Option&#8221;). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Interest on the outstanding loan balance will accrue at a variable annual rate equal to the greater of (i) <ix:nonFraction unitRef="number" contextRef="i8395b938be7d40d5a8124dea1975de06_I20190719" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMTAzMA_bb49397e-da78-424b-b55c-88352b36697a">8.65</ix:nonFraction>% and (ii) the prime rate plus <ix:nonFraction unitRef="number" contextRef="ie0b39aa3345f4829bedab97e315cd1cc_D20190719-20190719" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMTA2Mg_b9da9474-9dac-4241-be89-fa7c2732ea50">3.15</ix:nonFraction>%. The Company is required to make interest-only payments on the loans on a monthly basis through February 28, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, which was extended from February 28, 2022 pursuant to the Amended Credit Facility</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subsequent to the interest only periods, the Company is required to make equal monthly payments of principal plus interest until the loans mature on August 1, 2024. The Company has an option to prepay the loans in </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><ix:continuation id="i7c7f96319d4e4d549121d977f9d4c4c4" continuedAt="i1e229d28e59a44448e56327d67715850"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">whole, subject to a prepayment fee of <ix:nonFraction unitRef="number" contextRef="i6d8499bfe37347e19717295b49f69b19_D20190719-20190719" decimals="INF" name="evlo:DebtInstrumentPrepaymentFeePercentageOnPrincipal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTg5Mw_26d96526-6f22-4b15-84aa-3e57edf9a8d4">2</ix:nonFraction>% of the amount prepaid or, if the prepayment occurs after the <ix:nonNumeric contextRef="i6d8499bfe37347e19717295b49f69b19_D20190719-20190719" format="ixt-sec:durwordsen" name="evlo:DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTkwNA_b5b22784-aeed-4161-939d-bb4ce3b05d08">18-month</ix:nonNumeric> anniversary of the Amended Credit Facility Effective Date but prior to the maturity date, <ix:nonFraction unitRef="number" contextRef="i6d8499bfe37347e19717295b49f69b19_D20190719-20190719" decimals="INF" name="evlo:DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTkwNg_24fc317d-84fd-4c89-bbfe-39d27c8cbda7">1</ix:nonFraction>% of the amount prepaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the Amended Credit Facility, the Company has the option at any point prior to January 1, 2022 to elect to adjust the repayment schedule (the &#8220;Modified Repayment Schedule&#8221;) such that commencing on March 1, 2023, the Company can make consecutive equal monthly payments of principal and accrued and unpaid interest based on a notional thirty month repayment period. Under the Modified Repayment Schedule, the loan maturity date remains August 1, 2024.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any outstanding principal and unpaid interest is due at maturity. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon final payment or prepayment of the loans, the Company must pay a final payment equal to <ix:nonFraction unitRef="number" contextRef="i8395b938be7d40d5a8124dea1975de06_I20190719" decimals="INF" name="evlo:DebtInstrumentRepaymentOrPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTkxMA_4de46e40-4a45-4c22-91cc-8ce972503d5e">4.3</ix:nonFraction>% (or <ix:nonFraction unitRef="number" contextRef="id3212be8361644f79ddbc0fc27e74c3d_I20190719" decimals="INF" name="evlo:DebtInstrumentRepaymentOrPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTkxNg_aa79b994-6ed4-4015-9aef-a1904cd2eb6c">4.8</ix:nonFraction>% if the Company elects the Modified Repayment Schedule) of the aggregate original principal amount of the loans borrowed. The Company incurred fees associated with establishing the 2019 Credit Facility and fees related to the Amended Credit Facility of $<ix:nonFraction unitRef="usd" contextRef="i8395b938be7d40d5a8124dea1975de06_I20190719" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTkyMg_c4ed50eb-e927-4357-a795-78ff3b3add66">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id3212be8361644f79ddbc0fc27e74c3d_I20190719" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTkzNg_be1b6b01-094c-4ada-bca5-4ebdafbf2da3">0.3</ix:nonFraction>&#160;million, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Amended Credit Facility are collateralized by substantially all of the Company's personal property, excluding intellectual property, and the Company pledged its equity interests in its subsidiaries, subject to certain limitations with respect to its foreign subsidiaries. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Facility contains customary representations, warranties and covenants and also includes customary events of default, including payment defaults, breaches of covenants, change of control and occurrence of a material adverse effect. The Company has determined that the risk of subjective acceleration under the material adverse events clause was remote and therefore has classified the long-term portion of the outstanding principal in non-current liabilities. Upon the occurrence and continuation of an event of default, a default interest rate of an additional <ix:nonFraction unitRef="number" contextRef="i6d8499bfe37347e19717295b49f69b19_D20190719-20190719" decimals="INF" name="evlo:DebtInstrumentDebtDefaultPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjQ2Nw_38afcda0-e3e1-4741-a575-8644015f3aa6">5</ix:nonFraction>% per annum may be applied to the outstanding loan balances, and the administrative agent, collateral agent, and lenders may declare all outstanding obligations immediately due and payable and exercise all of their rights and remedies as set forth in the Amended Credit Facility and under applicable law. As of June 30, 2021, the Company was in compliance with all covenants under the Amended Credit Facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has concluded the Amended Credit Facility is a debt extinguishment for accounting purposes because the terms of the modified debt are considered substantially different than the terms of the debt prior to the amendment. As such, the Amended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit Facility was recorded at its estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="i7e37c8565f494644922932f469c3748e_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LinesOfCreditFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMTI2NDQzODM3NTA2OTE_ab0f77ca-48f1-4b79-91a8-b87e1519e7d9">46.6</ix:nonFraction>&#160;million which was determined using a combination of a discounted cash flow model and a binomial lattice model. <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMTI2NDQzODM3NTA3MDk_2730308c-b44a-4435-861e-a416fbcf61f8" continuedAt="i8562b31f68e24906b282dc7313823b66" escape="true">The Company utilized the following significant unobservable inputs (Level 3 inputs) to determine the estimated fair value of its debt as of the amendment date:</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i8562b31f68e24906b282dc7313823b66" continuedAt="if96ebc5e3d584f27ba29558230a67e7c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:52.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie40915ff285a4e0ca8014dd9b85400f9_I20210630" decimals="4" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmY4N2ZiNmFiMDQ2OTRhNzk5MzU1YWNhNGY1MDgzY2UzL3RhYmxlcmFuZ2U6Zjg3ZmI2YWIwNDY5NGE3OTkzNTVhY2E0ZjUwODNjZTNfMC0xLTEtMS0zMzU3_db608944-2b28-4814-871f-ca50fba14558">70.00</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6f257f1155f0451fa58717d6399f50e0_I20210630" decimals="4" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmY4N2ZiNmFiMDQ2OTRhNzk5MzU1YWNhNGY1MDgzY2UzL3RhYmxlcmFuZ2U6Zjg3ZmI2YWIwNDY5NGE3OTkzNTVhY2E0ZjUwODNjZTNfMS0xLTEtMS0zMzYw_472025f7-cdea-4985-a2b2-65b4ddf0aada">11.50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant increases (decreases) in either of these inputs could result in a significantly lower or higher fair value measurement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Warrant was deemed to be a freestanding financial instrument as it is legally detachable and separately exercisable from the debt obligations. The Company evaluated the terms and conditions of the warrant and concluded it met the criteria to be classified within equity. As such, the Company recorded the warrant as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional paid in capital at its issuance date fair value of $<ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-5" format="ixt:numdotdecimal" name="evlo:ClassOfWarrantOrRightFairValueMeasurement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMTI2NDQzODM3NTA2Nzc_c4f88aa1-960a-44bf-8640-cbcf00e859a0">1.8</ix:nonFraction>&#160;million. <ix:continuation id="if96ebc5e3d584f27ba29558230a67e7c" continuedAt="i8455e61bf847459493fb1f4a67ea6bc7">The</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8455e61bf847459493fb1f4a67ea6bc7" continuedAt="i011aa9c4ccdf493e9ce03f951d636baa"> Company utilized the Black-Scholes valuation method to determine the fair value of the warrant which utilized the following assumptions:</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i011aa9c4ccdf493e9ce03f951d636baa"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:64.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of underlying common stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic49bab0cb25344b6bfe44ce28d21e862_I20210630" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmNhYzQyYmZlMGUzYTQxMmI5MDMyNTE0MGU3MGJkOGIzL3RhYmxlcmFuZ2U6Y2FjNDJiZmUwZTNhNDEyYjkwMzI1MTQwZTcwYmQ4YjNfMC0xLTEtMS0zMzk1_29a85f31-d29e-4ec0-946d-e042a3111273">16.13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmNhYzQyYmZlMGUzYTQxMmI5MDMyNTE0MGU3MGJkOGIzL3RhYmxlcmFuZ2U6Y2FjNDJiZmUwZTNhNDEyYjkwMzI1MTQwZTcwYmQ4YjNfMS0xLTEtMS0zMzc3_ab3cd778-f766-4970-af88-7c4dd91fe641">13.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id28c87a274884b02ba4528a21cc51ba2_I20210630" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmNhYzQyYmZlMGUzYTQxMmI5MDMyNTE0MGU3MGJkOGIzL3RhYmxlcmFuZ2U6Y2FjNDJiZmUwZTNhNDEyYjkwMzI1MTQwZTcwYmQ4YjNfMi0xLTEtMS0zMzgw_9efeb3de-012c-4fd5-9197-c11cb6cf17f4">1.56</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie40915ff285a4e0ca8014dd9b85400f9_I20210630" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmNhYzQyYmZlMGUzYTQxMmI5MDMyNTE0MGU3MGJkOGIzL3RhYmxlcmFuZ2U6Y2FjNDJiZmUwZTNhNDEyYjkwMzI1MTQwZTcwYmQ4YjNfMy0xLTEtMS0zMzgy_2e5ecf50-4c6e-4467-b3f8-699f58be6d4d">70.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e3286835f544983bf8e9e5ef60645a8_I20210630" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmNhYzQyYmZlMGUzYTQxMmI5MDMyNTE0MGU3MGJkOGIzL3RhYmxlcmFuZ2U6Y2FjNDJiZmUwZTNhNDEyYjkwMzI1MTQwZTcwYmQ4YjNfNC0xLTEtMS0zMzg0_f66b6f57-1d21-45fb-a8d7-0006743ed4e0">10.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd82a12aaa9b4540a734fd0196a83792_I20210630" decimals="4" format="ixt:zerodash" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmNhYzQyYmZlMGUzYTQxMmI5MDMyNTE0MGU3MGJkOGIzL3RhYmxlcmFuZ2U6Y2FjNDJiZmUwZTNhNDEyYjkwMzI1MTQwZTcwYmQ4YjNfNS0xLTEtMS0zMzg3_00828b86-84bd-4d46-aae2-257394198925">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recorded a loss on the extinguishment of the existing debt of $<ix:nonFraction unitRef="usd" contextRef="i36ffcd3447c14d9996b5b94964c58bc7_D20210101-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTk1MA_cc3d3330-eeb9-40e2-81c9-4543ea8684d4">3.2</ix:nonFraction>&#160;million which equaled the difference between the reacquisition cost of the new debt, inclusive of the fair value of the Warrant and lender fees,  and the carrying amount of the existing debt.  The difference between (i) the carrying amount of the debt and (ii) the par value of the debt and the amount of the final payment due at maturity will be amortized as interest expense using the effective interest rate method.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i1e229d28e59a44448e56327d67715850"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMzAzNw_424b6f3c-92db-49a3-b818-5c2c37c657f0" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has the following minimum aggregate future loan payments at June 30, 2021 (in thousands). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:83.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve month period ending June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4ed55838494b35ab23f220a76b8c3b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmRmN2VjZGQzYThiNzQ2NTBhYjI4MDgwYjA0ZmU3OTNlL3RhYmxlcmFuZ2U6ZGY3ZWNkZDNhOGI3NDY1MGFiMjgwODBiMDRmZTc5M2VfMS0yLTEtMS0w_b521bc51-0a1b-472d-a869-8053d05dd8c4">3,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4ed55838494b35ab23f220a76b8c3b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmRmN2VjZGQzYThiNzQ2NTBhYjI4MDgwYjA0ZmU3OTNlL3RhYmxlcmFuZ2U6ZGY3ZWNkZDNhOGI3NDY1MGFiMjgwODBiMDRmZTc5M2VfMi0yLTEtMS0w_e55b9560-86be-45a9-8984-f3447985aaad">13,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4ed55838494b35ab23f220a76b8c3b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmRmN2VjZGQzYThiNzQ2NTBhYjI4MDgwYjA0ZmU3OTNlL3RhYmxlcmFuZ2U6ZGY3ZWNkZDNhOGI3NDY1MGFiMjgwODBiMDRmZTc5M2VfMy0yLTEtMS0w_3fe17898-2e93-4b11-8384-bc55fc52d1ee">32,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4ed55838494b35ab23f220a76b8c3b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmRmN2VjZGQzYThiNzQ2NTBhYjI4MDgwYjA0ZmU3OTNlL3RhYmxlcmFuZ2U6ZGY3ZWNkZDNhOGI3NDY1MGFiMjgwODBiMDRmZTc5M2VfNC0yLTEtMS0w_0daa9b46-4481-4617-a7ff-e130db115f92">7,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4ed55838494b35ab23f220a76b8c3b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmRmN2VjZGQzYThiNzQ2NTBhYjI4MDgwYjA0ZmU3OTNlL3RhYmxlcmFuZ2U6ZGY3ZWNkZDNhOGI3NDY1MGFiMjgwODBiMDRmZTc5M2VfNS0yLTEtMS0w_3c656950-8974-428b-9a30-699d44a8afd7">56,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest and discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a4ed55838494b35ab23f220a76b8c3b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmRmN2VjZGQzYThiNzQ2NTBhYjI4MDgwYjA0ZmU3OTNlL3RhYmxlcmFuZ2U6ZGY3ZWNkZDNhOGI3NDY1MGFiMjgwODBiMDRmZTc5M2VfNi0yLTEtMS0w_bf3111bd-dad5-4918-87f6-a73ee546907d">10,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4ed55838494b35ab23f220a76b8c3b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmRmN2VjZGQzYThiNzQ2NTBhYjI4MDgwYjA0ZmU3OTNlL3RhYmxlcmFuZ2U6ZGY3ZWNkZDNhOGI3NDY1MGFiMjgwODBiMDRmZTc5M2VfNy0yLTEtMS0w_bdb87cd7-ab3f-4084-b01f-f7b956d724da">46,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was approximately $<ix:nonFraction unitRef="usd" contextRef="i8a5c6f6b678f44e49e72b10e4ab0fa04_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjk5Mg_9a8100f2-ff72-4719-b1c7-5769f6b64366">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i70765e47bdc740f0bad65affe0499791_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMTA5OTUxMTY0NDE1MA_eaf0702e-d36d-475d-9fc0-9edf52eeede1">1.6</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ia4b11afcb9454eceac785c36df755e25_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA3NDA3NQ_704fc6f8-a55e-4339-a215-f3434ae815cc">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ifea6f295155b467cbdb20351f1ee7713_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA3NDA4OQ_7d189358-8631-4965-a26e-7467d2e5ebe3">0.8</ix:nonFraction>&#160;million for the three and six months ended  June 30, 2020.</span></div></ix:continuation><div id="ie2e49401044149ec86a5cefe42299a79_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:continuation id="ia7ec65ea2bc945778e7a9ab298554359" continuedAt="i92a506afe4c44c88bc95dac858894bb5">In-License Agreements</ix:continuation></span></div><ix:continuation id="i92a506afe4c44c88bc95dac858894bb5" continuedAt="i00ea7605cb4b4f46b4048c227f492a42"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mayo Foundation for Medical Education and Research</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2016, the Company entered into a Research and License Agreement, (the &#8220;2016 Mayo License Agreement&#8221;) with the Mayo Foundation for Medical Education and Research, an affiliate of Mayo Clinic (the &#8220;Mayo Clinic&#8221;). Under the 2016 Mayo License Agreement, the Mayo Clinic was entitled to certain participation rights in connection with the issuance and sale of preferred stock that was issued prior to the Company&#8217;s public offering and warrants which were issued in 2016 and exercised in 2018.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;6, 2017, the Company and the Mayo Clinic entered into a license agreement (&#8220;2017 Mayo License Agreement&#8221;). Under the 2017 Mayo License Agreement, the Mayo Clinic granted the Company (i)&#160;an exclusive, worldwide, sublicensable license under the Mayo Clinic&#8217;s rights to certain intellectual property and microbial strains and (ii)&#160;a non-exclusive, worldwide, sublicensable license to certain related know-how, in each case, to develop and commercialize certain microbial strains and licensed products incorporating any such strains. As consideration, the Company paid a nonrefundable upfront fee of $<ix:nonFraction unitRef="usd" contextRef="ie543e908236043ba8be6cd894642aa5a_D20170806-20170806" decimals="-5" format="ixt:numdotdecimal" name="evlo:NonRefundableUpfrontFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81NS9mcmFnOmMzMjU0NDBlMjRlYTQ1YzU4ZWNjZTdkOTMwMmM3NjRiL3RleHRyZWdpb246YzMyNTQ0MGUyNGVhNDVjNThlY2NlN2Q5MzAyYzc2NGJfMTE4OA_d70f6f62-d9c7-422b-afef-af2e72b7bac5">0.2</ix:nonFraction> million and will pay annual license maintenance fees. Nonrefundable upfront fees were expensed in full to research and development expense in 2017. Annual maintenance fees will be expensed as incurred over the term of the agreement. The Company may owe the Mayo Clinic milestone payments upon the achievement of certain development, regulatory, and commercial milestones, up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="if17724f9bb3d4db2ba6331a7cac91d1a_D20170806-20170806" decimals="INF" format="ixt:numdotdecimal" name="evlo:MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81NS9mcmFnOmMzMjU0NDBlMjRlYTQ1YzU4ZWNjZTdkOTMwMmM3NjRiL3RleHRyZWdpb246YzMyNTQ0MGUyNGVhNDVjNThlY2NlN2Q5MzAyYzc2NGJfMTU3NA_09f82eb8-4f27-4bc9-8d48-56e23e8beef9">56.0</ix:nonFraction> million in the aggregate, as well as royalties on net sales of licensed products in low single-digit percentages. As of June 30, 2021, the Company has incurred milestone payments to date totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i9b9e276c407a458f9f69449a649920dc_D20210630-20210630" decimals="-5" format="ixt:numdotdecimal" name="evlo:MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81NS9mcmFnOmMzMjU0NDBlMjRlYTQ1YzU4ZWNjZTdkOTMwMmM3NjRiL3RleHRyZWdpb246YzMyNTQ0MGUyNGVhNDVjNThlY2NlN2Q5MzAyYzc2NGJfMTc2OA_adbf8a98-40d3-4fb5-9ea2-9f2fef3e8323">0.3</ix:nonFraction> million under the agreement of which <ix:nonFraction unitRef="usd" contextRef="i7427f0ed143e4184939402103a418a1a_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractualObligation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81NS9mcmFnOmMzMjU0NDBlMjRlYTQ1YzU4ZWNjZTdkOTMwMmM3NjRiL3RleHRyZWdpb246YzMyNTQ0MGUyNGVhNDVjNThlY2NlN2Q5MzAyYzc2NGJfMTgwMA_1af8c0d4-8b9d-4187-98ba-8849ff1f82f9">no</ix:nonFraction></span><span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are currently due.</span><span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of Chicago</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><ix:continuation id="i00ea7605cb4b4f46b4048c227f492a42"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;10, 2016, the Company and the University of Chicago entered into a patent license agreement (&#8220;2016 University of Chicago Agreement&#8221;). Under the 2016 University of Chicago Agreement, the University of Chicago granted the Company (i)&#160;an exclusive, royalty-bearing and sublicensable license under the licensed patents and (ii)&#160;a non-exclusive, royalty-bearing, sublicensable license to access the technical information to diligently develop and commercialize licensed products. As consideration, the Company paid a nonrefundable upfront fee of less than $<ix:nonFraction unitRef="usd" contextRef="i86362fee842547b9bde5128b9b9d7696_D20160310-20160310" decimals="-5" format="ixt:numdotdecimal" name="evlo:NonRefundableUpfrontFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81NS9mcmFnOmMzMjU0NDBlMjRlYTQ1YzU4ZWNjZTdkOTMwMmM3NjRiL3RleHRyZWdpb246YzMyNTQ0MGUyNGVhNDVjNThlY2NlN2Q5MzAyYzc2NGJfMjQxMw_90e7c2e0-79d4-4878-8e39-7446673d68e7">0.5</ix:nonFraction> million and will pay annual license maintenance fees. Nonrefundable upfront fees were expensed in full to research and development expense in 2016. Annual maintenance fees will be expensed as incurred over the term of the agreement. The Company may owe the University of Chicago milestone payments, totaling an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="i941118753f0c4ff3a809cf847fa3cc04_D20160310-20160310" decimals="-5" format="ixt:numdotdecimal" name="evlo:MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81NS9mcmFnOmMzMjU0NDBlMjRlYTQ1YzU4ZWNjZTdkOTMwMmM3NjRiL3RleHRyZWdpb246YzMyNTQ0MGUyNGVhNDVjNThlY2NlN2Q5MzAyYzc2NGJfMjc0Ng_9ffa52e7-6ae6-4bc7-b0c0-83331642a975">60.9</ix:nonFraction> million upon the achievement of certain development, regulatory, and commercial milestones, as well as royalties on net sales of licensed products ranging from low to high single-digit percentages. As of June 30, 2021, the Company has incurred milestone payments to date totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i365ea6e18e0541caa57a11096b3a89a2_D20210630-20210630" decimals="-5" format="ixt:numdotdecimal" name="evlo:MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81NS9mcmFnOmMzMjU0NDBlMjRlYTQ1YzU4ZWNjZTdkOTMwMmM3NjRiL3RleHRyZWdpb246YzMyNTQ0MGUyNGVhNDVjNThlY2NlN2Q5MzAyYzc2NGJfMzAyNA_f16539cb-bc00-4ac1-b433-1a30f5489ae4">0.4</ix:nonFraction> million under the agreement of which <ix:nonFraction unitRef="usd" contextRef="i83fa1bd396e94b03ba1d3567b925edf7_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractualObligation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81NS9mcmFnOmMzMjU0NDBlMjRlYTQ1YzU4ZWNjZTdkOTMwMmM3NjRiL3RleHRyZWdpb246YzMyNTQ0MGUyNGVhNDVjNThlY2NlN2Q5MzAyYzc2NGJfMzA1Ng_d1785218-56c9-46d0-a963-a9566a93c5e7">no</ix:nonFraction></span><span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are currently due.</span></ix:continuation><span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="ie2e49401044149ec86a5cefe42299a79_58"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81OC9mcmFnOjFiNWI1ZTU0NjljZDRiOGJhMmY2ZWIwNTYwMmY0OTI4L3RleHRyZWdpb246MWI1YjVlNTQ2OWNkNGI4YmEyZjZlYjA1NjAyZjQ5MjhfMTg3NQ_856ab4fd-94d2-426e-aafb-1ded402a3d68" continuedAt="ibb3bd71e64dc494082f84c587ec5661e" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ibb3bd71e64dc494082f84c587ec5661e"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Collaboration Agreement with Sacco S.r.l.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company entered into an agreement with Sacco S.r.l. ("Sacco"), an affiliate of one of the Company&#8217;s existing contract manufacturing organizations, pursuant to which and subject to certain exceptions for pre-existing products for pre-existing customers, Sacco will manufacture and supply single strain, non-genetically modified microbes intended for oral delivery or oral use in pharmaceutical products exclusively for the Company for a period of <ix:nonNumeric contextRef="i92aa56851c3d4aa1842d25b81d3cf9b9_D20190701-20190731" format="ixt-sec:durwordsen" name="evlo:CollaborationArrangementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81OC9mcmFnOjFiNWI1ZTU0NjljZDRiOGJhMmY2ZWIwNTYwMmY0OTI4L3RleHRyZWdpb246MWI1YjVlNTQ2OWNkNGI4YmEyZjZlYjA1NjAyZjQ5MjhfNTQ0_e33f3a0c-7d18-4a8b-9712-0455c0c04e36">five years</ix:nonNumeric>. Sacco may terminate the agreement if the provision of manufacturing services has been, or is scheduled to be, inactive for a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81OC9mcmFnOjFiNWI1ZTU0NjljZDRiOGJhMmY2ZWIwNTYwMmY0OTI4L3RleHRyZWdpb246MWI1YjVlNTQ2OWNkNGI4YmEyZjZlYjA1NjAyZjQ5MjhfNjgz_325d5ea5-b4c5-433d-9fed-b5f892efb0bc">six</span> consecutive months. The Company has agreed to pay Sacco an aggregate of &#8364;<ix:nonFraction unitRef="eur" contextRef="i0d31ed85dd8b45629814b83f4f060752_I20190731" decimals="-5" format="ixt:numdotdecimal" name="evlo:AggregateAmountDueUnderCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81OC9mcmFnOjFiNWI1ZTU0NjljZDRiOGJhMmY2ZWIwNTYwMmY0OTI4L3RleHRyZWdpb246MWI1YjVlNTQ2OWNkNGI4YmEyZjZlYjA1NjAyZjQ5MjhfNzU4_39cad74e-fad9-466e-b541-c550645782af">3.0</ix:nonFraction> million, &#8364;<ix:nonFraction unitRef="eur" contextRef="i0d31ed85dd8b45629814b83f4f060752_I20190731" decimals="-5" format="ixt:numdotdecimal" name="evlo:AnnualAmountDueUnderCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81OC9mcmFnOjFiNWI1ZTU0NjljZDRiOGJhMmY2ZWIwNTYwMmY0OTI4L3RleHRyZWdpb246MWI1YjVlNTQ2OWNkNGI4YmEyZjZlYjA1NjAyZjQ5MjhfNzYy_f1d524fb-adba-4ce4-9b46-10d3cc193c50">0.6</ix:nonFraction> million annually, during the exclusivity period. The Company has incurred annual exclusivity fees to date totaling approximately &#8364;<ix:nonFraction unitRef="eur" contextRef="i164ea06cf00343df9b0f2f326af8a9e6_D20190701-20210630" decimals="-5" format="ixt:numdotdecimal" name="evlo:FeeIncurredUnderCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81OC9mcmFnOjFiNWI1ZTU0NjljZDRiOGJhMmY2ZWIwNTYwMmY0OTI4L3RleHRyZWdpb246MWI1YjVlNTQ2OWNkNGI4YmEyZjZlYjA1NjAyZjQ5MjhfODg2_0b37e039-6656-421c-b2d1-f0ab06998c73">1.2</ix:nonFraction> million, and no amounts are currently due as of June 30, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation and Other Proceedings</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may periodically become subject to legal proceedings and claims arising in connection with on-going business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which the Company is focused.&#160;The Company is not a party to any material litigation and does not have contingency reserves established for any litigation liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Notice of Opposition was filed against European Patent No. 3223834, which is held by the Company. In July 2021, the Company filed its reply to the Opposition. The patent at issue does not relate to any of the Company&#8217;s current product candidates, and any subsequent proceeding is not expected to affect any of the Company&#8217;s current development plans.</span></div></ix:continuation><div id="ie2e49401044149ec86a5cefe42299a79_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMTU5MA_23b165ce-b2fe-41a4-bad1-2dcf073e1266" continuedAt="if096e05c521242e98b449aafde7da87a" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="if096e05c521242e98b449aafde7da87a" continuedAt="iebf7963160a24ff6a71053706473ee52"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2019, the Company filed the Shelf with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof in the aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="i96b3bb04ea99475da5fa00256059d7c5_I20190603" decimals="INF" format="ixt:numdotdecimal" name="evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMjY0_acd4af90-d091-4bce-852f-082fd5d1d258">200.0</ix:nonFraction> million for a period of up to <ix:nonNumeric contextRef="i98b9be65b14c4e408ab7e4e90ae4e487_D20190603-20190603" format="ixt-sec:durwordsen" name="evlo:SaleOfStockConsiderationReceivedTerm" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMjg5_964abc37-5493-4d46-b984-e7b15e3f2f40">three years</ix:nonNumeric> from the date of the filing. The Company also simultaneously entered into the ATM, providing for the offering, issuance and sale by the Company of up to an aggregate $<ix:nonFraction unitRef="usd" contextRef="ie55b778fc78c4838bd7596f7406fc60a_I20190603" decimals="INF" format="ixt:numdotdecimal" name="evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfNDU4_1182f92b-0d15-47fb-8e26-907007650a7b">50.0</ix:nonFraction> million of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf. For the three and six months ended June 30, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i010bde50e313426284f4a5003a97bcf6_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfNTkw_77c44e54-6225-4df9-8bef-30aa5d6dedd5">no</ix:nonFraction> common shares and <ix:nonFraction unitRef="shares" contextRef="i76cffaf0b6414a3a83a13544db4cb9c8_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMTA5OTUxMTYyOTM3NA_4966a3ff-4b18-4654-abea-1ca72a3eeb1b">139,734</ix:nonFraction> common shares, respectively, under the ATM with offering prices ranging between $<ix:nonFraction unitRef="usdPerShare" contextRef="i0f65daef97744a4e9f23fb6fc142b479_I20210630" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfNjU4_f913adb4-7415-47a4-899b-3cd3170c0da3">12.54</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ia8fd128806d244458684e149d6ba270a_I20210630" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfNjY1_ed92506e-9b85-499c-be81-01283e661a5c">13.17</ix:nonFraction> per share for gross proceeds of net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i010bde50e313426284f4a5003a97bcf6_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfNzIz_41065bba-194e-4bac-b385-d9d2b42d771b">1.7</ix:nonFraction> million, after deducting commission and other offering expenses payable by the Company. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i97a49e3e6ef940f7bd323a42dee5db4e_D20210202-20210202" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfODQ1_86271de6-cac0-4fae-aab4-e6a1f61f59db">5,175,000</ix:nonFraction> shares of its common stock in an underwritten public offering at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i919df7faea17493d83eded85125492f6_I20210202" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfOTQw_b134e678-ffbf-49ba-b1c5-c84d2c663c60">15.00</ix:nonFraction> per share, including the underwriters' exercise of their option to purchase <ix:nonFraction unitRef="shares" contextRef="ie79b06c6d089457580ee83ab0fc4178c_D20210202-20210202" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMTAxOQ_c735e076-ac9d-4373-a3de-578977895417">675,000</ix:nonFraction> shares to cover over-allotment, generating gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i97a49e3e6ef940f7bd323a42dee5db4e_D20210202-20210202" decimals="-5" name="evlo:SaleOfStockGrossConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMTA4Mw_3cdb558c-9545-4191-82e6-da03959ae202">77.6</ix:nonFraction> million and net proceeds of underwriting discounts and commission of $<ix:nonFraction unitRef="usd" contextRef="i97a49e3e6ef940f7bd323a42dee5db4e_D20210202-20210202" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMTE0Nw_fc22d3b1-4d26-469c-a05a-46d859bfd619">72.7</ix:nonFraction> million, after deducting underwriting discounts and commission and other offering expenses paid by the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2021, the Company entered into a stock purchase agreement with ALJ Health Care &amp; Life Science Company Limited ("ALJ Health Care"), pursuant to which on February 2, 2021, ALJ Health Care purchased $<ix:nonFraction unitRef="usd" contextRef="i035578f695544ed4b1cd5c6d23c4dec9_D20210202-20210202" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMTMwMw_0db11a32-296a-456b-8c71-8d915cfe9ef9">7.5</ix:nonFraction> million of the Company's common stock in a private placement at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2be50d786c924771a879f8ead446e51e_I20210202" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMTM4Mg_0b43915c-4fe5-4e3f-bfcd-a77348fc5958">15.00</ix:nonFraction> per share, equal to the public offering price per share at which the Company's common stock was sold to the public as referred above. The sale of such shares was not registered under the Securities Act.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the entry into the Amended Credit Facility, the Company issued to K2 HealthVentures Equity Trust LLC, an affiliate of K2HV, a warrant to purchase up to <ix:nonFraction unitRef="shares" contextRef="ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMjc0ODc3OTA3OTYwMQ_eeb5519d-beaa-43f7-831a-5e469ce5a9d6">139,770</ix:nonFraction> shares of the Company&#8217;s common stock, with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMjc0ODc3OTA3OTYxMA_3d286587-f904-407d-955a-9ab29346f4d2">13.30</ix:nonFraction> per share, subject to customary per share adjustments. The Warrant is exercisable immediately and expires on June 16, 2031, provided that, under certain circumstances, the Warrant may terminate and expire earlier in connection with the closing of certain acquisition transactions involving the Company. The Warrant provides that the holder thereof may elect to exercise the Warrant on a net &#8220;cashless&#8221; basis at any time prior to the expiration thereof. The fair market value of one share of the Company&#8217;s common stock in connection with any cashless exercise shall be the closing price or last sale price per share of the Company&#8217;s common stock on </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="iebf7963160a24ff6a71053706473ee52">a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market on which the Company&#8217;s common stock is traded on the business day immediately prior to the date the holder elects to exercise the Warrant on a cashless basis. In addition, under the Amended Credit Facility, K2HV has the option, exercisable at any time, to convert up to $<ix:nonFraction unitRef="usd" contextRef="ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMjc0ODc3OTA3OTYxOA_7900ad16-c58b-4d09-a696-643eecb20587">5.0</ix:nonFraction>&#160;million of principal outstanding into shares of the Company&#8217;s common stock at a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMjc0ODc3OTA3OTYzMg_d4af917f-f333-4968-9cf2-42f995a213ed">13.30</ix:nonFraction> per share, subject to customary per share adjustments.</ix:continuation>  </span></div><div id="ie2e49401044149ec86a5cefe42299a79_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjQ1NA_8fa1e9ee-c6b4-40e1-ad4e-3cba6cfbe3a7" continuedAt="ia7c3f7855a3045d5877cb07b9918b791" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ia7c3f7855a3045d5877cb07b9918b791" continuedAt="i70b311e3ddaf4055bc0b3d1a6004baf5"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Inducement Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2021, the Company&#8217;s board of directors adopted the Evelo Biosciences, Inc. 2021 Employment Inducement Award Plan (the &#8220;Inducement Award Plan&#8221;) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules (&#8220;Rule 5635(c)(4)&#8221;). In accordance with Rule 5635(c)(4), cash and equity-based incentive awards under the Inducement Award Plan may only be made to a newly hired employee who has not previously been a member of the Company&#8217;s board of directors, or an employee who is being rehired following a bona fide period of non-employment by the Company or a subsidiary, as a material inducement to the employee&#8217;s entering into employment with the Company or its subsidiary. An aggregate of <ix:nonFraction unitRef="shares" contextRef="ifb6d09c7800f4db9a1cac4fda45089ce_I20210527" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjc0ODc3OTA4MDQzMw_10fc0422-2151-4bab-a492-ee0bd8486a4b">1,250,000</ix:nonFraction> shares of the Company&#8217;s common stock have been reserved for issuance under the Inducement Award Plan. The Company will continue to grant awards under the 2018 Incentive Award Plan (the &#8220;2018 Plan&#8221;) pursuant to the terms thereof.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options granted under the Inducement Award Plan will not be less than the fair market value of a share of the Company&#8217;s common stock on the grant date. Other terms of awards, including vesting requirements, are determined by the Company&#8217;s board of directors and are subject to the provisions of the Inducement Award Plan. Stock options granted to employees generally vest over a four-year period but may be granted with different vesting terms. Certain options may provide for accelerated vesting in the event of a change in control. Stock options granted under the Inducement Award Plan expire no more than <ix:nonNumeric contextRef="id28aed25ea8f4f7a93a8c6b2b8ce0a14_D20210527-20210527" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjc0ODc3OTA4MDQ0Ng_3d5f90d7-4466-4755-b4a1-0ae85946b416">10</ix:nonNumeric> years from the date of grant. As of June 30, 2021, stock option awards covering up to <ix:nonFraction unitRef="shares" contextRef="i20e8a93172c24d2e8206286eb8d49a61_D20210630-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjc0ODc3OTA4MDQ1OQ_425180bc-b7e8-463e-8f2d-21c69a0cddc3">550,000</ix:nonFraction> shares of the Company&#8217;s common stock have been issued under the Inducement Award Plan, none of which have been exercised or canceled. As of June 30, 2021, restricted stock unit (&#8220;RSU&#8221;) awards covering up to <ix:nonFraction unitRef="shares" contextRef="i07d88ed7511c4fb488a9c834ac2afc00_D20210630-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjc0ODc3OTA4MDQ2OA_b8f59b4c-d649-47b7-b007-22f30cd43352">4,545</ix:nonFraction> shares of the Company&#8217;s common stock have been granted under the Inducement Award Plan, none of which have vested or been forfeited.  As of June 30, 2021, <ix:nonFraction unitRef="shares" contextRef="i66585702ee8849e499356a9f4a40d9e0_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjc0ODc3OTA4MDQ3NQ_a3780fa1-585d-4d23-ba5d-aae7a0885377">695,455</ix:nonFraction> shares of common stock are available for future grant under the Inducement Award Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Incentive Award Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s board of directors adopted on April&#160;18, 2018, and the Company&#8217;s stockholders approved, the 2018 Plan, which became effective May 8, 2018 and under which the Company may grant cash and equity-based incentive awards to the Company&#8217;s employees, officers, directors, consultants and advisors. Following the effectiveness of the 2018 Plan, the Company ceased making grants under the 2015 Stock Incentive Plan (as amended, the "2015 Plan"). The 2018 Plan initially allowed the Company to grant awards for up to <ix:nonFraction unitRef="shares" contextRef="i6a806946e01c43c7ab029fa63c0a7c9c_I20180508" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjEz_fcf5d305-c09e-4597-9c19-e986c949fd9b">1,344,692</ix:nonFraction>&#160;shares of common stock plus that number of shares of common stock subject to awards outstanding under the 2015 Plan that expire, lapse or become terminated or are exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited following the effective date of the 2018 Plan. Each year starting with 2019 and ending in and including 2028, the number of shares available for grants of awards under the 2018 Plan will be increased automatically on January&#160;1 by a number of shares of common stock equal to the lesser of <ix:nonFraction unitRef="number" contextRef="i61004b706937441f80332b86f6a1bd00_D20180508-20180508" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMTE3MQ_6491258a-a92d-4dbf-9803-ed4885e14368">4</ix:nonFraction>% of the shares of common stock outstanding on the final day of the preceding calendar year or the number of shares determined by the Company&#8217;s board of directors. Accordingly, on January 1, 2021 and 2020, the number of shares authorized for issuance under the 2018 Plan was increased by <ix:nonFraction unitRef="shares" contextRef="i15a5020b711f4d87bba0d1d0b69566cd_D20210101-20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMTQ2MA_bc7d0a03-2dbd-412e-a102-8639be8ca629">1,898,805</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="ic350846ea0d2431d965b88729486c075_D20200101-20200101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMTQ3NA_42b6bb6c-0640-436e-b10d-892215a88331">1,286,824</ix:nonFraction> shares, respectively. The 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options granted under the 2018 Plan will not be less than the fair market value of a share of the Company&#8217;s common stock on the grant date. Other terms of awards, including vesting requirements, are determined by the board of directors and are subject to the provisions of the 2018 Plan. Stock options granted to employees generally vest over a <ix:nonNumeric contextRef="ic4d990381fac4ad886d7990c63587b3a_D20180508-20180508" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjQ1NQ_6e5bb034-0128-467c-b1f8-1ade87b18d30">four-year</ix:nonNumeric> period but may be granted with different vesting terms. Certain options provide for accelerated vesting in the event of a change in control. Awards granted to non-employee consultants generally vest monthly over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjIwMw_7adb7c68-f638-4357-9bd2-eeb01a3b009e">one</span> to <ix:nonNumeric contextRef="iccf9f430cf7d4c31a2c537f0e85686ac_D20180508-20180508" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjIwOQ_af4e4673-4970-473c-89e5-054495a47f4f">four years</ix:nonNumeric>. Stock options granted under the 2018 Plan expire no more than <ix:nonNumeric contextRef="i224b3142ac434b7d8db8a216dec30657_D20180508-20180508" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjI3NQ_bb9a69b9-a2a4-47d7-9799-5343ee19b1f8">10</ix:nonNumeric> years from the date of grant. As of June 30, 2021,&#160;stock options awards covering up to <ix:nonFraction unitRef="shares" contextRef="ib090cc4aa98c45f4b479a5057e7bfe0a_D20210630-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjM1NA_27cd79a2-ddd0-47b4-8860-d75142fc986a">6,557,456</ix:nonFraction> shares of the Company&#8217;s common stock have been issued under the 2018 Plan, of which <ix:nonFraction unitRef="shares" contextRef="ib090cc4aa98c45f4b479a5057e7bfe0a_D20210630-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjQ0MQ_2c9c4c71-12c0-44f9-908d-add2028376ae">34,748</ix:nonFraction> have been </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><ix:continuation id="i70b311e3ddaf4055bc0b3d1a6004baf5" continuedAt="ibd5072c530ee4b079579ea55e024a19d"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercised and <ix:nonFraction unitRef="shares" contextRef="ib090cc4aa98c45f4b479a5057e7bfe0a_D20210630-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjQ2OA_f5744003-980c-4e72-92f0-ab87a0c6306b">977,561</ix:nonFraction> have been canceled. As of June 30, 2021, <ix:nonFraction unitRef="shares" contextRef="i14af8565540e4dc6b3cb3fd98d163fef_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjUwMQ_7a9dc066-282b-4ee9-8dd9-1e6dc120742b">647,704</ix:nonFraction> shares of common stock are available for future grant under the 2018 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Stock Incentive Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the approval of the 2018 Plan, the Company granted equity awards under the 2015 Plan, which originally provided for grant of incentive stock options, non-qualified stock options, restricted stock awards ("RSAs"), and other stock-based awards to the Company&#8217;s employees, officers, directors, consultants and advisors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of equity award agreements, including vesting requirements, were determined by the board of directors and are subject to the provisions of the 2015 Plan. Stock options granted to employees generally vest over a <ix:nonNumeric contextRef="i8244e41e2b0347a1ad64c9419ce3ec00_D20150101-20151231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjQ1Ng_47ccda22-1823-40cd-bb4e-b171e9db1d4b">four-year</ix:nonNumeric> period but may be granted with different vesting terms. A limited number of awards contain performance-based vesting criteria and for such awards that are deemed probable of vesting, the Company records expense in the period in which such determination is made through any estimated remaining vesting period. Certain options provide for accelerated vesting in the event of a change in control. Awards granted to non-employee consultants generally vest monthly over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMzYzNw_fddafaeb-2db2-49ee-b233-bca37709f790">one</span> to <ix:nonNumeric contextRef="i633b84c50c4f4e7b81b89cb2a278bdee_D20150101-20151231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMzY0Mw_909fd93f-ab8f-437a-83d1-ce281968a9be">four years</ix:nonNumeric>. Stock options issued under the 2015 Plan expire no more than <ix:nonNumeric contextRef="i1a92391ffc2e4c5ea7bcfabcb58614d5_D20150101-20151231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMzcwOA_a4750b9f-e974-484e-867f-d867f96d682f">10</ix:nonNumeric> years from the date of grant. As of the effectiveness of the 2018 Plan, the Company ceased making awards under the 2015 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2015 Plan, the Company was authorized to grant equity awards up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i0b4b46cb61e94103b6de3a962ed2a13b_I20151231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMzkzMA_61c6ead6-8dfd-48aa-8acb-ce47bd5a20c5">5,417,044</ix:nonFraction> shares of common stock.&#160;As of June 30, 2021, an aggregate of <ix:nonFraction unitRef="shares" contextRef="ib60b517f490f4972bfa2ed9e3b09a3c0_D20150101-20210630" decimals="INF" format="ixt:numdotdecimal" name="evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjc0ODc3OTA3OTQ1OQ_b0a6aab0-3392-42ee-8f9a-a461b4e619e5">5,758,536</ix:nonFraction> options and other equity awards had been granted under the 2015 Plan, of which <ix:nonFraction unitRef="shares" contextRef="ib60b517f490f4972bfa2ed9e3b09a3c0_D20150101-20210630" decimals="INF" format="ixt:numdotdecimal" name="evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNDA2NQ_979045fd-8746-4b27-b11a-9e83d3ea3259">1,431,864</ix:nonFraction> have been exercised, <ix:nonFraction unitRef="shares" contextRef="ib60b517f490f4972bfa2ed9e3b09a3c0_D20150101-20210630" decimals="INF" format="ixt:numdotdecimal" name="evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNDA4OQ_f84765e6-13f6-48de-b886-3ef1d7fdd92b">1,275,971</ix:nonFraction> have been canceled and <ix:nonFraction unitRef="shares" contextRef="ib60b517f490f4972bfa2ed9e3b09a3c0_D20150101-20210630" decimals="INF" format="ixt:numdotdecimal" name="evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNDExNQ_54b607b5-7d9e-452a-a3d9-2e5c3eada79d">18,468</ix:nonFraction> have been repurchased as of June 30, 2021. A total of <ix:nonFraction unitRef="shares" contextRef="ie9c74ef2f71c45ad87a3378e98258fc9_D20150101-20151231" decimals="INF" format="ixt:numdotdecimal" name="evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNDE2MQ_02e65cb5-5046-4ad1-91e2-e126858f1c17">113,006</ix:nonFraction> shares previously reserved under the 2015 Plan that had not been exercised or were otherwise subject to outstanding exercise awards were no longer authorized for issuance under the 2015 Plan as of May&#160;8, 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjQ1Nw_6969490c-f020-4b81-b530-7d2ff601bfe6" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in the Company&#8217;s unaudited condensed consolidated statements of operations is as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:35.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e11f538a920421ba186e7c8b1a99dd5_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfMi0yLTEtMS0w_3ae1b289-87f5-420a-b932-b4d5f29652e8">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a6ab7adc80d4824b666be8b229cb0b6_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfMi00LTEtMS0w_fe108cfa-4562-43eb-b25d-d2fbfdc819f1">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ac84e56b51542e4a5d75700b09622de_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfMi02LTEtMS0zMzg_87823fc9-a527-4724-92f3-f9801b5e44d9">3,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46432b66afa646449b4065dc8c030013_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfMi04LTEtMS0zMzg_964bb541-bd8f-4d54-a70b-51ac280c4780">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1b9cbd25a6b46d6a7303f0144b6f001_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfMy0yLTEtMS0w_4fef77cd-cc5f-4610-864c-06973fe12220">2,049</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic45337ae21d448d582c46b1700091d22_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfMy00LTEtMS0w_f853c787-6161-4136-9ef8-8901a90e1dc1">1,083</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc9caf00ee42449ae612c261252ddf_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfMy02LTEtMS0zMzg_8a83b5ad-62b6-4c4e-8bbf-72807da99e51">3,872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ffafae80f64bc194e822d4073442a5_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfMy04LTEtMS0zMzg_52eb08cf-6d25-43ca-8922-a57148290dce">2,149</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfNC0yLTEtMS0w_aa067d3c-440b-4a30-97b0-ee326a3cdf08">3,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfNC00LTEtMS0w_8dcdba18-826c-4c15-806b-07600750b7ae">2,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfNC02LTEtMS0zMzg_92aaeb8c-8b9c-4c70-adf4-cb40059eb294">7,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfNC04LTEtMS0zMzg_fb0ed3cb-0eed-46db-ac15-bbd1326c0689">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjQ1Mg_5b02fc63-b954-42f9-8dc8-f2db1a1b7d1b" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity and related information is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.482%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfMS0yLTEtMS0w_d0fa8aee-82ae-4153-9af7-a3d194a94af1">6,610,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfMS00LTEtMS0w_6e56687d-11f2-4f18-a7b4-407a62ae1fa4">6.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfMi0yLTEtMS0w_21e5b50f-60fa-4404-804f-fc44e8e342ec">2,731,274</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfMi00LTEtMS0w_599b12a8-0bb7-4d87-b81d-6853553fbf7c">15.59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfMy0yLTEtMS0w_7c17d216-c7e0-46af-9bf9-fd3a7d85339d">85,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfMy00LTEtMS0w_ceeeb4c5-b9f0-43cc-b288-c2b0cb319273">6.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfNC0yLTEtMS0w_ccb427d6-5c82-4f11-927b-d23e6845fc73">110,267</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfNC00LTEtMS0w_54871677-c716-4d77-b4be-6077aced650a">10.46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfNS0yLTEtMS0w_f02cac83-4a44-43c5-b4b2-04c4c666846f">9,145,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfNS00LTEtMS0w_792ed8e1-9754-4765-88a1-89f203b52873">9.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfNi0yLTEtMS0w_ab0baf13-b252-4a3b-ac50-4594aaa23592">4,443,028</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfNi00LTEtMS0w_be70e306-295a-47eb-9ff5-b81accebc4f4">6.12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><ix:continuation id="ibd5072c530ee4b079579ea55e024a19d"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value of options granted during the six months ended June 30, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNDc1Mw_a619e74f-f3fe-4d87-83ee-fdd4b0c9d6ae">11.52</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNDc2MA_74c8e701-5d2f-4125-a634-4ac99606edad">4.45</ix:nonFraction>, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, total unrecognized stock-based compensation expense relating to unvested stock options was $<ix:nonFraction unitRef="usd" contextRef="i5ba9feb93d764efd96698e68714de654_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNDg3OQ_0211406e-af19-486c-907e-375171a21617">38.7</ix:nonFraction> million. This amount is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="ie2e1988c04664ea584a4c41ef9af23cc_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNDk1OA_5afa3a34-bf11-4792-b555-6ee4f074e067">2.76</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units </span></div><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjQ1OA_986a1513-e32c-4c73-bc12-7e70c6e8b147" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity and related information is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20fc0d52b2a44c50902a857e8d3130d5_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfMS0yLTEtMS0w_d1882404-8769-424c-a17d-710faaff1b8e">284,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20fc0d52b2a44c50902a857e8d3130d5_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfMS00LTEtMS0w_3ec38ffc-b1b6-4e74-bc56-1b8012ea698a">4.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bc4ea56ed944d86bdc1c166dd4863c8_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfMi0yLTEtMS0w_ea83024e-efa9-45fe-a9c4-1fbd2bebea88">172,450</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6bc4ea56ed944d86bdc1c166dd4863c8_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfMi00LTEtMS0w_c5b6d36b-4d3b-41f7-a2bc-f04581a01c62">15.50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bc4ea56ed944d86bdc1c166dd4863c8_D20210101-20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfMy0yLTEtMS0w_97231eba-3929-42af-80ec-1a89802c5fc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6bc4ea56ed944d86bdc1c166dd4863c8_D20210101-20210630" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfMy00LTEtMS0w_0f02486f-497c-4a7e-b411-a12d0462548e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6bc4ea56ed944d86bdc1c166dd4863c8_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfNC0yLTEtMS0w_424bca60-5e89-4f14-95b5-ceda36a34aac">36,190</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6bc4ea56ed944d86bdc1c166dd4863c8_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfNC00LTEtMS0w_ac248b52-7cb9-4650-bfe5-161b3efaa7b1">6.50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i262999f64df4419982435b7d11f2b955_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfNS0yLTEtMS0w_ab3e7b0e-d560-4f96-82b9-5b9fb49267a0">420,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i262999f64df4419982435b7d11f2b955_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfNS00LTEtMS0w_bc40b46c-72ce-4e1f-8c97-b305a3d27b5d">8.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to RSUs was $<ix:nonFraction unitRef="usd" contextRef="i729515b40c8f4158b6586a7ae12ab66e_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNTE0NQ_cca7c626-0970-4cc4-92f9-bfe35a033781">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6bc4ea56ed944d86bdc1c166dd4863c8_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMTA5OTUxMTYzNDM5Nw_5fd86b78-322a-46ba-91d6-1be900fd03fd">0.3</ix:nonFraction>&#160;million, respectively, for the three months and six months ended June 30, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's board of directors adopted on April&#160;18, 2018, and the Company&#8217;s stockholders approved, the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective on May&#160;8, 2018. A total of&#160;<ix:nonFraction unitRef="shares" contextRef="i264242fbfa064d8fbc4066b8f369a883_D20180508-20180508" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNTQxNw_70bb1b20-6ae5-4be4-b837-12a788d2d1ac">336,356</ix:nonFraction>&#160;shares of common stock were initially reserved for issuance under the ESPP. In addition, the number of shares of common stock that may be issued under the ESPP will automatically increase on the first day of each calendar year, beginning in 2020 and ending in and including 2028, by an amount equal to the lesser of (i)&#160;<ix:nonFraction unitRef="number" contextRef="i264242fbfa064d8fbc4066b8f369a883_D20180508-20180508" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNTc0MA_2996b1e2-128e-4ef3-8f21-d296063d935b">1</ix:nonFraction>%&#160;of the number of shares of the Company&#8217;s common stock outstanding on the last day of the applicable preceding calendar year and (ii)&#160;an amount determined by the Company&#8217;s board of directors. The Company's board of directors authorized an initial offering period under the ESPP commencing on February 1, 2020. Accordingly, on January 1, 2021, the number of shares authorized for issuance under the ESPP was increased by <ix:nonFraction unitRef="shares" contextRef="i13be462485cb4baebb145fda3b01ca07_D20210101-20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjE2Mg_e4d3c96e-0463-45a1-b55e-ab5ef90c3c93">474,701</ix:nonFraction> shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation expense recognized related to the ESPP for the three and six ended June 30, 2021 and 2020 was not material. There was a total of <ix:nonFraction unitRef="shares" contextRef="i57ce7e89580e42e29ea075112fdd665b_D20210401-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjI5Ng_21ea8e93-1f44-4756-9867-c395d0c5f9cf">0</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i237329bf49a34a118ff127ea889dd7d9_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMTA5OTUxMTYzNDM5Mg_67cc1b03-61fa-4c66-9dad-cea0ffd38557">27,587</ix:nonFraction> shares, respectively, purchased under the ESPP during the three and six months ended June 30, 2021. There were <ix:nonFraction unitRef="shares" contextRef="i72fbaf5f78e84aa9be31492a6dfcfb3b_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjM3Mw_1787e445-d2a9-49de-bbb2-58c7e7291b71"><ix:nonFraction unitRef="shares" contextRef="i28b06266364d412583cb80ca61576389_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjM3Mw_41c4c949-f741-40bb-abad-9f8f2874cd8c">no</ix:nonFraction></ix:nonFraction> shares purchased under the ESPP during both the three months and six months ended June 30, 2020.</span></div></ix:continuation><div id="ie2e49401044149ec86a5cefe42299a79_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82Ny9mcmFnOmRmMDQ4NWYwOTUyZjQwM2NiZTNlMWYxZjVlNGNkY2MwL3RleHRyZWdpb246ZGYwNDg1ZjA5NTJmNDAzY2JlM2UxZjFmNWU0Y2RjYzBfMTYzNQ_64ec0f03-fe4e-49a4-9082-dd2505d97a42" continuedAt="i62226fd9a2fb436a810a0e95bf41cbe2" escape="true"><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82Ny9mcmFnOmRmMDQ4NWYwOTUyZjQwM2NiZTNlMWYxZjVlNGNkY2MwL3RleHRyZWdpb246ZGYwNDg1ZjA5NTJmNDAzY2JlM2UxZjFmNWU0Y2RjYzBfMTY0MA_fa4d7dce-0ada-439a-a318-87bd03a7e7dd" continuedAt="i22c9f9d602e84618a0b03ebaebf75ee4" escape="true">Income Taxes</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i62226fd9a2fb436a810a0e95bf41cbe2" continuedAt="ifde31e5acceb41d086ca9164bf8c5e02"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i22c9f9d602e84618a0b03ebaebf75ee4">Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#8217;s otherwise recognizable net deferred tax assets.</ix:continuation></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was enacted on March 27, 2020. The CARES Act contained several key provisions including: (i) five year carryback of net operating losses (&#8220;NOLs&#8221;), (ii) increase in amount of business interest expense deductible under Section 163(j) of the Internal Revenue Code from 30% to 50% for  tax years 2019 and 2020, (iii) delay of payment of employer payroll taxes, (iv) temporary refundable employee retention credit, (v) suspension of certain aviation and alcohol excise taxes and (vi) technical correction for qualified improvement property. As of June 30, 2021, the Company had deferred $<ix:nonFraction unitRef="usd" contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630" decimals="-5" format="ixt:numdotdecimal" name="evlo:SocialSecurityTaxEmployerDeferralCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82Ny9mcmFnOmRmMDQ4NWYwOTUyZjQwM2NiZTNlMWYxZjVlNGNkY2MwL3RleHRyZWdpb246ZGYwNDg1ZjA5NTJmNDAzY2JlM2UxZjFmNWU0Y2RjYzBfMTI3OA_348567be-4687-432d-8ace-da2fec363906">0.4</ix:nonFraction> million in employer payroll taxes pursuant to the CARES Act, of which $<ix:nonFraction unitRef="usd" contextRef="id41c0cbe7c784fe3aab81511b93b8580_I20210630" decimals="-5" format="ixt:numdotdecimal" name="evlo:SocialSecurityTaxEmployerDeferralCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82Ny9mcmFnOmRmMDQ4NWYwOTUyZjQwM2NiZTNlMWYxZjVlNGNkY2MwL3RleHRyZWdpb246ZGYwNDg1ZjA5NTJmNDAzY2JlM2UxZjFmNWU0Y2RjYzBfMTM0Mw_b5b5fd1a-e571-49a8-a7b9-c24a04bcb4b9">0.2</ix:nonFraction> million is included in the accrued expenses and $<ix:nonFraction unitRef="usd" contextRef="id6fcef2a6164499a8a9a7fbb1013a8a9_I20210630" decimals="-5" format="ixt:numdotdecimal" name="evlo:SocialSecurityTaxEmployerDeferralCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82Ny9mcmFnOmRmMDQ4NWYwOTUyZjQwM2NiZTNlMWYxZjVlNGNkY2MwL3RleHRyZWdpb246ZGYwNDg1ZjA5NTJmNDAzY2JlM2UxZjFmNWU0Y2RjYzBfMTM4Ng_4d10accc-e11c-4fda-ad07-e426cc2885a8">0.2</ix:nonFraction> million is included in the other noncurrent liabilities in these unaudited condensed consolidated balance sheets.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifde31e5acceb41d086ca9164bf8c5e02">For the six months ended June 30, 2021 and 2020 the Company recorded a tax provision of $<ix:nonFraction unitRef="usd" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82Ny9mcmFnOmRmMDQ4NWYwOTUyZjQwM2NiZTNlMWYxZjVlNGNkY2MwL3RleHRyZWdpb246ZGYwNDg1ZjA5NTJmNDAzY2JlM2UxZjFmNWU0Y2RjYzBfMjc0ODc3OTA3MTE5OA_5a002361-bd07-4b9a-b342-02fddb5ec066">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82Ny9mcmFnOmRmMDQ4NWYwOTUyZjQwM2NiZTNlMWYxZjVlNGNkY2MwL3RleHRyZWdpb246ZGYwNDg1ZjA5NTJmNDAzY2JlM2UxZjFmNWU0Y2RjYzBfMTA5OTUxMTYyOTQ2MQ_dc617cf3-a410-47ff-b057-5d11623b868b">0.2</ix:nonFraction>&#160;million, respectively, primarily related to the Company's wholly-owned UK subsidiary.</ix:continuation></span></div><div id="ie2e49401044149ec86a5cefe42299a79_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RleHRyZWdpb246NGY3YzliNmYzNjY5NGMxNDlhODRhN2IzODJmMjlmNDdfOTU5_193c7653-508b-467a-b70e-4c82b5e34a9b" continuedAt="ib9863f14d7d24779be832e1ccf8262a1" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="ib9863f14d7d24779be832e1ccf8262a1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, issuance of common stock under the ESPP and restricted common stock, and exercise of the Warrant and Conversion Option under the Amended Credit Facility, outstanding during the period determined using the treasury stock methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and therefore basic and diluted net loss per share have been equivalent.</span></div><ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RleHRyZWdpb246NGY3YzliNmYzNjY5NGMxNDlhODRhN2IzODJmMjlmNDdfOTYw_66f8326e-62ec-4b6b-8cd2-a6e219e96772" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents securities that have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:67.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.837%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested common stock from early exercise of options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia30b6f5d35ce44e69d65001940192f50_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfMi0yLTEtMS0w_f78e8bdb-96f2-426f-9e7d-d5ed741354ce">18,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i498626a92f9c490982d76300e711e00a_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfMi00LTEtMS0w_e64fe155-0dcd-4acd-9418-eede43f26cfa">36,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a7d195f002343acae14514f10c6c103_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfMy0yLTEtMS0w_36504473-562e-4f9d-a552-67cf22613c72">9,145,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82ff1a0e1f834c328bc95de6abf47cac_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfMy00LTEtMS0w_b24df68c-d7c1-4f4e-b815-019d5c111b26">6,385,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9858c60d7bed47b2814be6df654dc03d_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfNC0yLTEtMS0w_960a02c5-c51c-40a0-ac74-76af0e9ff344">139,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id961f8a7a6d54ba294cfdd02a79a2129_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfNC00LTEtMS0w_9f57cd6a-d2bb-4a70-8a3b-bd33cf66bcad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39c0f1b46d6e4e668982c302cb6394a9_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfNS0yLTEtMS0yNjE2_f4f26d0b-a197-4ad0-8437-5cacad725ef9">375,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0a9f46458db4036b7b2307aa079dda5_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfNS00LTEtMS0zNDEy_f92d9ac0-23b6-498d-ae5e-7bd65f6db62f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock offering from ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff32a529f86d4871a555686343203169_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfNS0yLTEtMS0w_0bb9cd2f-da6e-4b91-8caa-48f72a1f0fde">10,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i410f08d8ccf041caa3ee3b193f8c60ce_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfNS00LTEtMS0w_70ba09dc-2568-47ae-b25c-04fe13bbeccc">23,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfNi0yLTEtMS0w_7e3233c4-c1a7-4f98-b61f-bff82d419cea">9,690,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfNi00LTEtMS0w_1d4f5eb4-5e54-4d9c-8494-6b90d610d58a">6,445,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="ie2e49401044149ec86a5cefe42299a79_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfNDYyNw_b62a6c6a-412c-4866-b914-f707026a3375" continuedAt="id96015fe8707400db7547a62404dd32c" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="id96015fe8707400db7547a62404dd32c" continuedAt="i031325341dc8496ab1751ce66b55e5ee"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives clinical advisory services from Weatherden Ltd. (&#8220;Weatherden&#8221;) under agreements that were entered into during 2017 and 2018. Duncan McHale, the Company&#8217;s Chief Medical Officer, is a part owner of Weatherden. During the six months ended June 30, 2021 and 2020, the Company paid Weatherden $<ix:nonFraction unitRef="usd" contextRef="i53f72d5181794c719cc51cf350c7bdf5_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMzMx_ab81991c-ecfa-4eec-a333-e65451d5c505">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id6b40b59cd064a4ca4af131a12d171b8_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMzM4_e8083e5a-d6ea-49f6-bd54-52fccebe3920">0.4</ix:nonFraction> million, respectively. As of June 30, 2021 and 2020, the amount due to Weatherden under the supply of service agreement was approximately <ix:nonFraction unitRef="usd" contextRef="ic8c74a5ad01f474d8d0477af135c17fb_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMTY0OTI2NzQ0NjM2Nw_ea8c406a-e342-4024-81c5-31341c576b06">0.1</ix:nonFraction> million and  $<ix:nonFraction unitRef="usd" contextRef="i31d0e9fb79cb425e871db75394a9796b_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfNDU4_3bef8e3e-077e-4f9a-860c-ad4b7299b632">0.1</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into a subleasing arrangement with Ring Therapeutics, Inc. (formerly VL46, Inc.), an affiliate of one of its stockholders, Flagship Venture Funds. Under the terms of the sublease, the Company invoiced Ring Therapeutics for an aggregate $<ix:nonFraction unitRef="usd" contextRef="i2aeea52635454325a295ece2390835bd_I20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfNzQ3_3b4a35a2-7f5c-4170-a013-31078637c9e6">0.9</ix:nonFraction> million in rent payments which were due during the period from July&#160;1, 2018 through April&#160;30, 2020, the sublease expiration date, plus related taxes and lease operating costs. For the three and six months ended June 30, 2020, $<ix:nonFraction unitRef="usd" contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMTY0OTI2NzQ2MDQwOQ_7c8d408b-2bb6-4448-9ed1-f834ed3e00df">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMjc0ODc3OTA4ODIzMA_545de8cf-da1d-4c6f-82f2-7ddd19055eeb">0.3</ix:nonFraction>&#160;million, respectively, related to this sublease, inclusive of rent payments, taxes and operating expenses, has been recorded as an offset to operating expense within the unaudited condensed consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a consulting agreement with David Epstein (the "Consulting Agreement"), the Company's Chairman of the Board, effective September 16, 2019 pursuant to which Mr. Epstein provides strategic advisory and other consulting services to the Company. The Consulting Agreement was amended on October 15, 2020 and again on April 9, 2021, and now has a term that is scheduled to end on June 30, 2022 unless terminated earlier by either Mr. Epstein or the Company upon <ix:nonNumeric contextRef="ie19faf0f5e0c4db3b2f52a5594e2b9af_D20210409-20210409" format="ixt-sec:durday" name="evlo:RelatedPartyTransactionConsultingContractTerminationNoticeTerm" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMTY0OQ_00a8886f-bb48-48c3-a0fd-d721007c2c1a">30</ix:nonNumeric> days&#8217; notice, or <ix:nonNumeric contextRef="ie19faf0f5e0c4db3b2f52a5594e2b9af_D20210409-20210409" format="ixt-sec:durhour" name="evlo:RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMTY2NA_23c24fd4-1176-4b06-9644-00e45f5da3dd">24</ix:nonNumeric> hours&#8217; notice by the non-breaching party in the event of a breach. In accordance with the terms of the Consulting Agreement, on September 16, 2019, Mr. Epstein was granted an option to purchase <ix:nonFraction unitRef="shares" contextRef="i9a42be16340a41089a1cd8a571d2ff8e_D20190916-20190916" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMTg1NQ_1d1c99c1-60a2-43b4-9a7e-a80ecf97b44a">75,000</ix:nonFraction> shares of the Company&#8217;s common stock, which award vests in <ix:nonFraction unitRef="installment" contextRef="i9a42be16340a41089a1cd8a571d2ff8e_D20190916-20190916" decimals="INF" name="evlo:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMTkxNw_fb4cbc14-5490-40f9-920a-877a3660bc13">36</ix:nonFraction> equal monthly installments subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting dates. Under the Consulting Agreement as amended on October 15, 2020, Mr. Epstein also is entitled to receive (i) an annual equity award on each anniversary of the effective date of the Consulting Agreement in the form of an option to purchase shares of the Company&#8217;s common stock having an aggregate grant date fair market value equal to approximately $<ix:nonFraction unitRef="usd" contextRef="ia236d54dd6634fc7a8f1bf3a6bc3d785_I20201015" decimals="-5" format="ixt:numdotdecimal" name="evlo:RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMjQzNg_124f9cbb-edf1-471f-8100-9dcc5bb09af1">0.2</ix:nonFraction>&#160;million, as determined by the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i031325341dc8496ab1751ce66b55e5ee">Board in its discretion based on customary option pricing methodologies, which award vests in <ix:nonFraction unitRef="installment" contextRef="ia16626e077c84f1a8616489f51dfdabb_D20201015-20201015" decimals="INF" name="evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMjU1NQ_b9461ef9-544a-413d-ae4e-74d3c75ccbfc">12</ix:nonFraction> equal monthly installments following the grant date, subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting date, and (ii) an aggregate annual cash consulting fee of $<ix:nonFraction unitRef="usd" contextRef="ia236d54dd6634fc7a8f1bf3a6bc3d785_I20201015" decimals="-5" format="ixt:numdotdecimal" name="evlo:RelatedPartyTransactionAnnualCashConsultingFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMjgwNQ_bc100a3b-8e1e-4c47-a268-0e28381ac035">0.3</ix:nonFraction>&#160;million for his consulting services. In the event the Consulting Agreement is renewed for a term of less than <ix:nonNumeric contextRef="ia16626e077c84f1a8616489f51dfdabb_D20201015-20201015" format="ixt-sec:durwordsen" name="evlo:RelatedPartyTransactionConsultingContractRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMjkxMA_4652c5a4-5ed3-4908-80d7-d6727ef62324">one year</ix:nonNumeric>, the aggregate grant date fair value of the corresponding annual equity award and the resulting number of shares of the Company&#8217;s common stock purchasable under such annual equity award and the vesting schedule shall be adjusted proportionately to the length of the renewal term. On October 11, 2020, in connection with the commencement of his second year of service as a consultant to the Company, Mr. Epstein was granted an annual equity award in the form of an option to purchase <ix:nonFraction unitRef="shares" contextRef="i6986f547b61f46cb9e428885d5c4f66a_D20201011-20201011" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMzM5Ng_665a1370-a8ae-4d1f-b60d-c96868a23828">44,743</ix:nonFraction> shares of the Company&#8217;s common stock, which award vests in <ix:nonFraction unitRef="installment" contextRef="i6986f547b61f46cb9e428885d5c4f66a_D20201011-20201011" decimals="INF" format="ixt-sec:numwordsen" name="evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMzQ1OA_1a62ec92-587e-44cb-8190-2ccae102f8dd">nine</ix:nonFraction> equal monthly installments, in each case subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting dates. Under the Consulting Agreement as amended on April 9, 2021, effective on June 30, 2021, Mr. Epstein is entitled to receive restricted stock units having an aggregate grant date fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="i7f75681a4eb440c497ad40de810da08d_I20210630" decimals="-5" format="ixt:numdotdecimal" name="evlo:RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMjc0ODc3OTA4ODI0NA_b0a1a7b2-c3ef-41f9-a343-14cd4d026f02">0.5</ix:nonFraction>&#160;million, as determined by our Board of Directors in its discretion based on a <ix:nonNumeric contextRef="iaf794c74c50e4917b5636aa96a990418_D20210630-20210630" format="ixt-sec:durwordsen" name="evlo:RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfNDYyOQ_91f90406-daee-44e1-bbf5-81d1e6a9aa15">10-day</ix:nonNumeric> trailing average of the closing price of our common stock on the Nasdaq Global Select Market, as his sole compensation for the provision of consulting services to the Company. The restricted stock units will vest in <ix:nonFraction unitRef="installment" contextRef="iaf794c74c50e4917b5636aa96a990418_D20210630-20210630" decimals="INF" name="evlo:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfNDE1NA_181f7332-a9a1-43fe-bb0c-712b07fff5bc">12</ix:nonFraction> substantially equal monthly installments following June 30, 2021, such that the restricted stock units shall be fully vested on June 30, 2022, subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting date. All of the foregoing options and restricted stock units, to the extent then outstanding, will be subject to accelerated vesting upon the occurrence of a change in control of the Company.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="ie2e49401044149ec86a5cefe42299a79_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and with our Annual Report on Form 10-K for the year ended December 31, 2020 (the "2020 Annual Report"), including the audited consolidated financial statements and notes thereto contained in our 2020 Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in Part II, Item 1A. &#8220;Risk Factors&#8221; of this Quarterly Report on Form 10-Q, our actual results could differ materially from the results described, in or implied, by these forward-looking statements. In this Quarterly Report on Form 10-Q, unless otherwise stated or as the context otherwise requires, references to &#8220;Evelo,&#8221; &#8220;Evelo Biosciences,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to Evelo Biosciences, Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are discovering and developing a new class of oral biologics that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. The target cells in the small intestine play a central role in governing human immune, metabolic and neurological systems. We refer to this biology as the small intestinal axis, or SINTAX</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have built a platform to discover and develop novel oral medicines which target the small intestinal axis. By harnessing the small intestinal axis, we have the potential to transform healthcare via medicines that have the potential to be effective, safe, convenient and affordable and to thereby treat patients at all stages of diseases and to treat patients globally.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first product candidates are orally delivered pharmaceutical preparations of naturally occurring, specific single strains of microbes. In preclinical models, our product candidates engaged immune cells in the small intestine and drove changes in systemic biology without any observed systemic exposure. We have observed in early clinical trials and preclinical studies that our approach led to modulated immune responses throughout the body by acting on the small intestinal axis. Our most advanced product candidate, EDP1815 is being developed for the treatment of inflammatory diseases and the hyperinflammatory response associated with COVID-19. Additional product candidates include EDP1867 and EDP2939 for the treatment of inflammatory disease and EDP1908 for the treatment of cancer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2020, the WHO declared the COVID-19 outbreak a pandemic. The outbreak has resulted in governments around the world implementing stringent measures to help control the spread of the virus, including quarantines, &#8220;shelter in place&#8221; and &#8220;stay at home&#8221; orders, travel restrictions, business closures and curtailments, and school closures. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has had, and for an extended period of time is expected to have, negative impacts on our operations and supply chain. Our ability to continue to operate without any significant negative impacts will, in part, depend on our ability to protect our employees and our supply chain. We have endeavored to follow recommended actions of government and health authorities to protect our employees with particular measures in place for those working in our laboratories, such as staggered work shifts and flexible schedules, and telecommuting for office workers. We are working with our contract manufacturing organizations ("CMOs") to minimize delays and disruptions to scheduled manufacturing batch runs for our product candidates and to ensure conformity to product specifications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has impacted and continues to impact our enrollment of new patients into, and the retention of existing patients in, our ongoing clinical trials, due primarily to lower patient participation. The pandemic likely will impact enrollment and retention of patients in new and existing clinical trials. We continue to recruit individuals in line with the local and national guidelines of the clinical research sites. We are keeping in close contact with our contract research organizations ("CROs") and clinical sites to provide support and guidance to ensure the safety of the patients in our clinical trials. We have prioritized our drug supply operations to secure the re-supply of patients currently enrolled in our clinical trials.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic impacts our business and finances will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States, the United Kingdom and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States, the United Kingdom and other countries to contain and treat the disease. See &#8220;Risk Factors &#8212; The COVID-19 pandemic has adversely impacted and may continue to adversely impact our business, including our preclinical studies and clinical trials and finances.&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Programs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EDP1815</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EDP1815 is an investigational oral biologic being developed for the treatment of inflammatory diseases. It is a strain of Prevotella histicola, selected for its specific pharmacology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Psoriasis and atopic dermatitis </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2 clinical trial in psoriasis </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on previously reported positive clinical data in two cohorts of individuals with mild to moderate psoriasis in a Phase 1b clinical trial, we advanced EDP1815 into a Phase 2 dose ranging trial, evaluating three doses of EDP1815 in capsules versus placebo in approximately 225 individuals with mild and moderate psoriasis. The primary endpoint of the trial is the mean reduction in Psoriasis Area and Severity Index (PASI) score at 16 weeks. Other clinical measures of psoriasis are also being evaluated. We initiated the Phase 2 clinical trial in October 2020, and have completed enrollment and plan to report topline data in the third quarter of 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to evaluate EDP1815 in additional inflammatory disease indications, depending on the results from the Phase 2 trial. Potential indications include psoriatic arthritis, axial spondylarthritis and rheumatoid arthritis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1b clinical trial in atopic dermatitis </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we initiated our ongoing Phase 1b double-blind placebo-controlled dose-escalating safety and tolerability study of EDP1815 in healthy volunteers and individuals with mild and moderate psoriasis or atopic dermatitis. The primary endpoint of the Phase 1b trial is safety and tolerability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020 and January 2021, we reported positive clinical data from a cohort of patients with mild and moderate atopic dermatitis (n=24), randomized 2:1 to receive EDP1815 in capsules or placebo for 56 days. Atopic dermatitis is the most common type of eczema. EDP1815 was well-tolerated with no treatment-related adverse events of moderate or severe intensity, and no serious adverse events. Secondary endpoints included a range of established markers of clinical efficacy in atopic dermatitis, such the Eczema Area and Severity Index (&#8220;EASI&#8221;), the Investigator&#8217;s Global Assessment times body surface are (&#8220;IGA* BSA&#8221;), and the SCORing Atopic Dermatitis (&#8220;SCORAD&#8221;) scores.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The data showed consistent improvements in percentage change from baseline compared to placebo for all three clinical scores: EASI, IGA*BSA, and SCORAD. In addition, 7 out of 16 (44%) patients treated with EDP1815 achieved an outcome of a 50% improvement from baseline in EASI score by day 70, compared with 0% in the placebo group, showing sustained improvement in those patients responding to EDP1815.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to physician-reported clinical outcomes, this trial also assessed patient-reported outcomes. Treatment with EDP1815 resulted in clinically meaningful improvement in the Dermatology Life Quality Index (&#8220;DLQI&#8221;) and the Patient-Oriented Eczema Measure (&#8220;POEM&#8221;). These patient-reported outcomes capture the important impact of the disease on patients, including the domains of itch and sleep, both of which saw improvements in patients receiving EDP1815 in the trial. All five measures of itch within the Pruritus-Numerical Rating Scale &#8220;(Pruritus-NRS&#8221;), SCORAD, POEM, and DLQI showed greater improvements in the treated group at day 56 compared with placebo. These results provide further evidence that modulating SINTAX can drive significant clinical benefit without the need for systemic exposure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to regulatory approval, we anticipate initiation of a Phase 2 trial of EDP1815 in atopic dermatitis in the third quarter of 2021 and plan to report topline data in the third quarter of 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EDP1815 is being evaluated in two ongoing clinical studies for the treatment of hospitalized COVID-19 patients. EDP1815 is included as a treatment arm in the TACTIC-E clinical trial. TACTIC-E is a Phase 2/3 randomized trial, sponsored by Cambridge University Hospitals NHS Foundation Trust, that is expected to evaluate up to 469 patients per arm at Addenbrooke&#8217;s Hospital and other leading clinical centers in the United Kingdom. The trial is investigating the safety and efficacy of certain experimental therapies in the prevention and treatment of life-threatening complications associated with COVID-19 in hospitalized individuals at early stages of the disease. The trial is enrolling individuals with COVID-19 who have identified risk factors for developing severe complications and are at risk of progression to the intensive care unit or death. The primary outcome measure of the trial is time to incidence (up to day 14) of any one of the following: death, mechanical ventilation, extracorporeal membrane oxygenation (ECMO), cardiovascular organ support, renal failure, hemofiltration or dialysis. Secondary outcome measures include duration of stay in hospital, duration of oxygen therapy, changes in biomarkers associated with COVID-19 progression, and time to clinical improvement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second study is a Phase 2 double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of EDP1815 for the treatment of individuals diagnosed with COVID-19 early in the course of their disease. The trial initially will evaluate 60 individuals to determine if early intervention with EDP1815 can prevent the progression of COVID-19 symptoms and the development of COVID-Related Complications. Individuals who have presented at the emergency room of the Robert Wood Johnson University Hospital within the last 36 hours and tested positive for SARS-CoV-2 are randomized 1:1 to receive the enteric capsule formulation of EDP1815 or placebo for 14 days, along with the standard of care. The primary endpoint is reduced requirements for oxygen therapy, as measured by the ratio of oxygen saturation (SpO2) / fraction of inspired oxygen (FiO2). Key secondary endpoints include total symptom duration, progression along the WHO scale of disease severity, and mortality. The trial is led by Reynold A. Panettieri, Jr., M.D., Vice Chancellor for Translational Medicine and Science at Rutgers Biomedical and Health Sciences and Professor of Medicine at Rutgers Robert Wood Johnson Medical School.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the varying infection rates that have occurred with the pandemic, we have experienced slower than expected enrollment in both trials and, therefore, do not know when we will be able to report data from the clinical trial being conducted at the Robert Wood Johnson University Hospital or TACTIC-E. In order to expedite patient recruitment and expand access to potential therapies for COVID-19, new trial sites have been opened for TACTIC-E, including in the United Kingdom, Brazil and Mexico.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If EDP1815 is successfully developed and approved as a treatment for COVID-19, we believe that we could rapidly scale the manufacturing of EDP1815 to supply the drug at a reasonable cost. If approved and proven effective for early intervention, we expect that oral EDP1815 could also be useful in the outpatient setting to control the community impact of the COVID-19 pandemic. If the Phase 2 trials are successful in COVID-19, we plan to investigate EDP1815 as a potential therapy for other diseases, such as influenza infection, in which hyperinflammation and cytokine storm can play a key role. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EDP1867</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EDP1867 is an inactivated investigational oral biologic being developed for the treatment of inflammatory diseases. EDP1867 was selected from a broad screen of single strains of microbes in in vitro cellular assays and in vivo models of inflammation. In preclinical studies EDP1867 was shown to resolve multiple pathways of inflammation. This observed activity suggests a number of possible initial clinical indications for EDP1867, including TH2-dependent inflammation which underlies atopic diseases and a large spectrum of asthma. We initiated our first Phase 1b clinical trial of EDP1867 in healthy volunteers and patients with moderate atopic dermatitis in February 2021 and expect to report interim data in the fourth quarter of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EDP2939</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EDP2939 is an extracellular vesicle (EV) investigational oral biologic being developed for the treatment of inflammatory diseases. In May 2021, we presented preclinical data for EDP2939 at the American Association of Immunologists Meeting.  EDP2939 is the first EV product candidate we have nominated in our inflammation program and we anticipate initiation of clinical development in 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EDP1908</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we announced EDP1908 as our lead candidate in oncology following presentation of preclinical data at the Society for Immunotherapy for Cancer meeting in November 2020. Preclinical data presented showed that orally administered EDP1908, an EV, resulted in superior tumor growth control versus the parent microbial strain or anti-PD-1 therapy, with an observed dose-dependent reduction in tumor growth. We anticipate initiation of clinical development in 2022. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we announced a strategic collaboration to develop and commercialize our lead inflammation product candidate, EDP1815, in the Middle East, Turkey, and Africa with Meddist Company Limited ("ALJ"), a company focused on accelerating access to affordable modern medical care while addressing unmet medical needs in developing markets around the world. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Together, we and ALJ will work to address the significant disparity in access to medical care in the fastest-growing populations and growth economies of the developing world. Africa&#8217;s population is projected to reach 1.7 billion by 2030 and 2.5 billion by 2050.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we received an upfront payment from ALJ. We will be primarily responsible for the development and manufacturing of EDP1815 worldwide, whilst ALJ will be primarily responsible for development, regulatory submissions and commercialization activities in the agreed-upon regions. ALJ and we will participate in a 50:50 profit share arrangement. See Note 3 of the notes to our unaudited condensed consolidated condensed financial statements in this Quarterly Report on Form 10-Q for additional information regarding the commercialization and license agreement with ALJ.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our incorporation in 2014, we have devoted substantially all of our resources to developing our clinical and preclinical candidates, building our intellectual property portfolio and process development and manufacturing function, business planning, raising capital and providing general and administrative support for these operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a development stage company and have not generated any revenue. All of our product candidates are in early clinical or preclinical development. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Since our inception, we have incurred significant operating losses and we continue to incur significant research and development and other expenses related to our operations. For the six months ended June 30, 2021, our net loss was $59.8 million. As of June 30, 2021, we had an accumulated deficit of $352.3 million. We do not expect to generate revenue from sales of any products for the foreseeable future, if at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our expenses will increase substantially in connection with our ongoing activities, particularly as we:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the ongoing trials for EDP1815 and EDP1867;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate additional clinical trials for EDP1815;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate or advance the clinical development of any additional product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct research and continue preclinical development of potential product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make strategic investments in manufacturing capabilities, including potentially planning and building our own manufacturing facility;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain our current intellectual property portfolio and opportunistically acquire complementary intellectual property;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase employees and employee-related expenses including salaries, benefits, travel and stock-based compensation expense; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to obtain regulatory approvals for our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we will need additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our inability to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenue to achieve profitability, and we may never do so.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months and six months ended June 30, 2021, pursuant to the June 2019 sales agreement with Cowen and Company, LLC, we sold no shares and 139,734 shares of our common stock, respectively, in &#8220;at-the-market&#8221; offerings under a registration statement on Form S-3 that we previously filed with the SEC with offering prices ranging between $12.54 to $13.17 per share for gross proceeds of $1.8 million and net proceeds of $1.7 million, after deducting commission and other offering expenses payable by us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we sold 5,175,000 shares of our common stock, which includes the underwriters' exercise of their option to purchase 675,000 shares to cover the over-allotment, in an underwritten public offering at a public offering price of $15.00 per share, generating gross proceeds of $77.6 million and net proceeds of underwriting discounts and commission of $72.7 million, after deducting underwriting discounts and commission and other offering expenses paid by us. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in February 2021, ALJ Health Care purchased $7.5 million of our common stock in a private placement at a purchase price of $15.00 per share, equal to the public offering price per share at which our common stock was sold to the public as referred above. The sale of such shares was not registered under the Securities Act.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we amended our loan and security agreement with K2 HealthVentures LLC and others (collectively, "K2HV") </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to, among other things, replace and supersede the existing $</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.0 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third tranche commitment with a new </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.0 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fourth tranche commitment, which we drew down on June 16, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (as amended, the &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amended Credit Facility&#8221;). The aggregate principal borrowings available under the Amended Credit Facility is $45.0 million. Pursuant to the Amended Credit Facility, we issued to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">K2 HealthVentures Equity Trust LLC, an affiliate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">K2HV, a warrant to purchase up to 139,770 shares of our common stock with an exercise price of $13.30 per share, subject to customary per share adjustments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Amended Credit Facility, K2HV has the option, exercisable at any time, to convert up to $5.0 million of principal outstanding into shares of our common stock at a conversion price of $13.30 per share, subject to customary per share adjustments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See &#8220;&#8212;Liquidity and Capital Resources&#8212;Debt financing."</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, our principal source of liquidity is cash and cash equivalents, which totaled approximately $123.3 million dollars. Based on our current operating plan, our existing cash and cash equivalents as of June 30, 2021 will be sufficient to enable us to fund operating expenses and capital expenditure requirements to late Q3&#8217;2022. Funds for Phase 3 clinical trials are not included in our forecast. We have based these estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. See &#8220;Liquidity and Capital Resources."</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products in the near future, if at all. As discussed in Note 3 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, we have entered into a collaboration agreement that will result in the recognition of $7.5 million of revenue upon regulatory approval of EDP1815 in certain designated markets. If our development efforts for our current product candidates or additional product candidates that we may develop in the future are successful and result in marketing approval or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from such collaboration or license agreements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses since inception have consisted primarily of research and development activities and general and administrative costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, which include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with third parties, including investigative sites, external laboratories and CROs that conduct research, preclinical activities and clinical trials on our behalf;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing process-development costs as well as technology transfer and other expenses incurred with CMOs that manufacture drug substance and drug product for use in our preclinical activities and any current or future clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">salaries, benefits and other related costs, including stock-based compensation expense, for personnel in our research and development functions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses to acquire technologies to be used in research and development;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of outside consultants, including their fees, stock-based compensation and related travel expenses;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to compliance with regulatory requirements; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility-related expenses, which include depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors and our clinical investigative sites. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid or accrued research and development expenses. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized when there is no alternative future use for the research and development. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary focus of research and development since inception has been building a platform to enable us to develop medicines based on an understanding that cells in the small intestine play a central role in governing the immune, metabolic and neurological systems and to show potential clinical utility. Our platform and program expenses consist principally of costs, such as preclinical research, clinical and preclinical manufacturing activity costs, clinical development costs, licensing expenses as well as an allocation of certain indirect costs, facility costs </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and depreciation expense. We do not allocate personnel costs, which primarily include salaries, discretionary bonus and stock-based compensation costs, as such costs are separately classified as research and development personnel costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase in the foreseeable future as we continue to implement our business strategy, continue our ongoing clinical trials for our product candidates, including EDP1815 and EDP1867, initiate additional clinical trials for EDP1815, continue to discover and develop additional product candidates, seek regulatory approvals for any products that successfully complete clinical trials, build manufacturing capabilities, hire additional research and development personnel, and expand into additional therapeutic areas.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from sales or licensing of our product candidates. This is due to the numerous risks and uncertainties associated with drug development, including the uncertainty of:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to add and retain key research and development personnel;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize, our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our successful enrollment and completion of clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delays in clinical trials as a result of the COVID-19 pandemic;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with the development of our current product candidates and/or any additional product candidates we identify in-house or acquire through collaborations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to discover, develop and utilize biomarkers to demonstrate target engagement, pathway engagement and the impact on disease progression of our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish an appropriate safety profile with IND-enabling toxicology studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain agreements with CMOs and other entities for clinical trial supply and future commercial supply, if our product candidates are approved;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any collaboration, license or other arrangement, including the terms and timing of any milestone payments thereunder;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain patent, trade secret and other intellectual property protection and regulatory exclusivity for our product candidates if and when approved;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to commercialize products, if and when approved, whether alone or in collaboration with others; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continued acceptable safety profiles of the product candidates following approval.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in any of these variables with respect to the development of any of our product candidates would significantly change the costs, timing and viability associated with the development of that product candidate. We expect our research and development expenses to increase at least over the next several years as we continue to implement our business strategy, advance our current programs, expand our research and development efforts, seek regulatory approvals for any product candidates that successfully complete clinical trials, identify and develop additional product candidates and incur expenses associated with hiring additional personnel to support our research and development efforts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel in our executive, finance, corporate and business development, and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; other professional fees for accounting, auditing, tax and administrative consulting services; insurance costs; administrative travel expenses; and facility-related expenses, which include depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support the expected growth in our research and development activities and the potential commercialization of our product candidates. We also expect to continue to incur increased expenses associated with being a public company, including increased costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance costs and investor and public relations costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, Net</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net primarily consists of interest expense incurred on our debt offset by interest earned on our cash, and cash equivalents. During each of the three and six months ended June 30, 2021 and 2020, interest expense, net consisted primarily of interest at the stated rate on borrowings under our loan and security agreements and amortization of deferred financing costs and interest expense related to the accretion of debt discount offset by interest earned on institutional money market instruments and U.S. treasury securities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">         </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on Extinguishment of Debt</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt for three and six months ended June 30, 2021 reflects the difference between</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the reacquisition cost of the new debt, inclusive of the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair value of the Warrant and lender fees, and the carrying amount of the existing debt. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This is a non-cash item.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">         Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net for the three and six months ended June 30, 2021 and 2020 primarily consists of foreign currency gains and government grants related to our operations in the United Kingdom.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense for the three and six months ended June 30, 2021 and 2020 reflects the provision for income taxes at our wholly owned UK subsidiary.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2014, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or our earned research and development tax credits, due to our uncertainty of realizing a benefit from those items.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended June 30, 2021 and 2020</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended June 30, 2021 and 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"></td><td style="width:37.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.653%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,656&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,245&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,411&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,656)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,245)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(458)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(356)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,889)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,571)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,563)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,982)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,598)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,652)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,946)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:48.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammation programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,015)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development personnel costs (including stock-based compensation)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,174&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $20.7 million for the three months ended Jun 30, 2021, compared to $15.2 million for the three months ended Jun 30, 2020. The increase of $5.5 million was primarily driven by $4.2 million for higher inflammation program costs from the progression of EDP1815 into two Phase 2 studies, and additional EDP1815 Psoriasis and Atopic Dermatitis and EDP1867 Phase 1b studies, partially offset by the closeout of the EDP1066 program. In addition, there were higher personnel costs of $1.7 million primarily due to headcount growth in clinical development and technical operations functions and higher platform expenses of $0.6 million  primarily driven by timing of preclinical studies and general lab related spend, which were partially offset by $1.0 million decrease in our oncology programs primarily related to the wind down of the EDP1503 program. Overall, we expect that our research and development expenses will continue to increase in the foreseeable future as we continue our clinical trials for our product candidates, including EDP1815 and EDP1867, initiate new clinical trials, expand into additional therapeutic areas, continue discovery and development efforts for additional product candidates, hire additional research and development personnel, and seek to increase manufacturing capabilities.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"></td><td style="width:40.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative personnel costs (including stock-based compensation)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility costs, office expense and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,001&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative expenses were $7.0 million for the three months ended June 30, 2021, compared to $5.1 million for the three months ended June 30, 2020.  The increase of $1.9 million was primarily driven by $1.5 million increase in personnel expenses to support our expanded R&amp;D business needs, as well as additional investment in facility, office and other employee related expenses.  We expect general and administrative expenses to increase due to higher personnel and related costs, professional, legal, and patent fees and consulting expenses in support of our continued growth.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Other Expense, Net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income, net for the three months ended June 30, 2021 was expense of $3.9 million compared to income of $0.3 million for the three months ended June 30, 2020. The $3.6 million increase in other expenses was primarily driven by a non-cash loss on extinguishment of debt of $3.2 million related to entry into the Amended Credit Facility in June 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the three months ended June 30, 2021 was $31.6 million, compared to $20.7 million for the three months ended June 30, 2020. The increase of $10.9 million  was primarily the result of the increases in research and development expenses, general and administrative expenses and decrease in total other income, net discussed above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Six Months Ended June 30, 2021 and 2020</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the six months ended June 30, 2021 and 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,127&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,506&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,621&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,127)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,506)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,621)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,579)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(940)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,492)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,459)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,619)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,539)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,080)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,794)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,693)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,101)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:37.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.462%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammation programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development personnel costs (including stock-based compensation)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,163&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $42.2 million for the six months ended June 30, 2021, compared to $32.6 million for the six months ended June 30, 2020. The increase of $9.6 million was primarily driven by $8.0 million in higher inflammation program costs from the progression of EDP1815 into two Phase 2 studies, additional EDP1815 Psoriasis and Atopic Dermatitis and EDP1867 Phase 1b studies, partially offset by the closeout of the EDP1066 program. In addition, there were higher personnel costs of $3.2 million primarily due to headcount growth in clinical development and technical operations functions, These increases were partially offset by $1.4 million decrease in our oncology programs primarily related to the wind down of the EDP1503 program and a $0.3 million decrease for platform expenses primarily driven by timing of preclinical studies and general lab related spend.  Overall, we expect that our research and development expenses will continue to increase in the foreseeable future as we continue our clinical trials for our product candidates, including EDP1815 and EDP1867, initiate new clinical trials, expand into additional therapeutic areas, continue discovery and development efforts for additional product candidates, hire additional research and development personnel, and seek to increase manufacturing capabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"><tr><td style="width:1.0%"></td><td style="width:42.287%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.967%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative personnel costs (including stock-based compensation)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility costs, office expense and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,964&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,913&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,051&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $13.0 million for the six months ended June 30, 2021, compared to $10.9 million for the six months ended June 30, 2020. The increase of $2.1 million was primarily driven by $2.0 million personnel costs increase to support expanded R&amp;D business needs. We expect general and administrative expenses to increase due to higher personnel and related costs, professional, legal, and patent fees and consulting expenses in support of our continued growth.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Other Expense, Net</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income, net for the six months ended June 30, 2021, was expense of $4.5 million compared to expense of less than $0.1 million for the six months ended June 30, 2020. The $4.5 million increase in other expenses was primarily driven by (i) a non-cash loss on extinguishment of debt of $3.2 million related to the entry into the Amended Credit Facility (ii) a decrease in interest income as a result of lower interest rates and an increase in interest expense as a result of a greater principal balance from the Amended Credit Facility , and (iii) a decrease in foreign currency gains  and a grant related to our operations in the United Kingdom.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the six months ended June 30, 2021 was $59.8 million, compared to $43.7 million for the six months ended June 30, 2020. The increase of $16.1 million was primarily the result of the increases in research and development expenses, general and administrative expenses and decrease in total other income, net discussed above.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred losses and generated negative operating cash flows since our inception and anticipate that we will continue to incur losses for at least the next several years. We incurred net losses of approximately $59.8 million and $43.7 million for the six months ended June 30, 2021 and 2020, respectively. To date, we have financed our operations primarily with proceeds from public and private offerings of our common stock, sales of our convertible preferred stock to our equity investors and borrowings under our debt facilities. From our inception through June 30, 2021, we have received gross proceeds of $429.7 million from such transactions, including a net $45.0 million borrowed under our debt facilities. As of June 30, 2021, we had cash and cash equivalents of $123.3 million and an accumulated deficit of $352.3 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months and six months ended June 30, 2021, pursuant to the June 2019 sales agreement with Cowen, we sold no shares and 139,734 shares of our common stock, respectively, in &#8220;at-the-market&#8221; offerings under a registration statement on Form S-3 that we previously filed with the SEC with offering prices ranging between $12.54 to $13.17 per share for gross proceeds of $1.8 million and net proceeds of $1.7 million, after deducting commission and other offering expenses payable by us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2021, we sold 5,175,000 shares of our common stock in an underwritten public offering at a public offering price of $15.00 per share, including the underwriters' exercise of their option to purchase 675,000 shares to cover over-allotment, generating gross proceeds of $77.6 million and net proceeds of $72.7 million, after deducting underwriting discounts and commission and other offering expenses paid by us. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2021, ALJ Health Care purchased $7.5 million of our common stock in a private placement at a purchase price of $15.00 per share, equal to the public offering price per share at which our common stock was sold to the public as referred above. The sale of such shares was not registered under the Securities Act. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">        Debt financing</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2019 we entered into the 2019 Credit Facility with K2HV providing for up to $45.0 million of current and future potential debt financing. The aggregate principal amount was available in three tranches of term loans of $20.0 million, $10.0 million, and $15.0 million, respectively. At closing on July 19, 2019, we borrowed $20.0 million, representing the first tranche under the 2019 Credit Facility. On July 14, 2020, we drew down the second tranche of $10.0 million and availability of the third tranche expired on January 15, 2021. Interest on the outstanding loan balance will accrue at a variable rate equal to the greater of (i) 8.65% and (ii) the prime rate as published in the Wall Street Journal, plus 3.15%.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021, or the Amended Credit Facility Effective Date, we entered into the Amended Credit Facility with K2HV, pursuant to which (i) the existing $15.0 million third tranche commitment was replaced and superseded with a new $15.0 million fourth tranche commitment, which we drew down on June 16, 2021, (ii) K2HV may convert up to $5.0 million of outstanding principal of the Loans (as defined in the 2019 Credit Facility) into shares of our common stock, (iii) the interest-only period is extended through February 28, 2023, with the first amortization payment on March 1, 2023, (iv) prior to January 1, 2022, at our election, the amortization schedule can be adjusted to be based on a 30-month repayment period, and if so adjusted, upon final payment or prepayment of the loans, we must pay a final payment equal to 4.8% of the loans borrowed, and (v) at our election, we may prepay the loans, subject to a prepayment fee of 2% of the amount prepaid if such prepayment occurs no later than the 18-month anniversary of the Amended Credit Facility Effective Date, or if the prepayment occurs after the 18-month anniversary of the Amended Credit Facility Effective Date but prior to the maturity date 1% of the amount prepaid. All of the other terms and conditions of the 2019 Credit Facility remain unchanged and in full force and effect.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our existing cash and cash equivalents as of June 30, 2021 will enable us to fund our planned operating expenses and capital expenditure requirements into the late third quarter of 2022. Funds for Phase 3 clinical trials are not included in our forecast.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate revenue from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings and potential collaborations, license and development agreements. To the extent that we raise additional capital through future equity offerings or debt financings, ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of the common stockholders. Debt and equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. There can be no assurance that such financings will be obtained on terms acceptable to us, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us we may have to significantly delay, scale back or discontinue our research and development programs or future commercialization efforts. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties for one or more of our current or future drug candidates, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates or to grant licenses on terms that may not be favorable to us. Our failure to raise capital as and when needed would have a material adverse effect on our financial condition and our ability to pursue our business strategy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash for each of the periods presented (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,712)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,891)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,147)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(645)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,476&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,340&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the six months ended June 30, 2021 was $41.7 million driven primarily by our net loss of $59.8 million. This was partially offset by non-cash charges including an extinguishment loss of $3.2 million, stock-based compensation expense of $7.0 million, non-cash lease expense of $0.9 million, depreciation expense of $1.1 million, non-cash interest expense of $0.2 million and changes in components of working capital. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the six months ended June 30, 2020 was $35.9 million driven primarily by our net loss of $43.7 million. This was partially offset by non-cash charges including stock-based compensation expense of $4.0 million, non-cash lease expense of $1.1 million, depreciation expense of $1.0 million, non-cash interest expense of $0.1 million and changes in components of working capital.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the six months ended June 30, 2021 was $1.1 million, driven by the  purchase of capital equipment totaling $1.1 million during the period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the six months ended June 30, 2020 was $0.6 million, primarily consisting of the purchase of capital equipment which totaled $0.6 million during the period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the six months ended June 30, 2021 was $97.3 million, consisting of proceeds from the issuance of common stock, net of issuance costs totaling $81.9 million, net proceeds from the issuance of long-term debt totaling $14.8 million, and proceeds from the issuance of common stock under the ESPP and the exercise of stock options totaling $0.7 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the six months ended June 30, 2020 was $48.9 million, consisting of proceeds from the issuance of common stock, net of issuance cost totaling $48.6 million and proceeds from the exercise of stock option totaling $0.2 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and are not required to provide this information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of recently adopted or issued accounting pronouncements please refer to Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities in our unaudited condensed consolidated financial statements, as well as the reported revenues and expenses during the reporting periods. These items, including estimates related to the application of ASC 606 to our collaboration agreement with ALJ, application of ASC 480, Distinguishing Liabilities from Equity and ASC 815, Derivatives and Hedging to our K2HV debt and warrants, accrued research and development expenses and stock-based compensation, are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates under different assumptions or conditions. In making estimates and judgments, management employs critical accounting policies.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our critical accounting policies during the three and six months ended June 30, 2021 from those described in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; included in our Annual Report on&#160;Form&#160;10-K&#160;that was filed with the SEC on March&#160;9, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="ie2e49401044149ec86a5cefe42299a79_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide this information.</span></div><div id="ie2e49401044149ec86a5cefe42299a79_82"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in management&#8217;s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act that occurred during the most recent financial quarter covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="ie2e49401044149ec86a5cefe42299a79_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="ie2e49401044149ec86a5cefe42299a79_88"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceeding</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in claims and proceedings arising in the course of our business. The outcome of any such claim or proceeding, regardless of the merits, is inherently uncertain. We are not subject to any material legal proceedings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, the European Patent Office issued a Communication of a Notice of Opposition for European patent EP 3223834, which is held by us. In July 2021, we filed our reply to the Notice of Opposition. The patent at issue does not relate to any of our current product candidates, and any subsequent proceeding is not expected to affect any of our current development plans. </span></div><div><span><br/></span></div><div id="ie2e49401044149ec86a5cefe42299a79_91"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and the related notes and Part I, Item 2. &#8220;Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition&#8221; and in our 2020 Annual Report on Form 10-K filed with the SEC on March 9, 2021, including our consolidated financial statements and the related notes thereto, before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a development-stage company and have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant operating losses. Our net loss was $59.8 million and $43.7 million for the six months ended June 30, 2021, and 2020, respectively. Our net loss was $93.7 million and $85.5 million for the years ended December 31, 2020 and 2019, respectively. As of June 30, 2021, we had an accumulated deficit of $352.3 million. Through June 30, 2021, we have financed our operations through private placements of our preferred stock, borrowings under loan and security agreements and proceeds from equity offerings of our common stock. We have devoted substantially all of our financial resources and efforts to developing our platform, identifying potential product candidates and conducting preclinical and clinical trials. We are in the early stages of developing our product candidates, and we have not completed the development of any product candidate. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase substantially as we:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to enhance our platform and discover and develop additional product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any products for which we may obtain regulatory approval;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts and to support our operations as a public company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we anticipate that our expenses will increase substantially if we experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">completing preclinical testing and clinical trials of our product candidates, discovering additional product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product and biological product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) or other regulatory authorities to perform preclinical studies or clinical trials in addition to those currently expected, or if there are any delays in completing our preclinical studies or clinical trials or the development of any of our product candidates, our expenses could increase and revenue could be further delayed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress our value and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or even continue our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need additional funding in order to complete development of our product candidates and commercialize our products, if approved. If we are unable to raise capital when needed, we could be forced to delay, reduce or discontinue our product development programs or commercialization efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct clinical trials, build manufacturing capacity and expand into additional therapeutic areas.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our existing cash and cash equivalents as of June 30, 2021, will enable us to fund our planned operating expenses and capital expenditure requirements into late third quarter of 2022. Funds for Phase 3 clinical trials are not included in our forecast. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the progress and results of any ongoing and future clinical trials;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the cost of manufacturing clinical supplies of our product candidates, including EDP1815, EDP1867,</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;EDP2939 and EDP1908;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any other future product candidates;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the costs and timing of future commercialization activities, including manufacturing, marketing, sales and &#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the revenue, if any, received from commercial sales of our product candidates for which we receive </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing approval;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intellectual property rights and defending any intellectual property-related claims;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the effect of competing technological and market developments; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the extent to which we acquire or invest in businesses, products and technologies, including entering into </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">licensing or collaboration arrangements for product candidates, although we currently have no &#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commitments or agreements to complete any such transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financing will be available in sufficient amounts or on terms acceptable to us, if at all. Additionally, market volatility resulting from the COVID-19 pandemic or other factors could also adversely impact our ability to access capital as and when needed. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity, including any shares subject to the Warrant issued in connection with the Amended Credit Facility, or of convertible securities, would dilute all of our stockholders. The occurrence of additional indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay, or discontinue one or more of our research or product development programs or the commercialization of any product candidates or cease our operations. In addition, we may be unable to make milestone and royalty payments due under our intellectual property license agreements or other payments under our agreements with CROs and academic research collaborators, or expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our limited operating history may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2014, we have devoted substantially all of our resources to identifying and developing our product candidates, building our intellectual property portfolio, process development and manufacturing function, planning our business, raising capital and providing general and administrative support for these operations. All of our product candidates are in clinical or preclinical development. We have not yet demonstrated our ability to successfully complete a Phase 2 clinical trial or a Phase 3 or other pivotal clinical trial, obtain regulatory approvals to commercialize a product, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Additionally, we expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The terms of our loan and security agreements place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Amended Credit Facility with K2HV for $45.0 million is secured by a lien covering substantially all of our personal property, excluding intellectual property. Contemporaneous with the closing of the first tranche of funding under the 2019 Credit Facility, we repaid the entire $15.0 million loan balance outstanding under our prior loan and security agreement with Pacific Western Bank. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021, or the Amended Credit Facility Effective Date, we entered into the Amended Credit Facility with K2HV, pursuant to which (i) the existing $15.0 million third tranche commitment was replaced and superseded with a new $15.0 million fourth tranche commitment, which we drew down on June 16, 2021, (ii) K2HV may convert up to $5.0 million of outstanding principal of the Loans (as defined in the Amended Credit Facility) into shares of our common stock, (iii) the interest-only period is extended through February 28, 2023, with the first amortization payment on March 1, 2023, (iv) prior to January 1, 2022, at our election, the amortization schedule can be adjusted to be based on a 30-month repayment period, and if so adjusted, upon final payment or prepayment of the loans, we must pay a final payment equal to 4.8% of the aggregate original principal amount of the loans borrowed, and (v) at our election, we may prepay the loans, subject to a prepayment fee of 2% of the amount prepaid if such prepayment occurs no later than the 18-month anniversary of the Amended Credit Facility Effective Date, or if the prepayment occurs after the 18-month anniversary of the Amended Credit Facility Effective Date but prior to the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maturity date 1% of the amount prepaid. All of the other terms and conditions of the 2019 Credit Facility remain unchanged and in full force and effect.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, the outstanding principal balance under the Amended Credit Facility was $45.0 million. The Amended Credit Facility contains customary representations, warranties, affirmative and negative covenants and events of default applicable to us and our subsidiaries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we default under the Amended Credit Facility, K2HV may accelerate all of our repayment obligations and exercise all of their rights and remedies under the Amended Credit Facility and applicable law, potentially requiring us to renegotiate our agreement on terms less favorable to us or to immediately cease operations. Further, if we are liquidated, the lenders&#8217; right to repayment would be senior to the rights of the holders of our common stock to receive any proceeds from the liquidation. K2HV could declare a default upon the occurrence of any event, among others, that they interpret as a material adverse effect or a change of control as delineated under the Amended Credit Facility, payment defaults, or breaches of covenants thereby requiring us to repay the loan immediately or to attempt to reverse the declaration of default through negotiation or litigation. Any declaration by the lenders of an event of default could significantly harm our business and prospects and could cause the price of our common stock to decline. If we raise any additional debt financing, the terms of such additional debt could further restrict our operating and financial flexibility.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are very early in our development efforts and may not be successful in our efforts to use our platform to build a pipeline of product candidates and develop marketable drugs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are using our technology platform to harness the small intestinal axis, with an initial focus on developing therapies in immunology, specifically inflammatory diseases, and also oncology. While we believe our preclinical studies and clinical trials to date have validated our platform to a degree, we are at an early stage of development and our platform has not yet, and may never lead to, approvable or marketable products. We are developing these product candidates and additional product candidates that we intend to use to treat broader immunological diseases, respiratory diseases, neuro-inflammation and degeneration, liver diseases, type I diabetes, food allergy, neurobehavior, cardiovascular disease and diseases of metabolism. We may have problems applying our technologies to these other areas, and our new product candidates may not demonstrate a comparable ability in treating disease as our initial product candidates. Even if we are successful in identifying additional product candidates, they may not be suitable for clinical development as a result of our inability to manufacture more complex oral biologics, limited efficacy, unacceptable safety profiles or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. The success of our product candidates will depend on several factors, including the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of preclinical studies and clinical trials with positive results;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making arrangements with CMOs, or establishing our own, commercial manufacturing capabilities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entering into new collaborations throughout the development process as appropriate, from preclinical studies through to commercialization;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our products, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with other therapies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining coverage and adequate reimbursement by third-party payors, including government payors, for our products, if approved;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protecting our rights in our intellectual property portfolio;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating without infringing or violating the valid and enforceable patents or other intellectual property of third parties;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining an acceptable safety profile of the products following approval; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining and growing an organization of scientists and business people who can develop and commercialize our products and technology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not successfully develop and commercialize product candidates based upon our technological approach, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are intended to act on cells in the small intestine to produce systemic therapeutic effects with limited systemic exposure. This biological interaction between the small intestine and the rest of the body may not function in humans the way we have observed in mice and our drugs may not reproduce the systemic effects we have seen in preclinical data.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our product candidates, including EDP1815, EDP1867, EDP2939 and EDP1908 have the potential to work by modulating systemic responses via interactions with cells in the small intestine. Dosing to achieve sufficient exposure may require an inconvenient dosing regimen. Even with successful formulation and delivery to achieve proper exposure of our microbes to the small intestine, we may not get sufficient or even any activity at the site of disease. This may be because our understanding of the mechanisms of the small intestine do not work in humans the way we believe they do. Despite there being strong academic literature to support the concept and our observations in preclinical studies in mice, these principles and the ability to use pharmaceutical preparations derived from single strains of microbes to modulate the immune system and other systems has not yet been proven in humans.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are an unproven approach to therapeutic intervention.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are based on targeting SINTAX. We have not, nor to our knowledge has any other company, received regulatory approval for an oral therapeutic based on this approach. We cannot be certain that our approach will lead to the development of approvable or marketable products. In addition, our product candidates may have different safety profiles and efficacy in various indications. Finally, the FDA or other regulatory agencies may lack experience in evaluating the safety and efficacy of products based on singe strains of microbes, which could result in a longer than expected regulatory review process, increase our expected development costs and delay or prevent commercialization of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our platform relies on third parties for biological materials to expand our microbial library.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platform relies on third parties for biological materials, including human samples containing bacteria, to expand our microbial library. Some biological materials have not always met our expectations or requirements, and any disruption in the supply of these biological materials could materially adversely affect our business and ability to build our pipeline of product candidates. For example, if any supplied biological materials are contaminated, we would not be able to use such biological materials. Although we have quality control processes and screening procedures, biological materials are susceptible to damage and contamination. Improper storage of these materials, by us or any third-party suppliers, may require us to destroy some of our raw materials or products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our product candidates do not cause off target adverse events, there may be immunotoxicity associated with the fundamental pharmacology of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates, including EDP1815, EDP1867, EDP2939 and EDP1908 are designed to work by modulating the immune system. While we have observed in preclinical studies that our product candidates have limited systemic exposure, the pharmacological immune effects we induce are systemic. Systemic immunomodulation from taking our product candidates could lead to immunotoxicity in patients, which may cause us or regulatory authorities to delay, limit or suspend clinical development. Other immunomodulatory agents have shown immunotoxicity. This includes immune suppressive agents, such as HUMIRA or REMICADE, which have shown an increased risk of infection or in rare instances certain types of blood cancer. In the case of immune activating agents, such as YERVOY, induction of adverse auto-immune events has been observed in some patients. Immunotoxicity in one program could cause regulators to view these adverse events as a class effect of our product candidates which may impact the timing of the development of our pipeline of potential product candidates. Even if the adverse events are manageable, the profile of the drug may be such that it limits or diminishes the possible number of patients who could receive our therapy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. For example, some of our product candidates may consist of live biological material that may remain viable in humans, which carries a risk of causing infections in patients. Some infections may require treatment with antibiotics to eliminate the bacteria. All our product candidates are screened for antibiotic sensitivity but it is possible that if antibiotic therapy does not eliminate the live biological material, a resistant version of our strain could remerge. These events, while unlikely, could cause a delay in our clinical development and/or could increase the regulatory standards for the entire class of our product candidates. In an instance where the infection risk of taking our product candidates is high, this may cause the benefit risk profile of therapy to be non-competitive in the market and may lead to discontinuation of development of the product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, it is possible that infections from our product candidates could be rare and not frequently observed in our clinical trials. In larger post marketing authorization trials, however, data could show that the infection risk, while small, does exist. If unacceptable side effects arise in the development of our product candidates, we, the FDA, comparable foreign regulatory authorities, the IRBs at the institutions in which our clinical trials are conducted or the data safety monitoring board could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;regulatory authorities may withdraw their approval of the product;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;we may be required to recall a product or change the way such product is administered to patients;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;additional restrictions may be imposed on the marketing of the particular product or the manufacturing  &#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">processes for the product or any component thereof;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;we may be required to conduct post-marketing studies or clinical trials;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;regulatory authorities may require the addition of labeling statements, such as a &#8216;&#8216;black box&#8217;&#8217; warning or a </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contraindication;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;we may be required to implement a risk evaluation and mitigation strategy or create a medication guide </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outlining the risks of such side effects for distribution to patients;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;we could be sued and held liable for harm caused to patients;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the product may become less competitive; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;our reputation may suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues to us, which would materially and adversely affect our results of operations and business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Companies with microbiome products or differing microbial products may produce negative clinical data which will adversely affect public perception of our product candidates, and may negatively impact regulatory approval of, or demand for, our potential products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are pharmaceutical compositions of commensal microbes. While we believe our approach is distinct from microbiome therapies, negative data from clinical trials using microbiome-based therapies (e.g., fecal transplant) and other microbial therapies could negatively impact the perception of the therapeutic use of microbial-based products. This could negatively impact our ability to enroll patients in clinical trials. The clinical and commercial success of our potential products will depend in part on the public and clinical communities&#8217; acceptance of the use of therapeutic microbes. Moreover, our success depends upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events in our preclinical studies or clinical trials or those of our competitors or of academic researchers utilizing therapeutic microbes, even if not ultimately attributable to our product candidates, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our potential product candidates, stricter labeling requirements for our product candidates that are approved, if any, and a decrease in demand for any such products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Catastrophic loss of our master cell banks could significantly impair our ability to manufacture our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates require that we manufacture from master cell banks ("MCBs") of our microbial strains. There is a possibility of a catastrophic failure or destruction of our MCBs. This could make it impossible for us to continue to manufacture a specific product. Recreating and recertifying our MCBs is possible but not certain and could put at risk the supply of our product candidates for preclinical studies or clinical trials or any products, if approved, to our customers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are currently in clinical or preclinical development. It is impossible to predict when or if any of our product candidates will prove effective and safe in humans or will receive regulatory approval, and the risk of failure through the product development process is high. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failed clinical trial can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. For example, in our clinical trials, investigational drug products are being delivered in a capsule for targeted release in the small intestine. This formulation has not previously been clinically tested, nor are we able to dose mice with a capsule for targeted release in the small intestine. Our ongoing clinical trials will be the first time this formulation is tested, and we cannot assure you that the results of this formulation will be consistent with the observations from our preclinical studies. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to adverse safety profiles or lack of efficacy, notwithstanding promising results in earlier trials, and we cannot be certain that we will not face similar setbacks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results from early clinical trials of product candidates may not predict the results that will be obtained in subsequent subjects or in subsequent human clinical trials of that product candidate. There can be no assurance that any trial will ultimately be successful or support further clinical advancement of any given product candidate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we cannot be certain as to the type and number of clinical trials the FDA will require us to conduct before we may successfully gain approval, referred to as licensure with respect to biological products in the United States, to market any of our product candidates. Requirements for us to conduct more clinical trials than we anticipate for a given product candidate could cause us to incur significant development costs, delay or prevent the commercialization of our products or otherwise adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;regulators, IRBs or ethics committees may not authorize us or our investigators to commence a clinical trial </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or conduct a clinical trial at a prospective trial site;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trial protocols with prospective trial sites;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;clinical trials of our product candidates may demonstrate undesirable side effects or produce negative or </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">abandon product development programs;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the number of patients required for clinical trials of our product candidates may be larger than we anticipate, </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enrollment in these clinical trials may be lower or slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;our CROs, CMOs and other third-party contractors may fail to comply with regulatory requirements or meet </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their contractual obligations to us in a timely manner, or at all;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;we may have to, or regulators or IRB may require, that we or our investigators, suspend </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or terminate clinical trials of our product candidates for various reasons, including noncompliance with </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates may be insufficient or inadequate;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;regulators may revise the requirements for approving our product candidates, or such requirements may not </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be as we anticipate; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;regarding trials managed by any future collaborators, our collaborators may face any of the above issues, </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and may conduct clinical trials in ways they view as advantageous to them but potentially suboptimal for us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be delayed in obtaining marketing approval for our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lose the support of any future collaborators, requiring us to bear more of the burden of developing certain microbial strains;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not obtain marketing approval at all;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain marketing approval in some countries and not in others;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval for indications or patient populations that are not as broad as we intend or desire;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to additional post-marketing testing requirements; or</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have the product removed from the market after obtaining marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will increase if we experience delays in clinical testing or in obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. For example we are developing certain product candidates, such as EDP1815 and EDP1867, to treat inflammatory diseases including psoriasis and atopic dermatitis. There are a limited number of patients from which to draw for clinical trials concerning any given indication.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is also affected by other factors including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity of the disease under investigation;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient eligibility criteria for the trial in question;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perceived risks and benefits of the product candidate under study;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of other treatments for the disease under investigation;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the existence of competing clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our payments for conducting clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient referral practices of physicians;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to monitor patients adequately during and after treatment; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity and availability of clinical trial sites for prospective patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll a sufficient number of patients or volunteers for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic has adversely impacted and may continue to adversely impact our business, including our preclinical studies and clinical trials, and finances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, a strain of novel coronavirus disease, COVID-19, was declared a pandemic and spread across the world, including throughout the United States, Europe and Asia. The pandemic and government measures taken in response have had and continue to have a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred, supply chains have been disrupted, facilities and production have been suspended, and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. In response to the spread of COVID-19, we have adopted and continue to employ several temporary business practices, including telecommuting and staggered work shifts in our laboratories, to protect our employees while continuing business operations. In addition, due to the COVID-19 pandemic, enrollment of new patients into, and the retention of existing patients in, our on-going clinical trials have been and continue to be impacted, due primarily to lower patient participation. As a result of the COVID-19 pandemic, we may continue to experience disruptions and face new disruptions that could severely impact our business, preclinical studies and clinical trials, and finances including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;delays or difficulties in enrolling patients in our clinical trials;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical site staff;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interruptions in global shipping that may affect the transport of clinical trial materials;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;changes in local regulations as part of a response to the COVID-19 pandemic which may require us to </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discontinue such clinical trials altogether;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;interruptions of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">travel imposed or recommended by governments, employers and others or interruption of clinical trial </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject visits and study procedures (such as skin biopsies that are deemed non-essential activities), which may impact the integrity of subject data and clinical trials endpoints;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;risk that participants enrolled in our clinical trials will contract COVID-19 while the clinical trial is ongoing, </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which could impact the results of the clinical trial, including by increasing the number of observed adverse &#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">events;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;interruptions or delays in the operations of the FDA and similar regulatory authorities, which may impact review and approval </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timelines;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;interruptions of, or delays in receiving, supplies of our product candidates from our CMOs due to staffing </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shortages, production slowdowns or stoppages and disruptions in delivery systems; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and clinical trials, including because of sickness of employees or their families or the desire of employees to </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">avoid contact with large groups of people;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;refusal of the FDA to accept data from clinical trials in affected geographies;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;impacts from prolonged remote work arrangements, such as increased cybersecurity risks and strains on </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our business continuity plans; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;delays or difficulties with equity offerings due to disruptions and uncertainties in securities markets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve. The extent to which the outbreak impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. While the potential economic impact brought by and the duration of the COVID-19 pandemic may be difficult to assess or predict, the widespread pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the COVID-19 pandemic could materially affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may conduct clinical trials for our product candidates in sites outside the United States, and the FDA may not accept data from trials conducted in foreign locations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future choose to conduct clinical trials outside the United States for our product candidates. Although the FDA may accept data from clinical trials conducted outside the United States not conducted under IND, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be conducted in accordance with Good Clinical Practice, and the FDA must also be able to validate the data from the study through an on-site inspection if necessary. In general, the patient population for any clinical trials conducted outside of the United States must be representative of the population for which we intend to seek approval for the product in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from our clinical trials of our product candidates, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt our development of our product candidates.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, "topline" and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates or will not be able to do so as soon as anticipated, and our ability to generate revenue will be materially impaired.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation and requirements by the FDA and other regulatory agencies in the United States, by the legislative bodies in the European Union (the "EU") and EU member states,  and by other regulatory authorities outside the United States. Failure to obtain marketing approval for a product candidate in any jurisdiction will prevent us from commercializing the product candidate in that jurisdiction, and may affect our plans for commercialization in other jurisdictions as well. We have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third parties to assist us in this process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy to such regulatory authorities&#8217; satisfaction. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals, both in the United States and abroad, is expensive and may take many years. The scope and amount of clinical data required to obtain marketing approvals can vary substantially from jurisdiction to jurisdiction, and it may be difficult to predict whether a particular regulatory body will require additional or different clinical trials than those conducted by a sponsor, especially for novel product candidates such as our product candidates. The FDA or other foreign regulatory authorities may delay, limit, or deny the approval of our product candidates for many reasons, including: our inability to demonstrate that the clinical benefits of our product candidates outweigh any safety or other perceived risks; the regulatory authority&#8217;s disagreement with the interpretation of data from nonclinical or clinical studies; the regulatory agency&#8217;s requirement that we conduct additional preclinical studies and clinical trials; changes in marketing approval policies during the development period; changes in or the enactment of additional statutes or regulations, or changes in regulatory review process for each submitted product application; or the regulatory authority&#8217;s failure to approve the manufacturing processes or third-party manufacturers with which we contract. Regulatory authorities have substantial discretion in the approval process and may refuse to accept a marketing application as deficient. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. Of the large number of drugs in development, only a small percentage successfully complete the FDA or other regulatory approval processes and are commercialized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our product candidates may not receive marketing approval even if they achieve their specified endpoints in clinical trials. Clinical data are often susceptible to varying interpretations and many companies that have believed that their products performed satisfactorily in clinical trials have nonetheless failed to obtain FDA or the applicable foreign regulatory agency approval for their products. The FDA or foreign regulatory authorities may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disagree with our trial design and our interpretation of data from nonclinical and clinical studies. Upon the review of data from any pivotal trial, the FDA or applicable foreign regulatory agency may request that the sponsor conduct additional analyses of the data and, if it believes the data are not satisfactory, could advise the sponsor to delay filing a marketing application.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we eventually complete clinical testing and receive approval of a Biologics License Application ("BLA") or foreign marketing authorization for one of our product candidates, the FDA, EMA or applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical trials which may be required after approval. The FDA or the applicable foreign regulatory agency may also approve our products for a more limited indication and/or a narrower patient population than we originally request, and the FDA, EMA or applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our products. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of our product candidates and would materially adversely impact our business and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of SINTAX medicines and their interactions with cells in the small intestine is an emerging field, and it is possible that the FDA or other regulatory authorities or bodies could issue regulations or new policies in the future affecting our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we intend to focus on developing product candidates for multiple initial indications that we identify as most likely to succeed, in terms of both regulatory approval and commercialization. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that may prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and product development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements, in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A fast track designation by the FDA may not actually lead to a faster development or regulatory review or approval process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek fast track designation for some of our product candidates. If a drug or biologic is intended for the treatment of a serious or life-threatening condition and nonclinical or clinical data demonstrate the potential to address unmet medical needs for this condition, the drug or biologic sponsor may apply for FDA fast track designation. Fast track designation provides increased opportunities for sponsor meetings with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed. The FDA has broad discretion whether or not to grant this designation, and even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. Fast track designation does not assure ultimate approval by the FDA. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our product development program.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A breakthrough therapy designation by the FDA for our product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek a breakthrough therapy designation for our product candidates. A breakthrough therapy is defined as a drug or biologic that is intended to treat a serious or life-threatening disease or condition, and preliminary clinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor can help to identify the most efficient path for clinical development. Drugs designated as breakthrough therapies by the FDA may also be eligible for accelerated approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the products no longer meet the conditions for qualification and rescind the designation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the global pandemic of COVID-19, on March 10, 2020 the FDA temporarily postponed most foreign inspections of manufacturing facilities and products. Subsequently, on July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Additionally, on April 15, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites. According to the guidance, the FDA intends to request such remote interactive  evaluations in situations where an in-person inspection would not be prioritized, deemed mission-critical, or where direct inspection is otherwise limited by travel restrictions, but where the FDA determines that remote evaluation would be appropriate. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to our Dependence on Third Parties and Manufacturing</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely, and expect to continue to rely, on third parties, such as CROs, clinical data management organizations, medical institutions, clinical investigators and potential pharmaceutical partners, to conduct and manage our clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on these third parties for research and development activities will reduce our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the FDA requires us to comply with regulatory standards, commonly referred to as good clinical practices, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, safety and welfare of trial participants are protected. Other countries&#8217; regulatory agencies also have requirements for clinical trials with which we must comply. We also may be required in certain instances to register ongoing clinical trials and post the results of completed clinical trials on government-sponsored databases, such as ClinicalTrials.gov, or similar foreign databases within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, do not meet expected deadlines, experience work stoppages, terminate their agreements with us or need to be replaced, or do not conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may need to enter into new arrangements with alternative third parties, which could be difficult, costly or impossible, and our clinical trials may be extended, delayed, or terminated or may need to be repeated. If any of the foregoing occur, we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and may not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect to rely on other third parties to store and distribute drug product required by our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential product revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties for the manufacture of our product candidates for preclinical and clinical testing and expect to continue to do so for the foreseeable future. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or that such quantities may not be available at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manufacture if any of our product candidates receive marketing approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reliance on third parties for the manufacture of our product candidates increases the risk that we will not have sufficient quantities of our product candidates on a timely basis or at all, or that such quantities will be available at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to establish agreements with third-party manufacturers on acceptable terms or at all. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;breach of manufacturing agreements by the third-party manufacturers;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;failure to manufacture our product according to our specifications;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;failure to manufacture our product according to our schedule or at all;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;misappropriation or disclosure of our proprietary information, including our trade secrets and know-how; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;termination or nonrenewal of agreements by third-party manufacturers at times that are costly or </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inconvenient for us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party manufacturers may not be able to comply with current Good Manufacturing Practice (&#8220;cGMP&#8221;)  regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocations, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. Some of the contract manufacturers we rely on to produce our product candidates have never produced a FDA-approved therapeutic. If our contract manufacturers are unable to comply with cGMP regulation or if the FDA does not approve their facility upon a pre-approval </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inspection, our product candidates may not be approved or may be delayed in obtaining approval. In addition, there are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing our products. Therefore, our product candidates and any future product candidates that we may develop may compete with other products for access to manufacturing facilities. Any failure to gain access to these limited manufacturing facilities could severely impact the clinical development, marketing approval and commercialization of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant sources of clinical supplies for both drug substance and drug product. If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all. Our current and anticipated future dependence upon others for the manufacture of our product candidates or products could delay, prevent or impair our development and commercialization efforts. Moreover, as a result of the COVID-19 pandemic, third-party manufacturers may be affected, which could disrupt their activities and, as a result, we could face difficulties and delays in the manufacture of our product candidates, which may negatively affect our preclinical and clinical development activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no experience manufacturing our product candidates at commercial scale, and if we decide to establish our own manufacturing facility, we cannot assure you that we can manufacture our product candidates in compliance with regulations at a cost or in quantities necessary to make them commercially viable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may establish a manufacturing facility for our product candidates for production at a commercial scale. We have no experience in commercial-scale manufacturing of our product candidates. We currently intend to develop our manufacturing capacity in part by expanding our current facility or building additional facilities. This activity will require substantial additional funds and we would need to hire and train a significant number of qualified employees to staff these facilities. We may not be able to develop commercial-scale manufacturing facilities that are adequate to produce materials for additional later-stage clinical trials or commercial use.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equipment and facilities employed in the manufacture of pharmaceuticals are subject to stringent qualification requirements by regulatory agencies, including validation of facility, equipment, systems, processes and analytics. We may be subject to lengthy delays and expense in conducting validation clinical trials, if we can meet the requirements at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates and Other Legal Compliance Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, hospitals, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current psoriasis treatment involves the use of steroids and biologics that are well established in the medical community, and physicians may continue to rely on these treatments. If our product candidates receive approval but do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of our approved product candidates, if any, will depend on a number of factors, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;their efficacy, safety and other potential advantages compared to alternative treatments;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the clinical indications for which our products are approved;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;our ability to offer them for sale at competitive prices;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;their convenience and ease of administration compared to alternative treatments;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the willingness of the target patient population to try new therapies and of physicians to prescribe these </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapies;</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the strength of marketing and distribution support;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the availability of third-party coverage and adequate reimbursement for our product candidates;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the prevalence and severity of their side effects and their overall safety profiles;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;any restrictions on the use of our products together with other medications;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;interactions of our products with other medicines patients are taking; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the inability of certain types of patients to take our product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no sales organization. If we are unable to establish effective sales, marketing and distribution capabilities or enter into agreements with third parties with such capabilities, we may not be successful in commercializing our product candidates if and when they are approved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of our product candidates. To achieve commercial success for any product for which we obtain marketing approval, we will need to establish a sales and marketing organization or make arrangements with third parties to perform sales and marketing functions and we may not be successful in doing so.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we expect to build a focused sales and marketing infrastructure to market or promote our product candidates in the United States and potentially elsewhere, if and when they are approved. There are risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our products on our own include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;our inability to recruit, train and retain an adequate number of effective sales and marketing personnel;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the inability of sales personnel to obtain access to or educate physicians on the benefits of our products;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the lack of complementary products to be offered by sales personnel, which may put us at a competitive </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disadvantage relative to companies with more extensive product lines;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;unforeseen costs and expenses associated with creating an independent sales and marketing organization; </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the inability to obtain sufficient coverage and reimbursement from third-party payors and governmental </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agencies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, we may rely on third parties to sell, market and distribute our product candidates. We may not be successful in entering into arrangements with such third parties or may be unable to do so on terms that are favorable to us. In addition, our product revenue and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drug and biologic products is highly competitive and is characterized by rapid and substantial technological development and product innovations. We face competition with respect to our current product candidates and will face competition with respect to product candidates that we may seek to develop or commercialize in the future, including from major pharmaceutical companies, specialty </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pharmaceutical companies and biotechnology companies worldwide. We are aware of a number of large pharmaceutical and biotechnology companies, including AbbVie Inc., Agenus Inc., AstraZeneca plc, Bristol-Myers Squibb, F. Hoffmann-La Roche A.G., Gilead Sciences, Inc., Incyte Corporation, Johnson &amp; Johnson, Merck, Novartis International A.G., Pfizer Inc. and Regeneron Pharmaceuticals, Inc., as well as smaller, early-stage companies, that are pursuing the development of products, including microbial-based therapeutics in some instances, for disease indications we are targeting. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, and others may be based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources, established presence in the market and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and reimbursement and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These third parties compete with us in recruiting and retaining qualified scientific, sales and marketing and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could delay us from obtaining FDA approval to market our product candidates and result in our competitors establishing a strong market position before we are able to enter the market, especially for any competitor developing a microbial-based therapeutic which will likely share our same regulatory approval requirements. For more information, please see "Risk Factors-Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated, which may delay us from marketing our product candidates." In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic or biosimilar products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, any of which could harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize any product candidates successfully will depend, in part, on the extent to which coverage and reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and impact reimbursement levels.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining adequate reimbursement for our products may be difficult. We cannot be certain if and when we will obtain coverage and an adequate level of reimbursement for our products by third-party payors. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for drugs. In addition, reimbursement rates from private health insurance companies vary depending on the company, the insurance plan and other factors. We may also be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval, and the royalties resulting from the sales of those products may also be adversely impacted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside the United States. Moreover, eligibility for reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be reimbursed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription drug pricing remains subject to continuing governmental control, including possible price reductions, even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval. There can be no assurance that our product candidates, if they are approved for sale in the United States or in other countries, will be considered medically necessary or cost-effective for a specific indication, or that coverage or an adequate level of reimbursement will be available.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and will face an even greater risk if we commercially sell any products that we develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;regulatory investigations, product recalls or withdrawals, or labeling, marketing or promotional restrictions;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;decreased demand for any product candidates or products that we may develop;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;injury to our reputation and significant negative media attention;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;withdrawal of clinical trial participants;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;significant costs to defend the related litigation;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;substantial monetary awards to trial participants or patients;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;loss of revenue;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;reduced resources of our management to pursue our business strategy; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the inability to commercialize any products that we may develop.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current product liability insurance coverage and any product liability insurance coverage that we acquire in the future may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated, which may delay us from marketing our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even if we are successful in achieving regulatory approval to commercialize a product candidate faster than our competitors, we may face competition from biosimilars. The Biologics Price Competition and Innovation Act (&#8220;BPCIA&#8221;)  created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product.  Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation.  Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, the European Commission has granted marketing authorizations for biosimilars pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In the EU, upon receiving marketing authorization, new innovative products generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents regulatory authorities in the EU from referencing the innovator's data to assess a biosimilar application. During the additional two-year period of market exclusivity, a biosimilar marketing authorization can be submitted, and the innovator's data may be referenced, but no biosimilar product can be marketed until the expiration of the market exclusivity. The overall 10-year of market exclusivity period may be extended to a maximum of 11 years if, during the first eight of those 10 years, the marketing authorization holder obtains an approval for one or more new therapeutic indications that bring significant clinical benefits compared with existing therapies. In addition, companies may be developing biosimilars in other countries that could compete with our products. If competitors are able to obtain marketing approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell our product candidates in the EU and many other jurisdictions, we or our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval in foreign countries may differ substantially from that required to obtain FDA or other applicable regulatory approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA or other applicable regulatory approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or our collaborators may not obtain approvals for our product candidates from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product candidate for which we obtain marketing approval could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to the continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP and similar requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. We and our contract manufacturers will also be subject to continual review and periodic inspections to assess compliance with cGMP and similar requirements. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to specific conditions of approval, including a requirement to implement a risk evaluation and mitigation strategy, which could include requirements for a medication guide, communication plan, or restricted distribution system. If any of our product candidates receives marketing approval, the accompanying label may limit the approved use of our drug, which could limit sales of the product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of our approved products. The FDA closely regulates the post-approval marketing and promotion of drugs and biologics to ensure they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we market our products outside of their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the FDA&#8217;s restrictions relating to the promotion of prescription drugs may also lead to investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if a regulatory agency or we later discover previously unknown problems with our products, such as adverse events of unanticipated severity or frequency, problems with manufacturers or manufacturing processes, or failure to comply with regulatory requirements, the regulatory agency may impose restrictions on the products or us, including requiring withdrawal of the product from the market. Any failure to comply with applicable regulatory requirements may yield various results, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;litigation involving patients taking our products;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;restrictions on such products, manufacturers or manufacturing processes;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;restrictions on the labeling or marketing of a product;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;restrictions on product distribution or use;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;requirements to conduct post-marketing studies or clinical trials;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;warning letters;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;withdrawal of products from the market;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;suspension or termination of ongoing clinical trials;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;recall of products;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;fines, restitution or disgorgement of profits or revenues;</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;suspension or withdrawal of marketing approvals;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;damage to relationships with potential collaborators;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;unfavorable press coverage and damage to our reputation;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;refusal to permit the import or export of our products;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;product seizure or detention;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;injunctions; or</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;imposition of civil or criminal penalties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompliance with similar EU requirements regarding safety monitoring or pharmacovigilance can also result in significant financial penalties. Similarly, failure to comply with U.S. and foreign regulatory requirements regarding the development of products for pediatric populations and the protection of personal health information can also lead to significant penalties and sanctions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. In addition, the FDA&#8217;s regulations, policies or guidance may change and new or additional statutes or government regulations may be enacted that could prevent or delay regulatory approval of our product candidates or further restrict or regulate post-approval activities. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenues. If regulatory sanctions are applied or if regulatory approval is withheld or withdrawn, the value of our company and our operating results will be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with customers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from governmental healthcare programs, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we may obtain marketing approval. Our future arrangements with third-party payors, physicians and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may restrict the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any good or service, for which payment may be made under a federal healthcare program, such as </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare and Medicaid; a person or entity does not need to have actual knowledge of the statute or specific </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intent to violate the statute to have committed a violation;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the false claims and civil monetary penalties laws, including the federal False Claims Act, which, among </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">against individuals or entities for knowingly presenting, or causing to be presented, to the federal </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government, claims for payment that are false or fraudulent, knowingly making, using or causing to be </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">made or used, a false record or statement material to a false or fraudulent claim or from knowingly or </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">making a false statement to avoid, decrease or conceal an obligation to pay money to the federal </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government. In addition, the government may assert that a claim including items or services resulting from a </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal False Claims Act;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA") imposes criminal and civil </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability for executing a scheme to defraud any healthcare benefit program or making false statements </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relating to healthcare matters; similar to the federal Anti-Kickback Statute, a person or entity does not need </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to have actual knowledge of these statutes or specific intent to violate them to have committed a violation;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the federal Physician Payment Sunshine Act requires applicable manufacturers of covered drugs to report </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments and other transfers of value to physicians, certain other healthcare professionals beginning in </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, and teaching hospitals, and ownership and investment interests held by physicians and their </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immediate family members; manufacturers are required to submit reports to the government by the 90th </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">day of each calendar year;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">apply to our business practices, including but not limited to, research, distribution, sales or marketing </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements and claims involving healthcare items or services reimbursed by non- governmental third-</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">party payors, including private insurers; state laws that require pharmaceutical companies to comply with </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">promulgated by the federal government and may require drug manufacturers to report information related to </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments and other transfers of value to physicians and other healthcare providers, pricing information or </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing expenditures; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;state and foreign laws that govern the privacy and security of health information in some circumstances, </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">many of which differ from each other in significant ways and often are not preempted by HIPAA, thus </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complicating compliance efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain a robust system to comply with multiple jurisdictions with different compliance and reporting requirements increases the possibility that a healthcare company may violate one or more of the requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and affect the prices we may obtain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the United States, the Patient Protection and Affordable Care Act (&#8220;ACA&#8221;) was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among the provisions of the ACA that are of importance to our potential product candidates are the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;establishment of a new pathway for approval of lower cost biosimilars to compete with biologic products, </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such as those we are developing;</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;an annual, nondeductible fee payable by any entity that manufactures or imports specified branded </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prescription drugs and biologic agents;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Program;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">point-of-sale discounts off negotiated prices;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;extension of manufacturers&#8217; Medicaid rebate liability;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;expansion of eligibility criteria for Medicaid programs;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;a new requirement to annually report drug samples that manufacturers and distributors provide to </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">physicians; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">comparative clinical effectiveness research, along with funding for such research.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order initiating a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare. It is unclear how healthcare reform measures enacted by Congress or implemented by the Biden administration or other challenges to the ACA, if any, will impact the ACA or our business.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through December 31, 2021, unless additional Congressional action is taken. On January 2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, including hospitals, and an increase in the statute of limitations period for the government to recover overpayments to providers from three to five years. Further, in March 2021, the American Rescue Plan Act of 2021 was signed into law, which, among other things, eliminated the statutory cap on drug manufacturers&#8217; Medicaid Drug Rebate Program rebate liability, effective January 1, 2024. Under current law enacted as part of the ACA, drug manufacturers&#8217; Medicaid Drug Rebate Program rebate liability is capped at 100% of the average manufacturer price for a covered outpatient drug. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates, if approved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. Individual states in the United States have become increasingly active in implementing regulations designed to contain pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, particularly the countries of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after coverage and reimbursement have been obtained. Reference pricing used by various European Union member states and parallel distribution or arbitrage between low-priced and high-priced member states, can further reduce prices. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If coverage and reimbursement of our products are unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials such as human stool. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to adequately protect our proprietary technology, or obtain and maintain issued patents which are sufficient to protect our product candidates, others could compete against us more directly, which would have a material adverse impact on our business, results of operations, financial condition and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our proprietary technology and products. We </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and product candidates. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost, in a timely manner, or in all jurisdictions. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, such as, with respect to proper priority claims, inventorship, claim scope or patent term adjustments. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and unenforceable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business, financial condition and operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our current and future license agreements with third parties, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. We may also require the cooperation of our licensors to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have numerous patent applications pending, we cannot provide any assurances that any of our pending patent applications will mature into issued patents and, if they do, that such patents or our current patents will include claims with a scope sufficient to protect our product candidates or otherwise provide any competitive advantage. For example, we are pursuing claims to compositions of certain bacterial populations. Any claims that are issued may provide coverage for such compositions and/or their use. However, such claims would not prevent a third party from commercializing alternative compositions that do not include the bacterial populations claimed in pending applications, potential applications or patents that have issued or may issue. There can be no assurance that any such alternative composition will not be equally effective. These and other factors may provide opportunities for our competitors to design around our patents, should they issue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, other parties have developed or may develop technologies that may be related or competitive to our approach, and may have filed or may file patent applications and may have received or may receive patents that may overlap or conflict with our patent applications, either by claiming similar methods or by claiming subject matter that could dominate our patent position. In addition, the standards that the United States Patent and Trademark Office (&#8220;USPTO&#8221;) and other jurisdictions use to grant patents are not always applied predictably or uniformly and can change. Similarly, the ultimate degree of protection that will be afforded to biotechnology inventions, including ours, in the United States and other jurisdictions, remains uncertain and is dependent upon the scope of the protection decided upon by patent offices, courts, and lawmakers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in any issued patents or pending patent applications, or that we were the first to file for patent protection of such inventions, nor can we know whether those from whom we may license patents were the first to make the inventions claimed or were the first to file. For these and other reasons, the issuance, scope, validity, enforceability and commercial value of our patent rights are subject to a level of uncertainty. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in the patent laws and/or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in derivation, reexamination, inter partes review, ex partes reexamination, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. For example, in February 2021, the European Patent Office informed us of a notice of opposition by a third party for a patent issued </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to us. In July 2021, we filed a reply to the notice of opposition. The patent at issue does not relate to our current product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any limitation on the protection of the subject technology could hinder our ability to develop and commercialize applicable product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Furthermore, an adverse decision in an interference proceeding can result in a third party receiving the patent right sought by us, which in turn could affect our ability to develop, market or otherwise commercialize our product candidates. The issuance, scope, validity, enforceability and commercial value of our patents are subject to a level of uncertainty.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. Due to legal standards relating to patentability, validity, enforceability and claim scope of patents covering biotechnological and pharmaceutical inventions, our ability to obtain, maintain and enforce patents is uncertain and involves complex legal and factual questions. Even if issued, a patent&#8217;s validity, inventorship, ownership or enforceability is not conclusive. Accordingly, rights under any existing patent or any patents we might obtain or license may not cover our product candidates, or may not provide us with sufficient protection for our product candidates to afford a commercial advantage against competitive products or processes, including those from branded and generic pharmaceutical companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;any of our pending patent applications, if issued, will include claims having a scope sufficient to protect our </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates or any other products or product candidates;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;any of our pending patent applications will issue as patents;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;we will be able to successfully commercialize our product candidates, if approved, before our relevant </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents expire;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;we were the first to make the inventions covered by any existing patent and pending patent applications;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;we were the first to file patent applications for these inventions;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;others will not develop similar or alternative technologies that do not infringe or design around our patents;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;others will not use pre-existing technology to effectively compete against us;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;any of our patents, if issued, will be found to ultimately be valid and enforceable;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;third parties will not compete with us in jurisdictions where we do not pursue and obtain patent protection;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;we will be able to obtain and/or maintain necessary or useful licenses on reasonable terms or at all;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;any patents issued to us will provide a basis for an exclusive market for our commercially viable products, </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will provide us with any competitive advantages or will not be challenged by third parties;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;we will develop additional proprietary technologies or product candidates that are separately patentable; or</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;our commercial activities or products will not infringe upon the patents or proprietary rights of others.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any litigation to enforce or defend our patent rights, even if we were to prevail, could be costly and time-consuming and would divert the attention of our management and key personnel from our business operations. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. Even if we are successful, domestic or foreign litigation, or USPTO or foreign patent office proceedings, may result in substantial costs and distraction to our management. We may not be able, alone or with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our licensors or potential collaborators, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose rights that are important to our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into and may be required to enter into in the future, intellectual property license agreements that are important to our business. These license agreements may impose various diligence, milestone payment, royalty and other obligations on us. For example, we have entered into exclusive license agreements with the University of Chicago and Mayo Clinic pursuant to which we are required to use efforts to engage in various development and commercialization activities with respect to licensed products and are required to satisfy specified milestone and royalty payment obligations. If we fail to comply with any obligations under our agreements with licensors, we may be subject to termination of the license agreement in whole or in part or increased financial obligations to our licensors, in which case our ability to develop or commercialize products covered by the license agreement will be impaired. Further, we may need to outsource and rely on third parties for many aspects of the clinical development, sales and marketing of our products covered under our current and future license agreements. Delay or failure by these third parties could adversely affect the continuation of our license agreements with our licensors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, disputes may arise regarding intellectual property subject to a license agreement, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the extent to which our technology and processes infringe intellectual property of the licensor that is not </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to the licensing agreement; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;our diligence obligations under the license agreement and what activities satisfy those obligations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The intellectual property which we have licensed from the University of Chicago and Mayo Clinic was discovered through government funded programs and thus may be subject to federal regulations such as "march-in" rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements, and limit our ability to contract with non-U.S. manufacturers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed certain intellectual property from the University of Chicago and Mayo Clinic. These agreements indicate that the rights licensed to us are subject to the obligations to and the rights of the U.S. government, including those set forth in the Bayh-Dole Act of 1980. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future therapeutics based on the licensed intellectual property. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or nonexclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations, also referred to as "march-in rights." While the U.S. government has sparingly used, and to our knowledge never successfully exercised, such march-in rights, any exercise of the march-in rights by the U.S. government could harm our competitive position, business, financial condition, results of operations and prospects. If the U.S. government exercises such march-in rights, we may receive compensation that is deemed reasonable by the U.S. government in its sole discretion, which may be less than what we might be able to obtain in the open market. Intellectual </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. government requires that any therapeutics embodying any invention generated through the use of U.S. government funding be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. therapeutic manufacturers for therapeutics covered by such intellectual property.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets and know-how, our business and competitive position would be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also seek to enter into confidentiality and invention or patent assignment agreements with our employees, advisors and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Our trade secrets may also be obtained by third parties by other means, such as breaches of our physical or computer security systems. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Patent reform legislation in the United States, including the Leahy-Smith America Invents Act (the" Leahy-Smith Act"), signed into law on September 16, 2011, could increase those uncertainties and costs. The Leahy-Smith Act included a number of significant changes to U.S. patent law. These changes included provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. In addition, the Leahy-Smith Act transformed the U.S. patent system into a &#8220;first to file&#8221; system. The first-to-file provisions, however, only became effective on March 16, 2013. Accordingly, it is not yet clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business, results of operations and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, recent United States Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. From time to time, the U.S. Supreme Court, other federal courts, the United States Congress, or the USPTO, may change the standards of patentability and any such changes could have a negative impact on our business.  Additionally, there have been recent proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to obtain patent protection for our proprietary technology or our ability to enforce our proprietary technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. For example, in Association for Molecular Pathology v. Myriad Genetics, Inc., the Supreme Court held that claims to isolated genomic DNA are not patentable, but claims to complementary DNA, or cDNA, molecules, which are not </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">genomic sequences, may be patent eligible because they are not a natural product. The effect of the decision on patents for other isolated natural products is uncertain.  Our current product candidates include natural products, therefore, this decision and its interpretation by the courts and the USPTO may impact prosecution, defense and enforcement of our patent portfolio. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Europe&#8217;s planned Unified Patent Court may in particular present uncertainties for our ability to protect and enforce our patent rights against competitors in Europe. While that new court is being implemented to provide more certainty and efficiency to patent enforcement throughout Europe, it will also provide our competitors with a new forum to use to centrally revoke our European patents. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by that court. We will have the right to opt our patents out of that system over the first seven years of the court, but doing so may preclude us from realizing the benefits of the new unified court.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to increasing uncertainty with regard to our ability to obtain future patents, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on these and other decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change or be interpreted in unpredictable ways that would weaken our ability to obtain new patents or to enforce any patents that may issue to us in the future. In addition, these events may adversely affect our ability to defend any patents that may issue in procedures in the USPTO or in courts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. While no such litigation has been brought against us and we have not been held by any court to have infringed a third party&#8217;s intellectual property rights, we cannot guarantee that our technology, products or use of our products do not infringe third-party patents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous patents and pending applications are owned by third parties in the fields in which we are developing product candidates, both in the United States and elsewhere. It is also possible that we have failed to identify relevant third-party patents or applications. For example, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to our product candidates and technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patent applications may issue with claims of relevance to our technology. In addition, we may be unaware of one or more issued patents that would be infringed by the manufacture, sale or use of a current or future product candidate, or we may incorrectly conclude that a third-party patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our products or the use of our products. We are aware of several pending patent applications containing one or more claims that could be construed to cover some of our product candidates or technology, should those claims issue in their original form or in the form presently being pursued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. Other parties may allege that our product candidates or the use of our technologies infringe patent claims or other intellectual property rights held by them or that we are employing their proprietary technology without authorization. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference or derivation proceedings before the USPTO and similar bodies in other countries. Third parties may assert infringement claims against us based on existing intellectual property rights and intellectual property rights that may be granted in the future. If we were to challenge the validity of an issued U.S. patent in court, such as an issued </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. patent of potential relevance to some of our product candidates or methods of use, we would need to overcome a statutory presumption of validity that attaches to every U.S. patent. This means that in order to prevail, we would have to present clear and convincing evidence as to the invalidity of the patent&#8217;s claims. There is no assurance that a court would find in our favor on questions of infringement or validity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent and other types of intellectual property litigation can involve complex factual and legal questions, and their outcome is uncertain. If we are found or believe there is a risk we may be found, to infringe a third party&#8217;s intellectual property rights, we could be required or may choose to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any such license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in these proceedings, we may incur substantial costs and divert management time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court, or redesign our products. Patent litigation is costly and time-consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, intellectual property litigation or claims could force us to do one or more of the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;cease developing, selling or otherwise commercializing our product candidates;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;pay substantial damages for past use of the asserted intellectual property;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;obtain a license from the holder of the asserted intellectual property, which license may not be available on </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonable terms, if at all; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;in the case of trademark claims, redesign or rename some or all of our product candidates or other brands </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to avoid infringing the intellectual property rights of third parties, which may not be possible and, even if </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">possible, could be costly and time-consuming.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these risks coming to fruition could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering our product candidates could be found invalid or unenforceable or could be interpreted narrowly if challenged in court.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our intellectual property, including our patents or the patents of our licensors. As a result, we may be required to file infringement claims to stop third-party infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. If we initiated legal proceedings against a third party to enforce a patent, if and when issued, covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include alleged failures to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement, or failure to claim patent eligible subject matter. Grounds for unenforceability assertions include allegations that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review and equivalent proceedings in foreign jurisdictions, such as opposition proceedings. Such proceedings could result in revocation or amendment of our patents in such a way that they no longer cover our product candidates or competitive products. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Moreover, even if not found invalid or unenforceable, the claims of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents could be construed narrowly or in a manner that does not cover the allegedly infringing technology in question. Such a loss of patent protection would have a material adverse impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and, in some jurisdictions, during the pendency of a patent application. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our policy to enter into confidentiality and intellectual property assignment agreements, including with our employees, consultants, contractors and advisors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights to us. For example, even if we have a consulting agreement in place with an academic advisor pursuant to which such academic advisor is required to assign any inventions developed in connection with providing services to us, such academic advisor may not have the right to assign such inventions to us, as it may conflict with his or her obligations to assign all such intellectual property to his or her employing institution.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may also engage advisors and consultants who are concurrently employed at universities or other organizations or who perform services for other entities. Although we try to ensure that our employees, advisors and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, advisors or consultants have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such party&#8217;s former or current employer or in violation of an agreement with another party. Although we have no knowledge of any such claims being alleged to date, if such claims were to arise, litigation may be necessary to defend against any such claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees, consultants, advisors and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Similarly, we may be subject to claims that an employee, advisor or consultant performed work for us that conflicts with that person&#8217;s obligations to a third party, such as an employer, and thus, that the third party has an ownership interest in the intellectual property arising out </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of work performed for us. Litigation may be necessary to defend against these claims. Although we have no knowledge of any such claims being alleged to date, if such claims were to arise, litigation may be necessary to defend against any such claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, domain names or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product candidates in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than in the United States, assuming that rights are obtained in the United States and assuming that rights are pursued outside the United States. The statutory deadlines for pursuing patent protection in individual foreign jurisdictions are based on the priority date of each of our patent applications. For some of the patent families in our portfolio, including the families that may provide coverage for our lead product candidates, the relevant statutory deadlines have not yet expired. Therefore, for each of the patent families that we believe provide coverage for our lead product candidates, we will need to decide whether and where to pursue protection outside the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, even if we do elect to pursue patent rights outside the United States, we may not be able to obtain relevant claims and/or we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may use our technologies in jurisdictions where we do not pursue and obtain patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we pursue and obtain issued patents in particular jurisdictions, our patent claims or other intellectual property rights may not be effective or sufficient to prevent third parties from so competing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to biotechnology. This could make it difficult for us to stop the infringement of our patents, if obtained, or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our ability to obtain and, if obtained, enforce our patents to stop infringing activities is inadequate, third parties may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Accordingly, our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property we develop or license.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Employee Matters and Managing Growth and Other Risks Related to Our Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on Balkrishan (Simba) Gill, our President and Chief Executive Officer, as well as the other principal members of our management, scientific and clinical team. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain "key person" insurance for any of our executives or other employees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time due to the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of product development, regulatory affairs, clinical affairs and manufacturing and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with operating internationally could materially adversely affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have limited international operations, but our business strategy incorporates potentially expanding internationally if any of our product candidates receive regulatory approval. Doing business internationally involves a number of risks, including but not limited to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;multiple, conflicting and changing laws and regulations, such as privacy regulations, tax laws, export and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">import restrictions, employment laws, regulatory requirements and other governmental approvals, permits </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and licenses;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;additional potentially relevant third-party patent rights;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;difficulties in staffing and managing foreign operations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;complexities associated with managing multiple payor reimbursement regimes, government payors or </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patient self-pay systems;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;limits in our ability to penetrate international markets;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and regional financial crises on demand and payment for our products and exposure to foreign currency </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exchange rate fluctuations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disease (e.g. the COVID-19 pandemic), boycotts, curtailment of trade and other business restrictions;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;certain expenses including, among others, expenses for travel, translation and insurance; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;regulatory and compliance risks that relate to maintaining accurate information and control over sales and </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provisions, or its anti-bribery provisions, or other anti-bribery and anti-corruption laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The United Kingdom&#8217;s withdrawal from the European Union may have a negative effect on global economic conditions, financial markets and our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a national referendum and enactment of legislation by the government of the United Kingdom, the United Kingdom formally withdrew from the European Union and ratified a trade and cooperation agreement governing its future relationship with the European Union.  The agreement, which is being applied provisionally from January 1, 2021 until it is ratified by the European Parliament and the Council of the European Union, addresses trade, economic arrangements, law enforcement, judicial cooperation and a governance framework including procedures for dispute resolution, among other things.  Because the agreement merely sets forth a framework in many respects and will require complex additional bilateral negotiations between the United Kingdom and the European Union as both parties continue to work on the rules for implementation, significant political and economic uncertainty remains about how the precise terms of the relationship between the parties will differ from the terms before withdrawal.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These developments, or the perception that any related developments could occur, have had and may continue to have a material adverse effect on global economic conditions and the stability of global financial markets, and may significantly reduce global market liquidity and restrict the ability of key market participants to operate in certain financial markets. Any of these factors could depress economic activity and restrict our access to capital, which could have a material adverse effect on our business, financial condition and results of operations and reduce the price of common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The uncertainty regarding new or modified arrangements between the United Kingdom and other countries following the withdrawal may have a material adverse effect on the movement of personnel, goods, information or data between the United Kingdom and members of the European Union and the United States, including the interruption of or delays in imports into the United Kingdom of goods originating within the European Union and exports from the United Kingdom of goods originating there. For example, shipments into the United Kingdom of drug substance manufactured for us in the European Union may be interrupted or delayed and thereby prevent or delay the manufacture in the United Kingdom of drug product. Similarly, shipments out of the United Kingdom of drug product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the United States or the European Union may be interrupted or delayed and thereby prevent or delay the delivery of drug product to clinical sites. Such a situation could hinder our ability to conduct current and planned clinical trials and have an adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of information technology and other system failures or security breaches of or unauthorized access to our systems.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our current and future contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, or to attachments to emails and other security breaches or unauthorized access by persons inside our organization or with access to our internal systems. The risk of a security breach or disruption, particularly through cyber-attacks or cyber-intrusions, including by computer hackers, foreign governments and cyber terrorists, generally has increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased.  In addition, our systems safeguard important confidential data, including personal data regarding patients enrolled in our clinical trials.  While we are not aware of any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption to our product development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties to manufacture our product candidates and conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on a set of cloud-based software services and access these services via the Internet for the vast majority of our computing, storage, bandwidth, and other services. Any disruption of or interference with our use of our cloud-based services would negatively affect our operations and could seriously harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use several distributed computing infrastructure platforms for business operations, or what is commonly referred to as "cloud" computing services and we access these services via the Internet. Any transition of the cloud services currently provided by an existing vendor to another cloud provider would be difficult to implement and will cause us to incur significant time and expense. Given this, any significant disruption of or interference with our use of these cloud computing services would negatively impact our operations and our business would be seriously harmed. If our employees or partners are not able to access our cloud computing services or encounter difficulties in doing so, we may experience business disruption. The level of service provided by our cloud computing vendors, including the ability to secure our confidential information and the confidential information of third parties that is shared with us, may also impact the perception of our company and could seriously harm our business and reputation and create liability for us. If a cloud computing service that we use experiences interruptions in service regularly or for a prolonged basis, or other similar issues, our business could be seriously harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a cloud computing service may take actions beyond our control that could seriously harm our business, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;discontinuing or limiting our access to its platform;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;increasing pricing terms;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;terminating or seeking to terminate our contractual relationship altogether;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;establishing more favorable relationships with one or more of our competitors; or</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;modifying or interpreting its terms of service or other policies in a manner that impacts our ability to run our </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business and operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cloud computing service providers have broad discretion to change and interpret their terms of service and other policies with respect to us, and those actions may be unfavorable to us. Our cloud computing service </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">providers may also alter how we are able to process data on the platform. If a cloud computing service provider makes changes or interpretations that are unfavorable to us, our business could be seriously harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts to protect the information shared with us may be unsuccessful due to the actions of third parties, software bugs, or other technical malfunctions, employee error or malfeasance, or other factors. In addition, third parties may attempt to fraudulently induce employees or users to disclose information to gain access to our data or third-party data entrusted to us. If any of these events occur, our or third-party information could be accessed or disclosed improperly. Some partners or collaborators may store information that we share with them on their own computing system. If these third parties fail to implement adequate data-security practices or fail to comply with our policies, our data may be improperly accessed or disclosed. And even if these third parties take all these steps, their networks may still suffer a breach, which could compromise our data.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any incidents where our information is accessed without authorization, or is improperly used, or incidents that violate our policies, could damage our reputation and our brand and diminish our competitive position. In addition, affected parties or government authorities could initiate legal or regulatory action against us over those incidents, which could cause us to incur significant expense and liability or result in orders or consent decrees forcing us to modify our business practices. Concerns over our privacy practices, whether actual or unfounded, could damage our reputation and brand and deter users, advertisers, and partners from using our products and services. Any of these occurrences could seriously harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks associated with data privacy issues, including evolving laws, regulations and associated compliance efforts, may adversely impact our business and financial results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislation in various countries around the world with regard to cybersecurity, privacy and data protection is rapidly expanding and creating a complex compliance environment. We are subject to many federal, state, and foreign laws and regulations, including those related to privacy, rights of publicity, data protection, content regulation, intellectual property, health and safety, competition, protection of minors, consumer protection, employment, and taxation. By way of example, the General Data Protection Regulation (the &#8220;GDPR&#8221;), which became effective in May 2018, has caused more stringent data protection requirements in the EU and the EEA. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and implement policies as part of its mandated privacy governance framework. It also requires data controllers to be transparent and disclose to data subjects how their personal data is to be used; imposes limitations on retention of personal data; introduces mandatory data breach notification requirements; and sets higher standards for data controllers to demonstrate that they have obtained valid consent for certain data processing activities. We are subject to the supervision of local data protection authorities in those EU jurisdictions where we have business operations or are otherwise subject to the GDPR. Certain breaches of the GDPR requirements could result in substantial fines, which can be up to four percent of worldwide revenue or 20 million Euros, whichever is greater. In addition to the foregoing, a breach of the GDPR could result in regulatory investigations, reputational damage, orders to cease/change our use of data, enforcement notices, as well as potential civil claims, including class action type litigation where individuals suffered harm. Relatedly, following the United Kingdom&#8217;s withdrawal from the EEA and the EU, and the expiration of the transition period, from January 1, 2021, companies have to comply with both the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. On January 1, 2021, the United Kingdom became a third country for the purposes of the GDPR. Similarly, California has enacted the California Consumer Privacy Act (the "CCPA"), which took effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Additionally, the California Privacy Rights Act (the &#8220;CPRA&#8221;) was recently enacted in California. The CPRA will impose additional data protection obligations on covered companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. The CCPA and CPRA may increase our compliance costs and potential liability, and similar laws have been proposed at the federal level and in other states. These laws and regulations are constantly evolving and may be interpreted, applied, created, or amended in a manner that could seriously harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions or joint ventures could disrupt our business, cause dilution to our stockholders and otherwise harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire other businesses, products or technologies as well as pursue strategic alliances, joint ventures, technology licenses or investments in complementary businesses. We have only made one acquisition to date, and our ability to do so successfully is unproven beyond this instance. Any of these transactions could be material to our financial condition and operating results and expose us to many risks, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;disruption in our relationships with future customers or with current or future distributors or suppliers as a </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">result of such a transaction;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;unanticipated liabilities related to acquired companies;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;difficulties integrating acquired personnel, technologies and operations into our existing business;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;diversion of management time and focus from operating our business to acquisition integration challenges;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;increases in our expenses and reductions in our cash available for operations and other uses;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;possible write-offs or impairment charges relating to acquired businesses; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;inability to develop a sales force for any additional product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign acquisitions involve unique risks in addition to those mentioned above, including those related to integration of operations across different cultures and languages, currency risks and the particular economic, political and regulatory risks associated with specific countries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the anticipated benefit of any acquisition may not materialize. Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on our operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock, and we could be subject to securities class action litigation as a result.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price is likely to be volatile. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your shares of common stock at or above the price at which you purchase the shares. The market price for our common stock may be influenced by many factors, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the success of competitive products or technologies;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;actual or anticipated changes in our growth rate relative to our competitors;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;results of clinical trials of our product candidates or those of our competitors;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;developments related to any future collaborations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;regulatory or legal developments in the United States and other countries;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;adverse actions taken by regulatory agencies with respect to our preclinical studies or clinical trials, </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing or sales and marketing activities;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;any adverse changes to our relationship with third party contractors or manufacturers;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;development of new product candidates that may address our markets and may make our existing product </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates less attractive;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;changes in physician, hospital or healthcare provider practices that may make our product candidates less </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">useful;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;announcements by us, our collaborators or our competitors of significant acquisitions, strategic </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partnerships, joint ventures, collaborations or capital commitments;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the recruitment or departure of key personnel;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the level of expenses related to any of our product candidates or product development programs;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;failure to meet or exceed financial estimates and projections of the investment community or that we </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provide to the public;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;press reports or other negative publicity, whether or not true, about our business;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the results of our efforts to discover, develop, acquire or in-license additional product candidates or </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;actual or anticipated changes in estimates as to financial results, development timelines or </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recommendations by securities analysts;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;changes in the structure of healthcare payment systems;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;speculative trading in and short sales of our stock, as well as trading phenomena such as the &#8220;short </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">squeeze&#8221;;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;general economic, industry and market conditions; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the other factors described in this "Risk Factors" section.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors may result in large and sudden changes in the volume and trading price of our common stock. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the number of shares of common stock outstanding as of June 30, 2021, our executive officers, directors and stockholders who own more than 5% of our outstanding common stock and their respective affiliates hold, in the aggregate, shares representing approximately 67% of our outstanding voting stock. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. They may also have interests that differ from yours and may vote in a way with which you disagree, and which may be adverse to your interests. This concentration of ownership control may have the effect of delaying, deferring or preventing a change in control of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our company, could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company and might ultimately affect the market price of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant portion of our total outstanding shares are eligible to be sold into the market, which could cause the market price of our common stock to drop significantly, even if our business is doing well.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Moreover, holders of an aggregate of approximately 18.4 million shares of our common stock as of June 30, 2021 have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders, including entities affiliated with Flagship Pioneering, until such shares can otherwise be sold without restriction under Rule 144 of the Securities Act or until the rights terminate pursuant to the terms of the investors&#8217; rights agreement between us and such holders. We have also registered and intend to continue to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an "emerging growth company" and a "smaller reporting company," and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an "emerging growth company" as that term is used in the Jumpstart Our Business Startups Act of 2012, (the &#8220;JOBS Act&#8221;) and may remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of the initial public offering of our common stock, or December 31, 2023, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our outstanding common stock that are held by non-affiliates exceeds $700 million as of the prior June 30, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;being permitted to provide only two years of audited financial statements, in addition to any required </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unaudited interim financial statements, with correspondingly reduced "Management&#8217;s Discussion and </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analysis of Financial Condition and Results of Operations" disclosure;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;not being required to comply with the auditor attestation requirements in the assessment of our internal &#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">control over financial reporting;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;not being required to comply with any requirement that may be adopted by the Public Company Accounting </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional information about the audit and the financial statements;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;reduced disclosure obligations regarding executive compensation; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shareholder approval of any golden parachute payments not previously approved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have elected to take advantage of this extended transition period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also a smaller reporting company, and we will remain a smaller reporting company until the fiscal year following the determination that our voting and non-voting common shares held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100 million during the most recently completed fiscal year and our voting and non-voting common shares held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter. Similar to emerging growth companies, smaller reporting companies are able to provide simplified executive compensation disclosure, are exempt from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("Section 404") and have certain other reduced disclosure obligations, including, among other things, being required to provide only two years of audited financial statements and not being required to provide selected financial data, supplemental financial information or risk factors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to take advantage of certain of the reduced reporting obligations, and may in the future take advantage of these or others. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our restated certificate of incorporation and amended and restated bylaws could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions include those establishing:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;a classified board of directors with three-year staggered terms, which may delay the ability of stockholders </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to change the membership of a majority of our board of directors;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">director candidates;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the board of directors or the resignation, death or removal of a director, which prevents stockholders from </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filling vacancies on our board of directors;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the terms of those shares, including preferences and voting rights, without stockholder approval, which </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could be used to significantly dilute the ownership of a hostile acquirer;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the ability of our board of directors to alter our bylaws without obtaining stockholder approval;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the required approval of the holders of at least two-thirds of the shares entitled to vote at an election of </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directors to adopt, amend or repeal our bylaws or repeal the provisions of our restated certificate of &#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incorporation regarding the election and removal of directors;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">annual or special meeting of our stockholders;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the requirement that a special meeting of stockholders may be called only by the chairman of the board of </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directors, the chief executive officer, the president or the board of directors, which may delay the ability of </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our stockholders to force consideration of a proposal or to take action, including the removal of directors; </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;advance notice procedures that stockholders must comply with in order to nominate candidates to our </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directors or otherwise attempting to obtain control of us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders and our bylaws designate the federal district courts of the United States as the exclusive forum for actions arising under the Securities Act, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty owed by any director, officer, employee or stockholder to us or our stockholders, any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware or any action asserting a claim governed by the internal affairs doctrine. In addition, our bylaws provide that the federal district courts of the United States are the exclusive forum for any complaint raising a cause of action arising under the Securities Act. We believe these provisions benefit us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes and in the application of the Securities Act by federal judges, as applicable, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. The provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes, and may have the effect of discouraging lawsuits, including those against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our restated certificate of incorporation or bylaws to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision contained in our restated certificate of incorporation or bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our results of operations and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the operation and expansion of our business. Therefore, you should not rely on an investment in our common stock as a source for any future dividend income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has significant discretion as to whether to distribute dividends. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on, among other things, our future results of operations and cash flow, our capital requirements and surplus, our financial condition, contractual restrictions and other factors deemed relevant by our board of directors. Accordingly, the return on your investment in our common stock will likely depend entirely on any future capital appreciation, if any, of our common stock. There is no guarantee that our common stock will appreciate in value or even maintain the price at which you purchased our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating losses and research and development tax credits to offset future taxable income or tax liabilities may be subject to certain limitations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had approximately $133.7 million and $129.4 million of Federal and state Net Operating Losses (&#8220;NOLs&#8221;), respectively. The Federal NOLs include $49.9 million which expire at various dates through 2037, and $83.8 million which carryforward indefinitely. The state NOLs expire at various dates through 2040. As of December 31, 2020, we had federal and state research credits of $5.0 million and $2.6 million, respectively, which expire at various dates through 2040. A portion of these NOLs and the tax credit carryforwards could expire unused and be unavailable to offset future income or tax liabilities, respectively. In addition, in general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the "Code"), a corporation that undergoes an "ownership change" is subject to limitations on its ability to utilize its pre-change NOLs or tax credits to offset future taxable income or tax liabilities. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. Our existing NOLs or tax credits may be subject to limitations arising </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from previous ownership changes, and if we undergo an ownership change in the future, our ability to utilize NOLs or credits could be further limited by Sections 382 and 383 of the Code. In addition, future changes in our stock ownership, many of which are outside of our control, could result in an ownership change under Sections 382 and 383 of the Code. Our NOLs or tax credits may also be impaired under state law. Our ability to utilize our NOLs or tax credits is also conditioned upon our attaining profitability and generating U.S. federal and state taxable income. We have incurred significant net losses since our inception; and therefore, we do not know whether or when we will generate the U.S. federal or state taxable income necessary to utilize our NOLs or tax credits. Even if we were to generate net taxable income, the deductibility of federal NOLs generated after December 31, 2017 is limited to 80% of taxable income with respect to taxable years beginning after December 31, 2020. Accordingly, we may not be able to utilize a material portion of our NOLs or tax credits, and we may be required to pay U.S. federal income taxes due to the 80% limitation on deductibility of NOLs even if we have NOLs that are otherwise available for use. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred and expect to continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, and particularly after we are no longer an emerging growth company, we have incurred and expect to continue to incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, these rules and regulations have increased our legal and financial compliance costs and made some activities more time consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to maintain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our business, our stock price and trading volume could decline.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our preclinical studies or clinical trials and/or operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></div><div id="ie2e49401044149ec86a5cefe42299a79_94"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as disclosed in our Current Report on Form 8-K filed with the SEC on February 2, 2021, there were no sales of unregistered equity securities during the six months ended June 30, 2021.</span></div><div><span><br/></span></div><div id="ie2e49401044149ec86a5cefe42299a79_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Defaults Upon Senior Securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie2e49401044149ec86a5cefe42299a79_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Mine Safety Disclosures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ie2e49401044149ec86a5cefe42299a79_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5. Other Information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="ie2e49401044149ec86a5cefe42299a79_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing<br/>Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed<br/>Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1694665/000119312518160865/d582561dex31.htm">Restated Certificate of Incorporation of Evelo Biosciences, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-38473</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/11/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1694665/000169466521000043/exhibit503.htm">Amended and Restated Bylaws of Evelo Biosciences, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-38473</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/18/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1694665/000169466521000098/exhibit41-eveloxwarrant.htm">Warrant to Purchase Common Stock, dated as of June 16, 2021, issued by Evelo Biosciences, Inc. to K2 HealthVentures Equity Trust LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-38473</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/17/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1694665/000169466521000066/eveloq12021exhibit102.htm">Amendment No. 2 to Consulting Agreement dated April 9, 2021 between Evelo Biosciences, Inc. and David R. Epstein</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-38473</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/29//2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1694665/000169466521000066/eveloq12021exhibit103.htm">Amendment dated April 9, 2021 to Letter Agreement between Evelo Biosciences, Inc. and David R. Epstein</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-38473</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/29/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="eveloq22021ex103non-employ.htm">Evelo Biosciences, Inc. Non-Employee Director Compensation Program, as amended June 9, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1694665/000119312521177687/d185542dex991.htm">Evelo Biosciences, Inc. 2021 Employment Inducement Award Plan, and U.K. sub-plan and forms of award agreements thereunder</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-256662</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/1/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1694665/000169466521000098/exhibit101-eveloxfourthame.htm">Fourth Amendment, dated as of June 16, 2021, to the Loan and Security Agreement by and among Evelo Biosciences, Inc. and the other borrowers party thereto, the lenders party thereto, K2 HealthVentures LLC, as administrative agent for such lenders, and Ankura Trust Company, LLC, as collateral agent for such lenders, dated July 19, 2019, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-38473</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/17/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="eveloq2202110-qexhibit311.htm">Certification of Principal Executive Officer</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="eveloq2202110-qexhibit311.htm"> Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="eveloq2202110-qexhibit312.htm">Certification of Principal </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="eveloq2202110-qexhibit312.htm">Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="eveloq2202110-qexhibit321.htm">Certification of Principal Executive Officer </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="eveloq2202110-qexhibit321.htm">Pursuant to 18 U.S.C. Section&#160;1350, as Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="eveloq2202110-qexhibit322.htm">Certification of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="eveloq2202110-qexhibit322.htm">Principal Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Inline XBRL Instance Document- the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File&#160;No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing<br/>Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed<br/>Herewith</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"></td><td style="width:5.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="ie2e49401044149ec86a5cefe42299a79_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie2e49401044149ec86a5cefe42299a79_10">Table of Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant in the capacities and on the dates indicated.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:46.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.865%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EVELO BIOSCIENCES, INC.</span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr><tr style="height:34pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Date: July 29, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ Balkrishan (Simba) Gill, Ph.D.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balkrishan (Simba) Gill, Ph.D.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">President and Chief Executive Officer</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Date: July 29, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ Luca Scavo</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Luca Scavo</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Chief Financial Officer</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(Principal Financial Officer)</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>eveloq22021ex103non-employ.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4410ada7787b4dce91dbbcf14c5a93fc_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Evelo Biosciences, Inc.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non-Employee Director Compensation Program</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Non-employee members of the board of directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of Evelo Biosciences, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as amended by the Board effective June 9, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The cash and equity compensation described in this Program shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Non-Employee Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) who is entitled to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company.  This Program shall remain in effect until it is revised or rescinded by further action of the Board.  This Program may be amended, modified or terminated by the Board at any time in its sole discretion.  The terms and conditions of this Program shall supersede any prior cash and&#47;or equity compensation arrangements for service as a member of the Board between the Company and any of its Non-Employee Directors.  No Non-Employee Director shall have any rights hereunder, except with respect to stock options granted pursuant to the Program.  This Program shall become effective on the Effective Date.</font></div><div style="margin-bottom:12pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.&#160;&#160;&#160;&#160;Cash Compensation</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Non-Employee Director shall receive an annual retainer of $40,000 for service on the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Annual Retainer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Annual Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition, each Non-Employee Director shall receive the following annual retainers (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Committee Member Retainer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27pt">Chairman of the Board or Lead Independent Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A Non-Employee Director serving as Chairman of the Board or Lead Independent Director shall receive an additional annual retainer of $30,000 for such service. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27pt">Audit Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A Non-Employee Director serving as Chairperson of the Audit Committee shall receive an additional annual retainer of $15,000 for such service. A Non-Employee Director serving as a member other than the Chairperson of the Audit Committee shall receive an additional annual retainer of $7,500 for such service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27pt">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A Non-Employee Director serving as Chairperson of the Compensation Committee shall receive an additional annual retainer of $10,000 for such service. A Non-Employee Director serving as a member other than the Chairperson of the Compensation Committee shall receive an additional annual retainer of $5,000 for such service. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27pt">Nominating and Corporate Governance Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A Non-Employee Director serving as Chairperson of the Nominating and Corporate Governance </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;revised 09 Jun 2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Committee shall receive an additional annual retainer of $8,000 for such service. A Non-Employee Director serving as a member other than the Chairperson of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $4,000 for such service. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27pt">Scientific and Technology Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A Non-Employee Director serving as Chairperson of the Scientific and Technology Committee shall receive an additional annual retainer of $8,000 for such service. A Non-Employee Director serving as a member other than the Chairperson of the Scientific and Technology Committee shall receive an additional annual retainer of $4,000 for such service. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;C.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment of Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Annual Retainer and Committee Member Retainer shall be earned on a quarterly basis based on a calendar quarter and shall be paid in cash by the Company in arrears not later than the fifteenth day following the end of each calendar quarter.  In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described in Section I(B), for an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for the portion of such calendar quarter actually served as a Non-Employee Director, or in such position, as applicable.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">II.&#160;&#160;&#160;&#160;Equity Compensation </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Non-Employee Directors shall be granted the equity awards described below.  The awards described below shall be granted under and shall be subject to the terms and provisions of the Company&#8217;s 2018 Incentive Award Plan or any other applicable Company equity incentive plan then-maintained by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Equity Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and shall be granted subject to award agreements, including attached exhibits, in substantially the form previously approved by the Board.  All applicable terms of the Equity Plan apply to this Program as if fully set forth herein, and all grants of stock options hereby are subject in all respects to the terms of the Equity Plan and the applicable award agreement.  For the avoidance of doubt, the share numbers in Sections II(A) and II(B) shall be subject to adjustment as provided in the Equity Plan, and in connection with any stock dividend, stock split, reverse stock split or other similar event affecting the Company&#8217;s common stock that is effected prior to the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Non-Employee Director who is initially elected or appointed to the Board after the Effective Date shall receive an option to purchase 35,000 shares of the Company&#8217;s common stock on the date of such initial election or appointment. The awards described in this Section II(A) shall be referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Initial Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;  No Non-Employee Director shall be granted more than one Initial Award. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subsequent Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A Non-Employee Director who (i) has been serving as a Non-Employee Director on the Board for at least six months as of the date of any annual meeting of the Company&#8217;s stockholders after the Effective Date and (ii) will continue to serve as a Non-Employee Director immediately following such meeting, shall be automatically granted an option to purchase 17,500 shares of the Company&#8217;s common stock on the date of such annual meeting.  The awards described in this Section II(B) shall be referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;  For the avoidance of doubt, a Non-Employee Director elected for the first time to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">revised 09 Jun 2021</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Board at an annual meeting of the Company&#8217;s stockholders shall only receive an Initial Award in connection with such election, and shall not receive any Subsequent Award on the date of such meeting as well.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination of Employment of Employee Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their employment with the Company and any parent or subsidiary of the Company and remain on the Board will not receive an Initial Award pursuant to Section II(A) above, but to the extent that they are otherwise entitled, will receive, after termination of employment with the Company and any parent or subsidiary of the Company, Subsequent Awards as described in Section II(B) above.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">D.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Terms of Awards Granted to Non-Employee Directors</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1.  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The per share exercise price of each option granted to a Non-Employee Director shall equal the Fair Market Value (as defined in the Equity Plan) of a share of the Company&#8217;s common stock on the date the option is granted. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Initial Award shall vest and become exercisable in thirty-six (36) substantially equal monthly installments following the date of grant, such that the Initial Award shall be fully vested on the third anniversary of the date of grant, subject to the Non-Employee Director continuing in service as a Non-Employee Director through each such vesting date.  Each Subsequent Award shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Company&#8217;s stockholders occurring after the date of grant, in either case subject to the Non-Employee Director continuing in service on the Board as a Non-Employee Director through each such vesting date.  Unless the Board otherwise determines, any portion of an Initial Award or Subsequent Award which is unvested or unexercisable at the time of a Non-Employee Director&#8217;s termination of service on the Board as a Non-Employee Director shall be immediately forfeited upon such termination of service and shall not thereafter become vested and exercisable.  All of a Non-Employee Director&#8217;s Initial Awards and Subsequent Awards shall vest in full immediately prior to the occurrence of a Change in Control (as defined in the Equity Plan), to the extent outstanding at such time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The maximum term of each stock option granted to a Non-Employee Director hereunder shall be ten (10) years from the date the option is granted. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">* * * * *</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">revised 09 Jun 2021</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>eveloq2202110-qexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i738d71971e9e48259accb5c9460c5637_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Balkrishan (Simba) Gill, Ph.D., certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Quarterly Report on Form 10-Q of Evelo Biosciences, Inc.&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.78pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:5.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.254%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.774%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; July 29, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Balkrishan (Simba) Gill, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balkrishan (Simba) Gill, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Executive Officer)</font></div><div><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>eveloq2202110-qexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ifb010ad5db32442bb0ab812f09f84735_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 31.2</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Luca Scavo, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:139%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q of Evelo Biosciences, Inc.&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:139%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:139%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:139%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:139%">&#160;</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:5.78pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:5.78pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:5.78pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.52pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:139%">&#160;</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:5.78pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:5.78pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.618%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; July 29, 2021</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Luca Scavo</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Luca Scavo</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer, Senior Vice President and Treasurer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>eveloq2202110-qexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i139bb55c393641979e907a834520e45b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 32.1</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Balkrishan (Simba) Gill, Ph.D., President and Chief Executive Officer of Evelo Biosciences, Inc. (the &#8220;Company&#8221;), hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:139%">&#160;</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:5.78pt">the Quarterly Report on Form 10-Q of the Company for the quarterly period ended June 30, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:5.78pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:36.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.048%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; July 29, 2021</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Balkrishan (Simba) Gill, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balkrishan (Simba) Gill, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>eveloq2202110-qexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib92a3da65eac4d94b7282773c72a7618_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 32.2</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Luca Scavo, Chief Financial Officer, Senior Vice President and Treasurer of Evelo Biosciences, Inc. (the &#8220;Company&#8221;), hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:139%">&#160;</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:5.78pt">the Quarterly Report on Form 10-Q of the Company for the quarterly period ended June 30, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:31.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:5.78pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:36.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.048%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;July 29, 2021</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Luca Scavo</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Luca Scavo</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer, Senior Vice President and Treasurer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;125509901.2&#124;&#124;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>evlo-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:aae86b17-43ea-4a10-aac9-9e83e0002ea1,g:814caf2c-83ae-43b0-8a9b-a2d97aa90ba1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:evlo="http://evelobio.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://evelobio.com/20210630">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evlo-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evlo-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evlo-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evlo-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://evelobio.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://evelobio.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://evelobio.com/role/Organization">
        <link:definition>2101101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationNarrativeDetails" roleURI="http://evelobio.com/role/OrganizationNarrativeDetails">
        <link:definition>2402401 - Disclosure - Organization - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ALJCommercializationandLicenseAgreement" roleURI="http://evelobio.com/role/ALJCommercializationandLicenseAgreement">
        <link:definition>2108103 - Disclosure - ALJ Commercialization and License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ALJCommercializationandLicenseAgreementDetails" roleURI="http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails">
        <link:definition>2409404 - Disclosure - ALJ Commercialization and License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://evelobio.com/role/Leases">
        <link:definition>2110104 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://evelobio.com/role/LeasesTables">
        <link:definition>2311302 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://evelobio.com/role/LeasesNarrativeDetails">
        <link:definition>2412405 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails" roleURI="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails">
        <link:definition>2413406 - Disclosure - Leases - Schedule of Minimum Aggregate Future Lease Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1" roleURI="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1">
        <link:definition>2413406 - Disclosure - Leases - Schedule of Minimum Aggregate Future Lease Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://evelobio.com/role/FairValueMeasurements">
        <link:definition>2114105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://evelobio.com/role/FairValueMeasurementsTables">
        <link:definition>2315303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>2416407 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://evelobio.com/role/PropertyandEquipmentNet">
        <link:definition>2117106 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://evelobio.com/role/PropertyandEquipmentNetTables">
        <link:definition>2318304 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" roleURI="http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails">
        <link:definition>2419408 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetNarrativeDetails" roleURI="http://evelobio.com/role/PropertyandEquipmentNetNarrativeDetails">
        <link:definition>2420409 - Disclosure - Property and Equipment, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanandSecurityAgreements" roleURI="http://evelobio.com/role/LoanandSecurityAgreements">
        <link:definition>2121107 - Disclosure - Loan and Security Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanandSecurityAgreementsTables" roleURI="http://evelobio.com/role/LoanandSecurityAgreementsTables">
        <link:definition>2322305 - Disclosure - Loan and Security Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanandSecurityAgreementsNarrativeDetails" roleURI="http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails">
        <link:definition>2423410 - Disclosure - Loan and Security Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails" roleURI="http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails">
        <link:definition>2424411 - Disclosure - Loan and Security Agreements - Significant Unobservable Inputs (level 3 Inputs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanandSecurityAgreementsFairValueofWarrantDetails" roleURI="http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails">
        <link:definition>2425412 - Disclosure - Loan and Security Agreements - Fair Value of Warrant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails" roleURI="http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails">
        <link:definition>2426413 - Disclosure - Loan and Security Agreements - Schedule of Minimum Aggregate Future Loan Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InLicenseAgreements" roleURI="http://evelobio.com/role/InLicenseAgreements">
        <link:definition>2127108 - Disclosure - In-License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InLicenseAgreementsNarrativeDetails" roleURI="http://evelobio.com/role/InLicenseAgreementsNarrativeDetails">
        <link:definition>2428414 - Disclosure - In-License Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://evelobio.com/role/CommitmentsandContingencies">
        <link:definition>2129109 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2430415 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://evelobio.com/role/StockholdersEquity">
        <link:definition>2131110 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://evelobio.com/role/StockholdersEquityDetails">
        <link:definition>2432416 - Disclosure - Stockholders&#8217; Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://evelobio.com/role/StockBasedCompensation">
        <link:definition>2133111 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://evelobio.com/role/StockBasedCompensationTables">
        <link:definition>2334306 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://evelobio.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2435417 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails" roleURI="http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails">
        <link:definition>2436418 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityDetails" roleURI="http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails">
        <link:definition>2437419 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails" roleURI="http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails">
        <link:definition>2438420 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://evelobio.com/role/IncomeTaxes">
        <link:definition>2139112 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://evelobio.com/role/IncomeTaxesDetails">
        <link:definition>2440421 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://evelobio.com/role/NetLossPerShare">
        <link:definition>2141113 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://evelobio.com/role/NetLossPerShareTables">
        <link:definition>2342307 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails" roleURI="http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails">
        <link:definition>2443422 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://evelobio.com/role/RelatedPartyTransactions">
        <link:definition>2144114 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsNarrativeDetails" roleURI="http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails">
        <link:definition>2445423 - Disclosure - Related Party Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="evlo_SecurityAndLoanAgreementTrancheOneMember" abstract="true" name="SecurityAndLoanAgreementTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_DebtInstrumentTrancheAxis" abstract="true" name="DebtInstrumentTrancheAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="evlo_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod" abstract="false" name="RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evlo_TwoThousandAndEighteenStockIncentivePlanMember" abstract="true" name="TwoThousandAndEighteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evlo_CommitmentAndContingenciesLineItems" abstract="true" name="CommitmentAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evlo_SaleOfStockGrossConsiderationReceivedOnTransaction" abstract="false" name="SaleOfStockGrossConsiderationReceivedOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_UniversityOfChicagoMember" abstract="true" name="UniversityOfChicagoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_DebtInstrumentTrancheDomain" abstract="true" name="DebtInstrumentTrancheDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_EmergingGrowthCompanyStatusPolicyTextBlock" abstract="false" name="EmergingGrowthCompanyStatusPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evlo_RegistrationStatementMember" abstract="true" name="RegistrationStatementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices" abstract="false" name="CollaborativeArrangementPeriodOfInactiveManufacturingServices" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evlo_FeeIncurredUnderCollaborativeArrangement" abstract="false" name="FeeIncurredUnderCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_WeatherdenLtdMember" abstract="true" name="WeatherdenLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage" abstract="false" name="DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evlo_NonCashOperatingLeaseExpense" abstract="false" name="NonCashOperatingLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage" abstract="false" name="DebtInstrumentRepaymentOrPrepaymentFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evlo_RelatedPartyTransactionConsultingContractRenewalTerm" abstract="false" name="RelatedPartyTransactionConsultingContractRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction" abstract="false" name="SaleOfStockMaximumValueOfSharesIssuedInTransaction" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_MayoClinicMember" abstract="true" name="MayoClinicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue" abstract="false" name="RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_TwoThousandAndFifteenStockIncentivePlanMember" abstract="true" name="TwoThousandAndFifteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum" abstract="false" name="CollaborativeArrangementSecondProductCandidateFeeMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_SocialSecurityTaxEmployerDeferralCARESAct" abstract="false" name="SocialSecurityTaxEmployerDeferralCARESAct" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_SecurityAndLoanAgreementTrancheTwoMember" abstract="true" name="SecurityAndLoanAgreementTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_VL46Member" abstract="true" name="VL46Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod" abstract="false" name="CollaborativeArrangementSecondProductCandidateNegotiationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evlo_NonCashInterestExpense" abstract="false" name="NonCashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evlo_SecurityAndLoanAgreementTrancheThreeMember" abstract="true" name="SecurityAndLoanAgreementTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_SaleOfStockConsiderationReceivedTerm" abstract="false" name="SaleOfStockConsiderationReceivedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue" abstract="false" name="RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_ComputersAndSoftwareMember" abstract="true" name="ComputersAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_NonRefundableUpfrontFee" abstract="false" name="NonRefundableUpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_DebtInstrumentDebtDefaultPercentage" abstract="false" name="DebtInstrumentDebtDefaultPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evlo_CommitmentAndContingenciesTable" abstract="true" name="CommitmentAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="evlo_SaccoS.r.l.Member" abstract="true" name="SaccoS.r.l.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_AggregateAmountDueUnderCollaborativeArrangement" abstract="false" name="AggregateAmountDueUnderCollaborativeArrangement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts" abstract="false" name="MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_PublicOfferingCostInAccruedExpense" abstract="false" name="PublicOfferingCostInAccruedExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_UnvestedCommonStockMember" abstract="true" name="UnvestedCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_CollaborationArrangementTerm" abstract="false" name="CollaborationArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evlo_ConsultingAgreementMember" abstract="true" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_SecurityAndLoanAgreementNumberOfTranches" abstract="false" name="SecurityAndLoanAgreementNumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evlo_TwoThousandAndTwentyOneStockInducementPlanMember" abstract="true" name="TwoThousandAndTwentyOneStockInducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne" abstract="false" name="DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage" abstract="false" name="CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm" abstract="false" name="RelatedPartyTransactionConsultingContractTerminationNoticeTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evlo_AnnualAmountDueUnderCollaborativeArrangement" abstract="false" name="AnnualAmountDueUnderCollaborativeArrangement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_AmendedCreditFacilityMember" abstract="true" name="AmendedCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm" abstract="false" name="RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evlo_A2018EmployeeStockPurchasePlanMember" abstract="true" name="A2018EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_SecurityAndLoanAgreementTrancheFourMember" abstract="true" name="SecurityAndLoanAgreementTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evlo_ClassOfWarrantOrRightFairValueMeasurement" abstract="false" name="ClassOfWarrantOrRightFairValueMeasurement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_MeddistCompanyLimitedMember" abstract="true" name="MeddistCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_A2019CreditFacilityMember" abstract="true" name="A2019CreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evlo_RelatedPartyTransactionAnnualCashConsultingFee" abstract="false" name="RelatedPartyTransactionAnnualCashConsultingFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_AtTheMarketMember" abstract="true" name="AtTheMarketMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal" abstract="false" name="DebtInstrumentPrepaymentFeePercentageOnPrincipal" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" abstract="false" name="MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" abstract="false" name="DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>evlo-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:aae86b17-43ea-4a10-aac9-9e83e0002ea1,g:814caf2c-83ae-43b0-8a9b-a2d97aa90ba1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="evlo-20210630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_546ee0c9-54e3-429f-abbf-9284f9ebb546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_85dadea6-da1d-46c3-b4d6-fb332a949589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_546ee0c9-54e3-429f-abbf-9284f9ebb546" xlink:to="loc_us-gaap_LiabilitiesCurrent_85dadea6-da1d-46c3-b4d6-fb332a949589" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c5ec6c28-8f49-4856-bcd4-7d5750c1f109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_546ee0c9-54e3-429f-abbf-9284f9ebb546" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c5ec6c28-8f49-4856-bcd4-7d5750c1f109" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_887b985b-6923-4fe7-bc26-336cf0612a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_546ee0c9-54e3-429f-abbf-9284f9ebb546" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_887b985b-6923-4fe7-bc26-336cf0612a6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_463fe4e3-eb27-46b8-9305-a99edddb6168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_546ee0c9-54e3-429f-abbf-9284f9ebb546" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_463fe4e3-eb27-46b8-9305-a99edddb6168" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_37e9266d-9330-4e0a-aed4-b3bfe0f01af1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_546ee0c9-54e3-429f-abbf-9284f9ebb546" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_37e9266d-9330-4e0a-aed4-b3bfe0f01af1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1db15c86-d9d3-482d-861e-89a6b981cc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_108fd866-0162-411d-965d-59eece41111d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1db15c86-d9d3-482d-861e-89a6b981cc7f" xlink:to="loc_us-gaap_PreferredStockValue_108fd866-0162-411d-965d-59eece41111d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_81c38f58-598c-412f-b467-30b2a80e425a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1db15c86-d9d3-482d-861e-89a6b981cc7f" xlink:to="loc_us-gaap_CommonStockValue_81c38f58-598c-412f-b467-30b2a80e425a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_477b6e22-de27-432f-89cd-4a1d2a1492d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1db15c86-d9d3-482d-861e-89a6b981cc7f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_477b6e22-de27-432f-89cd-4a1d2a1492d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b0250a76-16ed-4b93-972d-551dd977a123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1db15c86-d9d3-482d-861e-89a6b981cc7f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b0250a76-16ed-4b93-972d-551dd977a123" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f4cfbad7-2449-46f7-84da-e1225e754480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_250a0348-871b-4094-80f8-2f698d6ffe5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f4cfbad7-2449-46f7-84da-e1225e754480" xlink:to="loc_us-gaap_Liabilities_250a0348-871b-4094-80f8-2f698d6ffe5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6e48ff5f-5edc-4f74-b1a9-d1992a1873d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f4cfbad7-2449-46f7-84da-e1225e754480" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6e48ff5f-5edc-4f74-b1a9-d1992a1873d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f886b8b9-9f8b-4179-a7c7-c61b01294cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f4cfbad7-2449-46f7-84da-e1225e754480" xlink:to="loc_us-gaap_StockholdersEquity_f886b8b9-9f8b-4179-a7c7-c61b01294cd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5fa354fb-db49-42cc-b47d-fc3223fa9c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_164a4277-672e-4bdf-be6e-eeef2ad47d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5fa354fb-db49-42cc-b47d-fc3223fa9c17" xlink:to="loc_us-gaap_AccountsPayableCurrent_164a4277-672e-4bdf-be6e-eeef2ad47d19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f91c5864-7ebf-4e99-9c2e-ee617ca18c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5fa354fb-db49-42cc-b47d-fc3223fa9c17" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f91c5864-7ebf-4e99-9c2e-ee617ca18c58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ba10ad35-1ea2-4bb7-ba53-90964fd5f707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5fa354fb-db49-42cc-b47d-fc3223fa9c17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ba10ad35-1ea2-4bb7-ba53-90964fd5f707" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_94cfc603-b565-4491-af9c-58d49062bf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5fa354fb-db49-42cc-b47d-fc3223fa9c17" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_94cfc603-b565-4491-af9c-58d49062bf7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ec06b6fa-68a6-4b03-9d73-b66518899378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_554c277b-e771-4b1d-8a86-bb614e079b54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ec06b6fa-68a6-4b03-9d73-b66518899378" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_554c277b-e771-4b1d-8a86-bb614e079b54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dcfe5def-1138-42ae-8605-681c0b1e85bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ec06b6fa-68a6-4b03-9d73-b66518899378" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dcfe5def-1138-42ae-8605-681c0b1e85bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3c9de28f-71db-4360-8e8d-8d6234f0f6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e2d9a661-45b1-4aa1-980d-fcbdaf0af9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c9de28f-71db-4360-8e8d-8d6234f0f6af" xlink:to="loc_us-gaap_AssetsCurrent_e2d9a661-45b1-4aa1-980d-fcbdaf0af9e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_353c9e95-5cfd-49bf-9c94-65dfbaa67dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c9de28f-71db-4360-8e8d-8d6234f0f6af" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_353c9e95-5cfd-49bf-9c94-65dfbaa67dce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_555044f6-2a54-4fe4-b084-e18163ae3d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c9de28f-71db-4360-8e8d-8d6234f0f6af" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_555044f6-2a54-4fe4-b084-e18163ae3d8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b0110e45-cff7-4179-b454-f98cdcb20556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c9de28f-71db-4360-8e8d-8d6234f0f6af" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b0110e45-cff7-4179-b454-f98cdcb20556" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="evlo-20210630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ff3e12e6-1de5-4a5b-aaab-5672b7430408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e07806ca-cc48-4ddd-b520-b88378c0ff5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ff3e12e6-1de5-4a5b-aaab-5672b7430408" xlink:to="loc_us-gaap_OperatingExpenses_e07806ca-cc48-4ddd-b520-b88378c0ff5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ed9a0e10-ad89-47e4-b155-df40147d7ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ef6d7228-32e9-44ed-9793-d37a64631a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ed9a0e10-ad89-47e4-b155-df40147d7ee5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ef6d7228-32e9-44ed-9793-d37a64631a14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_888f8b26-eb4a-4443-8ef3-2f3b1b7684eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ed9a0e10-ad89-47e4-b155-df40147d7ee5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_888f8b26-eb4a-4443-8ef3-2f3b1b7684eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_13a998a4-2c8a-47eb-bb28-7b3c79f902ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_124132a2-1ad0-4d75-a4ac-4058aa42bbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_13a998a4-2c8a-47eb-bb28-7b3c79f902ae" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_124132a2-1ad0-4d75-a4ac-4058aa42bbfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_78dba2b2-7d15-4af9-a743-a7bc3cbfc822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_13a998a4-2c8a-47eb-bb28-7b3c79f902ae" xlink:to="loc_us-gaap_OperatingIncomeLoss_78dba2b2-7d15-4af9-a743-a7bc3cbfc822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9741bf6a-5bc5-409d-a294-74d1c264f9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_054de56d-18de-4f96-a5f9-79619a0be498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9741bf6a-5bc5-409d-a294-74d1c264f9f7" xlink:to="loc_us-gaap_InvestmentIncomeNet_054de56d-18de-4f96-a5f9-79619a0be498" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b586e829-e871-49ca-b6ac-3582579a1c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9741bf6a-5bc5-409d-a294-74d1c264f9f7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b586e829-e871-49ca-b6ac-3582579a1c8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2c63a2cc-4c90-4da7-b452-efe6f6a5f331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9741bf6a-5bc5-409d-a294-74d1c264f9f7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2c63a2cc-4c90-4da7-b452-efe6f6a5f331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_34a5cf75-441b-4abd-8cde-a828430282e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a267ec1d-d87c-4b15-8202-cbebff5385e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_34a5cf75-441b-4abd-8cde-a828430282e4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a267ec1d-d87c-4b15-8202-cbebff5385e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7b2fa593-ccfe-4dd5-9c3b-105e0c75410d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_34a5cf75-441b-4abd-8cde-a828430282e4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7b2fa593-ccfe-4dd5-9c3b-105e0c75410d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="evlo-20210630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a2b9adf-6505-40c9-bf81-972ad555b7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ed33bd55-a8e9-4265-9619-f952624ff62b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a2b9adf-6505-40c9-bf81-972ad555b7d9" xlink:to="loc_us-gaap_NetIncomeLoss_ed33bd55-a8e9-4265-9619-f952624ff62b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_52e6cc8b-efdf-4052-ad99-23214d382e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a2b9adf-6505-40c9-bf81-972ad555b7d9" xlink:to="loc_us-gaap_ShareBasedCompensation_52e6cc8b-efdf-4052-ad99-23214d382e64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f66e5048-2d3b-47c1-a441-7ac89da78b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a2b9adf-6505-40c9-bf81-972ad555b7d9" xlink:to="loc_us-gaap_Depreciation_f66e5048-2d3b-47c1-a441-7ac89da78b1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonCashInterestExpense_a3ffce1f-cad0-4fc5-b764-056cb5aa0695" xlink:href="evlo-20210630.xsd#evlo_NonCashInterestExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a2b9adf-6505-40c9-bf81-972ad555b7d9" xlink:to="loc_evlo_NonCashInterestExpense_a3ffce1f-cad0-4fc5-b764-056cb5aa0695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonCashOperatingLeaseExpense_c75d4a98-7f34-4c6a-814b-7f75f45d0f91" xlink:href="evlo-20210630.xsd#evlo_NonCashOperatingLeaseExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a2b9adf-6505-40c9-bf81-972ad555b7d9" xlink:to="loc_evlo_NonCashOperatingLeaseExpense_c75d4a98-7f34-4c6a-814b-7f75f45d0f91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9b553c22-9cd3-4431-b0cb-0a1c171db253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a2b9adf-6505-40c9-bf81-972ad555b7d9" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9b553c22-9cd3-4431-b0cb-0a1c171db253" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_671fc6ed-9af3-4854-a194-0842892ae210" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a2b9adf-6505-40c9-bf81-972ad555b7d9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_671fc6ed-9af3-4854-a194-0842892ae210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5a4bf94f-36d4-45fb-92b0-c9ee0492c8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a2b9adf-6505-40c9-bf81-972ad555b7d9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5a4bf94f-36d4-45fb-92b0-c9ee0492c8c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_6a59b39a-297b-406c-a7f6-277b13a19c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a2b9adf-6505-40c9-bf81-972ad555b7d9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_6a59b39a-297b-406c-a7f6-277b13a19c00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_771122bd-92f9-46b9-9ec0-0a751bce9341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a2b9adf-6505-40c9-bf81-972ad555b7d9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_771122bd-92f9-46b9-9ec0-0a751bce9341" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_080e4ba5-c4e9-4e5a-8d2c-2e25cd646115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a2b9adf-6505-40c9-bf81-972ad555b7d9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_080e4ba5-c4e9-4e5a-8d2c-2e25cd646115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_edd5c206-bcf6-496c-8c14-fead22d1fd33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a2b9adf-6505-40c9-bf81-972ad555b7d9" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_edd5c206-bcf6-496c-8c14-fead22d1fd33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_64539e2c-5e4a-4f92-bffe-d4bae409eda6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a2b9adf-6505-40c9-bf81-972ad555b7d9" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_64539e2c-5e4a-4f92-bffe-d4bae409eda6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a9ba2287-bf77-4820-81b7-b464f0cfda95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59341bef-7cac-4a05-a346-9c510c71e422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a9ba2287-bf77-4820-81b7-b464f0cfda95" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59341bef-7cac-4a05-a346-9c510c71e422" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5603f965-0516-4ad0-a68d-d77ad15368f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a9ba2287-bf77-4820-81b7-b464f0cfda95" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5603f965-0516-4ad0-a68d-d77ad15368f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_292ef6ae-531d-4c97-bcb9-a75eccc73d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a9ba2287-bf77-4820-81b7-b464f0cfda95" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_292ef6ae-531d-4c97-bcb9-a75eccc73d3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_527e175e-10ef-48a1-b381-7f3b8db648dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d0fb175f-1464-4620-9274-8875aaab6536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_527e175e-10ef-48a1-b381-7f3b8db648dc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d0fb175f-1464-4620-9274-8875aaab6536" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_aa2e872e-2793-40c1-a9a1-5fc6eb6bba23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_527e175e-10ef-48a1-b381-7f3b8db648dc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_aa2e872e-2793-40c1-a9a1-5fc6eb6bba23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d27da56a-8b67-4a48-b4b5-45f1013ec948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_527e175e-10ef-48a1-b381-7f3b8db648dc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d27da56a-8b67-4a48-b4b5-45f1013ec948" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ce49ee9-68b0-469e-beb2-e58c75fd4edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6aaa9764-3451-4ed1-bf75-d8ed54feacd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ce49ee9-68b0-469e-beb2-e58c75fd4edb" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6aaa9764-3451-4ed1-bf75-d8ed54feacd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_d2e0b4c0-a395-4a72-9f8e-1a8557ecb241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ce49ee9-68b0-469e-beb2-e58c75fd4edb" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_d2e0b4c0-a395-4a72-9f8e-1a8557ecb241" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_17d2064a-b8df-47c5-aab1-7fcf48ebb852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_165b15f2-9f2b-4f17-96e9-7da23edc3307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_17d2064a-b8df-47c5-aab1-7fcf48ebb852" xlink:to="loc_us-gaap_Cash_165b15f2-9f2b-4f17-96e9-7da23edc3307" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_88fd8640-f962-4780-bd6a-b69a216b4d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_17d2064a-b8df-47c5-aab1-7fcf48ebb852" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_88fd8640-f962-4780-bd6a-b69a216b4d19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a9d53b8-fe34-4bdd-a3b0-c47f189b4d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7c1eea0f-3411-4b88-a585-f2acde9402f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a9d53b8-fe34-4bdd-a3b0-c47f189b4d9f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7c1eea0f-3411-4b88-a585-f2acde9402f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_79acf433-6d27-483f-b018-f54dfd2f7e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a9d53b8-fe34-4bdd-a3b0-c47f189b4d9f" xlink:to="loc_us-gaap_RestrictedCash_79acf433-6d27-483f-b018-f54dfd2f7e2a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_11b149d6-39f8-491d-baa0-b10097e1c160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a99518f6-81b9-4758-9065-70d83c4b2965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_11b149d6-39f8-491d-baa0-b10097e1c160" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a99518f6-81b9-4758-9065-70d83c4b2965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d2f06cbf-b381-47ff-8c23-ea945b466181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_11b149d6-39f8-491d-baa0-b10097e1c160" xlink:to="loc_us-gaap_OperatingLeaseLiability_d2f06cbf-b381-47ff-8c23-ea945b466181" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="evlo-20210630.xsd#LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36fed762-439b-4130-9d54-20396b5a279f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2f64ef1d-4d7e-4ddb-86a0-8f270f17e788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36fed762-439b-4130-9d54-20396b5a279f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2f64ef1d-4d7e-4ddb-86a0-8f270f17e788" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dbd39fbd-4bff-46be-90d1-d268671aa3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36fed762-439b-4130-9d54-20396b5a279f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dbd39fbd-4bff-46be-90d1-d268671aa3fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_62c3c5f8-88aa-4860-8483-d5dce011d3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36fed762-439b-4130-9d54-20396b5a279f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_62c3c5f8-88aa-4860-8483-d5dce011d3d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c073f0bd-7abf-4098-90e8-e75416252b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36fed762-439b-4130-9d54-20396b5a279f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c073f0bd-7abf-4098-90e8-e75416252b2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dce2e1ee-a2e1-4fc5-9e1d-ef410597ea6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36fed762-439b-4130-9d54-20396b5a279f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dce2e1ee-a2e1-4fc5-9e1d-ef410597ea6a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_03154f0a-033b-47a9-9428-a054c2dee0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_50f3877e-2ace-482b-8ba5-069f4a5f90db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_03154f0a-033b-47a9-9428-a054c2dee0f1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_50f3877e-2ace-482b-8ba5-069f4a5f90db" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b9eca396-b2cc-4c2f-b6a9-137f0c79c0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_246f33bf-0d43-400a-9827-03acbc8613ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_b9eca396-b2cc-4c2f-b6a9-137f0c79c0b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_246f33bf-0d43-400a-9827-03acbc8613ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9f90df2d-3058-48d5-a39d-5b93eb14960f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_b9eca396-b2cc-4c2f-b6a9-137f0c79c0b4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9f90df2d-3058-48d5-a39d-5b93eb14960f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"/>
  <link:calculationLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_78148b92-acef-4a7a-8fd3-63fe376e6082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_e857daf8-2ef6-46b3-8ca0-8c8df8510ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_78148b92-acef-4a7a-8fd3-63fe376e6082" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_e857daf8-2ef6-46b3-8ca0-8c8df8510ff1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_41cac200-e67f-4c80-b55a-688355c8000d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_78148b92-acef-4a7a-8fd3-63fe376e6082" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_41cac200-e67f-4c80-b55a-688355c8000d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_a663bb2f-323d-4be3-9431-fadaf25b5644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_78148b92-acef-4a7a-8fd3-63fe376e6082" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_a663bb2f-323d-4be3-9431-fadaf25b5644" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_308ebd50-44df-4fe3-8859-83d5b183f562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_78148b92-acef-4a7a-8fd3-63fe376e6082" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_308ebd50-44df-4fe3-8859-83d5b183f562" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4e70d8ac-2064-4d92-8bbd-8d41c95844e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0ed57ba9-9c1a-4dfb-90ba-b7c701232edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4e70d8ac-2064-4d92-8bbd-8d41c95844e7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0ed57ba9-9c1a-4dfb-90ba-b7c701232edb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5ff6f9ac-8947-4525-bbea-580190ec1b60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4e70d8ac-2064-4d92-8bbd-8d41c95844e7" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5ff6f9ac-8947-4525-bbea-580190ec1b60" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>evlo-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:aae86b17-43ea-4a10-aac9-9e83e0002ea1,g:814caf2c-83ae-43b0-8a9b-a2d97aa90ba1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="evlo-20210630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i13c05558a3e341aba24a5a4eaf1dc8cf_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2ee098b0-00bf-4b68-b15a-8fa9d775fc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2ee098b0-00bf-4b68-b15a-8fa9d775fc76" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_286eaed4-0289-472b-a11a-2f9722123199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_SharesOutstanding_286eaed4-0289-472b-a11a-2f9722123199" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3f666921-947a-4c2c-92c5-7df0caac4dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockholdersEquity_3f666921-947a-4c2c-92c5-7df0caac4dcf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4e76d485-c06a-4474-b0b1-6a1545cabe6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4e76d485-c06a-4474-b0b1-6a1545cabe6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_385fcf78-cea8-4c75-8a10-17f22cea82cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_385fcf78-cea8-4c75-8a10-17f22cea82cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_26f49c8e-4332-4948-b768-a4f45dcf194b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_26f49c8e-4332-4948-b768-a4f45dcf194b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_92778586-dc82-4870-8efe-f1d33a6434a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_92778586-dc82-4870-8efe-f1d33a6434a6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f4b3b938-bfa0-45c5-8b54-086e03091757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f4b3b938-bfa0-45c5-8b54-086e03091757" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_006c95b5-b217-4952-8dfb-37e3c0683580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_006c95b5-b217-4952-8dfb-37e3c0683580" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4c1e45b9-86b6-4df4-b6b2-9e85cdd16763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4c1e45b9-86b6-4df4-b6b2-9e85cdd16763" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a2baf3a1-c962-4855-a442-072439e1b737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a2baf3a1-c962-4855-a442-072439e1b737" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4fe295c7-e3a7-4d0c-966b-86048abf101c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4fe295c7-e3a7-4d0c-966b-86048abf101c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_de5c5bc5-7575-4cc7-83b8-1fbd31228248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_de5c5bc5-7575-4cc7-83b8-1fbd31228248" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6707c7da-fb78-4946-8e7b-f77365d4be78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_NetIncomeLoss_6707c7da-fb78-4946-8e7b-f77365d4be78" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_90abaa06-7fc0-4517-85ba-4d0f14c77e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eb42f339-f638-4c26-8a75-326264764d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fb9fe387-8f1c-46ff-9c4a-bd38476c2db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2ee098b0-00bf-4b68-b15a-8fa9d775fc76" xlink:to="loc_us-gaap_StatementTable_fb9fe387-8f1c-46ff-9c4a-bd38476c2db0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fc785c95-cfe1-4c15-9f5a-56816142cbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_fb9fe387-8f1c-46ff-9c4a-bd38476c2db0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fc785c95-cfe1-4c15-9f5a-56816142cbaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fc785c95-cfe1-4c15-9f5a-56816142cbaa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fc785c95-cfe1-4c15-9f5a-56816142cbaa" xlink:to="loc_us-gaap_EquityComponentDomain_fc785c95-cfe1-4c15-9f5a-56816142cbaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5d735167-cd7d-4dce-8348-94310eb2a90d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fc785c95-cfe1-4c15-9f5a-56816142cbaa" xlink:to="loc_us-gaap_EquityComponentDomain_5d735167-cd7d-4dce-8348-94310eb2a90d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_97f0f4fe-cc2b-4610-90b7-7545a079649a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5d735167-cd7d-4dce-8348-94310eb2a90d" xlink:to="loc_us-gaap_CommonStockMember_97f0f4fe-cc2b-4610-90b7-7545a079649a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4ca144b9-58ff-42b4-b049-513678c9cfff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5d735167-cd7d-4dce-8348-94310eb2a90d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4ca144b9-58ff-42b4-b049-513678c9cfff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3b077882-9fb2-47ec-8045-d0698979ee28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5d735167-cd7d-4dce-8348-94310eb2a90d" xlink:to="loc_us-gaap_RetainedEarningsMember_3b077882-9fb2-47ec-8045-d0698979ee28" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/OrganizationNarrativeDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#OrganizationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/OrganizationNarrativeDetails" xlink:type="extended" id="i65645d1ad3b74425b558c8393ad7c0a6_OrganizationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction_212716d3-9315-4aa0-abe5-765576d0045e" xlink:href="evlo-20210630.xsd#evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:to="loc_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction_212716d3-9315-4aa0-abe5-765576d0045e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockConsiderationReceivedTerm_440723cf-6ba6-4f04-a8c8-f64e4cfd20b8" xlink:href="evlo-20210630.xsd#evlo_SaleOfStockConsiderationReceivedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:to="loc_evlo_SaleOfStockConsiderationReceivedTerm_440723cf-6ba6-4f04-a8c8-f64e4cfd20b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d35c840b-6b32-496a-abc3-26b2566b3725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d35c840b-6b32-496a-abc3-26b2566b3725" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4268cefa-e098-4839-8d36-a6ad57581e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4268cefa-e098-4839-8d36-a6ad57581e40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction_dce10206-9571-4523-a544-004dc1cd9b3e" xlink:href="evlo-20210630.xsd#evlo_SaleOfStockGrossConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:to="loc_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction_dce10206-9571-4523-a544-004dc1cd9b3e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_25d38aa6-9ad3-4ee7-90a4-8286fccd82c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_25d38aa6-9ad3-4ee7-90a4-8286fccd82c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_94e09183-304d-4d6e-9490-7a740ce3b90b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_94e09183-304d-4d6e-9490-7a740ce3b90b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ffbca50f-b2b4-42e3-b9bb-200fef5e70d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ffbca50f-b2b4-42e3-b9bb-200fef5e70d9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c5e4e980-12dc-42b7-b7b4-b488c09c4ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c5e4e980-12dc-42b7-b7b4-b488c09c4ebc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0280e491-99c0-4b9a-93ad-3e4945daea02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c5e4e980-12dc-42b7-b7b4-b488c09c4ebc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0280e491-99c0-4b9a-93ad-3e4945daea02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0280e491-99c0-4b9a-93ad-3e4945daea02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0280e491-99c0-4b9a-93ad-3e4945daea02" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0280e491-99c0-4b9a-93ad-3e4945daea02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2c8bbc6-2dff-4e31-8c56-8423f59e37cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0280e491-99c0-4b9a-93ad-3e4945daea02" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2c8bbc6-2dff-4e31-8c56-8423f59e37cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RegistrationStatementMember_6d4415bc-f97d-4f53-88c9-049e715b7d82" xlink:href="evlo-20210630.xsd#evlo_RegistrationStatementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2c8bbc6-2dff-4e31-8c56-8423f59e37cc" xlink:to="loc_evlo_RegistrationStatementMember_6d4415bc-f97d-4f53-88c9-049e715b7d82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AtTheMarketMember_42cd2373-6cb5-4552-bc9f-7ce4128573f3" xlink:href="evlo-20210630.xsd#evlo_AtTheMarketMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2c8bbc6-2dff-4e31-8c56-8423f59e37cc" xlink:to="loc_evlo_AtTheMarketMember_42cd2373-6cb5-4552-bc9f-7ce4128573f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_PublicStockOfferingMember_a3e2718f-3f2e-4b9e-ae49-9402b785a8d9" xlink:href="evlo-20210630.xsd#evlo_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2c8bbc6-2dff-4e31-8c56-8423f59e37cc" xlink:to="loc_evlo_PublicStockOfferingMember_a3e2718f-3f2e-4b9e-ae49-9402b785a8d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_a0bbe094-6f9c-469a-a1ca-c046f37baf60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2c8bbc6-2dff-4e31-8c56-8423f59e37cc" xlink:to="loc_us-gaap_OverAllotmentOptionMember_a0bbe094-6f9c-469a-a1ca-c046f37baf60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_41a60288-d0dd-4455-9886-e00618c1e6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2c8bbc6-2dff-4e31-8c56-8423f59e37cc" xlink:to="loc_us-gaap_PrivatePlacementMember_41a60288-d0dd-4455-9886-e00618c1e6aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b89d3008-130e-4132-abec-58a59bc416c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c5e4e980-12dc-42b7-b7b4-b488c09c4ebc" xlink:to="loc_srt_RangeAxis_b89d3008-130e-4132-abec-58a59bc416c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b89d3008-130e-4132-abec-58a59bc416c6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b89d3008-130e-4132-abec-58a59bc416c6" xlink:to="loc_srt_RangeMember_b89d3008-130e-4132-abec-58a59bc416c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb84b563-7e99-45d4-8029-8184df0f9a92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b89d3008-130e-4132-abec-58a59bc416c6" xlink:to="loc_srt_RangeMember_fb84b563-7e99-45d4-8029-8184df0f9a92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1d8efc26-ec09-4341-aca1-a256cc567af6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb84b563-7e99-45d4-8029-8184df0f9a92" xlink:to="loc_srt_MinimumMember_1d8efc26-ec09-4341-aca1-a256cc567af6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2282a6d9-ffc1-4dd8-b9c0-d9ac8e24fda3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb84b563-7e99-45d4-8029-8184df0f9a92" xlink:to="loc_srt_MaximumMember_2282a6d9-ffc1-4dd8-b9c0-d9ac8e24fda3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#ALJCommercializationandLicenseAgreementDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails" xlink:type="extended" id="i5f48f1e2c17445e88a4a1e380acc3b18_ALJCommercializationandLicenseAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86538505-e819-4d97-9d29-a5c4be725b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod_346ea61e-f40a-49b6-af22-feafd4959a30" xlink:href="evlo-20210630.xsd#evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86538505-e819-4d97-9d29-a5c4be725b99" xlink:to="loc_evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod_346ea61e-f40a-49b6-af22-feafd4959a30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum_954f695a-3e1a-4181-96d9-6e6eca047c0b" xlink:href="evlo-20210630.xsd#evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86538505-e819-4d97-9d29-a5c4be725b99" xlink:to="loc_evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum_954f695a-3e1a-4181-96d9-6e6eca047c0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_38855c74-10e5-46ed-8afd-52bf81d28bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86538505-e819-4d97-9d29-a5c4be725b99" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_38855c74-10e5-46ed-8afd-52bf81d28bd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage_bc3b57d8-2233-4794-9b9f-ce4e87702965" xlink:href="evlo-20210630.xsd#evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86538505-e819-4d97-9d29-a5c4be725b99" xlink:to="loc_evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage_bc3b57d8-2233-4794-9b9f-ce4e87702965" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_32392604-33e5-4a45-9e22-58202271fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86538505-e819-4d97-9d29-a5c4be725b99" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_32392604-33e5-4a45-9e22-58202271fd07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_88d42d7f-9098-4ef1-83c5-26698635c6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_32392604-33e5-4a45-9e22-58202271fd07" xlink:to="loc_us-gaap_TypeOfArrangementAxis_88d42d7f-9098-4ef1-83c5-26698635c6ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88d42d7f-9098-4ef1-83c5-26698635c6ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_88d42d7f-9098-4ef1-83c5-26698635c6ec" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88d42d7f-9098-4ef1-83c5-26698635c6ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1ca94aeb-9bd0-4253-adeb-90d14063eb67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_88d42d7f-9098-4ef1-83c5-26698635c6ec" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1ca94aeb-9bd0-4253-adeb-90d14063eb67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_68eb14e7-6ed7-41d2-89b7-3411021708de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1ca94aeb-9bd0-4253-adeb-90d14063eb67" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_68eb14e7-6ed7-41d2-89b7-3411021708de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cea7d292-7455-4738-a3f7-8123d1ccf5f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_32392604-33e5-4a45-9e22-58202271fd07" xlink:to="loc_srt_CounterpartyNameAxis_cea7d292-7455-4738-a3f7-8123d1ccf5f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cea7d292-7455-4738-a3f7-8123d1ccf5f6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_cea7d292-7455-4738-a3f7-8123d1ccf5f6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cea7d292-7455-4738-a3f7-8123d1ccf5f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1315869a-942e-4a28-897b-e8cec03568ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_cea7d292-7455-4738-a3f7-8123d1ccf5f6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1315869a-942e-4a28-897b-e8cec03568ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MeddistCompanyLimitedMember_0c014ad3-eb5c-4f00-a793-5be03aea07cf" xlink:href="evlo-20210630.xsd#evlo_MeddistCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1315869a-942e-4a28-897b-e8cec03568ec" xlink:to="loc_evlo_MeddistCompanyLimitedMember_0c014ad3-eb5c-4f00-a793-5be03aea07cf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended" id="i0e5ecadc924d41cbb14ed415ccd76346_FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b9e47477-e896-40a8-9625-6387e868c82c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_9e1dace3-8d54-4fea-9d26-cbb3b63a8bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b9e47477-e896-40a8-9625-6387e868c82c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_9e1dace3-8d54-4fea-9d26-cbb3b63a8bb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9f2cde9a-01fb-4e5c-9635-0b7817944c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9e1dace3-8d54-4fea-9d26-cbb3b63a8bb1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9f2cde9a-01fb-4e5c-9635-0b7817944c4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7915a04b-4b08-4c7f-b3c2-7b5c1d79e8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9e1dace3-8d54-4fea-9d26-cbb3b63a8bb1" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7915a04b-4b08-4c7f-b3c2-7b5c1d79e8ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_248d32da-d409-43bf-9f84-8e005347aa07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b9e47477-e896-40a8-9625-6387e868c82c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_248d32da-d409-43bf-9f84-8e005347aa07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9226bd87-828c-4bee-a358-7685a183dc04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_248d32da-d409-43bf-9f84-8e005347aa07" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9226bd87-828c-4bee-a358-7685a183dc04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9226bd87-828c-4bee-a358-7685a183dc04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9226bd87-828c-4bee-a358-7685a183dc04" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9226bd87-828c-4bee-a358-7685a183dc04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eef1c9d4-64d7-48e3-981f-87bc48731cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9226bd87-828c-4bee-a358-7685a183dc04" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eef1c9d4-64d7-48e3-981f-87bc48731cd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ef6583b1-edfe-4007-a3a6-af38e4099d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eef1c9d4-64d7-48e3-981f-87bc48731cd9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ef6583b1-edfe-4007-a3a6-af38e4099d73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f45fee8a-e4f7-4120-b9b9-0ec59c144826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eef1c9d4-64d7-48e3-981f-87bc48731cd9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f45fee8a-e4f7-4120-b9b9-0ec59c144826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1b7becea-adb8-478c-9978-05d61244eff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eef1c9d4-64d7-48e3-981f-87bc48731cd9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1b7becea-adb8-478c-9978-05d61244eff2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_cd0c3906-a7ee-430a-85d0-2ed74fb9caa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_248d32da-d409-43bf-9f84-8e005347aa07" xlink:to="loc_us-gaap_FinancialInstrumentAxis_cd0c3906-a7ee-430a-85d0-2ed74fb9caa5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cd0c3906-a7ee-430a-85d0-2ed74fb9caa5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_cd0c3906-a7ee-430a-85d0-2ed74fb9caa5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cd0c3906-a7ee-430a-85d0-2ed74fb9caa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8a05e7d6-fa83-4ecd-a33c-8e16e4b819b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_cd0c3906-a7ee-430a-85d0-2ed74fb9caa5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8a05e7d6-fa83-4ecd-a33c-8e16e4b819b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a9fa49f5-7f0a-45b3-86fc-b067ae884eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8a05e7d6-fa83-4ecd-a33c-8e16e4b819b0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a9fa49f5-7f0a-45b3-86fc-b067ae884eaa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="extended" id="id0a317040fff44a99a3346a84e0479e8_PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f2d97037-a195-46e5-89de-c52c7ebd7165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_d46c7e00-6359-448c-9ba2-f66e7edf29f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f2d97037-a195-46e5-89de-c52c7ebd7165" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_d46c7e00-6359-448c-9ba2-f66e7edf29f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5da04a30-5f70-4b36-8e5f-166d96296d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_d46c7e00-6359-448c-9ba2-f66e7edf29f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5da04a30-5f70-4b36-8e5f-166d96296d0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8dcf573c-9b2c-459c-86eb-7b9c23ba15da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_d46c7e00-6359-448c-9ba2-f66e7edf29f6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8dcf573c-9b2c-459c-86eb-7b9c23ba15da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_78d99fd0-27ae-448c-926c-81de2d2c4a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_d46c7e00-6359-448c-9ba2-f66e7edf29f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_78d99fd0-27ae-448c-926c-81de2d2c4a13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2dde0831-475f-478f-b17e-a8007b04a487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f2d97037-a195-46e5-89de-c52c7ebd7165" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2dde0831-475f-478f-b17e-a8007b04a487" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c960c646-10d4-4831-ac23-ec440a3e30c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2dde0831-475f-478f-b17e-a8007b04a487" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c960c646-10d4-4831-ac23-ec440a3e30c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c960c646-10d4-4831-ac23-ec440a3e30c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c960c646-10d4-4831-ac23-ec440a3e30c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c960c646-10d4-4831-ac23-ec440a3e30c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844b8918-f470-40ec-bc3a-02afc275770e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c960c646-10d4-4831-ac23-ec440a3e30c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844b8918-f470-40ec-bc3a-02afc275770e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_5a4a76bc-7c84-4f23-b17c-8ba44f1e5576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844b8918-f470-40ec-bc3a-02afc275770e" xlink:to="loc_us-gaap_EquipmentMember_5a4a76bc-7c84-4f23-b17c-8ba44f1e5576" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_16526191-1227-4fdd-8194-71ddcba3eaad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844b8918-f470-40ec-bc3a-02afc275770e" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_16526191-1227-4fdd-8194-71ddcba3eaad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c37e0368-a19a-4acd-8d5d-f3614b8ed6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844b8918-f470-40ec-bc3a-02afc275770e" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c37e0368-a19a-4acd-8d5d-f3614b8ed6aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ComputersAndSoftwareMember_a9bea99f-f412-4cdc-90b2-cff69c9e0b18" xlink:href="evlo-20210630.xsd#evlo_ComputersAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844b8918-f470-40ec-bc3a-02afc275770e" xlink:to="loc_evlo_ComputersAndSoftwareMember_a9bea99f-f412-4cdc-90b2-cff69c9e0b18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_0473de0d-6e8a-4b39-91d1-9054e2bda24d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844b8918-f470-40ec-bc3a-02afc275770e" xlink:to="loc_us-gaap_OfficeEquipmentMember_0473de0d-6e8a-4b39-91d1-9054e2bda24d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_c528230f-7518-4241-beec-4262698ca1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844b8918-f470-40ec-bc3a-02afc275770e" xlink:to="loc_us-gaap_ConstructionInProgressMember_c528230f-7518-4241-beec-4262698ca1ac" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#LoanandSecurityAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails" xlink:type="extended" id="icd9dc6bf1be340ec90fb52ba23523086_LoanandSecurityAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9c4952e4-778b-4b36-ae08-1ab284edd1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9c4952e4-778b-4b36-ae08-1ab284edd1d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementNumberOfTranches_cb133373-c113-4fb8-8f2d-b24a833d9bba" xlink:href="evlo-20210630.xsd#evlo_SecurityAndLoanAgreementNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_evlo_SecurityAndLoanAgreementNumberOfTranches_cb133373-c113-4fb8-8f2d-b24a833d9bba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a5d1c3c5-d619-44cc-9096-fcd2910b9039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a5d1c3c5-d619-44cc-9096-fcd2910b9039" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1dfb16a7-9133-48d9-b3b6-df07db3743ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1dfb16a7-9133-48d9-b3b6-df07db3743ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_793f35be-199b-4c26-a6b1-3b50ac5cd90d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_ConvertibleDebt_793f35be-199b-4c26-a6b1-3b50ac5cd90d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_38064b9b-f282-4f14-b7e4-62447591951d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_38064b9b-f282-4f14-b7e4-62447591951d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_faf90482-d11f-4f34-9c4c-219a338b4030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_faf90482-d11f-4f34-9c4c-219a338b4030" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_73049182-f3cc-4469-a304-3b9fc3d48a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_73049182-f3cc-4469-a304-3b9fc3d48a28" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal_8cd8bee7-9e93-4618-85fb-e7227a79682c" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal_8cd8bee7-9e93-4618-85fb-e7227a79682c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage_f0ab9ce3-686e-4856-ad80-dff442218a1f" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage_f0ab9ce3-686e-4856-ad80-dff442218a1f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne_d2cc0ce0-1b02-4951-8d96-ce1f43196975" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne_d2cc0ce0-1b02-4951-8d96-ce1f43196975" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage_e07fbcba-8207-4909-a249-512dff5ad334" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage_e07fbcba-8207-4909-a249-512dff5ad334" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_32cd0aa8-24ba-4007-9a69-e86a0fcd0163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_32cd0aa8-24ba-4007-9a69-e86a0fcd0163" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentDebtDefaultPercentage_07c5edf0-0fe6-4bc5-8a0a-2dab76117063" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentDebtDefaultPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_evlo_DebtInstrumentDebtDefaultPercentage_07c5edf0-0fe6-4bc5-8a0a-2dab76117063" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditFairValueDisclosure_0cf765fc-e687-462a-8898-31303c83c766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LinesOfCreditFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_LinesOfCreditFairValueDisclosure_0cf765fc-e687-462a-8898-31303c83c766" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ClassOfWarrantOrRightFairValueMeasurement_64303ac4-ab47-44a2-a53f-382a831303f2" xlink:href="evlo-20210630.xsd#evlo_ClassOfWarrantOrRightFairValueMeasurement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_evlo_ClassOfWarrantOrRightFairValueMeasurement_64303ac4-ab47-44a2-a53f-382a831303f2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0e140ba8-2cdd-434a-918c-ebc916bd7c52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0e140ba8-2cdd-434a-918c-ebc916bd7c52" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_3ddecd4d-bee6-48ee-a2a2-52c0e7b34ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_InterestExpenseDebt_3ddecd4d-bee6-48ee-a2a2-52c0e7b34ea0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_6cf971a8-e660-4a23-973c-9a90f608b18d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_6cf971a8-e660-4a23-973c-9a90f608b18d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_06180536-e11f-4665-9892-fd38fac3e192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6cf971a8-e660-4a23-973c-9a90f608b18d" xlink:to="loc_us-gaap_CreditFacilityAxis_06180536-e11f-4665-9892-fd38fac3e192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_06180536-e11f-4665-9892-fd38fac3e192_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_06180536-e11f-4665-9892-fd38fac3e192" xlink:to="loc_us-gaap_CreditFacilityDomain_06180536-e11f-4665-9892-fd38fac3e192_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_bde2faa4-a402-44e3-b7cb-5600350ea982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_06180536-e11f-4665-9892-fd38fac3e192" xlink:to="loc_us-gaap_CreditFacilityDomain_bde2faa4-a402-44e3-b7cb-5600350ea982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_03246ba7-7ea8-4c0b-b367-44acb687194d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_bde2faa4-a402-44e3-b7cb-5600350ea982" xlink:to="loc_us-gaap_LineOfCreditMember_03246ba7-7ea8-4c0b-b367-44acb687194d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3ae2bd5e-db23-4241-8d67-b7ce78f930ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6cf971a8-e660-4a23-973c-9a90f608b18d" xlink:to="loc_us-gaap_DebtInstrumentAxis_3ae2bd5e-db23-4241-8d67-b7ce78f930ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3ae2bd5e-db23-4241-8d67-b7ce78f930ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3ae2bd5e-db23-4241-8d67-b7ce78f930ed" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3ae2bd5e-db23-4241-8d67-b7ce78f930ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_67f735a1-2785-472c-af75-bfc69997fe11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3ae2bd5e-db23-4241-8d67-b7ce78f930ed" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_67f735a1-2785-472c-af75-bfc69997fe11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_A2019CreditFacilityMember_027463b8-6034-449a-8105-d9fb3c13b282" xlink:href="evlo-20210630.xsd#evlo_A2019CreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_67f735a1-2785-472c-af75-bfc69997fe11" xlink:to="loc_evlo_A2019CreditFacilityMember_027463b8-6034-449a-8105-d9fb3c13b282" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AmendedCreditFacilityMember_511c8c12-3c96-4a87-8a64-9506606b2e7d" xlink:href="evlo-20210630.xsd#evlo_AmendedCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_67f735a1-2785-472c-af75-bfc69997fe11" xlink:to="loc_evlo_AmendedCreditFacilityMember_511c8c12-3c96-4a87-8a64-9506606b2e7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_b45820a5-1861-4de6-ab82-ad496175003f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6cf971a8-e660-4a23-973c-9a90f608b18d" xlink:to="loc_us-gaap_VariableRateAxis_b45820a5-1861-4de6-ab82-ad496175003f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b45820a5-1861-4de6-ab82-ad496175003f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_b45820a5-1861-4de6-ab82-ad496175003f" xlink:to="loc_us-gaap_VariableRateDomain_b45820a5-1861-4de6-ab82-ad496175003f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b8eb7a1d-5ea3-430d-b9f1-5ff9692dbe87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_b45820a5-1861-4de6-ab82-ad496175003f" xlink:to="loc_us-gaap_VariableRateDomain_b8eb7a1d-5ea3-430d-b9f1-5ff9692dbe87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_0f97a608-a241-4c28-98c0-92cc5b7885e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_b8eb7a1d-5ea3-430d-b9f1-5ff9692dbe87" xlink:to="loc_us-gaap_PrimeRateMember_0f97a608-a241-4c28-98c0-92cc5b7885e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentTrancheAxis_36b40f54-7359-4a42-98ad-5f53dd382216" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentTrancheAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6cf971a8-e660-4a23-973c-9a90f608b18d" xlink:to="loc_evlo_DebtInstrumentTrancheAxis_36b40f54-7359-4a42-98ad-5f53dd382216" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentTrancheDomain_36b40f54-7359-4a42-98ad-5f53dd382216_default" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_evlo_DebtInstrumentTrancheAxis_36b40f54-7359-4a42-98ad-5f53dd382216" xlink:to="loc_evlo_DebtInstrumentTrancheDomain_36b40f54-7359-4a42-98ad-5f53dd382216_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentTrancheDomain_6d3c7828-5163-42da-8aa8-655f64238970" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_evlo_DebtInstrumentTrancheAxis_36b40f54-7359-4a42-98ad-5f53dd382216" xlink:to="loc_evlo_DebtInstrumentTrancheDomain_6d3c7828-5163-42da-8aa8-655f64238970" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheOneMember_1bef72b7-20fe-4ce2-b0e5-3c41e09031f9" xlink:href="evlo-20210630.xsd#evlo_SecurityAndLoanAgreementTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evlo_DebtInstrumentTrancheDomain_6d3c7828-5163-42da-8aa8-655f64238970" xlink:to="loc_evlo_SecurityAndLoanAgreementTrancheOneMember_1bef72b7-20fe-4ce2-b0e5-3c41e09031f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheTwoMember_5a10e041-9d47-47c7-8c5b-59b20b773192" xlink:href="evlo-20210630.xsd#evlo_SecurityAndLoanAgreementTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evlo_DebtInstrumentTrancheDomain_6d3c7828-5163-42da-8aa8-655f64238970" xlink:to="loc_evlo_SecurityAndLoanAgreementTrancheTwoMember_5a10e041-9d47-47c7-8c5b-59b20b773192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheThreeMember_f25a750d-e579-4ae5-a71e-cf11be9b9326" xlink:href="evlo-20210630.xsd#evlo_SecurityAndLoanAgreementTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evlo_DebtInstrumentTrancheDomain_6d3c7828-5163-42da-8aa8-655f64238970" xlink:to="loc_evlo_SecurityAndLoanAgreementTrancheThreeMember_f25a750d-e579-4ae5-a71e-cf11be9b9326" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheFourMember_9e86f49b-2fea-42fe-bb11-32c398bbfbd2" xlink:href="evlo-20210630.xsd#evlo_SecurityAndLoanAgreementTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evlo_DebtInstrumentTrancheDomain_6d3c7828-5163-42da-8aa8-655f64238970" xlink:to="loc_evlo_SecurityAndLoanAgreementTrancheFourMember_9e86f49b-2fea-42fe-bb11-32c398bbfbd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_b8b944bd-4f31-48d9-879f-d4d1da8af50b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6cf971a8-e660-4a23-973c-9a90f608b18d" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_b8b944bd-4f31-48d9-879f-d4d1da8af50b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b8b944bd-4f31-48d9-879f-d4d1da8af50b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_b8b944bd-4f31-48d9-879f-d4d1da8af50b" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b8b944bd-4f31-48d9-879f-d4d1da8af50b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ee92b26a-6706-47c9-8145-19088c2980c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_b8b944bd-4f31-48d9-879f-d4d1da8af50b" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ee92b26a-6706-47c9-8145-19088c2980c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_76689bb8-02d9-49d5-9908-be49bfd4e95d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ee92b26a-6706-47c9-8145-19088c2980c4" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_76689bb8-02d9-49d5-9908-be49bfd4e95d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_59f2a1b1-25a8-47ac-b6c2-609bab103ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_76689bb8-02d9-49d5-9908-be49bfd4e95d" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_59f2a1b1-25a8-47ac-b6c2-609bab103ae8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails" xlink:type="extended" id="iba9ab5ae2fa94b6d8447fe5c5801b1b6_LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13c27ff6-253e-449b-a7af-5df04078f8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_c5a16cc3-112d-4c76-847d-0272d365583c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13c27ff6-253e-449b-a7af-5df04078f8c8" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_c5a16cc3-112d-4c76-847d-0272d365583c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de3798e-8421-49eb-910f-a2d5f490fc19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13c27ff6-253e-449b-a7af-5df04078f8c8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de3798e-8421-49eb-910f-a2d5f490fc19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea2c7d8c-9aef-4e1a-b79a-c5ff1f6d8917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de3798e-8421-49eb-910f-a2d5f490fc19" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea2c7d8c-9aef-4e1a-b79a-c5ff1f6d8917" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea2c7d8c-9aef-4e1a-b79a-c5ff1f6d8917_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea2c7d8c-9aef-4e1a-b79a-c5ff1f6d8917" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea2c7d8c-9aef-4e1a-b79a-c5ff1f6d8917_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8a970123-0ef7-41e9-b4b0-a8f75304e0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea2c7d8c-9aef-4e1a-b79a-c5ff1f6d8917" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8a970123-0ef7-41e9-b4b0-a8f75304e0f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8a6f1bb3-b5e4-4ed1-b0be-c435efbda1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8a970123-0ef7-41e9-b4b0-a8f75304e0f6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8a6f1bb3-b5e4-4ed1-b0be-c435efbda1ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f81f6944-9b1e-45ef-ad01-c0efa3225d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de3798e-8421-49eb-910f-a2d5f490fc19" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f81f6944-9b1e-45ef-ad01-c0efa3225d9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f81f6944-9b1e-45ef-ad01-c0efa3225d9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f81f6944-9b1e-45ef-ad01-c0efa3225d9d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f81f6944-9b1e-45ef-ad01-c0efa3225d9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b5249a41-2852-4020-b178-a913cabea841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f81f6944-9b1e-45ef-ad01-c0efa3225d9d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b5249a41-2852-4020-b178-a913cabea841" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_d5fc7012-9261-48f2-b2a7-0c6bba9df241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5249a41-2852-4020-b178-a913cabea841" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_d5fc7012-9261-48f2-b2a7-0c6bba9df241" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_f1cebc85-5b4b-4c37-a0e5-7e8d6cca6a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5249a41-2852-4020-b178-a913cabea841" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_f1cebc85-5b4b-4c37-a0e5-7e8d6cca6a1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4899be75-1334-4426-8e4d-fffb6466d9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de3798e-8421-49eb-910f-a2d5f490fc19" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4899be75-1334-4426-8e4d-fffb6466d9e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4899be75-1334-4426-8e4d-fffb6466d9e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4899be75-1334-4426-8e4d-fffb6466d9e1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4899be75-1334-4426-8e4d-fffb6466d9e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_133d0254-23b7-4aae-a31d-8f9123ca85e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4899be75-1334-4426-8e4d-fffb6466d9e1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_133d0254-23b7-4aae-a31d-8f9123ca85e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_420c7842-9e7c-48b9-8cbf-a750b105dc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_133d0254-23b7-4aae-a31d-8f9123ca85e0" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_420c7842-9e7c-48b9-8cbf-a750b105dc5a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#LoanandSecurityAgreementsFairValueofWarrantDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails" xlink:type="extended" id="i6d2e6b75a54549d1888bdb8179216bfc_LoanandSecurityAgreementsFairValueofWarrantDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25296fbd-c266-496f-82f3-2660098f4c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_e54b4488-f292-4d2e-aa49-69174b823bee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25296fbd-c266-496f-82f3-2660098f4c22" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_e54b4488-f292-4d2e-aa49-69174b823bee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d1912253-7b7a-4aa5-9bfa-a5698c2416ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25296fbd-c266-496f-82f3-2660098f4c22" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d1912253-7b7a-4aa5-9bfa-a5698c2416ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bf7314b-749e-40ea-8799-1b4a0aae2d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25296fbd-c266-496f-82f3-2660098f4c22" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bf7314b-749e-40ea-8799-1b4a0aae2d67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_8b030dfc-4606-442c-b06d-3109657e2e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bf7314b-749e-40ea-8799-1b4a0aae2d67" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_8b030dfc-4606-442c-b06d-3109657e2e7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8b030dfc-4606-442c-b06d-3109657e2e7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8b030dfc-4606-442c-b06d-3109657e2e7a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8b030dfc-4606-442c-b06d-3109657e2e7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3b1f79ac-bc3a-4600-b551-ad7338d20eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8b030dfc-4606-442c-b06d-3109657e2e7a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3b1f79ac-bc3a-4600-b551-ad7338d20eb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_c4601ba5-36a5-4eab-af80-0306bea09f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3b1f79ac-bc3a-4600-b551-ad7338d20eb9" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_c4601ba5-36a5-4eab-af80-0306bea09f2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3b266860-6f17-42aa-a2f5-e3f06368b81f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3b1f79ac-bc3a-4600-b551-ad7338d20eb9" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3b266860-6f17-42aa-a2f5-e3f06368b81f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_97a4dbaa-bb1c-4535-8bf8-4be7e0e1217e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3b1f79ac-bc3a-4600-b551-ad7338d20eb9" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_97a4dbaa-bb1c-4535-8bf8-4be7e0e1217e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_a965858a-2c29-4b54-be11-9d432340fcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3b1f79ac-bc3a-4600-b551-ad7338d20eb9" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_a965858a-2c29-4b54-be11-9d432340fcc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_ef99f196-72b1-44e9-afd9-fa61e97267bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3b1f79ac-bc3a-4600-b551-ad7338d20eb9" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_ef99f196-72b1-44e9-afd9-fa61e97267bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3e39248-ed66-4076-8363-645d3cc88ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bf7314b-749e-40ea-8799-1b4a0aae2d67" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3e39248-ed66-4076-8363-645d3cc88ebc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e3e39248-ed66-4076-8363-645d3cc88ebc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3e39248-ed66-4076-8363-645d3cc88ebc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e3e39248-ed66-4076-8363-645d3cc88ebc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8730127-6cec-4738-bd74-3a4f3235433a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3e39248-ed66-4076-8363-645d3cc88ebc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8730127-6cec-4738-bd74-3a4f3235433a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6b428d87-5cc5-4c2d-97b8-74143b2145ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8730127-6cec-4738-bd74-3a4f3235433a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6b428d87-5cc5-4c2d-97b8-74143b2145ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_53b968b9-51e0-40bd-9de4-b7db2dda4bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bf7314b-749e-40ea-8799-1b4a0aae2d67" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_53b968b9-51e0-40bd-9de4-b7db2dda4bb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_53b968b9-51e0-40bd-9de4-b7db2dda4bb1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_53b968b9-51e0-40bd-9de4-b7db2dda4bb1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_53b968b9-51e0-40bd-9de4-b7db2dda4bb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d7dd92b-5ea5-4b78-b1fc-f8a334f8c5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_53b968b9-51e0-40bd-9de4-b7db2dda4bb1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d7dd92b-5ea5-4b78-b1fc-f8a334f8c5e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5ec29154-86c3-4162-bfbc-ef71a0980993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d7dd92b-5ea5-4b78-b1fc-f8a334f8c5e4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5ec29154-86c3-4162-bfbc-ef71a0980993" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails" xlink:type="extended" id="i3b845c67252f49a5bdbacb85aba2ade1_LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_7f034885-0f7a-4caf-b4e3-6c9c84977e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_4e9d00d1-d5ac-4ab7-bc1b-0b79412c4743" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7f034885-0f7a-4caf-b4e3-6c9c84977e8e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_4e9d00d1-d5ac-4ab7-bc1b-0b79412c4743" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_ea03c4e6-3c66-4724-8ef3-d1f4d7b47f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7f034885-0f7a-4caf-b4e3-6c9c84977e8e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_ea03c4e6-3c66-4724-8ef3-d1f4d7b47f02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_dcda0f32-3ffd-496d-9412-d0bf7cc4e1be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7f034885-0f7a-4caf-b4e3-6c9c84977e8e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_dcda0f32-3ffd-496d-9412-d0bf7cc4e1be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_45a9fb7d-71d6-490f-b54d-85c469b31aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7f034885-0f7a-4caf-b4e3-6c9c84977e8e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_45a9fb7d-71d6-490f-b54d-85c469b31aa3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5f5bdbd0-8346-49c5-9d7f-93f67ed60a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7f034885-0f7a-4caf-b4e3-6c9c84977e8e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5f5bdbd0-8346-49c5-9d7f-93f67ed60a67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_966e159e-3838-4cc5-a550-0ef9b2fff395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7f034885-0f7a-4caf-b4e3-6c9c84977e8e" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_966e159e-3838-4cc5-a550-0ef9b2fff395" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_44348bac-3847-442c-b0d8-201df4e6281b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7f034885-0f7a-4caf-b4e3-6c9c84977e8e" xlink:to="loc_us-gaap_LongTermDebt_44348bac-3847-442c-b0d8-201df4e6281b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_dda2f63e-6ffb-4c61-be5e-d0b07cb6e95e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7f034885-0f7a-4caf-b4e3-6c9c84977e8e" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_dda2f63e-6ffb-4c61-be5e-d0b07cb6e95e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8f34eaa7-720a-4ffc-a357-3e2628fa422e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dda2f63e-6ffb-4c61-be5e-d0b07cb6e95e" xlink:to="loc_us-gaap_CreditFacilityAxis_8f34eaa7-720a-4ffc-a357-3e2628fa422e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8f34eaa7-720a-4ffc-a357-3e2628fa422e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_8f34eaa7-720a-4ffc-a357-3e2628fa422e" xlink:to="loc_us-gaap_CreditFacilityDomain_8f34eaa7-720a-4ffc-a357-3e2628fa422e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ac31c329-181f-47a0-9f44-19b3c949470c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_8f34eaa7-720a-4ffc-a357-3e2628fa422e" xlink:to="loc_us-gaap_CreditFacilityDomain_ac31c329-181f-47a0-9f44-19b3c949470c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_1c02b9da-5c63-42de-bd46-d296876eca38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_ac31c329-181f-47a0-9f44-19b3c949470c" xlink:to="loc_us-gaap_LineOfCreditMember_1c02b9da-5c63-42de-bd46-d296876eca38" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/InLicenseAgreementsNarrativeDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#InLicenseAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/InLicenseAgreementsNarrativeDetails" xlink:type="extended" id="i30510606ee8049e89a6d49b2c3ba0569_InLicenseAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_10df4be4-da71-4ced-8803-010c016ff17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonRefundableUpfrontFee_c798b470-2e56-4253-a59e-70a0c727ff73" xlink:href="evlo-20210630.xsd#evlo_NonRefundableUpfrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_10df4be4-da71-4ced-8803-010c016ff17d" xlink:to="loc_evlo_NonRefundableUpfrontFee_c798b470-2e56-4253-a59e-70a0c727ff73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent_f9581c85-7a8a-49e4-ae71-d919fa84cb1f" xlink:href="evlo-20210630.xsd#evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_10df4be4-da71-4ced-8803-010c016ff17d" xlink:to="loc_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent_f9581c85-7a8a-49e4-ae71-d919fa84cb1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_ae527528-81df-4a54-9eae-fd753658ec40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_10df4be4-da71-4ced-8803-010c016ff17d" xlink:to="loc_us-gaap_ContractualObligation_ae527528-81df-4a54-9eae-fd753658ec40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts_fd0ac2b8-f91d-45a5-8eca-f52617fd0e1c" xlink:href="evlo-20210630.xsd#evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_10df4be4-da71-4ced-8803-010c016ff17d" xlink:to="loc_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts_fd0ac2b8-f91d-45a5-8eca-f52617fd0e1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_139793e5-37ea-489c-8af1-b6d1579a9c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_10df4be4-da71-4ced-8803-010c016ff17d" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_139793e5-37ea-489c-8af1-b6d1579a9c0b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_262adb84-99d3-4ca8-a6c3-4ff1ea95d5f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_139793e5-37ea-489c-8af1-b6d1579a9c0b" xlink:to="loc_srt_CounterpartyNameAxis_262adb84-99d3-4ca8-a6c3-4ff1ea95d5f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_262adb84-99d3-4ca8-a6c3-4ff1ea95d5f6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_262adb84-99d3-4ca8-a6c3-4ff1ea95d5f6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_262adb84-99d3-4ca8-a6c3-4ff1ea95d5f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5361f55-f4f7-4c22-b90c-8f745e7763e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_262adb84-99d3-4ca8-a6c3-4ff1ea95d5f6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5361f55-f4f7-4c22-b90c-8f745e7763e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MayoClinicMember_645ad14f-156b-408e-b4ff-c7bf467df369" xlink:href="evlo-20210630.xsd#evlo_MayoClinicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5361f55-f4f7-4c22-b90c-8f745e7763e4" xlink:to="loc_evlo_MayoClinicMember_645ad14f-156b-408e-b4ff-c7bf467df369" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_UniversityOfChicagoMember_670426e2-82ca-45d8-a11c-37b48420db60" xlink:href="evlo-20210630.xsd#evlo_UniversityOfChicagoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5361f55-f4f7-4c22-b90c-8f745e7763e4" xlink:to="loc_evlo_UniversityOfChicagoMember_670426e2-82ca-45d8-a11c-37b48420db60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cf92e782-6366-4d6c-aa3f-37e42a9338d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_139793e5-37ea-489c-8af1-b6d1579a9c0b" xlink:to="loc_srt_RangeAxis_cf92e782-6366-4d6c-aa3f-37e42a9338d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cf92e782-6366-4d6c-aa3f-37e42a9338d1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cf92e782-6366-4d6c-aa3f-37e42a9338d1" xlink:to="loc_srt_RangeMember_cf92e782-6366-4d6c-aa3f-37e42a9338d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_104f000d-0530-4cb1-9dac-0ac6ef96999f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cf92e782-6366-4d6c-aa3f-37e42a9338d1" xlink:to="loc_srt_RangeMember_104f000d-0530-4cb1-9dac-0ac6ef96999f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3be677dd-c3ab-43c1-a269-22b380add7e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_104f000d-0530-4cb1-9dac-0ac6ef96999f" xlink:to="loc_srt_MaximumMember_3be677dd-c3ab-43c1-a269-22b380add7e7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="id60f69053a0a4921b67a48c4a8b3fcad_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CommitmentAndContingenciesLineItems_cd0f3ce6-ffc0-469d-ba71-3019afc5386c" xlink:href="evlo-20210630.xsd#evlo_CommitmentAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborationArrangementTerm_ee6d6e5a-7552-44dd-a532-2d789247c5c0" xlink:href="evlo-20210630.xsd#evlo_CollaborationArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_cd0f3ce6-ffc0-469d-ba71-3019afc5386c" xlink:to="loc_evlo_CollaborationArrangementTerm_ee6d6e5a-7552-44dd-a532-2d789247c5c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices_935e6d81-1229-43c7-aeaf-4878618e556f" xlink:href="evlo-20210630.xsd#evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_cd0f3ce6-ffc0-469d-ba71-3019afc5386c" xlink:to="loc_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices_935e6d81-1229-43c7-aeaf-4878618e556f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AggregateAmountDueUnderCollaborativeArrangement_53a7548c-a762-47be-b93a-bed5ccb925af" xlink:href="evlo-20210630.xsd#evlo_AggregateAmountDueUnderCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_cd0f3ce6-ffc0-469d-ba71-3019afc5386c" xlink:to="loc_evlo_AggregateAmountDueUnderCollaborativeArrangement_53a7548c-a762-47be-b93a-bed5ccb925af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AnnualAmountDueUnderCollaborativeArrangement_a2c6757a-6e3e-4463-878c-4b26dc8cc4e2" xlink:href="evlo-20210630.xsd#evlo_AnnualAmountDueUnderCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_cd0f3ce6-ffc0-469d-ba71-3019afc5386c" xlink:to="loc_evlo_AnnualAmountDueUnderCollaborativeArrangement_a2c6757a-6e3e-4463-878c-4b26dc8cc4e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_FeeIncurredUnderCollaborativeArrangement_7b61da56-93e7-4fa5-93f0-355b3f3aabe8" xlink:href="evlo-20210630.xsd#evlo_FeeIncurredUnderCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_cd0f3ce6-ffc0-469d-ba71-3019afc5386c" xlink:to="loc_evlo_FeeIncurredUnderCollaborativeArrangement_7b61da56-93e7-4fa5-93f0-355b3f3aabe8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CommitmentAndContingenciesTable_1040fc7d-96a1-4409-a4d8-5eadbc667d0f" xlink:href="evlo-20210630.xsd#evlo_CommitmentAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_cd0f3ce6-ffc0-469d-ba71-3019afc5386c" xlink:to="loc_evlo_CommitmentAndContingenciesTable_1040fc7d-96a1-4409-a4d8-5eadbc667d0f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f6190a23-289b-439f-a236-3f852d0e6817" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_evlo_CommitmentAndContingenciesTable_1040fc7d-96a1-4409-a4d8-5eadbc667d0f" xlink:to="loc_srt_CounterpartyNameAxis_f6190a23-289b-439f-a236-3f852d0e6817" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f6190a23-289b-439f-a236-3f852d0e6817_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f6190a23-289b-439f-a236-3f852d0e6817" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f6190a23-289b-439f-a236-3f852d0e6817_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0563aec1-1fd8-46f6-a0ee-11c4412d22f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f6190a23-289b-439f-a236-3f852d0e6817" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0563aec1-1fd8-46f6-a0ee-11c4412d22f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaccoS.r.l.Member_25ae1663-313e-4ba4-a71c-9b2b6bac40c1" xlink:href="evlo-20210630.xsd#evlo_SaccoS.r.l.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0563aec1-1fd8-46f6-a0ee-11c4412d22f5" xlink:to="loc_evlo_SaccoS.r.l.Member_25ae1663-313e-4ba4-a71c-9b2b6bac40c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fc4dbd0f-d023-4583-87d5-675b89083955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_evlo_CommitmentAndContingenciesTable_1040fc7d-96a1-4409-a4d8-5eadbc667d0f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fc4dbd0f-d023-4583-87d5-675b89083955" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc4dbd0f-d023-4583-87d5-675b89083955_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fc4dbd0f-d023-4583-87d5-675b89083955" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc4dbd0f-d023-4583-87d5-675b89083955_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3d5b33c-2f60-4d4e-ab60-df69f477a8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fc4dbd0f-d023-4583-87d5-675b89083955" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3d5b33c-2f60-4d4e-ab60-df69f477a8b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_c72ebd82-ed0c-4177-807d-925835202092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3d5b33c-2f60-4d4e-ab60-df69f477a8b2" xlink:to="loc_us-gaap_CollaborativeArrangementMember_c72ebd82-ed0c-4177-807d-925835202092" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/StockholdersEquityDetails" xlink:type="extended" id="i26702043c017475fb3e1ef42f34d6fa2_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction_c56a0439-17f8-4dc6-af9d-7598252c8495" xlink:href="evlo-20210630.xsd#evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction_c56a0439-17f8-4dc6-af9d-7598252c8495" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockConsiderationReceivedTerm_54afdd97-c418-4fc5-b634-659b352061b5" xlink:href="evlo-20210630.xsd#evlo_SaleOfStockConsiderationReceivedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_evlo_SaleOfStockConsiderationReceivedTerm_54afdd97-c418-4fc5-b634-659b352061b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e1308244-602e-47a0-9915-81e48735ec95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e1308244-602e-47a0-9915-81e48735ec95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c3261dd9-2fcc-44ae-8bf5-219c274e8201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c3261dd9-2fcc-44ae-8bf5-219c274e8201" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e236f530-4454-46f7-a14c-f76975d02682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e236f530-4454-46f7-a14c-f76975d02682" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction_24c3fbc7-aa87-4b46-8aaf-f2f4b10f2b09" xlink:href="evlo-20210630.xsd#evlo_SaleOfStockGrossConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction_24c3fbc7-aa87-4b46-8aaf-f2f4b10f2b09" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50ee7890-f086-4ef6-8a5e-6d9a1dab8163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50ee7890-f086-4ef6-8a5e-6d9a1dab8163" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_fde82590-1398-4d04-981a-4eb2bde58d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_fde82590-1398-4d04-981a-4eb2bde58d84" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_cf166aeb-f712-41cd-a14b-f1443d8d2a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_us-gaap_ConvertibleDebt_cf166aeb-f712-41cd-a14b-f1443d8d2a99" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c5faa7c5-9831-454d-8571-60fb77dfbd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c5faa7c5-9831-454d-8571-60fb77dfbd5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_84a20332-a679-4a14-a194-93513bf1d9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5faa7c5-9831-454d-8571-60fb77dfbd5e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_84a20332-a679-4a14-a194-93513bf1d9dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_84a20332-a679-4a14-a194-93513bf1d9dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_84a20332-a679-4a14-a194-93513bf1d9dd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_84a20332-a679-4a14-a194-93513bf1d9dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1fcab764-0bdb-47b5-8ed9-0be867a208e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_84a20332-a679-4a14-a194-93513bf1d9dd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1fcab764-0bdb-47b5-8ed9-0be867a208e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RegistrationStatementMember_1cfb462a-2fda-4e04-acd6-0eb854a5177a" xlink:href="evlo-20210630.xsd#evlo_RegistrationStatementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1fcab764-0bdb-47b5-8ed9-0be867a208e4" xlink:to="loc_evlo_RegistrationStatementMember_1cfb462a-2fda-4e04-acd6-0eb854a5177a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AtTheMarketMember_1474d6ec-be02-4035-a9bd-b256ff3ade8b" xlink:href="evlo-20210630.xsd#evlo_AtTheMarketMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1fcab764-0bdb-47b5-8ed9-0be867a208e4" xlink:to="loc_evlo_AtTheMarketMember_1474d6ec-be02-4035-a9bd-b256ff3ade8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_PublicStockOfferingMember_01a37203-86fd-4b42-8d07-41b9ce504e4d" xlink:href="evlo-20210630.xsd#evlo_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1fcab764-0bdb-47b5-8ed9-0be867a208e4" xlink:to="loc_evlo_PublicStockOfferingMember_01a37203-86fd-4b42-8d07-41b9ce504e4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_66e5bd89-e989-4a81-ad62-6bd9823cad2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1fcab764-0bdb-47b5-8ed9-0be867a208e4" xlink:to="loc_us-gaap_OverAllotmentOptionMember_66e5bd89-e989-4a81-ad62-6bd9823cad2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_e4af5d24-49fa-43ad-8ce2-bcba33418177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1fcab764-0bdb-47b5-8ed9-0be867a208e4" xlink:to="loc_us-gaap_PrivatePlacementMember_e4af5d24-49fa-43ad-8ce2-bcba33418177" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a5af9c27-2399-4f5b-974a-1fd3026f8616" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5faa7c5-9831-454d-8571-60fb77dfbd5e" xlink:to="loc_srt_RangeAxis_a5af9c27-2399-4f5b-974a-1fd3026f8616" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a5af9c27-2399-4f5b-974a-1fd3026f8616_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a5af9c27-2399-4f5b-974a-1fd3026f8616" xlink:to="loc_srt_RangeMember_a5af9c27-2399-4f5b-974a-1fd3026f8616_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bf59f734-bfe7-4a33-8f33-02fe0164e3a2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a5af9c27-2399-4f5b-974a-1fd3026f8616" xlink:to="loc_srt_RangeMember_bf59f734-bfe7-4a33-8f33-02fe0164e3a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_58b1c0b3-277b-40db-9e05-663fd6b284e3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bf59f734-bfe7-4a33-8f33-02fe0164e3a2" xlink:to="loc_srt_MinimumMember_58b1c0b3-277b-40db-9e05-663fd6b284e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dd42fe0b-9315-4fa8-9e0d-b430034e62c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bf59f734-bfe7-4a33-8f33-02fe0164e3a2" xlink:to="loc_srt_MaximumMember_dd42fe0b-9315-4fa8-9e0d-b430034e62c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_86065220-5d77-4b47-8ee9-3b2b4dbc0758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5faa7c5-9831-454d-8571-60fb77dfbd5e" xlink:to="loc_us-gaap_CreditFacilityAxis_86065220-5d77-4b47-8ee9-3b2b4dbc0758" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_86065220-5d77-4b47-8ee9-3b2b4dbc0758_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_86065220-5d77-4b47-8ee9-3b2b4dbc0758" xlink:to="loc_us-gaap_CreditFacilityDomain_86065220-5d77-4b47-8ee9-3b2b4dbc0758_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8baa5c35-e363-4ebf-aab1-c857c867abed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_86065220-5d77-4b47-8ee9-3b2b4dbc0758" xlink:to="loc_us-gaap_CreditFacilityDomain_8baa5c35-e363-4ebf-aab1-c857c867abed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_12e95ed2-3439-43c3-895f-6898e0395870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_8baa5c35-e363-4ebf-aab1-c857c867abed" xlink:to="loc_us-gaap_LineOfCreditMember_12e95ed2-3439-43c3-895f-6898e0395870" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9756645c-849f-4c7f-aa5e-2b5165cafada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5faa7c5-9831-454d-8571-60fb77dfbd5e" xlink:to="loc_us-gaap_DebtInstrumentAxis_9756645c-849f-4c7f-aa5e-2b5165cafada" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9756645c-849f-4c7f-aa5e-2b5165cafada_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9756645c-849f-4c7f-aa5e-2b5165cafada" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9756645c-849f-4c7f-aa5e-2b5165cafada_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_215c2d63-fa73-4276-8f69-d7d479c07312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9756645c-849f-4c7f-aa5e-2b5165cafada" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_215c2d63-fa73-4276-8f69-d7d479c07312" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AmendedCreditFacilityMember_47a0c50a-feef-4dcb-908d-88e6b34c58c0" xlink:href="evlo-20210630.xsd#evlo_AmendedCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_215c2d63-fa73-4276-8f69-d7d479c07312" xlink:to="loc_evlo_AmendedCreditFacilityMember_47a0c50a-feef-4dcb-908d-88e6b34c58c0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="ifc753b26c28142f584fb262394be95af_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0f9fc75f-9db3-42dd-8233-dd7203c3a11d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0f9fc75f-9db3-42dd-8233-dd7203c3a11d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3781278a-8d9a-42d3-b04f-2fff5f87aec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3781278a-8d9a-42d3-b04f-2fff5f87aec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7f05d1fe-7481-40ab-8d2d-45faffc68b65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7f05d1fe-7481-40ab-8d2d-45faffc68b65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f6b4520a-da41-44cc-b96c-5167d87044f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f6b4520a-da41-44cc-b96c-5167d87044f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_24329e63-a82b-4ff5-82ed-7aa67748907e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_24329e63-a82b-4ff5-82ed-7aa67748907e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d62db98e-3258-4e4b-ab8a-7e60e0096e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d62db98e-3258-4e4b-ab8a-7e60e0096e15" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c70e9048-d5ec-4ac7-881a-3e368afa46ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c70e9048-d5ec-4ac7-881a-3e368afa46ab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5daff043-fbf1-4926-86fa-7d54129ebfab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5daff043-fbf1-4926-86fa-7d54129ebfab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_84ab33e2-edd6-4008-b11f-257ed864f59a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_84ab33e2-edd6-4008-b11f-257ed864f59a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted_1fabfb65-ba7f-4a97-acd4-d6d0f8298b7c" xlink:href="evlo-20210630.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted_1fabfb65-ba7f-4a97-acd4-d6d0f8298b7c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised_837ed281-9bfb-46ae-9210-69f5e867d753" xlink:href="evlo-20210630.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised_837ed281-9bfb-46ae-9210-69f5e867d753" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures_2850b796-2257-48aa-b4db-bf580bab71d3" xlink:href="evlo-20210630.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures_2850b796-2257-48aa-b4db-bf580bab71d3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased_3e106b33-40a2-4151-a93a-7471f56f7d0b" xlink:href="evlo-20210630.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased_3e106b33-40a2-4151-a93a-7471f56f7d0b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease_448cc2e1-f983-4dec-9c9d-1ce2959ea2d3" xlink:href="evlo-20210630.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease_448cc2e1-f983-4dec-9c9d-1ce2959ea2d3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e1038bae-6c48-430c-aa02-ec24b93ea419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e1038bae-6c48-430c-aa02-ec24b93ea419" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8f80ec8f-6d6a-4e6a-ad38-d0ccf481c7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8f80ec8f-6d6a-4e6a-ad38-d0ccf481c7e8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7f2ac5ad-6826-48c0-8e6b-ff5fcc7454d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7f2ac5ad-6826-48c0-8e6b-ff5fcc7454d3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_85fe3898-8baf-4fa6-a869-aff143d0b49c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_85fe3898-8baf-4fa6-a869-aff143d0b49c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_68d69b61-908b-4bc8-b6b4-d14ff0bc9e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_68d69b61-908b-4bc8-b6b4-d14ff0bc9e77" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4303e8df-b1a2-4170-85c7-d50d0ea0d993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4303e8df-b1a2-4170-85c7-d50d0ea0d993" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_76bcd135-158a-420b-a48c-e7d03d1e1b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4303e8df-b1a2-4170-85c7-d50d0ea0d993" xlink:to="loc_us-gaap_PlanNameAxis_76bcd135-158a-420b-a48c-e7d03d1e1b88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_76bcd135-158a-420b-a48c-e7d03d1e1b88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_76bcd135-158a-420b-a48c-e7d03d1e1b88" xlink:to="loc_us-gaap_PlanNameDomain_76bcd135-158a-420b-a48c-e7d03d1e1b88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8cf96e29-9843-478c-adf3-190e7ac918f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_76bcd135-158a-420b-a48c-e7d03d1e1b88" xlink:to="loc_us-gaap_PlanNameDomain_8cf96e29-9843-478c-adf3-190e7ac918f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_TwoThousandAndTwentyOneStockInducementPlanMember_0572ed88-d791-455d-81a0-bf31a0408420" xlink:href="evlo-20210630.xsd#evlo_TwoThousandAndTwentyOneStockInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8cf96e29-9843-478c-adf3-190e7ac918f9" xlink:to="loc_evlo_TwoThousandAndTwentyOneStockInducementPlanMember_0572ed88-d791-455d-81a0-bf31a0408420" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_TwoThousandAndEighteenStockIncentivePlanMember_4ff20a37-ec70-400b-98dc-f663fbdedc8c" xlink:href="evlo-20210630.xsd#evlo_TwoThousandAndEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8cf96e29-9843-478c-adf3-190e7ac918f9" xlink:to="loc_evlo_TwoThousandAndEighteenStockIncentivePlanMember_4ff20a37-ec70-400b-98dc-f663fbdedc8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_TwoThousandAndFifteenStockIncentivePlanMember_217feb96-2e24-49ba-878f-a4ca29b12e83" xlink:href="evlo-20210630.xsd#evlo_TwoThousandAndFifteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8cf96e29-9843-478c-adf3-190e7ac918f9" xlink:to="loc_evlo_TwoThousandAndFifteenStockIncentivePlanMember_217feb96-2e24-49ba-878f-a4ca29b12e83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_A2018EmployeeStockPurchasePlanMember_82e12a79-1ad1-4ef9-ae7c-dcf88a4d1f56" xlink:href="evlo-20210630.xsd#evlo_A2018EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8cf96e29-9843-478c-adf3-190e7ac918f9" xlink:to="loc_evlo_A2018EmployeeStockPurchasePlanMember_82e12a79-1ad1-4ef9-ae7c-dcf88a4d1f56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eb3463db-9594-44ae-9359-88ce5981e6cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4303e8df-b1a2-4170-85c7-d50d0ea0d993" xlink:to="loc_srt_RangeAxis_eb3463db-9594-44ae-9359-88ce5981e6cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb3463db-9594-44ae-9359-88ce5981e6cc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_eb3463db-9594-44ae-9359-88ce5981e6cc" xlink:to="loc_srt_RangeMember_eb3463db-9594-44ae-9359-88ce5981e6cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1de515c1-8db1-422b-8c1f-ccc16238594a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_eb3463db-9594-44ae-9359-88ce5981e6cc" xlink:to="loc_srt_RangeMember_1de515c1-8db1-422b-8c1f-ccc16238594a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_86a404a8-9b14-4fd8-bfde-13a48557cb7e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1de515c1-8db1-422b-8c1f-ccc16238594a" xlink:to="loc_srt_MaximumMember_86a404a8-9b14-4fd8-bfde-13a48557cb7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4f0e649d-9288-46e2-af4b-2e730382bfc1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1de515c1-8db1-422b-8c1f-ccc16238594a" xlink:to="loc_srt_MinimumMember_4f0e649d-9288-46e2-af4b-2e730382bfc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5d3d625a-e881-4475-951c-a81b58ef2d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4303e8df-b1a2-4170-85c7-d50d0ea0d993" xlink:to="loc_us-gaap_AwardTypeAxis_5d3d625a-e881-4475-951c-a81b58ef2d18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d3d625a-e881-4475-951c-a81b58ef2d18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5d3d625a-e881-4475-951c-a81b58ef2d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d3d625a-e881-4475-951c-a81b58ef2d18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7d236bb-946c-41c2-8d7d-72dc57fffd42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5d3d625a-e881-4475-951c-a81b58ef2d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7d236bb-946c-41c2-8d7d-72dc57fffd42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b19f4e63-5044-431e-bc4c-ec7922d4f936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7d236bb-946c-41c2-8d7d-72dc57fffd42" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b19f4e63-5044-431e-bc4c-ec7922d4f936" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2f99618d-b5b9-47de-895b-62b1fc398756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7d236bb-946c-41c2-8d7d-72dc57fffd42" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2f99618d-b5b9-47de-895b-62b1fc398756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_528686e6-5fb0-464e-8189-e6592a5ce443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7d236bb-946c-41c2-8d7d-72dc57fffd42" xlink:to="loc_us-gaap_EmployeeStockMember_528686e6-5fb0-464e-8189-e6592a5ce443" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_ee779570-e48c-4932-9089-6346f82728a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4303e8df-b1a2-4170-85c7-d50d0ea0d993" xlink:to="loc_us-gaap_GranteeStatusAxis_ee779570-e48c-4932-9089-6346f82728a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_ee779570-e48c-4932-9089-6346f82728a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_ee779570-e48c-4932-9089-6346f82728a5" xlink:to="loc_us-gaap_GranteeStatusDomain_ee779570-e48c-4932-9089-6346f82728a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_b6de0021-dbda-46ec-b371-5471e0d60c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_ee779570-e48c-4932-9089-6346f82728a5" xlink:to="loc_us-gaap_GranteeStatusDomain_b6de0021-dbda-46ec-b371-5471e0d60c3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_f0a4a169-e00c-4237-8b2b-7fb8f8d04775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_b6de0021-dbda-46ec-b371-5471e0d60c3d" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_f0a4a169-e00c-4237-8b2b-7fb8f8d04775" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_8fb5f506-e79b-46de-a15d-a4b492d5f154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_b6de0021-dbda-46ec-b371-5471e0d60c3d" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_8fb5f506-e79b-46de-a15d-a4b492d5f154" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails" xlink:type="extended" id="idbf2c045619e4b0395e3d30be45fe6ba_StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_29503b8c-9b3a-4836-9f87-266aff6e3a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6284e6cf-76d1-420a-8f50-1e4aa2ef0686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_29503b8c-9b3a-4836-9f87-266aff6e3a0d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6284e6cf-76d1-420a-8f50-1e4aa2ef0686" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3172e74b-ac83-4a44-b83b-ae7567b62149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_29503b8c-9b3a-4836-9f87-266aff6e3a0d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3172e74b-ac83-4a44-b83b-ae7567b62149" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_681565e8-db55-41db-9bb8-1ae9cd42547e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3172e74b-ac83-4a44-b83b-ae7567b62149" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_681565e8-db55-41db-9bb8-1ae9cd42547e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_681565e8-db55-41db-9bb8-1ae9cd42547e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_681565e8-db55-41db-9bb8-1ae9cd42547e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_681565e8-db55-41db-9bb8-1ae9cd42547e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9952af1a-2b71-46aa-b3e6-cb037ff41591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_681565e8-db55-41db-9bb8-1ae9cd42547e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9952af1a-2b71-46aa-b3e6-cb037ff41591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_148f2a19-e38a-40b9-8b92-db69fa7a4698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9952af1a-2b71-46aa-b3e6-cb037ff41591" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_148f2a19-e38a-40b9-8b92-db69fa7a4698" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_913f6d0c-cffb-4f4f-9adf-da743d389d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9952af1a-2b71-46aa-b3e6-cb037ff41591" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_913f6d0c-cffb-4f4f-9adf-da743d389d34" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails" xlink:type="extended" id="i4ca37dc2e5d94b0f8bcf7b236b121e37_StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51e9332b-bee2-4ac7-ab45-332ac7d59e74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_544df31b-885a-4cd8-9ceb-33a6ccde13eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51e9332b-bee2-4ac7-ab45-332ac7d59e74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_544df31b-885a-4cd8-9ceb-33a6ccde13eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a8e0e5dc-d830-4955-8e99-c7547db7a0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_544df31b-885a-4cd8-9ceb-33a6ccde13eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a8e0e5dc-d830-4955-8e99-c7547db7a0b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a37b547e-dad8-4b14-b66d-655ff8637336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_544df31b-885a-4cd8-9ceb-33a6ccde13eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a37b547e-dad8-4b14-b66d-655ff8637336" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_37436800-b5d2-49bf-a80a-920271b3ab68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_544df31b-885a-4cd8-9ceb-33a6ccde13eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_37436800-b5d2-49bf-a80a-920271b3ab68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e3d019ef-b433-4ce7-9da0-e7d5b8774ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_544df31b-885a-4cd8-9ceb-33a6ccde13eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e3d019ef-b433-4ce7-9da0-e7d5b8774ed8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e4443335-714f-43d6-bba1-ff41f277e63a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d4503e0b-86fe-4827-8ed5-99ce870e6b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51e9332b-bee2-4ac7-ab45-332ac7d59e74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d4503e0b-86fe-4827-8ed5-99ce870e6b86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d1ca8561-af39-4e75-b2d6-0ed255e2df41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d4503e0b-86fe-4827-8ed5-99ce870e6b86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d1ca8561-af39-4e75-b2d6-0ed255e2df41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12ed1a65-a156-4ef4-890b-bcb6001cba66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d4503e0b-86fe-4827-8ed5-99ce870e6b86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12ed1a65-a156-4ef4-890b-bcb6001cba66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9c4eda0f-1b75-4916-a2ab-c76aa688a851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d4503e0b-86fe-4827-8ed5-99ce870e6b86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9c4eda0f-1b75-4916-a2ab-c76aa688a851" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b74b977f-a0aa-4ee2-86ab-2d1d74447ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d4503e0b-86fe-4827-8ed5-99ce870e6b86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b74b977f-a0aa-4ee2-86ab-2d1d74447ddf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ba1ba6ab-d33e-4037-bb87-d8aec684e043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2e68e3e-c049-40ce-9c5a-0bb10a688539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51e9332b-bee2-4ac7-ab45-332ac7d59e74" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2e68e3e-c049-40ce-9c5a-0bb10a688539" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2ef7d86c-0644-4421-b8ac-ab2103a6627c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2e68e3e-c049-40ce-9c5a-0bb10a688539" xlink:to="loc_us-gaap_AwardTypeAxis_2ef7d86c-0644-4421-b8ac-ab2103a6627c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ef7d86c-0644-4421-b8ac-ab2103a6627c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2ef7d86c-0644-4421-b8ac-ab2103a6627c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ef7d86c-0644-4421-b8ac-ab2103a6627c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_815a4a24-717c-4984-9c7d-4066f0cf9a88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2ef7d86c-0644-4421-b8ac-ab2103a6627c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_815a4a24-717c-4984-9c7d-4066f0cf9a88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bb481672-ae16-4745-a957-6f84ecf04025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_815a4a24-717c-4984-9c7d-4066f0cf9a88" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bb481672-ae16-4745-a957-6f84ecf04025" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/IncomeTaxesDetails" xlink:type="extended" id="ib7ca8a15999845058a48229da074910f_IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_f9833cb3-1040-42aa-92ea-b90f8621e695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SocialSecurityTaxEmployerDeferralCARESAct_36772b98-a8f0-4bc8-9184-71da31de270e" xlink:href="evlo-20210630.xsd#evlo_SocialSecurityTaxEmployerDeferralCARESAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f9833cb3-1040-42aa-92ea-b90f8621e695" xlink:to="loc_evlo_SocialSecurityTaxEmployerDeferralCARESAct_36772b98-a8f0-4bc8-9184-71da31de270e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b5f9f7c-4981-439f-ab3d-4db33bb286b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f9833cb3-1040-42aa-92ea-b90f8621e695" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9b5f9f7c-4981-439f-ab3d-4db33bb286b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_4fc46f76-b5a6-4d4f-b202-6166b56f4c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f9833cb3-1040-42aa-92ea-b90f8621e695" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_4fc46f76-b5a6-4d4f-b202-6166b56f4c0f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7773d6d9-cbc2-4fc6-9bb7-89325884fb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_4fc46f76-b5a6-4d4f-b202-6166b56f4c0f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7773d6d9-cbc2-4fc6-9bb7-89325884fb5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7773d6d9-cbc2-4fc6-9bb7-89325884fb5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7773d6d9-cbc2-4fc6-9bb7-89325884fb5c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7773d6d9-cbc2-4fc6-9bb7-89325884fb5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_913b33af-6bb2-41eb-916c-c8a2c31c8e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7773d6d9-cbc2-4fc6-9bb7-89325884fb5c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_913b33af-6bb2-41eb-916c-c8a2c31c8e6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_1964bd41-cf10-4eef-9eed-558b1b459841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_913b33af-6bb2-41eb-916c-c8a2c31c8e6f" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_1964bd41-cf10-4eef-9eed-558b1b459841" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_d72af2ed-6ca9-4809-a50c-bc5cf48197f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_913b33af-6bb2-41eb-916c-c8a2c31c8e6f" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_d72af2ed-6ca9-4809-a50c-bc5cf48197f3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails" xlink:type="extended" id="ifb0b2645aeac466e9a19a6616abb055d_NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c0bb6f7b-5863-4758-941c-2957f07e7d24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_827bca0b-8dfb-4032-9af7-fefec3dc988e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c0bb6f7b-5863-4758-941c-2957f07e7d24" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_827bca0b-8dfb-4032-9af7-fefec3dc988e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_db68c912-5eb2-4f90-a0fb-b49a29ba2ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c0bb6f7b-5863-4758-941c-2957f07e7d24" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_db68c912-5eb2-4f90-a0fb-b49a29ba2ab1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a03088a-56fc-449a-b2e5-889a488e71bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_db68c912-5eb2-4f90-a0fb-b49a29ba2ab1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a03088a-56fc-449a-b2e5-889a488e71bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3a03088a-56fc-449a-b2e5-889a488e71bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a03088a-56fc-449a-b2e5-889a488e71bb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3a03088a-56fc-449a-b2e5-889a488e71bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8f93646-d9ac-44e0-ac81-362d01e2acc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a03088a-56fc-449a-b2e5-889a488e71bb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8f93646-d9ac-44e0-ac81-362d01e2acc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_UnvestedCommonStockMember_1fa1631a-6db0-4790-875f-becf35c73911" xlink:href="evlo-20210630.xsd#evlo_UnvestedCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8f93646-d9ac-44e0-ac81-362d01e2acc6" xlink:to="loc_evlo_UnvestedCommonStockMember_1fa1631a-6db0-4790-875f-becf35c73911" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c5f6dfc2-ecbe-4e9f-b473-99741772818d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8f93646-d9ac-44e0-ac81-362d01e2acc6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c5f6dfc2-ecbe-4e9f-b473-99741772818d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2625f35e-4aca-410b-b85f-4c2f9d2dbf49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8f93646-d9ac-44e0-ac81-362d01e2acc6" xlink:to="loc_us-gaap_WarrantMember_2625f35e-4aca-410b-b85f-4c2f9d2dbf49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_075c611d-3859-4520-9928-8ae95b8fe483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8f93646-d9ac-44e0-ac81-362d01e2acc6" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_075c611d-3859-4520-9928-8ae95b8fe483" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2fcb476a-f826-4762-af45-6fdb8f5308be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8f93646-d9ac-44e0-ac81-362d01e2acc6" xlink:to="loc_us-gaap_EmployeeStockMember_2fcb476a-f826-4762-af45-6fdb8f5308be" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended" id="i8fb28c38613d4d049bf1e59f20c52122_RelatedPartyTransactionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_b17e1acf-ad75-4104-9e14-3961ad5fb89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_b17e1acf-ad75-4104-9e14-3961ad5fb89b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_b5bfdfbf-1d71-4ecb-82c6-198245dd950a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_b5bfdfbf-1d71-4ecb-82c6-198245dd950a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_5cd3754f-3354-4fb8-9c61-8e91ac8adb03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_5cd3754f-3354-4fb8-9c61-8e91ac8adb03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_aec2b08b-e1fd-47d0-a9a9-bae0ee7ddf49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_us-gaap_SubleaseIncome_aec2b08b-e1fd-47d0-a9a9-bae0ee7ddf49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm_e0d9e86b-d820-46fd-8b95-d2f3dc10e017" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm_e0d9e86b-d820-46fd-8b95-d2f3dc10e017" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm_9ec172de-21a8-4c1c-a97f-adadc22c6ce1" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm_9ec172de-21a8-4c1c-a97f-adadc22c6ce1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2dc7f9c7-2eb4-412c-96d2-9d2cbc52e123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2dc7f9c7-2eb4-412c-96d2-9d2cbc52e123" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments_977dfb01-5155-4b56-950d-94e4be4dd5ab" xlink:href="evlo-20210630.xsd#evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments_977dfb01-5155-4b56-950d-94e4be4dd5ab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue_391910e6-9ea9-4210-b030-7851e2f7e6fd" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue_391910e6-9ea9-4210-b030-7851e2f7e6fd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments_c636efdf-84fb-458b-9938-c4840f5c4878" xlink:href="evlo-20210630.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments_c636efdf-84fb-458b-9938-c4840f5c4878" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionAnnualCashConsultingFee_b21b86e6-3fc9-4494-9ff5-da740a1edaeb" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionAnnualCashConsultingFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_evlo_RelatedPartyTransactionAnnualCashConsultingFee_b21b86e6-3fc9-4494-9ff5-da740a1edaeb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionConsultingContractRenewalTerm_784e875c-56a6-4380-91c1-e7c2c3739286" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionConsultingContractRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_evlo_RelatedPartyTransactionConsultingContractRenewalTerm_784e875c-56a6-4380-91c1-e7c2c3739286" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue_868b34eb-10af-42b3-aa5b-f59805220a3b" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue_868b34eb-10af-42b3-aa5b-f59805220a3b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod_3e53c8d5-1244-4618-8e11-f71555660809" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod_3e53c8d5-1244-4618-8e11-f71555660809" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47aea146-1cba-4524-a9b0-9f5abee2441f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47aea146-1cba-4524-a9b0-9f5abee2441f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_59d25f8f-e476-428d-a09f-5a59a75a3d15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47aea146-1cba-4524-a9b0-9f5abee2441f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_59d25f8f-e476-428d-a09f-5a59a75a3d15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_59d25f8f-e476-428d-a09f-5a59a75a3d15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_59d25f8f-e476-428d-a09f-5a59a75a3d15" xlink:to="loc_us-gaap_RelatedPartyDomain_59d25f8f-e476-428d-a09f-5a59a75a3d15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3538fc13-e3f6-4291-816c-ca83ea593053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_59d25f8f-e476-428d-a09f-5a59a75a3d15" xlink:to="loc_us-gaap_RelatedPartyDomain_3538fc13-e3f6-4291-816c-ca83ea593053" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_WeatherdenLtdMember_fea4f904-4ec3-4a10-8c6a-4123ab8259c7" xlink:href="evlo-20210630.xsd#evlo_WeatherdenLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3538fc13-e3f6-4291-816c-ca83ea593053" xlink:to="loc_evlo_WeatherdenLtdMember_fea4f904-4ec3-4a10-8c6a-4123ab8259c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_VL46Member_150dd468-f1b3-404b-b8de-048870400c18" xlink:href="evlo-20210630.xsd#evlo_VL46Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3538fc13-e3f6-4291-816c-ca83ea593053" xlink:to="loc_evlo_VL46Member_150dd468-f1b3-404b-b8de-048870400c18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_51822be5-f9b2-4eed-8c16-98d823156064" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3538fc13-e3f6-4291-816c-ca83ea593053" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_51822be5-f9b2-4eed-8c16-98d823156064" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1c172f82-ab0b-4e60-9c7d-05263c39bd35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47aea146-1cba-4524-a9b0-9f5abee2441f" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1c172f82-ab0b-4e60-9c7d-05263c39bd35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1c172f82-ab0b-4e60-9c7d-05263c39bd35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1c172f82-ab0b-4e60-9c7d-05263c39bd35" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1c172f82-ab0b-4e60-9c7d-05263c39bd35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_65a42bdf-7d14-40a0-84ff-cae0d76ddb87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1c172f82-ab0b-4e60-9c7d-05263c39bd35" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_65a42bdf-7d14-40a0-84ff-cae0d76ddb87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ConsultingAgreementMember_1f8b9b25-6eab-473c-8f36-6b5deb179553" xlink:href="evlo-20210630.xsd#evlo_ConsultingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_65a42bdf-7d14-40a0-84ff-cae0d76ddb87" xlink:to="loc_evlo_ConsultingAgreementMember_1f8b9b25-6eab-473c-8f36-6b5deb179553" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_31ab61d5-315a-4e49-9c45-f5f492bb79c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47aea146-1cba-4524-a9b0-9f5abee2441f" xlink:to="loc_us-gaap_AwardTypeAxis_31ab61d5-315a-4e49-9c45-f5f492bb79c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31ab61d5-315a-4e49-9c45-f5f492bb79c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_31ab61d5-315a-4e49-9c45-f5f492bb79c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31ab61d5-315a-4e49-9c45-f5f492bb79c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18d5a279-5db0-4836-8d9b-5aea13a357ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_31ab61d5-315a-4e49-9c45-f5f492bb79c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18d5a279-5db0-4836-8d9b-5aea13a357ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_55142e83-f81a-41a3-ab3e-1e784223532c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18d5a279-5db0-4836-8d9b-5aea13a357ec" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_55142e83-f81a-41a3-ab3e-1e784223532c" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>evlo-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:aae86b17-43ea-4a10-aac9-9e83e0002ea1,g:814caf2c-83ae-43b0-8a9b-a2d97aa90ba1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm_20bd7b07-349a-40f6-8744-9bad07ce193e_terseLabel_en-US" xlink:label="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination notice period of consulting arrangement</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm_label_en-US" xlink:label="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Consulting Contract, Termination Notice, Term</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm_documentation_en-US" xlink:label="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Consulting Contract, Termination Notice, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm" xlink:to="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_12435339-01b2-4646-9ebc-c9a5db1226ba_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_75598eaf-eb90-4005-b699-7d444243126b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_4fc5a08d-8aac-494a-a19b-6ee69bd5f43b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_941a4379-3525-415d-a261-ed43e0d5db11_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_27fff111-da32-466e-9f4f-40285e49817d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2f7e9d7e-24ce-4050-a62d-8fb2534ddb5a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_513eca0e-cf92-4f91-98b4-84d81d6e785d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts_ce30b5db-be08-448e-afeb-1be54fb043ab_terseLabel_en-US" xlink:label="lab_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments for development and commercialization of licensed products</link:label>
    <link:label id="lab_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts_label_en-US" xlink:label="lab_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments For Development And Commercialization Of Licensed Products</link:label>
    <link:label id="lab_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts_documentation_en-US" xlink:label="lab_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments For Development And Commercialization Of Licensed Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts" xlink:href="evlo-20210630.xsd#evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts" xlink:to="lab_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_c7d371b2-6c37-44af-8df9-efb8c38c7e52_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset - operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue_7f838c69-e440-4a36-840c-227be3ba2191_terseLabel_en-US" xlink:label="lab_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate grant date fair value</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue_label_en-US" xlink:label="lab_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Annual Share-based Payment Award, Options, Grant Date Fair Market Value</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue_documentation_en-US" xlink:label="lab_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Annual Share-based Payment Award, Options, Grant Date Fair Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue" xlink:to="lab_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_75227307-3baa-4c50-9c2f-2fa8652de6db_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_54db9979-f40a-426f-963e-64c159c74fc5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised_4053105d-6410-4f57-aa0c-0e65f53211d5_terseLabel_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, options and other equity awards exercised (in shares)</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised_label_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Exercised</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised_documentation_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised" xlink:href="evlo-20210630.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised" xlink:to="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8b5cbab2-aee6-4cc5-a16d-b425ad19b664_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1ca8c6db-32e0-48c9-9569-ff7191234020_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_17ef575f-8fab-4c50-a5b9-a31206e5910e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Minimum Aggregate Future Loan Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_A2019CreditFacilityMember_2e1832ed-5465-447c-8e6c-cfb59446ac3a_terseLabel_en-US" xlink:label="lab_evlo_A2019CreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Credit Facility</link:label>
    <link:label id="lab_evlo_A2019CreditFacilityMember_label_en-US" xlink:label="lab_evlo_A2019CreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Credit Facility [Member]</link:label>
    <link:label id="lab_evlo_A2019CreditFacilityMember_documentation_en-US" xlink:label="lab_evlo_A2019CreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_A2019CreditFacilityMember" xlink:href="evlo-20210630.xsd#evlo_A2019CreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_A2019CreditFacilityMember" xlink:to="lab_evlo_A2019CreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_c684c80b-7897-4e07-866c-9245843d1fd6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_f27e990e-092f-4485-a917-0d882f75ebd2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_e87ad5e2-3be9-4ff6-96dc-29a17436a81e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock at a conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ea4ee33f-a575-4860-b932-bafabd70c463_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_77be1460-919b-4234-9520-ed14ee385709_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_cf56f1e2-6705-4320-bb24-85ed0b6b4d53_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a6714435-2dc7-4ba8-9680-2394d4b05474_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_be6ee0a7-05fb-4544-af58-0337b7d46cc4_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_87067601-422b-400e-86ae-654e2aee5826_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f8b0b9ca-d410-43f9-bea1-13cbb28c5b2b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a965300f-b2fd-468b-900c-19b5cbd39676_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_DebtInstrumentTrancheAxis_30b87c62-98ed-43cd-bdab-2c4beada05fc_terseLabel_en-US" xlink:label="lab_evlo_DebtInstrumentTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Tranche [Axis]</link:label>
    <link:label id="lab_evlo_DebtInstrumentTrancheAxis_label_en-US" xlink:label="lab_evlo_DebtInstrumentTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Tranche [Axis]</link:label>
    <link:label id="lab_evlo_DebtInstrumentTrancheAxis_documentation_en-US" xlink:label="lab_evlo_DebtInstrumentTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentTrancheAxis" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentTrancheAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_DebtInstrumentTrancheAxis" xlink:to="lab_evlo_DebtInstrumentTrancheAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8738455c-172b-4657-84af-8a692d517c2b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9e2e2ede-93c7-480d-b5fb-93a6cac7bae1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices_1bd3e0f3-18ac-4339-aad2-6f3536258e68_terseLabel_en-US" xlink:label="lab_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of inactive manufacturing services causing termination under collaborative arrangement</link:label>
    <link:label id="lab_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices_label_en-US" xlink:label="lab_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Period Of Inactive Manufacturing Services</link:label>
    <link:label id="lab_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices_documentation_en-US" xlink:label="lab_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Period Of Inactive Manufacturing Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices" xlink:href="evlo-20210630.xsd#evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices" xlink:to="lab_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_0fd503a7-11d0-446f-9de1-5325e9949ca8_terseLabel_en-US" xlink:label="lab_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing and public offering costs in accounts payable and accrued expenses</link:label>
    <link:label id="lab_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_label_en-US" xlink:label="lab_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Public Offering Costs Included In Accounts Payable And Accrued Expenses</link:label>
    <link:label id="lab_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_documentation_en-US" xlink:label="lab_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Public Offering Costs Included In Accounts Payable And Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:href="evlo-20210630.xsd#evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="lab_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a22440ca-d00f-4c61-8da8-02b3d1b8695b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7a9a0929-525d-4667-aa04-39a41a77d9b0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e145d76d-d5ae-418e-886d-52b3191b5679_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_9381d013-66f8-4008-b0bb-87bbd2cebdf4_terseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mr. Epstein</link:label>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_label_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember" xlink:to="lab_srt_BoardOfDirectorsChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_RelatedPartyTransactionConsultingContractRenewalTerm_c787bfc2-e880-4683-a16c-6f43884cc303_terseLabel_en-US" xlink:label="lab_evlo_RelatedPartyTransactionConsultingContractRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionConsultingContractRenewalTerm_label_en-US" xlink:label="lab_evlo_RelatedPartyTransactionConsultingContractRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Consulting Contract, Renewal Term</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionConsultingContractRenewalTerm_documentation_en-US" xlink:label="lab_evlo_RelatedPartyTransactionConsultingContractRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Consulting Contract, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionConsultingContractRenewalTerm" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionConsultingContractRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_RelatedPartyTransactionConsultingContractRenewalTerm" xlink:to="lab_evlo_RelatedPartyTransactionConsultingContractRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_984a7f5b-8377-4091-a24f-3a784759f45d_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of securities excluded from computation of diluted weighted-average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5d67a36d-7c70-4bd2-9db6-de18456329e7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_37a6a331-f11e-4dd7-87ea-14a81bf03310_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_d6e3545c-9b02-4972-87cb-b4c7a868e6b1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_496b4936-0791-4ca4-a0c0-fb019b28d329_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_e9809b23-616f-4fda-8e25-dc2f39872e00_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2795025b-df40-44eb-966a-98055e871653_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_430ef8c5-398c-49f7-86f9-ec6c050cd0aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod_3db2c9d5-a9a4-434c-b868-473de5d584e4_terseLabel_en-US" xlink:label="lab_evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Negotiation period for second product candidate</link:label>
    <link:label id="lab_evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod_label_en-US" xlink:label="lab_evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Second Product Candidate, Negotiation Period</link:label>
    <link:label id="lab_evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod_documentation_en-US" xlink:label="lab_evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Second Product Candidate, Negotiation Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod" xlink:href="evlo-20210630.xsd#evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod" xlink:to="lab_evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e907e5f-635e-4abe-b09f-5a1fc2ee30f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_561f5bb8-57ff-404c-b2e6-e697c49bc9ee_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a69f2517-88cb-43e1-ab3a-54f7945ff444_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_4ce63f32-cfe4-4175-9960-0c650f9e93b2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4694c360-8730-4b86-980a-5603c400a69b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable as of period end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SaleOfStockConsiderationReceivedTerm_bffd9d31-ebac-49a1-b23f-3fb160dfb50f_terseLabel_en-US" xlink:label="lab_evlo_SaleOfStockConsiderationReceivedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, term (up to)</link:label>
    <link:label id="lab_evlo_SaleOfStockConsiderationReceivedTerm_label_en-US" xlink:label="lab_evlo_SaleOfStockConsiderationReceivedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration Received, Term</link:label>
    <link:label id="lab_evlo_SaleOfStockConsiderationReceivedTerm_documentation_en-US" xlink:label="lab_evlo_SaleOfStockConsiderationReceivedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration Received, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockConsiderationReceivedTerm" xlink:href="evlo-20210630.xsd#evlo_SaleOfStockConsiderationReceivedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SaleOfStockConsiderationReceivedTerm" xlink:to="lab_evlo_SaleOfStockConsiderationReceivedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_215145e7-3959-49b9-91de-d904eb5a8caf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_38b4bc13-42ab-4efc-9d8b-4172376b7d07_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding as of June 30, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_59262f5a-5bc0-4f53-ab35-918514f02db8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under employee stock purchase plan and exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4ebc95fa-4ef1-423b-a938-457da6a977a1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ed01b9ff-9d91-41e9-826b-9bdd5629746d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2cd1ab8e-745a-4496-8178-785fbcd0f6ce_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_20aa1211-6d8f-4523-a364-b73e7542a7e7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_f0850240-5097-429b-affc-df3009dc8b19_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_27119af7-b9e0-4201-bc49-3337b1244f5f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_553a6f7d-b5ac-42d6-bc2e-bd5b26761342_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_52471517-5e8c-442b-8198-f5ba5f564b26_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_561e24f1-0e56-467e-8b42-ee855ad2e051_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34010ff0-80e5-427c-8b7c-1a0935bc0e64_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_TwoThousandAndFifteenStockIncentivePlanMember_08d42ef4-9cc4-467c-9e75-2c816ea57a3a_terseLabel_en-US" xlink:label="lab_evlo_TwoThousandAndFifteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Stock Incentive Plan</link:label>
    <link:label id="lab_evlo_TwoThousandAndFifteenStockIncentivePlanMember_label_en-US" xlink:label="lab_evlo_TwoThousandAndFifteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Fifteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_evlo_TwoThousandAndFifteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_evlo_TwoThousandAndFifteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and fifteen stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_TwoThousandAndFifteenStockIncentivePlanMember" xlink:href="evlo-20210630.xsd#evlo_TwoThousandAndFifteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_TwoThousandAndFifteenStockIncentivePlanMember" xlink:to="lab_evlo_TwoThousandAndFifteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_ClassOfWarrantOrRightFairValueMeasurement_eb5ba2ea-bf1e-4d4a-8d19-15da3c5bed25_terseLabel_en-US" xlink:label="lab_evlo_ClassOfWarrantOrRightFairValueMeasurement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid in capital at its issuance date fair value</link:label>
    <link:label id="lab_evlo_ClassOfWarrantOrRightFairValueMeasurement_label_en-US" xlink:label="lab_evlo_ClassOfWarrantOrRightFairValueMeasurement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Fair Value Measurement</link:label>
    <link:label id="lab_evlo_ClassOfWarrantOrRightFairValueMeasurement_documentation_en-US" xlink:label="lab_evlo_ClassOfWarrantOrRightFairValueMeasurement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Fair Value Measurement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ClassOfWarrantOrRightFairValueMeasurement" xlink:href="evlo-20210630.xsd#evlo_ClassOfWarrantOrRightFairValueMeasurement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_ClassOfWarrantOrRightFairValueMeasurement" xlink:to="lab_evlo_ClassOfWarrantOrRightFairValueMeasurement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_174a1539-5afd-441c-a1dd-26c21f68009a_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment additions in accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_AnnualAmountDueUnderCollaborativeArrangement_9cb582f3-2212-4c8b-823b-b42e7fc5a1c5_terseLabel_en-US" xlink:label="lab_evlo_AnnualAmountDueUnderCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual amount due under collaborative arrangement</link:label>
    <link:label id="lab_evlo_AnnualAmountDueUnderCollaborativeArrangement_label_en-US" xlink:label="lab_evlo_AnnualAmountDueUnderCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Amount Due Under Collaborative Arrangement</link:label>
    <link:label id="lab_evlo_AnnualAmountDueUnderCollaborativeArrangement_documentation_en-US" xlink:label="lab_evlo_AnnualAmountDueUnderCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Amount Due Under Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AnnualAmountDueUnderCollaborativeArrangement" xlink:href="evlo-20210630.xsd#evlo_AnnualAmountDueUnderCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_AnnualAmountDueUnderCollaborativeArrangement" xlink:to="lab_evlo_AnnualAmountDueUnderCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_542cfec5-bc14-4f8e-a29f-04f80fb46e83_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c6b19317-5f7d-4ba9-9983-e09f3783eb80_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_bccabe86-8a16-4f4f-9948-11b41aaf3499_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due to related party</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f6fc83db-e0af-4b83-8c95-a3c9114e08b1_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_63526d49-9153-4375-9a4e-e9221f6bb40e_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Plus</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_678a28e3-5fa0-49df-b5e5-0ccc259168cf_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5e09a5ed-731d-44ee-a4c4-484cf59b3bf0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1f270d31-f7c7-4987-912b-a157a7702821_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_WeatherdenLtdMember_69b21da8-359f-40ac-8db4-a19eb6afa412_terseLabel_en-US" xlink:label="lab_evlo_WeatherdenLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weatherden Ltd</link:label>
    <link:label id="lab_evlo_WeatherdenLtdMember_label_en-US" xlink:label="lab_evlo_WeatherdenLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weatherden Ltd [Member]</link:label>
    <link:label id="lab_evlo_WeatherdenLtdMember_documentation_en-US" xlink:label="lab_evlo_WeatherdenLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weatherden Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_WeatherdenLtdMember" xlink:href="evlo-20210630.xsd#evlo_WeatherdenLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_WeatherdenLtdMember" xlink:to="lab_evlo_WeatherdenLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_62af9b84-5ac6-433b-953f-f75aa9e3a41d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_71f56f0a-1f99-44d8-932a-c0d730cf5374_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_b7d1ab12-8cb4-427c-bb46-85d2aa624fa2_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease rental income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ee679232-604c-47ba-a7cf-14b2f298e948_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance at December 31, 2020 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a334e14d-71d2-4873-ae8f-23ea68013019_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance at June 30, 2021 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ae28b4fa-1b6e-4718-96eb-a16f83a72fe8_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_b4146313-92f3-4bcf-8aea-997335a21f2d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_FeeIncurredUnderCollaborativeArrangement_30e6904b-6f49-4a38-a23b-dd3578f9f2b0_terseLabel_en-US" xlink:label="lab_evlo_FeeIncurredUnderCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee incurred under collaborative arrangement</link:label>
    <link:label id="lab_evlo_FeeIncurredUnderCollaborativeArrangement_label_en-US" xlink:label="lab_evlo_FeeIncurredUnderCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee Incurred Under Collaborative Arrangement</link:label>
    <link:label id="lab_evlo_FeeIncurredUnderCollaborativeArrangement_documentation_en-US" xlink:label="lab_evlo_FeeIncurredUnderCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee Incurred Under Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_FeeIncurredUnderCollaborativeArrangement" xlink:href="evlo-20210630.xsd#evlo_FeeIncurredUnderCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_FeeIncurredUnderCollaborativeArrangement" xlink:to="lab_evlo_FeeIncurredUnderCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_96fa1107-5e2c-4c8c-a37c-70837aed8add_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_0ae1985c-04ad-4f75-83cb-8c69834ef20d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_89dbde4f-8664-4af7-82d7-dfa31f0937ce_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SocialSecurityTaxEmployerDeferralCARESAct_d8cd4662-e65a-489d-9459-07894b025cdf_terseLabel_en-US" xlink:label="lab_evlo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred payroll taxes related to CARES Act</link:label>
    <link:label id="lab_evlo_SocialSecurityTaxEmployerDeferralCARESAct_label_en-US" xlink:label="lab_evlo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social Security Tax, Employer, Deferral, CARES Act</link:label>
    <link:label id="lab_evlo_SocialSecurityTaxEmployerDeferralCARESAct_documentation_en-US" xlink:label="lab_evlo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social Security Tax, Employer, Deferral, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:href="evlo-20210630.xsd#evlo_SocialSecurityTaxEmployerDeferralCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:to="lab_evlo_SocialSecurityTaxEmployerDeferralCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_815924e0-8511-4aee-806a-abb117e44254_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares originally authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_8ee2218e-5703-4883-892d-3a93c90ffd7f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows used for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_DebtInstrumentDebtDefaultPercentage_4d521517-a25b-4357-b642-f7f33fa62a72_terseLabel_en-US" xlink:label="lab_evlo_DebtInstrumentDebtDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt default interest rate per annum</link:label>
    <link:label id="lab_evlo_DebtInstrumentDebtDefaultPercentage_label_en-US" xlink:label="lab_evlo_DebtInstrumentDebtDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Default, Percentage</link:label>
    <link:label id="lab_evlo_DebtInstrumentDebtDefaultPercentage_documentation_en-US" xlink:label="lab_evlo_DebtInstrumentDebtDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Default, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentDebtDefaultPercentage" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentDebtDefaultPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_DebtInstrumentDebtDefaultPercentage" xlink:to="lab_evlo_DebtInstrumentDebtDefaultPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures_2eae648e-a0e8-4dac-9449-d555af178ae0_terseLabel_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, options and other equity awards canceled (in shares)</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures_label_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Forfeitures</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures_documentation_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures" xlink:href="evlo-20210630.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures" xlink:to="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_8e076940-a70a-47d8-b568-a9e69fa04a99_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheOneMember_4d6de46e-6361-4c01-912a-10e5c795babd_terseLabel_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche One</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheOneMember_label_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche One [Member]</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheOneMember_documentation_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheOneMember" xlink:href="evlo-20210630.xsd#evlo_SecurityAndLoanAgreementTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SecurityAndLoanAgreementTrancheOneMember" xlink:to="lab_evlo_SecurityAndLoanAgreementTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_1867f042-6773-4187-b435-03e447d3de96_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased_8eb17bc6-ae3d-4c8c-b550-236be183c5db_terseLabel_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares repurchased (in shares)</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased_label_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Repurchased</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased_documentation_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased" xlink:href="evlo-20210630.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased" xlink:to="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_b6363ab5-4776-4619-bda7-3af90ca24a6a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_1eb9a8ab-aa96-4a73-8d52-6c7a07677f04_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_fe5e147a-3c74-4d05-b01f-1cc5048fe713_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum payments</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_a3184d37-ab39-473f-aa55-508578545eed_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5b04d138-152c-48b3-88f8-bcddb8b950e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_33f0970a-46e4-454b-b7a5-5b4003ab4e2f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_5b1319cd-60ac-4b24-adc4-a65d8d183f39_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_108fe4c8-8292-42f6-a65c-cadee9b35a92_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3f9c6af1-07ff-4bd8-bda4-b11910033daf_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_f571c3f2-b27e-4c47-96fd-d177c59813a5_verboseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent due from sublease agreement</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_313bef34-89b3-4282-892d-70780d2af82f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_15ba302c-ccea-4183-a0f8-12f32d42bfa1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_a2f8789f-d9ff-4c3f-9207-ebdade74ab90_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SecurityAndLoanAgreementNumberOfTranches_d1aa0d50-ea5a-403c-841b-8bcc7de71626_terseLabel_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementNumberOfTranches_label_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Number Of Tranches</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementNumberOfTranches_documentation_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementNumberOfTranches" xlink:href="evlo-20210630.xsd#evlo_SecurityAndLoanAgreementNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SecurityAndLoanAgreementNumberOfTranches" xlink:to="lab_evlo_SecurityAndLoanAgreementNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c9ba0340-5191-47f7-8d4a-1fb5cc733916_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_3ae74a52-d144-4c10-8ab2-4eeab32e5db8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2d6e374f-55e4-4439-ab09-204e407fa216_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_e68a9492-3c1f-4345-9401-764b27ad61f9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_AggregateAmountDueUnderCollaborativeArrangement_50d18a68-7301-4a8c-a429-9451f2825bc7_terseLabel_en-US" xlink:label="lab_evlo_AggregateAmountDueUnderCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount due under collaborative arrangement</link:label>
    <link:label id="lab_evlo_AggregateAmountDueUnderCollaborativeArrangement_label_en-US" xlink:label="lab_evlo_AggregateAmountDueUnderCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Amount Due Under Collaborative Arrangement</link:label>
    <link:label id="lab_evlo_AggregateAmountDueUnderCollaborativeArrangement_documentation_en-US" xlink:label="lab_evlo_AggregateAmountDueUnderCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Amount Due Under Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AggregateAmountDueUnderCollaborativeArrangement" xlink:href="evlo-20210630.xsd#evlo_AggregateAmountDueUnderCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_AggregateAmountDueUnderCollaborativeArrangement" xlink:to="lab_evlo_AggregateAmountDueUnderCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4c193245-39fe-495c-895c-0d72c498ffad_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_66987ac4-96ee-42de-b28c-b1727f087314_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_87586ef0-771c-4842-a6d0-23f0f851f785_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_68f6a39c-19bd-4a3d-ab2a-9cfcdae4124b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e07fc346-f9bb-4a97-9341-c320c5ee0dd3_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_b7f3fc70-48fd-4838-a51a-1fa4824a752c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_1ecf42f1-a5bd-4d6a-9e37-b925a676bf43_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of fixed assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_121af5f6-d42c-42ac-b3b6-d81836004525_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_aab6d224-1b30-449e-aef6-ef9f343fca43_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_cdca829a-522a-41c1-b127-b5b6861241f1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_caa3446c-40f3-43ab-a1c7-ed22ad754054_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_07b40268-9e7d-4854-8398-a7393ec0bde7_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_2df2cc8b-fc7e-412b-905d-ba45c6a2db43_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan and Security Agreements</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_2edf49e4-3c5c-4e1e-9c44-5e0760c2b88d_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_1dd12138-3fd7-4c91-955d-cfc44ef76168_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0f81f210-ecbc-41a7-a2de-84898c42f324_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable as of period end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_7dfefe96-7a7c-4754-a222-54b78639c474_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_ca7df88f-eaba-40c8-b573-f5390e4fbf1b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0fbdd86d-74fc-494d-a380-9ed2a1154c36_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3ac3ab6d-7ba6-4ab0-9585-1e5c6886bf68_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_CommitmentAndContingenciesTable_3bb857d8-453e-4023-9433-c8505da1160b_terseLabel_en-US" xlink:label="lab_evlo_CommitmentAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment And Contingencies [Table]</link:label>
    <link:label id="lab_evlo_CommitmentAndContingenciesTable_label_en-US" xlink:label="lab_evlo_CommitmentAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment And Contingencies [Table]</link:label>
    <link:label id="lab_evlo_CommitmentAndContingenciesTable_documentation_en-US" xlink:label="lab_evlo_CommitmentAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment And Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CommitmentAndContingenciesTable" xlink:href="evlo-20210630.xsd#evlo_CommitmentAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_CommitmentAndContingenciesTable" xlink:to="lab_evlo_CommitmentAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_6e8352de-5b3f-4d6f-b7ac-ea534ffa0d73_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_67ae67c4-8220-4e56-8206-def170202840_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount due under license agreement</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ba1ad4d8-bce2-4778-afbe-c8780543e7eb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue_a2ac8a26-ddce-40e6-82dd-6a0cd129528b_terseLabel_en-US" xlink:label="lab_evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate grant date fair value for restricted stock units</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue_label_en-US" xlink:label="lab_evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Share-based Payment Award, Equity Instruments Other Than Options, Grant Date Fair Market Value</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue_documentation_en-US" xlink:label="lab_evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Share-based Payment Award, Equity Instruments Other Than Options, Grant Date Fair Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue" xlink:to="lab_evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_VL46Member_d5c145ca-cb56-420b-91ac-c3f4b07a3557_terseLabel_en-US" xlink:label="lab_evlo_VL46Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VL46</link:label>
    <link:label id="lab_evlo_VL46Member_label_en-US" xlink:label="lab_evlo_VL46Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">V- L- 46 [Member]</link:label>
    <link:label id="lab_evlo_VL46Member_documentation_en-US" xlink:label="lab_evlo_VL46Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VL46.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_VL46Member" xlink:href="evlo-20210630.xsd#evlo_VL46Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_VL46Member" xlink:to="lab_evlo_VL46Member" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheThreeMember_7ad06269-101b-49e0-9e9e-4a7b14eeadb9_terseLabel_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche Three</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheThreeMember_label_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche Three [Member]</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheThreeMember_documentation_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheThreeMember" xlink:href="evlo-20210630.xsd#evlo_SecurityAndLoanAgreementTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SecurityAndLoanAgreementTrancheThreeMember" xlink:to="lab_evlo_SecurityAndLoanAgreementTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_05359db5-2b92-4df0-901a-422817b04f2c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage_93fd327c-c7c2-434d-928f-ae9270fd9577_terseLabel_en-US" xlink:label="lab_evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of operating profits and losses and development, regulatory and commercialization costs.</link:label>
    <link:label id="lab_evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage_label_en-US" xlink:label="lab_evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Share Of Operating Profits And Losses And Development, Regulatory And Commercialization Costs, Percentage</link:label>
    <link:label id="lab_evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage_documentation_en-US" xlink:label="lab_evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Share Of Operating Profits And Losses And Development, Regulatory And Commercialization Costs, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage" xlink:href="evlo-20210630.xsd#evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage" xlink:to="lab_evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_415d3455-e86f-4a14-a315-51e8b19bf4df_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 200,000,000 shares authorized; 53,416,657 and 47,488,505 shares issued and 53,398,271 and 47,470,119 shares outstanding as of June 30, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_bc5868ff-6ed5-425a-87bf-383503f4bfb6_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9ec0e70a-65a9-414c-8b9d-49684494134c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation cost not yet recognized, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_237f463a-16b5-4826-9600-755a84ee635f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance at December 31, 2020 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_781600b4-44bb-4182-b292-e29387fc1bf6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance at June 30, 2021 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0cd520e7-03f7-4fa8-9b67-73307e005e58_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_a449729a-419e-4de5-8ff4-c2534c30930a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_40e6e5da-e3f8-49ee-9d15-495b1f8fa9c2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent_8404427f-3f4f-47ec-9e7a-da612ac2c7dc_terseLabel_en-US" xlink:label="lab_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments upon achievement of certain development, regulatory, and commercial events</link:label>
    <link:label id="lab_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent_label_en-US" xlink:label="lab_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments of Development, Regulatory, and Commercial Event</link:label>
    <link:label id="lab_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent_documentation_en-US" xlink:label="lab_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments of development, regulatory, and commercial event.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" xlink:href="evlo-20210630.xsd#evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" xlink:to="lab_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_ComputersAndSoftwareMember_a21ccee1-8db8-409d-978a-943629908b1a_terseLabel_en-US" xlink:label="lab_evlo_ComputersAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers and software</link:label>
    <link:label id="lab_evlo_ComputersAndSoftwareMember_label_en-US" xlink:label="lab_evlo_ComputersAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers And Software [Member]</link:label>
    <link:label id="lab_evlo_ComputersAndSoftwareMember_documentation_en-US" xlink:label="lab_evlo_ComputersAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers and software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ComputersAndSoftwareMember" xlink:href="evlo-20210630.xsd#evlo_ComputersAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_ComputersAndSoftwareMember" xlink:to="lab_evlo_ComputersAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9b4bc47b-6f88-402b-b5da-3f459ac8999b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (excluding amounts paid or in Accounts Payable as of 6/30/2021)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_4b93ad0f-b4cf-4fd6-a5f4-8c58188cf658_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_ee2ca0c8-3f21-42e7-bf0f-ac164e6cd764_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, measurement input</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:to="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7981d124-d886-4485-9327-a606c4891836_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9ea95811-a911-4315-9f0d-61e282b14e45_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_7aee92af-5b8b-49a4-b3ad-de90d0024355_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_44a70aba-05ed-4022-9e1d-0002697dca03_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_d8f6b363-8e57-42f5-934a-eee78585cd60_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_aca51cd5-8fc4-4403-8ec3-2a24e665831e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_f54ae183-8a4d-4967-87a1-baf038f6c809_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5b25b0a7-3337-4708-983a-5fd51dcbf775_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_4ff3ff0e-85fd-4b83-a3ff-44b393c93ad7_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ce5b7a62-28c6-4eba-81c4-cf6b4dfbef9e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_23abad6a-0147-4c04-bdde-bd89719e5467_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage_aebbb21a-f244-44b7-827f-2dfad94d0eb3_terseLabel_en-US" xlink:label="lab_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final payment under agreement as a percentage of loans borrowed</link:label>
    <link:label id="lab_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage_label_en-US" xlink:label="lab_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repayment Or Prepayment Fee Percentage</link:label>
    <link:label id="lab_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage_documentation_en-US" xlink:label="lab_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repayment Or Prepayment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage" xlink:to="lab_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_fdbba642-a67c-40f0-8b33-dac361f95a26_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5f491ddc-c87c-4340-a5b8-0c2037272275_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_5a79ec3f-c41e-496d-8096-c54013bf49cc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_b81bebda-f4c7-462a-8382-7d7e7d10b7a9_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income or Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_c9f416df-ee4e-47e0-b23b-c461c92e1e30_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments_d7e0492e-9428-4de7-8d0b-eb81426d24be_terseLabel_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual equity award, vesting period, number of equal monthly installments</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments_label_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Equity Award Vesting Period, Number Of Monthly Installments</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments_documentation_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Equity Award Vesting Period, Number Of Monthly Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" xlink:href="evlo-20210630.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" xlink:to="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b5d11203-1a41-4267-91dd-b9cbc6b0744e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_dc2df452-7a79-4a2c-a5ba-78e7ad81919a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_CommitmentAndContingenciesLineItems_92a78313-aa6d-4d5f-8da6-2a6b933c60ab_terseLabel_en-US" xlink:label="lab_evlo_CommitmentAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment And Contingencies [Line Items]</link:label>
    <link:label id="lab_evlo_CommitmentAndContingenciesLineItems_label_en-US" xlink:label="lab_evlo_CommitmentAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment And Contingencies [Line Items]</link:label>
    <link:label id="lab_evlo_CommitmentAndContingenciesLineItems_documentation_en-US" xlink:label="lab_evlo_CommitmentAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CommitmentAndContingenciesLineItems" xlink:href="evlo-20210630.xsd#evlo_CommitmentAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems" xlink:to="lab_evlo_CommitmentAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b012068d-13fc-4f96-8dd0-8c334ecfab61_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ab7597b4-3568-476d-92bc-0ee7bdbc9402_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_34510814-97fc-4327-9d92-0afb3a899c04_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_9a2ac3c9-6f81-4e1c-9e8d-a1302b278b56_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_e217b1ea-f905-410d-90f1-f149bb429e90_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALJ Commercialization and License Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_a73d3c09-ee2c-48b2-801d-e29d75a32ec6_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50d6caf8-3e5f-4489-9517-677aa882c10d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_328a2e56-1ffc-4bae-b849-6b461d3d646d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_be43ca18-8528-4e4e-a894-8ecb9e30f80d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_a9922d1b-9f6c-477d-89df-aa082a53eac5_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6ee581a6-80c4-4f0f-a8cb-180ae5f0a1f9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_31cf8f98-345f-4249-b529-3a129fef5a60_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_386c17c6-0289-481d-8e40-a1537cc6e320_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LinesOfCreditFairValueDisclosure_59acae1a-2528-4390-b61a-1cb6678d4ef1_terseLabel_en-US" xlink:label="lab_us-gaap_LinesOfCreditFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility estimate fair value</link:label>
    <link:label id="lab_us-gaap_LinesOfCreditFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LinesOfCreditFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lines of Credit, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LinesOfCreditFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LinesOfCreditFairValueDisclosure" xlink:to="lab_us-gaap_LinesOfCreditFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_4b0be414-6114-42b5-ae9b-8b677d689ad3_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_f231ec23-28c1-4516-bb5d-848e25936a38_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9b303557-960e-46ee-be53-c9124d5424a1_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_6958b1b7-258d-4f51-9825-c9dc338adcb2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_3210b343-01d6-48a9-8e80-b64e6eb6a88f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for Tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_b58b1e47-c8b6-4d2d-b6eb-7f20f8c48c05_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares called by warrants (in shares) (up to)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_d7f42ed4-d9ce-4055-855d-cceef1b36f3a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1e7b45ac-8383-49e8-bdcb-6cd30ca510f9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_50bc04b8-26fe-4ca0-8742-321d4197e042_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_abb0d160-da86-46ab-94eb-5fb9c45f8df2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_727afc76-cec9-4d93-874d-5916bfd96197_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c7b92122-983c-46c1-ba85-40a0548df979_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction_836f8e9f-c913-47c4-8428-c6df8652a9a4_terseLabel_en-US" xlink:label="lab_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from transactions</link:label>
    <link:label id="lab_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Gross Consideration Received on Transaction</link:label>
    <link:label id="lab_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction_documentation_en-US" xlink:label="lab_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Gross Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:href="evlo-20210630.xsd#evlo_SaleOfStockGrossConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:to="lab_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_db17888a-9703-4d23-a9cf-6b7cbbf14c2a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_NonCashOperatingLeaseExpense_8f2d011b-d828-4ad7-a99b-2a2ab191fc61_terseLabel_en-US" xlink:label="lab_evlo_NonCashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_evlo_NonCashOperatingLeaseExpense_label_en-US" xlink:label="lab_evlo_NonCashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Operating Lease Expense</link:label>
    <link:label id="lab_evlo_NonCashOperatingLeaseExpense_documentation_en-US" xlink:label="lab_evlo_NonCashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Operating Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonCashOperatingLeaseExpense" xlink:href="evlo-20210630.xsd#evlo_NonCashOperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_NonCashOperatingLeaseExpense" xlink:to="lab_evlo_NonCashOperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_ff52b37a-52cf-4372-8986-d53d9d766140_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7ea085f0-8f66-4d9f-ba4d-ff4bedd03963_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_64d3b100-736c-47df-937e-f5d3b0b6fd1f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7a0ba467-4b3c-46e5-a9f2-c132a8ecaa46_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Minimum Aggregate Future Lease Commitments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_9516dca5-7a24-48f8-8056-1ef8d4b30b96_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_7f7d282c-c67e-4c99-bf2d-188641c7c627_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e937d1b9-908e-491c-86a4-e942bd97d985_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_15f00652-48f4-4a13-bd77-d34629a7fc62_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_66faba4f-f331-40ab-b723-b20837da32cf_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_12233dc5-e128-47cc-a477-a3950ab8e12d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_784734c8-fcfb-4001-91cc-0f57d3ecb4bf_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_b55b871f-c244-408d-9a96-bc889a530f05_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_15f2df76-cd78-491f-8e1b-74acbfa707b9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_7a83fc70-b3bc-4bba-8606-dc5f9ddf4efa_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholder&#8217;s equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_516988ce-cbdc-4a79-bceb-94e33d71f854_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_A2018EmployeeStockPurchasePlanMember_9754cc57-db1d-4272-8961-5a67ab876641_terseLabel_en-US" xlink:label="lab_evlo_A2018EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_evlo_A2018EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_evlo_A2018EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_evlo_A2018EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_evlo_A2018EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_A2018EmployeeStockPurchasePlanMember" xlink:href="evlo-20210630.xsd#evlo_A2018EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_A2018EmployeeStockPurchasePlanMember" xlink:to="lab_evlo_A2018EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_ae5e6afc-a867-44c3-a115-ab29b15adca1_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_61af442b-0db4-4a57-a82e-0653616eaa98_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e70b7045-bc51-42af-aec3-a1e74cb3cf3f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_91399240-a7ae-46e8-8662-855060d680a0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4997bf0d-790e-4ad6-bbc9-f9da208e3a2b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_fe4afc31-9c73-46d3-b9d3-35069f5f2183_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2ba0fe11-61a9-4c6c-a590-7fa80a424086_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_78220c59-2323-4654-ba2d-0ceb7b655bdc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c2684c7b-6a96-4f5b-87d1-1911764fae95_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, maximum expiration period (no more than)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_28ea636e-ecd0-4155-9abc-6184647606bd_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_69c2daaa-a3ff-4a0c-87f0-c06d20df613e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b5e816b8-5306-4cd4-a9cd-b26f23fdc49b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under the Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5b2b7907-8579-4cf0-a4de-664ffac7f2b2_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_7ca56f59-3d0f-45e7-81c9-676dbf293935_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_858e8dec-9128-432f-9d54-011aa906dfe2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9c2571c0-9fae-41e3-af36-4c5b466b9607_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_072a1663-0aff-4571-bbaf-55a17fe452c5_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_aa89f0d2-26a8-4613-8a85-358b66c53f32_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt (up to)</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_729cd2b8-a561-40af-b8c5-da87e879d774_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_4af97c5a-1454-4c1f-8612-5124b5a6a95b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_27bfbac7-465b-4a88-a433-9a3a5ab86980_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_72c25513-dd6b-4b9c-86fa-846a27b01913_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e92c214d-622c-440c-8362-5f001955e895_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5b80a144-5467-4478-83c1-30826edae2c0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of long-term debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_33f956e9-712a-4102-ba86-90beddfb4e03_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_3c6b60c5-9244-4f15-bc01-f0af607953e9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a3d3d232-9ea7-4e5b-ac8b-0df791313274_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_bd799a96-b131-4677-9061-9c3d28521bcc_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1bf56965-c862-4bd5-9aa9-ecbd2b268ec2_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_5d51d6ff-272b-4c45-a639-f966b6944305_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_539541c1-73d6-4fe3-b9df-e8ee326f9776_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted_09907223-4e3e-4b9d-96f5-b21f5535a2c5_terseLabel_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, options and other equity awards granted (in shares)</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted_label_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Granted</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted" xlink:href="evlo-20210630.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted" xlink:to="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_fcc8580f-2678-4ed1-a4a8-53ae981c1ded_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum rental payments received</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income, Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_08fd5e5f-868c-4041-a652-f5e1f9aeb514_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7d763d82-e530-4b96-b5d3-208e247f4fa3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d17527b8-7889-49a9-a56b-925955b369f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_e4fd7f34-c407-4c2f-9ed4-572c0b3fbe1b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fd829a0b-dc2f-46ff-841f-f21bb093080f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_2b5838c7-9822-4176-920b-0e06724d5428_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4baa4b43-6b1b-44e8-9d3e-4e85670621a9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ac68f8f7-d9ac-4f87-8c39-604420f3e6a1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d7866b9d-cca4-48f0-b002-48ce88eecfba_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b25bf1e1-d628-4a12-ab81-8fa1cfaee773_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_4942db7d-aed8-486b-82ac-ce5d8046373b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_3540366e-8f26-4960-a7f1-6a651cb529cc_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_a14909bd-286f-4182-8a11-1e9cc1056781_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_ConsultingAgreementMember_221fd93d-6d44-4da0-85b8-ff5f05d23a51_terseLabel_en-US" xlink:label="lab_evlo_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement</link:label>
    <link:label id="lab_evlo_ConsultingAgreementMember_label_en-US" xlink:label="lab_evlo_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement [Member]</link:label>
    <link:label id="lab_evlo_ConsultingAgreementMember_documentation_en-US" xlink:label="lab_evlo_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ConsultingAgreementMember" xlink:href="evlo-20210630.xsd#evlo_ConsultingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_ConsultingAgreementMember" xlink:to="lab_evlo_ConsultingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fbb4da92-7c1e-451c-ad17-690ccf5f1594_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_6d0be34b-72e9-41b7-bfc6-52161e805cd3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3f6a306c-911e-4d9b-920a-bc11a9f7234c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c6cb34c2-8f42-4a6d-9307-fb518ea32da6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued for purchase (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_453fa1dc-5cef-47c7-8485-5c2932db1c3c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_47dd9462-b71f-4efc-8715-66edc6439cf1_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheTwoMember_b872a315-bf84-4574-820c-452309785c27_terseLabel_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche Two</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheTwoMember_label_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche Two [Member]</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheTwoMember_documentation_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheTwoMember" xlink:href="evlo-20210630.xsd#evlo_SecurityAndLoanAgreementTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SecurityAndLoanAgreementTrancheTwoMember" xlink:to="lab_evlo_SecurityAndLoanAgreementTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_339e1fc1-6665-4432-a156-e68d42a5bc1e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_c1e81c9a-3c76-42f6-8438-6be9d8525c50_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees incurred to establish facility</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_66464498-b9a3-456c-a147-ea71283d928b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_d62f69a8-cdd0-4fc7-887c-420ab597855c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c02aa7f5-cf21-4dc7-a087-6b0d2b746856_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_6aa8766d-301e-45c6-836d-e7b69d24df85_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_a08f1130-b7d9-4a57-bd4f-3bc860dc28eb_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e7839b6a-c58b-4d60-96a5-260ce78622a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_3782a77d-e7b8-4276-bcf7-d9b98a9fe872_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_dec4da70-98c6-40f0-8b63-63070b65df9b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_84897442-ee18-4443-adeb-e52d184ddd6d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod_f90b64ba-b8a3-4f62-ba76-0403ad9a639a_terseLabel_en-US" xlink:label="lab_evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for trailing average closing common stock price</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod_label_en-US" xlink:label="lab_evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Closing Common Stock Price, Trailing Average, Period</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod_documentation_en-US" xlink:label="lab_evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Closing Common Stock Price, Trailing Average, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod" xlink:to="lab_evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d22fdfae-0af2-4414-8ba0-f9e020406d08_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_MayoClinicMember_b7785f0e-395c-4c47-8ab5-c2af6f421cb4_terseLabel_en-US" xlink:label="lab_evlo_MayoClinicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mayo Clinic</link:label>
    <link:label id="lab_evlo_MayoClinicMember_label_en-US" xlink:label="lab_evlo_MayoClinicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mayo Clinic [Member]</link:label>
    <link:label id="lab_evlo_MayoClinicMember_documentation_en-US" xlink:label="lab_evlo_MayoClinicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mayo Clinic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MayoClinicMember" xlink:href="evlo-20210630.xsd#evlo_MayoClinicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_MayoClinicMember" xlink:to="lab_evlo_MayoClinicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_bd5eaa09-4628-4a78-b7f4-420ccd5c404b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a0e521fc-fdac-4b5e-99f9-a8e92cd77b8c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_9096fed6-f61e-4117-bb09-1a87903a880c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_252bdc9e-e39d-435d-be93-c41f2952565e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_bfdddaab-b5e1-45cf-a96a-6c18a4ba2eb9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_54b65fdc-4a4b-426c-af53-6c5437643b2f_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_NonCashInterestExpense_a69b78dd-67ff-4dd8-bb06-ff5291c72788_terseLabel_en-US" xlink:label="lab_evlo_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_evlo_NonCashInterestExpense_label_en-US" xlink:label="lab_evlo_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense</link:label>
    <link:label id="lab_evlo_NonCashInterestExpense_documentation_en-US" xlink:label="lab_evlo_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonCashInterestExpense" xlink:href="evlo-20210630.xsd#evlo_NonCashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_NonCashInterestExpense" xlink:to="lab_evlo_NonCashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_482456bd-24e1-4ee4-8a87-e5f9e2253fa6_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_14181262-f5f8-418a-b5bf-ab26052efea8_netLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options granted (up to, in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_615c4deb-fdd5-4949-9107-646c7794119a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_75fc911a-23ec-43cf-8c0b-1c5057b6ce68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_e50d5d6a-c5dd-4dfa-b968-580703e5b8f9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5ef91ac1-c96d-435c-ac82-b4ec505fff3b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d509e9e9-54ca-45d9-8650-a732523f3aa4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_81542164-78aa-4be5-ab97-cf4280367726_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_b554e585-7440-4726-8149-ef9079dfc0fb_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance cost</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9954ac30-516f-41d6-a8fa-286e4004dc62_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_738d3f8b-8235-4706-9019-7f0d46dd4001_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_2eca972b-0194-4bf2-be01-972a6cf7287a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_7174b766-1701-49ea-a32f-e1a9acb1619d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_46134f5d-d692-43be-81f1-3de7df7bd605_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of underlying common stock</link:label>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputSharePriceMember" xlink:to="lab_us-gaap_MeasurementInputSharePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f6335468-ac88-49f3-9651-3b22f7ccfd99_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction_a28bb7b4-f709-455c-914a-68330c69ef52_terseLabel_en-US" xlink:label="lab_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum value of shares issued in transaction (up to)</link:label>
    <link:label id="lab_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Value of Shares Issued In Transaction</link:label>
    <link:label id="lab_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction_documentation_en-US" xlink:label="lab_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Value of Shares Issued In Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction" xlink:href="evlo-20210630.xsd#evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction" xlink:to="lab_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8d4d06ac-f3cb-4d09-bdcf-136885e2fcda_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan and security agreement, interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheFourMember_e90363f8-550a-4cc4-9ff1-b055930d9d21_terseLabel_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche Four</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheFourMember_label_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche Four [Member]</link:label>
    <link:label id="lab_evlo_SecurityAndLoanAgreementTrancheFourMember_documentation_en-US" xlink:label="lab_evlo_SecurityAndLoanAgreementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security And Loan Agreement, Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheFourMember" xlink:href="evlo-20210630.xsd#evlo_SecurityAndLoanAgreementTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SecurityAndLoanAgreementTrancheFourMember" xlink:to="lab_evlo_SecurityAndLoanAgreementTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_73101e6b-0d88-4b20-a7a4-2ff5383540ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_fa937d04-62ea-49c6-aa3d-1f4b2d02139f_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm_beb6c4fd-a207-4c0a-9e30-5a7e27013a75_terseLabel_en-US" xlink:label="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination notice period by non-breaching party in event of a breach</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm_label_en-US" xlink:label="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Consulting Contract, Termination Notice Upon Breach Of Contract, Term</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm_documentation_en-US" xlink:label="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Consulting Contract, Termination Notice Upon Breach Of Contract, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm" xlink:to="lab_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6e7e5991-ae9d-415e-bb0b-200eac265a92_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_58b229c1-f633-480c-a04f-bcf79c240bfd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_bb4da2e4-d626-411b-a2b5-33ef24c9065a_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9c102b0-e855-4d4d-8968-ef6f6bce02a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_513adba6-b377-4019-811f-af3a41e7259b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_MeddistCompanyLimitedMember_395851de-d33f-4a86-b243-4cee1d48ec47_terseLabel_en-US" xlink:label="lab_evlo_MeddistCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ALJ</link:label>
    <link:label id="lab_evlo_MeddistCompanyLimitedMember_label_en-US" xlink:label="lab_evlo_MeddistCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Meddist Company Limited [Member]</link:label>
    <link:label id="lab_evlo_MeddistCompanyLimitedMember_documentation_en-US" xlink:label="lab_evlo_MeddistCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Meddist Company Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MeddistCompanyLimitedMember" xlink:href="evlo-20210630.xsd#evlo_MeddistCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_MeddistCompanyLimitedMember" xlink:to="lab_evlo_MeddistCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_85261c04-7057-4845-9aca-7a8678563bfa_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e1b629bd-2c91-4556-b274-27a18a9c7346_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_57f6d246-e961-469d-b6ef-a57b210a5348_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price of shares sold in public offering (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_EmergingGrowthCompanyStatusPolicyTextBlock_4e96cf83-cf2c-4575-8178-64c821969a89_terseLabel_en-US" xlink:label="lab_evlo_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Growth Company Status</link:label>
    <link:label id="lab_evlo_EmergingGrowthCompanyStatusPolicyTextBlock_label_en-US" xlink:label="lab_evlo_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Growth Company Status [Policy Text Block]</link:label>
    <link:label id="lab_evlo_EmergingGrowthCompanyStatusPolicyTextBlock_documentation_en-US" xlink:label="lab_evlo_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging growth company status.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:href="evlo-20210630.xsd#evlo_EmergingGrowthCompanyStatusPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="lab_evlo_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_4a85e261-f3aa-4019-b0a5-78eec7090a8b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other information:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_f6f60370-a217-4a5c-a3bf-9c8a944b9276_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_DebtInstrumentTrancheDomain_0cdda392-276a-4b50-84cf-228e60d6a2e2_terseLabel_en-US" xlink:label="lab_evlo_DebtInstrumentTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Tranche [Domain]</link:label>
    <link:label id="lab_evlo_DebtInstrumentTrancheDomain_label_en-US" xlink:label="lab_evlo_DebtInstrumentTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Tranche [Domain]</link:label>
    <link:label id="lab_evlo_DebtInstrumentTrancheDomain_documentation_en-US" xlink:label="lab_evlo_DebtInstrumentTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Tranche [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentTrancheDomain" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentTrancheDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_DebtInstrumentTrancheDomain" xlink:to="lab_evlo_DebtInstrumentTrancheDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_254368e6-9fd7-4075-8d03-dcaa50a6a0ca_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_32ed9e37-bae3-4382-9fb0-6c9c72826d48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_00239c37-fff7-47fc-bd14-28a41d41fbf5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_PublicOfferingCostInAccruedExpense_ab66da45-b108-47f4-8de3-664ed2f5c365_terseLabel_en-US" xlink:label="lab_evlo_PublicOfferingCostInAccruedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering cost in accrued expense</link:label>
    <link:label id="lab_evlo_PublicOfferingCostInAccruedExpense_label_en-US" xlink:label="lab_evlo_PublicOfferingCostInAccruedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering Cost In Accrued Expense</link:label>
    <link:label id="lab_evlo_PublicOfferingCostInAccruedExpense_documentation_en-US" xlink:label="lab_evlo_PublicOfferingCostInAccruedExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering Cost In Accrued Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_PublicOfferingCostInAccruedExpense" xlink:href="evlo-20210630.xsd#evlo_PublicOfferingCostInAccruedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_PublicOfferingCostInAccruedExpense" xlink:to="lab_evlo_PublicOfferingCostInAccruedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_147f2e42-40fc-482c-a243-f9e0d350a074_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal_3d6df03e-080a-4487-9a45-a05a535d9f86_terseLabel_en-US" xlink:label="lab_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee percentage</link:label>
    <link:label id="lab_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal_label_en-US" xlink:label="lab_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Fee Percentage On Principal</link:label>
    <link:label id="lab_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal_documentation_en-US" xlink:label="lab_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument prepayment fee percentage on principal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal" xlink:to="lab_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_910690cb-0772-4c1d-b2fc-f07322b7d7b5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_AmendedCreditFacilityMember_ebd9ccb9-5ec9-494a-9643-77ff09fc8d65_terseLabel_en-US" xlink:label="lab_evlo_AmendedCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility</link:label>
    <link:label id="lab_evlo_AmendedCreditFacilityMember_label_en-US" xlink:label="lab_evlo_AmendedCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility [Member]</link:label>
    <link:label id="lab_evlo_AmendedCreditFacilityMember_documentation_en-US" xlink:label="lab_evlo_AmendedCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AmendedCreditFacilityMember" xlink:href="evlo-20210630.xsd#evlo_AmendedCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_AmendedCreditFacilityMember" xlink:to="lab_evlo_AmendedCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_UniversityOfChicagoMember_444ed366-cbb5-4343-8763-213390821d50_terseLabel_en-US" xlink:label="lab_evlo_UniversityOfChicagoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Chicago Agreement</link:label>
    <link:label id="lab_evlo_UniversityOfChicagoMember_label_en-US" xlink:label="lab_evlo_UniversityOfChicagoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Chicago [Member]</link:label>
    <link:label id="lab_evlo_UniversityOfChicagoMember_documentation_en-US" xlink:label="lab_evlo_UniversityOfChicagoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Chicago.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_UniversityOfChicagoMember" xlink:href="evlo-20210630.xsd#evlo_UniversityOfChicagoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_UniversityOfChicagoMember" xlink:to="lab_evlo_UniversityOfChicagoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c2546a67-9883-44e9-8283-a5cbc38d0bfb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ba4a59cf-5804-4e18-ac85-38a1e364fe41_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_CollaborationArrangementTerm_1692c85f-f1cd-49a5-ad1f-286ae58a3339_terseLabel_en-US" xlink:label="lab_evlo_CollaborationArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration arrangement</link:label>
    <link:label id="lab_evlo_CollaborationArrangementTerm_label_en-US" xlink:label="lab_evlo_CollaborationArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Term</link:label>
    <link:label id="lab_evlo_CollaborationArrangementTerm_documentation_en-US" xlink:label="lab_evlo_CollaborationArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborationArrangementTerm" xlink:href="evlo-20210630.xsd#evlo_CollaborationArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_CollaborationArrangementTerm" xlink:to="lab_evlo_CollaborationArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_NonRefundableUpfrontFee_7de8b5d2-349b-487e-9089-d30706061e37_terseLabel_en-US" xlink:label="lab_evlo_NonRefundableUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront fee</link:label>
    <link:label id="lab_evlo_NonRefundableUpfrontFee_label_en-US" xlink:label="lab_evlo_NonRefundableUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Refundable Upfront Fee</link:label>
    <link:label id="lab_evlo_NonRefundableUpfrontFee_documentation_en-US" xlink:label="lab_evlo_NonRefundableUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non refundable upfront fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonRefundableUpfrontFee" xlink:href="evlo-20210630.xsd#evlo_NonRefundableUpfrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_NonRefundableUpfrontFee" xlink:to="lab_evlo_NonRefundableUpfrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_3b5f1416-0084-4dca-8147-d083ff5b5515_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_RelatedPartyTransactionAnnualCashConsultingFee_a50b5388-8cf4-414f-b20e-108dcf5963ec_terseLabel_en-US" xlink:label="lab_evlo_RelatedPartyTransactionAnnualCashConsultingFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate annual cash consulting fee</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionAnnualCashConsultingFee_label_en-US" xlink:label="lab_evlo_RelatedPartyTransactionAnnualCashConsultingFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Annual Cash Consulting Fee</link:label>
    <link:label id="lab_evlo_RelatedPartyTransactionAnnualCashConsultingFee_documentation_en-US" xlink:label="lab_evlo_RelatedPartyTransactionAnnualCashConsultingFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Annual Cash Consulting Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionAnnualCashConsultingFee" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionAnnualCashConsultingFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_RelatedPartyTransactionAnnualCashConsultingFee" xlink:to="lab_evlo_RelatedPartyTransactionAnnualCashConsultingFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ec345b6f-f60d-4139-8bb7-b7e696d48d2d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_070b4558-2eb7-4f37-a1d0-f85c97521959_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments_35a99dd6-3263-4761-a134-d4bea105dfb8_terseLabel_en-US" xlink:label="lab_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to purchase shares, vesting period, number of equal monthly installments</link:label>
    <link:label id="lab_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments_label_en-US" xlink:label="lab_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Number Of Monthly Installments</link:label>
    <link:label id="lab_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments_documentation_en-US" xlink:label="lab_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Number Of Monthly Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" xlink:href="evlo-20210630.xsd#evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" xlink:to="lab_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_eadfbc27-66dc-4382-8865-9e6eb574e837_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_e9ea7ac6-f0de-4106-829b-9ea68217b65a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_6d231be5-b806-41c9-9ef9-1f275966af78_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_93cbb7eb-e50f-4cf3-ab5d-dfac5c4fce62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b66c3f39-71c8-4563-87b7-73958c9047ca_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a974b3d5-d558-4838-a235-8ceb89673eda_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f12c137b-6729-4753-8269-4d2f83ea6d1c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_d170b31a-f5ac-4448-ae26-0cf313a6e185_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d0aafc87-fd3e-4cc5-8bcb-01fa7836675a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_552b46c3-ed15-487d-a2a8-0044cd43657c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract_54ac759a-56ae-4d2a-bb5c-808e7d7f7ad9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment:</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_52a50e1e-c6fb-4a67-ad1a-9273f8e4e478_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_57f5ec6c-9dd2-4bdd-9fa9-111aa68ad10a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b22e34b7-563a-4597-a2e2-f1f3fad2e66c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_8296b189-a97d-44ba-b4f5-a4e3a1abdf6f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_040d411e-da2d-4124-a55c-e9ba49d1a365_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_bdf2b2b1-6185-4e74-acd7-c3e3b1406421_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_72090e41-6ae8-43a3-bb28-d28ac379d5a8_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9f55c95b-e2e2-498e-8b34-c3d4abc4d2b4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock exercise prices (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1533554b-a27d-4592-83ad-fe923822db91_netLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_af7f98c1-2850-406f-b716-55ded274c027_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage_34def900-fdf7-4776-9115-bcbbb96e6281_terseLabel_en-US" xlink:label="lab_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anniversary of funding date for determining prepayment fee percentage</link:label>
    <link:label id="lab_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage_label_en-US" xlink:label="lab_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Anniversary For Determining Prepayment Fee Percentage</link:label>
    <link:label id="lab_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage_documentation_en-US" xlink:label="lab_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Anniversary For Determining Prepayment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage" xlink:to="lab_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_3349bc10-689e-4a4b-8818-632119994883_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_bb75b67e-548b-4501-b40e-706d0791f904_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_36689ab8-b42d-4aa3-af2f-9b2b98c32319_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0d5284c0-0d71-4a36-83fa-98fac14cf716_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0918a65c-9a99-4a00-936d-3a6fff3dcfda_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_7a76f4e6-afad-4613-bf94-a8f1e0512623_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f0169078-036d-4168-9d51-4c84bb2c3d06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_64a1c9cb-37f0-45a6-936a-4083e34df68e_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6bcf25d0-f112-4953-a167-9ade7f461efe_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_9a5d7c34-4174-4708-859f-8a145d130189_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion option</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_3900c404-0feb-4936-9dcb-614eb2e6e770_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_224052b2-9ed4-4750-b3ab-a01c7bf4b8d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_063b2eba-569d-4e6d-8b6d-9666cbc4fa06_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_SaccoS.r.l.Member_3d0e65ea-3873-44f9-9ef3-cc428a5febbc_terseLabel_en-US" xlink:label="lab_evlo_SaccoS.r.l.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sacco</link:label>
    <link:label id="lab_evlo_SaccoS.r.l.Member_label_en-US" xlink:label="lab_evlo_SaccoS.r.l.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sacco S.r.l. [Member]</link:label>
    <link:label id="lab_evlo_SaccoS.r.l.Member_documentation_en-US" xlink:label="lab_evlo_SaccoS.r.l.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sacco S.r.l. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaccoS.r.l.Member" xlink:href="evlo-20210630.xsd#evlo_SaccoS.r.l.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_SaccoS.r.l.Member" xlink:to="lab_evlo_SaccoS.r.l.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_dc672ca1-61c7-4313-a565-5e6a6cf70954_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_999e3336-13a0-414b-90c8-b2a25b14d265_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_a5687919-0879-48fb-a070-1d1f5ad5a7a4_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction-in-process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3d6b1bc7-437e-4b23-8208-cf8076095040_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of fixed assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_98d5bdb4-9477-4753-8e7a-f927e2d3803e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash &#8211; beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2e59b447-7047-49dd-b25a-ec7dae3cf499_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash &#8211; end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5151428a-cd9f-44cb-aa3e-d149652e32bf_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6878c1f0-638a-4d75-b056-7e9db4914881_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold in public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0636bbf9-0d55-4736-a4b7-5c49b830bac0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_c337de2d-dace-4b1a-a4b1-c290d361d326_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6c4fc0ea-482e-4855-95e7-e786a9bdd7e7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bfac06ac-6a88-4319-9f53-8df740675575_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_eea5ca87-fb76-4a74-8d2d-e26ed3fe25cf_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_46c943bd-76a9-491d-a445-b4db2f64bbb3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_df7fcef1-4cd4-4f56-9042-49c507a25ce6_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_c2d73d74-b192-4f13-9035-2c0bb2f36924_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_deb88428-fa63-46aa-add3-38a831b8da6b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_245784e9-1565-4d4e-a5a7-42a175e9cbe2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4aa19d88-fc54-447f-926e-2357db15dfb1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_152a000a-f5d0-4eaa-93e1-68fc3e0fee1a_netLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c598808f-e29f-4d71-b3ff-853e9ee422e3_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ecc3f930-afbe-4205-a8fa-17735003dc11_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_5e6257db-60b1-4d52-b005-92bf9cf22111_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_e156d4e5-4dd7-4a50-9415-b193df723ae0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_0a9b9717-976b-4270-8e65-f3c7ce3289c2_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_0a852acd-eed7-4005-bd4d-027ee5ab71c9_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_89f66e94-3eda-4011-8dec-4bb6e5838e4e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_88e8d533-b588-4d02-b4bb-e1f6cb1bb76e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_95c30c94-fd5f-473c-9405-c9e1835a7204_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_01c6f2b6-b938-4038-94e6-36a8e5a4fd04_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan and security agreement, basis spread on interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0a9aaa76-8b0f-47e1-b859-6a3429e42921_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_72a8ebf8-c1aa-4fec-93e7-e153d1df610c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_34a5c0c3-c6c9-4375-be1d-03b6ed1ed669_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5df34b37-583d-4185-82c7-f6a65d0a7f82_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_TwoThousandAndEighteenStockIncentivePlanMember_16aab9ab-607f-4490-8bf8-1a72c8180589_terseLabel_en-US" xlink:label="lab_evlo_TwoThousandAndEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Stock Incentive Plan</link:label>
    <link:label id="lab_evlo_TwoThousandAndEighteenStockIncentivePlanMember_label_en-US" xlink:label="lab_evlo_TwoThousandAndEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Eighteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_evlo_TwoThousandAndEighteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_evlo_TwoThousandAndEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_TwoThousandAndEighteenStockIncentivePlanMember" xlink:href="evlo-20210630.xsd#evlo_TwoThousandAndEighteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_TwoThousandAndEighteenStockIncentivePlanMember" xlink:to="lab_evlo_TwoThousandAndEighteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_6517c305-9fe2-40ba-9e29-05a2d747b85d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_757084e3-9136-4fac-9e3b-81e1adc78653_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_1aa1ec35-233a-46ee-9d1f-f189b8f8cb51_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfLand_7adba5f5-cd9b-45b6-abe0-f490a58036ba_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of leased office and research development space (in square feet)</link:label>
    <link:label id="lab_us-gaap_AreaOfLand_label_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfLand"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d69065de-9a9d-4faa-9873-aec83809dc3a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_d777c28f-e1ec-4955-a91e-785fbec2a317_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5da76944-41b8-483b-8b27-4bce955c3a34_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4b2b52d6-18ed-4bac-b471-2110a2911c28_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_255c4983-9d84-479c-82b4-9fce5b43cae8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_4eb89d6f-5c51-4e3b-a86e-221ff7b49bb7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction with party to collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c71a8dee-df41-4ff6-befb-7d59fea110ae_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a6728089-4996-44f1-925d-246354954c0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_814439a7-6493-4abd-ba23-6a9a28916c44_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_aabf9673-e096-40ff-a68c-1b1a3940493d_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease_4ebccd6c-1b25-4508-ba83-17f310e9413e_terseLabel_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares no longer authorized (in shares)</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease_label_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Increase Decrease</link:label>
    <link:label id="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease_documentation_en-US" xlink:label="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Increase Decrease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease" xlink:href="evlo-20210630.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease" xlink:to="lab_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_f9c02fed-412c-4e0f-93a3-53a7a9dfb0d8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_2283db1d-0d48-40dd-95f3-79b08a75569c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_29d30e98-ac88-43be-98d5-1d5eb40eb003_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_a3d10eb5-f2a6-4822-9ff3-fc7c930b8086_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock offering from ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum_3146d9ad-cc10-46e9-9d08-a27dfca71e39_terseLabel_en-US" xlink:label="lab_evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum fee for second product option</link:label>
    <link:label id="lab_evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum_label_en-US" xlink:label="lab_evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Second Product Candidate, Fee, Maximum</link:label>
    <link:label id="lab_evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum_documentation_en-US" xlink:label="lab_evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Second Product Candidate, Fee, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum" xlink:href="evlo-20210630.xsd#evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum" xlink:to="lab_evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_02ae2ba5-a74b-4f09-84aa-a8834dcabe93_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity (up to)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_RegistrationStatementMember_f347ce6b-7e9d-44e9-a7e0-63f8cedf3e03_terseLabel_en-US" xlink:label="lab_evlo_RegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Statement</link:label>
    <link:label id="lab_evlo_RegistrationStatementMember_label_en-US" xlink:label="lab_evlo_RegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Statement [Member]</link:label>
    <link:label id="lab_evlo_RegistrationStatementMember_documentation_en-US" xlink:label="lab_evlo_RegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Statement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RegistrationStatementMember" xlink:href="evlo-20210630.xsd#evlo_RegistrationStatementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_RegistrationStatementMember" xlink:to="lab_evlo_RegistrationStatementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_c2edc12c-c207-49ac-a8a8-45d0fc70e370_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3137275a-5d20-43cc-9a2f-b7906d46543d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_e76e4da8-d458-425c-a505-98c9b96dec9e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_3eba9fd3-cd5d-4df0-a685-2ec1f2b23cfa_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less amounts representing interest and discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_AtTheMarketMember_f6728daf-1ee8-4297-8a6f-d8a0754094ff_terseLabel_en-US" xlink:label="lab_evlo_AtTheMarketMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market</link:label>
    <link:label id="lab_evlo_AtTheMarketMember_label_en-US" xlink:label="lab_evlo_AtTheMarketMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market [Member]</link:label>
    <link:label id="lab_evlo_AtTheMarketMember_documentation_en-US" xlink:label="lab_evlo_AtTheMarketMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AtTheMarketMember" xlink:href="evlo-20210630.xsd#evlo_AtTheMarketMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_AtTheMarketMember" xlink:to="lab_evlo_AtTheMarketMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_TwoThousandAndTwentyOneStockInducementPlanMember_308b05d4-5b02-41b9-9cc2-e1bcb37aa1ac_terseLabel_en-US" xlink:label="lab_evlo_TwoThousandAndTwentyOneStockInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Stock Inducement Plan</link:label>
    <link:label id="lab_evlo_TwoThousandAndTwentyOneStockInducementPlanMember_label_en-US" xlink:label="lab_evlo_TwoThousandAndTwentyOneStockInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Twenty One Stock Inducement Plan [Member]</link:label>
    <link:label id="lab_evlo_TwoThousandAndTwentyOneStockInducementPlanMember_documentation_en-US" xlink:label="lab_evlo_TwoThousandAndTwentyOneStockInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Twenty One Stock Inducement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_TwoThousandAndTwentyOneStockInducementPlanMember" xlink:href="evlo-20210630.xsd#evlo_TwoThousandAndTwentyOneStockInducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_TwoThousandAndTwentyOneStockInducementPlanMember" xlink:to="lab_evlo_TwoThousandAndTwentyOneStockInducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_2d6ba5dd-3e62-489b-bb82-28d29d28daa3_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_c93ebb26-c1ca-41e6-a137-ccaf835f3921_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_bfd344ac-cbde-43d2-b007-a0807b112962_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_c0f28f17-eb82-46a0-b7f7-917873f3ca07_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Financial Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b6b9d75a-d181-4761-af35-ea024c0a7ebf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7782fd6e-76a7-4f2a-9c1d-ad11b8a1722c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_dc6be065-6a21-4228-a170-23301888afe0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Accounting Pronouncements Issued and Not Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_3b29134d-492b-469d-9e5e-f6d7d070e0f8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_26efdfed-2d46-4070-bd7b-e18b4ded9a03_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_PublicStockOfferingMember_25c8ed19-62c0-4c1a-821a-8391f84f9072_terseLabel_en-US" xlink:label="lab_evlo_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:label id="lab_evlo_PublicStockOfferingMember_label_en-US" xlink:label="lab_evlo_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_evlo_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_evlo_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_PublicStockOfferingMember" xlink:href="evlo-20210630.xsd#evlo_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_PublicStockOfferingMember" xlink:to="lab_evlo_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne_fe6368eb-6327-40d5-82af-6900eae4c0d7_terseLabel_en-US" xlink:label="lab_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee percentage after specified period</link:label>
    <link:label id="lab_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne_label_en-US" xlink:label="lab_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Fee Percentage After Specified Period One</link:label>
    <link:label id="lab_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne_documentation_en-US" xlink:label="lab_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument prepayment fee percentage after specified period one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne" xlink:to="lab_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_6663b22f-481b-4d3c-bb2f-cf7a683672d8_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_a909c95f-159a-48d9-859e-f72176e0260b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_92f75da9-002a-4401-a99c-bef7fb19ce19_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_86b1a399-6c35-437a-a5f8-5c4f497f973d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evlo_UnvestedCommonStockMember_09f77915-dd59-438b-9102-e7c954652e01_terseLabel_en-US" xlink:label="lab_evlo_UnvestedCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested common stock from early exercise of options</link:label>
    <link:label id="lab_evlo_UnvestedCommonStockMember_label_en-US" xlink:label="lab_evlo_UnvestedCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Common Stock [Member]</link:label>
    <link:label id="lab_evlo_UnvestedCommonStockMember_documentation_en-US" xlink:label="lab_evlo_UnvestedCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_UnvestedCommonStockMember" xlink:href="evlo-20210630.xsd#evlo_UnvestedCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evlo_UnvestedCommonStockMember" xlink:to="lab_evlo_UnvestedCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a047b45b-3e50-4b0b-ae89-3ca2d3a1a1da_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a14f1b55-d0f1-4c47-9467-9533421e130d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>evlo-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:aae86b17-43ea-4a10-aac9-9e83e0002ea1,g:814caf2c-83ae-43b0-8a9b-a2d97aa90ba1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://evelobio.com/role/CoverPage" xlink:type="simple" xlink:href="evlo-20210630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_320dd059-0466-4f94-ac8d-b0aa16f7722f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_DocumentType_320dd059-0466-4f94-ac8d-b0aa16f7722f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_18991ed0-9513-4d66-8732-7b1db1a4a49c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_DocumentQuarterlyReport_18991ed0-9513-4d66-8732-7b1db1a4a49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_503f3b36-d354-4116-8a77-c01a53ef622c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_DocumentPeriodEndDate_503f3b36-d354-4116-8a77-c01a53ef622c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c1af21a9-3125-45da-ab3d-66ffdb730b0b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_DocumentTransitionReport_c1af21a9-3125-45da-ab3d-66ffdb730b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8cb48eaf-3d36-4a69-ae32-75ec108d597c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_EntityFileNumber_8cb48eaf-3d36-4a69-ae32-75ec108d597c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_08ecefe5-5a02-4a10-b84d-b0a63a4d129f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_EntityRegistrantName_08ecefe5-5a02-4a10-b84d-b0a63a4d129f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_32d699fd-ded5-4816-b865-443cca159133" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_32d699fd-ded5-4816-b865-443cca159133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_11bd8568-2933-45cf-a2ac-70803e42bd3b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_EntityTaxIdentificationNumber_11bd8568-2933-45cf-a2ac-70803e42bd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2b8f30c8-f67d-4d58-b148-cee7537f24cb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_EntityAddressAddressLine1_2b8f30c8-f67d-4d58-b148-cee7537f24cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ed477397-2abb-4d65-93d8-309afd70edba" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_EntityAddressCityOrTown_ed477397-2abb-4d65-93d8-309afd70edba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3f7e2b8f-92ff-4f00-b6f5-35a6bf37fcdb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_EntityAddressStateOrProvince_3f7e2b8f-92ff-4f00-b6f5-35a6bf37fcdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0af0047f-291e-4526-95b2-3e99e9752542" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_EntityAddressPostalZipCode_0af0047f-291e-4526-95b2-3e99e9752542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c19c1c94-523d-4dda-aeb5-84c6efa5cbfc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_CityAreaCode_c19c1c94-523d-4dda-aeb5-84c6efa5cbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d6a47656-8f57-4e69-a6e0-7e055ad548a4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_LocalPhoneNumber_d6a47656-8f57-4e69-a6e0-7e055ad548a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8fb0f3ca-372e-408a-8c47-e4ff2bc516ca" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_Security12bTitle_8fb0f3ca-372e-408a-8c47-e4ff2bc516ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d46a504c-5c0c-4bb9-b773-a73803145131" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_TradingSymbol_d46a504c-5c0c-4bb9-b773-a73803145131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c04ab10e-5ff0-4e9a-a526-9bedc78d3c9e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_SecurityExchangeName_c04ab10e-5ff0-4e9a-a526-9bedc78d3c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7411ece4-828a-47e3-97aa-22999149a7f2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_EntityCurrentReportingStatus_7411ece4-828a-47e3-97aa-22999149a7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_79d861b9-c221-4574-bf6d-144415415b5f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_EntityInteractiveDataCurrent_79d861b9-c221-4574-bf6d-144415415b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2efbe546-381d-4e4e-b808-693908e244a8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_EntityFilerCategory_2efbe546-381d-4e4e-b808-693908e244a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d7d93ebf-918b-4e46-8e4c-438e7f19b8fb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_EntitySmallBusiness_d7d93ebf-918b-4e46-8e4c-438e7f19b8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_78a99cb8-63af-4a11-a436-a1f0dfa7919c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_EntityEmergingGrowthCompany_78a99cb8-63af-4a11-a436-a1f0dfa7919c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_ee5f2659-f2a4-44d4-a7d6-9bfecca60202" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_EntityExTransitionPeriod_ee5f2659-f2a4-44d4-a7d6-9bfecca60202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_af0be7c3-5858-42e4-9d1f-34805385c7cc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_EntityShellCompany_af0be7c3-5858-42e4-9d1f-34805385c7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c6c50e62-5c2a-4288-830f-dde64d3e027a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c6c50e62-5c2a-4288-830f-dde64d3e027a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e4b3eaff-58b6-48f1-889b-07b8c2c15e46" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_AmendmentFlag_e4b3eaff-58b6-48f1-889b-07b8c2c15e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_88787724-56b1-4f10-a682-d39fe7d508c5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_DocumentFiscalYearFocus_88787724-56b1-4f10-a682-d39fe7d508c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8dd8bf5a-41c6-4a69-bd82-71c8d9105763" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8dd8bf5a-41c6-4a69-bd82-71c8d9105763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_76ad33b4-8202-4535-a2c2-77f502f02cf4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_EntityCentralIndexKey_76ad33b4-8202-4535-a2c2-77f502f02cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b7a516aa-87cf-487c-836c-7112a4f20636" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ee303bf8-f069-46ce-9bc6-b8d8d8cbc08b" xlink:to="loc_dei_CurrentFiscalYearEndDate_b7a516aa-87cf-487c-836c-7112a4f20636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="evlo-20210630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_03874f76-3332-4921-aa2c-4a0d8ee4cec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6da15faa-ccdb-42f2-b746-f1dcb3ae1ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_03874f76-3332-4921-aa2c-4a0d8ee4cec7" xlink:to="loc_us-gaap_AssetsAbstract_6da15faa-ccdb-42f2-b746-f1dcb3ae1ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3bfcfc57-834b-499b-b5bd-7f014b33bdc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6da15faa-ccdb-42f2-b746-f1dcb3ae1ee8" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3bfcfc57-834b-499b-b5bd-7f014b33bdc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_94286a4f-2a87-4167-802b-4e7735e480be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3bfcfc57-834b-499b-b5bd-7f014b33bdc1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_94286a4f-2a87-4167-802b-4e7735e480be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_500d3c5c-c499-473d-861a-e52692d88730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3bfcfc57-834b-499b-b5bd-7f014b33bdc1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_500d3c5c-c499-473d-861a-e52692d88730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9ec1e286-cc9a-4314-9d88-641d624c1985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3bfcfc57-834b-499b-b5bd-7f014b33bdc1" xlink:to="loc_us-gaap_AssetsCurrent_9ec1e286-cc9a-4314-9d88-641d624c1985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7bdf2ee8-871e-45d7-a2bd-34cac0ccf3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6da15faa-ccdb-42f2-b746-f1dcb3ae1ee8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7bdf2ee8-871e-45d7-a2bd-34cac0ccf3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e17b8eaf-20c5-4eae-84c9-4d2bb9bc4cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6da15faa-ccdb-42f2-b746-f1dcb3ae1ee8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e17b8eaf-20c5-4eae-84c9-4d2bb9bc4cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_05b4c651-63c6-49b6-b9fa-26e8ab57f5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6da15faa-ccdb-42f2-b746-f1dcb3ae1ee8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_05b4c651-63c6-49b6-b9fa-26e8ab57f5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_497527d4-777a-45a8-9de5-b20d9f64d3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6da15faa-ccdb-42f2-b746-f1dcb3ae1ee8" xlink:to="loc_us-gaap_Assets_497527d4-777a-45a8-9de5-b20d9f64d3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_29dc30eb-9326-4638-be5f-500abc28087e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_03874f76-3332-4921-aa2c-4a0d8ee4cec7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_29dc30eb-9326-4638-be5f-500abc28087e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_78239bd5-4c85-434e-bbc2-6df7c3bebdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_29dc30eb-9326-4638-be5f-500abc28087e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_78239bd5-4c85-434e-bbc2-6df7c3bebdb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_99053d7f-c7b8-4bc0-9e34-7ec5c273a77a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_78239bd5-4c85-434e-bbc2-6df7c3bebdb7" xlink:to="loc_us-gaap_AccountsPayableCurrent_99053d7f-c7b8-4bc0-9e34-7ec5c273a77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9f7cd6e5-28e1-4cfd-977b-c5b62de80344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_78239bd5-4c85-434e-bbc2-6df7c3bebdb7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9f7cd6e5-28e1-4cfd-977b-c5b62de80344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_689178c5-c306-4b65-af43-33ae5fe0f4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_78239bd5-4c85-434e-bbc2-6df7c3bebdb7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_689178c5-c306-4b65-af43-33ae5fe0f4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_d56efaf9-11b9-4b67-b204-e2c6a00781bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_78239bd5-4c85-434e-bbc2-6df7c3bebdb7" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_d56efaf9-11b9-4b67-b204-e2c6a00781bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7a6c31ca-c33f-4343-b73d-0b56792501f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_78239bd5-4c85-434e-bbc2-6df7c3bebdb7" xlink:to="loc_us-gaap_LiabilitiesCurrent_7a6c31ca-c33f-4343-b73d-0b56792501f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_785d65b9-793f-451f-9f90-51f91113aafb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_29dc30eb-9326-4638-be5f-500abc28087e" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_785d65b9-793f-451f-9f90-51f91113aafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d6bcf6af-e3d3-4452-855d-011d1d4e66a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_785d65b9-793f-451f-9f90-51f91113aafb" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d6bcf6af-e3d3-4452-855d-011d1d4e66a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0f0836ac-b3f4-4ef6-9afc-1e23b75a9b85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_785d65b9-793f-451f-9f90-51f91113aafb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0f0836ac-b3f4-4ef6-9afc-1e23b75a9b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f4f76384-1011-4d7f-b3ca-1d881f132515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_785d65b9-793f-451f-9f90-51f91113aafb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f4f76384-1011-4d7f-b3ca-1d881f132515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3593bfac-5c20-46b9-a5f8-aeaba4ec824f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_785d65b9-793f-451f-9f90-51f91113aafb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3593bfac-5c20-46b9-a5f8-aeaba4ec824f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9d8fddc2-9e39-4a92-8ff8-704cd99859fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_29dc30eb-9326-4638-be5f-500abc28087e" xlink:to="loc_us-gaap_Liabilities_9d8fddc2-9e39-4a92-8ff8-704cd99859fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_73f80180-fa03-46b1-84b4-a09350050fae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_29dc30eb-9326-4638-be5f-500abc28087e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_73f80180-fa03-46b1-84b4-a09350050fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1432737f-1e08-4172-ab07-e9d352b6bb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_29dc30eb-9326-4638-be5f-500abc28087e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1432737f-1e08-4172-ab07-e9d352b6bb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_06542fd0-9c40-4243-ac4f-d2c02993687b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1432737f-1e08-4172-ab07-e9d352b6bb1a" xlink:to="loc_us-gaap_PreferredStockValue_06542fd0-9c40-4243-ac4f-d2c02993687b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7bb3c982-ea42-4178-9920-096768ede4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1432737f-1e08-4172-ab07-e9d352b6bb1a" xlink:to="loc_us-gaap_CommonStockValue_7bb3c982-ea42-4178-9920-096768ede4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9176900c-b1ac-4832-bb48-41fefd91e8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1432737f-1e08-4172-ab07-e9d352b6bb1a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9176900c-b1ac-4832-bb48-41fefd91e8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6a9ee991-2fbe-4511-9d96-e072fcfbbbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1432737f-1e08-4172-ab07-e9d352b6bb1a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6a9ee991-2fbe-4511-9d96-e072fcfbbbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0fb0e369-ce48-406d-a511-fc4e4430b09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1432737f-1e08-4172-ab07-e9d352b6bb1a" xlink:to="loc_us-gaap_StockholdersEquity_0fb0e369-ce48-406d-a511-fc4e4430b09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_20182137-6f54-445b-a7e9-d88c5be4b2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_29dc30eb-9326-4638-be5f-500abc28087e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_20182137-6f54-445b-a7e9-d88c5be4b2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="evlo-20210630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_da0ba5eb-c581-40b6-82fd-eb03b2ce1368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3e17bc83-4e7a-4850-9ae2-2760325c1e59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_da0ba5eb-c581-40b6-82fd-eb03b2ce1368" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3e17bc83-4e7a-4850-9ae2-2760325c1e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_407a5f2c-ee07-4a8d-a1cd-4f11d40d97c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_da0ba5eb-c581-40b6-82fd-eb03b2ce1368" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_407a5f2c-ee07-4a8d-a1cd-4f11d40d97c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_2207eab5-afc6-4081-99f3-f52652f5da99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_da0ba5eb-c581-40b6-82fd-eb03b2ce1368" xlink:to="loc_us-gaap_PreferredStockSharesIssued_2207eab5-afc6-4081-99f3-f52652f5da99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c1b903c4-40d4-401b-a135-99a019af59ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_da0ba5eb-c581-40b6-82fd-eb03b2ce1368" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_c1b903c4-40d4-401b-a135-99a019af59ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b956e978-988c-4db4-aa8f-71e4d75c01d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_da0ba5eb-c581-40b6-82fd-eb03b2ce1368" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b956e978-988c-4db4-aa8f-71e4d75c01d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a9511093-32ee-402e-bb53-c405a2fc2a02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_da0ba5eb-c581-40b6-82fd-eb03b2ce1368" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a9511093-32ee-402e-bb53-c405a2fc2a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_af7f3a7a-1243-4336-a396-29442dd2fcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_da0ba5eb-c581-40b6-82fd-eb03b2ce1368" xlink:to="loc_us-gaap_CommonStockSharesIssued_af7f3a7a-1243-4336-a396-29442dd2fcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4c92c58d-1797-4b2b-af44-6c16149983f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_da0ba5eb-c581-40b6-82fd-eb03b2ce1368" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4c92c58d-1797-4b2b-af44-6c16149983f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="evlo-20210630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_416b9c65-10bc-4099-b408-a863146f2fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_fbf0546f-1ff9-4119-8700-f3eb937ddca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_416b9c65-10bc-4099-b408-a863146f2fb6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_fbf0546f-1ff9-4119-8700-f3eb937ddca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ad3aa0a0-8e0b-4ccf-96d8-6b02f3b108e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fbf0546f-1ff9-4119-8700-f3eb937ddca6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ad3aa0a0-8e0b-4ccf-96d8-6b02f3b108e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_74553cb8-3f21-4896-b7d3-204c5719e5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fbf0546f-1ff9-4119-8700-f3eb937ddca6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_74553cb8-3f21-4896-b7d3-204c5719e5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0915842c-0a74-4388-878b-28cd72426806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fbf0546f-1ff9-4119-8700-f3eb937ddca6" xlink:to="loc_us-gaap_OperatingExpenses_0915842c-0a74-4388-878b-28cd72426806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_dfd5b87c-6008-48b2-8ec3-c980eb3ce11b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fbf0546f-1ff9-4119-8700-f3eb937ddca6" xlink:to="loc_us-gaap_OperatingIncomeLoss_dfd5b87c-6008-48b2-8ec3-c980eb3ce11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_88b4a24f-c72e-4df5-a148-c62213c9a3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fbf0546f-1ff9-4119-8700-f3eb937ddca6" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_88b4a24f-c72e-4df5-a148-c62213c9a3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_a2d05d42-9308-4b45-910e-1f83169817de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_88b4a24f-c72e-4df5-a148-c62213c9a3c0" xlink:to="loc_us-gaap_InvestmentIncomeNet_a2d05d42-9308-4b45-910e-1f83169817de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_87fc03c2-9a27-49bb-8b9c-19e320d7e45e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_88b4a24f-c72e-4df5-a148-c62213c9a3c0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_87fc03c2-9a27-49bb-8b9c-19e320d7e45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_801d49e8-bad5-4c2e-8202-97c80223d697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_88b4a24f-c72e-4df5-a148-c62213c9a3c0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_801d49e8-bad5-4c2e-8202-97c80223d697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_34a76ef5-2687-497d-b32b-ae35d3ab8ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_88b4a24f-c72e-4df5-a148-c62213c9a3c0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_34a76ef5-2687-497d-b32b-ae35d3ab8ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e223d28b-db75-49b3-aff7-3ae627be14aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_416b9c65-10bc-4099-b408-a863146f2fb6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e223d28b-db75-49b3-aff7-3ae627be14aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b3360474-885b-45dd-a4b9-a55f0d89499a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_416b9c65-10bc-4099-b408-a863146f2fb6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b3360474-885b-45dd-a4b9-a55f0d89499a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2ee028d4-b70b-40df-aaab-af65600ea189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_416b9c65-10bc-4099-b408-a863146f2fb6" xlink:to="loc_us-gaap_NetIncomeLoss_2ee028d4-b70b-40df-aaab-af65600ea189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a09124c2-bcab-4f4c-b99a-e066d65e8126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_416b9c65-10bc-4099-b408-a863146f2fb6" xlink:to="loc_us-gaap_EarningsPerShareBasic_a09124c2-bcab-4f4c-b99a-e066d65e8126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c8a43965-4dea-4bf6-9058-66a1d1d8b8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_416b9c65-10bc-4099-b408-a863146f2fb6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c8a43965-4dea-4bf6-9058-66a1d1d8b8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_328cf65f-b654-4d92-9c21-8c25de5b479a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_416b9c65-10bc-4099-b408-a863146f2fb6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_328cf65f-b654-4d92-9c21-8c25de5b479a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_00377fd6-62e2-47fb-b749-ec7a0566da5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_416b9c65-10bc-4099-b408-a863146f2fb6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_00377fd6-62e2-47fb-b749-ec7a0566da5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="evlo-20210630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_61e7f933-4fb1-40b0-87fd-d693b5a754f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fb9fe387-8f1c-46ff-9c4a-bd38476c2db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_61e7f933-4fb1-40b0-87fd-d693b5a754f2" xlink:to="loc_us-gaap_StatementTable_fb9fe387-8f1c-46ff-9c4a-bd38476c2db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fc785c95-cfe1-4c15-9f5a-56816142cbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fb9fe387-8f1c-46ff-9c4a-bd38476c2db0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fc785c95-cfe1-4c15-9f5a-56816142cbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5d735167-cd7d-4dce-8348-94310eb2a90d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fc785c95-cfe1-4c15-9f5a-56816142cbaa" xlink:to="loc_us-gaap_EquityComponentDomain_5d735167-cd7d-4dce-8348-94310eb2a90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_97f0f4fe-cc2b-4610-90b7-7545a079649a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5d735167-cd7d-4dce-8348-94310eb2a90d" xlink:to="loc_us-gaap_CommonStockMember_97f0f4fe-cc2b-4610-90b7-7545a079649a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4ca144b9-58ff-42b4-b049-513678c9cfff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5d735167-cd7d-4dce-8348-94310eb2a90d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4ca144b9-58ff-42b4-b049-513678c9cfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3b077882-9fb2-47ec-8045-d0698979ee28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5d735167-cd7d-4dce-8348-94310eb2a90d" xlink:to="loc_us-gaap_RetainedEarningsMember_3b077882-9fb2-47ec-8045-d0698979ee28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2ee098b0-00bf-4b68-b15a-8fa9d775fc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fb9fe387-8f1c-46ff-9c4a-bd38476c2db0" xlink:to="loc_us-gaap_StatementLineItems_2ee098b0-00bf-4b68-b15a-8fa9d775fc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2ee098b0-00bf-4b68-b15a-8fa9d775fc76" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_286eaed4-0289-472b-a11a-2f9722123199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_SharesOutstanding_286eaed4-0289-472b-a11a-2f9722123199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3f666921-947a-4c2c-92c5-7df0caac4dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockholdersEquity_3f666921-947a-4c2c-92c5-7df0caac4dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4e76d485-c06a-4474-b0b1-6a1545cabe6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4e76d485-c06a-4474-b0b1-6a1545cabe6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_385fcf78-cea8-4c75-8a10-17f22cea82cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_385fcf78-cea8-4c75-8a10-17f22cea82cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_26f49c8e-4332-4948-b768-a4f45dcf194b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_26f49c8e-4332-4948-b768-a4f45dcf194b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_92778586-dc82-4870-8efe-f1d33a6434a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_92778586-dc82-4870-8efe-f1d33a6434a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f4b3b938-bfa0-45c5-8b54-086e03091757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f4b3b938-bfa0-45c5-8b54-086e03091757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_006c95b5-b217-4952-8dfb-37e3c0683580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_006c95b5-b217-4952-8dfb-37e3c0683580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4c1e45b9-86b6-4df4-b6b2-9e85cdd16763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4c1e45b9-86b6-4df4-b6b2-9e85cdd16763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a2baf3a1-c962-4855-a442-072439e1b737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a2baf3a1-c962-4855-a442-072439e1b737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4fe295c7-e3a7-4d0c-966b-86048abf101c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4fe295c7-e3a7-4d0c-966b-86048abf101c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_de5c5bc5-7575-4cc7-83b8-1fbd31228248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_de5c5bc5-7575-4cc7-83b8-1fbd31228248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6707c7da-fb78-4946-8e7b-f77365d4be78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_NetIncomeLoss_6707c7da-fb78-4946-8e7b-f77365d4be78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_90abaa06-7fc0-4517-85ba-4d0f14c77e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_SharesOutstanding_90abaa06-7fc0-4517-85ba-4d0f14c77e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eb42f339-f638-4c26-8a75-326264764d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_459df318-d2ca-4f9e-91d8-5f97680ea38c" xlink:to="loc_us-gaap_StockholdersEquity_eb42f339-f638-4c26-8a75-326264764d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="evlo-20210630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ce134469-f30b-49e8-966e-7b966e758c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_abe7663c-493e-47c6-b4a9-767dc67c1d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce134469-f30b-49e8-966e-7b966e758c3c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_abe7663c-493e-47c6-b4a9-767dc67c1d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e41acabe-afb9-434a-8e88-62347d3e432c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_abe7663c-493e-47c6-b4a9-767dc67c1d65" xlink:to="loc_us-gaap_NetIncomeLoss_e41acabe-afb9-434a-8e88-62347d3e432c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2401efda-b6be-4798-b768-ea0985a9e301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_abe7663c-493e-47c6-b4a9-767dc67c1d65" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2401efda-b6be-4798-b768-ea0985a9e301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_556efc70-fa21-4682-902a-b599b992ee88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2401efda-b6be-4798-b768-ea0985a9e301" xlink:to="loc_us-gaap_ShareBasedCompensation_556efc70-fa21-4682-902a-b599b992ee88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_195a5a61-4172-4b11-a7b7-e379742c68e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2401efda-b6be-4798-b768-ea0985a9e301" xlink:to="loc_us-gaap_Depreciation_195a5a61-4172-4b11-a7b7-e379742c68e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonCashInterestExpense_8ca7e745-c7ec-4833-9ad6-39af96ae8adb" xlink:href="evlo-20210630.xsd#evlo_NonCashInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2401efda-b6be-4798-b768-ea0985a9e301" xlink:to="loc_evlo_NonCashInterestExpense_8ca7e745-c7ec-4833-9ad6-39af96ae8adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonCashOperatingLeaseExpense_04ca2004-83ea-4d2b-a6a9-0a5449260cab" xlink:href="evlo-20210630.xsd#evlo_NonCashOperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2401efda-b6be-4798-b768-ea0985a9e301" xlink:to="loc_evlo_NonCashOperatingLeaseExpense_04ca2004-83ea-4d2b-a6a9-0a5449260cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_def73a94-3df2-4240-9ad4-7e3bf15ec543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2401efda-b6be-4798-b768-ea0985a9e301" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_def73a94-3df2-4240-9ad4-7e3bf15ec543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_18f8de81-53c9-4c07-9958-158a4e71f2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2401efda-b6be-4798-b768-ea0985a9e301" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_18f8de81-53c9-4c07-9958-158a4e71f2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dfee8c9c-65d5-4979-aab3-932b10060875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2401efda-b6be-4798-b768-ea0985a9e301" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dfee8c9c-65d5-4979-aab3-932b10060875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_264fe601-d187-4266-91ed-daadf277d820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dfee8c9c-65d5-4979-aab3-932b10060875" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_264fe601-d187-4266-91ed-daadf277d820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ded706c3-260a-405a-b13a-d3a346b0da8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dfee8c9c-65d5-4979-aab3-932b10060875" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ded706c3-260a-405a-b13a-d3a346b0da8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e40f14f1-018c-4985-8c98-9911df19282b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dfee8c9c-65d5-4979-aab3-932b10060875" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e40f14f1-018c-4985-8c98-9911df19282b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_dfaefca5-5ee7-4c44-969b-d29cccc64fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dfee8c9c-65d5-4979-aab3-932b10060875" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_dfaefca5-5ee7-4c44-969b-d29cccc64fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_cf9ac735-7165-4cc5-9bb4-0d77946ff478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dfee8c9c-65d5-4979-aab3-932b10060875" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_cf9ac735-7165-4cc5-9bb4-0d77946ff478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0b57b74f-7198-4430-9adc-c59ca0284261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dfee8c9c-65d5-4979-aab3-932b10060875" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0b57b74f-7198-4430-9adc-c59ca0284261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e601677c-a586-4dd1-b236-6df747c76a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_abe7663c-493e-47c6-b4a9-767dc67c1d65" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e601677c-a586-4dd1-b236-6df747c76a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d8e67cef-2e32-4bc2-8921-7e75f643d2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce134469-f30b-49e8-966e-7b966e758c3c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d8e67cef-2e32-4bc2-8921-7e75f643d2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f8ff896e-b737-4dc2-9fe5-a82b6ad9c87e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d8e67cef-2e32-4bc2-8921-7e75f643d2e8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f8ff896e-b737-4dc2-9fe5-a82b6ad9c87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_26da7b92-6ea7-42b3-a84b-c3ae0cba38b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d8e67cef-2e32-4bc2-8921-7e75f643d2e8" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_26da7b92-6ea7-42b3-a84b-c3ae0cba38b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a0d04b04-680f-4dae-9c3f-d162c21dc0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d8e67cef-2e32-4bc2-8921-7e75f643d2e8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a0d04b04-680f-4dae-9c3f-d162c21dc0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e484f3ff-487d-42ae-afb4-9dc9a55f7a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce134469-f30b-49e8-966e-7b966e758c3c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e484f3ff-487d-42ae-afb4-9dc9a55f7a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1c3f76f7-5f52-4279-ba6d-7903a00d0b64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e484f3ff-487d-42ae-afb4-9dc9a55f7a4c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1c3f76f7-5f52-4279-ba6d-7903a00d0b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0e59eec5-3a62-4115-afca-ef48ad11adf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e484f3ff-487d-42ae-afb4-9dc9a55f7a4c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0e59eec5-3a62-4115-afca-ef48ad11adf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_bd56d5c7-4556-49c4-8d20-866e385e671e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e484f3ff-487d-42ae-afb4-9dc9a55f7a4c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_bd56d5c7-4556-49c4-8d20-866e385e671e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef65f7ab-6cfe-4039-b50f-13855286776d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e484f3ff-487d-42ae-afb4-9dc9a55f7a4c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef65f7ab-6cfe-4039-b50f-13855286776d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4438e8c3-7276-4de0-8c0c-8c0c5e1994ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce134469-f30b-49e8-966e-7b966e758c3c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4438e8c3-7276-4de0-8c0c-8c0c5e1994ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9684af66-9fc7-4fe2-bc75-238258681a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce134469-f30b-49e8-966e-7b966e758c3c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9684af66-9fc7-4fe2-bc75-238258681a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_acf70573-bb5c-482c-b561-04e17cadd26b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce134469-f30b-49e8-966e-7b966e758c3c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_acf70573-bb5c-482c-b561-04e17cadd26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_fbb8d9c4-a1a8-440c-b2f0-bc378dbbbfe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce134469-f30b-49e8-966e-7b966e758c3c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_fbb8d9c4-a1a8-440c-b2f0-bc378dbbbfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_54b4156b-454c-46fb-a01f-26f1f85f40db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_fbb8d9c4-a1a8-440c-b2f0-bc378dbbbfe8" xlink:to="loc_us-gaap_InterestPaidNet_54b4156b-454c-46fb-a01f-26f1f85f40db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_12286b4f-1706-4723-812f-c57ad66cb6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_fbb8d9c4-a1a8-440c-b2f0-bc378dbbbfe8" xlink:to="loc_us-gaap_IncomeTaxesPaid_12286b4f-1706-4723-812f-c57ad66cb6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c1c02eca-840d-497f-893e-76bcec98baa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce134469-f30b-49e8-966e-7b966e758c3c" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c1c02eca-840d-497f-893e-76bcec98baa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_30be8698-836c-4e60-9f13-055092f10c56" xlink:href="evlo-20210630.xsd#evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c1c02eca-840d-497f-893e-76bcec98baa8" xlink:to="loc_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_30be8698-836c-4e60-9f13-055092f10c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_PublicOfferingCostInAccruedExpense_86b0a2cd-0bc2-40f1-b634-1b4a36418d92" xlink:href="evlo-20210630.xsd#evlo_PublicOfferingCostInAccruedExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c1c02eca-840d-497f-893e-76bcec98baa8" xlink:to="loc_evlo_PublicOfferingCostInAccruedExpense_86b0a2cd-0bc2-40f1-b634-1b4a36418d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8ffa45cb-f02d-4aec-bbe1-154fc7b66d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c1c02eca-840d-497f-893e-76bcec98baa8" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8ffa45cb-f02d-4aec-bbe1-154fc7b66d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_f507aa6c-9b67-47fd-8ae7-7b74f270d2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c1c02eca-840d-497f-893e-76bcec98baa8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_f507aa6c-9b67-47fd-8ae7-7b74f270d2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/Organization" xlink:type="simple" xlink:href="evlo-20210630.xsd#Organization"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aae55621-c401-422c-a21e-0cdd885e64e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_65fbc82c-46a1-480e-a9f5-29d019cb7690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aae55621-c401-422c-a21e-0cdd885e64e9" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_65fbc82c-46a1-480e-a9f5-29d019cb7690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/OrganizationNarrativeDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#OrganizationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/OrganizationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72c8af34-82b0-4873-a828-7e8dccadb9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c5e4e980-12dc-42b7-b7b4-b488c09c4ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72c8af34-82b0-4873-a828-7e8dccadb9bb" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c5e4e980-12dc-42b7-b7b4-b488c09c4ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0280e491-99c0-4b9a-93ad-3e4945daea02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c5e4e980-12dc-42b7-b7b4-b488c09c4ebc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0280e491-99c0-4b9a-93ad-3e4945daea02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2c8bbc6-2dff-4e31-8c56-8423f59e37cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0280e491-99c0-4b9a-93ad-3e4945daea02" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2c8bbc6-2dff-4e31-8c56-8423f59e37cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RegistrationStatementMember_6d4415bc-f97d-4f53-88c9-049e715b7d82" xlink:href="evlo-20210630.xsd#evlo_RegistrationStatementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2c8bbc6-2dff-4e31-8c56-8423f59e37cc" xlink:to="loc_evlo_RegistrationStatementMember_6d4415bc-f97d-4f53-88c9-049e715b7d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AtTheMarketMember_42cd2373-6cb5-4552-bc9f-7ce4128573f3" xlink:href="evlo-20210630.xsd#evlo_AtTheMarketMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2c8bbc6-2dff-4e31-8c56-8423f59e37cc" xlink:to="loc_evlo_AtTheMarketMember_42cd2373-6cb5-4552-bc9f-7ce4128573f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_PublicStockOfferingMember_a3e2718f-3f2e-4b9e-ae49-9402b785a8d9" xlink:href="evlo-20210630.xsd#evlo_PublicStockOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2c8bbc6-2dff-4e31-8c56-8423f59e37cc" xlink:to="loc_evlo_PublicStockOfferingMember_a3e2718f-3f2e-4b9e-ae49-9402b785a8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_a0bbe094-6f9c-469a-a1ca-c046f37baf60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2c8bbc6-2dff-4e31-8c56-8423f59e37cc" xlink:to="loc_us-gaap_OverAllotmentOptionMember_a0bbe094-6f9c-469a-a1ca-c046f37baf60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_41a60288-d0dd-4455-9886-e00618c1e6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2c8bbc6-2dff-4e31-8c56-8423f59e37cc" xlink:to="loc_us-gaap_PrivatePlacementMember_41a60288-d0dd-4455-9886-e00618c1e6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b89d3008-130e-4132-abec-58a59bc416c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c5e4e980-12dc-42b7-b7b4-b488c09c4ebc" xlink:to="loc_srt_RangeAxis_b89d3008-130e-4132-abec-58a59bc416c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb84b563-7e99-45d4-8029-8184df0f9a92" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b89d3008-130e-4132-abec-58a59bc416c6" xlink:to="loc_srt_RangeMember_fb84b563-7e99-45d4-8029-8184df0f9a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1d8efc26-ec09-4341-aca1-a256cc567af6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb84b563-7e99-45d4-8029-8184df0f9a92" xlink:to="loc_srt_MinimumMember_1d8efc26-ec09-4341-aca1-a256cc567af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2282a6d9-ffc1-4dd8-b9c0-d9ac8e24fda3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb84b563-7e99-45d4-8029-8184df0f9a92" xlink:to="loc_srt_MaximumMember_2282a6d9-ffc1-4dd8-b9c0-d9ac8e24fda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c5e4e980-12dc-42b7-b7b4-b488c09c4ebc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction_212716d3-9315-4aa0-abe5-765576d0045e" xlink:href="evlo-20210630.xsd#evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:to="loc_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction_212716d3-9315-4aa0-abe5-765576d0045e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockConsiderationReceivedTerm_440723cf-6ba6-4f04-a8c8-f64e4cfd20b8" xlink:href="evlo-20210630.xsd#evlo_SaleOfStockConsiderationReceivedTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:to="loc_evlo_SaleOfStockConsiderationReceivedTerm_440723cf-6ba6-4f04-a8c8-f64e4cfd20b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d35c840b-6b32-496a-abc3-26b2566b3725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d35c840b-6b32-496a-abc3-26b2566b3725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4268cefa-e098-4839-8d36-a6ad57581e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4268cefa-e098-4839-8d36-a6ad57581e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction_dce10206-9571-4523-a544-004dc1cd9b3e" xlink:href="evlo-20210630.xsd#evlo_SaleOfStockGrossConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:to="loc_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction_dce10206-9571-4523-a544-004dc1cd9b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_25d38aa6-9ad3-4ee7-90a4-8286fccd82c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_25d38aa6-9ad3-4ee7-90a4-8286fccd82c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_94e09183-304d-4d6e-9490-7a740ce3b90b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_94e09183-304d-4d6e-9490-7a740ce3b90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ffbca50f-b2b4-42e3-b9bb-200fef5e70d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9c80e965-4aef-40bf-ac87-25c6258abf78" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ffbca50f-b2b4-42e3-b9bb-200fef5e70d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="evlo-20210630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c974e95d-ef16-4b8c-881b-6fa5fcb1a0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8b99c31d-b3ab-4e9c-94fd-4175efb786b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c974e95d-ef16-4b8c-881b-6fa5fcb1a0f6" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8b99c31d-b3ab-4e9c-94fd-4175efb786b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="evlo-20210630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_12d81b10-6ea9-4e44-b1d0-5c02228c0e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ba161ef6-71d5-4e41-956e-ec5df3a0f12e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12d81b10-6ea9-4e44-b1d0-5c02228c0e7b" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ba161ef6-71d5-4e41-956e-ec5df3a0f12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_f6b3b3e0-e0cf-4741-9b01-adccc9d4c796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12d81b10-6ea9-4e44-b1d0-5c02228c0e7b" xlink:to="loc_us-gaap_UseOfEstimates_f6b3b3e0-e0cf-4741-9b01-adccc9d4c796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_3e73a483-7aec-4a59-93ad-56edc6cea117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12d81b10-6ea9-4e44-b1d0-5c02228c0e7b" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_3e73a483-7aec-4a59-93ad-56edc6cea117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_EmergingGrowthCompanyStatusPolicyTextBlock_fd8fda1a-bd84-4c22-8957-e1582eb864f6" xlink:href="evlo-20210630.xsd#evlo_EmergingGrowthCompanyStatusPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12d81b10-6ea9-4e44-b1d0-5c02228c0e7b" xlink:to="loc_evlo_EmergingGrowthCompanyStatusPolicyTextBlock_fd8fda1a-bd84-4c22-8957-e1582eb864f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_6453a90b-f79b-492f-9ac7-7b4311682362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12d81b10-6ea9-4e44-b1d0-5c02228c0e7b" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_6453a90b-f79b-492f-9ac7-7b4311682362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ca872cbb-eda9-4f9d-9b04-7e0e77295353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12d81b10-6ea9-4e44-b1d0-5c02228c0e7b" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ca872cbb-eda9-4f9d-9b04-7e0e77295353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_0a1c8081-1759-4d32-85e8-39b6ab315e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12d81b10-6ea9-4e44-b1d0-5c02228c0e7b" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_0a1c8081-1759-4d32-85e8-39b6ab315e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_9650ec7d-6e19-465f-9645-6b1751bc65f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12d81b10-6ea9-4e44-b1d0-5c02228c0e7b" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_9650ec7d-6e19-465f-9645-6b1751bc65f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f58912e6-20f0-46d5-9d01-fc44d67cc0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12d81b10-6ea9-4e44-b1d0-5c02228c0e7b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f58912e6-20f0-46d5-9d01-fc44d67cc0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_00cc659d-029a-403d-af78-4a877f781db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12d81b10-6ea9-4e44-b1d0-5c02228c0e7b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_00cc659d-029a-403d-af78-4a877f781db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2e6cfcc9-7040-4ea0-882e-45a02cbe8912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12d81b10-6ea9-4e44-b1d0-5c02228c0e7b" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2e6cfcc9-7040-4ea0-882e-45a02cbe8912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_065c893c-4d40-4d11-88bf-1466906bd95a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12d81b10-6ea9-4e44-b1d0-5c02228c0e7b" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_065c893c-4d40-4d11-88bf-1466906bd95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2e02012f-b50e-494b-8fe0-a432e0c1d1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12d81b10-6ea9-4e44-b1d0-5c02228c0e7b" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2e02012f-b50e-494b-8fe0-a432e0c1d1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_72e2b35c-cb4e-412e-9512-aa4a9ea39f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12d81b10-6ea9-4e44-b1d0-5c02228c0e7b" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_72e2b35c-cb4e-412e-9512-aa4a9ea39f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="evlo-20210630.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_48a12c1f-6375-444d-9882-679a6a041e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_cbbfcd1c-2dd9-4790-81db-db029ee85a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48a12c1f-6375-444d-9882-679a6a041e94" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_cbbfcd1c-2dd9-4790-81db-db029ee85a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d79f4c50-b9ef-42fa-a08f-5bc766cb8632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48a12c1f-6375-444d-9882-679a6a041e94" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d79f4c50-b9ef-42fa-a08f-5bc766cb8632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4c42de00-ec45-4707-8e83-e27fb75d00f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_e9d9fad7-5a6b-4cf8-9265-e49a3fbcdc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c42de00-ec45-4707-8e83-e27fb75d00f1" xlink:to="loc_us-gaap_RestrictedCashCurrent_e9d9fad7-5a6b-4cf8-9265-e49a3fbcdc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_3c6f8f0a-b641-4444-972d-abf0ac52c9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c42de00-ec45-4707-8e83-e27fb75d00f1" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_3c6f8f0a-b641-4444-972d-abf0ac52c9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_cbbf0139-3efe-4f78-8a3c-df77eda4c2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c42de00-ec45-4707-8e83-e27fb75d00f1" xlink:to="loc_us-gaap_NumberOfOperatingSegments_cbbf0139-3efe-4f78-8a3c-df77eda4c2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b40f4562-9c9b-49ff-aa30-1f102742c865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_97cc460b-41a3-4a49-85c5-b1856e4ae008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b40f4562-9c9b-49ff-aa30-1f102742c865" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_97cc460b-41a3-4a49-85c5-b1856e4ae008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_2090e161-78de-4551-97fc-bb03e8d98211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_97cc460b-41a3-4a49-85c5-b1856e4ae008" xlink:to="loc_us-gaap_Cash_2090e161-78de-4551-97fc-bb03e8d98211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_c1629473-7125-49e7-989a-b7091216d478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_97cc460b-41a3-4a49-85c5-b1856e4ae008" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_c1629473-7125-49e7-989a-b7091216d478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_04ad869d-3899-4123-aca1-b1fc71d7df13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_97cc460b-41a3-4a49-85c5-b1856e4ae008" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_04ad869d-3899-4123-aca1-b1fc71d7df13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_7b0812ab-6f57-4bd0-8cfa-b8086984bdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b40f4562-9c9b-49ff-aa30-1f102742c865" xlink:to="loc_us-gaap_RestrictedCash_7b0812ab-6f57-4bd0-8cfa-b8086984bdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_27e0f9cd-6190-4fb3-aa71-d4cefab5237e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b40f4562-9c9b-49ff-aa30-1f102742c865" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_27e0f9cd-6190-4fb3-aa71-d4cefab5237e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/ALJCommercializationandLicenseAgreement" xlink:type="simple" xlink:href="evlo-20210630.xsd#ALJCommercializationandLicenseAgreement"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/ALJCommercializationandLicenseAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3691d221-397b-4f48-9a99-e48ee67c356e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_35d10545-43b7-439d-b3da-6d027761b489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3691d221-397b-4f48-9a99-e48ee67c356e" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_35d10545-43b7-439d-b3da-6d027761b489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#ALJCommercializationandLicenseAgreementDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8831ad31-be09-4bb2-9e9b-7477e75f9175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_32392604-33e5-4a45-9e22-58202271fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8831ad31-be09-4bb2-9e9b-7477e75f9175" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_32392604-33e5-4a45-9e22-58202271fd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_88d42d7f-9098-4ef1-83c5-26698635c6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_32392604-33e5-4a45-9e22-58202271fd07" xlink:to="loc_us-gaap_TypeOfArrangementAxis_88d42d7f-9098-4ef1-83c5-26698635c6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1ca94aeb-9bd0-4253-adeb-90d14063eb67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_88d42d7f-9098-4ef1-83c5-26698635c6ec" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1ca94aeb-9bd0-4253-adeb-90d14063eb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_68eb14e7-6ed7-41d2-89b7-3411021708de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1ca94aeb-9bd0-4253-adeb-90d14063eb67" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_68eb14e7-6ed7-41d2-89b7-3411021708de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cea7d292-7455-4738-a3f7-8123d1ccf5f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_32392604-33e5-4a45-9e22-58202271fd07" xlink:to="loc_srt_CounterpartyNameAxis_cea7d292-7455-4738-a3f7-8123d1ccf5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1315869a-942e-4a28-897b-e8cec03568ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_cea7d292-7455-4738-a3f7-8123d1ccf5f6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1315869a-942e-4a28-897b-e8cec03568ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MeddistCompanyLimitedMember_0c014ad3-eb5c-4f00-a793-5be03aea07cf" xlink:href="evlo-20210630.xsd#evlo_MeddistCompanyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1315869a-942e-4a28-897b-e8cec03568ec" xlink:to="loc_evlo_MeddistCompanyLimitedMember_0c014ad3-eb5c-4f00-a793-5be03aea07cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86538505-e819-4d97-9d29-a5c4be725b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_32392604-33e5-4a45-9e22-58202271fd07" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86538505-e819-4d97-9d29-a5c4be725b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod_346ea61e-f40a-49b6-af22-feafd4959a30" xlink:href="evlo-20210630.xsd#evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86538505-e819-4d97-9d29-a5c4be725b99" xlink:to="loc_evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod_346ea61e-f40a-49b6-af22-feafd4959a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum_954f695a-3e1a-4181-96d9-6e6eca047c0b" xlink:href="evlo-20210630.xsd#evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86538505-e819-4d97-9d29-a5c4be725b99" xlink:to="loc_evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum_954f695a-3e1a-4181-96d9-6e6eca047c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_38855c74-10e5-46ed-8afd-52bf81d28bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86538505-e819-4d97-9d29-a5c4be725b99" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_38855c74-10e5-46ed-8afd-52bf81d28bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage_bc3b57d8-2233-4794-9b9f-ce4e87702965" xlink:href="evlo-20210630.xsd#evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_86538505-e819-4d97-9d29-a5c4be725b99" xlink:to="loc_evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage_bc3b57d8-2233-4794-9b9f-ce4e87702965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/Leases" xlink:type="simple" xlink:href="evlo-20210630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fa05f08d-d236-4a2d-b3d2-289fc3511267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_6e3adf5a-344e-4380-a018-c9c38a6e6d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fa05f08d-d236-4a2d-b3d2-289fc3511267" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_6e3adf5a-344e-4380-a018-c9c38a6e6d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LeasesTables" xlink:type="simple" xlink:href="evlo-20210630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f1d8221d-6cad-426c-9044-4b64fdf219c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fc1d03b3-1762-440b-9522-946becd152fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f1d8221d-6cad-426c-9044-4b64fdf219c4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fc1d03b3-1762-440b-9522-946becd152fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c563c25e-93bd-4f34-9280-1bd54e40aafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_56ccd511-8a48-449c-989b-1d315fbcc2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfLand"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c563c25e-93bd-4f34-9280-1bd54e40aafa" xlink:to="loc_us-gaap_AreaOfLand_56ccd511-8a48-449c-989b-1d315fbcc2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_13b41c31-5014-4d77-8377-625af7060c34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c563c25e-93bd-4f34-9280-1bd54e40aafa" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_13b41c31-5014-4d77-8377-625af7060c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_8d4bf1bc-565f-4e30-8c66-18b35663700d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c563c25e-93bd-4f34-9280-1bd54e40aafa" xlink:to="loc_us-gaap_OperatingLeaseExpense_8d4bf1bc-565f-4e30-8c66-18b35663700d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_9a54afa6-1600-40d2-9670-1c01cdfdde36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c563c25e-93bd-4f34-9280-1bd54e40aafa" xlink:to="loc_us-gaap_SubleaseIncome_9a54afa6-1600-40d2-9670-1c01cdfdde36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_96b1f4e3-3918-4703-95b2-59c3cf5dc5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_83f02185-f34f-4c55-90ae-8cec3a81bed0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_96b1f4e3-3918-4703-95b2-59c3cf5dc5bb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_83f02185-f34f-4c55-90ae-8cec3a81bed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_509a1947-f8c1-4972-b0a1-7602e5fb0ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_96b1f4e3-3918-4703-95b2-59c3cf5dc5bb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_509a1947-f8c1-4972-b0a1-7602e5fb0ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0d37bd88-72e0-469a-bae4-03f875142029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_96b1f4e3-3918-4703-95b2-59c3cf5dc5bb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0d37bd88-72e0-469a-bae4-03f875142029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7a5540c1-bb88-4694-86eb-907242c9353b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_96b1f4e3-3918-4703-95b2-59c3cf5dc5bb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7a5540c1-bb88-4694-86eb-907242c9353b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e4974595-881d-44e1-bce2-6b12417a1f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_96b1f4e3-3918-4703-95b2-59c3cf5dc5bb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e4974595-881d-44e1-bce2-6b12417a1f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0600e2e2-a80e-479b-96fc-5a0013b11136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_96b1f4e3-3918-4703-95b2-59c3cf5dc5bb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0600e2e2-a80e-479b-96fc-5a0013b11136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9ef49cef-48a1-4075-a33a-20fcc45cb0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_96b1f4e3-3918-4703-95b2-59c3cf5dc5bb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9ef49cef-48a1-4075-a33a-20fcc45cb0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b513d66d-50e3-4a79-a1b1-872ae6f05c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_96b1f4e3-3918-4703-95b2-59c3cf5dc5bb" xlink:to="loc_us-gaap_OperatingLeaseLiability_b513d66d-50e3-4a79-a1b1-872ae6f05c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_c30aadd4-25e6-4741-a41e-dd21052cab7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_96b1f4e3-3918-4703-95b2-59c3cf5dc5bb" xlink:to="loc_us-gaap_LeaseCostAbstract_c30aadd4-25e6-4741-a41e-dd21052cab7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_4b527d30-c35f-460f-97f9-bc7098b280d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_c30aadd4-25e6-4741-a41e-dd21052cab7a" xlink:to="loc_us-gaap_OperatingLeasePayments_4b527d30-c35f-460f-97f9-bc7098b280d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fbc4d349-596d-4c72-89a1-be45dcd6c7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_c30aadd4-25e6-4741-a41e-dd21052cab7a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fbc4d349-596d-4c72-89a1-be45dcd6c7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_95c5ce01-60a8-400b-89d6-ed093c3aab6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_c30aadd4-25e6-4741-a41e-dd21052cab7a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_95c5ce01-60a8-400b-89d6-ed093c3aab6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="evlo-20210630.xsd#LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://evelobio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="evlo-20210630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6c66b370-075d-46db-bd61-81e46ec7ce05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_09e7a8f7-3b78-4d53-b3fe-dafda5c8af0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6c66b370-075d-46db-bd61-81e46ec7ce05" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_09e7a8f7-3b78-4d53-b3fe-dafda5c8af0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="evlo-20210630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_96b41c13-22a9-4cd5-81d3-34370b068756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_d4161e04-66c7-41be-a07b-89dde01f23c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_96b41c13-22a9-4cd5-81d3-34370b068756" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_d4161e04-66c7-41be-a07b-89dde01f23c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_417fe4ee-3e8d-433a-9dcc-d86bc9d56e05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_248d32da-d409-43bf-9f84-8e005347aa07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_417fe4ee-3e8d-433a-9dcc-d86bc9d56e05" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_248d32da-d409-43bf-9f84-8e005347aa07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9226bd87-828c-4bee-a358-7685a183dc04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_248d32da-d409-43bf-9f84-8e005347aa07" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9226bd87-828c-4bee-a358-7685a183dc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eef1c9d4-64d7-48e3-981f-87bc48731cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9226bd87-828c-4bee-a358-7685a183dc04" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eef1c9d4-64d7-48e3-981f-87bc48731cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ef6583b1-edfe-4007-a3a6-af38e4099d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eef1c9d4-64d7-48e3-981f-87bc48731cd9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ef6583b1-edfe-4007-a3a6-af38e4099d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f45fee8a-e4f7-4120-b9b9-0ec59c144826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eef1c9d4-64d7-48e3-981f-87bc48731cd9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f45fee8a-e4f7-4120-b9b9-0ec59c144826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1b7becea-adb8-478c-9978-05d61244eff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eef1c9d4-64d7-48e3-981f-87bc48731cd9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1b7becea-adb8-478c-9978-05d61244eff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_cd0c3906-a7ee-430a-85d0-2ed74fb9caa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_248d32da-d409-43bf-9f84-8e005347aa07" xlink:to="loc_us-gaap_FinancialInstrumentAxis_cd0c3906-a7ee-430a-85d0-2ed74fb9caa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8a05e7d6-fa83-4ecd-a33c-8e16e4b819b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_cd0c3906-a7ee-430a-85d0-2ed74fb9caa5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8a05e7d6-fa83-4ecd-a33c-8e16e4b819b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a9fa49f5-7f0a-45b3-86fc-b067ae884eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8a05e7d6-fa83-4ecd-a33c-8e16e4b819b0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a9fa49f5-7f0a-45b3-86fc-b067ae884eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b9e47477-e896-40a8-9625-6387e868c82c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_248d32da-d409-43bf-9f84-8e005347aa07" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b9e47477-e896-40a8-9625-6387e868c82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_9e1dace3-8d54-4fea-9d26-cbb3b63a8bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b9e47477-e896-40a8-9625-6387e868c82c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_9e1dace3-8d54-4fea-9d26-cbb3b63a8bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9f2cde9a-01fb-4e5c-9635-0b7817944c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9e1dace3-8d54-4fea-9d26-cbb3b63a8bb1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9f2cde9a-01fb-4e5c-9635-0b7817944c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7915a04b-4b08-4c7f-b3c2-7b5c1d79e8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9e1dace3-8d54-4fea-9d26-cbb3b63a8bb1" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7915a04b-4b08-4c7f-b3c2-7b5c1d79e8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="evlo-20210630.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8120f1cd-f7e2-4db4-89b9-4b9e8dbf4501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_bd730156-61c6-4e8c-807b-cf900818955c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8120f1cd-f7e2-4db4-89b9-4b9e8dbf4501" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_bd730156-61c6-4e8c-807b-cf900818955c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="evlo-20210630.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dec2bc73-e891-4ce6-a6f4-06c6556c9c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_658b65b3-b1fb-49e8-a35e-df00e3fae45e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_dec2bc73-e891-4ce6-a6f4-06c6556c9c6c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_658b65b3-b1fb-49e8-a35e-df00e3fae45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c955031e-a6fe-459e-8e68-200516329171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2dde0831-475f-478f-b17e-a8007b04a487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c955031e-a6fe-459e-8e68-200516329171" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2dde0831-475f-478f-b17e-a8007b04a487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c960c646-10d4-4831-ac23-ec440a3e30c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2dde0831-475f-478f-b17e-a8007b04a487" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c960c646-10d4-4831-ac23-ec440a3e30c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844b8918-f470-40ec-bc3a-02afc275770e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c960c646-10d4-4831-ac23-ec440a3e30c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844b8918-f470-40ec-bc3a-02afc275770e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_5a4a76bc-7c84-4f23-b17c-8ba44f1e5576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844b8918-f470-40ec-bc3a-02afc275770e" xlink:to="loc_us-gaap_EquipmentMember_5a4a76bc-7c84-4f23-b17c-8ba44f1e5576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_16526191-1227-4fdd-8194-71ddcba3eaad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844b8918-f470-40ec-bc3a-02afc275770e" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_16526191-1227-4fdd-8194-71ddcba3eaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c37e0368-a19a-4acd-8d5d-f3614b8ed6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844b8918-f470-40ec-bc3a-02afc275770e" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c37e0368-a19a-4acd-8d5d-f3614b8ed6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ComputersAndSoftwareMember_a9bea99f-f412-4cdc-90b2-cff69c9e0b18" xlink:href="evlo-20210630.xsd#evlo_ComputersAndSoftwareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844b8918-f470-40ec-bc3a-02afc275770e" xlink:to="loc_evlo_ComputersAndSoftwareMember_a9bea99f-f412-4cdc-90b2-cff69c9e0b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_0473de0d-6e8a-4b39-91d1-9054e2bda24d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844b8918-f470-40ec-bc3a-02afc275770e" xlink:to="loc_us-gaap_OfficeEquipmentMember_0473de0d-6e8a-4b39-91d1-9054e2bda24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_c528230f-7518-4241-beec-4262698ca1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_844b8918-f470-40ec-bc3a-02afc275770e" xlink:to="loc_us-gaap_ConstructionInProgressMember_c528230f-7518-4241-beec-4262698ca1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f2d97037-a195-46e5-89de-c52c7ebd7165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2dde0831-475f-478f-b17e-a8007b04a487" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f2d97037-a195-46e5-89de-c52c7ebd7165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_d46c7e00-6359-448c-9ba2-f66e7edf29f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f2d97037-a195-46e5-89de-c52c7ebd7165" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_d46c7e00-6359-448c-9ba2-f66e7edf29f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5da04a30-5f70-4b36-8e5f-166d96296d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_d46c7e00-6359-448c-9ba2-f66e7edf29f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5da04a30-5f70-4b36-8e5f-166d96296d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8dcf573c-9b2c-459c-86eb-7b9c23ba15da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_d46c7e00-6359-448c-9ba2-f66e7edf29f6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8dcf573c-9b2c-459c-86eb-7b9c23ba15da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_78d99fd0-27ae-448c-926c-81de2d2c4a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_d46c7e00-6359-448c-9ba2-f66e7edf29f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_78d99fd0-27ae-448c-926c-81de2d2c4a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/PropertyandEquipmentNetNarrativeDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#PropertyandEquipmentNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/PropertyandEquipmentNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b576dab4-05cf-464a-88f9-d2d6eeea376b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cafc6eaa-c561-4cb6-87ae-dd35dc08ddca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b576dab4-05cf-464a-88f9-d2d6eeea376b" xlink:to="loc_us-gaap_Depreciation_cafc6eaa-c561-4cb6-87ae-dd35dc08ddca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreements" xlink:type="simple" xlink:href="evlo-20210630.xsd#LoanandSecurityAgreements"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4852fd10-ffb6-4b1d-b44f-0118c0b2e7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_db62ee49-7883-47db-97ec-a76f6bde3b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4852fd10-ffb6-4b1d-b44f-0118c0b2e7ab" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_db62ee49-7883-47db-97ec-a76f6bde3b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsTables" xlink:type="simple" xlink:href="evlo-20210630.xsd#LoanandSecurityAgreementsTables"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b089ee3c-9115-413d-9b8b-dad38d55e5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_52e3c4e6-1086-4434-b585-e408c3931e67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b089ee3c-9115-413d-9b8b-dad38d55e5c8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_52e3c4e6-1086-4434-b585-e408c3931e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_85961dea-50c9-4785-8984-61d803a47fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b089ee3c-9115-413d-9b8b-dad38d55e5c8" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_85961dea-50c9-4785-8984-61d803a47fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#LoanandSecurityAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3f5becac-6526-4c2f-86a8-7c40fc0dfb41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_6cf971a8-e660-4a23-973c-9a90f608b18d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3f5becac-6526-4c2f-86a8-7c40fc0dfb41" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_6cf971a8-e660-4a23-973c-9a90f608b18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_06180536-e11f-4665-9892-fd38fac3e192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6cf971a8-e660-4a23-973c-9a90f608b18d" xlink:to="loc_us-gaap_CreditFacilityAxis_06180536-e11f-4665-9892-fd38fac3e192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_bde2faa4-a402-44e3-b7cb-5600350ea982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_06180536-e11f-4665-9892-fd38fac3e192" xlink:to="loc_us-gaap_CreditFacilityDomain_bde2faa4-a402-44e3-b7cb-5600350ea982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_03246ba7-7ea8-4c0b-b367-44acb687194d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_bde2faa4-a402-44e3-b7cb-5600350ea982" xlink:to="loc_us-gaap_LineOfCreditMember_03246ba7-7ea8-4c0b-b367-44acb687194d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3ae2bd5e-db23-4241-8d67-b7ce78f930ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6cf971a8-e660-4a23-973c-9a90f608b18d" xlink:to="loc_us-gaap_DebtInstrumentAxis_3ae2bd5e-db23-4241-8d67-b7ce78f930ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_67f735a1-2785-472c-af75-bfc69997fe11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3ae2bd5e-db23-4241-8d67-b7ce78f930ed" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_67f735a1-2785-472c-af75-bfc69997fe11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_A2019CreditFacilityMember_027463b8-6034-449a-8105-d9fb3c13b282" xlink:href="evlo-20210630.xsd#evlo_A2019CreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_67f735a1-2785-472c-af75-bfc69997fe11" xlink:to="loc_evlo_A2019CreditFacilityMember_027463b8-6034-449a-8105-d9fb3c13b282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AmendedCreditFacilityMember_511c8c12-3c96-4a87-8a64-9506606b2e7d" xlink:href="evlo-20210630.xsd#evlo_AmendedCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_67f735a1-2785-472c-af75-bfc69997fe11" xlink:to="loc_evlo_AmendedCreditFacilityMember_511c8c12-3c96-4a87-8a64-9506606b2e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_b45820a5-1861-4de6-ab82-ad496175003f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6cf971a8-e660-4a23-973c-9a90f608b18d" xlink:to="loc_us-gaap_VariableRateAxis_b45820a5-1861-4de6-ab82-ad496175003f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b8eb7a1d-5ea3-430d-b9f1-5ff9692dbe87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_b45820a5-1861-4de6-ab82-ad496175003f" xlink:to="loc_us-gaap_VariableRateDomain_b8eb7a1d-5ea3-430d-b9f1-5ff9692dbe87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_0f97a608-a241-4c28-98c0-92cc5b7885e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_b8eb7a1d-5ea3-430d-b9f1-5ff9692dbe87" xlink:to="loc_us-gaap_PrimeRateMember_0f97a608-a241-4c28-98c0-92cc5b7885e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentTrancheAxis_36b40f54-7359-4a42-98ad-5f53dd382216" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentTrancheAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6cf971a8-e660-4a23-973c-9a90f608b18d" xlink:to="loc_evlo_DebtInstrumentTrancheAxis_36b40f54-7359-4a42-98ad-5f53dd382216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentTrancheDomain_6d3c7828-5163-42da-8aa8-655f64238970" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentTrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_DebtInstrumentTrancheAxis_36b40f54-7359-4a42-98ad-5f53dd382216" xlink:to="loc_evlo_DebtInstrumentTrancheDomain_6d3c7828-5163-42da-8aa8-655f64238970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheOneMember_1bef72b7-20fe-4ce2-b0e5-3c41e09031f9" xlink:href="evlo-20210630.xsd#evlo_SecurityAndLoanAgreementTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_DebtInstrumentTrancheDomain_6d3c7828-5163-42da-8aa8-655f64238970" xlink:to="loc_evlo_SecurityAndLoanAgreementTrancheOneMember_1bef72b7-20fe-4ce2-b0e5-3c41e09031f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheTwoMember_5a10e041-9d47-47c7-8c5b-59b20b773192" xlink:href="evlo-20210630.xsd#evlo_SecurityAndLoanAgreementTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_DebtInstrumentTrancheDomain_6d3c7828-5163-42da-8aa8-655f64238970" xlink:to="loc_evlo_SecurityAndLoanAgreementTrancheTwoMember_5a10e041-9d47-47c7-8c5b-59b20b773192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheThreeMember_f25a750d-e579-4ae5-a71e-cf11be9b9326" xlink:href="evlo-20210630.xsd#evlo_SecurityAndLoanAgreementTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_DebtInstrumentTrancheDomain_6d3c7828-5163-42da-8aa8-655f64238970" xlink:to="loc_evlo_SecurityAndLoanAgreementTrancheThreeMember_f25a750d-e579-4ae5-a71e-cf11be9b9326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementTrancheFourMember_9e86f49b-2fea-42fe-bb11-32c398bbfbd2" xlink:href="evlo-20210630.xsd#evlo_SecurityAndLoanAgreementTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_DebtInstrumentTrancheDomain_6d3c7828-5163-42da-8aa8-655f64238970" xlink:to="loc_evlo_SecurityAndLoanAgreementTrancheFourMember_9e86f49b-2fea-42fe-bb11-32c398bbfbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_b8b944bd-4f31-48d9-879f-d4d1da8af50b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6cf971a8-e660-4a23-973c-9a90f608b18d" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_b8b944bd-4f31-48d9-879f-d4d1da8af50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ee92b26a-6706-47c9-8145-19088c2980c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_b8b944bd-4f31-48d9-879f-d4d1da8af50b" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ee92b26a-6706-47c9-8145-19088c2980c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_76689bb8-02d9-49d5-9908-be49bfd4e95d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ee92b26a-6706-47c9-8145-19088c2980c4" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_76689bb8-02d9-49d5-9908-be49bfd4e95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_59f2a1b1-25a8-47ac-b6c2-609bab103ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_76689bb8-02d9-49d5-9908-be49bfd4e95d" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_59f2a1b1-25a8-47ac-b6c2-609bab103ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6cf971a8-e660-4a23-973c-9a90f608b18d" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9c4952e4-778b-4b36-ae08-1ab284edd1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9c4952e4-778b-4b36-ae08-1ab284edd1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SecurityAndLoanAgreementNumberOfTranches_cb133373-c113-4fb8-8f2d-b24a833d9bba" xlink:href="evlo-20210630.xsd#evlo_SecurityAndLoanAgreementNumberOfTranches"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_evlo_SecurityAndLoanAgreementNumberOfTranches_cb133373-c113-4fb8-8f2d-b24a833d9bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a5d1c3c5-d619-44cc-9096-fcd2910b9039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a5d1c3c5-d619-44cc-9096-fcd2910b9039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1dfb16a7-9133-48d9-b3b6-df07db3743ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1dfb16a7-9133-48d9-b3b6-df07db3743ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_793f35be-199b-4c26-a6b1-3b50ac5cd90d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_ConvertibleDebt_793f35be-199b-4c26-a6b1-3b50ac5cd90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_38064b9b-f282-4f14-b7e4-62447591951d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_38064b9b-f282-4f14-b7e4-62447591951d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_faf90482-d11f-4f34-9c4c-219a338b4030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_faf90482-d11f-4f34-9c4c-219a338b4030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_73049182-f3cc-4469-a304-3b9fc3d48a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_73049182-f3cc-4469-a304-3b9fc3d48a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal_8cd8bee7-9e93-4618-85fb-e7227a79682c" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal_8cd8bee7-9e93-4618-85fb-e7227a79682c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage_f0ab9ce3-686e-4856-ad80-dff442218a1f" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage_f0ab9ce3-686e-4856-ad80-dff442218a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne_d2cc0ce0-1b02-4951-8d96-ce1f43196975" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne_d2cc0ce0-1b02-4951-8d96-ce1f43196975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage_e07fbcba-8207-4909-a249-512dff5ad334" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage_e07fbcba-8207-4909-a249-512dff5ad334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_32cd0aa8-24ba-4007-9a69-e86a0fcd0163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_32cd0aa8-24ba-4007-9a69-e86a0fcd0163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_DebtInstrumentDebtDefaultPercentage_07c5edf0-0fe6-4bc5-8a0a-2dab76117063" xlink:href="evlo-20210630.xsd#evlo_DebtInstrumentDebtDefaultPercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_evlo_DebtInstrumentDebtDefaultPercentage_07c5edf0-0fe6-4bc5-8a0a-2dab76117063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditFairValueDisclosure_0cf765fc-e687-462a-8898-31303c83c766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LinesOfCreditFairValueDisclosure"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_LinesOfCreditFairValueDisclosure_0cf765fc-e687-462a-8898-31303c83c766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ClassOfWarrantOrRightFairValueMeasurement_64303ac4-ab47-44a2-a53f-382a831303f2" xlink:href="evlo-20210630.xsd#evlo_ClassOfWarrantOrRightFairValueMeasurement"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_evlo_ClassOfWarrantOrRightFairValueMeasurement_64303ac4-ab47-44a2-a53f-382a831303f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0e140ba8-2cdd-434a-918c-ebc916bd7c52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0e140ba8-2cdd-434a-918c-ebc916bd7c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_3ddecd4d-bee6-48ee-a2a2-52c0e7b34ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_178d4a4b-21c3-4494-914b-f60bc01e6273" xlink:to="loc_us-gaap_InterestExpenseDebt_3ddecd4d-bee6-48ee-a2a2-52c0e7b34ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_84095ff0-f81c-4c3f-895c-77fc9f6ec4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de3798e-8421-49eb-910f-a2d5f490fc19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_84095ff0-f81c-4c3f-895c-77fc9f6ec4e0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de3798e-8421-49eb-910f-a2d5f490fc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea2c7d8c-9aef-4e1a-b79a-c5ff1f6d8917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de3798e-8421-49eb-910f-a2d5f490fc19" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea2c7d8c-9aef-4e1a-b79a-c5ff1f6d8917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8a970123-0ef7-41e9-b4b0-a8f75304e0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea2c7d8c-9aef-4e1a-b79a-c5ff1f6d8917" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8a970123-0ef7-41e9-b4b0-a8f75304e0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8a6f1bb3-b5e4-4ed1-b0be-c435efbda1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8a970123-0ef7-41e9-b4b0-a8f75304e0f6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8a6f1bb3-b5e4-4ed1-b0be-c435efbda1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f81f6944-9b1e-45ef-ad01-c0efa3225d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de3798e-8421-49eb-910f-a2d5f490fc19" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f81f6944-9b1e-45ef-ad01-c0efa3225d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b5249a41-2852-4020-b178-a913cabea841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f81f6944-9b1e-45ef-ad01-c0efa3225d9d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b5249a41-2852-4020-b178-a913cabea841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_d5fc7012-9261-48f2-b2a7-0c6bba9df241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5249a41-2852-4020-b178-a913cabea841" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_d5fc7012-9261-48f2-b2a7-0c6bba9df241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_f1cebc85-5b4b-4c37-a0e5-7e8d6cca6a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b5249a41-2852-4020-b178-a913cabea841" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_f1cebc85-5b4b-4c37-a0e5-7e8d6cca6a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4899be75-1334-4426-8e4d-fffb6466d9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de3798e-8421-49eb-910f-a2d5f490fc19" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4899be75-1334-4426-8e4d-fffb6466d9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_133d0254-23b7-4aae-a31d-8f9123ca85e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4899be75-1334-4426-8e4d-fffb6466d9e1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_133d0254-23b7-4aae-a31d-8f9123ca85e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_420c7842-9e7c-48b9-8cbf-a750b105dc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_133d0254-23b7-4aae-a31d-8f9123ca85e0" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_420c7842-9e7c-48b9-8cbf-a750b105dc5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13c27ff6-253e-449b-a7af-5df04078f8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4de3798e-8421-49eb-910f-a2d5f490fc19" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13c27ff6-253e-449b-a7af-5df04078f8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_c5a16cc3-112d-4c76-847d-0272d365583c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13c27ff6-253e-449b-a7af-5df04078f8c8" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_c5a16cc3-112d-4c76-847d-0272d365583c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#LoanandSecurityAgreementsFairValueofWarrantDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_399ebdc2-6dcb-47f9-9be5-074f3c83c6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bf7314b-749e-40ea-8799-1b4a0aae2d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_399ebdc2-6dcb-47f9-9be5-074f3c83c6d5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bf7314b-749e-40ea-8799-1b4a0aae2d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_8b030dfc-4606-442c-b06d-3109657e2e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bf7314b-749e-40ea-8799-1b4a0aae2d67" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_8b030dfc-4606-442c-b06d-3109657e2e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3b1f79ac-bc3a-4600-b551-ad7338d20eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8b030dfc-4606-442c-b06d-3109657e2e7a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3b1f79ac-bc3a-4600-b551-ad7338d20eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_c4601ba5-36a5-4eab-af80-0306bea09f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3b1f79ac-bc3a-4600-b551-ad7338d20eb9" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_c4601ba5-36a5-4eab-af80-0306bea09f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3b266860-6f17-42aa-a2f5-e3f06368b81f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3b1f79ac-bc3a-4600-b551-ad7338d20eb9" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3b266860-6f17-42aa-a2f5-e3f06368b81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_97a4dbaa-bb1c-4535-8bf8-4be7e0e1217e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3b1f79ac-bc3a-4600-b551-ad7338d20eb9" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_97a4dbaa-bb1c-4535-8bf8-4be7e0e1217e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_a965858a-2c29-4b54-be11-9d432340fcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3b1f79ac-bc3a-4600-b551-ad7338d20eb9" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_a965858a-2c29-4b54-be11-9d432340fcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_ef99f196-72b1-44e9-afd9-fa61e97267bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3b1f79ac-bc3a-4600-b551-ad7338d20eb9" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_ef99f196-72b1-44e9-afd9-fa61e97267bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3e39248-ed66-4076-8363-645d3cc88ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bf7314b-749e-40ea-8799-1b4a0aae2d67" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3e39248-ed66-4076-8363-645d3cc88ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8730127-6cec-4738-bd74-3a4f3235433a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e3e39248-ed66-4076-8363-645d3cc88ebc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8730127-6cec-4738-bd74-3a4f3235433a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6b428d87-5cc5-4c2d-97b8-74143b2145ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8730127-6cec-4738-bd74-3a4f3235433a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6b428d87-5cc5-4c2d-97b8-74143b2145ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_53b968b9-51e0-40bd-9de4-b7db2dda4bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bf7314b-749e-40ea-8799-1b4a0aae2d67" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_53b968b9-51e0-40bd-9de4-b7db2dda4bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d7dd92b-5ea5-4b78-b1fc-f8a334f8c5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_53b968b9-51e0-40bd-9de4-b7db2dda4bb1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d7dd92b-5ea5-4b78-b1fc-f8a334f8c5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5ec29154-86c3-4162-bfbc-ef71a0980993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d7dd92b-5ea5-4b78-b1fc-f8a334f8c5e4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5ec29154-86c3-4162-bfbc-ef71a0980993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25296fbd-c266-496f-82f3-2660098f4c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bf7314b-749e-40ea-8799-1b4a0aae2d67" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25296fbd-c266-496f-82f3-2660098f4c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_e54b4488-f292-4d2e-aa49-69174b823bee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25296fbd-c266-496f-82f3-2660098f4c22" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_e54b4488-f292-4d2e-aa49-69174b823bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d1912253-7b7a-4aa5-9bfa-a5698c2416ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_25296fbd-c266-496f-82f3-2660098f4c22" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d1912253-7b7a-4aa5-9bfa-a5698c2416ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_555fa406-eda2-462a-bc3b-42fe94a98c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_dda2f63e-6ffb-4c61-be5e-d0b07cb6e95e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_555fa406-eda2-462a-bc3b-42fe94a98c5b" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_dda2f63e-6ffb-4c61-be5e-d0b07cb6e95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8f34eaa7-720a-4ffc-a357-3e2628fa422e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dda2f63e-6ffb-4c61-be5e-d0b07cb6e95e" xlink:to="loc_us-gaap_CreditFacilityAxis_8f34eaa7-720a-4ffc-a357-3e2628fa422e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ac31c329-181f-47a0-9f44-19b3c949470c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_8f34eaa7-720a-4ffc-a357-3e2628fa422e" xlink:to="loc_us-gaap_CreditFacilityDomain_ac31c329-181f-47a0-9f44-19b3c949470c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_1c02b9da-5c63-42de-bd46-d296876eca38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_ac31c329-181f-47a0-9f44-19b3c949470c" xlink:to="loc_us-gaap_LineOfCreditMember_1c02b9da-5c63-42de-bd46-d296876eca38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_7f034885-0f7a-4caf-b4e3-6c9c84977e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dda2f63e-6ffb-4c61-be5e-d0b07cb6e95e" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_7f034885-0f7a-4caf-b4e3-6c9c84977e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_4e9d00d1-d5ac-4ab7-bc1b-0b79412c4743" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7f034885-0f7a-4caf-b4e3-6c9c84977e8e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths_4e9d00d1-d5ac-4ab7-bc1b-0b79412c4743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_ea03c4e6-3c66-4724-8ef3-d1f4d7b47f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7f034885-0f7a-4caf-b4e3-6c9c84977e8e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_ea03c4e6-3c66-4724-8ef3-d1f4d7b47f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_dcda0f32-3ffd-496d-9412-d0bf7cc4e1be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7f034885-0f7a-4caf-b4e3-6c9c84977e8e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_dcda0f32-3ffd-496d-9412-d0bf7cc4e1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_45a9fb7d-71d6-490f-b54d-85c469b31aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7f034885-0f7a-4caf-b4e3-6c9c84977e8e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_45a9fb7d-71d6-490f-b54d-85c469b31aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5f5bdbd0-8346-49c5-9d7f-93f67ed60a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7f034885-0f7a-4caf-b4e3-6c9c84977e8e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5f5bdbd0-8346-49c5-9d7f-93f67ed60a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_966e159e-3838-4cc5-a550-0ef9b2fff395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7f034885-0f7a-4caf-b4e3-6c9c84977e8e" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_966e159e-3838-4cc5-a550-0ef9b2fff395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_44348bac-3847-442c-b0d8-201df4e6281b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_7f034885-0f7a-4caf-b4e3-6c9c84977e8e" xlink:to="loc_us-gaap_LongTermDebt_44348bac-3847-442c-b0d8-201df4e6281b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/InLicenseAgreements" xlink:type="simple" xlink:href="evlo-20210630.xsd#InLicenseAgreements"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/InLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_9351b35e-9239-4ba4-90fa-4b319ae2b5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e5cf156f-5aef-486b-8825-6dbd94fdfbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_9351b35e-9239-4ba4-90fa-4b319ae2b5d7" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e5cf156f-5aef-486b-8825-6dbd94fdfbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/InLicenseAgreementsNarrativeDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#InLicenseAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/InLicenseAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0f5edae7-063c-4eb8-a858-bf9ea6d249b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_139793e5-37ea-489c-8af1-b6d1579a9c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0f5edae7-063c-4eb8-a858-bf9ea6d249b5" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_139793e5-37ea-489c-8af1-b6d1579a9c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_262adb84-99d3-4ca8-a6c3-4ff1ea95d5f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_139793e5-37ea-489c-8af1-b6d1579a9c0b" xlink:to="loc_srt_CounterpartyNameAxis_262adb84-99d3-4ca8-a6c3-4ff1ea95d5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5361f55-f4f7-4c22-b90c-8f745e7763e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_262adb84-99d3-4ca8-a6c3-4ff1ea95d5f6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5361f55-f4f7-4c22-b90c-8f745e7763e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MayoClinicMember_645ad14f-156b-408e-b4ff-c7bf467df369" xlink:href="evlo-20210630.xsd#evlo_MayoClinicMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5361f55-f4f7-4c22-b90c-8f745e7763e4" xlink:to="loc_evlo_MayoClinicMember_645ad14f-156b-408e-b4ff-c7bf467df369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_UniversityOfChicagoMember_670426e2-82ca-45d8-a11c-37b48420db60" xlink:href="evlo-20210630.xsd#evlo_UniversityOfChicagoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c5361f55-f4f7-4c22-b90c-8f745e7763e4" xlink:to="loc_evlo_UniversityOfChicagoMember_670426e2-82ca-45d8-a11c-37b48420db60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cf92e782-6366-4d6c-aa3f-37e42a9338d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_139793e5-37ea-489c-8af1-b6d1579a9c0b" xlink:to="loc_srt_RangeAxis_cf92e782-6366-4d6c-aa3f-37e42a9338d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_104f000d-0530-4cb1-9dac-0ac6ef96999f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cf92e782-6366-4d6c-aa3f-37e42a9338d1" xlink:to="loc_srt_RangeMember_104f000d-0530-4cb1-9dac-0ac6ef96999f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3be677dd-c3ab-43c1-a269-22b380add7e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_104f000d-0530-4cb1-9dac-0ac6ef96999f" xlink:to="loc_srt_MaximumMember_3be677dd-c3ab-43c1-a269-22b380add7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_10df4be4-da71-4ced-8803-010c016ff17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_139793e5-37ea-489c-8af1-b6d1579a9c0b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_10df4be4-da71-4ced-8803-010c016ff17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_NonRefundableUpfrontFee_c798b470-2e56-4253-a59e-70a0c727ff73" xlink:href="evlo-20210630.xsd#evlo_NonRefundableUpfrontFee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_10df4be4-da71-4ced-8803-010c016ff17d" xlink:to="loc_evlo_NonRefundableUpfrontFee_c798b470-2e56-4253-a59e-70a0c727ff73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent_f9581c85-7a8a-49e4-ae71-d919fa84cb1f" xlink:href="evlo-20210630.xsd#evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_10df4be4-da71-4ced-8803-010c016ff17d" xlink:to="loc_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent_f9581c85-7a8a-49e4-ae71-d919fa84cb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_ae527528-81df-4a54-9eae-fd753658ec40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_10df4be4-da71-4ced-8803-010c016ff17d" xlink:to="loc_us-gaap_ContractualObligation_ae527528-81df-4a54-9eae-fd753658ec40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts_fd0ac2b8-f91d-45a5-8eca-f52617fd0e1c" xlink:href="evlo-20210630.xsd#evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_10df4be4-da71-4ced-8803-010c016ff17d" xlink:to="loc_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts_fd0ac2b8-f91d-45a5-8eca-f52617fd0e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="evlo-20210630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1e68d2d2-6e3a-48c3-9a7a-8b01b38d02a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_577f8f3f-1641-48aa-95ee-2d930694b082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1e68d2d2-6e3a-48c3-9a7a-8b01b38d02a5" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_577f8f3f-1641-48aa-95ee-2d930694b082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c9c2936a-189c-452d-8b48-7ea9d5f3a3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CommitmentAndContingenciesTable_1040fc7d-96a1-4409-a4d8-5eadbc667d0f" xlink:href="evlo-20210630.xsd#evlo_CommitmentAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c9c2936a-189c-452d-8b48-7ea9d5f3a3f6" xlink:to="loc_evlo_CommitmentAndContingenciesTable_1040fc7d-96a1-4409-a4d8-5eadbc667d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f6190a23-289b-439f-a236-3f852d0e6817" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_CommitmentAndContingenciesTable_1040fc7d-96a1-4409-a4d8-5eadbc667d0f" xlink:to="loc_srt_CounterpartyNameAxis_f6190a23-289b-439f-a236-3f852d0e6817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0563aec1-1fd8-46f6-a0ee-11c4412d22f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f6190a23-289b-439f-a236-3f852d0e6817" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0563aec1-1fd8-46f6-a0ee-11c4412d22f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaccoS.r.l.Member_25ae1663-313e-4ba4-a71c-9b2b6bac40c1" xlink:href="evlo-20210630.xsd#evlo_SaccoS.r.l.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0563aec1-1fd8-46f6-a0ee-11c4412d22f5" xlink:to="loc_evlo_SaccoS.r.l.Member_25ae1663-313e-4ba4-a71c-9b2b6bac40c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fc4dbd0f-d023-4583-87d5-675b89083955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_CommitmentAndContingenciesTable_1040fc7d-96a1-4409-a4d8-5eadbc667d0f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fc4dbd0f-d023-4583-87d5-675b89083955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3d5b33c-2f60-4d4e-ab60-df69f477a8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fc4dbd0f-d023-4583-87d5-675b89083955" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3d5b33c-2f60-4d4e-ab60-df69f477a8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_c72ebd82-ed0c-4177-807d-925835202092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f3d5b33c-2f60-4d4e-ab60-df69f477a8b2" xlink:to="loc_us-gaap_CollaborativeArrangementMember_c72ebd82-ed0c-4177-807d-925835202092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CommitmentAndContingenciesLineItems_cd0f3ce6-ffc0-469d-ba71-3019afc5386c" xlink:href="evlo-20210630.xsd#evlo_CommitmentAndContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_CommitmentAndContingenciesTable_1040fc7d-96a1-4409-a4d8-5eadbc667d0f" xlink:to="loc_evlo_CommitmentAndContingenciesLineItems_cd0f3ce6-ffc0-469d-ba71-3019afc5386c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborationArrangementTerm_ee6d6e5a-7552-44dd-a532-2d789247c5c0" xlink:href="evlo-20210630.xsd#evlo_CollaborationArrangementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_cd0f3ce6-ffc0-469d-ba71-3019afc5386c" xlink:to="loc_evlo_CollaborationArrangementTerm_ee6d6e5a-7552-44dd-a532-2d789247c5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices_935e6d81-1229-43c7-aeaf-4878618e556f" xlink:href="evlo-20210630.xsd#evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_cd0f3ce6-ffc0-469d-ba71-3019afc5386c" xlink:to="loc_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices_935e6d81-1229-43c7-aeaf-4878618e556f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AggregateAmountDueUnderCollaborativeArrangement_53a7548c-a762-47be-b93a-bed5ccb925af" xlink:href="evlo-20210630.xsd#evlo_AggregateAmountDueUnderCollaborativeArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_cd0f3ce6-ffc0-469d-ba71-3019afc5386c" xlink:to="loc_evlo_AggregateAmountDueUnderCollaborativeArrangement_53a7548c-a762-47be-b93a-bed5ccb925af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AnnualAmountDueUnderCollaborativeArrangement_a2c6757a-6e3e-4463-878c-4b26dc8cc4e2" xlink:href="evlo-20210630.xsd#evlo_AnnualAmountDueUnderCollaborativeArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_cd0f3ce6-ffc0-469d-ba71-3019afc5386c" xlink:to="loc_evlo_AnnualAmountDueUnderCollaborativeArrangement_a2c6757a-6e3e-4463-878c-4b26dc8cc4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_FeeIncurredUnderCollaborativeArrangement_7b61da56-93e7-4fa5-93f0-355b3f3aabe8" xlink:href="evlo-20210630.xsd#evlo_FeeIncurredUnderCollaborativeArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evlo_CommitmentAndContingenciesLineItems_cd0f3ce6-ffc0-469d-ba71-3019afc5386c" xlink:to="loc_evlo_FeeIncurredUnderCollaborativeArrangement_7b61da56-93e7-4fa5-93f0-355b3f3aabe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="evlo-20210630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ebd7f0bd-de7e-41ef-a993-7950930b817f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_27b2b64e-6b9f-4ec6-adb7-c2424564545b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ebd7f0bd-de7e-41ef-a993-7950930b817f" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_27b2b64e-6b9f-4ec6-adb7-c2424564545b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_96dee9a9-bca3-452d-a53d-b6d90483829d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c5faa7c5-9831-454d-8571-60fb77dfbd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_96dee9a9-bca3-452d-a53d-b6d90483829d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c5faa7c5-9831-454d-8571-60fb77dfbd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_84a20332-a679-4a14-a194-93513bf1d9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5faa7c5-9831-454d-8571-60fb77dfbd5e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_84a20332-a679-4a14-a194-93513bf1d9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1fcab764-0bdb-47b5-8ed9-0be867a208e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_84a20332-a679-4a14-a194-93513bf1d9dd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1fcab764-0bdb-47b5-8ed9-0be867a208e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RegistrationStatementMember_1cfb462a-2fda-4e04-acd6-0eb854a5177a" xlink:href="evlo-20210630.xsd#evlo_RegistrationStatementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1fcab764-0bdb-47b5-8ed9-0be867a208e4" xlink:to="loc_evlo_RegistrationStatementMember_1cfb462a-2fda-4e04-acd6-0eb854a5177a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AtTheMarketMember_1474d6ec-be02-4035-a9bd-b256ff3ade8b" xlink:href="evlo-20210630.xsd#evlo_AtTheMarketMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1fcab764-0bdb-47b5-8ed9-0be867a208e4" xlink:to="loc_evlo_AtTheMarketMember_1474d6ec-be02-4035-a9bd-b256ff3ade8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_PublicStockOfferingMember_01a37203-86fd-4b42-8d07-41b9ce504e4d" xlink:href="evlo-20210630.xsd#evlo_PublicStockOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1fcab764-0bdb-47b5-8ed9-0be867a208e4" xlink:to="loc_evlo_PublicStockOfferingMember_01a37203-86fd-4b42-8d07-41b9ce504e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_66e5bd89-e989-4a81-ad62-6bd9823cad2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1fcab764-0bdb-47b5-8ed9-0be867a208e4" xlink:to="loc_us-gaap_OverAllotmentOptionMember_66e5bd89-e989-4a81-ad62-6bd9823cad2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_e4af5d24-49fa-43ad-8ce2-bcba33418177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1fcab764-0bdb-47b5-8ed9-0be867a208e4" xlink:to="loc_us-gaap_PrivatePlacementMember_e4af5d24-49fa-43ad-8ce2-bcba33418177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a5af9c27-2399-4f5b-974a-1fd3026f8616" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5faa7c5-9831-454d-8571-60fb77dfbd5e" xlink:to="loc_srt_RangeAxis_a5af9c27-2399-4f5b-974a-1fd3026f8616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bf59f734-bfe7-4a33-8f33-02fe0164e3a2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a5af9c27-2399-4f5b-974a-1fd3026f8616" xlink:to="loc_srt_RangeMember_bf59f734-bfe7-4a33-8f33-02fe0164e3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_58b1c0b3-277b-40db-9e05-663fd6b284e3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bf59f734-bfe7-4a33-8f33-02fe0164e3a2" xlink:to="loc_srt_MinimumMember_58b1c0b3-277b-40db-9e05-663fd6b284e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dd42fe0b-9315-4fa8-9e0d-b430034e62c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bf59f734-bfe7-4a33-8f33-02fe0164e3a2" xlink:to="loc_srt_MaximumMember_dd42fe0b-9315-4fa8-9e0d-b430034e62c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_86065220-5d77-4b47-8ee9-3b2b4dbc0758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5faa7c5-9831-454d-8571-60fb77dfbd5e" xlink:to="loc_us-gaap_CreditFacilityAxis_86065220-5d77-4b47-8ee9-3b2b4dbc0758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8baa5c35-e363-4ebf-aab1-c857c867abed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_86065220-5d77-4b47-8ee9-3b2b4dbc0758" xlink:to="loc_us-gaap_CreditFacilityDomain_8baa5c35-e363-4ebf-aab1-c857c867abed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_12e95ed2-3439-43c3-895f-6898e0395870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_8baa5c35-e363-4ebf-aab1-c857c867abed" xlink:to="loc_us-gaap_LineOfCreditMember_12e95ed2-3439-43c3-895f-6898e0395870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9756645c-849f-4c7f-aa5e-2b5165cafada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5faa7c5-9831-454d-8571-60fb77dfbd5e" xlink:to="loc_us-gaap_DebtInstrumentAxis_9756645c-849f-4c7f-aa5e-2b5165cafada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_215c2d63-fa73-4276-8f69-d7d479c07312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9756645c-849f-4c7f-aa5e-2b5165cafada" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_215c2d63-fa73-4276-8f69-d7d479c07312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_AmendedCreditFacilityMember_47a0c50a-feef-4dcb-908d-88e6b34c58c0" xlink:href="evlo-20210630.xsd#evlo_AmendedCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_215c2d63-fa73-4276-8f69-d7d479c07312" xlink:to="loc_evlo_AmendedCreditFacilityMember_47a0c50a-feef-4dcb-908d-88e6b34c58c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5faa7c5-9831-454d-8571-60fb77dfbd5e" xlink:to="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction_c56a0439-17f8-4dc6-af9d-7598252c8495" xlink:href="evlo-20210630.xsd#evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction_c56a0439-17f8-4dc6-af9d-7598252c8495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockConsiderationReceivedTerm_54afdd97-c418-4fc5-b634-659b352061b5" xlink:href="evlo-20210630.xsd#evlo_SaleOfStockConsiderationReceivedTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_evlo_SaleOfStockConsiderationReceivedTerm_54afdd97-c418-4fc5-b634-659b352061b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e1308244-602e-47a0-9915-81e48735ec95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e1308244-602e-47a0-9915-81e48735ec95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c3261dd9-2fcc-44ae-8bf5-219c274e8201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c3261dd9-2fcc-44ae-8bf5-219c274e8201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e236f530-4454-46f7-a14c-f76975d02682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e236f530-4454-46f7-a14c-f76975d02682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction_24c3fbc7-aa87-4b46-8aaf-f2f4b10f2b09" xlink:href="evlo-20210630.xsd#evlo_SaleOfStockGrossConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction_24c3fbc7-aa87-4b46-8aaf-f2f4b10f2b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50ee7890-f086-4ef6-8a5e-6d9a1dab8163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50ee7890-f086-4ef6-8a5e-6d9a1dab8163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_fde82590-1398-4d04-981a-4eb2bde58d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_fde82590-1398-4d04-981a-4eb2bde58d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_cf166aeb-f712-41cd-a14b-f1443d8d2a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a6da62de-0362-49b9-94d7-0277ebb0d694" xlink:to="loc_us-gaap_ConvertibleDebt_cf166aeb-f712-41cd-a14b-f1443d8d2a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="evlo-20210630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e29aabf9-72b8-4fb2-8f2f-e2d24dd8c27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_20001df0-0da3-4bbb-884a-11a690ee169e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e29aabf9-72b8-4fb2-8f2f-e2d24dd8c27f" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_20001df0-0da3-4bbb-884a-11a690ee169e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="evlo-20210630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_01c3358f-94a5-4c1d-83bc-dc876e356d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6b60650c-e29f-49ae-85f1-d4c895070da3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_01c3358f-94a5-4c1d-83bc-dc876e356d50" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6b60650c-e29f-49ae-85f1-d4c895070da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_00be8474-70b4-43c6-8930-41a8cb8db65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_01c3358f-94a5-4c1d-83bc-dc876e356d50" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_00be8474-70b4-43c6-8930-41a8cb8db65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_a32c8380-9b70-4cf7-8d09-626f11a905b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_01c3358f-94a5-4c1d-83bc-dc876e356d50" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_a32c8380-9b70-4cf7-8d09-626f11a905b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e879658e-9954-4976-af96-b89ee3eccdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4303e8df-b1a2-4170-85c7-d50d0ea0d993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e879658e-9954-4976-af96-b89ee3eccdc3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4303e8df-b1a2-4170-85c7-d50d0ea0d993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_76bcd135-158a-420b-a48c-e7d03d1e1b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4303e8df-b1a2-4170-85c7-d50d0ea0d993" xlink:to="loc_us-gaap_PlanNameAxis_76bcd135-158a-420b-a48c-e7d03d1e1b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8cf96e29-9843-478c-adf3-190e7ac918f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_76bcd135-158a-420b-a48c-e7d03d1e1b88" xlink:to="loc_us-gaap_PlanNameDomain_8cf96e29-9843-478c-adf3-190e7ac918f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_TwoThousandAndTwentyOneStockInducementPlanMember_0572ed88-d791-455d-81a0-bf31a0408420" xlink:href="evlo-20210630.xsd#evlo_TwoThousandAndTwentyOneStockInducementPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8cf96e29-9843-478c-adf3-190e7ac918f9" xlink:to="loc_evlo_TwoThousandAndTwentyOneStockInducementPlanMember_0572ed88-d791-455d-81a0-bf31a0408420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_TwoThousandAndEighteenStockIncentivePlanMember_4ff20a37-ec70-400b-98dc-f663fbdedc8c" xlink:href="evlo-20210630.xsd#evlo_TwoThousandAndEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8cf96e29-9843-478c-adf3-190e7ac918f9" xlink:to="loc_evlo_TwoThousandAndEighteenStockIncentivePlanMember_4ff20a37-ec70-400b-98dc-f663fbdedc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_TwoThousandAndFifteenStockIncentivePlanMember_217feb96-2e24-49ba-878f-a4ca29b12e83" xlink:href="evlo-20210630.xsd#evlo_TwoThousandAndFifteenStockIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8cf96e29-9843-478c-adf3-190e7ac918f9" xlink:to="loc_evlo_TwoThousandAndFifteenStockIncentivePlanMember_217feb96-2e24-49ba-878f-a4ca29b12e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_A2018EmployeeStockPurchasePlanMember_82e12a79-1ad1-4ef9-ae7c-dcf88a4d1f56" xlink:href="evlo-20210630.xsd#evlo_A2018EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8cf96e29-9843-478c-adf3-190e7ac918f9" xlink:to="loc_evlo_A2018EmployeeStockPurchasePlanMember_82e12a79-1ad1-4ef9-ae7c-dcf88a4d1f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eb3463db-9594-44ae-9359-88ce5981e6cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4303e8df-b1a2-4170-85c7-d50d0ea0d993" xlink:to="loc_srt_RangeAxis_eb3463db-9594-44ae-9359-88ce5981e6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1de515c1-8db1-422b-8c1f-ccc16238594a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_eb3463db-9594-44ae-9359-88ce5981e6cc" xlink:to="loc_srt_RangeMember_1de515c1-8db1-422b-8c1f-ccc16238594a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_86a404a8-9b14-4fd8-bfde-13a48557cb7e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1de515c1-8db1-422b-8c1f-ccc16238594a" xlink:to="loc_srt_MaximumMember_86a404a8-9b14-4fd8-bfde-13a48557cb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4f0e649d-9288-46e2-af4b-2e730382bfc1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1de515c1-8db1-422b-8c1f-ccc16238594a" xlink:to="loc_srt_MinimumMember_4f0e649d-9288-46e2-af4b-2e730382bfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5d3d625a-e881-4475-951c-a81b58ef2d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4303e8df-b1a2-4170-85c7-d50d0ea0d993" xlink:to="loc_us-gaap_AwardTypeAxis_5d3d625a-e881-4475-951c-a81b58ef2d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7d236bb-946c-41c2-8d7d-72dc57fffd42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5d3d625a-e881-4475-951c-a81b58ef2d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7d236bb-946c-41c2-8d7d-72dc57fffd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b19f4e63-5044-431e-bc4c-ec7922d4f936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7d236bb-946c-41c2-8d7d-72dc57fffd42" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b19f4e63-5044-431e-bc4c-ec7922d4f936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2f99618d-b5b9-47de-895b-62b1fc398756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7d236bb-946c-41c2-8d7d-72dc57fffd42" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2f99618d-b5b9-47de-895b-62b1fc398756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_528686e6-5fb0-464e-8189-e6592a5ce443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7d236bb-946c-41c2-8d7d-72dc57fffd42" xlink:to="loc_us-gaap_EmployeeStockMember_528686e6-5fb0-464e-8189-e6592a5ce443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_ee779570-e48c-4932-9089-6346f82728a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4303e8df-b1a2-4170-85c7-d50d0ea0d993" xlink:to="loc_us-gaap_GranteeStatusAxis_ee779570-e48c-4932-9089-6346f82728a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_b6de0021-dbda-46ec-b371-5471e0d60c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_ee779570-e48c-4932-9089-6346f82728a5" xlink:to="loc_us-gaap_GranteeStatusDomain_b6de0021-dbda-46ec-b371-5471e0d60c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_f0a4a169-e00c-4237-8b2b-7fb8f8d04775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_b6de0021-dbda-46ec-b371-5471e0d60c3d" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_f0a4a169-e00c-4237-8b2b-7fb8f8d04775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_8fb5f506-e79b-46de-a15d-a4b492d5f154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_b6de0021-dbda-46ec-b371-5471e0d60c3d" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_8fb5f506-e79b-46de-a15d-a4b492d5f154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4303e8df-b1a2-4170-85c7-d50d0ea0d993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0f9fc75f-9db3-42dd-8233-dd7203c3a11d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0f9fc75f-9db3-42dd-8233-dd7203c3a11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3781278a-8d9a-42d3-b04f-2fff5f87aec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3781278a-8d9a-42d3-b04f-2fff5f87aec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7f05d1fe-7481-40ab-8d2d-45faffc68b65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7f05d1fe-7481-40ab-8d2d-45faffc68b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f6b4520a-da41-44cc-b96c-5167d87044f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f6b4520a-da41-44cc-b96c-5167d87044f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_24329e63-a82b-4ff5-82ed-7aa67748907e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_24329e63-a82b-4ff5-82ed-7aa67748907e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d62db98e-3258-4e4b-ab8a-7e60e0096e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d62db98e-3258-4e4b-ab8a-7e60e0096e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c70e9048-d5ec-4ac7-881a-3e368afa46ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c70e9048-d5ec-4ac7-881a-3e368afa46ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5daff043-fbf1-4926-86fa-7d54129ebfab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5daff043-fbf1-4926-86fa-7d54129ebfab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_84ab33e2-edd6-4008-b11f-257ed864f59a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_84ab33e2-edd6-4008-b11f-257ed864f59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted_1fabfb65-ba7f-4a97-acd4-d6d0f8298b7c" xlink:href="evlo-20210630.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted_1fabfb65-ba7f-4a97-acd4-d6d0f8298b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised_837ed281-9bfb-46ae-9210-69f5e867d753" xlink:href="evlo-20210630.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised_837ed281-9bfb-46ae-9210-69f5e867d753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures_2850b796-2257-48aa-b4db-bf580bab71d3" xlink:href="evlo-20210630.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures_2850b796-2257-48aa-b4db-bf580bab71d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased_3e106b33-40a2-4151-a93a-7471f56f7d0b" xlink:href="evlo-20210630.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased_3e106b33-40a2-4151-a93a-7471f56f7d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease_448cc2e1-f983-4dec-9c9d-1ce2959ea2d3" xlink:href="evlo-20210630.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease_448cc2e1-f983-4dec-9c9d-1ce2959ea2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e1038bae-6c48-430c-aa02-ec24b93ea419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e1038bae-6c48-430c-aa02-ec24b93ea419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8f80ec8f-6d6a-4e6a-ad38-d0ccf481c7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8f80ec8f-6d6a-4e6a-ad38-d0ccf481c7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7f2ac5ad-6826-48c0-8e6b-ff5fcc7454d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7f2ac5ad-6826-48c0-8e6b-ff5fcc7454d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_85fe3898-8baf-4fa6-a869-aff143d0b49c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_85fe3898-8baf-4fa6-a869-aff143d0b49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_68d69b61-908b-4bc8-b6b4-d14ff0bc9e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ad259c0-5e31-4f45-93e5-c414023f77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_68d69b61-908b-4bc8-b6b4-d14ff0bc9e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bdb9756c-10a9-4ecb-9ff6-3ac6c9c5d4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3172e74b-ac83-4a44-b83b-ae7567b62149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bdb9756c-10a9-4ecb-9ff6-3ac6c9c5d4d1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3172e74b-ac83-4a44-b83b-ae7567b62149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_681565e8-db55-41db-9bb8-1ae9cd42547e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3172e74b-ac83-4a44-b83b-ae7567b62149" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_681565e8-db55-41db-9bb8-1ae9cd42547e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9952af1a-2b71-46aa-b3e6-cb037ff41591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_681565e8-db55-41db-9bb8-1ae9cd42547e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9952af1a-2b71-46aa-b3e6-cb037ff41591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_148f2a19-e38a-40b9-8b92-db69fa7a4698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9952af1a-2b71-46aa-b3e6-cb037ff41591" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_148f2a19-e38a-40b9-8b92-db69fa7a4698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_913f6d0c-cffb-4f4f-9adf-da743d389d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9952af1a-2b71-46aa-b3e6-cb037ff41591" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_913f6d0c-cffb-4f4f-9adf-da743d389d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_29503b8c-9b3a-4836-9f87-266aff6e3a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3172e74b-ac83-4a44-b83b-ae7567b62149" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_29503b8c-9b3a-4836-9f87-266aff6e3a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6284e6cf-76d1-420a-8f50-1e4aa2ef0686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_29503b8c-9b3a-4836-9f87-266aff6e3a0d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6284e6cf-76d1-420a-8f50-1e4aa2ef0686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#StockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bc5fa4fe-b8de-4413-8495-c689b052222a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7cdb63d1-47f1-4439-9a91-da07b281ca64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bc5fa4fe-b8de-4413-8495-c689b052222a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7cdb63d1-47f1-4439-9a91-da07b281ca64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b11d3bb8-0049-43c6-bfa1-db335abed336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7cdb63d1-47f1-4439-9a91-da07b281ca64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b11d3bb8-0049-43c6-bfa1-db335abed336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d04f7034-5a1f-4189-bd45-3f0d721ae584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7cdb63d1-47f1-4439-9a91-da07b281ca64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d04f7034-5a1f-4189-bd45-3f0d721ae584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_93b32c12-0832-46b2-9db4-ddb85284ed3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7cdb63d1-47f1-4439-9a91-da07b281ca64" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_93b32c12-0832-46b2-9db4-ddb85284ed3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_aca9bffc-21cb-4a8d-998c-0b39c41e1279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7cdb63d1-47f1-4439-9a91-da07b281ca64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_aca9bffc-21cb-4a8d-998c-0b39c41e1279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c18ca11d-fa19-4d54-88eb-3b8c07713f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7cdb63d1-47f1-4439-9a91-da07b281ca64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c18ca11d-fa19-4d54-88eb-3b8c07713f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f78f0426-5c99-4298-941a-7e67c4bc0a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bc5fa4fe-b8de-4413-8495-c689b052222a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f78f0426-5c99-4298-941a-7e67c4bc0a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_adea6253-6ec5-4b21-a20c-a5f594afe99b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bc5fa4fe-b8de-4413-8495-c689b052222a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_adea6253-6ec5-4b21-a20c-a5f594afe99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_73a35886-5ca4-4d6b-97d1-cd2fb8bd1900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_adea6253-6ec5-4b21-a20c-a5f594afe99b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_73a35886-5ca4-4d6b-97d1-cd2fb8bd1900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_49065da9-6510-44c7-80de-81ee131f124d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_adea6253-6ec5-4b21-a20c-a5f594afe99b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_49065da9-6510-44c7-80de-81ee131f124d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_038474d4-f6a5-40be-85b0-38551790d9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_adea6253-6ec5-4b21-a20c-a5f594afe99b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_038474d4-f6a5-40be-85b0-38551790d9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_385b6a4e-00b2-4f85-a7f8-6f52863c51fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_adea6253-6ec5-4b21-a20c-a5f594afe99b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_385b6a4e-00b2-4f85-a7f8-6f52863c51fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5c2dd36d-c648-4f90-b333-bacf85ea15b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_adea6253-6ec5-4b21-a20c-a5f594afe99b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5c2dd36d-c648-4f90-b333-bacf85ea15b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_076ca1d8-53a5-46f8-850c-dad756456c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bc5fa4fe-b8de-4413-8495-c689b052222a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_076ca1d8-53a5-46f8-850c-dad756456c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63ae12d3-1c4e-49e4-9c56-32bd981834e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2e68e3e-c049-40ce-9c5a-0bb10a688539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63ae12d3-1c4e-49e4-9c56-32bd981834e9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2e68e3e-c049-40ce-9c5a-0bb10a688539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2ef7d86c-0644-4421-b8ac-ab2103a6627c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2e68e3e-c049-40ce-9c5a-0bb10a688539" xlink:to="loc_us-gaap_AwardTypeAxis_2ef7d86c-0644-4421-b8ac-ab2103a6627c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_815a4a24-717c-4984-9c7d-4066f0cf9a88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2ef7d86c-0644-4421-b8ac-ab2103a6627c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_815a4a24-717c-4984-9c7d-4066f0cf9a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bb481672-ae16-4745-a957-6f84ecf04025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_815a4a24-717c-4984-9c7d-4066f0cf9a88" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bb481672-ae16-4745-a957-6f84ecf04025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51e9332b-bee2-4ac7-ab45-332ac7d59e74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d2e68e3e-c049-40ce-9c5a-0bb10a688539" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51e9332b-bee2-4ac7-ab45-332ac7d59e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_544df31b-885a-4cd8-9ceb-33a6ccde13eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51e9332b-bee2-4ac7-ab45-332ac7d59e74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_544df31b-885a-4cd8-9ceb-33a6ccde13eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a8e0e5dc-d830-4955-8e99-c7547db7a0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_544df31b-885a-4cd8-9ceb-33a6ccde13eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a8e0e5dc-d830-4955-8e99-c7547db7a0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a37b547e-dad8-4b14-b66d-655ff8637336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_544df31b-885a-4cd8-9ceb-33a6ccde13eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a37b547e-dad8-4b14-b66d-655ff8637336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_37436800-b5d2-49bf-a80a-920271b3ab68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_544df31b-885a-4cd8-9ceb-33a6ccde13eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_37436800-b5d2-49bf-a80a-920271b3ab68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e3d019ef-b433-4ce7-9da0-e7d5b8774ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_544df31b-885a-4cd8-9ceb-33a6ccde13eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e3d019ef-b433-4ce7-9da0-e7d5b8774ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e4443335-714f-43d6-bba1-ff41f277e63a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_544df31b-885a-4cd8-9ceb-33a6ccde13eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e4443335-714f-43d6-bba1-ff41f277e63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d4503e0b-86fe-4827-8ed5-99ce870e6b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51e9332b-bee2-4ac7-ab45-332ac7d59e74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d4503e0b-86fe-4827-8ed5-99ce870e6b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d1ca8561-af39-4e75-b2d6-0ed255e2df41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d4503e0b-86fe-4827-8ed5-99ce870e6b86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d1ca8561-af39-4e75-b2d6-0ed255e2df41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12ed1a65-a156-4ef4-890b-bcb6001cba66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d4503e0b-86fe-4827-8ed5-99ce870e6b86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12ed1a65-a156-4ef4-890b-bcb6001cba66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9c4eda0f-1b75-4916-a2ab-c76aa688a851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d4503e0b-86fe-4827-8ed5-99ce870e6b86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9c4eda0f-1b75-4916-a2ab-c76aa688a851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b74b977f-a0aa-4ee2-86ab-2d1d74447ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d4503e0b-86fe-4827-8ed5-99ce870e6b86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b74b977f-a0aa-4ee2-86ab-2d1d74447ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ba1ba6ab-d33e-4037-bb87-d8aec684e043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d4503e0b-86fe-4827-8ed5-99ce870e6b86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ba1ba6ab-d33e-4037-bb87-d8aec684e043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="evlo-20210630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_83e07bcf-a634-4f42-b599-5ba5a783a5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_b901ebe4-544c-46c5-996f-bd4c04eeee20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_83e07bcf-a634-4f42-b599-5ba5a783a5e5" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_b901ebe4-544c-46c5-996f-bd4c04eeee20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fb2c1d22-887d-4fca-b2ba-f00382737fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_4fc46f76-b5a6-4d4f-b202-6166b56f4c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb2c1d22-887d-4fca-b2ba-f00382737fe4" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_4fc46f76-b5a6-4d4f-b202-6166b56f4c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7773d6d9-cbc2-4fc6-9bb7-89325884fb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_4fc46f76-b5a6-4d4f-b202-6166b56f4c0f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7773d6d9-cbc2-4fc6-9bb7-89325884fb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_913b33af-6bb2-41eb-916c-c8a2c31c8e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7773d6d9-cbc2-4fc6-9bb7-89325884fb5c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_913b33af-6bb2-41eb-916c-c8a2c31c8e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_1964bd41-cf10-4eef-9eed-558b1b459841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_913b33af-6bb2-41eb-916c-c8a2c31c8e6f" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_1964bd41-cf10-4eef-9eed-558b1b459841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_d72af2ed-6ca9-4809-a50c-bc5cf48197f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_913b33af-6bb2-41eb-916c-c8a2c31c8e6f" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_d72af2ed-6ca9-4809-a50c-bc5cf48197f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_f9833cb3-1040-42aa-92ea-b90f8621e695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_4fc46f76-b5a6-4d4f-b202-6166b56f4c0f" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_f9833cb3-1040-42aa-92ea-b90f8621e695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SocialSecurityTaxEmployerDeferralCARESAct_36772b98-a8f0-4bc8-9184-71da31de270e" xlink:href="evlo-20210630.xsd#evlo_SocialSecurityTaxEmployerDeferralCARESAct"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f9833cb3-1040-42aa-92ea-b90f8621e695" xlink:to="loc_evlo_SocialSecurityTaxEmployerDeferralCARESAct_36772b98-a8f0-4bc8-9184-71da31de270e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b5f9f7c-4981-439f-ab3d-4db33bb286b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_f9833cb3-1040-42aa-92ea-b90f8621e695" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9b5f9f7c-4981-439f-ab3d-4db33bb286b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="evlo-20210630.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b05822f9-2470-417d-a324-17171905a4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_c04b425c-7c22-4b61-929f-5d58ae793c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b05822f9-2470-417d-a324-17171905a4a6" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_c04b425c-7c22-4b61-929f-5d58ae793c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="evlo-20210630.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a0d1882b-c375-4c0d-9bdd-6ffad20dbe01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c583852c-f547-4fc2-b30c-a2df811a6523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a0d1882b-c375-4c0d-9bdd-6ffad20dbe01" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c583852c-f547-4fc2-b30c-a2df811a6523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d47523c5-9397-4a83-839c-19ed63499ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_db68c912-5eb2-4f90-a0fb-b49a29ba2ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d47523c5-9397-4a83-839c-19ed63499ffb" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_db68c912-5eb2-4f90-a0fb-b49a29ba2ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a03088a-56fc-449a-b2e5-889a488e71bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_db68c912-5eb2-4f90-a0fb-b49a29ba2ab1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a03088a-56fc-449a-b2e5-889a488e71bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8f93646-d9ac-44e0-ac81-362d01e2acc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a03088a-56fc-449a-b2e5-889a488e71bb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8f93646-d9ac-44e0-ac81-362d01e2acc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_UnvestedCommonStockMember_1fa1631a-6db0-4790-875f-becf35c73911" xlink:href="evlo-20210630.xsd#evlo_UnvestedCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8f93646-d9ac-44e0-ac81-362d01e2acc6" xlink:to="loc_evlo_UnvestedCommonStockMember_1fa1631a-6db0-4790-875f-becf35c73911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c5f6dfc2-ecbe-4e9f-b473-99741772818d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8f93646-d9ac-44e0-ac81-362d01e2acc6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c5f6dfc2-ecbe-4e9f-b473-99741772818d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2625f35e-4aca-410b-b85f-4c2f9d2dbf49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8f93646-d9ac-44e0-ac81-362d01e2acc6" xlink:to="loc_us-gaap_WarrantMember_2625f35e-4aca-410b-b85f-4c2f9d2dbf49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_075c611d-3859-4520-9928-8ae95b8fe483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8f93646-d9ac-44e0-ac81-362d01e2acc6" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_075c611d-3859-4520-9928-8ae95b8fe483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2fcb476a-f826-4762-af45-6fdb8f5308be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e8f93646-d9ac-44e0-ac81-362d01e2acc6" xlink:to="loc_us-gaap_EmployeeStockMember_2fcb476a-f826-4762-af45-6fdb8f5308be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c0bb6f7b-5863-4758-941c-2957f07e7d24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_db68c912-5eb2-4f90-a0fb-b49a29ba2ab1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c0bb6f7b-5863-4758-941c-2957f07e7d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_827bca0b-8dfb-4032-9af7-fefec3dc988e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c0bb6f7b-5863-4758-941c-2957f07e7d24" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_827bca0b-8dfb-4032-9af7-fefec3dc988e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="evlo-20210630.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_44026d7a-b4bf-4b8d-a8a5-883e861cde4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_70f22971-d8ea-4dc4-9c8a-c06d815064e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_44026d7a-b4bf-4b8d-a8a5-883e861cde4c" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_70f22971-d8ea-4dc4-9c8a-c06d815064e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="evlo-20210630.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_7ce88a98-686a-4d7a-98d8-ef389cd22f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47aea146-1cba-4524-a9b0-9f5abee2441f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_7ce88a98-686a-4d7a-98d8-ef389cd22f1e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47aea146-1cba-4524-a9b0-9f5abee2441f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_59d25f8f-e476-428d-a09f-5a59a75a3d15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47aea146-1cba-4524-a9b0-9f5abee2441f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_59d25f8f-e476-428d-a09f-5a59a75a3d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3538fc13-e3f6-4291-816c-ca83ea593053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_59d25f8f-e476-428d-a09f-5a59a75a3d15" xlink:to="loc_us-gaap_RelatedPartyDomain_3538fc13-e3f6-4291-816c-ca83ea593053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_WeatherdenLtdMember_fea4f904-4ec3-4a10-8c6a-4123ab8259c7" xlink:href="evlo-20210630.xsd#evlo_WeatherdenLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3538fc13-e3f6-4291-816c-ca83ea593053" xlink:to="loc_evlo_WeatherdenLtdMember_fea4f904-4ec3-4a10-8c6a-4123ab8259c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_VL46Member_150dd468-f1b3-404b-b8de-048870400c18" xlink:href="evlo-20210630.xsd#evlo_VL46Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3538fc13-e3f6-4291-816c-ca83ea593053" xlink:to="loc_evlo_VL46Member_150dd468-f1b3-404b-b8de-048870400c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_51822be5-f9b2-4eed-8c16-98d823156064" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3538fc13-e3f6-4291-816c-ca83ea593053" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_51822be5-f9b2-4eed-8c16-98d823156064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1c172f82-ab0b-4e60-9c7d-05263c39bd35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47aea146-1cba-4524-a9b0-9f5abee2441f" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1c172f82-ab0b-4e60-9c7d-05263c39bd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_65a42bdf-7d14-40a0-84ff-cae0d76ddb87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1c172f82-ab0b-4e60-9c7d-05263c39bd35" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_65a42bdf-7d14-40a0-84ff-cae0d76ddb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ConsultingAgreementMember_1f8b9b25-6eab-473c-8f36-6b5deb179553" xlink:href="evlo-20210630.xsd#evlo_ConsultingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_65a42bdf-7d14-40a0-84ff-cae0d76ddb87" xlink:to="loc_evlo_ConsultingAgreementMember_1f8b9b25-6eab-473c-8f36-6b5deb179553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_31ab61d5-315a-4e49-9c45-f5f492bb79c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47aea146-1cba-4524-a9b0-9f5abee2441f" xlink:to="loc_us-gaap_AwardTypeAxis_31ab61d5-315a-4e49-9c45-f5f492bb79c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18d5a279-5db0-4836-8d9b-5aea13a357ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_31ab61d5-315a-4e49-9c45-f5f492bb79c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18d5a279-5db0-4836-8d9b-5aea13a357ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_55142e83-f81a-41a3-ab3e-1e784223532c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18d5a279-5db0-4836-8d9b-5aea13a357ec" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_55142e83-f81a-41a3-ab3e-1e784223532c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47aea146-1cba-4524-a9b0-9f5abee2441f" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_b17e1acf-ad75-4104-9e14-3961ad5fb89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_b17e1acf-ad75-4104-9e14-3961ad5fb89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_b5bfdfbf-1d71-4ecb-82c6-198245dd950a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_b5bfdfbf-1d71-4ecb-82c6-198245dd950a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_5cd3754f-3354-4fb8-9c61-8e91ac8adb03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_5cd3754f-3354-4fb8-9c61-8e91ac8adb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_aec2b08b-e1fd-47d0-a9a9-bae0ee7ddf49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_us-gaap_SubleaseIncome_aec2b08b-e1fd-47d0-a9a9-bae0ee7ddf49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm_e0d9e86b-d820-46fd-8b95-d2f3dc10e017" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm_e0d9e86b-d820-46fd-8b95-d2f3dc10e017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm_9ec172de-21a8-4c1c-a97f-adadc22c6ce1" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm_9ec172de-21a8-4c1c-a97f-adadc22c6ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2dc7f9c7-2eb4-412c-96d2-9d2cbc52e123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2dc7f9c7-2eb4-412c-96d2-9d2cbc52e123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments_977dfb01-5155-4b56-950d-94e4be4dd5ab" xlink:href="evlo-20210630.xsd#evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments_977dfb01-5155-4b56-950d-94e4be4dd5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue_391910e6-9ea9-4210-b030-7851e2f7e6fd" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue_391910e6-9ea9-4210-b030-7851e2f7e6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments_c636efdf-84fb-458b-9938-c4840f5c4878" xlink:href="evlo-20210630.xsd#evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments_c636efdf-84fb-458b-9938-c4840f5c4878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionAnnualCashConsultingFee_b21b86e6-3fc9-4494-9ff5-da740a1edaeb" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionAnnualCashConsultingFee"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_evlo_RelatedPartyTransactionAnnualCashConsultingFee_b21b86e6-3fc9-4494-9ff5-da740a1edaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionConsultingContractRenewalTerm_784e875c-56a6-4380-91c1-e7c2c3739286" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionConsultingContractRenewalTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_evlo_RelatedPartyTransactionConsultingContractRenewalTerm_784e875c-56a6-4380-91c1-e7c2c3739286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue_868b34eb-10af-42b3-aa5b-f59805220a3b" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue_868b34eb-10af-42b3-aa5b-f59805220a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod_3e53c8d5-1244-4618-8e11-f71555660809" xlink:href="evlo-20210630.xsd#evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_78554412-4e1e-4d1c-9014-fecfcf187d4b" xlink:to="loc_evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod_3e53c8d5-1244-4618-8e11-f71555660809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>evlo-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:evlo="http://evelobio.com/20210630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="evlo-20210630.xsd" xlink:type="simple"/>
    <context id="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5f6db314b99346ebbead6e9d841d0f45_I20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <instant>2021-07-26</instant>
        </period>
    </context>
    <context id="i21310fe58f274896a1e3326b4c181e8a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1047ebbdeebc4d77b8061fc1199a9403_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i496f247ca1974d999a4a692af25a7310_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia903db629d1f42498076678919475602_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1ad19fa9e57493cbbb0ec828961188a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie0082109a8164d348f4eb2e8bce5f920_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6c148be66be64d989af7e78bf5f7e8d7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i665d710a2f79419090640d7ff83c1e4f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2f497cc4181641a9b457299d6d76b330_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id5474d339e8b4928a498360c356f0674_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6c423f72409a4144b91ea6e7fba1bc55_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i42d970e789bb4ed69e098925d5c8a0c3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1c8dbcdf157a4b2b85173162a11cd155_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i075b5732e8484f448eed30f1294e7346_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i24f9bb3e88f14426994ec8102cb6c5a1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8a9c8fdb6a934f87b09daf63f58245ad_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i68735d053ae34d3daf17984648ece5c5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i65392f8598ed436ebc29041d16bf2d07_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iff63c5d4e86b4a5ca1fe0b493c057332_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i060d039adfbb4d8ab83d6aa4f7896176_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic10cbcf9e0f3462b97277a8c1acc0b01_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i910bfcb82bce48de9eda4ec378464e1d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie0ef059b44c043199b23fba40659d54b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib269a5f35e344a0b841bce34774788d6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i968563ce77b0413db17b14b0756a3fc0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iba4439be2d484dedb8b5567da52d763e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6cb30a9294094ef39b668ef2a3b5440d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i71fefa044970467da0b5615dbc48bb75_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i454196204dfa4d2ea9e26fd433432149_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3c4bac8c6185474aa56292423c6a0d41_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i86b33bf63e00425ab9a0a9ae9659ec7b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4b34c1b61faf48b9bb62d38f5e3f1dbf_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i47ff8e84f8d84df58cf0940f1bc78215_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i058de24e899b4c6da6e959fc62c7250f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i73c5206c27a94431b96f27c4ffdc0c14_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ife2588c54a3d47cab5b870f2e150b48c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i472afffea565444284f0fbc04891b4e7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i35ec3f05885c4394ad39da1354b18446_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic09b152b78114532b0d0a72a5d0cb108_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i96b3bb04ea99475da5fa00256059d7c5_I20190603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:RegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-03</instant>
        </period>
    </context>
    <context id="i98b9be65b14c4e408ab7e4e90ae4e487_D20190603-20190603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:RegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-03</startDate>
            <endDate>2019-06-03</endDate>
        </period>
    </context>
    <context id="ie55b778fc78c4838bd7596f7406fc60a_I20190603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-03</instant>
        </period>
    </context>
    <context id="i010bde50e313426284f4a5003a97bcf6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i76cffaf0b6414a3a83a13544db4cb9c8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0f65daef97744a4e9f23fb6fc142b479_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia8fd128806d244458684e149d6ba270a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i97a49e3e6ef940f7bd323a42dee5db4e_D20210202-20210202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-02</startDate>
            <endDate>2021-02-02</endDate>
        </period>
    </context>
    <context id="i919df7faea17493d83eded85125492f6_I20210202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">evlo:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-02</instant>
        </period>
    </context>
    <context id="ie79b06c6d089457580ee83ab0fc4178c_D20210202-20210202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-02</startDate>
            <endDate>2021-02-02</endDate>
        </period>
    </context>
    <context id="i035578f695544ed4b1cd5c6d23c4dec9_D20210202-20210202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-02</startDate>
            <endDate>2021-02-02</endDate>
        </period>
    </context>
    <context id="i2be50d786c924771a879f8ead446e51e_I20210202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-02</instant>
        </period>
    </context>
    <context id="ib0beb087c81f498590a475a3ae51c18c_D20210317-20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MeddistCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-17</startDate>
            <endDate>2021-03-17</endDate>
        </period>
    </context>
    <context id="idaee624f24ba426fa56b1769371f486f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MeddistCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i39b550ef2206421ab7236b2a064fb4bd_I20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="i244f5424f2ec4fca8f67abaebe241481_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if77f269a0e0f4ac4ba3ac6fabe81d5f7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia81c752f261c4005a844833c47dd60a5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5f28cecd7ac744ffa9db9eccbde588cf_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iffae4009f9494e7a838aac21210c8f97_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i757a3246f9b845c897fa5b6fbdb51641_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i77ada78732004e3bb019864a37b2c2a1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i197c24816d1b446ca101f657ac31cb79_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9451b4b98a6a4654890a9b2dafd8be53_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib3ba13fe044647afa24e9ed23ec77aec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44a958aa41b64d44abd88f59e0828525_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iecbdbafb5b334e01b4cb6165e4b047c6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia80c368b20a040ebac30679ad7b3f3bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i924d154f1d224e19b69e08a1f7497b5f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia6edb25555144d479ada5f406941de92_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icacd72f8312b40c2bfd30c623da239e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i623a78eb6d4049dcad99dc88c1d3a291_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3a72f314a6f1407f9083b56e679da505_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a81873e97c845b084025eedbb21adbc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibc33321abf024a529d8629c6428a7a86_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc6cc6e7c6414c369c9ac7674119f897_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">evlo:ComputersAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i40ecdaafb89540fdbb9ad851b26912d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">evlo:ComputersAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ee77ba9c28c44fe8fb28f1d573090d2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i169ecd01600544e1b2bef1b7ee506185_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i83f266dfe3fb4f89a36d8d7e81051de3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id22668e852ea4c39a1f0366200d33039_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8395b938be7d40d5a8124dea1975de06_I20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-19</instant>
        </period>
    </context>
    <context id="ia9d83da110a8438d9278f2c13f4fc35d_I20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="evlo:DebtInstrumentTrancheAxis">evlo:SecurityAndLoanAgreementTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-19</instant>
        </period>
    </context>
    <context id="i06308d75bfe6481f9b1dc21e9c8b5b6e_I20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="evlo:DebtInstrumentTrancheAxis">evlo:SecurityAndLoanAgreementTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-19</instant>
        </period>
    </context>
    <context id="i2b79658da2214b768872e3db030721a9_I20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="evlo:DebtInstrumentTrancheAxis">evlo:SecurityAndLoanAgreementTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-19</instant>
        </period>
    </context>
    <context id="ia79249ea576049a0a0ea2eee88767eca_I20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="evlo:DebtInstrumentTrancheAxis">evlo:SecurityAndLoanAgreementTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="i16a46e8e0f914f659f755b6f361a3246_I20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="evlo:DebtInstrumentTrancheAxis">evlo:SecurityAndLoanAgreementTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:AmendedCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="ie0b39aa3345f4829bedab97e315cd1cc_D20190719-20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-19</startDate>
            <endDate>2019-07-19</endDate>
        </period>
    </context>
    <context id="i6d8499bfe37347e19717295b49f69b19_D20190719-20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-19</startDate>
            <endDate>2019-07-19</endDate>
        </period>
    </context>
    <context id="id3212be8361644f79ddbc0fc27e74c3d_I20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:AmendedCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-19</instant>
        </period>
    </context>
    <context id="i7e37c8565f494644922932f469c3748e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie40915ff285a4e0ca8014dd9b85400f9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6f257f1155f0451fa58717d6399f50e0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic49bab0cb25344b6bfe44ce28d21e862_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id28c87a274884b02ba4528a21cc51ba2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0e3286835f544983bf8e9e5ef60645a8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icd82a12aaa9b4540a734fd0196a83792_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i36ffcd3447c14d9996b5b94964c58bc7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:AmendedCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2a4ed55838494b35ab23f220a76b8c3b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8a5c6f6b678f44e49e72b10e4ab0fa04_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i70765e47bdc740f0bad65affe0499791_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia4b11afcb9454eceac785c36df755e25_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifea6f295155b467cbdb20351f1ee7713_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evlo:A2019CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie543e908236043ba8be6cd894642aa5a_D20170806-20170806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MayoClinicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-06</startDate>
            <endDate>2017-08-06</endDate>
        </period>
    </context>
    <context id="if17724f9bb3d4db2ba6331a7cac91d1a_D20170806-20170806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MayoClinicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-06</startDate>
            <endDate>2017-08-06</endDate>
        </period>
    </context>
    <context id="i9b9e276c407a458f9f69449a649920dc_D20210630-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MayoClinicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7427f0ed143e4184939402103a418a1a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:MayoClinicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i86362fee842547b9bde5128b9b9d7696_D20160310-20160310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:UniversityOfChicagoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-10</startDate>
            <endDate>2016-03-10</endDate>
        </period>
    </context>
    <context id="i941118753f0c4ff3a809cf847fa3cc04_D20160310-20160310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:UniversityOfChicagoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-10</startDate>
            <endDate>2016-03-10</endDate>
        </period>
    </context>
    <context id="i365ea6e18e0541caa57a11096b3a89a2_D20210630-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:UniversityOfChicagoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i83fa1bd396e94b03ba1d3567b925edf7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:UniversityOfChicagoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i92aa56851c3d4aa1842d25b81d3cf9b9_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:SaccoS.r.l.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i0d31ed85dd8b45629814b83f4f060752_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:SaccoS.r.l.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i164ea06cf00343df9b0f2f326af8a9e6_D20190701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evlo:SaccoS.r.l.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifb6d09c7800f4db9a1cac4fda45089ce_I20210527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndTwentyOneStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-27</instant>
        </period>
    </context>
    <context id="id28aed25ea8f4f7a93a8c6b2b8ce0a14_D20210527-20210527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndTwentyOneStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-27</startDate>
            <endDate>2021-05-27</endDate>
        </period>
    </context>
    <context id="i20e8a93172c24d2e8206286eb8d49a61_D20210630-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndTwentyOneStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i07d88ed7511c4fb488a9c834ac2afc00_D20210630-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndTwentyOneStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i66585702ee8849e499356a9f4a40d9e0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndTwentyOneStockInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6a806946e01c43c7ab029fa63c0a7c9c_I20180508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-08</instant>
        </period>
    </context>
    <context id="i61004b706937441f80332b86f6a1bd00_D20180508-20180508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-08</startDate>
            <endDate>2018-05-08</endDate>
        </period>
    </context>
    <context id="i15a5020b711f4d87bba0d1d0b69566cd_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ic350846ea0d2431d965b88729486c075_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="ic4d990381fac4ad886d7990c63587b3a_D20180508-20180508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-08</startDate>
            <endDate>2018-05-08</endDate>
        </period>
    </context>
    <context id="i9f9dcd078cc74893ab6e630a095c99b4_D20180508-20180508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-08</startDate>
            <endDate>2018-05-08</endDate>
        </period>
    </context>
    <context id="iccf9f430cf7d4c31a2c537f0e85686ac_D20180508-20180508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-08</startDate>
            <endDate>2018-05-08</endDate>
        </period>
    </context>
    <context id="i224b3142ac434b7d8db8a216dec30657_D20180508-20180508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-08</startDate>
            <endDate>2018-05-08</endDate>
        </period>
    </context>
    <context id="ib090cc4aa98c45f4b479a5057e7bfe0a_D20210630-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i14af8565540e4dc6b3cb3fd98d163fef_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8244e41e2b0347a1ad64c9419ce3ec00_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i4760145ee72249da980779ab7e2946dc_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i633b84c50c4f4e7b81b89cb2a278bdee_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i1a92391ffc2e4c5ea7bcfabcb58614d5_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i0b4b46cb61e94103b6de3a962ed2a13b_I20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="ib60b517f490f4972bfa2ed9e3b09a3c0_D20150101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie9c74ef2f71c45ad87a3378e98258fc9_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:TwoThousandAndFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i5e11f538a920421ba186e7c8b1a99dd5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6a6ab7adc80d4824b666be8b229cb0b6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8ac84e56b51542e4a5d75700b09622de_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i46432b66afa646449b4065dc8c030013_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic1b9cbd25a6b46d6a7303f0144b6f001_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic45337ae21d448d582c46b1700091d22_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7fdc9caf00ee42449ae612c261252ddf_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if4ffafae80f64bc194e822d4073442a5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5ba9feb93d764efd96698e68714de654_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie2e1988c04664ea584a4c41ef9af23cc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i20fc0d52b2a44c50902a857e8d3130d5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6bc4ea56ed944d86bdc1c166dd4863c8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i262999f64df4419982435b7d11f2b955_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i729515b40c8f4158b6586a7ae12ab66e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i264242fbfa064d8fbc4066b8f369a883_D20180508-20180508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-08</startDate>
            <endDate>2018-05-08</endDate>
        </period>
    </context>
    <context id="i13be462485cb4baebb145fda3b01ca07_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i57ce7e89580e42e29ea075112fdd665b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i237329bf49a34a118ff127ea889dd7d9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i72fbaf5f78e84aa9be31492a6dfcfb3b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i28b06266364d412583cb80ca61576389_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evlo:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id41c0cbe7c784fe3aab81511b93b8580_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id6fcef2a6164499a8a9a7fbb1013a8a9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia30b6f5d35ce44e69d65001940192f50_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evlo:UnvestedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i498626a92f9c490982d76300e711e00a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evlo:UnvestedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8a7d195f002343acae14514f10c6c103_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i82ff1a0e1f834c328bc95de6abf47cac_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9858c60d7bed47b2814be6df654dc03d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id961f8a7a6d54ba294cfdd02a79a2129_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i39c0f1b46d6e4e668982c302cb6394a9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if0a9f46458db4036b7b2307aa079dda5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iff32a529f86d4871a555686343203169_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i410f08d8ccf041caa3ee3b193f8c60ce_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i53f72d5181794c719cc51cf350c7bdf5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:WeatherdenLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id6b40b59cd064a4ca4af131a12d171b8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:WeatherdenLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic8c74a5ad01f474d8d0477af135c17fb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:WeatherdenLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i31d0e9fb79cb425e871db75394a9796b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:WeatherdenLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2aeea52635454325a295ece2390835bd_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evlo:VL46Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ie19faf0f5e0c4db3b2f52a5594e2b9af_D20210409-20210409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evlo:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-09</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="i9a42be16340a41089a1cd8a571d2ff8e_D20190916-20190916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evlo:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-16</startDate>
            <endDate>2019-09-16</endDate>
        </period>
    </context>
    <context id="ia236d54dd6634fc7a8f1bf3a6bc3d785_I20201015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evlo:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-15</instant>
        </period>
    </context>
    <context id="ia16626e077c84f1a8616489f51dfdabb_D20201015-20201015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evlo:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-15</startDate>
            <endDate>2020-10-15</endDate>
        </period>
    </context>
    <context id="i6986f547b61f46cb9e428885d5c4f66a_D20201011-20201011">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evlo:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-11</startDate>
            <endDate>2020-10-11</endDate>
        </period>
    </context>
    <context id="i7f75681a4eb440c497ad40de810da08d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iaf794c74c50e4917b5636aa96a990418_D20210630-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001694665</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evlo:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>evlo:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="tranche">
        <measure>evlo:tranche</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="installment">
        <measure>evlo:installment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80L2ZyYWc6ODhiNGQ3YzU5YzkwNDgzNDllYzUxNzUxNTdkNGU4NjkvdGFibGU6OWQ5OWNkZWQ3NDYwNDEzN2FkN2EzNTc3MThmMmQ1ZDgvdGFibGVyYW5nZTo5ZDk5Y2RlZDc0NjA0MTM3YWQ3YTM1NzcxOGYyZDVkOF8xLTEtMS0xLTA_3b0acea1-ba32-41ff-ac5d-79706451ecd9">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80L2ZyYWc6ODhiNGQ3YzU5YzkwNDgzNDllYzUxNzUxNTdkNGU4NjkvdGFibGU6OWQ5OWNkZWQ3NDYwNDEzN2FkN2EzNTc3MThmMmQ1ZDgvdGFibGVyYW5nZTo5ZDk5Y2RlZDc0NjA0MTM3YWQ3YTM1NzcxOGYyZDVkOF8yLTEtMS0xLTA_ba18a2ee-5110-4ccc-a7d3-2d202e0c2927">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80L2ZyYWc6ODhiNGQ3YzU5YzkwNDgzNDllYzUxNzUxNTdkNGU4NjkvdGFibGU6OWQ5OWNkZWQ3NDYwNDEzN2FkN2EzNTc3MThmMmQ1ZDgvdGFibGVyYW5nZTo5ZDk5Y2RlZDc0NjA0MTM3YWQ3YTM1NzcxOGYyZDVkOF8zLTEtMS0xLTA_516025ef-21f5-48d0-a25d-efc87e10bc37">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80L2ZyYWc6ODhiNGQ3YzU5YzkwNDgzNDllYzUxNzUxNTdkNGU4NjkvdGFibGU6OWQ5OWNkZWQ3NDYwNDEzN2FkN2EzNTc3MThmMmQ1ZDgvdGFibGVyYW5nZTo5ZDk5Y2RlZDc0NjA0MTM3YWQ3YTM1NzcxOGYyZDVkOF80LTEtMS0xLTA_65598105-9395-4dfa-b98a-a5b65564e40e">0001694665</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80L2ZyYWc6ODhiNGQ3YzU5YzkwNDgzNDllYzUxNzUxNTdkNGU4NjkvdGFibGU6OWQ5OWNkZWQ3NDYwNDEzN2FkN2EzNTc3MThmMmQ1ZDgvdGFibGVyYW5nZTo5ZDk5Y2RlZDc0NjA0MTM3YWQ3YTM1NzcxOGYyZDVkOF81LTEtMS0xLTA_2e8cb2f9-532e-470f-ae5f-7960e7a3edd5">--12-31</dei:CurrentFiscalYearEndDate>
    <evlo:CollaborativeArrangementPeriodOfInactiveManufacturingServices
      contextRef="i92aa56851c3d4aa1842d25b81d3cf9b9_D20190701-20190731"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81OC9mcmFnOjFiNWI1ZTU0NjljZDRiOGJhMmY2ZWIwNTYwMmY0OTI4L3RleHRyZWdpb246MWI1YjVlNTQ2OWNkNGI4YmEyZjZlYjA1NjAyZjQ5MjhfNjgz_325d5ea5-b4c5-433d-9fed-b5f892efb0bc">P6M</evlo:CollaborativeArrangementPeriodOfInactiveManufacturingServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9f9dcd078cc74893ab6e630a095c99b4_D20180508-20180508"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjIwMw_7adb7c68-f638-4357-9bd2-eeb01a3b009e">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4760145ee72249da980779ab7e2946dc_D20150101-20151231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMzYzNw_fddafaeb-2db2-49ee-b233-bca37709f790">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18yMTk5MDIzMjU3Njk3_7182a06e-fbaa-437e-9334-1e704341451b">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6OWZjZWEzNjQyY2Q5NDA0MGIzOWUzMzlhZmNlMjk1MWUvdGFibGVyYW5nZTo5ZmNlYTM2NDJjZDk0MDQwYjM5ZTMzOWFmY2UyOTUxZV8wLTAtMS0xLTA_bf0a7f2b-bd9f-48da-a3ce-0e214f00f637">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18xMjE_9d582d2c-53d9-492e-b7b1-09f74546c7c9">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6MmRjMzFhYmI1NzU3NDllMGI1MDViYTgwOGE4OWJjZTMvdGFibGVyYW5nZToyZGMzMWFiYjU3NTc0OWUwYjUwNWJhODA4YTg5YmNlM18wLTAtMS0xLTA_4e0efa52-7368-4b3c-b916-ed4b8bfe4102">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18yMDI1_97ab6a8f-7701-4bac-bb66-29bfdee8f290">001-38473</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18yMDI2_8539206e-b7a3-4fda-8c6e-2872d10b0ef0">Evelo Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6MGYxYzE1NWFhZWI2NGQ4MmE3NzY5MmQyNjJjZjBhMzEvdGFibGVyYW5nZTowZjFjMTU1YWFlYjY0ZDgyYTc3NjkyZDI2MmNmMGEzMV8wLTAtMS0xLTA_3331ab58-0bee-44a8-b1f3-197f0c6411fc">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6MGYxYzE1NWFhZWI2NGQ4MmE3NzY5MmQyNjJjZjBhMzEvdGFibGVyYW5nZTowZjFjMTU1YWFlYjY0ZDgyYTc3NjkyZDI2MmNmMGEzMV8wLTItMS0xLTA_fd3f2971-3df5-4676-98f5-b79547bee653">46-5594527</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6MGYxYzE1NWFhZWI2NGQ4MmE3NzY5MmQyNjJjZjBhMzEvdGFibGVyYW5nZTowZjFjMTU1YWFlYjY0ZDgyYTc3NjkyZDI2MmNmMGEzMV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoxMDk1YjRiODQyOTA0MmM5OWQ4YzFmNjMwODg5ODVlMV80_2483dfa9-8c90-46a9-ae27-00e928a14379">620 Memorial Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6MGYxYzE1NWFhZWI2NGQ4MmE3NzY5MmQyNjJjZjBhMzEvdGFibGVyYW5nZTowZjFjMTU1YWFlYjY0ZDgyYTc3NjkyZDI2MmNmMGEzMV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoxMDk1YjRiODQyOTA0MmM5OWQ4YzFmNjMwODg5ODVlMV83_62977f2c-0a1f-4ff7-90d8-2541c90b2580">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6MGYxYzE1NWFhZWI2NGQ4MmE3NzY5MmQyNjJjZjBhMzEvdGFibGVyYW5nZTowZjFjMTU1YWFlYjY0ZDgyYTc3NjkyZDI2MmNmMGEzMV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoxMDk1YjRiODQyOTA0MmM5OWQ4YzFmNjMwODg5ODVlMV8xMQ_c927e46a-1db7-4377-8daa-58201b59e365">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6MGYxYzE1NWFhZWI2NGQ4MmE3NzY5MmQyNjJjZjBhMzEvdGFibGVyYW5nZTowZjFjMTU1YWFlYjY0ZDgyYTc3NjkyZDI2MmNmMGEzMV8zLTItMS0xLTA_37fc9723-c5e0-4cc1-98e1-64c4e7eafde8">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18yMDI3_f47723dc-fc75-43ed-bf42-ed807c1802f8">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18yMDI4_2c82b4ea-adf8-4d0d-968e-55837f7e977b">577-0300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6YTcyMzBhYjU1NDRiNGM1M2EyYjJlNGVkMWFlZWU1MTQvdGFibGVyYW5nZTphNzIzMGFiNTU0NGI0YzUzYTJiMmU0ZWQxYWVlZTUxNF8yLTAtMS0xLTA_9d0e31a9-8b9c-40bf-a2c5-08f87badbc5a">Common Stock,$0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6YTcyMzBhYjU1NDRiNGM1M2EyYjJlNGVkMWFlZWU1MTQvdGFibGVyYW5nZTphNzIzMGFiNTU0NGI0YzUzYTJiMmU0ZWQxYWVlZTUxNF8yLTItMS0xLTA_c3ab9d7d-7c6f-4445-b0a3-e7c540da04bb">EVLO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6YTcyMzBhYjU1NDRiNGM1M2EyYjJlNGVkMWFlZWU1MTQvdGFibGVyYW5nZTphNzIzMGFiNTU0NGI0YzUzYTJiMmU0ZWQxYWVlZTUxNF8yLTQtMS0xLTA_f792338c-d06a-4cc1-93ce-e13734fa3665">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18yMDI5_3fcd2ffa-293b-42f6-ac8c-29ec303445b5">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18yMDMw_455b5bec-abd0-479f-be11-5c5cd0bd8218">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6ZTg5ZWE5MGIzZjdmNGE4ZjhlZTNlY2FhODRiMTI2ZWIvdGFibGVyYW5nZTplODllYTkwYjNmN2Y0YThmOGVlM2VjYWE4NGIxMjZlYl8yLTAtMS0xLTA_fcace697-e0de-4b2b-a2f9-a93b055c07d0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6ZTg5ZWE5MGIzZjdmNGE4ZjhlZTNlY2FhODRiMTI2ZWIvdGFibGVyYW5nZTplODllYTkwYjNmN2Y0YThmOGVlM2VjYWE4NGIxMjZlYl8yLTYtMS0xLTA_c8fb7638-7fe5-4a2e-bacb-b277c3a80e66">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGFibGU6ZTg5ZWE5MGIzZjdmNGE4ZjhlZTNlY2FhODRiMTI2ZWIvdGFibGVyYW5nZTplODllYTkwYjNmN2Y0YThmOGVlM2VjYWE4NGIxMjZlYl80LTYtMS0xLTA_6108f659-525f-4d5c-a28d-d8b349184d3c">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18yMDIz_a0c18e15-1693-4b58-90ad-07f837eb20e7">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18yMDI0_4f0d105f-84d9-4a7e-b868-fa09127fdcca">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i5f6db314b99346ebbead6e9d841d0f45_I20210726"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xL2ZyYWc6ZDE3MDNjZmJkYTE0NDc5NGI0ODRlOWMwZGMxOTRiMGMvdGV4dHJlZ2lvbjpkMTcwM2NmYmRhMTQ0Nzk0YjQ4NGU5YzBkYzE5NGIwY18xNDI5MzY1MTE2NDA1Mg_d661b22d-9acb-42b1-94d2-71216222f369"
      unitRef="shares">53398292</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMy0yLTEtMS0w_dda79b86-f70f-4891-bcbf-ec9b2421fbee"
      unitRef="usd">123333000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMy00LTEtMS0w_d2a3a5f5-fddd-4b34-ad6a-2ab0ae2ce711"
      unitRef="usd">68857000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfNC0yLTEtMS0w_0dd175d1-174d-48ca-a8d5-4ccf91330cb4"
      unitRef="usd">3034000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfNC00LTEtMS0w_024ebe4e-410c-4c91-8f2b-b954d037564e"
      unitRef="usd">2123000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfNi0yLTEtMS0w_d2969df0-6c9e-4a76-8d5e-749deb894907"
      unitRef="usd">126367000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfNi00LTEtMS0w_d7ff23ca-5bcc-461d-bd21-a2a082679e55"
      unitRef="usd">70980000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfNy0yLTEtMS0w_88842991-607a-4ecc-a725-4a7ca46526cc"
      unitRef="usd">7520000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfNy00LTEtMS0w_765a13c2-738c-4f32-b22a-3b9b194e78c8"
      unitRef="usd">7478000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfOC0yLTEtMS0w_e4099355-ed3b-4903-a245-fa38d6d14101"
      unitRef="usd">9856000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfOC00LTEtMS0w_e101c4b3-1a80-4aaf-8d16-131aafe64b86"
      unitRef="usd">10757000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfOS0yLTEtMS0w_096e0aa5-04f1-4e35-987f-e8306a4ce820"
      unitRef="usd">1315000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfOS00LTEtMS0w_f18f5371-38a2-4533-b84e-f3d04183e7ef"
      unitRef="usd">1424000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTAtMi0xLTEtMA_8b777aac-800e-4c89-8372-298d5812d11e"
      unitRef="usd">145058000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTAtNC0xLTEtMA_ebde4d00-d544-4bff-b7aa-5c42036cdc4d"
      unitRef="usd">90639000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTMtMi0xLTEtMA_37c74168-aa33-46f2-9ce0-3fe02546854e"
      unitRef="usd">2319000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTMtNC0xLTEtMA_d6beb803-1ddf-473c-b0ee-535dba92eced"
      unitRef="usd">1442000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTQtMi0xLTEtMA_80b762e1-80cf-4582-8626-524b58717a82"
      unitRef="usd">15011000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTQtNC0xLTEtMA_70db11ee-b00d-410c-acf4-e0b6eef3bdd3"
      unitRef="usd">16254000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTUtMi0xLTEtMA_c2b2ac62-67f3-4b87-9fe8-e0d53b4f6f37"
      unitRef="usd">1812000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTUtNC0xLTEtMA_fc3bd21b-5756-493f-979e-d3e831108ffa"
      unitRef="usd">1674000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTctMi0xLTEtMA_26b45fb9-dc67-43e2-85a7-942e03822da9"
      unitRef="usd">654000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTctNC0xLTEtMA_243970f9-8b6c-44c6-b865-f6ab05596188"
      unitRef="usd">463000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTgtMi0xLTEtMA_0929ffd7-9ed1-4438-837d-7e692401ae79"
      unitRef="usd">19796000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMTgtNC0xLTEtMA_5e69bf12-57cc-4074-9f90-71c0f1274ea3"
      unitRef="usd">19833000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjAtMi0xLTEtMA_db12ae54-68af-49d2-8880-09c9808146d7"
      unitRef="usd">46482000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjAtNC0xLTEtMA_f14a730d-5229-4973-a47e-ae97db5c511c"
      unitRef="usd">30048000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjEtMi0xLTEtMA_7f2dd450-cb0d-4a93-881b-cc41cc38575d"
      unitRef="usd">8924000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjEtNC0xLTEtMA_223e7f22-5a0b-49a5-a5d4-55136f380254"
      unitRef="usd">9989000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjItMi0xLTEtMA_4f433e18-489d-4a63-8007-ccbdd363d2d6"
      unitRef="usd">7500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjItNC0xLTEtMA_e7a752c1-2207-4102-81d8-2a6cc31ecf52"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjMtMi0xLTEtMA_f0cef2ca-82bd-4e51-a8c8-a9b7acb40ef5"
      unitRef="usd">263000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjMtNC0xLTEtMA_54620b03-b337-4c06-93ad-3f3250144d57"
      unitRef="usd">284000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjQtMi0xLTEtMA_d50311da-8a06-4b93-88d7-0cb45614ccf1"
      unitRef="usd">82965000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjQtNC0xLTEtMA_a0511074-d86e-4c0c-b047-75d99e9497eb"
      unitRef="usd">60154000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjUtMi0xLTEtMA_ad29c89d-b0c0-4dae-9502-0745fb2f8238"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjUtNC0xLTEtMA_7cff6040-ba04-49df-9808-c2facb3b5928"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjY1ZDNjNjZhZjdiZjRmNTc4ZmM0MmU3Nzk0YWJkNzc2XzIx_0d2b42ea-27f4-431b-b795-9e77430d3fc2"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjY1ZDNjNjZhZjdiZjRmNTc4ZmM0MmU3Nzk0YWJkNzc2XzIx_5cb8b1d2-e04c-4b3d-a338-ed3d4443b182"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjY1ZDNjNjZhZjdiZjRmNTc4ZmM0MmU3Nzk0YWJkNzc2XzM1_35696a61-a6fc-46bd-8a21-da175728e297"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjY1ZDNjNjZhZjdiZjRmNTc4ZmM0MmU3Nzk0YWJkNzc2XzM1_3e2bbe71-6245-440b-938e-9ac7ba0f6b52"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjY1ZDNjNjZhZjdiZjRmNTc4ZmM0MmU3Nzk0YWJkNzc2XzU3_043f1a67-0d0d-46f4-a52c-c6783695a310"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjY1ZDNjNjZhZjdiZjRmNTc4ZmM0MmU3Nzk0YWJkNzc2XzU3_4ef630fe-0b04-4e3e-9552-b345ace38b65"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjY1ZDNjNjZhZjdiZjRmNTc4ZmM0MmU3Nzk0YWJkNzc2XzU3_5f3765f1-048b-4782-adfd-b3fe0de2bfa3"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjY1ZDNjNjZhZjdiZjRmNTc4ZmM0MmU3Nzk0YWJkNzc2XzU3_a3051940-8f28-457c-80e2-b37a50b4311f"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctMi0xLTEtMA_dd66bfd9-5b33-4204-8979-9b973be7430e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjctNC0xLTEtMA_4ece9b7e-9559-4ca5-9726-201af86fc97e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmVmYWMwZGQwZTAwYTQ0ZTRiMzU2MGYxMGJmY2Q1MTM4XzE4_3bd5b857-a586-4cb4-a2c7-00eb47647f8f"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmVmYWMwZGQwZTAwYTQ0ZTRiMzU2MGYxMGJmY2Q1MTM4XzE4_e7a2f3c8-9a6a-4053-b9f3-18cd63ac48b0"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmVmYWMwZGQwZTAwYTQ0ZTRiMzU2MGYxMGJmY2Q1MTM4XzMy_70412eaa-17e6-4584-b3e4-77fdb1348d73"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmVmYWMwZGQwZTAwYTQ0ZTRiMzU2MGYxMGJmY2Q1MTM4XzMy_8aa88247-7f4c-42c2-a7e0-7c876a1f9e66"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmVmYWMwZGQwZTAwYTQ0ZTRiMzU2MGYxMGJmY2Q1MTM4XzU0_736d8ff4-0b7e-4d43-b84f-57eda06492ed"
      unitRef="shares">53416657</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmVmYWMwZGQwZTAwYTQ0ZTRiMzU2MGYxMGJmY2Q1MTM4XzYx_c0701d55-deb7-4263-8714-c82ccffbbe91"
      unitRef="shares">47488505</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmVmYWMwZGQwZTAwYTQ0ZTRiMzU2MGYxMGJmY2Q1MTM4Xzgy_ef98fec4-a987-4aff-97b1-80011223e557"
      unitRef="shares">53398271</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmVmYWMwZGQwZTAwYTQ0ZTRiMzU2MGYxMGJmY2Q1MTM4Xzg5_f2c39827-38bc-4760-aa08-9d9f30101839"
      unitRef="shares">47470119</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtMi0xLTEtMA_dcea001f-ff7e-4a07-9572-41aa177be348"
      unitRef="usd">53000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjgtNC0xLTEtMA_f1cc6077-c2e9-4495-a7f5-4de12b7f5d03"
      unitRef="usd">47000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjktMi0xLTEtMA_9bd8294a-da1f-4b1c-a572-e2a17764f789"
      unitRef="usd">414353000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMjktNC0xLTEtMA_a17e4aeb-6c7a-4f50-921b-883d54457525"
      unitRef="usd">322957000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMzAtMi0xLTEtMA_4f41017f-1232-4699-8f95-0ab9883565bd"
      unitRef="usd">-352313000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMzAtNC0xLTEtMA_3adb8c88-bc98-4251-a1b2-c85ec55c7199"
      unitRef="usd">-292519000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMzEtMi0xLTEtMA_12d30343-2d1a-48ba-8600-25a5289797e7"
      unitRef="usd">62093000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMzEtNC0xLTEtMA_3cce9be7-864e-46c2-9a88-dcaa8b656dd1"
      unitRef="usd">30485000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMzItMi0xLTEtMA_2bba43dd-bae2-4b99-a1f0-283d3e0fcfe6"
      unitRef="usd">145058000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8xOS9mcmFnOjFiMjlhZTNhYzIwZDQ2YTA4YTI5ZWY4ODYwMGUzYWQ4L3RhYmxlOmRkYzg5ODgyNmVhMTQzZTk4YjMwYTE5NDA5OWU4YTFmL3RhYmxlcmFuZ2U6ZGRjODk4ODI2ZWExNDNlOThiMzBhMTk0MDk5ZThhMWZfMzItNC0xLTEtMA_1998d953-b229-489f-ac55-2dae895355e9"
      unitRef="usd">90639000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMy0yLTEtMS0w_a47220fb-b320-4930-8842-c4e181a9aa94"
      unitRef="usd">20655000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMy00LTEtMS0w_045e5ca0-fa88-4cdf-b13e-af5aa14d20b4"
      unitRef="usd">15174000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMy02LTEtMS05Mg_27e1be46-3ee4-4fb8-8abd-74f2086c6394"
      unitRef="usd">42163000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMy04LTEtMS05Mg_150dd201-a47a-4932-84fa-492c2d44cbc5"
      unitRef="usd">32593000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNC0yLTEtMS0w_1fc4e3d2-def6-4b04-a58d-7f8a1b95c4f2"
      unitRef="usd">7001000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNC00LTEtMS0w_640b2856-aa5b-4f28-8b3e-4dc35a17f2d8"
      unitRef="usd">5071000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNC02LTEtMS05Mg_cdbdd19f-43f4-4749-8cba-69d16d68071e"
      unitRef="usd">12964000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNC04LTEtMS05Mg_7e293495-dbb3-4dee-90d4-79b3ef6210da"
      unitRef="usd">10913000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNS0yLTEtMS0w_d6a21f03-34c8-4ac0-85de-4573b55caa0e"
      unitRef="usd">27656000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNS00LTEtMS0w_6d807f8a-e0e4-4cea-8781-ef4d37847b28"
      unitRef="usd">20245000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNS02LTEtMS05Mg_2fc7172b-58d3-4f10-bb42-e70b4bec8e7f"
      unitRef="usd">55127000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNS04LTEtMS05Mg_894b4d3a-67ea-4fee-b639-b7abc5d9bf00"
      unitRef="usd">43506000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNi0yLTEtMS0w_07f615eb-2373-400a-933a-02ca3b223359"
      unitRef="usd">-27656000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNi00LTEtMS0w_1eb2319f-5058-4a0e-a683-2ad685466a1a"
      unitRef="usd">-20245000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNi02LTEtMS05Mg_db18447f-9aee-4ed6-b612-ec6e44868867"
      unitRef="usd">-55127000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfNi04LTEtMS05Mg_f7ce4f6d-eafb-46d4-a286-670d29fed2fe"
      unitRef="usd">-43506000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOC0yLTEtMS0w_90a48300-8729-45ef-a448-cd7cb4017165"
      unitRef="usd">-814000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOC00LTEtMS0w_6d57c8e1-17f2-4328-af99-8c4ad13cd091"
      unitRef="usd">-458000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOC02LTEtMS05Mg_7ede3d98-0d3a-4940-b583-7e92d53e8616"
      unitRef="usd">-1579000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOC04LTEtMS05Mg_d2dd1c92-2d58-4e9c-8600-8a800ae14c2b"
      unitRef="usd">-639000</us-gaap:InvestmentIncomeNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOS0yLTEtMS0xNDgz_4bf95a20-ae21-4534-9021-2db0080192e0"
      unitRef="usd">-3226000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOS00LTEtMS0xNDgz_c0239658-f8ab-4261-b04b-ebe220d0d1ae"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOS02LTEtMS0xNDgz_a7236d53-3f47-446d-a522-45d08379f880"
      unitRef="usd">-3226000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOS04LTEtMS0xNDgz_32a1d8b3-3cec-423b-8fbc-dae1378438f8"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOS0yLTEtMS0w_5a1585c9-8526-4c8f-87e5-78e40e0d8236"
      unitRef="usd">151000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOS00LTEtMS0w_549cb445-532b-4ee0-af12-604a3d6a02b6"
      unitRef="usd">140000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOS02LTEtMS05Mg_3316674f-d1e6-4b93-b9a2-5d24edf7a587"
      unitRef="usd">313000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfOS04LTEtMS05Mg_43443a7e-c197-4903-a9b9-38cc4ddac287"
      unitRef="usd">606000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTAtMi0xLTEtMA_abd77e25-0841-49cd-996a-02da25601742"
      unitRef="usd">-3889000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTAtNC0xLTEtMA_e6257006-aa1f-493a-9f0c-98ab5e466027"
      unitRef="usd">-318000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTAtNi0xLTEtOTI_5fd3decd-4762-4b99-97ad-90722f39c67d"
      unitRef="usd">-4492000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTAtOC0xLTEtOTI_b20ffd15-223e-49d7-b765-d08630b900df"
      unitRef="usd">-33000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTEtMi0xLTEtMA_ffbe2ad8-18b8-48f7-8476-7ec21047ee50"
      unitRef="usd">-31545000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTEtNC0xLTEtMA_06fb3abb-46ac-4561-b85f-d7b88b974285"
      unitRef="usd">-20563000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTEtNi0xLTEtOTI_2dd0af40-3486-4c35-aa7b-e3503d897283"
      unitRef="usd">-59619000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTEtOC0xLTEtOTI_1a7b335b-62b4-43e1-a620-8d265c86a603"
      unitRef="usd">-43539000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTItMi0xLTEtMA_eabdeba6-5a63-42af-a772-458c82f8dbeb"
      unitRef="usd">53000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTItNC0xLTEtMA_5a15679f-150d-4202-b3dd-07d1882f3599"
      unitRef="usd">89000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTItNi0xLTEtOTI_fa145e2f-62c4-46e7-b8f8-678d70dfca7e"
      unitRef="usd">175000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTItOC0xLTEtOTI_bb6be2ed-01c4-40ca-a898-aae7d9f15b86"
      unitRef="usd">154000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTMtMi0xLTEtMA_4fab678f-eacb-4537-b52f-57ae3bb55cf0"
      unitRef="usd">-31598000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTMtNC0xLTEtMA_cdae8442-5842-4209-8af6-b038000c1ff0"
      unitRef="usd">-20652000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTQtNi0xLTEtOTI_da3388f6-aa2c-4dff-a533-79ba920b6504"
      unitRef="usd">-59794000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTQtOC0xLTEtOTI_c95df018-4943-4f05-81fa-a2dd83b3e373"
      unitRef="usd">-43693000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTUtMi0xLTEtMA_48dfeff7-88dc-422a-b1fd-66d871509f70"
      unitRef="usdPerShare">-0.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTUtMi0xLTEtMA_f5b62f25-b08d-41d8-ba37-868ba3070f46"
      unitRef="usdPerShare">-0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTUtNC0xLTEtMA_3a6e8721-e919-49d9-8ce5-c505b6afd2fd"
      unitRef="usdPerShare">-0.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTUtNC0xLTEtMA_8db5f595-785b-42e4-837c-2d6fe44350ef"
      unitRef="usdPerShare">-0.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTUtNi0xLTEtOTk_666b9601-a218-4d63-a033-d9ddff296f70"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTUtNi0xLTEtOTk_bd70bc65-65e8-48cd-b765-d6ec4dfeb50a"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTUtOC0xLTEtOTk_3215b07b-f47a-4210-a516-5cdbdb0dd802"
      unitRef="usdPerShare">-1.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTUtOC0xLTEtOTk_d880a7a7-5153-4e68-ad1a-85daeb7def9a"
      unitRef="usdPerShare">-1.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTYtMi0xLTEtMA_83e15df6-7071-4306-8fe6-93dcec901256"
      unitRef="shares">53379415</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTYtMi0xLTEtMA_bd460c1b-a45b-46b4-b3c7-2ce676d1df26"
      unitRef="shares">53379415</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTYtNC0xLTEtMA_4f4e186c-e1a0-433d-9d90-b8cb761a699d"
      unitRef="shares">32634468</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTYtNC0xLTEtMA_be17a49e-e0ae-4433-83b5-d87b471a06f8"
      unitRef="shares">32634468</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTYtNi0xLTEtOTk_6591539c-037d-4a25-8e8f-79bf4220371f"
      unitRef="shares">52340608</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTYtNi0xLTEtOTk_740526f1-7b8f-45c7-b4d6-f24c9b859e0d"
      unitRef="shares">52340608</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTYtOC0xLTEtOTk_e1e3ac14-f738-4ed4-b5be-cf207a66f9eb"
      unitRef="shares">32442259</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yMi9mcmFnOjQyMTA3NTc3NjQ4YzQ3MWVhYTMyNTBhNzViMmQxOGFlL3RhYmxlOjdmZThlMjYwMzA1MTRiZmNhYmQyZDQxOTQ2MDI0OTNjL3RhYmxlcmFuZ2U6N2ZlOGUyNjAzMDUxNGJmY2FiZDJkNDE5NDYwMjQ5M2NfMTYtOC0xLTEtOTk_f702251e-15f3-44ff-9577-2859b67f8f37"
      unitRef="shares">32442259</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i1047ebbdeebc4d77b8061fc1199a9403_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMi0yLTEtMS0w_c21d36fb-a40e-43d5-8ad0-c82da7cc0071"
      unitRef="shares">47470119</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1047ebbdeebc4d77b8061fc1199a9403_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMi00LTEtMS0w_929c77d7-3baa-4e24-b70d-cd3999ff4341"
      unitRef="usd">47000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i496f247ca1974d999a4a692af25a7310_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMi02LTEtMS0w_e58e1aca-ebe6-4972-988f-80683cdac05d"
      unitRef="usd">322957000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia903db629d1f42498076678919475602_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMi04LTEtMS0w_9e89eb5f-62e6-4f9c-8d30-126cd119dfcb"
      unitRef="usd">-292519000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMi0xMC0xLTEtMA_f3964e7c-e4f3-44de-8d2a-ca74fc9c3b27"
      unitRef="usd">30485000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if1ad19fa9e57493cbbb0ec828961188a_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMy0yLTEtMS0w_384f5994-5cf0-419d-bb9c-b65a04c894a4"
      unitRef="shares">5814734</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if1ad19fa9e57493cbbb0ec828961188a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMy00LTEtMS0w_dcb5fc8e-df08-4f82-813d-0cc451907b64"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie0082109a8164d348f4eb2e8bce5f920_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMy02LTEtMS0w_4cd288cd-722b-4cad-887c-c28a67ab7121"
      unitRef="usd">81955000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6c148be66be64d989af7e78bf5f7e8d7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMy0xMC0xLTEtMA_86c94ea9-0b95-4b9a-ba01-5842ca7f8701"
      unitRef="usd">81961000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if1ad19fa9e57493cbbb0ec828961188a_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNC0yLTEtMS0w_e8092f56-747e-47ee-9cf1-cf885625b9a4"
      unitRef="shares">27587</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ie0082109a8164d348f4eb2e8bce5f920_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNC02LTEtMS0w_6b945170-aa31-4b3b-b469-579f25cb2b6a"
      unitRef="usd">90000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6c148be66be64d989af7e78bf5f7e8d7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNC0xMC0xLTEtMA_8427cac9-4c76-4ac4-905b-f758fe22f581"
      unitRef="usd">90000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if1ad19fa9e57493cbbb0ec828961188a_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNS0yLTEtMS0w_338c3b9b-52b0-46ed-8709-91a7a2231048"
      unitRef="shares">45299</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie0082109a8164d348f4eb2e8bce5f920_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNS02LTEtMS0w_2abce18d-5679-430d-a493-e73f10e158b8"
      unitRef="usd">235000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6c148be66be64d989af7e78bf5f7e8d7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNS0xMC0xLTEtMA_bbea3707-4368-44be-82a4-1beee49f08cb"
      unitRef="usd">235000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie0082109a8164d348f4eb2e8bce5f920_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNi02LTEtMS0w_287e83f8-2b00-4d51-baf4-9c76c53ce50a"
      unitRef="usd">3264000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6c148be66be64d989af7e78bf5f7e8d7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNi0xMC0xLTEtMA_6d5cb69d-a03d-457e-9b70-60333cb28e9d"
      unitRef="usd">3264000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i665d710a2f79419090640d7ff83c1e4f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNy04LTEtMS0w_50f28a50-181b-423d-90d7-1e65b6734463"
      unitRef="usd">-28196000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6c148be66be64d989af7e78bf5f7e8d7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfNy0xMC0xLTEtMA_2622920c-19df-4afb-aab0-6943c1d4f21b"
      unitRef="usd">-28196000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i2f497cc4181641a9b457299d6d76b330_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfOC0yLTEtMS0w_9d943b99-b99d-4551-97be-9036aa0c22e9"
      unitRef="shares">53357739</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2f497cc4181641a9b457299d6d76b330_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfOC00LTEtMS0w_2f6be337-50df-459d-8a2f-c24f081bb012"
      unitRef="usd">53000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id5474d339e8b4928a498360c356f0674_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfOC02LTEtMS0w_5c6ab738-c79f-4035-bd57-87abd2816838"
      unitRef="usd">408501000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c423f72409a4144b91ea6e7fba1bc55_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfOC04LTEtMS0w_53684aad-1040-4841-bb1b-340b4978801f"
      unitRef="usd">-320715000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i42d970e789bb4ed69e098925d5c8a0c3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfOC0xMC0xLTEtMA_dba0543a-55e6-46ca-8fae-08cee70a7f0d"
      unitRef="usd">87839000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1c8dbcdf157a4b2b85173162a11cd155_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTEtMi0xLTEtMjIx_7e5a6eb9-92ce-4e12-b1a7-dcd82539a4bd"
      unitRef="shares">40532</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i075b5732e8484f448eed30f1294e7346_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTEtNi0xLTEtMjI3_4c2a8f5b-d911-4f0d-8d44-b39de3d48529"
      unitRef="usd">330000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTEtMTAtMS0xLTM4OA_6d7a404a-8955-4dc4-9cfd-ea9530e2d3d7"
      unitRef="usd">330000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i075b5732e8484f448eed30f1294e7346_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTItNi0xLTEtMjI3_764c7e59-ac3e-4f65-a265-a79c53429665"
      unitRef="usd">3772000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTItMTAtMS0xLTM4OA_8560ad4d-dd37-4ae0-9de3-397d4725a9c6"
      unitRef="usd">3772000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i075b5732e8484f448eed30f1294e7346_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTMtNi0xLTEtMjQzNA_805c571e-c260-4151-916e-6a26035df38b"
      unitRef="usd">1750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTMtMTAtMS0xLTI0Mzc_4321701e-bed3-4fdb-b63b-062811175abf"
      unitRef="usd">1750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="i24f9bb3e88f14426994ec8102cb6c5a1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTMtOC0xLTEtMjM3_dc13c160-381b-4d41-a773-e41b030f29bb"
      unitRef="usd">-31598000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTMtMTAtMS0xLTM4OA_b0c78886-cf5f-4bc1-9722-013e3b10bc3f"
      unitRef="usd">-31598000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i8a9c8fdb6a934f87b09daf63f58245ad_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTQtMi0xLTEtMzc5_50ce78c1-2fb3-4758-a5db-73753f3c2689"
      unitRef="shares">53398271</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8a9c8fdb6a934f87b09daf63f58245ad_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTQtNC0xLTEtMzgx_564ab4f3-272d-4940-8714-176d19038240"
      unitRef="usd">53000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i68735d053ae34d3daf17984648ece5c5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTQtNi0xLTEtMzgz_2549218d-5a14-4d7b-ac95-dd69680ebc45"
      unitRef="usd">414353000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i65392f8598ed436ebc29041d16bf2d07_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTQtOC0xLTEtMzkw_8c65af5c-efdf-40c7-9dd4-88cf4aa1bb33"
      unitRef="usd">-352313000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjYyOWFjMDIwM2FhOTRlM2ZhMWY4YjdkMWM1MTNjY2Y3L3RhYmxlcmFuZ2U6NjI5YWMwMjAzYWE5NGUzZmExZjhiN2QxYzUxM2NjZjdfMTQtMTAtMS0xLTM4OA_829c973c-446c-4884-9acf-db6bf881e3b1"
      unitRef="usd">62093000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="iff63c5d4e86b4a5ca1fe0b493c057332_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMi0yLTEtMS0w_e768f66b-4aed-4e49-a2e4-15f58bec2e01"
      unitRef="shares">32170605</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iff63c5d4e86b4a5ca1fe0b493c057332_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMi00LTEtMS0w_9a4980b2-8f4d-4e59-8956-862c8706f0c5"
      unitRef="usd">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i060d039adfbb4d8ab83d6aa4f7896176_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMi02LTEtMS0w_0bedf787-1573-40ea-b9e0-438b4f434e00"
      unitRef="usd">259018000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic10cbcf9e0f3462b97277a8c1acc0b01_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMi04LTEtMS0w_953f863d-8dd7-454f-abaf-e3416553d2c0"
      unitRef="usd">-198853000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i910bfcb82bce48de9eda4ec378464e1d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMi0xMC0xLTEtMA_3afb9e74-38ce-4ac4-9605-e1cae9b02031"
      unitRef="usd">60197000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ie0ef059b44c043199b23fba40659d54b_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMy0yLTEtMS0w_99e19a12-6065-41a1-899a-bba74ced741b"
      unitRef="shares">13390</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ib269a5f35e344a0b841bce34774788d6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMy02LTEtMS0w_52dbc699-bc51-4567-b891-e84c9a486e95"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i968563ce77b0413db17b14b0756a3fc0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMy0xMC0xLTEtMA_005e5af9-cd8d-43f9-9bdd-30e9f2dc0e15"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie0ef059b44c043199b23fba40659d54b_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNC0yLTEtMS0w_7e0ffa44-8dbf-43f2-8735-341f88d8c071"
      unitRef="shares">137213</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib269a5f35e344a0b841bce34774788d6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNC02LTEtMS0w_474c52f8-df59-4564-90a1-3a014ba3e763"
      unitRef="usd">226000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i968563ce77b0413db17b14b0756a3fc0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNC0xMC0xLTEtMA_a4a750fb-5e42-4656-bba6-4eea16f78b7c"
      unitRef="usd">226000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib269a5f35e344a0b841bce34774788d6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNS02LTEtMS0w_e38daa10-73eb-4d98-ae8f-e75d317ba692"
      unitRef="usd">1955000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i968563ce77b0413db17b14b0756a3fc0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNS0xMC0xLTEtMA_6d49a99e-e5ef-4572-bcfb-c7b56b057b17"
      unitRef="usd">1955000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="iba4439be2d484dedb8b5567da52d763e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNi04LTEtMS0w_28eaaac7-ad27-4a29-9c26-a23c52e0eeab"
      unitRef="usd">-23041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i968563ce77b0413db17b14b0756a3fc0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNi0xMC0xLTEtMA_b2e91bbe-09c9-4d7b-b2cb-c448b3d04f9e"
      unitRef="usd">-23041000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i6cb30a9294094ef39b668ef2a3b5440d_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNy0yLTEtMS0w_d4d5b04b-620b-409f-8a64-ee0c0047438c"
      unitRef="shares">32321208</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6cb30a9294094ef39b668ef2a3b5440d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNy00LTEtMS0w_f44fd61a-4145-4139-b70c-105ae70e213f"
      unitRef="usd">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i71fefa044970467da0b5615dbc48bb75_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNy02LTEtMS0w_a5ab14f8-287f-46e7-87af-b7cdb52aa825"
      unitRef="usd">261206000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i454196204dfa4d2ea9e26fd433432149_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNy04LTEtMS0w_b581e529-97a2-45de-96b9-63308c0ddcf7"
      unitRef="usd">-221894000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c4bac8c6185474aa56292423c6a0d41_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfNy0xMC0xLTEtMA_f6993f9c-87f0-46eb-9127-cea8bb687940"
      unitRef="usd">39344000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i86b33bf63e00425ab9a0a9ae9659ec7b_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfOC0yLTEtMS0xNzg_92b86400-0300-4ebd-a9f9-b3f2349b4a01"
      unitRef="shares">13800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i86b33bf63e00425ab9a0a9ae9659ec7b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfOC00LTEtMS0xNzg_e371ecb9-6620-4f55-b400-ec83b9fee649"
      unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4b34c1b61faf48b9bb62d38f5e3f1dbf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfOC02LTEtMS0xOTQ_63d1bc91-b4db-49bb-b7da-74faf3fa074a"
      unitRef="usd">48393000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfOC0xMC0xLTEtMzk1_7015b93d-bf32-4fc8-a085-2f0b02239225"
      unitRef="usd">48407000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4b34c1b61faf48b9bb62d38f5e3f1dbf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTAtNi0xLTEtMjU0MQ_f7325997-a79d-4374-8baf-5c22cbcb7afc"
      unitRef="usd">2093000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTAtMTAtMS0xLTI1NDE_74788ca6-274f-43c7-9bc0-881b72e6bdc9"
      unitRef="usd">2093000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i86b33bf63e00425ab9a0a9ae9659ec7b_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfOS0yLTEtMS0xNzg_3ce39250-3128-4ae4-bca9-8e45f28b0ec0"
      unitRef="shares">11491</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i4b34c1b61faf48b9bb62d38f5e3f1dbf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfOS02LTEtMS0xOTQ_e4bf739d-3edf-4cd7-b847-4d230118560d"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfOS0xMC0xLTEtMzk1_3bbd88fa-08f0-469b-94a1-7d462cb1f66c"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i86b33bf63e00425ab9a0a9ae9659ec7b_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTAtMi0xLTEtMTc4_3db79d7d-2cbe-4969-b4d8-d21563e5bf95"
      unitRef="shares">3944</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4b34c1b61faf48b9bb62d38f5e3f1dbf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTAtNi0xLTEtMTk0_28e07c38-0d0e-4ef9-8817-f5c354dc4d46"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTAtMTAtMS0xLTM5NQ_909207d5-8ca0-4f57-99d3-1602e5aba179"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="i47ff8e84f8d84df58cf0940f1bc78215_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTEtOC0xLTEtMjAy_f9166618-0077-46c3-9ab5-c81fe6beaf28"
      unitRef="usd">-20652000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTEtMTAtMS0xLTM5NQ_1a570277-b5e7-4f52-9f42-dd3d42a5f117"
      unitRef="usd">-20652000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i058de24e899b4c6da6e959fc62c7250f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTItMi0xLTEtNDAw_53a45b86-bc23-44d8-9885-0a74d02c7b08"
      unitRef="shares">46136643</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i058de24e899b4c6da6e959fc62c7250f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTItNC0xLTEtNDAy_c73ccab3-6a69-45c2-a836-17e8ef1f8433"
      unitRef="usd">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i73c5206c27a94431b96f27c4ffdc0c14_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTItNi0xLTEtNDA0_c22626bf-a084-4a14-b417-7caa0458ad1b"
      unitRef="usd">311706000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ife2588c54a3d47cab5b870f2e150b48c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTItOC0xLTEtMzk4_ab12bd08-cb59-41b8-95a2-2f24092484d4"
      unitRef="usd">-242546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i472afffea565444284f0fbc04891b4e7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yNS9mcmFnOjMzN2U4ZDk1MDdkZDQ4MWM5M2Q3ZGRmMzRkOTJlZTI3L3RhYmxlOjgyNjRmM2VjZWE0OTQwNzJiYzVlZjNhNjViZTUwYjg2L3RhYmxlcmFuZ2U6ODI2NGYzZWNlYTQ5NDA3MmJjNWVmM2E2NWJlNTBiODZfMTItMTAtMS0xLTM5NQ_5acacc82-98ef-4946-b518-42d21cdf791d"
      unitRef="usd">69206000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMy0yLTEtMS0w_7f47b167-4507-4ef8-8042-d030e0d741d9"
      unitRef="usd">-59794000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMy00LTEtMS0w_d3884518-ea4a-4e32-a547-8d0c585b7f04"
      unitRef="usd">-43693000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfNS0yLTEtMS0w_a355891c-4c7a-4485-b6df-8ddc51872d17"
      unitRef="usd">7036000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfNS00LTEtMS0w_5fe63b41-a4bf-4962-a516-d1ea38350bd8"
      unitRef="usd">4048000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfNi0yLTEtMS0w_7aef8870-41c3-4eb6-bf6b-4dabe1915409"
      unitRef="usd">1090000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfNi00LTEtMS0w_04cd6d1e-6602-4bad-8dfa-e0ae48fa56a1"
      unitRef="usd">1031000</us-gaap:Depreciation>
    <evlo:NonCashInterestExpense
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfNy0yLTEtMS0w_c970d594-49fa-44e5-8151-bcf9c29d9484"
      unitRef="usd">180000</evlo:NonCashInterestExpense>
    <evlo:NonCashInterestExpense
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfNy00LTEtMS0w_5586f7af-f3f1-4823-9f12-5fd90c16a9b3"
      unitRef="usd">132000</evlo:NonCashInterestExpense>
    <evlo:NonCashOperatingLeaseExpense
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfOC0yLTEtMS0w_ffd8e563-b2d2-49c5-8323-db1ec2cfe23a"
      unitRef="usd">901000</evlo:NonCashOperatingLeaseExpense>
    <evlo:NonCashOperatingLeaseExpense
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfOC00LTEtMS0w_1ead29bb-e59c-464c-b25a-58a66d0cc9e3"
      unitRef="usd">1117000</evlo:NonCashOperatingLeaseExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfOS0yLTEtMS0xNTE2_580bed6c-9d32-4b9b-a895-d78f6890b10f"
      unitRef="usd">-3226000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfOS00LTEtMS0yMDc2_70f07e7b-454c-4f4a-988a-8910af4f869a"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfOS0yLTEtMS0w_9d875bd9-2fcd-4e93-b09f-1e2a701ac525"
      unitRef="usd">4000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfOS00LTEtMS0w_5b0fe05f-f8ed-485a-8944-f43d553df5be"
      unitRef="usd">5000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTEtMi0xLTEtMA_6d0d5649-a3e1-4c05-a32d-6ab51867340a"
      unitRef="usd">789000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTEtNC0xLTEtMA_97b4e145-b1c3-41bf-b54e-b26f57431860"
      unitRef="usd">-632000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTMtMi0xLTEtMA_cba525fb-563e-4c07-8d87-7b325bbed903"
      unitRef="usd">877000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTMtNC0xLTEtMA_ef9d408a-13a2-4c14-9ce6-9fe1f64bd342"
      unitRef="usd">2812000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTQtMi0xLTEtMA_e560f35b-76a2-46f0-a16b-e8eb50c2273a"
      unitRef="usd">-987000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTQtNC0xLTEtMA_be65b610-4060-474e-a8f8-88d215f9d516"
      unitRef="usd">-1001000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTUtMi0xLTEtMA_41892e0f-e3be-4f7e-a8cb-c4c57e823c17"
      unitRef="usd">-927000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTUtNC0xLTEtMA_4fb069a7-cc34-4916-b525-1a8919389dc7"
      unitRef="usd">-1111000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTYtMi0xLTEtMA_eebb369c-edc8-420e-b5bb-d3511b8508bc"
      unitRef="usd">7500000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTYtNC0xLTEtMA_f7953200-8bad-4d67-8db4-621e5f6d47a2"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTctMi0xLTEtMA_47761e28-20fa-4f50-8165-8eab4cd6494a"
      unitRef="usd">-21000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTctNC0xLTEtMA_a19e050e-1612-4c4e-8acf-9965f26c96bd"
      unitRef="usd">147000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTgtMi0xLTEtMA_7f560417-f709-4324-b800-3c8a08af163b"
      unitRef="usd">-41712000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMTgtNC0xLTEtMA_44c9440e-ad27-4a98-918f-77455809286a"
      unitRef="usd">-35891000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjAtMi0xLTEtMA_f61a30dc-8c1b-47f0-ab5a-91f1c58a0c0d"
      unitRef="usd">1151000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjAtNC0xLTEtMA_fa905716-2a87-48a8-a199-e8e2ba145582"
      unitRef="usd">651000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjEtMi0xLTEtMA_a8c92b41-a77f-4fd9-95ae-e1529745b874"
      unitRef="usd">4000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjEtNC0xLTEtMA_503bc5c0-00f0-43d7-a454-2a4230f855d9"
      unitRef="usd">6000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjItMi0xLTEtMA_0c6df94c-e688-4afc-acac-7408f190e65a"
      unitRef="usd">-1147000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjItNC0xLTEtMA_eafbb861-ad9f-4694-af8a-15d3436eea5d"
      unitRef="usd">-645000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjQtMi0xLTEtMA_e97d2641-00c3-4913-93f0-8c400c61ee79"
      unitRef="usd">81902000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjQtNC0xLTEtMA_521b815e-f279-4ab5-a5ac-7c3f4e2d8d40"
      unitRef="usd">48641000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjUtMi0xLTEtMTUyMQ_ab56c97f-c42b-4d05-b051-372eeefd0f40"
      unitRef="usd">14778000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjUtNC0xLTEtMjA3OA_858c4801-f7a6-4259-9fc1-bb400f230150"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjUtMi0xLTEtMA_638dd8bb-bdcc-48d5-87b3-f64e51e6f550"
      unitRef="usd">655000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjUtNC0xLTEtMA_ba224c34-d1d4-4fdb-8cbb-e2fc4476710e"
      unitRef="usd">235000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjYtMi0xLTEtMA_24ea5e18-c23a-457f-b33a-46293290087d"
      unitRef="usd">97335000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjYtNC0xLTEtMA_bd1a6890-4671-4908-9098-0ccb9e554d02"
      unitRef="usd">48876000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjctMi0xLTEtMA_6fc721cf-39f1-48a1-8c4d-b29f7ad33619"
      unitRef="usd">54476000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjctNC0xLTEtMA_1b8fb50d-4253-4463-b745-0a2c0641c38c"
      unitRef="usd">12340000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjgtMi0xLTEtMA_5790e1b3-bce5-440f-aeb0-9d0ec48e88b1"
      unitRef="usd">70420000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i910bfcb82bce48de9eda4ec378464e1d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjgtNC0xLTEtMA_3292c253-3b82-42fd-b5ab-a66734ee0f60"
      unitRef="usd">79333000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjktMi0xLTEtMA_2a90d6cd-7ec0-42e6-bf71-48506a324464"
      unitRef="usd">124896000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i472afffea565444284f0fbc04891b4e7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMjktNC0xLTEtMA_c0337e92-3006-47e3-a4ce-b7fef33ccfbc"
      unitRef="usd">91673000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzEtMi0xLTEtMA_54610842-b0c1-4678-ac28-4605be187717"
      unitRef="usd">1388000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzEtNC0xLTEtMA_55a9fce3-6e96-469b-8e05-681beffc726c"
      unitRef="usd">875000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzItMi0xLTEtNDEy_236c79b9-6bd7-4570-a253-6e873c5c006d"
      unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzItNC0xLTEtMjU0_e25ea245-47ee-4217-9bb0-e0f4a150de61"
      unitRef="usd">20000</us-gaap:IncomeTaxesPaid>
    <evlo:DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzUtMi0xLTEtNDE2_16214373-703f-4c3c-8f1e-e6a5c699553e"
      unitRef="usd">0</evlo:DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <evlo:DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzUtNC0xLTEtMjYy_f5c236f0-5f60-4f5f-8d94-3bf8df8a2d79"
      unitRef="usd">234000</evlo:DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <evlo:PublicOfferingCostInAccruedExpense
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzYtMi0xLTEtMzgxMw_87747366-f243-4743-8555-05da4d88a51d"
      unitRef="usd">59000</evlo:PublicOfferingCostInAccruedExpense>
    <evlo:PublicOfferingCostInAccruedExpense
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzYtNC0xLTEtMzgxNQ_90d732eb-c453-49ad-9412-ada3c7b764c8"
      unitRef="usd">0</evlo:PublicOfferingCostInAccruedExpense>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzQtMi0xLTEtMA_c9dcf9d2-3510-4dc1-b54d-d6b8b5f03800"
      unitRef="usd">172000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzQtNC0xLTEtMA_0ff61f74-d4d0-4d77-9c94-b11436990329"
      unitRef="usd">248000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i35ec3f05885c4394ad39da1354b18446_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzctMi0xLTEtMzMxMQ_f6c733ea-326f-4ad5-8320-b4f92f8a928b"
      unitRef="usd">1750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ic09b152b78114532b0d0a72a5d0cb108_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8yOC9mcmFnOmEzZTMxNzE4NDg5MzRjNDliYjU0ZWUyMmZkMmI0ZmM4L3RhYmxlOmY5MGYyODFmN2Q0YjRhMGY4NzViY2FlZmViM2IyMGExL3RhYmxlcmFuZ2U6ZjkwZjI4MWY3ZDRiNGEwZjg3NWJjYWVmZWIzYjIwYTFfMzctNC0xLTEtMzMxMw_e2b25aa7-cfbf-4659-abd1-25cb384589e6"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfNDcwOA_b76bd144-9e4f-405f-adad-6008eafb2641">Organization&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evelo Biosciences, Inc. ("Evelo" or the "Company&#x201d;) is a biotechnology company which was incorporated in Delaware on May 6, 2014. The Company is discovering and developing a new class of oral biologics that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. The Company is advancing these oral biologics with the aim of treating a broad range of immune mediated diseases with an initial focus on inflammatory diseases and oncology. The Company is headquartered in Cambridge, Massachusetts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception, the Company has devoted substantially all of its efforts to research and development and raising capital. The Company has not generated any revenue related to its primary business purpose to date. The Company is subject to a number of risks similar to those of other development stage companies, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, and the need to obtain adequate additional financing to fund the development of its products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has financed operations primarily with the proceeds from the issuance of common stock combined with proceeds from previous sales of convertible preferred stock to equity investors and debt financing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 3, 2019, the Company filed a Registration Statement on Form S-3 (File No. 333-231911) (the &#x201c;Shelf&#x201d;) with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof in the aggregate amount of up to $200.0 million for a period of up to three years from the date of its effectiveness on June 6, 2019. The Company also simultaneously entered into a sales agreement (the "ATM") with Cowen and Company, LLC, as sales agent, providing for the offering, issuance and sale by the Company of up to an aggregate $50.0&#160;million of its common stock from time to time in &#x201c;at-the-market&#x201d; offerings under the Shelf. For the three and six months ended June 30, 2021, the Company sold no shares and 139,734 shares, respectively, under the ATM with offering prices ranging between $12.54 and $13.17 per share for gross proceeds of $1.8 million, and net proceeds of $1.7 million, after deducting commission and other offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 2, 2021, the Company sold 5,175,000 shares of its common stock in an underwritten public offering at a public offering price of $15.00 per share, including the underwriters' exercise of their option to purchase 675,000 shares to cover over-allotment, generating gross proceeds of $77.6&#160;million and net proceeds of underwriting discounts and commission of $72.7&#160;million, after deducting underwriting discounts and commission and other offering expenses paid by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 28, 2021, the Company entered into a stock purchase agreement with ALJ Health Care &amp;amp; Life Science Company Limited ("ALJ Health Care"), pursuant to which on February 2, 2021, ALJ Health Care purchased $7.5&#160;million of our common stock in a private placement at a purchase price of $15.00 per share, equal to the public offering price per share at which our common stock was sold to the public as referred above. The sale of such shares was not registered under the Securities Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred operating losses since inception and expects such losses and negative operating cash flows to continue for the foreseeable future. The Company historically has funded its operations from the issuance of convertible notes, convertible preferred stock and common stock, and through debt financings. As of June 30, 2021, the Company had cash and cash equivalents of $123.3 million and an accumulated deficit of $352.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects that its cash and cash equivalents as of June 30, 2021 will be sufficient to fund the operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these unaudited condensed consolidated financial statements. The future viability of the Company beyond one year from the date of issuance of these unaudited condensed consolidated financial statements is dependent on its ability to raise additional capital to finance its operations. The Company's inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction
      contextRef="i96b3bb04ea99475da5fa00256059d7c5_I20190603"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMTYwNQ_acd4af90-d091-4bce-852f-082fd5d1d258"
      unitRef="usd">200000000.0</evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction>
    <evlo:SaleOfStockConsiderationReceivedTerm
      contextRef="i98b9be65b14c4e408ab7e4e90ae4e487_D20190603-20190603"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMTYzMA_964abc37-5493-4d46-b984-e7b15e3f2f40">P3Y</evlo:SaleOfStockConsiderationReceivedTerm>
    <evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction
      contextRef="ie55b778fc78c4838bd7596f7406fc60a_I20190603"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMTg4OA_b79b62cc-425d-47ce-9738-b789b0fda106"
      unitRef="usd">50000000.0</evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i010bde50e313426284f4a5003a97bcf6_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjAyMw_77c44e54-6225-4df9-8bef-30aa5d6dedd5"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i76cffaf0b6414a3a83a13544db4cb9c8_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMTA5OTUxMTYzMjYzNA_4966a3ff-4b18-4654-abea-1ca72a3eeb1b"
      unitRef="shares">139734</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i0f65daef97744a4e9f23fb6fc142b479_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjA5MQ_f913adb4-7415-47a4-899b-3cd3170c0da3"
      unitRef="usdPerShare">12.54</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia8fd128806d244458684e149d6ba270a_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjA5OA_ed92506e-9b85-499c-be81-01283e661a5c"
      unitRef="usdPerShare">13.17</us-gaap:SaleOfStockPricePerShare>
    <evlo:SaleOfStockGrossConsiderationReceivedOnTransaction
      contextRef="i76cffaf0b6414a3a83a13544db4cb9c8_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMTA5OTUxMTYzMjYzOQ_3a0fb1e2-b736-49c9-a0ec-dd6d67271554"
      unitRef="usd">1800000</evlo:SaleOfStockGrossConsiderationReceivedOnTransaction>
    <evlo:SaleOfStockGrossConsiderationReceivedOnTransaction
      contextRef="i010bde50e313426284f4a5003a97bcf6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMTA5OTUxMTYzMjYzOQ_641f667a-786b-4ce2-a6ce-ab86d93fa7a2"
      unitRef="usd">1800000</evlo:SaleOfStockGrossConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i010bde50e313426284f4a5003a97bcf6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMTA5OTUxMTYzMjY0Ng_a3ecae17-0ce3-492f-918a-f149e6e09bc2"
      unitRef="usd">1700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i76cffaf0b6414a3a83a13544db4cb9c8_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMTA5OTUxMTYzMjY0Ng_c068a902-49fb-4919-aa78-685ab493b6da"
      unitRef="usd">1700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i97a49e3e6ef940f7bd323a42dee5db4e_D20210202-20210202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjc0ODc3OTA4MTcwMA_0190997f-000d-4f53-afc2-b28d8f41308f"
      unitRef="shares">5175000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i919df7faea17493d83eded85125492f6_I20210202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjc0ODc3OTA4MTcxMQ_7b1c8c94-a33f-486a-bf54-b582bdabc12e"
      unitRef="usdPerShare">15.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie79b06c6d089457580ee83ab0fc4178c_D20210202-20210202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjc0ODc3OTA4MTcxOQ_9334c621-6dfa-4497-9240-037ec6e2cf6e"
      unitRef="shares">675000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <evlo:SaleOfStockGrossConsiderationReceivedOnTransaction
      contextRef="i97a49e3e6ef940f7bd323a42dee5db4e_D20210202-20210202"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjc0ODc3OTA4MTcyOA_2556e575-b2a5-4b70-9ae3-5a0bfdf676fe"
      unitRef="usd">77600000</evlo:SaleOfStockGrossConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i97a49e3e6ef940f7bd323a42dee5db4e_D20210202-20210202"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjc0ODc3OTA4MTc0Mw_9ebf8f49-83f4-4739-a822-11442caa423b"
      unitRef="usd">72700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i035578f695544ed4b1cd5c6d23c4dec9_D20210202-20210202"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjc0ODc3OTA4MTc1OA_15c4b850-6165-4900-b2f4-c853c3250dc5"
      unitRef="usd">7500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i2be50d786c924771a879f8ead446e51e_I20210202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMjc0ODc3OTA4MTc3Mg_4b908f89-12ca-486b-9a60-013ea18a265b"
      unitRef="usdPerShare">15.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMzU0Mg_a22d8ebd-bcdc-48f0-8488-a7199bc6ee3a"
      unitRef="usd">123300000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNC9mcmFnOjFjM2Y5NWJiNmJkODQxYjBhOWQ3NDViZDNhMWE0NGIwL3RleHRyZWdpb246MWMzZjk1YmI2YmQ4NDFiMGE5ZDc0NWJkM2ExYTQ0YjBfMzU3NQ_125d8901-2e05-449c-8d89-ee8fdb280691"
      unitRef="usd">-352300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1OTg_64b09849-d61b-4fa8-862e-f40412bf4198">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#x201c;ASC&#x201d;) and ASU of the FASB. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations.&#160;Accordingly, these financial statements should be read in conjunction with the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and notes thereto.&#160;The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company&#x2019;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments which are necessary to present fairly the Company&#x2019;s financial position as of June 30, 2021, the results of its operations and stockholders' equity for the three and six months ended June 30, 2021 and 2020 and cash flows for the six months ended June 30, 2021 and 2020. Such adjustments are of a normal and recurring nature. The results for the three and six months ended June 30, 2021 are not necessarily indicative of the results for the year ending December 31, 2021, or for any future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, estimates related to the application of ASC 606 to our collaboration agreement, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evelo is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Evelo may take advantage of these exemptions until it is no longer an emerging growth company. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. Evelo has elected to use the extended transition period for complying with new or revised accounting standards, and, as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. Evelo may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its IPO or such earlier time that it is no longer an emerging growth company. Evelo would cease to be an emerging growth company if it has more than $1.07 billion in annual revenue, it has more than $700.0 million in market value of its stock held by non-affiliates (and has been a public company for at least 12&#160;months and has filed one annual report on Form&#160;10-K), or it has issued more than $1.0 billion of non-convertible debt securities over a three-year period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive Income or Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) consists of net income (loss) and changes in equity during a period from transactions and other equity and circumstances generated from non-owner sources. The Company&#x2019;s net loss equals comprehensive loss for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are comprised of highly liquid investments that are readily convertible into cash with original maturities of three months or less. Cash and cash equivalents include cash held in banks and amounts held in money market funds. Cash equivalents are stated at cost, which approximates market value. The Company&#x2019;s restricted cash consists of restricted cash in connection with building leases for the Company&#x2019;s office and laboratory premises and deposits held in relation to the company's credit card facility. As of June 30, 2021 and December 31, 2020 the Company had $0.3&#160;million in current restricted cash within prepaid expenses and other current assets and $1.3&#160;million in noncurrent restricted cash which were included within other assets in the unaudited condensed consolidated balance sheets. The following reconciles cash, cash equivalents and restricted cash as of June 30, 2021 and December 31, 2020, as presented on the Company's statements of cash flows, to its related balance sheet accounts (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 820,&#160;Fair Value Measurement&#160;(&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2 inputs are inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 inputs are unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings. The Company did not elect to measure any additional financial instruments or other items at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,  Collaborative Arrangements ("ASC 808") to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and its collaboration partner are within the scope of other accounting literature, including ASC 606, Revenue from Contracts with Customers ("ASC 606"). If it is concluded that some or all aspects of the arrangement represent a transaction with a customer, the Company will account for those aspects of the arrangement within the scope of ASC 606. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 808 provides guidance for the presentation and disclosure of transactions in collaborative arrangements, but it does not provide recognition or measurement guidance. Therefore, if the Company concludes a counterparty to a transaction is not a customer or otherwise not within the scope of ASC 606, the Company considers the guidance in other accounting literature, including the guidance in ASC 606, as applicable or by analogy to account for such transaction. The classification of transactions under the Company&#x2019;s arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of Accounting Standards Codification ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities.  If the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, it performs the following steps: (i) identify the contract(s) with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) each performance obligation is satisfied. ASC 606 requires significant judgment and estimates and results in changes to, but not limited to: (i) the determination of the transaction price, including estimates of variable consideration, (ii) the allocation of the transaction price, including the determination of estimated selling price, and (iii) the pattern of recognition, including the application of proportional performance as a measure of progress on service-related promises and application of point-in-time recognition for supply-related promises. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promised good or services in the Company&#x2019;s arrangement may consist of license rights to the Company&#x2019;s intellectual property or research and development services. The Company also may have optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price may be comprised of fixed payments, often an upfront payment due at contract inception, or other types of variable consideration in the form of payments for the Company&#x2019;s services and materials and milestone payments due upon the achievement of specified events. Other payments the Company could be entitled to include tiered royalties earned when customers recognize net sales of licensed products. The Company considers the existence of any significant financing component within its arrangements to the extent there is a significant difference between the timing of payment and the transfer of control of the performance obligations.  In making that determination, the Company considers whether substantive business purposes exist to support the payment structure other than to provide a significant benefit of financing. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;promised goods and/or services to the customer. The Company utilizes either the expected value method or the most likely amount method to estimate the amount of variable consideration, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. With respect to arrangements that include payments for a development or regulatory milestone payment, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the Company&#x2019;s or the licensee&#x2019;s control, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company re-evaluates the probability of achievement of each milestone and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, wherein the license is deemed to be the sole or predominant item to which the payments relate, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements with more than one performance obligation, the Company generally allocates the transaction price to each performance obligation based on a relative standalone selling price basis. The Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated research and development costs. However, in certain instances, the Company may allocate variable consideration entirely to one or more performance obligation if the terms of the variable consideration relate to the satisfaction of the respective performance obligation and the amount allocated is consistent with the amount the Company would expect to receive for the satisfaction of the respective performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. For performance obligations that are satisfied at a point in time, the Company recognizes revenue when control of the goods and/or services is transferred to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer.  With respect to arrangements containing a license to its intellectual property that is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from amounts allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records a contract liability, classified as deferred revenue on its condensed consolidated balance sheet, when it has received payment but has not yet satisfied the related performance obligations. In the event of an early termination of a contract with a customer, any contract liabilities would be recognized in the period in which all Company obligations under the agreement have been fulfilled.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed in the period incurred. Research and development expenses consist of both internal and external costs such as payroll, consulting, and manufacturing costs associated with the development of the Company&#x2019;s product candidates. Costs for certain development activities, such as clinical trials and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the unaudited condensed consolidated balance sheets as prepaid or accrued research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire licenses, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects. Any milestone payments made for Intellectual Property after regulatory approval, or that have alternative future use, are capitalized and amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records stock-based compensation for equity awards granted to employees and directors based on the grant date fair value of awards issued. The expense is recorded over the requisite service period, which is the vesting period, on a straight-line basis. The Company uses the Black-Scholes option-pricing model to determine the fair value of options. The determination of the fair value of options on the date of grant using an option-pricing model is affected by the Company&#x2019;s common stock price, as well as a number of other assumptions. The Company records forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation arrangements with&#160;non-employees&#160;based upon the fair value of the consideration received or the equity instruments issued, whichever is more reliably measurable. The measurement date for&#160;non-employee&#160;awards is generally the date performance of services required from the&#160;non-employee&#160;is complete. Stock-based compensation costs for&#160;non-employee&#160;awards are recognized as services are provided, which is generally the vesting period, on a straight-line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating segment. The Company's chief operating decision maker, its Chief Executive Officer, manages the Company's operations on a consolidated basis for the purposes of allocating resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019 -12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new standard was effective for the Company on January 1, 2021 and it includes several provisions which simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The Company adopted ASU No. 2019-12 on January 1, 2021 and has concluded the adoption did not have a material impact on its unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Issued and Not Adopted as of June 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326)&#x2014;Measurement of Credit Losses on Financial Instruments, which has been subsequently amended by ASU No. 2018-19, ASU No. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2019-04, ASU No. 2019-05, ASU No. 2019-10, ASU No. 2019-11 and ASU No. 2020-03 (&#x201c;ASU 2016-13&#x201d;). The provisions of ASU 2016-13 modify the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology and require a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 is effective for the Company on January 1, 2023, with early adoption permitted. The Company is currently evaluating the potential impact that this standard may have on its financial position and results of operations, as well as the timing of its adoption of this standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Debt with Conversion and Other Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 5, 2020, the FASB issued ASU No. 2020-06, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU-2020-06&#x201d;), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models in ASC 470-20 that require separate accounting for embedded conversion features from convertible instruments. As a result, after adopting the ASU&#x2019;s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Additionally, the guidance simplifies the evaluation of whether a contract in the issuer&#x2019;s own equity can be classified in equity or an embedded feature qualifies for the derivative scope exception. Although the guidance is not effective until 2022, early adoption of ASU 2020-06 is permitted for all entities for fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of this new guidance on the Company&#x2019;s condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1OTk_fdbc732f-d050-402a-851f-d0ac9f5c5bca">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#x201c;ASC&#x201d;) and ASU of the FASB. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations.&#160;Accordingly, these financial statements should be read in conjunction with the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and notes thereto.&#160;The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company&#x2019;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments which are necessary to present fairly the Company&#x2019;s financial position as of June 30, 2021, the results of its operations and stockholders' equity for the three and six months ended June 30, 2021 and 2020 and cash flows for the six months ended June 30, 2021 and 2020. Such adjustments are of a normal and recurring nature. The results for the three and six months ended June 30, 2021 are not necessarily indicative of the results for the year ending December 31, 2021, or for any future period.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1ODc_5be25984-9cf0-40ca-bccf-960d0b884058">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, estimates related to the application of ASC 606 to our collaboration agreement, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1ODg_6a312a07-bfa5-4e30-bd9d-2edaf6ed2161">Principles of ConsolidationThe unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <evlo:EmergingGrowthCompanyStatusPolicyTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1ODk_a032c0b4-4a1d-4b59-98b2-cbc014702b55">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evelo is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Evelo may take advantage of these exemptions until it is no longer an emerging growth company. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. Evelo has elected to use the extended transition period for complying with new or revised accounting standards, and, as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. Evelo may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its IPO or such earlier time that it is no longer an emerging growth company. Evelo would cease to be an emerging growth company if it has more than $1.07 billion in annual revenue, it has more than $700.0 million in market value of its stock held by non-affiliates (and has been a public company for at least 12&#160;months and has filed one annual report on Form&#160;10-K), or it has issued more than $1.0 billion of non-convertible debt securities over a three-year period.&lt;/span&gt;&lt;/div&gt;</evlo:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1OTM_6f1a3c66-2175-42ce-bfaa-8ca1d8f0db6a">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive Income or Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) consists of net income (loss) and changes in equity during a period from transactions and other equity and circumstances generated from non-owner sources. The Company&#x2019;s net loss equals comprehensive loss for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1OTA_e6898dfa-950d-42f2-b796-3b8178f8ea99">Cash, Cash Equivalents, and Restricted CashCash equivalents are comprised of highly liquid investments that are readily convertible into cash with original maturities of three months or less. Cash and cash equivalents include cash held in banks and amounts held in money market funds. Cash equivalents are stated at cost, which approximates market value. The Company&#x2019;s restricted cash consists of restricted cash in connection with building leases for the Company&#x2019;s office and laboratory premises and deposits held in relation to the company's credit card facility.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashCurrent
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfNDkzNQ_648c4bce-055a-4a9d-92bd-80a956b7ffc2"
      unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfNDkzNQ_ca2270ee-0e53-434e-b798-f6fb20bf14b9"
      unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfNTAxOA_a30aa693-d350-4288-a8d6-74241856bb52"
      unitRef="usd">1300000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfNTAxOA_f6abfc33-d700-4b0c-8587-ac9730445f03"
      unitRef="usd">1300000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1ODQ_4424d345-5f41-47b3-908f-b6821d27c777">The following reconciles cash, cash equivalents and restricted cash as of June 30, 2021 and December 31, 2020, as presented on the Company's statements of cash flows, to its related balance sheet accounts (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ2MDE_6c904fd4-db2d-4384-ac70-57b6b05692f4">The following reconciles cash, cash equivalents and restricted cash as of June 30, 2021 and December 31, 2020, as presented on the Company's statements of cash flows, to its related balance sheet accounts (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:Cash
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfMi0yLTEtMS0w_22d2d34f-f521-4a4d-bcc3-6f2e15cd0377"
      unitRef="usd">2964000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfMi00LTEtMS0w_d5758a25-b38b-445a-b123-b5daad68d1a8"
      unitRef="usd">4487000</us-gaap:Cash>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfMy0yLTEtMS0w_8725527a-3cc2-45dd-88c9-dd1384aae45d"
      unitRef="usd">120369000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfMy00LTEtMS0w_9f1d945c-bb16-42ae-86f5-492958f6339d"
      unitRef="usd">64370000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfNC0yLTEtMS0w_0ca30d89-dc3d-49a8-be2c-68ca7df16f87"
      unitRef="usd">123333000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfNC00LTEtMS0w_baee30fc-2b73-449b-9027-c54254852abd"
      unitRef="usd">68857000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfNS0yLTEtMS0w_08431979-d817-42eb-a5b6-c2fc43ae751d"
      unitRef="usd">1563000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfNS00LTEtMS0w_f019a79a-2e0d-4021-b8f8-82c13a2d5f20"
      unitRef="usd">1563000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfNi0yLTEtMS0w_c5a9d64a-1656-42b1-ab91-bdf4f37eccac"
      unitRef="usd">124896000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RhYmxlOjA2ODYyMzM0MWZhZDQwYzRhMTNmZWE2MWJiZmFhYTY1L3RhYmxlcmFuZ2U6MDY4NjIzMzQxZmFkNDBjNGExM2ZlYTYxYmJmYWFhNjVfNi00LTEtMS0w_f42593d2-a11a-4cb5-b987-4c792c100466"
      unitRef="usd">70420000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ2MDI_5e4fb1f0-4740-4193-8334-ff982aa6701f">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 820,&#160;Fair Value Measurement&#160;(&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2 inputs are inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 inputs are unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings. The Company did not elect to measure any additional financial instruments or other items at fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1OTQ_800170da-7a89-4676-91d9-ec2979802f37">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,  Collaborative Arrangements ("ASC 808") to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and its collaboration partner are within the scope of other accounting literature, including ASC 606, Revenue from Contracts with Customers ("ASC 606"). If it is concluded that some or all aspects of the arrangement represent a transaction with a customer, the Company will account for those aspects of the arrangement within the scope of ASC 606. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 808 provides guidance for the presentation and disclosure of transactions in collaborative arrangements, but it does not provide recognition or measurement guidance. Therefore, if the Company concludes a counterparty to a transaction is not a customer or otherwise not within the scope of ASC 606, the Company considers the guidance in other accounting literature, including the guidance in ASC 606, as applicable or by analogy to account for such transaction. The classification of transactions under the Company&#x2019;s arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1OTE_8048e1ba-b1ca-44d9-be6f-a8192e7411bc">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of Accounting Standards Codification ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities.  If the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, it performs the following steps: (i) identify the contract(s) with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) each performance obligation is satisfied. ASC 606 requires significant judgment and estimates and results in changes to, but not limited to: (i) the determination of the transaction price, including estimates of variable consideration, (ii) the allocation of the transaction price, including the determination of estimated selling price, and (iii) the pattern of recognition, including the application of proportional performance as a measure of progress on service-related promises and application of point-in-time recognition for supply-related promises. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promised good or services in the Company&#x2019;s arrangement may consist of license rights to the Company&#x2019;s intellectual property or research and development services. The Company also may have optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price may be comprised of fixed payments, often an upfront payment due at contract inception, or other types of variable consideration in the form of payments for the Company&#x2019;s services and materials and milestone payments due upon the achievement of specified events. Other payments the Company could be entitled to include tiered royalties earned when customers recognize net sales of licensed products. The Company considers the existence of any significant financing component within its arrangements to the extent there is a significant difference between the timing of payment and the transfer of control of the performance obligations.  In making that determination, the Company considers whether substantive business purposes exist to support the payment structure other than to provide a significant benefit of financing. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;promised goods and/or services to the customer. The Company utilizes either the expected value method or the most likely amount method to estimate the amount of variable consideration, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. With respect to arrangements that include payments for a development or regulatory milestone payment, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the Company&#x2019;s or the licensee&#x2019;s control, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company re-evaluates the probability of achievement of each milestone and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, wherein the license is deemed to be the sole or predominant item to which the payments relate, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements with more than one performance obligation, the Company generally allocates the transaction price to each performance obligation based on a relative standalone selling price basis. The Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated research and development costs. However, in certain instances, the Company may allocate variable consideration entirely to one or more performance obligation if the terms of the variable consideration relate to the satisfaction of the respective performance obligation and the amount allocated is consistent with the amount the Company would expect to receive for the satisfaction of the respective performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. For performance obligations that are satisfied at a point in time, the Company recognizes revenue when control of the goods and/or services is transferred to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer.  With respect to arrangements containing a license to its intellectual property that is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from amounts allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records a contract liability, classified as deferred revenue on its condensed consolidated balance sheet, when it has received payment but has not yet satisfied the related performance obligations. In the event of an early termination of a contract with a customer, any contract liabilities would be recognized in the period in which all Company obligations under the agreement have been fulfilled.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1OTI_f3ec125d-b1e7-4f05-b889-57a64db96f7f">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed in the period incurred. Research and development expenses consist of both internal and external costs such as payroll, consulting, and manufacturing costs associated with the development of the Company&#x2019;s product candidates. Costs for certain development activities, such as clinical trials and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the unaudited condensed consolidated balance sheets as prepaid or accrued research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire licenses, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects. Any milestone payments made for Intellectual Property after regulatory approval, or that have alternative future use, are capitalized and amortized.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1ODU_dcc25942-fe9b-4050-9fce-7bdd194dff8a">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records stock-based compensation for equity awards granted to employees and directors based on the grant date fair value of awards issued. The expense is recorded over the requisite service period, which is the vesting period, on a straight-line basis. The Company uses the Black-Scholes option-pricing model to determine the fair value of options. The determination of the fair value of options on the date of grant using an option-pricing model is affected by the Company&#x2019;s common stock price, as well as a number of other assumptions. The Company records forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation arrangements with&#160;non-employees&#160;based upon the fair value of the consideration received or the equity instruments issued, whichever is more reliably measurable. The measurement date for&#160;non-employee&#160;awards is generally the date performance of services required from the&#160;non-employee&#160;is complete. Stock-based compensation costs for&#160;non-employee&#160;awards are recognized as services are provided, which is generally the vesting period, on a straight-line basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1OTY_d353fa66-e274-479b-bcc2-389a17fda036">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating segment. The Company's chief operating decision maker, its Chief Executive Officer, manages the Company's operations on a consolidated basis for the purposes of allocating resources.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjE0MDc_71e707c7-cea3-49c2-8531-9729075b4601"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV8zNy9mcmFnOjg0OTVhODAwYzFjMjQ2ZGM4MDZkZWYwMWU1NzgyZmVkL3RleHRyZWdpb246ODQ5NWE4MDBjMWMyNDZkYzgwNmRlZjAxZTU3ODJmZWRfMjQ1ODY_88561f44-e078-4be1-a7fc-5ce3b4e653ae">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019 -12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new standard was effective for the Company on January 1, 2021 and it includes several provisions which simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The Company adopted ASU No. 2019-12 on January 1, 2021 and has concluded the adoption did not have a material impact on its unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Issued and Not Adopted as of June 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326)&#x2014;Measurement of Credit Losses on Financial Instruments, which has been subsequently amended by ASU No. 2018-19, ASU No. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2019-04, ASU No. 2019-05, ASU No. 2019-10, ASU No. 2019-11 and ASU No. 2020-03 (&#x201c;ASU 2016-13&#x201d;). The provisions of ASU 2016-13 modify the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology and require a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 is effective for the Company on January 1, 2023, with early adoption permitted. The Company is currently evaluating the potential impact that this standard may have on its financial position and results of operations, as well as the timing of its adoption of this standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Debt with Conversion and Other Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 5, 2020, the FASB issued ASU No. 2020-06, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU-2020-06&#x201d;), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models in ASC 470-20 that require separate accounting for embedded conversion features from convertible instruments. As a result, after adopting the ASU&#x2019;s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Additionally, the guidance simplifies the evaluation of whether a contract in the issuer&#x2019;s own equity can be classified in equity or an embedded feature qualifies for the derivative scope exception. Although the guidance is not effective until 2022, early adoption of ASU 2020-06 is permitted for all entities for fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of this new guidance on the Company&#x2019;s condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80MC9mcmFnOmUyYjFlNzM2MWMyMDRmNzBiMzNjN2E2YTdlZDAxMTUyL3RleHRyZWdpb246ZTJiMWU3MzYxYzIwNGY3MGIzM2M3YTZhN2VkMDExNTJfMjg0Mw_4eef2ae2-3b37-4ec2-88be-fd8508c210c8">ALJ Commercialization and License Agreement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 17, 2021, the Company entered into a commercialization and license agreement (the &#x201c;ALJ Agreement&#x201d;) with ALJ. Pursuant to the ALJ Agreement, the Company granted to ALJ an exclusive, non-transferable, sublicensable license to the Company&#x2019;s product candidate, EDP1815 (together with any replacement or second products of the Company described below, the &#x201c;Products&#x201d;) solely (i) to conduct development activities relating to the Products allocated to ALJ in a development plan agreed with the Company, (ii) to conduct manufacturing activities relating to the Products in all therapeutic uses in humans (the &#x201c;Field&#x201d;) throughout the world, subject to certain conditions and requirements, and (iii) to commercialize the Products in the Field in all countries of Africa and the Middle East-Turkey, excluding certain restricted countries (the &#x201c;Territory&#x201d;). If the Company ceases development of EDP1815 prior to receipt of regulatory approval required for commercialization of EDP1815 in any one of the United States, the United Kingdom, France, Germany, Spain, Italy, China or Japan, then ALJ will have the right to designate another product candidate of the Company as a replacement to EDP1815 or terminate the ALJ Agreement, subject to certain conditions and requirements. Further, for the first two years of the term, ALJ has the option to negotiate with the Company to add a second product candidate of the Company subject to certain conditions and requirements, for an additional license fee not to exceed $7.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the rights the Company granted under the ALJ Agreement, ALJ obligated to pay to the Company a one-time, non-refundable upfront payment of $7.5&#160;million. The parties will also share the future operating profits and losses for all Products in the Territory equally (50:50) as well as certain development, regulatory and commercialization costs. The Company concluded that the delivery of the license to ALJ, should be accounted for under ASC 606. The development, regulatory and commercialization activities within the Territory will be accounted for under ASC 808.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not recognized any revenue under the ALJ Agreement to date as they have not completed any performance obligation within the agreement. As of June 30, 2021, the Company has recognized $7.5&#160;million of deferred revenue, which is classified as a non-current liability in the accompanying unaudited condensed consolidated balance sheets as the performance obligation is not expected to be completed within the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company anticipates that payments under the costs share or profit and loss sharing arrangements, will be classified in the statement of operations consistent with the guidance in ASC 808. To date, the Company has not received or made any costs sharing or profit and loss payments. &lt;/span&gt;&lt;/div&gt;In-License Agreements&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mayo Foundation for Medical Education and Research&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 10, 2016, the Company entered into a Research and License Agreement, (the &#x201c;2016 Mayo License Agreement&#x201d;) with the Mayo Foundation for Medical Education and Research, an affiliate of Mayo Clinic (the &#x201c;Mayo Clinic&#x201d;). Under the 2016 Mayo License Agreement, the Mayo Clinic was entitled to certain participation rights in connection with the issuance and sale of preferred stock that was issued prior to the Company&#x2019;s public offering and warrants which were issued in 2016 and exercised in 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;6, 2017, the Company and the Mayo Clinic entered into a license agreement (&#x201c;2017 Mayo License Agreement&#x201d;). Under the 2017 Mayo License Agreement, the Mayo Clinic granted the Company (i)&#160;an exclusive, worldwide, sublicensable license under the Mayo Clinic&#x2019;s rights to certain intellectual property and microbial strains and (ii)&#160;a non-exclusive, worldwide, sublicensable license to certain related know-how, in each case, to develop and commercialize certain microbial strains and licensed products incorporating any such strains. As consideration, the Company paid a nonrefundable upfront fee of $0.2 million and will pay annual license maintenance fees. Nonrefundable upfront fees were expensed in full to research and development expense in 2017. Annual maintenance fees will be expensed as incurred over the term of the agreement. The Company may owe the Mayo Clinic milestone payments upon the achievement of certain development, regulatory, and commercial milestones, up to a maximum of $56.0 million in the aggregate, as well as royalties on net sales of licensed products in low single-digit percentages. As of June 30, 2021, the Company has incurred milestone payments to date totaling approximately $0.3 million under the agreement of which no&lt;/span&gt;&lt;span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are currently due.&lt;/span&gt;&lt;span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;University of Chicago&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;10, 2016, the Company and the University of Chicago entered into a patent license agreement (&#x201c;2016 University of Chicago Agreement&#x201d;). Under the 2016 University of Chicago Agreement, the University of Chicago granted the Company (i)&#160;an exclusive, royalty-bearing and sublicensable license under the licensed patents and (ii)&#160;a non-exclusive, royalty-bearing, sublicensable license to access the technical information to diligently develop and commercialize licensed products. As consideration, the Company paid a nonrefundable upfront fee of less than $0.5 million and will pay annual license maintenance fees. Nonrefundable upfront fees were expensed in full to research and development expense in 2016. Annual maintenance fees will be expensed as incurred over the term of the agreement. The Company may owe the University of Chicago milestone payments, totaling an aggregate of approximately $60.9 million upon the achievement of certain development, regulatory, and commercial milestones, as well as royalties on net sales of licensed products ranging from low to high single-digit percentages. As of June 30, 2021, the Company has incurred milestone payments to date totaling approximately $0.4 million under the agreement of which no&lt;/span&gt;&lt;span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are currently due.&lt;/span&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <evlo:CollaborativeArrangementSecondProductCandidateNegotiationPeriod
      contextRef="ib0beb087c81f498590a475a3ae51c18c_D20210317-20210317"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80MC9mcmFnOmUyYjFlNzM2MWMyMDRmNzBiMzNjN2E2YTdlZDAxMTUyL3RleHRyZWdpb246ZTJiMWU3MzYxYzIwNGY3MGIzM2M3YTZhN2VkMDExNTJfMTM1MA_1ed04078-5bab-4f5a-b73a-b7950201ec5c">P2Y</evlo:CollaborativeArrangementSecondProductCandidateNegotiationPeriod>
    <evlo:CollaborativeArrangementSecondProductCandidateFeeMaximum
      contextRef="ib0beb087c81f498590a475a3ae51c18c_D20210317-20210317"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80MC9mcmFnOmUyYjFlNzM2MWMyMDRmNzBiMzNjN2E2YTdlZDAxMTUyL3RleHRyZWdpb246ZTJiMWU3MzYxYzIwNGY3MGIzM2M3YTZhN2VkMDExNTJfMTU1Ng_c230d33b-d5ac-4163-a02a-138e38d4525c"
      unitRef="usd">7500000</evlo:CollaborativeArrangementSecondProductCandidateFeeMaximum>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="idaee624f24ba426fa56b1769371f486f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80MC9mcmFnOmUyYjFlNzM2MWMyMDRmNzBiMzNjN2E2YTdlZDAxMTUyL3RleHRyZWdpb246ZTJiMWU3MzYxYzIwNGY3MGIzM2M3YTZhN2VkMDExNTJfMTcyMA_68f2f048-f3c9-4a7b-92e4-cd795542c2e8"
      unitRef="usd">7500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <evlo:CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage
      contextRef="ib0beb087c81f498590a475a3ae51c18c_D20210317-20210317"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80MC9mcmFnOmUyYjFlNzM2MWMyMDRmNzBiMzNjN2E2YTdlZDAxMTUyL3RleHRyZWdpb246ZTJiMWU3MzYxYzIwNGY3MGIzM2M3YTZhN2VkMDExNTJfMTgzNQ_f5362841-bcef-4605-b7ec-44988ae72926"
      unitRef="number">0.50</evlo:CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="idaee624f24ba426fa56b1769371f486f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80MC9mcmFnOmUyYjFlNzM2MWMyMDRmNzBiMzNjN2E2YTdlZDAxMTUyL3RleHRyZWdpb246ZTJiMWU3MzYxYzIwNGY3MGIzM2M3YTZhN2VkMDExNTJfMjMyNA_68f2f048-f3c9-4a7b-92e4-cd795542c2e8"
      unitRef="usd">7500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfMTI4OA_596188f7-2e49-48a6-b806-4faa5eb8a86f">Leases&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, the Company entered into an&#160;operating sublease arrangement to lease approximately 40,765 square feet for its office and research development space at 620 Memorial Drive, Cambridge, MA 02139 from February 2018 to September 2025. The Company maintained an additional separate operating lease for office and laboratory space that expired in May 2020. The leases require security deposits, which the Company has primarily met with letters of credit from a financial institution that is secured with cash on deposit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the Company entered into a sublease arrangement with a third party to lease space subject to an operating lease that expired in April 2020. The minimum rental payments received under this agreement totaled $0.1 million and $0.2&#160;million, respectively, for the three months and six months ended June 30, 2020 and were equivalent to the minimum payments due from the Company to the landlord.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months and six months ended June 30, 2021,  the Company recorded rent expense of $0.7 million and $1.5 million, respectively. For the three months and six months ended June 30, 2020,  the Company recorded rent expense of $0.7&#160;million and $1.4&#160;million, respectively.There was no sublease rental income for the three months and six months ended June 30, 2021. For the three months and six months ended June 30, 2020, the Company recorded rent expense net of sublease rental income of $0.1&#160;million and $0.3&#160;million, respectively. Sublease rental income is inclusive of rental payments, taxes and operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The minimum aggregate future lease commitments at June 30, 2021, are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2021 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"&gt;excluding amounts paid or in Accounts Payable as of 6/30/2021)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,252&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,154&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,491&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,208&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,472)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,736&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,230&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="i39b550ef2206421ab7236b2a064fb4bd_I20180131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfMTE0_30027265-b7dc-4182-ac8a-f5533f637bc9"
      unitRef="sqft">40765</us-gaap:AreaOfLand>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfNzYw_167c2f4a-3a59-4525-88b7-a7a2f647ee3c"
      unitRef="usd">100000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfMTA5OTUxMTYyOTIwNA_b7159c0d-0a11-4193-8444-dbd0c3264dd6"
      unitRef="usd">200000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseExpense
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfOTQ3_230c2adc-906f-49be-8eff-d09b3c1aa215"
      unitRef="usd">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfMTY0OTI2NzQ0MzQxOA_ccbbd3c5-b410-4d06-9c14-26fe4fd281f1"
      unitRef="usd">1500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfMTQyOTM2NTExNjMxMTc_52e22525-c326-4b54-9736-3aff19bf134f"
      unitRef="usd">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfMTQyOTM2NTExNjMxMzE_e9d199b7-db1b-4c05-823c-bdd5a665e187"
      unitRef="usd">1400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfOTYx_c7e0cd18-09f2-4982-b6e8-e3ff5941f613"
      unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfOTYx_e547bceb-821d-47e1-935c-27223d7116d5"
      unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfMTY0OTI2NzQ0MzQ1OA_7c8d408b-2bb6-4448-9ed1-f834ed3e00df"
      unitRef="usd">100000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfMTY0OTI2NzQ0MzQ2OA_6bbe3d64-fefe-45e6-8e6f-48b52cce1730"
      unitRef="usd">300000</us-gaap:SubleaseIncome>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RleHRyZWdpb246MDJkYTI2MjNkYTYxNGY5NjkzZWQwYWZjOTM5OTNjNDVfMTI4OQ_f90ed4dd-b2e9-4fd7-8701-f37e02e0d4cd">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The minimum aggregate future lease commitments at June 30, 2021, are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2021 (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"&gt;excluding amounts paid or in Accounts Payable as of 6/30/2021)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,252&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,154&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,491&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,208&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,472)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,736&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,230&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfMS0yLTEtMS0w_5f1ab918-b5dd-4143-8412-1893ce469c70"
      unitRef="usd">1252000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfMi0yLTEtMS0w_62e336f0-a4f5-44c2-baf4-daf8a40759fd"
      unitRef="usd">3062000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfMy0yLTEtMS0w_6de00370-8706-4c84-9f08-b13f6601f45b"
      unitRef="usd">3154000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfNC0yLTEtMS0w_d986fd8f-5eef-48c2-b1ce-b659d4730331"
      unitRef="usd">3249000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfNS0yLTEtMS0w_c264f210-d80f-48ad-b303-1953f25dbc61"
      unitRef="usd">2491000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfNi0yLTEtMS0w_4b1dd91f-ad4b-46c7-9b38-f165d5b859f4"
      unitRef="usd">13208000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfNy0yLTEtMS0w_9b6fd16b-0c15-48a8-b241-9bc0f0d880ed"
      unitRef="usd">2472000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfOC0yLTEtMS0w_7fc230eb-3a25-4789-821a-10f57206eae6"
      unitRef="usd">10736000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfMTEtMi0xLTEtMA_3bcb4d3e-9f77-4e31-bdcf-8451797dca5e"
      unitRef="usd">1230000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfMTItMi0xLTEtMA_5c9e1175-f2c9-4244-8803-018a6d8d6259">P4Y3M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80My9mcmFnOjAyZGEyNjIzZGE2MTRmOTY5M2VkMGFmYzkzOTkzYzQ1L3RhYmxlOmU5NjQwYzllYmFmZjQ3ZmY4NzE3YWFmZTdmNTI4ZDAxL3RhYmxlcmFuZ2U6ZTk2NDBjOWViYWZmNDdmZjg3MTdhYWZlN2Y1MjhkMDFfMTMtMi0xLTEtMA_2fbdfd2c-3f07-47d0-9903-703a2cded49a"
      unitRef="number">0.095</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RleHRyZWdpb246ZTc2OWZhOTU2YTY4NDc5NThlZTI0MTZhZWQ3YTgxMzVfNTI5_7da50e74-6cd5-4924-a0d2-60657b1dac41">Fair Value Measurements&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities that have been measured at fair value as of June 30, 2021 and December 31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds included within cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds included within cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;June 30, 2021&#160;and&#160;December 31, 2020, the Company's cash equivalents have been initially valued at the transaction price and subsequently valued utilizing a third party pricing service. The Company validates the prices provided by its third-party pricing service by understanding the models used and obtaining market values from other pricing sources.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RleHRyZWdpb246ZTc2OWZhOTU2YTY4NDc5NThlZTI0MTZhZWQ3YTgxMzVfNTMw_c57a3e85-f214-4ef5-811c-59441ba4a0bb">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities that have been measured at fair value as of June 30, 2021 and December 31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds included within cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds included within cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i244f5424f2ec4fca8f67abaebe241481_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmIwNTFiMzU2MWI2ZjRkMjM4Y2EwOTM1MjY1MjMyNzI5L3RhYmxlcmFuZ2U6YjA1MWIzNTYxYjZmNGQyMzhjYTA5MzUyNjUyMzI3MjlfMi0yLTEtMS0w_f7fbb752-1c2f-45b2-8314-e4cbbad95a0b"
      unitRef="usd">120369000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if77f269a0e0f4ac4ba3ac6fabe81d5f7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmIwNTFiMzU2MWI2ZjRkMjM4Y2EwOTM1MjY1MjMyNzI5L3RhYmxlcmFuZ2U6YjA1MWIzNTYxYjZmNGQyMzhjYTA5MzUyNjUyMzI3MjlfMi00LTEtMS0w_c1eada2d-a69e-4a12-946f-2fa658c9113a"
      unitRef="usd">120369000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia81c752f261c4005a844833c47dd60a5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmIwNTFiMzU2MWI2ZjRkMjM4Y2EwOTM1MjY1MjMyNzI5L3RhYmxlcmFuZ2U6YjA1MWIzNTYxYjZmNGQyMzhjYTA5MzUyNjUyMzI3MjlfMi02LTEtMS0w_cb78b726-d1a9-4098-8e75-d06179761660"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5f28cecd7ac744ffa9db9eccbde588cf_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmIwNTFiMzU2MWI2ZjRkMjM4Y2EwOTM1MjY1MjMyNzI5L3RhYmxlcmFuZ2U6YjA1MWIzNTYxYjZmNGQyMzhjYTA5MzUyNjUyMzI3MjlfMi04LTEtMS0w_b9060c16-efbf-4677-b371-b8985ad4569b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmIwNTFiMzU2MWI2ZjRkMjM4Y2EwOTM1MjY1MjMyNzI5L3RhYmxlcmFuZ2U6YjA1MWIzNTYxYjZmNGQyMzhjYTA5MzUyNjUyMzI3MjlfMy0yLTEtMS0w_7548c804-d49b-4ce4-8832-0fd8f14d02da"
      unitRef="usd">120369000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iffae4009f9494e7a838aac21210c8f97_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmIwNTFiMzU2MWI2ZjRkMjM4Y2EwOTM1MjY1MjMyNzI5L3RhYmxlcmFuZ2U6YjA1MWIzNTYxYjZmNGQyMzhjYTA5MzUyNjUyMzI3MjlfMy00LTEtMS0w_d8bfbab6-b6ad-4176-a7c4-1569563c4854"
      unitRef="usd">120369000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i757a3246f9b845c897fa5b6fbdb51641_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmIwNTFiMzU2MWI2ZjRkMjM4Y2EwOTM1MjY1MjMyNzI5L3RhYmxlcmFuZ2U6YjA1MWIzNTYxYjZmNGQyMzhjYTA5MzUyNjUyMzI3MjlfMy02LTEtMS0w_4a6e7e47-7f64-48c9-8896-e3b431b542ef"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i77ada78732004e3bb019864a37b2c2a1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmIwNTFiMzU2MWI2ZjRkMjM4Y2EwOTM1MjY1MjMyNzI5L3RhYmxlcmFuZ2U6YjA1MWIzNTYxYjZmNGQyMzhjYTA5MzUyNjUyMzI3MjlfMy04LTEtMS0w_0328a56a-fa6d-4c37-9a5f-cc41692f7712"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i197c24816d1b446ca101f657ac31cb79_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmU4ODBjZTRjNmM5MzRkYmZiNDY3MmFkZTU1MDg3YmI0L3RhYmxlcmFuZ2U6ZTg4MGNlNGM2YzkzNGRiZmI0NjcyYWRlNTUwODdiYjRfMi0yLTEtMS0w_dd46601a-d153-4eff-917c-c9094077021d"
      unitRef="usd">64370000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9451b4b98a6a4654890a9b2dafd8be53_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmU4ODBjZTRjNmM5MzRkYmZiNDY3MmFkZTU1MDg3YmI0L3RhYmxlcmFuZ2U6ZTg4MGNlNGM2YzkzNGRiZmI0NjcyYWRlNTUwODdiYjRfMi00LTEtMS0w_a1edd7ca-1b35-4966-9493-943a2fa6a682"
      unitRef="usd">64370000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib3ba13fe044647afa24e9ed23ec77aec_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmU4ODBjZTRjNmM5MzRkYmZiNDY3MmFkZTU1MDg3YmI0L3RhYmxlcmFuZ2U6ZTg4MGNlNGM2YzkzNGRiZmI0NjcyYWRlNTUwODdiYjRfMi02LTEtMS0w_ab01bf04-6ee8-4ec4-b85f-02052f2c2e3c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i44a958aa41b64d44abd88f59e0828525_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmU4ODBjZTRjNmM5MzRkYmZiNDY3MmFkZTU1MDg3YmI0L3RhYmxlcmFuZ2U6ZTg4MGNlNGM2YzkzNGRiZmI0NjcyYWRlNTUwODdiYjRfMi04LTEtMS0w_ecef389f-30ce-470e-a98f-5356dd7ec03e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmU4ODBjZTRjNmM5MzRkYmZiNDY3MmFkZTU1MDg3YmI0L3RhYmxlcmFuZ2U6ZTg4MGNlNGM2YzkzNGRiZmI0NjcyYWRlNTUwODdiYjRfMy0yLTEtMS0w_75f4d7c2-8cd4-4c9e-b858-571c95e167ee"
      unitRef="usd">64370000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iecbdbafb5b334e01b4cb6165e4b047c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmU4ODBjZTRjNmM5MzRkYmZiNDY3MmFkZTU1MDg3YmI0L3RhYmxlcmFuZ2U6ZTg4MGNlNGM2YzkzNGRiZmI0NjcyYWRlNTUwODdiYjRfMy00LTEtMS0w_e906d7cb-7846-4f11-8abc-ae4ed7333abb"
      unitRef="usd">64370000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia80c368b20a040ebac30679ad7b3f3bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmU4ODBjZTRjNmM5MzRkYmZiNDY3MmFkZTU1MDg3YmI0L3RhYmxlcmFuZ2U6ZTg4MGNlNGM2YzkzNGRiZmI0NjcyYWRlNTUwODdiYjRfMy02LTEtMS0w_5b086e0e-af7a-4a4f-963e-6f6f5d3dd657"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i924d154f1d224e19b69e08a1f7497b5f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80Ni9mcmFnOmU3NjlmYTk1NmE2ODQ3OTU4ZWUyNDE2YWVkN2E4MTM1L3RhYmxlOmU4ODBjZTRjNmM5MzRkYmZiNDY3MmFkZTU1MDg3YmI0L3RhYmxlcmFuZ2U6ZTg4MGNlNGM2YzkzNGRiZmI0NjcyYWRlNTUwODdiYjRfMy04LTEtMS0w_65a3c0be-9a73-453c-b621-92d1f427b5cb"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RleHRyZWdpb246YTRmMzcyYTRlOWU1NGUwOGJkNzhlZjkwMzQzNjE5NzJfMTg1_2e39be78-6579-4cb7-a12d-8439c887209a">Property and Equipment, Net&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized $0.5 million and $1.1&#160;million of depreciation expense for the three and six months ended June 30, 2021, respectively, and $0.5 million and $1.0 million of depreciation expense for the three and six months ended June 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RleHRyZWdpb246YTRmMzcyYTRlOWU1NGUwOGJkNzhlZjkwMzQzNjE5NzJfMTg2_99d38f53-8cd0-4487-bbf2-ca5cf8733027">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia6edb25555144d479ada5f406941de92_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfMi0yLTEtMS0w_8c644692-8c03-4157-97c8-bcac8902f9f9"
      unitRef="usd">9744000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icacd72f8312b40c2bfd30c623da239e6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfMi00LTEtMS0w_6b285628-ebd6-42e8-9408-4622605aad50"
      unitRef="usd">8831000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i623a78eb6d4049dcad99dc88c1d3a291_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfMy0yLTEtMS0w_99e90411-70d8-4c96-b1cc-3c323a65a179"
      unitRef="usd">2157000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3a72f314a6f1407f9083b56e679da505_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfMy00LTEtMS0w_7125b6a4-eb0b-4270-b53e-cbd97ec9c6fa"
      unitRef="usd">2157000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8a81873e97c845b084025eedbb21adbc_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfNC0yLTEtMS0w_32b7a294-0f17-4cdb-9164-751abf1a2274"
      unitRef="usd">822000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibc33321abf024a529d8629c6428a7a86_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfNC00LTEtMS0w_ffc0bd36-007c-47c2-b683-d55b6a33a60c"
      unitRef="usd">822000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifc6cc6e7c6414c369c9ac7674119f897_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfNS0yLTEtMS0w_64fb45e9-416a-4485-8b6f-5078ce4b1ec2"
      unitRef="usd">230000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i40ecdaafb89540fdbb9ad851b26912d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfNS00LTEtMS0w_23672155-345a-46e0-a602-ffebf594f377"
      unitRef="usd">230000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6ee77ba9c28c44fe8fb28f1d573090d2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfNi0yLTEtMS0w_305073bf-86eb-43a3-ad46-8f477f54b5a3"
      unitRef="usd">14000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i169ecd01600544e1b2bef1b7ee506185_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfNi00LTEtMS0w_190aee2c-9e53-40c4-909f-53a989ec7868"
      unitRef="usd">3000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i83f266dfe3fb4f89a36d8d7e81051de3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfNy0yLTEtMS0w_7987b957-9b56-4e24-9e0b-0250c587b9e8"
      unitRef="usd">1272000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id22668e852ea4c39a1f0366200d33039_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfNy00LTEtMS0w_012e6598-4418-48d0-b200-bdfbd3339e3d"
      unitRef="usd">1078000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfOC0yLTEtMS0w_492c652e-dfad-49a4-9b52-96b90dbccd90"
      unitRef="usd">14239000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfOC00LTEtMS0w_e0707443-40ff-43de-8b33-616dcfed5fc4"
      unitRef="usd">13121000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfOS0yLTEtMS0w_3b212433-bab9-4f58-9e1f-fdb8e3364b4c"
      unitRef="usd">6719000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfOS00LTEtMS0w_998c8eab-3ade-4129-afe0-80efb0be0da0"
      unitRef="usd">5643000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfMTAtMi0xLTEtMA_387a300b-4c49-45be-baee-b5a5d6ee6926"
      unitRef="usd">7520000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RhYmxlOjVjOWE3YjYxNDBjMTRkNDc5YTU3YmQ0ZmExMjMwYzVjL3RhYmxlcmFuZ2U6NWM5YTdiNjE0MGMxNGQ0NzlhNTdiZDRmYTEyMzBjNWNfMTAtNC0xLTEtMA_7b1ec2ad-f963-49fa-b22f-dde64c5a9bc9"
      unitRef="usd">7478000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RleHRyZWdpb246YTRmMzcyYTRlOWU1NGUwOGJkNzhlZjkwMzQzNjE5NzJfMTI1_8b0b212f-dff2-4bc7-bb7c-2b7028f1c356"
      unitRef="usd">500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RleHRyZWdpb246YTRmMzcyYTRlOWU1NGUwOGJkNzhlZjkwMzQzNjE5NzJfMTA5OTUxMTYyNzk5Nw_27ac4422-bf5e-4be7-9457-1d9cd58ca81b"
      unitRef="usd">1100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RleHRyZWdpb246YTRmMzcyYTRlOWU1NGUwOGJkNzhlZjkwMzQzNjE5NzJfMTA5OTUxMTYyODA5OQ_3740b55a-267f-48a3-ac2e-e0bd2d95fe9d"
      unitRef="usd">500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV80OS9mcmFnOmE0ZjM3MmE0ZTllNTRlMDhiZDc4ZWY5MDM0MzYxOTcyL3RleHRyZWdpb246YTRmMzcyYTRlOWU1NGUwOGJkNzhlZjkwMzQzNjE5NzJfMTA5OTUxMTYyODEwNw_e6a87555-1fc2-4ef3-9108-8da22068ca54"
      unitRef="usd">1000000.0</us-gaap:Depreciation>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMzAzNg_3c831350-19f1-4b07-a0b9-2bed5ba6f967">Loan and Security Agreements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 19, 2019, the Company entered into a loan and security agreement&#160;(as amended, the "2019 Credit Facility") with K2 HealthVentures LLC and others (collectively, "K2HV") pursuant to which the K2HV agreed to make term loans in an aggregate principal amount of up to $45.0 million available to the Company in three tranches. The initial tranche of $20.0 million was funded upon closing on July 19, 2019. As amended on May 15, 2020, the second tranche of $10.0 million was available to be funded between December 1, 2019 and July 15, 2020 and was drawn down on July 14, 2020. The availability of the third tranche of $15.0 million expired on January 15, 2021. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 16, 2021 (the "Amended Credit Facility Effective Date"), the parties further amended the 2019 Credit Facility (as so amended, the &#x201c;Amended Credit Facility&#x201d;) to, among other things, replace and supersede the existing $15.0&#160;million third tranche commitment with a new $15.0&#160;million fourth tranche commitment, which the Company drew down on June 16, 2021. In connection with the Amended Credit Facility, the Company issued to K2 HealthVentures Equity Trust LLC, an affiliate of K2HV a warrant to purchase up to 139,770 shares of the Company&#x2019;s common stock with an exercise price of $13.30 per share, subject to customary per share adjustments that are within the Company's control (&#x201c;the Warrant&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, under the Amended Credit Facility, K2HV has the option, exercisable at any time, to convert up to $5.0&#160;million of principal outstanding into shares of the Company&#x2019;s common stock at a conversion price of $13.30 per share, subject to customary per share adjustments within the Company's control (the "Conversion Option&#x201d;). &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Interest on the outstanding loan balance will accrue at a variable annual rate equal to the greater of (i) 8.65% and (ii) the prime rate plus 3.15%. The Company is required to make interest-only payments on the loans on a monthly basis through February 28, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, which was extended from February 28, 2022 pursuant to the Amended Credit Facility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Subsequent to the interest only periods, the Company is required to make equal monthly payments of principal plus interest until the loans mature on August 1, 2024. The Company has an option to prepay the loans in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;whole, subject to a prepayment fee of 2% of the amount prepaid or, if the prepayment occurs after the 18-month anniversary of the Amended Credit Facility Effective Date but prior to the maturity date, 1% of the amount prepaid.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Pursuant to the Amended Credit Facility, the Company has the option at any point prior to January 1, 2022 to elect to adjust the repayment schedule (the &#x201c;Modified Repayment Schedule&#x201d;) such that commencing on March 1, 2023, the Company can make consecutive equal monthly payments of principal and accrued and unpaid interest based on a notional thirty month repayment period. Under the Modified Repayment Schedule, the loan maturity date remains August 1, 2024.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Any outstanding principal and unpaid interest is due at maturity. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Upon final payment or prepayment of the loans, the Company must pay a final payment equal to 4.3% (or 4.8% if the Company elects the Modified Repayment Schedule) of the aggregate original principal amount of the loans borrowed. The Company incurred fees associated with establishing the 2019 Credit Facility and fees related to the Amended Credit Facility of $0.4&#160;million and $0.3&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the Amended Credit Facility are collateralized by substantially all of the Company's personal property, excluding intellectual property, and the Company pledged its equity interests in its subsidiaries, subject to certain limitations with respect to its foreign subsidiaries. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Credit Facility contains customary representations, warranties and covenants and also includes customary events of default, including payment defaults, breaches of covenants, change of control and occurrence of a material adverse effect. The Company has determined that the risk of subjective acceleration under the material adverse events clause was remote and therefore has classified the long-term portion of the outstanding principal in non-current liabilities. Upon the occurrence and continuation of an event of default, a default interest rate of an additional 5% per annum may be applied to the outstanding loan balances, and the administrative agent, collateral agent, and lenders may declare all outstanding obligations immediately due and payable and exercise all of their rights and remedies as set forth in the Amended Credit Facility and under applicable law. As of June 30, 2021, the Company was in compliance with all covenants under the Amended Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has concluded the Amended Credit Facility is a debt extinguishment for accounting purposes because the terms of the modified debt are considered substantially different than the terms of the debt prior to the amendment. As such, the Amended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credit Facility was recorded at its estimated fair value of $46.6&#160;million which was determined using a combination of a discounted cash flow model and a binomial lattice model. The Company utilized the following significant unobservable inputs (Level 3 inputs) to determine the estimated fair value of its debt as of the amendment date:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant increases (decreases) in either of these inputs could result in a significantly lower or higher fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Warrant was deemed to be a freestanding financial instrument as it is legally detachable and separately exercisable from the debt obligations. The Company evaluated the terms and conditions of the warrant and concluded it met the criteria to be classified within equity. As such, the Company recorded the warrant as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;additional paid in capital at its issuance date fair value of $1.8&#160;million. The&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Company utilized the Black-Scholes valuation method to determine the fair value of the warrant which utilized the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of underlying common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company recorded a loss on the extinguishment of the existing debt of $3.2&#160;million which equaled the difference between the reacquisition cost of the new debt, inclusive of the fair value of the Warrant and lender fees,  and the carrying amount of the existing debt.  The difference between (i) the carrying amount of the debt and (ii) the par value of the debt and the amount of the final payment due at maturity will be amortized as interest expense using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company has the following minimum aggregate future loan payments at June 30, 2021 (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Twelve month period ending June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest and discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense was approximately $0.8 million and $1.6 million for the three and six months ended June 30, 2021, respectively, and $0.4&#160;million and $0.8&#160;million for the three and six months ended  June 30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i8395b938be7d40d5a8124dea1975de06_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMzA3_2e26cd5f-c6bd-4617-a9ae-2caf8a200f05"
      unitRef="usd">45000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <evlo:SecurityAndLoanAgreementNumberOfTranches
      contextRef="i8395b938be7d40d5a8124dea1975de06_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMzM4_57e632b2-f70c-40b6-848b-554c48ab7e6e"
      unitRef="tranche">3</evlo:SecurityAndLoanAgreementNumberOfTranches>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia9d83da110a8438d9278f2c13f4fc35d_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMzc0_8d7f85d6-4dfc-4ea5-bc94-5222064a537b"
      unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i06308d75bfe6481f9b1dc21e9c8b5b6e_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfNDY5_08b9532e-f6b3-4948-a3ee-7416f49cdefd"
      unitRef="usd">10000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2b79658da2214b768872e3db030721a9_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfNjAw_beed73ed-ab25-4f70-af2e-16ef1259cee5"
      unitRef="usd">15000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia79249ea576049a0a0ea2eee88767eca_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMTI2NDQzODM3NTA2NDU_13c45106-0cc9-4835-bbeb-925f759eefaa"
      unitRef="usd">15000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i16a46e8e0f914f659f755b6f361a3246_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMTI2NDQzODM3NTA2NjI_c10adb78-39e4-4dcb-9839-585db6ade8b0"
      unitRef="usd">15000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTg1NA_a0c7060f-527f-4ca8-bd42-85c8cbfa9798"
      unitRef="shares">139770</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTg2Mw_15159086-4ced-4cae-b00c-048898beacb1"
      unitRef="usdPerShare">13.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ConvertibleDebt
      contextRef="ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTg3MQ_cc5af828-dd0c-41ee-916d-13700f85dcee"
      unitRef="usd">5000000.0</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTg4NQ_634e49e8-5ae2-4b57-bea0-07414225c843"
      unitRef="usdPerShare">13.30</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8395b938be7d40d5a8124dea1975de06_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMTAzMA_bb49397e-da78-424b-b55c-88352b36697a"
      unitRef="number">0.0865</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie0b39aa3345f4829bedab97e315cd1cc_D20190719-20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMTA2Mg_b9da9474-9dac-4241-be89-fa7c2732ea50"
      unitRef="number">0.0315</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <evlo:DebtInstrumentPrepaymentFeePercentageOnPrincipal
      contextRef="i6d8499bfe37347e19717295b49f69b19_D20190719-20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTg5Mw_26d96526-6f22-4b15-84aa-3e57edf9a8d4"
      unitRef="number">0.02</evlo:DebtInstrumentPrepaymentFeePercentageOnPrincipal>
    <evlo:DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage
      contextRef="i6d8499bfe37347e19717295b49f69b19_D20190719-20190719"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTkwNA_b5b22784-aeed-4161-939d-bb4ce3b05d08">P18M</evlo:DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage>
    <evlo:DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne
      contextRef="i6d8499bfe37347e19717295b49f69b19_D20190719-20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTkwNg_24fc317d-84fd-4c89-bbfe-39d27c8cbda7"
      unitRef="number">0.01</evlo:DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne>
    <evlo:DebtInstrumentRepaymentOrPrepaymentFeePercentage
      contextRef="i8395b938be7d40d5a8124dea1975de06_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTkxMA_4de46e40-4a45-4c22-91cc-8ce972503d5e"
      unitRef="number">0.043</evlo:DebtInstrumentRepaymentOrPrepaymentFeePercentage>
    <evlo:DebtInstrumentRepaymentOrPrepaymentFeePercentage
      contextRef="id3212be8361644f79ddbc0fc27e74c3d_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTkxNg_aa79b994-6ed4-4015-9aef-a1904cd2eb6c"
      unitRef="number">0.048</evlo:DebtInstrumentRepaymentOrPrepaymentFeePercentage>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i8395b938be7d40d5a8124dea1975de06_I20190719"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTkyMg_c4ed50eb-e927-4357-a795-78ff3b3add66"
      unitRef="usd">400000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="id3212be8361644f79ddbc0fc27e74c3d_I20190719"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTkzNg_be1b6b01-094c-4ada-bca5-4ebdafbf2da3"
      unitRef="usd">300000</us-gaap:DeferredFinanceCostsGross>
    <evlo:DebtInstrumentDebtDefaultPercentage
      contextRef="i6d8499bfe37347e19717295b49f69b19_D20190719-20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjQ2Nw_38afcda0-e3e1-4741-a575-8644015f3aa6"
      unitRef="number">0.05</evlo:DebtInstrumentDebtDefaultPercentage>
    <us-gaap:LinesOfCreditFairValueDisclosure
      contextRef="i7e37c8565f494644922932f469c3748e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMTI2NDQzODM3NTA2OTE_ab0f77ca-48f1-4b79-91a8-b87e1519e7d9"
      unitRef="usd">46600000</us-gaap:LinesOfCreditFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMTI2NDQzODM3NTA3MDk_2730308c-b44a-4435-861e-a416fbcf61f8">The Company utilized the following significant unobservable inputs (Level 3 inputs) to determine the estimated fair value of its debt as of the amendment date:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;The Company utilized the Black-Scholes valuation method to determine the fair value of the warrant which utilized the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of underlying common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="ie40915ff285a4e0ca8014dd9b85400f9_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmY4N2ZiNmFiMDQ2OTRhNzk5MzU1YWNhNGY1MDgzY2UzL3RhYmxlcmFuZ2U6Zjg3ZmI2YWIwNDY5NGE3OTkzNTVhY2E0ZjUwODNjZTNfMC0xLTEtMS0zMzU3_db608944-2b28-4814-871f-ca50fba14558"
      unitRef="number">0.7000</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="i6f257f1155f0451fa58717d6399f50e0_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmY4N2ZiNmFiMDQ2OTRhNzk5MzU1YWNhNGY1MDgzY2UzL3RhYmxlcmFuZ2U6Zjg3ZmI2YWIwNDY5NGE3OTkzNTVhY2E0ZjUwODNjZTNfMS0xLTEtMS0zMzYw_472025f7-cdea-4985-a2b2-65b4ddf0aada"
      unitRef="number">0.1150</us-gaap:DebtInstrumentMeasurementInput>
    <evlo:ClassOfWarrantOrRightFairValueMeasurement
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMTI2NDQzODM3NTA2Nzc_c4f88aa1-960a-44bf-8640-cbcf00e859a0"
      unitRef="usd">1800000</evlo:ClassOfWarrantOrRightFairValueMeasurement>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ic49bab0cb25344b6bfe44ce28d21e862_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmNhYzQyYmZlMGUzYTQxMmI5MDMyNTE0MGU3MGJkOGIzL3RhYmxlcmFuZ2U6Y2FjNDJiZmUwZTNhNDEyYjkwMzI1MTQwZTcwYmQ4YjNfMC0xLTEtMS0zMzk1_29a85f31-d29e-4ec0-946d-e042a3111273"
      unitRef="number">16.13</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmNhYzQyYmZlMGUzYTQxMmI5MDMyNTE0MGU3MGJkOGIzL3RhYmxlcmFuZ2U6Y2FjNDJiZmUwZTNhNDEyYjkwMzI1MTQwZTcwYmQ4YjNfMS0xLTEtMS0zMzc3_ab3cd778-f766-4970-af88-7c4dd91fe641"
      unitRef="usdPerShare">13.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="id28c87a274884b02ba4528a21cc51ba2_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmNhYzQyYmZlMGUzYTQxMmI5MDMyNTE0MGU3MGJkOGIzL3RhYmxlcmFuZ2U6Y2FjNDJiZmUwZTNhNDEyYjkwMzI1MTQwZTcwYmQ4YjNfMi0xLTEtMS0zMzgw_9efeb3de-012c-4fd5-9197-c11cb6cf17f4"
      unitRef="number">0.0156</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ie40915ff285a4e0ca8014dd9b85400f9_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmNhYzQyYmZlMGUzYTQxMmI5MDMyNTE0MGU3MGJkOGIzL3RhYmxlcmFuZ2U6Y2FjNDJiZmUwZTNhNDEyYjkwMzI1MTQwZTcwYmQ4YjNfMy0xLTEtMS0zMzgy_2e5ecf50-4c6e-4467-b3f8-699f58be6d4d"
      unitRef="number">0.700</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i0e3286835f544983bf8e9e5ef60645a8_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmNhYzQyYmZlMGUzYTQxMmI5MDMyNTE0MGU3MGJkOGIzL3RhYmxlcmFuZ2U6Y2FjNDJiZmUwZTNhNDEyYjkwMzI1MTQwZTcwYmQ4YjNfNC0xLTEtMS0zMzg0_f66b6f57-1d21-45fb-a8d7-0006743ed4e0"
      unitRef="number">10.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="icd82a12aaa9b4540a734fd0196a83792_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmNhYzQyYmZlMGUzYTQxMmI5MDMyNTE0MGU3MGJkOGIzL3RhYmxlcmFuZ2U6Y2FjNDJiZmUwZTNhNDEyYjkwMzI1MTQwZTcwYmQ4YjNfNS0xLTEtMS0zMzg3_00828b86-84bd-4d46-aae2-257394198925"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i36ffcd3447c14d9996b5b94964c58bc7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA4NTk1MA_cc3d3330-eeb9-40e2-81c9-4543ea8684d4"
      unitRef="usd">-3200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMzAzNw_424b6f3c-92db-49a3-b818-5c2c37c657f0">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company has the following minimum aggregate future loan payments at June 30, 2021 (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Twelve month period ending June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest and discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths
      contextRef="i2a4ed55838494b35ab23f220a76b8c3b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmRmN2VjZGQzYThiNzQ2NTBhYjI4MDgwYjA0ZmU3OTNlL3RhYmxlcmFuZ2U6ZGY3ZWNkZDNhOGI3NDY1MGFiMjgwODBiMDRmZTc5M2VfMS0yLTEtMS0w_b521bc51-0a1b-472d-a869-8053d05dd8c4"
      unitRef="usd">3893000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
      contextRef="i2a4ed55838494b35ab23f220a76b8c3b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmRmN2VjZGQzYThiNzQ2NTBhYjI4MDgwYjA0ZmU3OTNlL3RhYmxlcmFuZ2U6ZGY3ZWNkZDNhOGI3NDY1MGFiMjgwODBiMDRmZTc5M2VfMi0yLTEtMS0w_e55b9560-86be-45a9-8984-f3447985aaad"
      unitRef="usd">13348000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree
      contextRef="i2a4ed55838494b35ab23f220a76b8c3b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmRmN2VjZGQzYThiNzQ2NTBhYjI4MDgwYjA0ZmU3OTNlL3RhYmxlcmFuZ2U6ZGY3ZWNkZDNhOGI3NDY1MGFiMjgwODBiMDRmZTc5M2VfMy0yLTEtMS0w_3fe17898-2e93-4b11-8384-bc55fc52d1ee"
      unitRef="usd">32096000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour
      contextRef="i2a4ed55838494b35ab23f220a76b8c3b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmRmN2VjZGQzYThiNzQ2NTBhYjI4MDgwYjA0ZmU3OTNlL3RhYmxlcmFuZ2U6ZGY3ZWNkZDNhOGI3NDY1MGFiMjgwODBiMDRmZTc5M2VfNC0yLTEtMS0w_0daa9b46-4481-4617-a7ff-e130db115f92"
      unitRef="usd">7316000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2a4ed55838494b35ab23f220a76b8c3b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmRmN2VjZGQzYThiNzQ2NTBhYjI4MDgwYjA0ZmU3OTNlL3RhYmxlcmFuZ2U6ZGY3ZWNkZDNhOGI3NDY1MGFiMjgwODBiMDRmZTc5M2VfNS0yLTEtMS0w_3c656950-8974-428b-9a30-699d44a8afd7"
      unitRef="usd">56653000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i2a4ed55838494b35ab23f220a76b8c3b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmRmN2VjZGQzYThiNzQ2NTBhYjI4MDgwYjA0ZmU3OTNlL3RhYmxlcmFuZ2U6ZGY3ZWNkZDNhOGI3NDY1MGFiMjgwODBiMDRmZTc5M2VfNi0yLTEtMS0w_bf3111bd-dad5-4918-87f6-a73ee546907d"
      unitRef="usd">10171000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i2a4ed55838494b35ab23f220a76b8c3b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RhYmxlOmRmN2VjZGQzYThiNzQ2NTBhYjI4MDgwYjA0ZmU3OTNlL3RhYmxlcmFuZ2U6ZGY3ZWNkZDNhOGI3NDY1MGFiMjgwODBiMDRmZTc5M2VfNy0yLTEtMS0w_bdb87cd7-ab3f-4084-b01f-f7b956d724da"
      unitRef="usd">46482000</us-gaap:LongTermDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i8a5c6f6b678f44e49e72b10e4ab0fa04_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjk5Mg_9a8100f2-ff72-4719-b1c7-5769f6b64366"
      unitRef="usd">800000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i70765e47bdc740f0bad65affe0499791_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMTA5OTUxMTY0NDE1MA_eaf0702e-d36d-475d-9fc0-9edf52eeede1"
      unitRef="usd">1600000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ia4b11afcb9454eceac785c36df755e25_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA3NDA3NQ_704fc6f8-a55e-4339-a215-f3434ae815cc"
      unitRef="usd">400000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ifea6f295155b467cbdb20351f1ee7713_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81Mi9mcmFnOmNmYjBkNGE2NDllNjQ3MGViNDU0YTg0YjdmMDI5NDE0L3RleHRyZWdpb246Y2ZiMGQ0YTY0OWU2NDcwZWI0NTRhODRiN2YwMjk0MTRfMjc0ODc3OTA3NDA4OQ_7d189358-8631-4965-a26e-7467d2e5ebe3"
      unitRef="usd">800000</us-gaap:InterestExpenseDebt>
    <evlo:NonRefundableUpfrontFee
      contextRef="ie543e908236043ba8be6cd894642aa5a_D20170806-20170806"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81NS9mcmFnOmMzMjU0NDBlMjRlYTQ1YzU4ZWNjZTdkOTMwMmM3NjRiL3RleHRyZWdpb246YzMyNTQ0MGUyNGVhNDVjNThlY2NlN2Q5MzAyYzc2NGJfMTE4OA_d70f6f62-d9c7-422b-afef-af2e72b7bac5"
      unitRef="usd">200000</evlo:NonRefundableUpfrontFee>
    <evlo:MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent
      contextRef="if17724f9bb3d4db2ba6331a7cac91d1a_D20170806-20170806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81NS9mcmFnOmMzMjU0NDBlMjRlYTQ1YzU4ZWNjZTdkOTMwMmM3NjRiL3RleHRyZWdpb246YzMyNTQ0MGUyNGVhNDVjNThlY2NlN2Q5MzAyYzc2NGJfMTU3NA_09f82eb8-4f27-4bc9-8d48-56e23e8beef9"
      unitRef="usd">56000000.0</evlo:MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent>
    <evlo:MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent
      contextRef="i9b9e276c407a458f9f69449a649920dc_D20210630-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81NS9mcmFnOmMzMjU0NDBlMjRlYTQ1YzU4ZWNjZTdkOTMwMmM3NjRiL3RleHRyZWdpb246YzMyNTQ0MGUyNGVhNDVjNThlY2NlN2Q5MzAyYzc2NGJfMTc2OA_adbf8a98-40d3-4fb5-9ea2-9f2fef3e8323"
      unitRef="usd">300000</evlo:MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent>
    <us-gaap:ContractualObligation
      contextRef="i7427f0ed143e4184939402103a418a1a_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81NS9mcmFnOmMzMjU0NDBlMjRlYTQ1YzU4ZWNjZTdkOTMwMmM3NjRiL3RleHRyZWdpb246YzMyNTQ0MGUyNGVhNDVjNThlY2NlN2Q5MzAyYzc2NGJfMTgwMA_1af8c0d4-8b9d-4187-98ba-8849ff1f82f9"
      unitRef="usd">0</us-gaap:ContractualObligation>
    <evlo:NonRefundableUpfrontFee
      contextRef="i86362fee842547b9bde5128b9b9d7696_D20160310-20160310"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81NS9mcmFnOmMzMjU0NDBlMjRlYTQ1YzU4ZWNjZTdkOTMwMmM3NjRiL3RleHRyZWdpb246YzMyNTQ0MGUyNGVhNDVjNThlY2NlN2Q5MzAyYzc2NGJfMjQxMw_90e7c2e0-79d4-4878-8e39-7446673d68e7"
      unitRef="usd">500000</evlo:NonRefundableUpfrontFee>
    <evlo:MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent
      contextRef="i941118753f0c4ff3a809cf847fa3cc04_D20160310-20160310"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81NS9mcmFnOmMzMjU0NDBlMjRlYTQ1YzU4ZWNjZTdkOTMwMmM3NjRiL3RleHRyZWdpb246YzMyNTQ0MGUyNGVhNDVjNThlY2NlN2Q5MzAyYzc2NGJfMjc0Ng_9ffa52e7-6ae6-4bc7-b0c0-83331642a975"
      unitRef="usd">60900000</evlo:MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent>
    <evlo:MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts
      contextRef="i365ea6e18e0541caa57a11096b3a89a2_D20210630-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81NS9mcmFnOmMzMjU0NDBlMjRlYTQ1YzU4ZWNjZTdkOTMwMmM3NjRiL3RleHRyZWdpb246YzMyNTQ0MGUyNGVhNDVjNThlY2NlN2Q5MzAyYzc2NGJfMzAyNA_f16539cb-bc00-4ac1-b433-1a30f5489ae4"
      unitRef="usd">400000</evlo:MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts>
    <us-gaap:ContractualObligation
      contextRef="i83fa1bd396e94b03ba1d3567b925edf7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81NS9mcmFnOmMzMjU0NDBlMjRlYTQ1YzU4ZWNjZTdkOTMwMmM3NjRiL3RleHRyZWdpb246YzMyNTQ0MGUyNGVhNDVjNThlY2NlN2Q5MzAyYzc2NGJfMzA1Ng_d1785218-56c9-46d0-a963-a9566a93c5e7"
      unitRef="usd">0</us-gaap:ContractualObligation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81OC9mcmFnOjFiNWI1ZTU0NjljZDRiOGJhMmY2ZWIwNTYwMmY0OTI4L3RleHRyZWdpb246MWI1YjVlNTQ2OWNkNGI4YmEyZjZlYjA1NjAyZjQ5MjhfMTg3NQ_856ab4fd-94d2-426e-aafb-1ded402a3d68">Commitments and Contingencies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Collaboration Agreement with Sacco S.r.l.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company entered into an agreement with Sacco S.r.l. ("Sacco"), an affiliate of one of the Company&#x2019;s existing contract manufacturing organizations, pursuant to which and subject to certain exceptions for pre-existing products for pre-existing customers, Sacco will manufacture and supply single strain, non-genetically modified microbes intended for oral delivery or oral use in pharmaceutical products exclusively for the Company for a period of five years. Sacco may terminate the agreement if the provision of manufacturing services has been, or is scheduled to be, inactive for a period of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81OC9mcmFnOjFiNWI1ZTU0NjljZDRiOGJhMmY2ZWIwNTYwMmY0OTI4L3RleHRyZWdpb246MWI1YjVlNTQ2OWNkNGI4YmEyZjZlYjA1NjAyZjQ5MjhfNjgz_325d5ea5-b4c5-433d-9fed-b5f892efb0bc"&gt;six&lt;/span&gt; consecutive months. The Company has agreed to pay Sacco an aggregate of &#x20ac;3.0 million, &#x20ac;0.6 million annually, during the exclusivity period. The Company has incurred annual exclusivity fees to date totaling approximately &#x20ac;1.2 million, and no amounts are currently due as of June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation and Other Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may periodically become subject to legal proceedings and claims arising in connection with on-going business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which the Company is focused.&#160;The Company is not a party to any material litigation and does not have contingency reserves established for any litigation liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A Notice of Opposition was filed against European Patent No. 3223834, which is held by the Company. In July 2021, the Company filed its reply to the Opposition. The patent at issue does not relate to any of the Company&#x2019;s current product candidates, and any subsequent proceeding is not expected to affect any of the Company&#x2019;s current development plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <evlo:CollaborationArrangementTerm
      contextRef="i92aa56851c3d4aa1842d25b81d3cf9b9_D20190701-20190731"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81OC9mcmFnOjFiNWI1ZTU0NjljZDRiOGJhMmY2ZWIwNTYwMmY0OTI4L3RleHRyZWdpb246MWI1YjVlNTQ2OWNkNGI4YmEyZjZlYjA1NjAyZjQ5MjhfNTQ0_e33f3a0c-7d18-4a8b-9712-0455c0c04e36">P5Y</evlo:CollaborationArrangementTerm>
    <evlo:AggregateAmountDueUnderCollaborativeArrangement
      contextRef="i0d31ed85dd8b45629814b83f4f060752_I20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81OC9mcmFnOjFiNWI1ZTU0NjljZDRiOGJhMmY2ZWIwNTYwMmY0OTI4L3RleHRyZWdpb246MWI1YjVlNTQ2OWNkNGI4YmEyZjZlYjA1NjAyZjQ5MjhfNzU4_39cad74e-fad9-466e-b541-c550645782af"
      unitRef="eur">3000000.0</evlo:AggregateAmountDueUnderCollaborativeArrangement>
    <evlo:AnnualAmountDueUnderCollaborativeArrangement
      contextRef="i0d31ed85dd8b45629814b83f4f060752_I20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81OC9mcmFnOjFiNWI1ZTU0NjljZDRiOGJhMmY2ZWIwNTYwMmY0OTI4L3RleHRyZWdpb246MWI1YjVlNTQ2OWNkNGI4YmEyZjZlYjA1NjAyZjQ5MjhfNzYy_f1d524fb-adba-4ce4-9b46-10d3cc193c50"
      unitRef="eur">600000</evlo:AnnualAmountDueUnderCollaborativeArrangement>
    <evlo:FeeIncurredUnderCollaborativeArrangement
      contextRef="i164ea06cf00343df9b0f2f326af8a9e6_D20190701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81OC9mcmFnOjFiNWI1ZTU0NjljZDRiOGJhMmY2ZWIwNTYwMmY0OTI4L3RleHRyZWdpb246MWI1YjVlNTQ2OWNkNGI4YmEyZjZlYjA1NjAyZjQ5MjhfODg2_0b37e039-6656-421c-b2d1-f0ab06998c73"
      unitRef="eur">1200000</evlo:FeeIncurredUnderCollaborativeArrangement>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMTU5MA_23b165ce-b2fe-41a4-bad1-2dcf073e1266">Stockholders&#x2019; Equity&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 3, 2019, the Company filed the Shelf with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof in the aggregate amount of up to $200.0 million for a period of up to three years from the date of the filing. The Company also simultaneously entered into the ATM, providing for the offering, issuance and sale by the Company of up to an aggregate $50.0 million of its common stock from time to time in &#x201c;at-the-market&#x201d; offerings under the Shelf. For the three and six months ended June 30, 2021, the Company sold no common shares and 139,734 common shares, respectively, under the ATM with offering prices ranging between $12.54 and $13.17 per share for gross proceeds of net proceeds of $1.7 million, after deducting commission and other offering expenses payable by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 2, 2021, the Company sold 5,175,000 shares of its common stock in an underwritten public offering at a public offering price of $15.00 per share, including the underwriters' exercise of their option to purchase 675,000 shares to cover over-allotment, generating gross proceeds of $77.6 million and net proceeds of underwriting discounts and commission of $72.7 million, after deducting underwriting discounts and commission and other offering expenses paid by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 28, 2021, the Company entered into a stock purchase agreement with ALJ Health Care &amp;amp; Life Science Company Limited ("ALJ Health Care"), pursuant to which on February 2, 2021, ALJ Health Care purchased $7.5 million of the Company's common stock in a private placement at a purchase price of $15.00 per share, equal to the public offering price per share at which the Company's common stock was sold to the public as referred above. The sale of such shares was not registered under the Securities Act.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the entry into the Amended Credit Facility, the Company issued to K2 HealthVentures Equity Trust LLC, an affiliate of K2HV, a warrant to purchase up to 139,770 shares of the Company&#x2019;s common stock, with an exercise price of $13.30 per share, subject to customary per share adjustments. The Warrant is exercisable immediately and expires on June 16, 2031, provided that, under certain circumstances, the Warrant may terminate and expire earlier in connection with the closing of certain acquisition transactions involving the Company. The Warrant provides that the holder thereof may elect to exercise the Warrant on a net &#x201c;cashless&#x201d; basis at any time prior to the expiration thereof. The fair market value of one share of the Company&#x2019;s common stock in connection with any cashless exercise shall be the closing price or last sale price per share of the Company&#x2019;s common stock on &lt;/span&gt;&lt;/div&gt;a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market on which the Company&#x2019;s common stock is traded on the business day immediately prior to the date the holder elects to exercise the Warrant on a cashless basis. In addition, under the Amended Credit Facility, K2HV has the option, exercisable at any time, to convert up to $5.0&#160;million of principal outstanding into shares of the Company&#x2019;s common stock at a conversion price of $13.30 per share, subject to customary per share adjustments.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction
      contextRef="i96b3bb04ea99475da5fa00256059d7c5_I20190603"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMjY0_acd4af90-d091-4bce-852f-082fd5d1d258"
      unitRef="usd">200000000.0</evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction>
    <evlo:SaleOfStockConsiderationReceivedTerm
      contextRef="i98b9be65b14c4e408ab7e4e90ae4e487_D20190603-20190603"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMjg5_964abc37-5493-4d46-b984-e7b15e3f2f40">P3Y</evlo:SaleOfStockConsiderationReceivedTerm>
    <evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction
      contextRef="ie55b778fc78c4838bd7596f7406fc60a_I20190603"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfNDU4_1182f92b-0d15-47fb-8e26-907007650a7b"
      unitRef="usd">50000000.0</evlo:SaleOfStockMaximumValueOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i010bde50e313426284f4a5003a97bcf6_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfNTkw_77c44e54-6225-4df9-8bef-30aa5d6dedd5"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i76cffaf0b6414a3a83a13544db4cb9c8_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMTA5OTUxMTYyOTM3NA_4966a3ff-4b18-4654-abea-1ca72a3eeb1b"
      unitRef="shares">139734</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i0f65daef97744a4e9f23fb6fc142b479_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfNjU4_f913adb4-7415-47a4-899b-3cd3170c0da3"
      unitRef="usdPerShare">12.54</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia8fd128806d244458684e149d6ba270a_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfNjY1_ed92506e-9b85-499c-be81-01283e661a5c"
      unitRef="usdPerShare">13.17</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i010bde50e313426284f4a5003a97bcf6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfNzIz_41065bba-194e-4bac-b385-d9d2b42d771b"
      unitRef="usd">1700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i97a49e3e6ef940f7bd323a42dee5db4e_D20210202-20210202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfODQ1_86271de6-cac0-4fae-aab4-e6a1f61f59db"
      unitRef="shares">5175000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i919df7faea17493d83eded85125492f6_I20210202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfOTQw_b134e678-ffbf-49ba-b1c5-c84d2c663c60"
      unitRef="usdPerShare">15.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie79b06c6d089457580ee83ab0fc4178c_D20210202-20210202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMTAxOQ_c735e076-ac9d-4373-a3de-578977895417"
      unitRef="shares">675000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <evlo:SaleOfStockGrossConsiderationReceivedOnTransaction
      contextRef="i97a49e3e6ef940f7bd323a42dee5db4e_D20210202-20210202"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMTA4Mw_3cdb558c-9545-4191-82e6-da03959ae202"
      unitRef="usd">77600000</evlo:SaleOfStockGrossConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i97a49e3e6ef940f7bd323a42dee5db4e_D20210202-20210202"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMTE0Nw_fc22d3b1-4d26-469c-a05a-46d859bfd619"
      unitRef="usd">72700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i035578f695544ed4b1cd5c6d23c4dec9_D20210202-20210202"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMTMwMw_0db11a32-296a-456b-8c71-8d915cfe9ef9"
      unitRef="usd">7500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i2be50d786c924771a879f8ead446e51e_I20210202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMTM4Mg_0b43915c-4fe5-4e3f-bfcd-a77348fc5958"
      unitRef="usdPerShare">15.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMjc0ODc3OTA3OTYwMQ_eeb5519d-beaa-43f7-831a-5e469ce5a9d6"
      unitRef="shares">139770</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMjc0ODc3OTA3OTYxMA_3d286587-f904-407d-955a-9ab29346f4d2"
      unitRef="usdPerShare">13.30</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ConvertibleDebt
      contextRef="ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMjc0ODc3OTA3OTYxOA_7900ad16-c58b-4d09-a696-643eecb20587"
      unitRef="usd">5000000.0</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82MS9mcmFnOjc5ZjBmODJkNzU3ZDQzMGFhNjIxOWJhMjNjYmRiMjAzL3RleHRyZWdpb246NzlmMGY4MmQ3NTdkNDMwYWE2MjE5YmEyM2NiZGIyMDNfMjc0ODc3OTA3OTYzMg_d4af917f-f333-4968-9cf2-42f995a213ed"
      unitRef="usdPerShare">13.30</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjQ1NA_8fa1e9ee-c6b4-40e1-ad4e-3cba6cfbe3a7">Stock-Based Compensation&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Inducement Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 27, 2021, the Company&#x2019;s board of directors adopted the Evelo Biosciences, Inc. 2021 Employment Inducement Award Plan (the &#x201c;Inducement Award Plan&#x201d;) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules (&#x201c;Rule 5635(c)(4)&#x201d;). In accordance with Rule 5635(c)(4), cash and equity-based incentive awards under the Inducement Award Plan may only be made to a newly hired employee who has not previously been a member of the Company&#x2019;s board of directors, or an employee who is being rehired following a bona fide period of non-employment by the Company or a subsidiary, as a material inducement to the employee&#x2019;s entering into employment with the Company or its subsidiary. An aggregate of 1,250,000 shares of the Company&#x2019;s common stock have been reserved for issuance under the Inducement Award Plan. The Company will continue to grant awards under the 2018 Incentive Award Plan (the &#x201c;2018 Plan&#x201d;) pursuant to the terms thereof.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price of stock options granted under the Inducement Award Plan will not be less than the fair market value of a share of the Company&#x2019;s common stock on the grant date. Other terms of awards, including vesting requirements, are determined by the Company&#x2019;s board of directors and are subject to the provisions of the Inducement Award Plan. Stock options granted to employees generally vest over a four-year period but may be granted with different vesting terms. Certain options may provide for accelerated vesting in the event of a change in control. Stock options granted under the Inducement Award Plan expire no more than 10 years from the date of grant. As of June 30, 2021, stock option awards covering up to 550,000 shares of the Company&#x2019;s common stock have been issued under the Inducement Award Plan, none of which have been exercised or canceled. As of June 30, 2021, restricted stock unit (&#x201c;RSU&#x201d;) awards covering up to 4,545 shares of the Company&#x2019;s common stock have been granted under the Inducement Award Plan, none of which have vested or been forfeited.  As of June 30, 2021, 695,455 shares of common stock are available for future grant under the Inducement Award Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Incentive Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s board of directors adopted on April&#160;18, 2018, and the Company&#x2019;s stockholders approved, the 2018 Plan, which became effective May 8, 2018 and under which the Company may grant cash and equity-based incentive awards to the Company&#x2019;s employees, officers, directors, consultants and advisors. Following the effectiveness of the 2018 Plan, the Company ceased making grants under the 2015 Stock Incentive Plan (as amended, the "2015 Plan"). The 2018 Plan initially allowed the Company to grant awards for up to 1,344,692&#160;shares of common stock plus that number of shares of common stock subject to awards outstanding under the 2015 Plan that expire, lapse or become terminated or are exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited following the effective date of the 2018 Plan. Each year starting with 2019 and ending in and including 2028, the number of shares available for grants of awards under the 2018 Plan will be increased automatically on January&#160;1 by a number of shares of common stock equal to the lesser of 4% of the shares of common stock outstanding on the final day of the preceding calendar year or the number of shares determined by the Company&#x2019;s board of directors. Accordingly, on January 1, 2021 and 2020, the number of shares authorized for issuance under the 2018 Plan was increased by 1,898,805 shares and 1,286,824 shares, respectively. The 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price of stock options granted under the 2018 Plan will not be less than the fair market value of a share of the Company&#x2019;s common stock on the grant date. Other terms of awards, including vesting requirements, are determined by the board of directors and are subject to the provisions of the 2018 Plan. Stock options granted to employees generally vest over a four-year period but may be granted with different vesting terms. Certain options provide for accelerated vesting in the event of a change in control. Awards granted to non-employee consultants generally vest monthly over a period of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjIwMw_7adb7c68-f638-4357-9bd2-eeb01a3b009e"&gt;one&lt;/span&gt; to four years. Stock options granted under the 2018 Plan expire no more than 10 years from the date of grant. As of June 30, 2021,&#160;stock options awards covering up to 6,557,456 shares of the Company&#x2019;s common stock have been issued under the 2018 Plan, of which 34,748 have been &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;exercised and 977,561 have been canceled. As of June 30, 2021, 647,704 shares of common stock are available for future grant under the 2018 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2015 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the approval of the 2018 Plan, the Company granted equity awards under the 2015 Plan, which originally provided for grant of incentive stock options, non-qualified stock options, restricted stock awards ("RSAs"), and other stock-based awards to the Company&#x2019;s employees, officers, directors, consultants and advisors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of equity award agreements, including vesting requirements, were determined by the board of directors and are subject to the provisions of the 2015 Plan. Stock options granted to employees generally vest over a four-year period but may be granted with different vesting terms. A limited number of awards contain performance-based vesting criteria and for such awards that are deemed probable of vesting, the Company records expense in the period in which such determination is made through any estimated remaining vesting period. Certain options provide for accelerated vesting in the event of a change in control. Awards granted to non-employee consultants generally vest monthly over a period of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMzYzNw_fddafaeb-2db2-49ee-b233-bca37709f790"&gt;one&lt;/span&gt; to four years. Stock options issued under the 2015 Plan expire no more than 10 years from the date of grant. As of the effectiveness of the 2018 Plan, the Company ceased making awards under the 2015 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2015 Plan, the Company was authorized to grant equity awards up to an aggregate of 5,417,044 shares of common stock.&#160;As of June 30, 2021, an aggregate of 5,758,536 options and other equity awards had been granted under the 2015 Plan, of which 1,431,864 have been exercised, 1,275,971 have been canceled and 18,468 have been repurchased as of June 30, 2021. A total of 113,006 shares previously reserved under the 2015 Plan that had not been exercised or were otherwise subject to outstanding exercise awards were no longer authorized for issuance under the 2015 Plan as of May&#160;8, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense included in the Company&#x2019;s unaudited condensed consolidated statements of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity and related information is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,610,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,731,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,145,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,443,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average fair value of options granted during the six months ended June 30, 2021 and 2020 was $11.52 and $4.45, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2021, total unrecognized stock-based compensation expense relating to unvested stock options was $38.7 million. This amount is expected to be recognized over a weighted average period of 2.76 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the RSU activity and related information is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to RSUs was $0.2 million and $0.3&#160;million, respectively, for the three months and six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's board of directors adopted on April&#160;18, 2018, and the Company&#x2019;s stockholders approved, the 2018 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which became effective on May&#160;8, 2018. A total of&#160;336,356&#160;shares of common stock were initially reserved for issuance under the ESPP. In addition, the number of shares of common stock that may be issued under the ESPP will automatically increase on the first day of each calendar year, beginning in 2020 and ending in and including 2028, by an amount equal to the lesser of (i)&#160;1%&#160;of the number of shares of the Company&#x2019;s common stock outstanding on the last day of the applicable preceding calendar year and (ii)&#160;an amount determined by the Company&#x2019;s board of directors. The Company's board of directors authorized an initial offering period under the ESPP commencing on February 1, 2020. Accordingly, on January 1, 2021, the number of shares authorized for issuance under the ESPP was increased by 474,701 shares.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The compensation expense recognized related to the ESPP for the three and six ended June 30, 2021 and 2020 was not material. There was a total of 0 shares and 27,587 shares, respectively, purchased under the ESPP during the three and six months ended June 30, 2021. There were no shares purchased under the ESPP during both the three months and six months ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ifb6d09c7800f4db9a1cac4fda45089ce_I20210527"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjc0ODc3OTA4MDQzMw_10fc0422-2151-4bab-a492-ee0bd8486a4b"
      unitRef="shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="id28aed25ea8f4f7a93a8c6b2b8ce0a14_D20210527-20210527"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjc0ODc3OTA4MDQ0Ng_3d5f90d7-4466-4755-b4a1-0ae85946b416">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i20e8a93172c24d2e8206286eb8d49a61_D20210630-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjc0ODc3OTA4MDQ1OQ_425180bc-b7e8-463e-8f2d-21c69a0cddc3"
      unitRef="shares">550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i07d88ed7511c4fb488a9c834ac2afc00_D20210630-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjc0ODc3OTA4MDQ2OA_b8f59b4c-d649-47b7-b007-22f30cd43352"
      unitRef="shares">4545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i66585702ee8849e499356a9f4a40d9e0_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjc0ODc3OTA4MDQ3NQ_a3780fa1-585d-4d23-ba5d-aae7a0885377"
      unitRef="shares">695455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i6a806946e01c43c7ab029fa63c0a7c9c_I20180508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjEz_fcf5d305-c09e-4597-9c19-e986c949fd9b"
      unitRef="shares">1344692</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i61004b706937441f80332b86f6a1bd00_D20180508-20180508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMTE3MQ_6491258a-a92d-4dbf-9803-ed4885e14368"
      unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i15a5020b711f4d87bba0d1d0b69566cd_D20210101-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMTQ2MA_bc7d0a03-2dbd-412e-a102-8639be8ca629"
      unitRef="shares">1898805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ic350846ea0d2431d965b88729486c075_D20200101-20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMTQ3NA_42b6bb6c-0640-436e-b10d-892215a88331"
      unitRef="shares">1286824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic4d990381fac4ad886d7990c63587b3a_D20180508-20180508"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjQ1NQ_6e5bb034-0128-467c-b1f8-1ade87b18d30">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iccf9f430cf7d4c31a2c537f0e85686ac_D20180508-20180508"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjIwOQ_af4e4673-4970-473c-89e5-054495a47f4f">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i224b3142ac434b7d8db8a216dec30657_D20180508-20180508"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjI3NQ_bb9a69b9-a2a4-47d7-9799-5343ee19b1f8">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ib090cc4aa98c45f4b479a5057e7bfe0a_D20210630-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjM1NA_27cd79a2-ddd0-47b4-8860-d75142fc986a"
      unitRef="shares">6557456</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib090cc4aa98c45f4b479a5057e7bfe0a_D20210630-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjQ0MQ_2c9c4c71-12c0-44f9-908d-add2028376ae"
      unitRef="shares">34748</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ib090cc4aa98c45f4b479a5057e7bfe0a_D20210630-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjQ2OA_f5744003-980c-4e72-92f0-ab87a0c6306b"
      unitRef="shares">977561</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i14af8565540e4dc6b3cb3fd98d163fef_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjUwMQ_7a9dc066-282b-4ee9-8dd9-1e6dc120742b"
      unitRef="shares">647704</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8244e41e2b0347a1ad64c9419ce3ec00_D20150101-20151231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjQ1Ng_47ccda22-1823-40cd-bb4e-b171e9db1d4b">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i633b84c50c4f4e7b81b89cb2a278bdee_D20150101-20151231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMzY0Mw_909fd93f-ab8f-437a-83d1-ce281968a9be">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i1a92391ffc2e4c5ea7bcfabcb58614d5_D20150101-20151231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMzcwOA_a4750b9f-e974-484e-867f-d867f96d682f">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i0b4b46cb61e94103b6de3a962ed2a13b_I20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMzkzMA_61c6ead6-8dfd-48aa-8acb-ce47bd5a20c5"
      unitRef="shares">5417044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted
      contextRef="ib60b517f490f4972bfa2ed9e3b09a3c0_D20150101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjc0ODc3OTA3OTQ1OQ_b0a6aab0-3392-42ee-8f9a-a461b4e619e5"
      unitRef="shares">5758536</evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted>
    <evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised
      contextRef="ib60b517f490f4972bfa2ed9e3b09a3c0_D20150101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNDA2NQ_979045fd-8746-4b27-b11a-9e83d3ea3259"
      unitRef="shares">1431864</evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised>
    <evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures
      contextRef="ib60b517f490f4972bfa2ed9e3b09a3c0_D20150101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNDA4OQ_f84765e6-13f6-48de-b886-3ef1d7fdd92b"
      unitRef="shares">1275971</evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures>
    <evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased
      contextRef="ib60b517f490f4972bfa2ed9e3b09a3c0_D20150101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNDExNQ_54b607b5-7d9e-452a-a3d9-2e5c3eada79d"
      unitRef="shares">18468</evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased>
    <evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease
      contextRef="ie9c74ef2f71c45ad87a3378e98258fc9_D20150101-20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNDE2MQ_02e65cb5-5046-4ad1-91e2-e126858f1c17"
      unitRef="shares">113006</evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjQ1Nw_6969490c-f020-4b81-b530-7d2ff601bfe6">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense included in the Company&#x2019;s unaudited condensed consolidated statements of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5e11f538a920421ba186e7c8b1a99dd5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfMi0yLTEtMS0w_3ae1b289-87f5-420a-b932-b4d5f29652e8"
      unitRef="usd">1723000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6a6ab7adc80d4824b666be8b229cb0b6_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfMi00LTEtMS0w_fe108cfa-4562-43eb-b25d-d2fbfdc819f1"
      unitRef="usd">1010000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8ac84e56b51542e4a5d75700b09622de_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfMi02LTEtMS0zMzg_87823fc9-a527-4724-92f3-f9801b5e44d9"
      unitRef="usd">3164000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i46432b66afa646449b4065dc8c030013_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfMi04LTEtMS0zMzg_964bb541-bd8f-4d54-a70b-51ac280c4780"
      unitRef="usd">1899000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic1b9cbd25a6b46d6a7303f0144b6f001_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfMy0yLTEtMS0w_4fef77cd-cc5f-4610-864c-06973fe12220"
      unitRef="usd">2049000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic45337ae21d448d582c46b1700091d22_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfMy00LTEtMS0w_f853c787-6161-4136-9ef8-8901a90e1dc1"
      unitRef="usd">1083000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7fdc9caf00ee42449ae612c261252ddf_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfMy02LTEtMS0zMzg_8a83b5ad-62b6-4c4e-8bbf-72807da99e51"
      unitRef="usd">3872000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if4ffafae80f64bc194e822d4073442a5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfMy04LTEtMS0zMzg_52eb08cf-6d25-43ca-8922-a57148290dce"
      unitRef="usd">2149000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfNC0yLTEtMS0w_aa067d3c-440b-4a30-97b0-ee326a3cdf08"
      unitRef="usd">3772000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfNC00LTEtMS0w_8dcdba18-826c-4c15-806b-07600750b7ae"
      unitRef="usd">2093000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfNC02LTEtMS0zMzg_92aaeb8c-8b9c-4c70-adf4-cb40059eb294"
      unitRef="usd">7036000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOmQ3YzBhYjJkZmQzZDQ5NmI5ZWU3MjkxZTRkYzA2NWNjL3RhYmxlcmFuZ2U6ZDdjMGFiMmRmZDNkNDk2YjllZTcyOTFlNGRjMDY1Y2NfNC04LTEtMS0zMzg_fb0ed3cb-0eed-46db-ac15-bbd1326c0689"
      unitRef="usd">4048000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjQ1Mg_5b02fc63-b954-42f9-8dc8-f2db1a1b7d1b">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity and related information is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,610,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,731,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,145,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,443,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfMS0yLTEtMS0w_d0fa8aee-82ae-4153-9af7-a3d194a94af1"
      unitRef="shares">6610662</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8a14b89c4bf046f7a9854dd49b9140b1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfMS00LTEtMS0w_6e56687d-11f2-4f18-a7b4-407a62ae1fa4"
      unitRef="usdPerShare">6.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfMi0yLTEtMS0w_21e5b50f-60fa-4404-804f-fc44e8e342ec"
      unitRef="shares">2731274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfMi00LTEtMS0w_599b12a8-0bb7-4d87-b81d-6853553fbf7c"
      unitRef="usdPerShare">15.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfMy0yLTEtMS0w_7c17d216-c7e0-46af-9bf9-fd3a7d85339d"
      unitRef="shares">85831</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfMy00LTEtMS0w_ceeeb4c5-b9f0-43cc-b288-c2b0cb319273"
      unitRef="usdPerShare">6.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfNC0yLTEtMS0w_ccb427d6-5c82-4f11-927b-d23e6845fc73"
      unitRef="shares">110267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfNC00LTEtMS0w_54871677-c716-4d77-b4be-6077aced650a"
      unitRef="usdPerShare">10.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfNS0yLTEtMS0w_f02cac83-4a44-43c5-b4b2-04c4c666846f"
      unitRef="shares">9145838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfNS00LTEtMS0w_792ed8e1-9754-4765-88a1-89f203b52873"
      unitRef="usdPerShare">9.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfNi0yLTEtMS0w_ab0baf13-b252-4a3b-ac50-4594aaa23592"
      unitRef="shares">4443028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjQ3NDI0YTk3ZmM1YTQzMGFiOWI3NThiOTdlNDk3NjY3L3RhYmxlcmFuZ2U6NDc0MjRhOTdmYzVhNDMwYWI5Yjc1OGI5N2U0OTc2NjdfNi00LTEtMS0w_be70e306-295a-47eb-9ff5-b81accebc4f4"
      unitRef="usdPerShare">6.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNDc1Mw_a619e74f-f3fe-4d87-83ee-fdd4b0c9d6ae"
      unitRef="usdPerShare">11.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNDc2MA_74c8e701-5d2f-4125-a634-4ac99606edad"
      unitRef="usdPerShare">4.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i5ba9feb93d764efd96698e68714de654_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNDg3OQ_0211406e-af19-486c-907e-375171a21617"
      unitRef="usd">38700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie2e1988c04664ea584a4c41ef9af23cc_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNDk1OA_5afa3a34-bf11-4792-b555-6ee4f074e067">P2Y9M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjQ1OA_986a1513-e32c-4c73-bc12-7e70c6e8b147">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the RSU activity and related information is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i20fc0d52b2a44c50902a857e8d3130d5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfMS0yLTEtMS0w_d1882404-8769-424c-a17d-710faaff1b8e"
      unitRef="shares">284000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i20fc0d52b2a44c50902a857e8d3130d5_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfMS00LTEtMS0w_3ec38ffc-b1b6-4e74-bc56-1b8012ea698a"
      unitRef="usdPerShare">4.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6bc4ea56ed944d86bdc1c166dd4863c8_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfMi0yLTEtMS0w_ea83024e-efa9-45fe-a9c4-1fbd2bebea88"
      unitRef="shares">172450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6bc4ea56ed944d86bdc1c166dd4863c8_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfMi00LTEtMS0w_c5b6d36b-4d3b-41f7-a2bc-f04581a01c62"
      unitRef="usdPerShare">15.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i6bc4ea56ed944d86bdc1c166dd4863c8_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfMy0yLTEtMS0w_97231eba-3929-42af-80ec-1a89802c5fc8"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6bc4ea56ed944d86bdc1c166dd4863c8_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfMy00LTEtMS0w_0f02486f-497c-4a7e-b411-a12d0462548e"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i6bc4ea56ed944d86bdc1c166dd4863c8_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfNC0yLTEtMS0w_424bca60-5e89-4f14-95b5-ceda36a34aac"
      unitRef="shares">36190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i6bc4ea56ed944d86bdc1c166dd4863c8_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfNC00LTEtMS0w_ac248b52-7cb9-4650-bfe5-161b3efaa7b1"
      unitRef="usdPerShare">6.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i262999f64df4419982435b7d11f2b955_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfNS0yLTEtMS0w_ab3e7b0e-d560-4f96-82b9-5b9fb49267a0"
      unitRef="shares">420260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i262999f64df4419982435b7d11f2b955_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RhYmxlOjliZWY0MjM0YzhlZTQzNmM5NWM0NGE3NTRkZDM1YzNjL3RhYmxlcmFuZ2U6OWJlZjQyMzRjOGVlNDM2Yzk1YzQ0YTc1NGRkMzVjM2NfNS00LTEtMS0w_bc40b46c-72ce-4e1f-8c97-b305a3d27b5d"
      unitRef="usdPerShare">8.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i729515b40c8f4158b6586a7ae12ab66e_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNTE0NQ_cca7c626-0970-4cc4-92f9-bfe35a033781"
      unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6bc4ea56ed944d86bdc1c166dd4863c8_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMTA5OTUxMTYzNDM5Nw_5fd86b78-322a-46ba-91d6-1be900fd03fd"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i264242fbfa064d8fbc4066b8f369a883_D20180508-20180508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNTQxNw_70bb1b20-6ae5-4be4-b837-12a788d2d1ac"
      unitRef="shares">336356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i264242fbfa064d8fbc4066b8f369a883_D20180508-20180508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNTc0MA_2996b1e2-128e-4ef3-8f21-d296063d935b"
      unitRef="number">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i13be462485cb4baebb145fda3b01ca07_D20210101-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjE2Mg_e4d3c96e-0463-45a1-b55e-ab5ef90c3c93"
      unitRef="shares">474701</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i57ce7e89580e42e29ea075112fdd665b_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjI5Ng_21ea8e93-1f44-4756-9867-c395d0c5f9cf"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i237329bf49a34a118ff127ea889dd7d9_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMTA5OTUxMTYzNDM5Mg_67cc1b03-61fa-4c66-9dad-cea0ffd38557"
      unitRef="shares">27587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i72fbaf5f78e84aa9be31492a6dfcfb3b_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjM3Mw_1787e445-d2a9-49de-bbb2-58c7e7291b71"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i28b06266364d412583cb80ca61576389_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfNjM3Mw_41c4c949-f741-40bb-abad-9f8f2874cd8c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82Ny9mcmFnOmRmMDQ4NWYwOTUyZjQwM2NiZTNlMWYxZjVlNGNkY2MwL3RleHRyZWdpb246ZGYwNDg1ZjA5NTJmNDAzY2JlM2UxZjFmNWU0Y2RjYzBfMTYzNQ_64ec0f03-fe4e-49a4-9082-dd2505d97a42">Income Taxes&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#x2019;s otherwise recognizable net deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) was enacted on March 27, 2020. The CARES Act contained several key provisions including: (i) five year carryback of net operating losses (&#x201c;NOLs&#x201d;), (ii) increase in amount of business interest expense deductible under Section 163(j) of the Internal Revenue Code from 30% to 50% for  tax years 2019 and 2020, (iii) delay of payment of employer payroll taxes, (iv) temporary refundable employee retention credit, (v) suspension of certain aviation and alcohol excise taxes and (vi) technical correction for qualified improvement property. As of June 30, 2021, the Company had deferred $0.4 million in employer payroll taxes pursuant to the CARES Act, of which $0.2 million is included in the accrued expenses and $0.2 million is included in the other noncurrent liabilities in these unaudited condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;For the six months ended June 30, 2021 and 2020 the Company recorded a tax provision of $0.2&#160;million and $0.2&#160;million, respectively, primarily related to the Company's wholly-owned UK subsidiary.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82Ny9mcmFnOmRmMDQ4NWYwOTUyZjQwM2NiZTNlMWYxZjVlNGNkY2MwL3RleHRyZWdpb246ZGYwNDg1ZjA5NTJmNDAzY2JlM2UxZjFmNWU0Y2RjYzBfMTY0MA_fa4d7dce-0ada-439a-a318-87bd03a7e7dd">Income TaxesDeferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#x2019;s otherwise recognizable net deferred tax assets.</us-gaap:IncomeTaxPolicyTextBlock>
    <evlo:SocialSecurityTaxEmployerDeferralCARESAct
      contextRef="i21310fe58f274896a1e3326b4c181e8a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82Ny9mcmFnOmRmMDQ4NWYwOTUyZjQwM2NiZTNlMWYxZjVlNGNkY2MwL3RleHRyZWdpb246ZGYwNDg1ZjA5NTJmNDAzY2JlM2UxZjFmNWU0Y2RjYzBfMTI3OA_348567be-4687-432d-8ace-da2fec363906"
      unitRef="usd">400000</evlo:SocialSecurityTaxEmployerDeferralCARESAct>
    <evlo:SocialSecurityTaxEmployerDeferralCARESAct
      contextRef="id41c0cbe7c784fe3aab81511b93b8580_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82Ny9mcmFnOmRmMDQ4NWYwOTUyZjQwM2NiZTNlMWYxZjVlNGNkY2MwL3RleHRyZWdpb246ZGYwNDg1ZjA5NTJmNDAzY2JlM2UxZjFmNWU0Y2RjYzBfMTM0Mw_b5b5fd1a-e571-49a8-a7b9-c24a04bcb4b9"
      unitRef="usd">200000</evlo:SocialSecurityTaxEmployerDeferralCARESAct>
    <evlo:SocialSecurityTaxEmployerDeferralCARESAct
      contextRef="id6fcef2a6164499a8a9a7fbb1013a8a9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82Ny9mcmFnOmRmMDQ4NWYwOTUyZjQwM2NiZTNlMWYxZjVlNGNkY2MwL3RleHRyZWdpb246ZGYwNDg1ZjA5NTJmNDAzY2JlM2UxZjFmNWU0Y2RjYzBfMTM4Ng_4d10accc-e11c-4fda-ad07-e426cc2885a8"
      unitRef="usd">200000</evlo:SocialSecurityTaxEmployerDeferralCARESAct>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82Ny9mcmFnOmRmMDQ4NWYwOTUyZjQwM2NiZTNlMWYxZjVlNGNkY2MwL3RleHRyZWdpb246ZGYwNDg1ZjA5NTJmNDAzY2JlM2UxZjFmNWU0Y2RjYzBfMjc0ODc3OTA3MTE5OA_5a002361-bd07-4b9a-b342-02fddb5ec066"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82Ny9mcmFnOmRmMDQ4NWYwOTUyZjQwM2NiZTNlMWYxZjVlNGNkY2MwL3RleHRyZWdpb246ZGYwNDg1ZjA5NTJmNDAzY2JlM2UxZjFmNWU0Y2RjYzBfMTA5OTUxMTYyOTQ2MQ_dc617cf3-a410-47ff-b057-5d11623b868b"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RleHRyZWdpb246NGY3YzliNmYzNjY5NGMxNDlhODRhN2IzODJmMjlmNDdfOTU5_193c7653-508b-467a-b70e-4c82b5e34a9b">Net Loss Per Share&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, issuance of common stock under the ESPP and restricted common stock, and exercise of the Warrant and Conversion Option under the Amended Credit Facility, outstanding during the period determined using the treasury stock methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and therefore basic and diluted net loss per share have been equivalent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents securities that have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested common stock from early exercise of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,145,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,385,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock offering from ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,690,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,445,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RleHRyZWdpb246NGY3YzliNmYzNjY5NGMxNDlhODRhN2IzODJmMjlmNDdfOTYw_66f8326e-62ec-4b6b-8cd2-a6e219e96772">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents securities that have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested common stock from early exercise of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,145,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,385,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Conversion option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock offering from ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,690,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,445,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia30b6f5d35ce44e69d65001940192f50_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfMi0yLTEtMS0w_f78e8bdb-96f2-426f-9e7d-d5ed741354ce"
      unitRef="shares">18386</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i498626a92f9c490982d76300e711e00a_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfMi00LTEtMS0w_e64fe155-0dcd-4acd-9418-eede43f26cfa"
      unitRef="shares">36772</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8a7d195f002343acae14514f10c6c103_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfMy0yLTEtMS0w_36504473-562e-4f9d-a552-67cf22613c72"
      unitRef="shares">9145838</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i82ff1a0e1f834c328bc95de6abf47cac_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfMy00LTEtMS0w_b24df68c-d7c1-4f4e-b815-019d5c111b26"
      unitRef="shares">6385572</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9858c60d7bed47b2814be6df654dc03d_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfNC0yLTEtMS0w_960a02c5-c51c-40a0-ac74-76af0e9ff344"
      unitRef="shares">139770</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id961f8a7a6d54ba294cfdd02a79a2129_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfNC00LTEtMS0w_9f57cd6a-d2bb-4a70-8a3b-bd33cf66bcad"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i39c0f1b46d6e4e668982c302cb6394a9_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfNS0yLTEtMS0yNjE2_f4f26d0b-a197-4ad0-8437-5cacad725ef9"
      unitRef="shares">375939</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if0a9f46458db4036b7b2307aa079dda5_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfNS00LTEtMS0zNDEy_f92d9ac0-23b6-498d-ae5e-7bd65f6db62f"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iff32a529f86d4871a555686343203169_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfNS0yLTEtMS0w_0bb9cd2f-da6e-4b91-8caa-48f72a1f0fde"
      unitRef="shares">10743</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i410f08d8ccf041caa3ee3b193f8c60ce_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfNS00LTEtMS0w_70ba09dc-2568-47ae-b25c-04fe13bbeccc"
      unitRef="shares">23492</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfNi0yLTEtMS0w_7e3233c4-c1a7-4f98-b61f-bff82d419cea"
      unitRef="shares">9690676</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83MC9mcmFnOjRmN2M5YjZmMzY2OTRjMTQ5YTg0YTdiMzgyZjI5ZjQ3L3RhYmxlOjUxNjlmY2RiMTY0ZDQ4NjRhZTdjZmJlNmU2ODQzMTg0L3RhYmxlcmFuZ2U6NTE2OWZjZGIxNjRkNDg2NGFlN2NmYmU2ZTY4NDMxODRfNi00LTEtMS0w_1d4f5eb4-5e54-4d9c-8494-6b90d610d58a"
      unitRef="shares">6445836</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfNDYyNw_b62a6c6a-412c-4866-b914-f707026a3375">Related Party Transactions&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives clinical advisory services from Weatherden Ltd. (&#x201c;Weatherden&#x201d;) under agreements that were entered into during 2017 and 2018. Duncan McHale, the Company&#x2019;s Chief Medical Officer, is a part owner of Weatherden. During the six months ended June 30, 2021 and 2020, the Company paid Weatherden $0.1 million and $0.4 million, respectively. As of June 30, 2021 and 2020, the amount due to Weatherden under the supply of service agreement was approximately 0.1 million and  $0.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the Company entered into a subleasing arrangement with Ring Therapeutics, Inc. (formerly VL46, Inc.), an affiliate of one of its stockholders, Flagship Venture Funds. Under the terms of the sublease, the Company invoiced Ring Therapeutics for an aggregate $0.9 million in rent payments which were due during the period from July&#160;1, 2018 through April&#160;30, 2020, the sublease expiration date, plus related taxes and lease operating costs. For the three and six months ended June 30, 2020, $0.1&#160;million and $0.3&#160;million, respectively, related to this sublease, inclusive of rent payments, taxes and operating expenses, has been recorded as an offset to operating expense within the unaudited condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a consulting agreement with David Epstein (the "Consulting Agreement"), the Company's Chairman of the Board, effective September 16, 2019 pursuant to which Mr. Epstein provides strategic advisory and other consulting services to the Company. The Consulting Agreement was amended on October 15, 2020 and again on April 9, 2021, and now has a term that is scheduled to end on June 30, 2022 unless terminated earlier by either Mr. Epstein or the Company upon 30 days&#x2019; notice, or 24 hours&#x2019; notice by the non-breaching party in the event of a breach. In accordance with the terms of the Consulting Agreement, on September 16, 2019, Mr. Epstein was granted an option to purchase 75,000 shares of the Company&#x2019;s common stock, which award vests in 36 equal monthly installments subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting dates. Under the Consulting Agreement as amended on October 15, 2020, Mr. Epstein also is entitled to receive (i) an annual equity award on each anniversary of the effective date of the Consulting Agreement in the form of an option to purchase shares of the Company&#x2019;s common stock having an aggregate grant date fair market value equal to approximately $0.2&#160;million, as determined by the &lt;/span&gt;&lt;/div&gt;Board in its discretion based on customary option pricing methodologies, which award vests in 12 equal monthly installments following the grant date, subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting date, and (ii) an aggregate annual cash consulting fee of $0.3&#160;million for his consulting services. In the event the Consulting Agreement is renewed for a term of less than one year, the aggregate grant date fair value of the corresponding annual equity award and the resulting number of shares of the Company&#x2019;s common stock purchasable under such annual equity award and the vesting schedule shall be adjusted proportionately to the length of the renewal term. On October 11, 2020, in connection with the commencement of his second year of service as a consultant to the Company, Mr. Epstein was granted an annual equity award in the form of an option to purchase 44,743 shares of the Company&#x2019;s common stock, which award vests in nine equal monthly installments, in each case subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting dates. Under the Consulting Agreement as amended on April 9, 2021, effective on June 30, 2021, Mr. Epstein is entitled to receive restricted stock units having an aggregate grant date fair value of approximately $0.5&#160;million, as determined by our Board of Directors in its discretion based on a 10-day trailing average of the closing price of our common stock on the Nasdaq Global Select Market, as his sole compensation for the provision of consulting services to the Company. The restricted stock units will vest in 12 substantially equal monthly installments following June 30, 2021, such that the restricted stock units shall be fully vested on June 30, 2022, subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting date. All of the foregoing options and restricted stock units, to the extent then outstanding, will be subject to accelerated vesting upon the occurrence of a change in control of the Company.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i53f72d5181794c719cc51cf350c7bdf5_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMzMx_ab81991c-ecfa-4eec-a333-e65451d5c505"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="id6b40b59cd064a4ca4af131a12d171b8_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMzM4_e8083e5a-d6ea-49f6-bd54-52fccebe3920"
      unitRef="usd">400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="ic8c74a5ad01f474d8d0477af135c17fb_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMTY0OTI2NzQ0NjM2Nw_ea8c406a-e342-4024-81c5-31341c576b06"
      unitRef="usd">100000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i31d0e9fb79cb425e871db75394a9796b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfNDU4_3bef8e3e-077e-4f9a-860c-ad4b7299b632"
      unitRef="usd">100000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i2aeea52635454325a295ece2390835bd_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfNzQ3_3b4a35a2-7f5c-4170-a013-31078637c9e6"
      unitRef="usd">900000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:SubleaseIncome
      contextRef="i6fcf73a3984d40db89f1eb2f15b08489_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMTY0OTI2NzQ2MDQwOQ_7c8d408b-2bb6-4448-9ed1-f834ed3e00df"
      unitRef="usd">100000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ia5e5f0be84e44e35888c7983719c6508_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMjc0ODc3OTA4ODIzMA_545de8cf-da1d-4c6f-82f2-7ddd19055eeb"
      unitRef="usd">300000</us-gaap:SubleaseIncome>
    <evlo:RelatedPartyTransactionConsultingContractTerminationNoticeTerm
      contextRef="ie19faf0f5e0c4db3b2f52a5594e2b9af_D20210409-20210409"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMTY0OQ_00a8886f-bb48-48c3-a0fd-d721007c2c1a">P30D</evlo:RelatedPartyTransactionConsultingContractTerminationNoticeTerm>
    <evlo:RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm
      contextRef="ie19faf0f5e0c4db3b2f52a5594e2b9af_D20210409-20210409"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMTY2NA_23c24fd4-1176-4b06-9644-00e45f5da3dd">PT24H</evlo:RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9a42be16340a41089a1cd8a571d2ff8e_D20190916-20190916"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMTg1NQ_1d1c99c1-60a2-43b4-9a7e-a80ecf97b44a"
      unitRef="shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <evlo:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments
      contextRef="i9a42be16340a41089a1cd8a571d2ff8e_D20190916-20190916"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMTkxNw_fb4cbc14-5490-40f9-920a-877a3660bc13"
      unitRef="installment">36</evlo:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments>
    <evlo:RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue
      contextRef="ia236d54dd6634fc7a8f1bf3a6bc3d785_I20201015"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMjQzNg_124f9cbb-edf1-471f-8100-9dcc5bb09af1"
      unitRef="usd">200000</evlo:RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue>
    <evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments
      contextRef="ia16626e077c84f1a8616489f51dfdabb_D20201015-20201015"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMjU1NQ_b9461ef9-544a-413d-ae4e-74d3c75ccbfc"
      unitRef="installment">12</evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments>
    <evlo:RelatedPartyTransactionAnnualCashConsultingFee
      contextRef="ia236d54dd6634fc7a8f1bf3a6bc3d785_I20201015"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMjgwNQ_bc100a3b-8e1e-4c47-a268-0e28381ac035"
      unitRef="usd">300000</evlo:RelatedPartyTransactionAnnualCashConsultingFee>
    <evlo:RelatedPartyTransactionConsultingContractRenewalTerm
      contextRef="ia16626e077c84f1a8616489f51dfdabb_D20201015-20201015"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMjkxMA_4652c5a4-5ed3-4908-80d7-d6727ef62324">P1Y</evlo:RelatedPartyTransactionConsultingContractRenewalTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i6986f547b61f46cb9e428885d5c4f66a_D20201011-20201011"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMzM5Ng_665a1370-a8ae-4d1f-b60d-c96868a23828"
      unitRef="shares">44743</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments
      contextRef="i6986f547b61f46cb9e428885d5c4f66a_D20201011-20201011"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMzQ1OA_1a62ec92-587e-44cb-8190-2ccae102f8dd"
      unitRef="installment">9</evlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments>
    <evlo:RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue
      contextRef="i7f75681a4eb440c497ad40de810da08d_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfMjc0ODc3OTA4ODI0NA_b0a1a7b2-c3ef-41f9-a343-14cd4d026f02"
      unitRef="usd">500000</evlo:RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue>
    <evlo:RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod
      contextRef="iaf794c74c50e4917b5636aa96a990418_D20210630-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfNDYyOQ_91f90406-daee-44e1-bbf5-81d1e6a9aa15">P10D</evlo:RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod>
    <evlo:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments
      contextRef="iaf794c74c50e4917b5636aa96a990418_D20210630-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV83My9mcmFnOjg4NWIzMDMwZWIxMjQxNTA5ZWZhZGIzNzA4MzVjNTY2L3RleHRyZWdpb246ODg1YjMwMzBlYjEyNDE1MDllZmFkYjM3MDgzNWM1NjZfNDE1NA_181f7332-a9a1-43fe-bb0c-712b07fff5bc"
      unitRef="installment">12</evlo:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507897838680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jul. 26, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Evelo Biosciences, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-5594527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">620 Memorial Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">577-0300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock,$0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EVLO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,398,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001694665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507896611768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 123,333<span></span>
</td>
<td class="nump">$ 68,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,034<span></span>
</td>
<td class="nump">2,123<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">126,367<span></span>
</td>
<td class="nump">70,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,520<span></span>
</td>
<td class="nump">7,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset - operating lease</a></td>
<td class="nump">9,856<span></span>
</td>
<td class="nump">10,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,315<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">145,058<span></span>
</td>
<td class="nump">90,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,319<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">15,011<span></span>
</td>
<td class="nump">16,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current portion</a></td>
<td class="nump">1,812<span></span>
</td>
<td class="nump">1,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">654<span></span>
</td>
<td class="nump">463<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">19,796<span></span>
</td>
<td class="nump">19,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">46,482<span></span>
</td>
<td class="nump">30,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">8,924<span></span>
</td>
<td class="nump">9,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">82,965<span></span>
</td>
<td class="nump">60,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholder&#8217;s equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding as of June 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized; 53,416,657 and 47,488,505 shares issued and 53,398,271 and 47,470,119 shares outstanding as of June 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">414,353<span></span>
</td>
<td class="nump">322,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(352,313)<span></span>
</td>
<td class="num">(292,519)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">62,093<span></span>
</td>
<td class="nump">30,485<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 145,058<span></span>
</td>
<td class="nump">$ 90,639<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507982607416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">53,416,657<span></span>
</td>
<td class="nump">47,488,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">53,398,271<span></span>
</td>
<td class="nump">47,470,119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507897600296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 20,655<span></span>
</td>
<td class="nump">$ 15,174<span></span>
</td>
<td class="nump">$ 42,163<span></span>
</td>
<td class="nump">$ 32,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,001<span></span>
</td>
<td class="nump">5,071<span></span>
</td>
<td class="nump">12,964<span></span>
</td>
<td class="nump">10,913<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">27,656<span></span>
</td>
<td class="nump">20,245<span></span>
</td>
<td class="nump">55,127<span></span>
</td>
<td class="nump">43,506<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(27,656)<span></span>
</td>
<td class="num">(20,245)<span></span>
</td>
<td class="num">(55,127)<span></span>
</td>
<td class="num">(43,506)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest expense, net</a></td>
<td class="num">(814)<span></span>
</td>
<td class="num">(458)<span></span>
</td>
<td class="num">(1,579)<span></span>
</td>
<td class="num">(639)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(3,226)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,226)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="nump">606<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(3,889)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
<td class="num">(4,492)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
<td class="num">(31,545)<span></span>
</td>
<td class="num">(20,563)<span></span>
</td>
<td class="num">(59,619)<span></span>
</td>
<td class="num">(43,539)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (31,598)<span></span>
</td>
<td class="num">$ (20,652)<span></span>
</td>
<td class="num">$ (59,794)<span></span>
</td>
<td class="num">$ (43,693)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic (in dollars per share)</a></td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (1.35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted (in dollars per share)</a></td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (1.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares outstanding, basic (in shares)</a></td>
<td class="nump">53,379,415<span></span>
</td>
<td class="nump">32,634,468<span></span>
</td>
<td class="nump">52,340,608<span></span>
</td>
<td class="nump">32,442,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares outstanding, diluted (in shares)</a></td>
<td class="nump">53,379,415<span></span>
</td>
<td class="nump">32,634,468<span></span>
</td>
<td class="nump">52,340,608<span></span>
</td>
<td class="nump">32,442,259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507982549640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,170,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 60,197<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 259,018<span></span>
</td>
<td class="num">$ (198,853)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,041)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,321,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">39,344<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">261,206<span></span>
</td>
<td class="num">(221,894)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,170,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">60,197<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">259,018<span></span>
</td>
<td class="num">(198,853)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(43,693)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,136,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">69,206<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">311,706<span></span>
</td>
<td class="num">(242,546)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,321,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">39,344<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">261,206<span></span>
</td>
<td class="num">(221,894)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">48,407<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">48,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,652)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,652)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,136,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">69,206<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">311,706<span></span>
</td>
<td class="num">(242,546)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,470,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">30,485<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">322,957<span></span>
</td>
<td class="num">(292,519)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,814,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">81,961<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">81,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(28,196)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,196)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,357,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">87,839<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">408,501<span></span>
</td>
<td class="num">(320,715)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,470,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 30,485<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">322,957<span></span>
</td>
<td class="num">(292,519)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">85,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (59,794)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,398,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">62,093<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">414,353<span></span>
</td>
<td class="num">(352,313)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,357,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">87,839<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">408,501<span></span>
</td>
<td class="num">(320,715)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrants</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(31,598)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,598)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,398,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 62,093<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 414,353<span></span>
</td>
<td class="num">$ (352,313)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507894081656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (59,794)<span></span>
</td>
<td class="num">$ (43,693)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">7,036<span></span>
</td>
<td class="nump">4,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,090<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_NonCashOperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">901<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">3,226<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of fixed assets, net</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(789)<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">2,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(987)<span></span>
</td>
<td class="num">(1,001)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(927)<span></span>
</td>
<td class="num">(1,111)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(41,712)<span></span>
</td>
<td class="num">(35,891)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,151)<span></span>
</td>
<td class="num">(651)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from sale of fixed assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,147)<span></span>
</td>
<td class="num">(645)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance cost</a></td>
<td class="nump">81,902<span></span>
</td>
<td class="nump">48,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from the issuance of long-term debt, net of issuance costs</a></td>
<td class="nump">14,778<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under employee stock purchase plan and exercise of stock options</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">97,335<span></span>
</td>
<td class="nump">48,876<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">54,476<span></span>
</td>
<td class="nump">12,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash &#8211; beginning of period</a></td>
<td class="nump">70,420<span></span>
</td>
<td class="nump">79,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash &#8211; end of period</a></td>
<td class="nump">124,896<span></span>
</td>
<td class="nump">91,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,388<span></span>
</td>
<td class="nump">875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses', window );">Deferred financing and public offering costs in accounts payable and accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_PublicOfferingCostInAccruedExpense', window );">Public offering cost in accrued expense</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment additions in accrued expenses</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Public Offering Costs Included In Accounts Payable And Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_NonCashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Operating Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_NonCashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_PublicOfferingCostInAccruedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Public Offering Cost In Accrued Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_PublicOfferingCostInAccruedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507891524744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evelo Biosciences, Inc. ("Evelo" or the "Company&#8221;) is a biotechnology company which was incorporated in Delaware on May 6, 2014. The Company is discovering and developing a new class of oral biologics that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. The Company is advancing these oral biologics with the aim of treating a broad range of immune mediated diseases with an initial focus on inflammatory diseases and oncology. The Company is headquartered in Cambridge, Massachusetts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has devoted substantially all of its efforts to research and development and raising capital. The Company has not generated any revenue related to its primary business purpose to date. The Company is subject to a number of risks similar to those of other development stage companies, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, and the need to obtain adequate additional financing to fund the development of its products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has financed operations primarily with the proceeds from the issuance of common stock combined with proceeds from previous sales of convertible preferred stock to equity investors and debt financing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2019, the Company filed a Registration Statement on Form S-3 (File No. 333-231911) (the &#8220;Shelf&#8221;) with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof in the aggregate amount of up to $200.0 million for a period of up to three years from the date of its effectiveness on June 6, 2019. The Company also simultaneously entered into a sales agreement (the "ATM") with Cowen and Company, LLC, as sales agent, providing for the offering, issuance and sale by the Company of up to an aggregate $50.0&#160;million of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf. For the three and six months ended June 30, 2021, the Company sold no shares and 139,734 shares, respectively, under the ATM with offering prices ranging between $12.54 and $13.17 per share for gross proceeds of $1.8 million, and net proceeds of $1.7 million, after deducting commission and other offering expenses payable by the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2021, the Company sold 5,175,000 shares of its common stock in an underwritten public offering at a public offering price of $15.00 per share, including the underwriters' exercise of their option to purchase 675,000 shares to cover over-allotment, generating gross proceeds of $77.6&#160;million and net proceeds of underwriting discounts and commission of $72.7&#160;million, after deducting underwriting discounts and commission and other offering expenses paid by the Company. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2021, the Company entered into a stock purchase agreement with ALJ Health Care &amp; Life Science Company Limited ("ALJ Health Care"), pursuant to which on February 2, 2021, ALJ Health Care purchased $7.5&#160;million of our common stock in a private placement at a purchase price of $15.00 per share, equal to the public offering price per share at which our common stock was sold to the public as referred above. The sale of such shares was not registered under the Securities Act.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses since inception and expects such losses and negative operating cash flows to continue for the foreseeable future. The Company historically has funded its operations from the issuance of convertible notes, convertible preferred stock and common stock, and through debt financings. As of June 30, 2021, the Company had cash and cash equivalents of $123.3 million and an accumulated deficit of $352.3 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects that its cash and cash equivalents as of June 30, 2021 will be sufficient to fund the operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these unaudited condensed consolidated financial statements. The future viability of the Company beyond one year from the date of issuance of these unaudited condensed consolidated financial statements is dependent on its ability to raise additional capital to finance its operations. The Company's inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507893459480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and ASU of the FASB. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations.&#160;Accordingly, these financial statements should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and notes thereto.&#160;The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments which are necessary to present fairly the Company&#8217;s financial position as of June 30, 2021, the results of its operations and stockholders' equity for the three and six months ended June 30, 2021 and 2020 and cash flows for the six months ended June 30, 2021 and 2020. Such adjustments are of a normal and recurring nature. The results for the three and six months ended June 30, 2021 are not necessarily indicative of the results for the year ending December 31, 2021, or for any future period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, estimates related to the application of ASC 606 to our collaboration agreement, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evelo is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Evelo may take advantage of these exemptions until it is no longer an emerging growth company. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. Evelo has elected to use the extended transition period for complying with new or revised accounting standards, and, as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. Evelo may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its IPO or such earlier time that it is no longer an emerging growth company. Evelo would cease to be an emerging growth company if it has more than $1.07 billion in annual revenue, it has more than $700.0 million in market value of its stock held by non-affiliates (and has been a public company for at least 12&#160;months and has filed one annual report on Form&#160;10-K), or it has issued more than $1.0 billion of non-convertible debt securities over a three-year period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Income or Loss</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) consists of net income (loss) and changes in equity during a period from transactions and other equity and circumstances generated from non-owner sources. The Company&#8217;s net loss equals comprehensive loss for all periods presented.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are comprised of highly liquid investments that are readily convertible into cash with original maturities of three months or less. Cash and cash equivalents include cash held in banks and amounts held in money market funds. Cash equivalents are stated at cost, which approximates market value. The Company&#8217;s restricted cash consists of restricted cash in connection with building leases for the Company&#8217;s office and laboratory premises and deposits held in relation to the company's credit card facility. As of June 30, 2021 and December 31, 2020 the Company had $0.3&#160;million in current restricted cash within prepaid expenses and other current assets and $1.3&#160;million in noncurrent restricted cash which were included within other assets in the unaudited condensed consolidated balance sheets. The following reconciles cash, cash equivalents and restricted cash as of June 30, 2021 and December 31, 2020, as presented on the Company's statements of cash flows, to its related balance sheet accounts (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:55.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.058%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,964&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,487&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,333&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,857&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,896&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,420&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820,&#160;Fair Value Measurement&#160;(&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 inputs are inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly; and</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings. The Company did not elect to measure any additional financial instruments or other items at fair value.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreements </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,  Collaborative Arrangements ("ASC 808") to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and its collaboration partner are within the scope of other accounting literature, including ASC 606, Revenue from Contracts with Customers ("ASC 606"). If it is concluded that some or all aspects of the arrangement represent a transaction with a customer, the Company will account for those aspects of the arrangement within the scope of ASC 606. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 808 provides guidance for the presentation and disclosure of transactions in collaborative arrangements, but it does not provide recognition or measurement guidance. Therefore, if the Company concludes a counterparty to a transaction is not a customer or otherwise not within the scope of ASC 606, the Company considers the guidance in other accounting literature, including the guidance in ASC 606, as applicable or by analogy to account for such transaction. The classification of transactions under the Company&#8217;s arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of Accounting Standards Codification ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities.  If the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC 606.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, it performs the following steps: (i) identify the contract(s) with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) each performance obligation is satisfied. ASC 606 requires significant judgment and estimates and results in changes to, but not limited to: (i) the determination of the transaction price, including estimates of variable consideration, (ii) the allocation of the transaction price, including the determination of estimated selling price, and (iii) the pattern of recognition, including the application of proportional performance as a measure of progress on service-related promises and application of point-in-time recognition for supply-related promises. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised good or services in the Company&#8217;s arrangement may consist of license rights to the Company&#8217;s intellectual property or research and development services. The Company also may have optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price may be comprised of fixed payments, often an upfront payment due at contract inception, or other types of variable consideration in the form of payments for the Company&#8217;s services and materials and milestone payments due upon the achievement of specified events. Other payments the Company could be entitled to include tiered royalties earned when customers recognize net sales of licensed products. The Company considers the existence of any significant financing component within its arrangements to the extent there is a significant difference between the timing of payment and the transfer of control of the performance obligations.  In making that determination, the Company considers whether substantive business purposes exist to support the payment structure other than to provide a significant benefit of financing. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">promised goods and/or services to the customer. The Company utilizes either the expected value method or the most likely amount method to estimate the amount of variable consideration, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. With respect to arrangements that include payments for a development or regulatory milestone payment, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the Company&#8217;s or the licensee&#8217;s control, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company re-evaluates the probability of achievement of each milestone and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, wherein the license is deemed to be the sole or predominant item to which the payments relate, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements with more than one performance obligation, the Company generally allocates the transaction price to each performance obligation based on a relative standalone selling price basis. The Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated research and development costs. However, in certain instances, the Company may allocate variable consideration entirely to one or more performance obligation if the terms of the variable consideration relate to the satisfaction of the respective performance obligation and the amount allocated is consistent with the amount the Company would expect to receive for the satisfaction of the respective performance obligation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. For performance obligations that are satisfied at a point in time, the Company recognizes revenue when control of the goods and/or services is transferred to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer.  With respect to arrangements containing a license to its intellectual property that is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from amounts allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Liabilities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a contract liability, classified as deferred revenue on its condensed consolidated balance sheet, when it has received payment but has not yet satisfied the related performance obligations. In the event of an early termination of a contract with a customer, any contract liabilities would be recognized in the period in which all Company obligations under the agreement have been fulfilled.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period incurred. Research and development expenses consist of both internal and external costs such as payroll, consulting, and manufacturing costs associated with the development of the Company&#8217;s product candidates. Costs for certain development activities, such as clinical trials and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the unaudited condensed consolidated balance sheets as prepaid or accrued research and development expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire licenses, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects. Any milestone payments made for Intellectual Property after regulatory approval, or that have alternative future use, are capitalized and amortized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records stock-based compensation for equity awards granted to employees and directors based on the grant date fair value of awards issued. The expense is recorded over the requisite service period, which is the vesting period, on a straight-line basis. The Company uses the Black-Scholes option-pricing model to determine the fair value of options. The determination of the fair value of options on the date of grant using an option-pricing model is affected by the Company&#8217;s common stock price, as well as a number of other assumptions. The Company records forfeitures as they occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation arrangements with&#160;non-employees&#160;based upon the fair value of the consideration received or the equity instruments issued, whichever is more reliably measurable. The measurement date for&#160;non-employee&#160;awards is generally the date performance of services required from the&#160;non-employee&#160;is complete. Stock-based compensation costs for&#160;non-employee&#160;awards are recognized as services are provided, which is generally the vesting period, on a straight-line basis.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating segment. The Company's chief operating decision maker, its Chief Executive Officer, manages the Company's operations on a consolidated basis for the purposes of allocating resources.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019 -12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new standard was effective for the Company on January 1, 2021 and it includes several provisions which simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The Company adopted ASU No. 2019-12 on January 1, 2021 and has concluded the adoption did not have a material impact on its unaudited condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements Issued and Not Adopted as of June 30, 2021</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Instruments - Credit Losses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326)&#8212;Measurement of Credit Losses on Financial Instruments, which has been subsequently amended by ASU No. 2018-19, ASU No. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019-04, ASU No. 2019-05, ASU No. 2019-10, ASU No. 2019-11 and ASU No. 2020-03 (&#8220;ASU 2016-13&#8221;). The provisions of ASU 2016-13 modify the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology and require a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 is effective for the Company on January 1, 2023, with early adoption permitted. The Company is currently evaluating the potential impact that this standard may have on its financial position and results of operations, as well as the timing of its adoption of this standard.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Debt with Conversion and Other Options</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2020, the FASB issued ASU No. 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU-2020-06&#8221;), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models in ASC 470-20 that require separate accounting for embedded conversion features from convertible instruments. As a result, after adopting the ASU&#8217;s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Additionally, the guidance simplifies the evaluation of whether a contract in the issuer&#8217;s own equity can be classified in equity or an embedded feature qualifies for the derivative scope exception. Although the guidance is not effective until 2022, early adoption of ASU 2020-06 is permitted for all entities for fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of this new guidance on the Company&#8217;s condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507891514744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ALJ Commercialization and License Agreement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">ALJ Commercialization and License Agreement</a></td>
<td class="text">ALJ Commercialization and License Agreement<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, the Company entered into a commercialization and license agreement (the &#8220;ALJ Agreement&#8221;) with ALJ. Pursuant to the ALJ Agreement, the Company granted to ALJ an exclusive, non-transferable, sublicensable license to the Company&#8217;s product candidate, EDP1815 (together with any replacement or second products of the Company described below, the &#8220;Products&#8221;) solely (i) to conduct development activities relating to the Products allocated to ALJ in a development plan agreed with the Company, (ii) to conduct manufacturing activities relating to the Products in all therapeutic uses in humans (the &#8220;Field&#8221;) throughout the world, subject to certain conditions and requirements, and (iii) to commercialize the Products in the Field in all countries of Africa and the Middle East-Turkey, excluding certain restricted countries (the &#8220;Territory&#8221;). If the Company ceases development of EDP1815 prior to receipt of regulatory approval required for commercialization of EDP1815 in any one of the United States, the United Kingdom, France, Germany, Spain, Italy, China or Japan, then ALJ will have the right to designate another product candidate of the Company as a replacement to EDP1815 or terminate the ALJ Agreement, subject to certain conditions and requirements. Further, for the first two years of the term, ALJ has the option to negotiate with the Company to add a second product candidate of the Company subject to certain conditions and requirements, for an additional license fee not to exceed $7.5&#160;million.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the rights the Company granted under the ALJ Agreement, ALJ obligated to pay to the Company a one-time, non-refundable upfront payment of $7.5&#160;million. The parties will also share the future operating profits and losses for all Products in the Territory equally (50:50) as well as certain development, regulatory and commercialization costs. The Company concluded that the delivery of the license to ALJ, should be accounted for under ASC 606. The development, regulatory and commercialization activities within the Territory will be accounted for under ASC 808.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not recognized any revenue under the ALJ Agreement to date as they have not completed any performance obligation within the agreement. As of June 30, 2021, the Company has recognized $7.5&#160;million of deferred revenue, which is classified as a non-current liability in the accompanying unaudited condensed consolidated balance sheets as the performance obligation is not expected to be completed within the next twelve months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates that payments under the costs share or profit and loss sharing arrangements, will be classified in the statement of operations consistent with the guidance in ASC 808. To date, the Company has not received or made any costs sharing or profit and loss payments. </span></div>In-License Agreements<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mayo Foundation for Medical Education and Research</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2016, the Company entered into a Research and License Agreement, (the &#8220;2016 Mayo License Agreement&#8221;) with the Mayo Foundation for Medical Education and Research, an affiliate of Mayo Clinic (the &#8220;Mayo Clinic&#8221;). Under the 2016 Mayo License Agreement, the Mayo Clinic was entitled to certain participation rights in connection with the issuance and sale of preferred stock that was issued prior to the Company&#8217;s public offering and warrants which were issued in 2016 and exercised in 2018.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;6, 2017, the Company and the Mayo Clinic entered into a license agreement (&#8220;2017 Mayo License Agreement&#8221;). Under the 2017 Mayo License Agreement, the Mayo Clinic granted the Company (i)&#160;an exclusive, worldwide, sublicensable license under the Mayo Clinic&#8217;s rights to certain intellectual property and microbial strains and (ii)&#160;a non-exclusive, worldwide, sublicensable license to certain related know-how, in each case, to develop and commercialize certain microbial strains and licensed products incorporating any such strains. As consideration, the Company paid a nonrefundable upfront fee of $0.2 million and will pay annual license maintenance fees. Nonrefundable upfront fees were expensed in full to research and development expense in 2017. Annual maintenance fees will be expensed as incurred over the term of the agreement. The Company may owe the Mayo Clinic milestone payments upon the achievement of certain development, regulatory, and commercial milestones, up to a maximum of $56.0 million in the aggregate, as well as royalties on net sales of licensed products in low single-digit percentages. As of June 30, 2021, the Company has incurred milestone payments to date totaling approximately $0.3 million under the agreement of which no</span><span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are currently due.</span><span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of Chicago</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;10, 2016, the Company and the University of Chicago entered into a patent license agreement (&#8220;2016 University of Chicago Agreement&#8221;). Under the 2016 University of Chicago Agreement, the University of Chicago granted the Company (i)&#160;an exclusive, royalty-bearing and sublicensable license under the licensed patents and (ii)&#160;a non-exclusive, royalty-bearing, sublicensable license to access the technical information to diligently develop and commercialize licensed products. As consideration, the Company paid a nonrefundable upfront fee of less than $0.5 million and will pay annual license maintenance fees. Nonrefundable upfront fees were expensed in full to research and development expense in 2016. Annual maintenance fees will be expensed as incurred over the term of the agreement. The Company may owe the University of Chicago milestone payments, totaling an aggregate of approximately $60.9 million upon the achievement of certain development, regulatory, and commercial milestones, as well as royalties on net sales of licensed products ranging from low to high single-digit percentages. As of June 30, 2021, the Company has incurred milestone payments to date totaling approximately $0.4 million under the agreement of which no</span><span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are currently due.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507891312168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company entered into an&#160;operating sublease arrangement to lease approximately 40,765 square feet for its office and research development space at 620 Memorial Drive, Cambridge, MA 02139 from February 2018 to September 2025. The Company maintained an additional separate operating lease for office and laboratory space that expired in May 2020. The leases require security deposits, which the Company has primarily met with letters of credit from a financial institution that is secured with cash on deposit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into a sublease arrangement with a third party to lease space subject to an operating lease that expired in April 2020. The minimum rental payments received under this agreement totaled $0.1 million and $0.2&#160;million, respectively, for the three months and six months ended June 30, 2020 and were equivalent to the minimum payments due from the Company to the landlord.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months and six months ended June 30, 2021,  the Company recorded rent expense of $0.7 million and $1.5 million, respectively. For the three months and six months ended June 30, 2020,  the Company recorded rent expense of $0.7&#160;million and $1.4&#160;million, respectively.There was no sublease rental income for the three months and six months ended June 30, 2021. For the three months and six months ended June 30, 2020, the Company recorded rent expense net of sublease rental income of $0.1&#160;million and $0.3&#160;million, respectively. Sublease rental income is inclusive of rental payments, taxes and operating expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum aggregate future lease commitments at June 30, 2021, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.814%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2021 (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">excluding amounts paid or in Accounts Payable as of 6/30/2021)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,252</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,154</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,491</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,208</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,472)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,736</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used for operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507893070152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities that have been measured at fair value as of June 30, 2021 and December 31, 2020 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.227%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds included within cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,369&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,369&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.227%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds included within cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,370&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,370&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;June 30, 2021&#160;and&#160;December 31, 2020, the Company's cash equivalents have been initially valued at the transaction price and subsequently valued utilizing a third party pricing service. The Company validates the prices provided by its third-party pricing service by understanding the models used and obtaining market values from other pricing sources.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507893125160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:57.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.747%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,744&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,831&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,239&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,121&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,719)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,643)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,520&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,478&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $0.5 million and $1.1&#160;million of depreciation expense for the three and six months ended June 30, 2021, respectively, and $0.5 million and $1.0 million of depreciation expense for the three and six months ended June 30, 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507985088840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan and Security Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Loan and Security Agreements</a></td>
<td class="text">Loan and Security Agreements<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2019, the Company entered into a loan and security agreement&#160;(as amended, the "2019 Credit Facility") with K2 HealthVentures LLC and others (collectively, "K2HV") pursuant to which the K2HV agreed to make term loans in an aggregate principal amount of up to $45.0 million available to the Company in three tranches. The initial tranche of $20.0 million was funded upon closing on July 19, 2019. As amended on May 15, 2020, the second tranche of $10.0 million was available to be funded between December 1, 2019 and July 15, 2020 and was drawn down on July 14, 2020. The availability of the third tranche of $15.0 million expired on January 15, 2021. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021 (the "Amended Credit Facility Effective Date"), the parties further amended the 2019 Credit Facility (as so amended, the &#8220;Amended Credit Facility&#8221;) to, among other things, replace and supersede the existing $15.0&#160;million third tranche commitment with a new $15.0&#160;million fourth tranche commitment, which the Company drew down on June 16, 2021. In connection with the Amended Credit Facility, the Company issued to K2 HealthVentures Equity Trust LLC, an affiliate of K2HV a warrant to purchase up to 139,770 shares of the Company&#8217;s common stock with an exercise price of $13.30 per share, subject to customary per share adjustments that are within the Company's control (&#8220;the Warrant&#8221;).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Amended Credit Facility, K2HV has the option, exercisable at any time, to convert up to $5.0&#160;million of principal outstanding into shares of the Company&#8217;s common stock at a conversion price of $13.30 per share, subject to customary per share adjustments within the Company's control (the "Conversion Option&#8221;). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Interest on the outstanding loan balance will accrue at a variable annual rate equal to the greater of (i) 8.65% and (ii) the prime rate plus 3.15%. The Company is required to make interest-only payments on the loans on a monthly basis through February 28, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, which was extended from February 28, 2022 pursuant to the Amended Credit Facility</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subsequent to the interest only periods, the Company is required to make equal monthly payments of principal plus interest until the loans mature on August 1, 2024. The Company has an option to prepay the loans in </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">whole, subject to a prepayment fee of 2% of the amount prepaid or, if the prepayment occurs after the 18-month anniversary of the Amended Credit Facility Effective Date but prior to the maturity date, 1% of the amount prepaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the Amended Credit Facility, the Company has the option at any point prior to January 1, 2022 to elect to adjust the repayment schedule (the &#8220;Modified Repayment Schedule&#8221;) such that commencing on March 1, 2023, the Company can make consecutive equal monthly payments of principal and accrued and unpaid interest based on a notional thirty month repayment period. Under the Modified Repayment Schedule, the loan maturity date remains August 1, 2024.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any outstanding principal and unpaid interest is due at maturity. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon final payment or prepayment of the loans, the Company must pay a final payment equal to 4.3% (or 4.8% if the Company elects the Modified Repayment Schedule) of the aggregate original principal amount of the loans borrowed. The Company incurred fees associated with establishing the 2019 Credit Facility and fees related to the Amended Credit Facility of $0.4&#160;million and $0.3&#160;million, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Amended Credit Facility are collateralized by substantially all of the Company's personal property, excluding intellectual property, and the Company pledged its equity interests in its subsidiaries, subject to certain limitations with respect to its foreign subsidiaries. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Facility contains customary representations, warranties and covenants and also includes customary events of default, including payment defaults, breaches of covenants, change of control and occurrence of a material adverse effect. The Company has determined that the risk of subjective acceleration under the material adverse events clause was remote and therefore has classified the long-term portion of the outstanding principal in non-current liabilities. Upon the occurrence and continuation of an event of default, a default interest rate of an additional 5% per annum may be applied to the outstanding loan balances, and the administrative agent, collateral agent, and lenders may declare all outstanding obligations immediately due and payable and exercise all of their rights and remedies as set forth in the Amended Credit Facility and under applicable law. As of June 30, 2021, the Company was in compliance with all covenants under the Amended Credit Facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has concluded the Amended Credit Facility is a debt extinguishment for accounting purposes because the terms of the modified debt are considered substantially different than the terms of the debt prior to the amendment. As such, the Amended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit Facility was recorded at its estimated fair value of $46.6&#160;million which was determined using a combination of a discounted cash flow model and a binomial lattice model. The Company utilized the following significant unobservable inputs (Level 3 inputs) to determine the estimated fair value of its debt as of the amendment date:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:52.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.00&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant increases (decreases) in either of these inputs could result in a significantly lower or higher fair value measurement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Warrant was deemed to be a freestanding financial instrument as it is legally detachable and separately exercisable from the debt obligations. The Company evaluated the terms and conditions of the warrant and concluded it met the criteria to be classified within equity. As such, the Company recorded the warrant as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional paid in capital at its issuance date fair value of $1.8&#160;million. The</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Company utilized the Black-Scholes valuation method to determine the fair value of the warrant which utilized the following assumptions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:64.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of underlying common stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recorded a loss on the extinguishment of the existing debt of $3.2&#160;million which equaled the difference between the reacquisition cost of the new debt, inclusive of the fair value of the Warrant and lender fees,  and the carrying amount of the existing debt.  The difference between (i) the carrying amount of the debt and (ii) the par value of the debt and the amount of the final payment due at maturity will be amortized as interest expense using the effective interest rate method.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has the following minimum aggregate future loan payments at June 30, 2021 (in thousands). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:83.504%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve month period ending June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest and discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,482&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was approximately $0.8 million and $1.6 million for the three and six months ended June 30, 2021, respectively, and $0.4&#160;million and $0.8&#160;million for the three and six months ended  June 30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507891295832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>In-License Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">In-License Agreements</a></td>
<td class="text">ALJ Commercialization and License Agreement<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, the Company entered into a commercialization and license agreement (the &#8220;ALJ Agreement&#8221;) with ALJ. Pursuant to the ALJ Agreement, the Company granted to ALJ an exclusive, non-transferable, sublicensable license to the Company&#8217;s product candidate, EDP1815 (together with any replacement or second products of the Company described below, the &#8220;Products&#8221;) solely (i) to conduct development activities relating to the Products allocated to ALJ in a development plan agreed with the Company, (ii) to conduct manufacturing activities relating to the Products in all therapeutic uses in humans (the &#8220;Field&#8221;) throughout the world, subject to certain conditions and requirements, and (iii) to commercialize the Products in the Field in all countries of Africa and the Middle East-Turkey, excluding certain restricted countries (the &#8220;Territory&#8221;). If the Company ceases development of EDP1815 prior to receipt of regulatory approval required for commercialization of EDP1815 in any one of the United States, the United Kingdom, France, Germany, Spain, Italy, China or Japan, then ALJ will have the right to designate another product candidate of the Company as a replacement to EDP1815 or terminate the ALJ Agreement, subject to certain conditions and requirements. Further, for the first two years of the term, ALJ has the option to negotiate with the Company to add a second product candidate of the Company subject to certain conditions and requirements, for an additional license fee not to exceed $7.5&#160;million.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the rights the Company granted under the ALJ Agreement, ALJ obligated to pay to the Company a one-time, non-refundable upfront payment of $7.5&#160;million. The parties will also share the future operating profits and losses for all Products in the Territory equally (50:50) as well as certain development, regulatory and commercialization costs. The Company concluded that the delivery of the license to ALJ, should be accounted for under ASC 606. The development, regulatory and commercialization activities within the Territory will be accounted for under ASC 808.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not recognized any revenue under the ALJ Agreement to date as they have not completed any performance obligation within the agreement. As of June 30, 2021, the Company has recognized $7.5&#160;million of deferred revenue, which is classified as a non-current liability in the accompanying unaudited condensed consolidated balance sheets as the performance obligation is not expected to be completed within the next twelve months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates that payments under the costs share or profit and loss sharing arrangements, will be classified in the statement of operations consistent with the guidance in ASC 808. To date, the Company has not received or made any costs sharing or profit and loss payments. </span></div>In-License Agreements<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mayo Foundation for Medical Education and Research</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2016, the Company entered into a Research and License Agreement, (the &#8220;2016 Mayo License Agreement&#8221;) with the Mayo Foundation for Medical Education and Research, an affiliate of Mayo Clinic (the &#8220;Mayo Clinic&#8221;). Under the 2016 Mayo License Agreement, the Mayo Clinic was entitled to certain participation rights in connection with the issuance and sale of preferred stock that was issued prior to the Company&#8217;s public offering and warrants which were issued in 2016 and exercised in 2018.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;6, 2017, the Company and the Mayo Clinic entered into a license agreement (&#8220;2017 Mayo License Agreement&#8221;). Under the 2017 Mayo License Agreement, the Mayo Clinic granted the Company (i)&#160;an exclusive, worldwide, sublicensable license under the Mayo Clinic&#8217;s rights to certain intellectual property and microbial strains and (ii)&#160;a non-exclusive, worldwide, sublicensable license to certain related know-how, in each case, to develop and commercialize certain microbial strains and licensed products incorporating any such strains. As consideration, the Company paid a nonrefundable upfront fee of $0.2 million and will pay annual license maintenance fees. Nonrefundable upfront fees were expensed in full to research and development expense in 2017. Annual maintenance fees will be expensed as incurred over the term of the agreement. The Company may owe the Mayo Clinic milestone payments upon the achievement of certain development, regulatory, and commercial milestones, up to a maximum of $56.0 million in the aggregate, as well as royalties on net sales of licensed products in low single-digit percentages. As of June 30, 2021, the Company has incurred milestone payments to date totaling approximately $0.3 million under the agreement of which no</span><span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are currently due.</span><span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of Chicago</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;10, 2016, the Company and the University of Chicago entered into a patent license agreement (&#8220;2016 University of Chicago Agreement&#8221;). Under the 2016 University of Chicago Agreement, the University of Chicago granted the Company (i)&#160;an exclusive, royalty-bearing and sublicensable license under the licensed patents and (ii)&#160;a non-exclusive, royalty-bearing, sublicensable license to access the technical information to diligently develop and commercialize licensed products. As consideration, the Company paid a nonrefundable upfront fee of less than $0.5 million and will pay annual license maintenance fees. Nonrefundable upfront fees were expensed in full to research and development expense in 2016. Annual maintenance fees will be expensed as incurred over the term of the agreement. The Company may owe the University of Chicago milestone payments, totaling an aggregate of approximately $60.9 million upon the achievement of certain development, regulatory, and commercial milestones, as well as royalties on net sales of licensed products ranging from low to high single-digit percentages. As of June 30, 2021, the Company has incurred milestone payments to date totaling approximately $0.4 million under the agreement of which no</span><span style="color:#0094ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are currently due.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507891571768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Collaboration Agreement with Sacco S.r.l.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company entered into an agreement with Sacco S.r.l. ("Sacco"), an affiliate of one of the Company&#8217;s existing contract manufacturing organizations, pursuant to which and subject to certain exceptions for pre-existing products for pre-existing customers, Sacco will manufacture and supply single strain, non-genetically modified microbes intended for oral delivery or oral use in pharmaceutical products exclusively for the Company for a period of five years. Sacco may terminate the agreement if the provision of manufacturing services has been, or is scheduled to be, inactive for a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV81OC9mcmFnOjFiNWI1ZTU0NjljZDRiOGJhMmY2ZWIwNTYwMmY0OTI4L3RleHRyZWdpb246MWI1YjVlNTQ2OWNkNGI4YmEyZjZlYjA1NjAyZjQ5MjhfNjgz_325d5ea5-b4c5-433d-9fed-b5f892efb0bc">six</span> consecutive months. The Company has agreed to pay Sacco an aggregate of &#8364;3.0 million, &#8364;0.6 million annually, during the exclusivity period. The Company has incurred annual exclusivity fees to date totaling approximately &#8364;1.2 million, and no amounts are currently due as of June 30, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation and Other Proceedings</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may periodically become subject to legal proceedings and claims arising in connection with on-going business activities, including claims or disputes related to patents that have been issued or that are pending in the field of research on which the Company is focused.&#160;The Company is not a party to any material litigation and does not have contingency reserves established for any litigation liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Notice of Opposition was filed against European Patent No. 3223834, which is held by the Company. In July 2021, the Company filed its reply to the Opposition. The patent at issue does not relate to any of the Company&#8217;s current product candidates, and any subsequent proceeding is not expected to affect any of the Company&#8217;s current development plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507893443256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2019, the Company filed the Shelf with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof in the aggregate amount of up to $200.0 million for a period of up to three years from the date of the filing. The Company also simultaneously entered into the ATM, providing for the offering, issuance and sale by the Company of up to an aggregate $50.0 million of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf. For the three and six months ended June 30, 2021, the Company sold no common shares and 139,734 common shares, respectively, under the ATM with offering prices ranging between $12.54 and $13.17 per share for gross proceeds of net proceeds of $1.7 million, after deducting commission and other offering expenses payable by the Company. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2021, the Company sold 5,175,000 shares of its common stock in an underwritten public offering at a public offering price of $15.00 per share, including the underwriters' exercise of their option to purchase 675,000 shares to cover over-allotment, generating gross proceeds of $77.6 million and net proceeds of underwriting discounts and commission of $72.7 million, after deducting underwriting discounts and commission and other offering expenses paid by the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2021, the Company entered into a stock purchase agreement with ALJ Health Care &amp; Life Science Company Limited ("ALJ Health Care"), pursuant to which on February 2, 2021, ALJ Health Care purchased $7.5 million of the Company's common stock in a private placement at a purchase price of $15.00 per share, equal to the public offering price per share at which the Company's common stock was sold to the public as referred above. The sale of such shares was not registered under the Securities Act.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the entry into the Amended Credit Facility, the Company issued to K2 HealthVentures Equity Trust LLC, an affiliate of K2HV, a warrant to purchase up to 139,770 shares of the Company&#8217;s common stock, with an exercise price of $13.30 per share, subject to customary per share adjustments. The Warrant is exercisable immediately and expires on June 16, 2031, provided that, under certain circumstances, the Warrant may terminate and expire earlier in connection with the closing of certain acquisition transactions involving the Company. The Warrant provides that the holder thereof may elect to exercise the Warrant on a net &#8220;cashless&#8221; basis at any time prior to the expiration thereof. The fair market value of one share of the Company&#8217;s common stock in connection with any cashless exercise shall be the closing price or last sale price per share of the Company&#8217;s common stock on </span></div>a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market on which the Company&#8217;s common stock is traded on the business day immediately prior to the date the holder elects to exercise the Warrant on a cashless basis. In addition, under the Amended Credit Facility, K2HV has the option, exercisable at any time, to convert up to $5.0&#160;million of principal outstanding into shares of the Company&#8217;s common stock at a conversion price of $13.30 per share, subject to customary per share adjustments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507893111304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Inducement Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2021, the Company&#8217;s board of directors adopted the Evelo Biosciences, Inc. 2021 Employment Inducement Award Plan (the &#8220;Inducement Award Plan&#8221;) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules (&#8220;Rule 5635(c)(4)&#8221;). In accordance with Rule 5635(c)(4), cash and equity-based incentive awards under the Inducement Award Plan may only be made to a newly hired employee who has not previously been a member of the Company&#8217;s board of directors, or an employee who is being rehired following a bona fide period of non-employment by the Company or a subsidiary, as a material inducement to the employee&#8217;s entering into employment with the Company or its subsidiary. An aggregate of 1,250,000 shares of the Company&#8217;s common stock have been reserved for issuance under the Inducement Award Plan. The Company will continue to grant awards under the 2018 Incentive Award Plan (the &#8220;2018 Plan&#8221;) pursuant to the terms thereof.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options granted under the Inducement Award Plan will not be less than the fair market value of a share of the Company&#8217;s common stock on the grant date. Other terms of awards, including vesting requirements, are determined by the Company&#8217;s board of directors and are subject to the provisions of the Inducement Award Plan. Stock options granted to employees generally vest over a four-year period but may be granted with different vesting terms. Certain options may provide for accelerated vesting in the event of a change in control. Stock options granted under the Inducement Award Plan expire no more than 10 years from the date of grant. As of June 30, 2021, stock option awards covering up to 550,000 shares of the Company&#8217;s common stock have been issued under the Inducement Award Plan, none of which have been exercised or canceled. As of June 30, 2021, restricted stock unit (&#8220;RSU&#8221;) awards covering up to 4,545 shares of the Company&#8217;s common stock have been granted under the Inducement Award Plan, none of which have vested or been forfeited.  As of June 30, 2021, 695,455 shares of common stock are available for future grant under the Inducement Award Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Incentive Award Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s board of directors adopted on April&#160;18, 2018, and the Company&#8217;s stockholders approved, the 2018 Plan, which became effective May 8, 2018 and under which the Company may grant cash and equity-based incentive awards to the Company&#8217;s employees, officers, directors, consultants and advisors. Following the effectiveness of the 2018 Plan, the Company ceased making grants under the 2015 Stock Incentive Plan (as amended, the "2015 Plan"). The 2018 Plan initially allowed the Company to grant awards for up to 1,344,692&#160;shares of common stock plus that number of shares of common stock subject to awards outstanding under the 2015 Plan that expire, lapse or become terminated or are exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited following the effective date of the 2018 Plan. Each year starting with 2019 and ending in and including 2028, the number of shares available for grants of awards under the 2018 Plan will be increased automatically on January&#160;1 by a number of shares of common stock equal to the lesser of 4% of the shares of common stock outstanding on the final day of the preceding calendar year or the number of shares determined by the Company&#8217;s board of directors. Accordingly, on January 1, 2021 and 2020, the number of shares authorized for issuance under the 2018 Plan was increased by 1,898,805 shares and 1,286,824 shares, respectively. The 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options granted under the 2018 Plan will not be less than the fair market value of a share of the Company&#8217;s common stock on the grant date. Other terms of awards, including vesting requirements, are determined by the board of directors and are subject to the provisions of the 2018 Plan. Stock options granted to employees generally vest over a four-year period but may be granted with different vesting terms. Certain options provide for accelerated vesting in the event of a change in control. Awards granted to non-employee consultants generally vest monthly over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMjIwMw_7adb7c68-f638-4357-9bd2-eeb01a3b009e">one</span> to four years. Stock options granted under the 2018 Plan expire no more than 10 years from the date of grant. As of June 30, 2021,&#160;stock options awards covering up to 6,557,456 shares of the Company&#8217;s common stock have been issued under the 2018 Plan, of which 34,748 have been </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercised and 977,561 have been canceled. As of June 30, 2021, 647,704 shares of common stock are available for future grant under the 2018 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Stock Incentive Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the approval of the 2018 Plan, the Company granted equity awards under the 2015 Plan, which originally provided for grant of incentive stock options, non-qualified stock options, restricted stock awards ("RSAs"), and other stock-based awards to the Company&#8217;s employees, officers, directors, consultants and advisors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of equity award agreements, including vesting requirements, were determined by the board of directors and are subject to the provisions of the 2015 Plan. Stock options granted to employees generally vest over a four-year period but may be granted with different vesting terms. A limited number of awards contain performance-based vesting criteria and for such awards that are deemed probable of vesting, the Company records expense in the period in which such determination is made through any estimated remaining vesting period. Certain options provide for accelerated vesting in the event of a change in control. Awards granted to non-employee consultants generally vest monthly over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyZTQ5NDAxMDQ0MTQ5ZWM4NmE1Y2VmZTQyMjk5YTc5L3NlYzplMmU0OTQwMTA0NDE0OWVjODZhNWNlZmU0MjI5OWE3OV82NC9mcmFnOmYyOTNlOTJiZTRkNzQ0MGM5ZjY0MGIwNGM1NDUzNzViL3RleHRyZWdpb246ZjI5M2U5MmJlNGQ3NDQwYzlmNjQwYjA0YzU0NTM3NWJfMzYzNw_fddafaeb-2db2-49ee-b233-bca37709f790">one</span> to four years. Stock options issued under the 2015 Plan expire no more than 10 years from the date of grant. As of the effectiveness of the 2018 Plan, the Company ceased making awards under the 2015 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2015 Plan, the Company was authorized to grant equity awards up to an aggregate of 5,417,044 shares of common stock.&#160;As of June 30, 2021, an aggregate of 5,758,536 options and other equity awards had been granted under the 2015 Plan, of which 1,431,864 have been exercised, 1,275,971 have been canceled and 18,468 have been repurchased as of June 30, 2021. A total of 113,006 shares previously reserved under the 2015 Plan that had not been exercised or were otherwise subject to outstanding exercise awards were no longer authorized for issuance under the 2015 Plan as of May&#160;8, 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in the Company&#8217;s unaudited condensed consolidated statements of operations is as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:35.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,093&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,036&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity and related information is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.482%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,610,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,731,274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,267)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,145,838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,443,028&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value of options granted during the six months ended June 30, 2021 and 2020 was $11.52 and $4.45, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, total unrecognized stock-based compensation expense relating to unvested stock options was $38.7 million. This amount is expected to be recognized over a weighted average period of 2.76 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity and related information is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.920%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,190)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to RSUs was $0.2 million and $0.3&#160;million, respectively, for the three months and six months ended June 30, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's board of directors adopted on April&#160;18, 2018, and the Company&#8217;s stockholders approved, the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective on May&#160;8, 2018. A total of&#160;336,356&#160;shares of common stock were initially reserved for issuance under the ESPP. In addition, the number of shares of common stock that may be issued under the ESPP will automatically increase on the first day of each calendar year, beginning in 2020 and ending in and including 2028, by an amount equal to the lesser of (i)&#160;1%&#160;of the number of shares of the Company&#8217;s common stock outstanding on the last day of the applicable preceding calendar year and (ii)&#160;an amount determined by the Company&#8217;s board of directors. The Company's board of directors authorized an initial offering period under the ESPP commencing on February 1, 2020. Accordingly, on January 1, 2021, the number of shares authorized for issuance under the ESPP was increased by 474,701 shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation expense recognized related to the ESPP for the three and six ended June 30, 2021 and 2020 was not material. There was a total of 0 shares and 27,587 shares, respectively, purchased under the ESPP during the three and six months ended June 30, 2021. There were no shares purchased under the ESPP during both the three months and six months ended June 30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507892909352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#8217;s otherwise recognizable net deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was enacted on March 27, 2020. The CARES Act contained several key provisions including: (i) five year carryback of net operating losses (&#8220;NOLs&#8221;), (ii) increase in amount of business interest expense deductible under Section 163(j) of the Internal Revenue Code from 30% to 50% for  tax years 2019 and 2020, (iii) delay of payment of employer payroll taxes, (iv) temporary refundable employee retention credit, (v) suspension of certain aviation and alcohol excise taxes and (vi) technical correction for qualified improvement property. As of June 30, 2021, the Company had deferred $0.4 million in employer payroll taxes pursuant to the CARES Act, of which $0.2 million is included in the accrued expenses and $0.2 million is included in the other noncurrent liabilities in these unaudited condensed consolidated balance sheets.</span></div>For the six months ended June 30, 2021 and 2020 the Company recorded a tax provision of $0.2&#160;million and $0.2&#160;million, respectively, primarily related to the Company's wholly-owned UK subsidiary.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507893055928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, issuance of common stock under the ESPP and restricted common stock, and exercise of the Warrant and Conversion Option under the Amended Credit Facility, outstanding during the period determined using the treasury stock methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and therefore basic and diluted net loss per share have been equivalent.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents securities that have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:67.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.837%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested common stock from early exercise of options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,145,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,385,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock offering from ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,690,676&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,445,836&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507891351624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives clinical advisory services from Weatherden Ltd. (&#8220;Weatherden&#8221;) under agreements that were entered into during 2017 and 2018. Duncan McHale, the Company&#8217;s Chief Medical Officer, is a part owner of Weatherden. During the six months ended June 30, 2021 and 2020, the Company paid Weatherden $0.1 million and $0.4 million, respectively. As of June 30, 2021 and 2020, the amount due to Weatherden under the supply of service agreement was approximately 0.1 million and  $0.1 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into a subleasing arrangement with Ring Therapeutics, Inc. (formerly VL46, Inc.), an affiliate of one of its stockholders, Flagship Venture Funds. Under the terms of the sublease, the Company invoiced Ring Therapeutics for an aggregate $0.9 million in rent payments which were due during the period from July&#160;1, 2018 through April&#160;30, 2020, the sublease expiration date, plus related taxes and lease operating costs. For the three and six months ended June 30, 2020, $0.1&#160;million and $0.3&#160;million, respectively, related to this sublease, inclusive of rent payments, taxes and operating expenses, has been recorded as an offset to operating expense within the unaudited condensed consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a consulting agreement with David Epstein (the "Consulting Agreement"), the Company's Chairman of the Board, effective September 16, 2019 pursuant to which Mr. Epstein provides strategic advisory and other consulting services to the Company. The Consulting Agreement was amended on October 15, 2020 and again on April 9, 2021, and now has a term that is scheduled to end on June 30, 2022 unless terminated earlier by either Mr. Epstein or the Company upon 30 days&#8217; notice, or 24 hours&#8217; notice by the non-breaching party in the event of a breach. In accordance with the terms of the Consulting Agreement, on September 16, 2019, Mr. Epstein was granted an option to purchase 75,000 shares of the Company&#8217;s common stock, which award vests in 36 equal monthly installments subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting dates. Under the Consulting Agreement as amended on October 15, 2020, Mr. Epstein also is entitled to receive (i) an annual equity award on each anniversary of the effective date of the Consulting Agreement in the form of an option to purchase shares of the Company&#8217;s common stock having an aggregate grant date fair market value equal to approximately $0.2&#160;million, as determined by the </span></div>Board in its discretion based on customary option pricing methodologies, which award vests in 12 equal monthly installments following the grant date, subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting date, and (ii) an aggregate annual cash consulting fee of $0.3&#160;million for his consulting services. In the event the Consulting Agreement is renewed for a term of less than one year, the aggregate grant date fair value of the corresponding annual equity award and the resulting number of shares of the Company&#8217;s common stock purchasable under such annual equity award and the vesting schedule shall be adjusted proportionately to the length of the renewal term. On October 11, 2020, in connection with the commencement of his second year of service as a consultant to the Company, Mr. Epstein was granted an annual equity award in the form of an option to purchase 44,743 shares of the Company&#8217;s common stock, which award vests in nine equal monthly installments, in each case subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting dates. Under the Consulting Agreement as amended on April 9, 2021, effective on June 30, 2021, Mr. Epstein is entitled to receive restricted stock units having an aggregate grant date fair value of approximately $0.5&#160;million, as determined by our Board of Directors in its discretion based on a 10-day trailing average of the closing price of our common stock on the Nasdaq Global Select Market, as his sole compensation for the provision of consulting services to the Company. The restricted stock units will vest in 12 substantially equal monthly installments following June 30, 2021, such that the restricted stock units shall be fully vested on June 30, 2022, subject to his continued provision of consulting services to the Company pursuant to the Consulting Agreement on the applicable vesting date. All of the foregoing options and restricted stock units, to the extent then outstanding, will be subject to accelerated vesting upon the occurrence of a change in control of the Company.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507982535048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and ASU of the FASB. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations.&#160;Accordingly, these financial statements should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and notes thereto.&#160;The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments which are necessary to present fairly the Company&#8217;s financial position as of June 30, 2021, the results of its operations and stockholders' equity for the three and six months ended June 30, 2021 and 2020 and cash flows for the six months ended June 30, 2021 and 2020. Such adjustments are of a normal and recurring nature. The results for the three and six months ended June 30, 2021 are not necessarily indicative of the results for the year ending December 31, 2021, or for any future period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, estimates related to the application of ASC 606 to our collaboration agreement, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">Principles of ConsolidationThe unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned, controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evelo is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"), and it may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Evelo may take advantage of these exemptions until it is no longer an emerging growth company. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. Evelo has elected to use the extended transition period for complying with new or revised accounting standards, and, as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. Evelo may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its IPO or such earlier time that it is no longer an emerging growth company. Evelo would cease to be an emerging growth company if it has more than $1.07 billion in annual revenue, it has more than $700.0 million in market value of its stock held by non-affiliates (and has been a public company for at least 12&#160;months and has filed one annual report on Form&#160;10-K), or it has issued more than $1.0 billion of non-convertible debt securities over a three-year period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income or Loss</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Income or Loss</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) consists of net income (loss) and changes in equity during a period from transactions and other equity and circumstances generated from non-owner sources. The Company&#8217;s net loss equals comprehensive loss for all periods presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents, and Restricted CashCash equivalents are comprised of highly liquid investments that are readily convertible into cash with original maturities of three months or less. Cash and cash equivalents include cash held in banks and amounts held in money market funds. Cash equivalents are stated at cost, which approximates market value. The Company&#8217;s restricted cash consists of restricted cash in connection with building leases for the Company&#8217;s office and laboratory premises and deposits held in relation to the company's credit card facility.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820,&#160;Fair Value Measurement&#160;(&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes between the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 inputs are inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly; and</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in earnings. The Company did not elect to measure any additional financial instruments or other items at fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Agreements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreements </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,  Collaborative Arrangements ("ASC 808") to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, the Company assesses whether aspects of the arrangement between the Company and its collaboration partner are within the scope of other accounting literature, including ASC 606, Revenue from Contracts with Customers ("ASC 606"). If it is concluded that some or all aspects of the arrangement represent a transaction with a customer, the Company will account for those aspects of the arrangement within the scope of ASC 606. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 808 provides guidance for the presentation and disclosure of transactions in collaborative arrangements, but it does not provide recognition or measurement guidance. Therefore, if the Company concludes a counterparty to a transaction is not a customer or otherwise not within the scope of ASC 606, the Company considers the guidance in other accounting literature, including the guidance in ASC 606, as applicable or by analogy to account for such transaction. The classification of transactions under the Company&#8217;s arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition and Contract Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of Accounting Standards Codification ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities.  If the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those aspects of the arrangement within the scope of ASC 606.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, it performs the following steps: (i) identify the contract(s) with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) each performance obligation is satisfied. ASC 606 requires significant judgment and estimates and results in changes to, but not limited to: (i) the determination of the transaction price, including estimates of variable consideration, (ii) the allocation of the transaction price, including the determination of estimated selling price, and (iii) the pattern of recognition, including the application of proportional performance as a measure of progress on service-related promises and application of point-in-time recognition for supply-related promises. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised good or services in the Company&#8217;s arrangement may consist of license rights to the Company&#8217;s intellectual property or research and development services. The Company also may have optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price may be comprised of fixed payments, often an upfront payment due at contract inception, or other types of variable consideration in the form of payments for the Company&#8217;s services and materials and milestone payments due upon the achievement of specified events. Other payments the Company could be entitled to include tiered royalties earned when customers recognize net sales of licensed products. The Company considers the existence of any significant financing component within its arrangements to the extent there is a significant difference between the timing of payment and the transfer of control of the performance obligations.  In making that determination, the Company considers whether substantive business purposes exist to support the payment structure other than to provide a significant benefit of financing. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">promised goods and/or services to the customer. The Company utilizes either the expected value method or the most likely amount method to estimate the amount of variable consideration, depending on which method is expected to better predict the amount of consideration to which the Company will be entitled. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. With respect to arrangements that include payments for a development or regulatory milestone payment, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the Company&#8217;s or the licensee&#8217;s control, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company re-evaluates the probability of achievement of each milestone and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, wherein the license is deemed to be the sole or predominant item to which the payments relate, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements with more than one performance obligation, the Company generally allocates the transaction price to each performance obligation based on a relative standalone selling price basis. The Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation in consideration of applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated research and development costs. However, in certain instances, the Company may allocate variable consideration entirely to one or more performance obligation if the terms of the variable consideration relate to the satisfaction of the respective performance obligation and the amount allocated is consistent with the amount the Company would expect to receive for the satisfaction of the respective performance obligation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. For performance obligations that are satisfied at a point in time, the Company recognizes revenue when control of the goods and/or services is transferred to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer.  With respect to arrangements containing a license to its intellectual property that is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from amounts allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Liabilities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a contract liability, classified as deferred revenue on its condensed consolidated balance sheet, when it has received payment but has not yet satisfied the related performance obligations. In the event of an early termination of a contract with a customer, any contract liabilities would be recognized in the period in which all Company obligations under the agreement have been fulfilled.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period incurred. Research and development expenses consist of both internal and external costs such as payroll, consulting, and manufacturing costs associated with the development of the Company&#8217;s product candidates. Costs for certain development activities, such as clinical trials and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the unaudited condensed consolidated balance sheets as prepaid or accrued research and development expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire licenses, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects. Any milestone payments made for Intellectual Property after regulatory approval, or that have alternative future use, are capitalized and amortized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records stock-based compensation for equity awards granted to employees and directors based on the grant date fair value of awards issued. The expense is recorded over the requisite service period, which is the vesting period, on a straight-line basis. The Company uses the Black-Scholes option-pricing model to determine the fair value of options. The determination of the fair value of options on the date of grant using an option-pricing model is affected by the Company&#8217;s common stock price, as well as a number of other assumptions. The Company records forfeitures as they occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation arrangements with&#160;non-employees&#160;based upon the fair value of the consideration received or the equity instruments issued, whichever is more reliably measurable. The measurement date for&#160;non-employee&#160;awards is generally the date performance of services required from the&#160;non-employee&#160;is complete. Stock-based compensation costs for&#160;non-employee&#160;awards are recognized as services are provided, which is generally the vesting period, on a straight-line basis.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating segment. The Company's chief operating decision maker, its Chief Executive Officer, manages the Company's operations on a consolidated basis for the purposes of allocating resources.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Accounting Pronouncements Issued and Not Adopted</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019 -12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The new standard was effective for the Company on January 1, 2021 and it includes several provisions which simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The Company adopted ASU No. 2019-12 on January 1, 2021 and has concluded the adoption did not have a material impact on its unaudited condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements Issued and Not Adopted as of June 30, 2021</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Instruments - Credit Losses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326)&#8212;Measurement of Credit Losses on Financial Instruments, which has been subsequently amended by ASU No. 2018-19, ASU No. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019-04, ASU No. 2019-05, ASU No. 2019-10, ASU No. 2019-11 and ASU No. 2020-03 (&#8220;ASU 2016-13&#8221;). The provisions of ASU 2016-13 modify the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology and require a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 is effective for the Company on January 1, 2023, with early adoption permitted. The Company is currently evaluating the potential impact that this standard may have on its financial position and results of operations, as well as the timing of its adoption of this standard.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Debt with Conversion and Other Options</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2020, the FASB issued ASU No. 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU-2020-06&#8221;), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models in ASC 470-20 that require separate accounting for embedded conversion features from convertible instruments. As a result, after adopting the ASU&#8217;s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Additionally, the guidance simplifies the evaluation of whether a contract in the issuer&#8217;s own equity can be classified in equity or an embedded feature qualifies for the derivative scope exception. Although the guidance is not effective until 2022, early adoption of ASU 2020-06 is permitted for all entities for fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of this new guidance on the Company&#8217;s condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesDeferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company&#8217;s otherwise recognizable net deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507892967384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">The following reconciles cash, cash equivalents and restricted cash as of June 30, 2021 and December 31, 2020, as presented on the Company's statements of cash flows, to its related balance sheet accounts (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:55.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.058%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,964&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,487&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,333&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,857&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,896&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,420&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">The following reconciles cash, cash equivalents and restricted cash as of June 30, 2021 and December 31, 2020, as presented on the Company's statements of cash flows, to its related balance sheet accounts (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:55.064%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.058%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,964&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,487&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,333&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,857&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,896&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,420&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507892976216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Minimum Aggregate Future Lease Commitments</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum aggregate future lease commitments at June 30, 2021, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.814%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2021 (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">excluding amounts paid or in Accounts Payable as of 6/30/2021)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,252</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,154</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,491</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,208</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,472)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,736</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used for operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507891325224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Financial Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s financial assets and liabilities that have been measured at fair value as of June 30, 2021 and December 31, 2020 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.227%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds included within cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,369&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,369&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.227%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds included within cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,370&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,370&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507984753688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:57.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.747%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,744&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,831&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,239&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,121&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,719)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,643)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,520&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,478&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507893140296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan and Security Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text">The Company utilized the following significant unobservable inputs (Level 3 inputs) to determine the estimated fair value of its debt as of the amendment date:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:52.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.00&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table>The Company utilized the Black-Scholes valuation method to determine the fair value of the warrant which utilized the following assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:64.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of underlying common stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Minimum Aggregate Future Loan Payments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has the following minimum aggregate future loan payments at June 30, 2021 (in thousands). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:83.504%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve month period ending June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest and discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,482&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507891641368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in the Company&#8217;s unaudited condensed consolidated statements of operations is as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:35.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,093&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,036&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity and related information is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.482%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,610,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,731,274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,267)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,145,838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,443,028&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity and related information is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.920%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,190)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507891529896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares Outstanding</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents securities that have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:67.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.837%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested common stock from early exercise of options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,145,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,385,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock offering from ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,690,676&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,445,836&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507977117208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 02, 2021</div></th>
<th class="th"><div>Jun. 03, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,300,000<span></span>
</td>
<td class="nump">$ 123,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 352,313,000<span></span>
</td>
<td class="nump">$ 352,313,000<span></span>
</td>
<td class="nump">$ 292,519,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_RegistrationStatementMember', window );">Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction', window );">Maximum value of shares issued in transaction (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SaleOfStockConsiderationReceivedTerm', window );">Sale of stock, term (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_AtTheMarketMember', window );">At-the-market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction', window );">Maximum value of shares issued in transaction (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold in public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">139,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction', window );">Gross proceeds from transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_AtTheMarketMember', window );">At-the-market | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold in public offering (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.54<span></span>
</td>
<td class="nump">$ 12.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_AtTheMarketMember', window );">At-the-market | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold in public offering (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.17<span></span>
</td>
<td class="nump">$ 13.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold in public offering (in shares)</a></td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold in public offering (in dollars per share)</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction', window );">Gross proceeds from transactions</a></td>
<td class="nump">$ 77,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 72,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold in public offering (in shares)</a></td>
<td class="nump">675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold in public offering (in dollars per share)</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SaleOfStockConsiderationReceivedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Consideration Received, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SaleOfStockConsiderationReceivedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Gross Consideration Received on Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SaleOfStockGrossConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Value of Shares Issued In Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_RegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=evlo_RegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=evlo_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=evlo_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507889834632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Current restricted cash</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Noncurrent restricted cash</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507893239528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 2,964<span></span>
</td>
<td class="nump">$ 4,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">120,369<span></span>
</td>
<td class="nump">64,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">123,333<span></span>
</td>
<td class="nump">68,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,563<span></span>
</td>
<td class="nump">1,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 124,896<span></span>
</td>
<td class="nump">$ 70,420<span></span>
</td>
<td class="nump">$ 91,673<span></span>
</td>
<td class="nump">$ 79,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507977170680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ALJ Commercialization and License Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 17, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Transaction with party to collaborative arrangement | ALJ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod', window );">Negotiation period for second product candidate</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum', window );">Maximum fee for second product option</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage', window );">Share of operating profits and losses and development, regulatory and commercialization costs.</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Second Product Candidate, Fee, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Second Product Candidate, Negotiation Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Share Of Operating Profits And Losses And Development, Regulatory And Commercialization Costs, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=evlo_MeddistCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=evlo_MeddistCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507897483928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of leased office and research development space (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Minimum rental payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease rental income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI http://asc.fasb.org/extlink&amp;oid=124502072&amp;loc=SL77927221-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507976898984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Minimum Aggregate Future Lease Commitments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (excluding amounts paid or in Accounts Payable as of 6/30/2021)</a></td>
<td class="nump">$ 1,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">3,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">3,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">3,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">2,491<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">13,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(2,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">10,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Other information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used for operating leases</a></td>
<td class="nump">$ 1,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">4 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">9.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507896882056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 120,369<span></span>
</td>
<td class="nump">$ 64,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds included within cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">120,369<span></span>
</td>
<td class="nump">64,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">120,369<span></span>
</td>
<td class="nump">64,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Money market funds included within cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">120,369<span></span>
</td>
<td class="nump">64,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Money market funds included within cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Money market funds included within cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507894094904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 14,239<span></span>
</td>
<td class="nump">$ 13,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(6,719)<span></span>
</td>
<td class="num">(5,643)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,520<span></span>
</td>
<td class="nump">7,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">9,744<span></span>
</td>
<td class="nump">8,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">2,157<span></span>
</td>
<td class="nump">2,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">822<span></span>
</td>
<td class="nump">822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=evlo_ComputersAndSoftwareMember', window );">Computers and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 1,272<span></span>
</td>
<td class="nump">$ 1,078<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=evlo_ComputersAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=evlo_ComputersAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507894075784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 1,090<span></span>
</td>
<td class="nump">$ 1,031<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507897223800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan and Security Agreements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 19, 2019 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 16, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock exercise prices (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_ClassOfWarrantOrRightFairValueMeasurement', window );">Additional paid in capital at its issuance date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,226,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,226,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditFairValueDisclosure', window );">Credit Facility estimate fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evlo_A2019CreditFacilityMember', window );">2019 Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | 2019 Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity (up to)</a></td>
<td class="nump">$ 45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SecurityAndLoanAgreementNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Loan and security agreement, interest rate</a></td>
<td class="nump">8.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal', window );">Prepayment fee percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage', window );">Anniversary of funding date for determining prepayment fee percentage</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne', window );">Prepayment fee percentage after specified period</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage', window );">Final payment under agreement as a percentage of loans borrowed</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Fees incurred to establish facility</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_DebtInstrumentDebtDefaultPercentage', window );">Debt default interest rate per annum</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | 2019 Credit Facility | Security And Loan Agreement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity (up to)</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | 2019 Credit Facility | Security And Loan Agreement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity (up to)</a></td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | 2019 Credit Facility | Security And Loan Agreement, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity (up to)</a></td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | 2019 Credit Facility | Security And Loan Agreement, Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | 2019 Credit Facility | Prime Plus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Loan and security agreement, basis spread on interest rate</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Amended Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares) (up to) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock exercise prices (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Common stock at a conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage', window );">Final payment under agreement as a percentage of loans borrowed</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Fees incurred to establish facility</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_ClassOfWarrantOrRightFairValueMeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Fair Value Measurement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_ClassOfWarrantOrRightFairValueMeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Anniversary For Determining Prepayment Fee Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_DebtInstrumentDebtDefaultPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Default, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_DebtInstrumentDebtDefaultPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument prepayment fee percentage after specified period one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument prepayment fee percentage on principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repayment Or Prepayment Fee Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SecurityAndLoanAgreementNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Security And Loan Agreement, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SecurityAndLoanAgreementNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evlo_A2019CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evlo_A2019CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_DebtInstrumentTrancheAxis=evlo_SecurityAndLoanAgreementTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_DebtInstrumentTrancheAxis=evlo_SecurityAndLoanAgreementTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_DebtInstrumentTrancheAxis=evlo_SecurityAndLoanAgreementTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_DebtInstrumentTrancheAxis=evlo_SecurityAndLoanAgreementTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_DebtInstrumentTrancheAxis=evlo_SecurityAndLoanAgreementTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_DebtInstrumentTrancheAxis=evlo_SecurityAndLoanAgreementTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_DebtInstrumentTrancheAxis=evlo_SecurityAndLoanAgreementTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_DebtInstrumentTrancheAxis=evlo_SecurityAndLoanAgreementTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evlo_AmendedCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evlo_AmendedCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507889778808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loan and Security Agreements - Significant Unobservable Inputs (level 3 Inputs) (Details) - (Level 3) - Fair Value, Recurring<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt instrument, measurement input</a></td>
<td class="nump">0.7000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Expected yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt instrument, measurement input</a></td>
<td class="nump">0.1150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507897608584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loan and Security Agreements - Fair Value of Warrant (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 13.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Fair value of underlying common stock | (Level 3) | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">16.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | (Level 3) | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility | (Level 3) | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years) | (Level 3) | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">10.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Expected dividend yield | (Level 3) | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507893195384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loan and Security Agreements - Schedule of Minimum Aggregate Future Loan Payments (Details) - Line of Credit<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths', window );">2022</a></td>
<td class="nump">$ 3,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo', window );">2023</a></td>
<td class="nump">13,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree', window );">2024</a></td>
<td class="nump">32,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour', window );">2025</a></td>
<td class="nump">7,316<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total minimum payments</a></td>
<td class="nump">56,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less amounts representing interest and discount</a></td>
<td class="num">(10,171)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total minimum payments</a></td>
<td class="nump">$ 46,482<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507896821784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>In-License Agreements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 06, 2017</div></th>
<th class="th"><div>Mar. 10, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=evlo_MayoClinicMember', window );">Mayo Clinic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_NonRefundableUpfrontFee', window );">Non-refundable upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent', window );">Milestone payments upon achievement of certain development, regulatory, and commercial events</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Amount due under license agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=evlo_MayoClinicMember', window );">Mayo Clinic | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent', window );">Milestone payments upon achievement of certain development, regulatory, and commercial events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=evlo_UniversityOfChicagoMember', window );">University of Chicago Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent', window );">Milestone payments upon achievement of certain development, regulatory, and commercial events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Amount due under license agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts', window );">Milestone payments for development and commercialization of licensed products</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=evlo_UniversityOfChicagoMember', window );">University of Chicago Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_NonRefundableUpfrontFee', window );">Non-refundable upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments For Development And Commercialization Of Licensed Products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments of development, regulatory, and commercial event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_NonRefundableUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non refundable upfront fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_NonRefundableUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=evlo_MayoClinicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=evlo_MayoClinicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=evlo_UniversityOfChicagoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=evlo_UniversityOfChicagoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507897839160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - Sacco - Collaborative Arrangement - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_CollaborationArrangementTerm', window );">Term of collaboration arrangement</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices', window );">Period of inactive manufacturing services causing termination under collaborative arrangement</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_AggregateAmountDueUnderCollaborativeArrangement', window );">Aggregate amount due under collaborative arrangement</a></td>
<td class="nump">&#8364; 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_AnnualAmountDueUnderCollaborativeArrangement', window );">Annual amount due under collaborative arrangement</a></td>
<td class="nump">&#8364; 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_FeeIncurredUnderCollaborativeArrangement', window );">Fee incurred under collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_AggregateAmountDueUnderCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Amount Due Under Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_AggregateAmountDueUnderCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_AnnualAmountDueUnderCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Amount Due Under Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_AnnualAmountDueUnderCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_CollaborationArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_CollaborationArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Period Of Inactive Manufacturing Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_CommitmentAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_CommitmentAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_FeeIncurredUnderCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fee Incurred Under Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_FeeIncurredUnderCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=evlo_SaccoS.r.l.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=evlo_SaccoS.r.l.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507896581064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 02, 2021</div></th>
<th class="th"><div>Jun. 03, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 16, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Amended Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares) (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Common stock at a conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_RegistrationStatementMember', window );">Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction', window );">Maximum value of shares issued in transaction (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SaleOfStockConsiderationReceivedTerm', window );">Sale of stock, term (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_AtTheMarketMember', window );">At-the-market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction', window );">Maximum value of shares issued in transaction (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold in public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">139,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction', window );">Gross proceeds from transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_AtTheMarketMember', window );">At-the-market | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold in public offering (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.54<span></span>
</td>
<td class="nump">$ 12.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_AtTheMarketMember', window );">At-the-market | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold in public offering (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.17<span></span>
</td>
<td class="nump">$ 13.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold in public offering (in shares)</a></td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold in public offering (in dollars per share)</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 72,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction', window );">Gross proceeds from transactions</a></td>
<td class="nump">$ 77,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold in public offering (in shares)</a></td>
<td class="nump">675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold in public offering (in dollars per share)</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SaleOfStockConsiderationReceivedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Consideration Received, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SaleOfStockConsiderationReceivedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SaleOfStockGrossConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Gross Consideration Received on Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SaleOfStockGrossConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Value of Shares Issued In Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evlo_AmendedCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evlo_AmendedCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_RegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=evlo_RegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=evlo_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=evlo_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=evlo_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507884459992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">78 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 27, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>May 08, 2018</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted (up to, in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,731,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.52<span></span>
</td>
<td class="nump">$ 4.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,772,000<span></span>
</td>
<td class="nump">$ 2,093,000<span></span>
</td>
<td class="nump">$ 7,036,000<span></span>
</td>
<td class="nump">$ 4,048,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 38,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndTwentyOneStockInducementPlanMember', window );">2021 Stock Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares originally authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock available for future grant (in shares)</a></td>
<td class="nump">695,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">695,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">695,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">695,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndTwentyOneStockInducementPlanMember', window );">2021 Stock Inducement Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, maximum expiration period (no more than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted (up to, in shares)</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndTwentyOneStockInducementPlanMember', window );">2021 Stock Inducement Plan | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted (up to, in shares)</a></td>
<td class="nump">4,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndEighteenStockIncentivePlanMember', window );">2018 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares originally authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,344,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted (up to, in shares)</a></td>
<td class="nump">6,557,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock available for future grant (in shares)</a></td>
<td class="nump">647,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">647,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">647,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">647,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,898,805<span></span>
</td>
<td class="nump">1,286,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares exercised (in shares)</a></td>
<td class="nump">34,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares canceled (in shares)</a></td>
<td class="nump">977,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndEighteenStockIncentivePlanMember', window );">2018 Stock Incentive Plan | Stock Options | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndEighteenStockIncentivePlanMember', window );">2018 Stock Incentive Plan | Maximum | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, maximum expiration period (no more than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndEighteenStockIncentivePlanMember', window );">2018 Stock Incentive Plan | Maximum | Stock Options | Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndEighteenStockIncentivePlanMember', window );">2018 Stock Incentive Plan | Minimum | Stock Options | Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,417,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted', window );">Number of shares, options and other equity awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,758,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised', window );">Number of shares, options and other equity awards exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,431,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures', window );">Number of shares, options and other equity awards canceled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,275,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased', window );">Number of shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease', window );">Number of shares no longer authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan | Stock Options | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan | Maximum | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, maximum expiration period (no more than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan | Maximum | Stock Options | Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan | Minimum | Stock Options | Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evlo_A2018EmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued for purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,587<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Increase Decrease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Repurchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Forfeitures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndTwentyOneStockInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=evlo_TwoThousandAndTwentyOneStockInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=evlo_TwoThousandAndEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=evlo_TwoThousandAndFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=evlo_TwoThousandAndFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=evlo_A2018EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=evlo_A2018EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507977114952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,772,000<span></span>
</td>
<td class="nump">$ 2,093,000<span></span>
</td>
<td class="nump">$ 7,036,000<span></span>
</td>
<td class="nump">$ 4,048,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,723,000<span></span>
</td>
<td class="nump">1,010,000<span></span>
</td>
<td class="nump">3,164,000<span></span>
</td>
<td class="nump">1,899,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,049,000<span></span>
</td>
<td class="nump">$ 1,083,000<span></span>
</td>
<td class="nump">$ 3,872,000<span></span>
</td>
<td class="nump">$ 2,149,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507982630088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">6,610,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,731,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(85,831)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(110,267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">9,145,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable as of period end (in shares)</a></td>
<td class="nump">4,443,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 6.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">15.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">6.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in dollars per share)</a></td>
<td class="nump">10.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">9.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable as of period end (in dollars per share)</a></td>
<td class="nump">$ 6.12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507897823960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details) - Warrant<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance at December 31, 2020 (in shares) | shares</a></td>
<td class="nump">284,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">172,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(36,190)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance at June 30, 2021 (in shares) | shares</a></td>
<td class="nump">420,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance at December 31, 2020 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">15.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">6.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance at June 30, 2021 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507897076488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SocialSecurityTaxEmployerDeferralCARESAct', window );">Deferred payroll taxes related to CARES Act</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SocialSecurityTaxEmployerDeferralCARESAct', window );">Deferred payroll taxes related to CARES Act</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SocialSecurityTaxEmployerDeferralCARESAct', window );">Deferred payroll taxes related to CARES Act</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SocialSecurityTaxEmployerDeferralCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Social Security Tax, Employer, Deferral, CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SocialSecurityTaxEmployerDeferralCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507894235784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares Outstanding (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total number of securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">9,690,676<span></span>
</td>
<td class="nump">6,445,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evlo_UnvestedCommonStockMember', window );">Unvested common stock from early exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total number of securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">18,386<span></span>
</td>
<td class="nump">36,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total number of securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">9,145,838<span></span>
</td>
<td class="nump">6,385,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total number of securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">139,770<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Conversion option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total number of securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">375,939<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Common stock offering from ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total number of securities excluded from computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">10,743<span></span>
</td>
<td class="nump">23,492<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evlo_UnvestedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evlo_UnvestedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140507897797576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th"><div>Apr. 09, 2021</div></th>
<th class="th">
<div>Oct. 15, 2020 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Oct. 11, 2020 </div>
<div>installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 16, 2019 </div>
<div>installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease rental income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,731,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=evlo_WeatherdenLtdMember', window );">Weatherden Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Payment to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Amounts due to related party</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=evlo_VL46Member', window );">VL46</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Rent due from sublease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Mr. Epstein | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue', window );">Aggregate grant date fair value for restricted stock units</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Mr. Epstein | Consulting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm', window );">Termination notice period of consulting arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm', window );">Termination notice period by non-breaching party in event of a breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 hours<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,743<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments', window );">Option to purchase shares, vesting period, number of equal monthly installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue', window );">Aggregate grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments', window );">Annual equity award, vesting period, number of equal monthly installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_RelatedPartyTransactionAnnualCashConsultingFee', window );">Aggregate annual cash consulting fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_RelatedPartyTransactionConsultingContractRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Mr. Epstein | Consulting Agreement | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments', window );">Option to purchase shares, vesting period, number of equal monthly installments | installment</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod', window );">Period for trailing average closing common stock price</a></td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_RelatedPartyTransactionAnnualCashConsultingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Annual Cash Consulting Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_RelatedPartyTransactionAnnualCashConsultingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Annual Share-based Payment Award, Options, Grant Date Fair Market Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Closing Common Stock Price, Trailing Average, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_RelatedPartyTransactionConsultingContractRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Consulting Contract, Renewal Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_RelatedPartyTransactionConsultingContractRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Consulting Contract, Termination Notice, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Consulting Contract, Termination Notice Upon Breach Of Contract, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Share-based Payment Award, Equity Instruments Other Than Options, Grant Date Fair Market Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Annual Equity Award Vesting Period, Number Of Monthly Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Number Of Monthly Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=evlo_WeatherdenLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=evlo_WeatherdenLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=evlo_VL46Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=evlo_VL46Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=evlo_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=evlo_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "6._U26PYW]%$%  #\%0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;*68VV[C-A"&K[=/01B]V 7B2*)\B!>. <=)VK0Y.'&ZQ;;H!2W1-A%)="G*
M3MZ^0\F6G( >J=B;1*?Y_6E(_3/D<"O52[KB7)/7.$K2\]9*Z_57QTF#%8]9
M>BK7/($["ZEBIN%4+9UTK3@+\Z X<JCK]IR8B:0U&N;7IFHTE)F.1,*GBJ19
M'#/U=L$CN3UO>:W]A2>Q7&ESP1D-UVS)9US_L9XJ.'-*E5#$/$F%3(CBB_/6
MV/LZ\7T3D#_Q3?!M>G!,S*O,I7PQ)S?A><LU1#SB@382#/YM^(1'D5$"CG]W
MHJWR-TW@X?%>_3I_>7B9.4OY1$9_BE"OSEMG+1+R!<LB_22WO_+="W6-7B"C
M-/]+ML6SG4Z+!%FJ9;P+!H)8),5_]KI+Q&& >R2 [@+HAP#OV"_XNX \<TY!
MEK_6)=-L-%1R2Y1Y&M3,09Z;/!K>1B1F&&=:P5T!<7HTD1NNR!1&C+1)NF**
MIT-'@["Y[00[D8M"A!X1Z9$[F>A52JZ2D(?OXQT *JGHGNJ"HH*_9<DI\=T3
M0EWJ67@F=>'1*:$]6_@['+],DI_K^6B2_A[/4ZU@WOV#2'9*R4XNV3DB>2F#
M#+X&39[?UMR6<3S<<]N/"$6WI.@VHWC,F-)<16_DB:^ETC8B7$JKC"-$O9*H
MUXQHRI60H9E1!":V-46XTGX._?3I4\TTZ)=L_89CIACX6&Y#Q].%:RU8E&+Y
M.BN9SE"=JT0+_4:N1<3)?1;/N;*QX!JNZ[7]LT[?1W@&)<^@"<\37PKSL4"R
M[EEL';T:G0U4&'(A9!H(G@0\/2$W27"*$'IN97EN$T;0DPI&CYF!/"$S#=.,
M2$4F,DNT>H/_H16\1OWR"H,\\&6O">0S>R4W(4PZL1!!3HH,<XUDI]?N=@>=
M+NUCA+0BI$T(QV$(10/&9W= ;N$Y\I#8<X=+]JA+[G@LE6 1N510X#'2RKX]
M_W^13LP9C/2SW"962EQNPN*Y$N$2A:L*@8=;^4>X<AY.E=P(F/I60ESS;HRA
M5=7!PSW](]I4IAH&YB^Q/OYQX(I@Q/X 8ZOJA(?;>SZ&8^A<CZ/@ I][7O\+
MAE*5!0_W\EL90%:F*YE@'EPCTNWWVZ[ONAA1510\W-&?A89Z(!?$HY_G7\B,
M!YF"?%FQ<*6)C&/PG)F6P<O)S^XIU JR9HIL6)1QLH:V*&\:,>JJ='BXYT-9
M#46R)+.W>"XC*VQ-T?AV^X!UGU6%H+B'[Q-&KEZ#%4N@.3Y6Q6J$[L>SRS'6
MJ=&J(-!&!6&2*65ZD*+QR-,%AI%9N_8:Q>\?>_WW9%4AH(T*P4T"'62Q+#,M
M&]NC6LEPQ1JRROAI(^,WW1'4=?#5I536KZ!&YUXF;18$L/B$;H&'A2!&6+D_
M;>3^LYA%$;G(4KB=VL<2UZEIOVGE^;21YU_%7"W-[/H%%/0*3#9>L\2>NQ]:
M&-#*\2ENV'NRU\/^NU@F6+%PM;H&G%;V3W'GW@_ABL,08GGZL14!K=R?-EH3
MO+-NP#-K>_*0::CAB?%9Z[JZ4.[FRF8+:#/J^O[@C [HT-G8J"IWI[@YCV'I
M%.;+I^N(V7[\HD:@+D%^9>]^38N^7\A=B]24[N\<*MHU7+1^>35B=7L,E<'[
MN!U_I-JM@(]SX7*/%*.JS-UO9.X3 %, =9.$_)7\SJTSO$;*A>:A-^CT>EV,
M[&!3IJ8-WU7"PT'$M@MJY-IMC[9]ZU Z!_MKQA?S;<>4!&:A6&RUE5?+K<UQ
MOJ'G5(\7^Z)WS-AJ2B*^@%#WM ^?FBJV&HL3+=?Y;MU<:BWC_'#%6<B5>0#N
M+Z34^Q/S ^6&[^@_4$L#!!0    ( )8[_5+K+OP^L04  $L6   8    >&PO
M=V]R:W-H965T<R]S:&5E=#(N>&ULM5AM;]LV$/XKA%<,&^#$)/6>.@;:!,,V
M;&O0M-MG6J)CHI+HD532[-?O*#N2+5**"VP!DNCE[O@<=7P>'I=/4GW16\X-
M^EJ5M;Z>;8W972T6.M_RBNE+N>,UO-E(53$#M^IAH7>*LZ)UJLH%Q3A>5$S4
ML]6R?7:G5DO9F%+4_$XAW5054\_O>2F?KF=D]O+@HWC8&OM@L5KNV ._Y^;S
M[D[!W:*+4HB*UUK(&BF^N9Z](U<W-+,.K<6?@C_IHVMD4UE+^<7>_%)<S[!%
MQ$N>&QN"P;]'?L/+TD8"''\?@LZZ,:WC\?5+])_:Y"&9-=/\1I9_B<)LKV?I
M#!5\PYK2?)1//_-#0I&-E\M2MW_1T\$6SU#>:".K@S,@J$2]_\^^'B;BR(&$
M(P[TX$#/=0@.#D&;Z!Y9F]8M,VRU5/()*6L-T>Q%.S>M-V0C:OL9[XV"MP+\
MS.I&U@5\%%X@N-*R% 4S</.>E:S..;JW@36Z0)_O;]$/;WY$;Y"HT:>M;#2K
M"[U<&,!@(RWRPWCO]^/1D?%^;>I+%. YHI@2C_O-M/LMS\&=M.[XU'T!F7?I
MTRY]VL8+QM)OE.*U04QKR/-J(F+010S:B.%81*:W".8&Y?:"_]V(1U;"$-ZY
MVH>*VU!VP3VN" W@9[EX/)X3URQ.TRCIK$Z AAW0<!+HG>([)@K$O^YL >@6
MM#1;KJ#NCF?%!WP?.CI"%. @',!VC2BDYT<==:BC2=2?I&'E&0 C9VQ"XR!.
M!A!=LP1G*?9CC#N,\2LS"RRKS',[H[8"=L![9HYJ;GQ08Q=#1/$ J,<H3%(_
MSJ3#F4SB;#D;R0UJ--]/)2QT"YT943^@D@,]^@ G#I8LC>(!8->(X&2L9M,.
M<3J)^$-;GN-?/74'#4@T0.8Q"FGH!Y9UP+(SRG(<6.89,\)1.H#FFF4X#C(_
M-H)[CL=GL5PIV%J4P@@^277D2#S(9-KO\EPVP&UHQY[9NO16RR'$"0T$)!MD
M[K$B84A',N_IG=#7 *J&]R3G!4C=H2-,R!"AQRRFT4CAD%XOR+1@?#A=<-U'
M>IYW-+>3RNYYO. #%U5*Z!"[QRI.QJ#W"D*F)>3#B5H<59<7J2L'<324#(]1
M&(](!NDU@WR+:+R&TR,=69(-^<UKE@9C6'OM(/'D6OU#UAZ@D\NUYWLR3?B_
MR?KAPG!5P49W[=4BXM)V&(>I4T^N68!Q.*)'I*=W\@J_CZ\%$$\K5><L"9?@
MTXPZE>9:95DZ1K6]#I!I(;CE&PX("VAQ'GG=^!G1I?DDPD/%]UB-[$MH+P04
MG[%@:V^)^9 >PIUP=SS<G?J,TA%NH;VTT&EIV:_9U_"YJI'2+!XJOL<LQF2,
MNNE1\S"M+C>RJH2QF[O][CF7M2U>7N=C>"?CV9;]2N]8SJ]GT)-KKA[Y;(5\
M7=)_$.@TYUZN:##)3_=&YE^VLBRX^OZ[E)+DK6[WN.9YBJ-HKRGTU;;DL(*T
M'6F.WN!+C GL,!2"3JKA;Q'!<XS;7Z2W3-G6I3%;J<0_O'@+U?WR5&AMM5\J
M)!NC#7PARRQ,6QZ!/I1W?6C[\:"UY-4:EL=+>SF'-:QWO#UG*)^]G]-5J^$J
MGC0YG:)>SNBTG-FRD_7X_% \.4%1, ])/(^CI,T[3.9AFLYA-SJ8-_L2;(,L
MG=.$=+8)GA.2O=C^7S/KJFOD\(YK$X[T%[277SK=N[TK"F&%!;C'=L<7HH9&
M?B> B[PPW;8L)&'@0G7M DJSL7:(]HI.IQ4=]K=-U93MF4W!-R(77EFGKEY?
M!!%LPQV@'D.:T8B,""/MI9U.2_N>SW7/'OI 'P?V\,)V-3JF.'- NV8!;$:B
M$<B]EM-SFKHC"6JK^1M3R-PC'E_GY['SM7Z+HY,^>\SZ.U,/HM:P7=J '[Y,
M8!+4_N1R?V/DKCW\6TMC9-5>;CD#[-8 WF^D-"\W]CRQ.S]>_0M02P,$%
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M(71=:FGN@[@;6J!E'T19%%C&K!"4&]$!R4$G.1B5_%5J$"Q[&80)#GH=8&'
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MNP' ^ZV4^GAC&NB.2^?_ E!+ P04    " "6._U213?\.-\'  #F+@  &
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MZ D-=D(#I]#YK2B35$Z>5+H=KF+=1(%J:-@"8-@"C"QK*=S)"8^3 PU7:$C
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M[U=%4=_=-!\B[SYM/_L/4$L#!!0    ( )8[_5(7'6^2R 8  ,(;   8
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MU 60SD%Z9"CQ8\Q&C-G;,)8<HAX"F#F39Q&> 71E,,:)'R&.IF8;!3'^9,K
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MYP7X7CC07?? !_17VY=_ 5!+ P04    " "6._U2<1ZJ+5<?   59P  &
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M"9Q6J.H7L%W\_'YC@-2PI:(!'#J'2@N$;,>ZJ%@ITP)KC@$9E]E99YC'21F
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MVIZ][#1EBN-\VI3"6W"I#& ?O35,,XD9WX!G@H$I6V.3K+7E>4DW)2^0[JU
MNP#W]3SA4G?W9."3H)%C5AN<!N!E51S;I=/MG6(UO>L[,8&CRN8^G_"X;_;?
MGA?OAL](J\J?!*L  $YE9R"R5)2&(W<*/6/2!/!<'#J23;('1BU))8WOQ"XQ
MO>>-JYA43"'I'3K933>(+N?%IWWP]T"5=,<H/E)<@/+M>=2_<J-DQUKMTQ,D
MM"X*_1)X*$^QWRE3RW9&@W]FPL(@/LP*#6_"1Y*_U0_L_Q!PFKPY_6 Z_Q&4
M-"N? #<96M[P?<QXEQK\$PIWG,:4:Q,W2%H>K0\Z4"MR\.*>R1$N,!BCO&OT
ML0)3CV"5K)22/#3'3F!O80H$<G]\1CHL-D0D;*/L@LKT",N%E;W1#B.(4;D]
M()!=:BI><=;@ZG7Q$Q*X.$NY\-?>HFXBK).L<4)65R=<_:# BK?&6V:B8E@D
MYBQA):#TZ\%BYR,LS]:0'/5\^:'9]/#&%$*4).^K[/,S*#U#*U0&^*/#E$Y+
M25[^])KX/8?R(H5R1-]\64J'6BM*:OKT#THJ^  VAO0B#'GNT*0:V%:Z=KS[
MN O<(CJ]*3)AR&#7-"V#RSG-2G=8N6I"8B+AR9AKQ@CLE[Y:(V/OE[!@$DR4
MXMM^$,;B;4F>_S*K?R ,?DW$2+(<[!&F01>YVS->)3Q>@^O_3TY]"7D!E"3_
M$,<'\M4T3MB.I&=,XE+D4K[ WB,,_#)6+@CL72^4@>$NR7:+(SRN!;!P6Z!D
M=8^4NB@WUG+(+X,PC_\XN@EV-$JIA;)P@5^Y=0,##I\D\0L["!TADC2Y[8'Z
MO_9(D;X!Y-:$P37,R--C!,@Y9IX:\<X.[V!/EE@]!O\^(74//C2K[%A)@$ ;
M:3O(;5>&2HK\9HH!2M96%66P  /CN @I[1$48#B?INVO?=K>90 HF/WQGY)?
M'R3ZVQ:-ED2CEF348>I8BTX#IQ,%+.$D5X))]16$EXN7LQ0(4*[7Z93'1S+J
MZ 2G]P*@PPJ46,J@@/C8UC#/+]:@]\$E/\PBH.[FL!>>H?5F&2/EHQ-EL+34
MFD# 9)I)-I!,A)P <9-U8G(3[H;H_;-W>:E@$1=(?"-?/=IN4>HQ%]B7)2FC
ME6PM++:O['2Z<92N@UC.4OQ$)AT)I5 28BD@G3>UH<,20<X,B"Q,K$P17**^
MF$$%'8[4 5Z>B:W#IU)9FD&(02DY=BUOL/Z@$$8*U6^H"TJWGD7@A2/P@M^N
M)*>(P2#;3D*[DS05E:&G]QJ\+'0W$A^(NU6D]4JW.3))DF578H9151U89HI.
ML(FY)UC,O(>V%&_B=VG##B4;0EL'K98FR"C+D8I7*BM<!02$598:0D*ZGZ)I
MX&6V;6VJF ,XI*3 !;!$O;R$Y+&/;AOA1;?('%3BSS%K>-V(VZ"PJ#*"WQW
MUFRX*GF?[%#';I[FJ9PW?"VL@JG]6*,!")>L%>V:MY00GZ0VV2'K\K(&D8L=
M/4,JQ;KA7K23J387-> @*.%N +9\(BF8*<;!HRRH,.,>NV'D=1F8]$G(D]SK
M]X+Y(>&2_PV#L=\HY?).J:CL_K_;BK=3 OD_K@Y#2NN/J\*/*16E!Z&U$!.
MC^8#8,KL,COZ<CPQ);IKE*'/&,X'",&W\M.[@VX**0$,QID97!Y0%A ?[MRK
MXMB<^!C_T7>%D"0>NY,H:AYKKV'\\ 69G_2/A<AWK8(63^>C5^'='#DIA2B
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M:S%S;CZC#I=-R0!8Q_N$@RU/^:,<-!)C-8(&F0L]  \%H0.=2$PH52;K<#^
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M/#_BG)3_ )J2?OAD:;O.;NG/C4;SC /@>_RM!/\!%PB_A//=?P-02P,$%
M  @ ECO]4L'0D 9C"0  EQP  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6S-6>]SV[@1_5<PZDWG,B-+LN(?:>)XQO'%;=)+SQ,G[8=./T D1*(! 1X
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M"H4U/GE-GGA5&YFE8!W(3V4.B6AM!,+0T.]<A<SK!3Q?$#VFH-KT7+=K^LP
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MSU+A$N5I MXOG8O= VW0?XL\_S=02P,$%     @ ECO]4IBC$OGF!   " P
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ME7;8',.QPJK.Q@O@?:FUVSUX!\/R?_874$L#!!0    ( )8[_5*-E2]R5P,
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MEIJL7];TJJ%V G1?*64?-HY@>">7OP!02P,$%     @ ECO]4GN_RGAE#
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MF=)?72>FJEL!Q;-7U5M FG=C6!B5;FDV1"!5:/%JM#&WTG-21:<:U57Y?B,
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MQ>@6_+%4N$1Y6H#?Y\[%]@L=T+TSO/DG4$L#!!0    ( )8[_5+E&DY#D@0
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MU^D(EF,@91NZ<C9JNV9;:PZGBP@3(KBH1[C+#%<^ O><W@&@#?3:-MP\U%_
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MP$QX[(6)T[5_8"VTPXSPPQ+?QV!H WXOM';MA 1T+^[+_P!02P,$%     @
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M5JSS'-G$00B+PYEL8^Q0YI:- EXEQ2*BXXB#Q^)]1\B[-,M 'A%2U.SJM:&
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M2'0!.,Q$L/"8JL< <,BHG<ZD=*V)2KP=:%O369,M52QS9!42E4\:W(<Y#LS
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M#&B^4)3BYP^W0'?S6OX+4$L#!!0    ( )8[_5)Q_?&() 8  ,L.   9
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M:_ ^62IW:"Z\'HW6\6'@:.54IDE3S3-_;1H.L(3H 8<-W9?CB S.K%CU7>#
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M(7AP6SQ031:,+.PC]B-^H)A#B0;DHQO9'C:8D8P_K#&0QFBQ5IH1VWJF"-S
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M(N*=GNN/X?#^&OB,L4*U"]^"FUQE\9=/X_Q%&O4Y"2(^2$E@G&8)$(7[5WY
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ME!61-G!JGT1V/KBB+H[1V$I!;_"<>LG:?\\9<QEK%#PH9[CY1J0JM &D??[
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MWBSH*X7:.=!YKI3=+ER"]KLW^PM02P,$%     @ ECO]4J)78)G@ @  -08
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M<VAE970R-BYX;6Q]5=MNVS@0_96!METX@->ZV8Z;M0TX28.V2( @\78?%OM
M2R.+"$6J)&7'^_4[I!35*1*_2+S-F3/#,\/Y7NDG4R):>*Z$-(N@M+:^"$.3
ME5@Q,U(U2MHIE*Z8I:G>AJ;6R')O5(DPB:)I6#$N@^7<K]WKY5PU5G")]QI,
M4U5,'RY1J/TBB(.7A0>^+:U;")?SFFWQ$>U?];VF6=BCY+Q":;B2H+%8!*OX
MXG+BSOL#WSGNS=$87"0;I9[<Y&N^"")'" 5FUB$P^NWP"H5P0$3C1X<9]"Z=
MX?'X!?W&QTZQ;)C!*R7^YKDM%\$L@!P+U@C[H/9?L(O'$\R4,/X+^_;L9!)
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MN*^*7:L6<VVX"]?9/5\V8,ZG@44:6AR4.\BK'C(^ IFQSTK:VK"/LH+JK7V
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M\03+"70I*%-GQ=@ODNB<UD_8-9<E7@<X'2%0G.7G+ I':7;,A;<2G* :"*U
M^LD(_=G1T#%).\1@O35(_31-_# NG+]1?$H"V2"!['LE@$*V6I04@%X-#U+8
MDUHX"?V=6KB]>_C_*7^03^@\&BUY0SDYG.^XP,H)J8+341H-V8[RV$_'H<MU
MR+[T0$Z;\?NAQ1M[!>X(.TLR/YJ$3@+A0>:_92TF:1!K,<H/EVVP=]VVH-?N
M46'P6.BD[6_>879XMRSZZ_K;\O[1\YGKM4#E-;!"TW"48[WJ_B'1#ZS:N,M[
MJ2P^!5RWQK<7:%J _U=*V=<!$0RON?E?4$L#!!0    ( )8[_5(<#*.#)0,
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ME+X42T^N!26Q!:6)AWP_]%+"LLYH:.]-Q6C(<Y6PC$X%D'F:$O%M3!.^O>G
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MW4&BV'\L+A1?V_VR.5>*I_9T14E,A1'0SQ><J]<+LP57[0*/_@-02P,$%
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M1VD-S'TNA-YOK(/N/R3Y"U!+ P04    " "6._U2(F'P']0"  !Z"   &0
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M<'F99@I?/$3H 'B?<*[V'3U!\PTU_0=02P,$%     @ ECO]4F/4>K!E P
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M#82)UFQF8;6Q:%T-S4P;ITKHMU3CU.@&4P&>,<L)N"-8YH+H'BD)OH%IT5C
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M6=-3K2VV&R-K]]W/I4$7<<L2_R2@; (^7TAIUALKT/^;TE]02P,$%     @
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MSSO/.U/;F6RD>M)K $->!*_TU%L;4Y_ZOB[6(*@^D354N+*42E"#4[7R=:V
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M3!VDNB=8[.@(8*\FA>R@L>P'(OL_)W'=V'.<Q3BZ[,OB0>'9Z#_0@(;T!2+
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MLO@^^.D*7W#0S@#/ETK9W<(Y:/X3C/\!4$L#!!0    ( )8[_5* 7[5)W00
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M4RKM /-^)H1^N[%?\38?DGO_ E!+ P04    " "6._U2M32:&B,(  !/,@
M&0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6S-6UUOV[@2_2N$L1=(@306
M/R4OD@!-TK1NW&ZPW>X^+.X#8S.V4'VX$I4TB_WQEY1DTXXD4HZ#"[^TECPS
M''$XYQQ2SNECFGW/%T)(\#..DOQLL)!R^>MPF$\7(N;Y2;H4B?KF/LUB+M5E
M-A_FRTSP6>D41T/D>6P8\S 9G)^6]VZS\].TD%&8B-L,Y$4<\^SI0D3IX]D
M#E8W?@_G"ZEO#,]/EWPNO@KY;7F;J:OA.LHLC$62AVD",G%_-G@'?YWXI4-I
M\6<H'O.-ST _REV:?M<7X]G9P-,9B4A,I0[!U7\/XE)$D8ZD\OA1!QVLQ]2.
MFY]7T:_+AU</<\=S<9E&?X4SN3@;! ,P$_>\B.3OZ>-'43\0U?&F:927_X+'
MVM8;@&F1RS2NG54&<9A4__.?]41L.$#2X8!J!_3< 7<XX-H!]QV!U ZDKP.M
M'6C?E%CMP/J.X-<.?E^'H'8(GCF@+H=1[3#J.P+T5I7S>KNLB]V[VG!5;EC6
M>U@MK')57G')ST^S]!%DVE[%TQ_*I5WZJ\48)KH+O\I,?1LJ/WG^5:;3[V\O
MU#J>@<LT5LV=\[(]WH(O/,NX[A%P="4D#Z/\C;K[[>L5./KE#?@%#$&^X)G(
M09B ;TDH\V-U4WW^8Y$6.4]F^>E0J@SU.,-IG<U%E0WJR.93D9P [!T#Y"'8
MXGYI=__,GP#R.[VO'(-S-;@'.]W?]W?W6MROW;E[@?:&08OWA_TF[F-_][;<
MQ_N-_FF_T6_L[E=BJMS+B8>TQ7WRXN2'JIG6'876'87*>+BKHW13O+UK=M0[
MU4[)7"@*D^#N"6S:W?*G\O:[1Y[-P-\3%1*,I8CS_UH2PNN$<)D0Z4CH2Q'?
MB0RD]R#7S0[2I4XG!W.5CE2#'Q5+(--CW;I50[]I6P'5&+0<0U/[PSGR,40^
M.1T^M"1'ULF1OLE58")^BFP:ZDDYLB=$&@D%-,"P/1VZ3H?NELZ4)U,E&9S9
MT$8V$'J(^>WIL'4ZS)K.7Z6(4*/S!Y$I403N>9B!!QX50N?8J*3*<99&$<]R
ML%2/4>;;FFXU;+"5[@E%ZVRKMFU:D1-"VQ_)7S^2;WVDBG"J93_=; _Q4W\6
M;=A7160;>6#?5SK3V\[W8],.>2/<L!LW[7P/LX;=IZ8=\4BP:;<U!<%Z"@+W
M%(#?JN)9&GRTCC<Z#,2!GE$5GO41OR69F*;S)/RG?YDOZIA;=0[\YU7Y4)M1
MN]FX7[2)TVQ[!C9T%;3.P%8AIFDN09)*\*3V569FCG67AND,J-W4ZK:V;V5@
M^W!(A=9M/P)QFLA%#C"8\2?;ZH*&T""RHY 6@HFTQ3)<!/&!K%7#0-!.02]!
MI#KD-M0T5F#3"'<N+,-0T$Y16J: "D+&R:R85E-V&_'$-AN&<2 [D (9QH!V
MRFB0<IJ%\S#A4?0$>"$7ZE+#C&ZB,,\+S=@.NKZL1]SB:T2]3FB'!MNA'=Q-
MLFHMJ5ZL11=_4!LH?A>),LW[0A:9J'C;D>I%/=YFJFQ$":7/8;&?W;BGW<1M
MMSU#AJW@Z(4+&/P+^G(C,E2$O,-8T,AP [*#]6_;NNU8[^C#N(@UXH19E5W-
M#$=)JA!=K16YX$GK4G:,!;V*&6R);VQM[$SP*EN)BWJ0S95%+;V'#+D@^T['
MNK+<+(8,92!R(&O*T +JO7/9IS3-?0RA79(?&5)!]GV,/M18%V:J9D&?*CDH
M"QE^0/Z!5,.P .K+ J]%6=>HB<<0$\)&J*,Z!I"1'9!?:>F,FGQ!J4\H:\\/
M&P3']LW$JU,J;NX@&/%]CSRCU)YVXYYV$[?=]@P90L%VD+\5F>XJ?4*@CP4*
MF4N>S,)D7L]"VWIRA"0GGO<?V^F3(0W<ES3X;%;N;WBT:HN7]<(5;C((#$9!
MX#T3,>_;#%'  M0UY1N':KU/U78[N+K S:,T3'P2=&1D2 GO>)36\^SJ C>/
MTD:^3UG'61HVG(1=6Y4.V'\N]-3U^W@9I4]"V):<X1M\()L8;$@*VS<Q?XI<
MZH:L=%UK0]H#$*>.PX:>L)V>;(7Y7&O1_EH<&Z;!!W)210RY$#NYO*86OW:,
MU4.+$X/YQ''BLWL-U?67-!'N3B,&W,F!O.T@!IF)'9G=G>8(X.XTLO%ZPP[*
MUBJ%R7Y5,D!,Z(%4R4 TL6\)>E3)'@"65;+E8K"9V*%5OSC<=7M"#-B2X$ F
MW^ PZ:OX7T=1WY"F^*<$*F7;H;.HP6?:5_Q7PQ^OMR=*X8)4+M27XD<12K6Q
MTI.U_3:L.^4);8IQZM. XH[]"C7(3.W(O'O*?;7CI!YY2\\2# /6-<\&R&GO
MHYV>2?>4EQ/:IL%].O*[WM4:I*<[:O!,+(MLNN!]9K*IPF% 6(<*IP;PZ8XJ
M7(F&*%5MGFUN=ASM1)N*'$+L>5U+<^/UME.1MR/=RQ0Y-7!/#T214X/Z=$]%
M?N,(X-8)U) $=2KRSL+LKLBI80)Z((J<&<1G_S]%?N,8JX<B9P;WF5.1[UK#
MWEJ/&2!G!Z+(F<%IMJ<BOW$$<'<:,P#-G(J\NTI[*G)F@)@=B")G&[\UVE.1
MWS@".!4Y,]C,G(H\6!-078S;FMI7Q;)];4O"8#([$.'.#%PSNW!_R4&O(R1T
M'/3Z!KC]OE+]U0YZ_:9()S[Q/;A]SGO=8H<QPUWO'GR#Z?YN6K[,O'Z(E=9T
M/,0'ORG:&[]<<YJ,6TR4B@[\;;-/UDC5) PW?BZN_]3B,\_FH4*Y2-PK'^_$
M5\Y9]=<+U85,E^4OR.]2*=.X_+@0?"8R;:"^OT]3N;K0/TI?_PW)^?\ 4$L#
M!!0    ( )8[_5(01[O4+@,  #@+   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0V+GAM;,U674_;,!3]*U:T!Y" .!_]0FVE?FUC&E)%87N8]N FMTU$8G>V
MV\*_G^VD(25IA#8A\=+8SCWG7A^?N+>_9_Q11  2/:4)%0,KDG)S;=LBB" E
MXHIM@*HW*\93(M64KVVQX4!" TH3V\6X;:<DIM:P;];F?-AG6YG$%.8<B6V:
M$OX\AH3M!Y9C'1;NXG4D]8(][&_(&A8@'S9SKF9VP1+&*5 1,XHXK ;6R+F>
M.5@#3,2/&/:B-$9Z*TO&'O7D)AQ86%<$"0124Q#UV,$$DD0SJ3K^Y*16D5,#
MR^,#^V>S>;69)1$P8<G/.)31P.I:*(05V2;RCNV_0KZAEN8+6"+,+]KGL=A"
MP59(EN9@54$:T^Q)GG(A2@#%4P]P<X#[&N"? '@YP'MK!C\'^&_-T,H!9NMV
MMG<CW)1(,NQSMD=<1RLV/3#J&[32*Z;:* O)U=M8X>1P(5GP>#E64H=HPE+E
M/T',"5ZB1>8=Q%8HBUI6HV9/>@SH; J2Q(DX5[B'Q12=?3I'GU!,T7W$MH+0
M4/1MJ<K52>T@+VV<E>:>*,U#MXS*2* 9#2&LP4^;\>T&O*UD*K1R#UJ-W4;"
M;UMZA3Q\@5SL.C7U3-X.QW7;^;_LLW_.?B2&5QC',WS>*>-$A$.=)4:<$[H&
M=9E(M'Q&Y;@Y>3;+HSWAX<4Q;,*$1+^^JRSH1D(J?C?4Z!<U^J9&_T2-]TR2
M!(F2>8-R2LC,6^?,C+=M>/5=NQMZG8ZZ?)5RN_*)5^-<W/,J<=-J7 =[[4K<
MK!KG8[];CCL2HE4(T6H4X@M0X$H*]2$B$JIK)!:2$WU%-ZC<+LC;']8)G:+&
MSCLY(>-ME4[$Z;C5$Y[4Q&$'5YU0C?.<ME]U0@U?M]<[Z81N(42W48@[$$!X
M$!DKA+!3G<)&GT2#QKV"NO=A?>#@E_\[_$Y.R(F//W:_5[5"3:"#NS6W0DV@
MUZVY9F9UJ1V_Q@UVJ1-(@:]-"R;4%K=49G=[L5JT>2/3W+Q:'SO7$Z=F?:K;
M0M-YO-!G/>4MX>N8"I3 2J7"5QWE79ZU:=E$LHWI0Y9,JJ[&#"/5V@+7 >K]
MBC%YF.@$1;,\_ M02P,$%     @ ECO]4I"6B_Y! P  + L  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#<N>&ULK59M;]HP$/XK5K0/J]22.&_ !$BEW:M4
M#:W:]MDD!UAU;&:;TO[[V4X(="1I*HT/Q'9\S_/<V7>YR5[(![4!T.BI8%Q-
MO8W6VP^^K[(-%$0-Q!:X>;,2LB#:3.7:5UL))'=&!?/#($C]@E#NS29N;2%G
M$['3C')82*1V14'D\QR8V$\][!T6?M#U1ML%?S;9DC7<@_ZY74@S\VN4G!;
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M'Y] 9E2]SI^>\5^-DE&$F^F'-?VPD_[&!IZ]SCX\9\<X"--A,_VHIA^]_6*
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M1-_U0.0!^OV<<[4=Y +5[;'_%U!+ P04    " "6._U2V@[(]+$#  #I#P
M&0   'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6S-5TN/VS@,_BN"3UN@';\2
M.RZ2 #.9*;:+/H)FNW-8[$%C,XDPMI25Y&3Z[TO)'MMY&>W-ET0/DOK(CQ+-
MZ4'(9[4%T.2ER+F:.5NM=^]=5Z5;**BZ$3O@N+,6LJ :IW+CJIT$FEFE(G<#
MSXO<@C+NS*=V;2GG4U'JG'%82J+*HJ#RQQWDXC!S?.=UX1O;;+59<.?3'=W
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "6._U2 -G/;$$$   6(@  #P
M 'AL+W=O<FMB;V]K+GAM;,6:WV_;-A" _Q7"3QVPS-8/IVU0%TB;=<O@ID8=
MY+5@)-HF0I$>225-_OH=I7@]+?9A+U<_V:(L^A,IW7<\Z=V#\W>WSMV)[XVQ
M83;:Q+@]&X]#M5&-#+^YK;*P9^5\(R-L^O4X;+V2==@H%1LSSB>3TW$CM1V]
M?[?K:^''>,-%547M+#2FAANM'L*/_6E3W.N@;[71\7$VZKX;-1*-MKK13ZJ>
MC28C$3;NX4_G]9.S49IEY9TQLU'6[[A1/NKJ1?,R05[+V]"U1'G[50+(;'0Z
M@0Y7VH?8_:+K7P+CO8(?]UMM=)^TB<I?R*C^\*[=:KM.W<!9C-%I=..P^^P'
M\<S_GV%TJY6NU(6KVD;9V(^C5R8!VK#1VS 25C9J-OKH[I47"[E6Z:3@7R[K
M_@0CD*'A\F<:=OC+NF/DY+&ULD'5 KX%9W0-'+7X((VTE1((,B<@\R-"?LL1
M9$% %D>!7"8<.!1!E@1D>43(P4A."<CI,2$+!'E*0)[R0G[Q:VGU4[<#$;TF
MB%[S$BW;II'^4;B56.JUU7"8M%&<5Y5K;=0(\@T!^887\GS^%\QJTRA?:6F>
MQT](6XLY=(!'\BT!^987<JYD4 $'Z D5H2>\-)^D]N)&FE:)SP#6^A1.X@"/
M% BS02 EV(*P'[M)_/WO5F_3 ;^**Q4Q(J6/C-D?<R?[:VRIJM9#7B+.UUZ]
M'$;*'AFS/B[M27<'!'4 CK)&QJZ-IM&Q0^K&$>)RA Q*V4H/[Q/*&AFS-I;1
M57<;9VKEP[?N2HR/F(V21<9LBX[MY(/LI=9 3^&_YL@H=63,[KBTE6N4N);?
MA_-)F2)C5@4$$#%W(8@%9,S+C?2#E)G20\;LAZ^I$69R(5/<N_829K-;%.&Q
MRREGY,S.('.!09Z74^[(F=U!8^),+R>7']S^Z/(!\0K6DT:%7S 6I8R<61D'
M$H,=)\:DY)$SRX-($!(JQJ3TD3/K@TH2@!-C4B;)CV22YUG'F)10<F:AO S>
M>V\?RB\YLU_P"DZ<B"OIO4Q5(_'J0D6)UTLY)9N<639TC"QQ\8,R3G%4XTPQ
M)F6<@MDXY/IS6$JBC%/\'..\O"K-X/XIR'H7LW[^95Q"9W5K5)K[SZG,VS80
M.S$FI9^"63^'+ G<Z9+%F)1^"F;]4)8$5(Q)Z:=@U@^->84Q*?T4S/HA97Z"
MR]H%I:""64$DYC :40HJN.MA)"9.TTM*026S@FA,;,J24E#)K*"]E9X?H1YC
M4@HJV1^Z$#4?<8(Q*0N5S!;:5_79Z\J2?.S"+*&#67L_[1B3DE#Y,TIH^S&3
M+#$F):'R6&N@A#D(FR4EH9+[@0R).0B;E(1*9@GAVM_^.X=R3\GLGCT+R>?,
MK5MLX">6E'NFS.XY7!+L;G&,2;EGVK^2L'L/H58K;55]!7\1H+V2IEIXD3[Z
M9RKE--5!5ZTQ'Z'MBP4#UKO7&G:O9+S_!U!+ P04    " "6._U2H9?JE,D!
M  "@'@  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=FY;L) %(7A
M5T%^ (:[F"R"5&G21KR 189%++8\$P7>/@@*<JP4::(YE36V?/W+Q2=K/'N/
M^R9OVV/:;+LT.AWVQS2O-CEWSR&DY28>FC1NNWB\7%FU_:')EV6_#EVSW#7K
M&'0RF8;^YXSJ9?9SYFAQ[N)?)K:KU7897]OEYR$>\R^#PU?;[](FQER-%DV_
MCGE>A=/^?CJ%ZT'&E\G5Z.UC7O5O'U*%TD$*05H^R"#(R@<Y!'GYH!J"ZO)!
M4PB:E@]Z@*"'\D&/$/18/N@)@I[*!\D$99P0) VP)M!:D&LA\%H0;"$06Y!L
M(3!;$&TA4%N0;2%P6Q!N(9!;D&XAL%L0;R'06U%O)=!;46\ET%L'']L$>BOJ
MK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z&^IM!'H;ZFT$>AOJ
M;01ZVV"SA$!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O1[V=0&]'
MO9U ;T>]G4!O1[V=0&\?;'83Z.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^A=
MH]XU@=XUZEW_I]XIG_<QW7MN:WS^?U*=+_?&^^.OR]O)P4NXXAS@A_3+-U!+
M P04    " "6._U2*+1H$\,!  ")'@  $P   %M#;VYT96YT7U1Y<&5S72YX
M;6S-V<ENPC 4!=!?0=E6Q'B #@(V;;<MB_Z FSP@(HDMVU#X^SIAD%K1J(A*
MO9M$B>UW7VSI;#)^VUGRO6U5UGZ2+$.P#XSY;$F5]JFQ5,>1N7&5#O'1+9C5
MV4HOB(G!8,0R4P>J0S\T-9+I^(GF>EV&WO,VOO:%J2>)H](GO<?]Q"9KDFAK
MRR+3(8ZS39U_2^D?$M*XLIWCEX7U-W%"PLXF-",_!QS6O6[(N2*GWDR[\**K
M.(MM2^;#KB2?=I<XTZ.9SXN,<I.MJ[@D]=:1SOV2*%1ENB]ZTYT<X@[3_LJO
MSF_+= 7&F3-GK(\GYNCRN..1-*O[-A8B%XKN3SPEQM)7?Q\UIYU3_LOLN+T?
MQJW:\_"LO5V_QU_/^%3_PCX$2!\2I \%TL<0I(\12!^W('W<@?1Q#](''Z T
M@B(J1R&5HYC*45#E**IR%%8YBJL<!5:.(JM D56@R"I09!4HL@H4606*K )%
M5H$BJT"15:#(*E%DE2BR2A19)8JL$D56B2*K1)%5HL@J4625*+(J%%D5BJP*
M15:%(JM"D56AR*I09%4HLBH4616*K$,468?_*>N[,:N__CG:W--*%_4QG[5_
MH*>?4$L! A0#%     @ ECO]4@=!36*!    L0   !               ( !
M     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "6._U2)Y-YR.\    K
M @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M    " "6._U2F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE
M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( )8[_5);#G?T404  /P5   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " "6._U2ZR[\/K$%  !+%@  &               @(&5#0  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ECO]4F8ONV'K @  L@D
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M965T-RYX;6Q02P$"% ,4    " "6._U2<1ZJ+5<?   59P  &
M    @(&?-   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
MECO]4L'0D 9C"0  EQP  !@              ("!+%0  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( )8[_5*8HQ+YY@0   @,   9
M          " @<5=  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#
M%     @ ECO]4HV5+W)7 P  -@@  !D              ("!XF(  'AL+W=O
M<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " "6._U2L4T^+!4#   S
M!P  &0              @(%P9@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM
M;%!+ 0(4 Q0    ( )8[_5)[O\IX90P  ,X@   9              " @;QI
M  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ ECO]4M""
MP%-4"0  /QP  !D              ("!6'8  'AL+W=O<FMS:&5E=',O<VAE
M970Q-"YX;6Q02P$"% ,4    " "6._U2Y1I.0Y($  !2"@  &0
M    @('C?P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M )8[_5+RMF$Q2P8  'T/   9              " @:R$  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ ECO]4FHI,Z99#   O2@  !D
M             ("!+HL  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " "6._U2L;#1*L8$  !,"@  &0              @(&^EP  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( )8[_5([S0:P(00
M (4)   9              " @;N<  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ ECO]4G']\8@D!@  RPX  !D              ("!
M$Z$  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "6._U2
M7TMPN!<@  #V;0  &0              @(%NIP  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( )8[_5)4X@ZJ!0,  !D)   9
M      " @;S'  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ ECO]4M)T6T/P @  )08  !D              ("!^,H  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " "6._U221/_"^P"   #!P
M&0              @($?S@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( )8[_5*B5V"9X (  #4&   9              " @4+1  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ ECO]4JN>0[^\
M P  [ <  !D              ("!6=0  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " "6._U2R+WQHP,$  #9"0  &0
M@(%,V   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( )8[
M_5(<#*.#)0,  (H&   9              " @8;<  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ ECO]4C$E^NJ^!   $18  !D
M         ("!XM\  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    " "6._U2P<,"7X,"  !/!@  &0              @('7Y   >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( )8[_5(B8? ?U (  'H(
M   9              " @9'G  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ ECO]4M!W474* P  Q @  !D              ("!G.H
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " "6._U2S831
M< (#  !/"0  &0              @('=[0  >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    ( )8[_5)CU'JP90,   L*   9
M  " @1;Q  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
MECO]4B6;HC-. P  60X  !D              ("!LO0  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " "6._U2+-,!:&<#  #W#0  &0
M            @($W^   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( )8[_5(+Q^)_<@(  *<&   9              " @=7[  !X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ ECO]4A%BQY57!@
M9Q\  !D              ("!?OX  'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " "6._U2D9DP?74"   U!@  &0              @($,
M!0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( )8[_5+1
M."PZ, ,  #T,   9              " @;@' 0!X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ ECO]4C3[!*VE @  [P8  !D
M     ("!'PL! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )8[_5(01[O4+@,  #@+   9              "
M@30B 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ ECO]
M4I"6B_Y! P  + L  !D              ("!F24! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    " "6._U2C%M&9!X#  !I"@  &0
M        @($1*0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( )8[_5+9H!1V"0,  $D*   9              " @68L 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ ECO]4MH.R/2Q P  Z0\
M !D              ("!IB\! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    " "6._U28ERJ@T\%  ![%P  &0              @(&.,P$
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( )8[_5*XEZ:G
M7@,  /05   -              "  10Y 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ ECO]4I>*NQS     $P(   L              ( !G3P! %]R96QS
M+RYR96QS4$L! A0#%     @ ECO]4@#9SVQ!!   %B(   \
M ( !ACT! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( )8[_5*AE^J4R0$
M * >   :              "  ?1! 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( )8[_5(HM&@3PP$  (D>   3              "
M ?5# 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     [ #L %!   .E% 0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>186</ContextCount>
  <ElementCount>335</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - ALJ Commercialization and License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/ALJCommercializationandLicenseAgreement</Role>
      <ShortName>ALJ Commercialization and License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117106 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121107 - Disclosure - Loan and Security Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/LoanandSecurityAgreements</Role>
      <ShortName>Loan and Security Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127108 - Disclosure - In-License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/InLicenseAgreements</Role>
      <ShortName>In-License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2129109 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2131110 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2133111 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2139112 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2141113 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2144114 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://evelobio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://evelobio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://evelobio.com/role/Leases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://evelobio.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://evelobio.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Loan and Security Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/LoanandSecurityAgreementsTables</Role>
      <ShortName>Loan and Security Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://evelobio.com/role/LoanandSecurityAgreements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2334306 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://evelobio.com/role/StockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2342307 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://evelobio.com/role/NetLossPerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/OrganizationNarrativeDetails</Role>
      <ShortName>Organization - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - ALJ Commercialization and License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails</Role>
      <ShortName>ALJ Commercialization and License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://evelobio.com/role/ALJCommercializationandLicenseAgreement</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Leases - Schedule of Minimum Aggregate Future Lease Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails</Role>
      <ShortName>Leases - Schedule of Minimum Aggregate Future Lease Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - Property and Equipment, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/PropertyandEquipmentNetNarrativeDetails</Role>
      <ShortName>Property and Equipment, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - Loan and Security Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails</Role>
      <ShortName>Loan and Security Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Loan and Security Agreements - Significant Unobservable Inputs (level 3 Inputs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails</Role>
      <ShortName>Loan and Security Agreements - Significant Unobservable Inputs (level 3 Inputs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Loan and Security Agreements - Fair Value of Warrant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails</Role>
      <ShortName>Loan and Security Agreements - Fair Value of Warrant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Loan and Security Agreements - Schedule of Minimum Aggregate Future Loan Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails</Role>
      <ShortName>Loan and Security Agreements - Schedule of Minimum Aggregate Future Loan Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - In-License Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/InLicenseAgreementsNarrativeDetails</Role>
      <ShortName>In-License Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Stockholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://evelobio.com/role/StockholdersEquity</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2435417 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2436418 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2437419 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://evelobio.com/role/IncomeTaxes</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2443422 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="evlo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2445423 - Disclosure - Related Party Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>Related Party Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="evlo-20210630.htm">evlo-20210630.htm</File>
    <File>eveloq2202110-qexhibit311.htm</File>
    <File>eveloq2202110-qexhibit312.htm</File>
    <File>eveloq2202110-qexhibit321.htm</File>
    <File>eveloq2202110-qexhibit322.htm</File>
    <File>eveloq22021ex103non-employ.htm</File>
    <File>evlo-20210630.xsd</File>
    <File>evlo-20210630_cal.xml</File>
    <File>evlo-20210630_def.xml</File>
    <File>evlo-20210630_lab.xml</File>
    <File>evlo-20210630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>70
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "evlo-20210630.htm": {
   "axisCustom": 1,
   "axisStandard": 22,
   "contextCount": 186,
   "dts": {
    "calculationLink": {
     "local": [
      "evlo-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "evlo-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "evlo-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "evlo-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "evlo-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "evlo-20210630.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd"
     ]
    }
   },
   "elementCount": 448,
   "entityCount": 1,
   "hidden": {
    "http://evelobio.com/20210630": 1,
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 8
   },
   "keyCustom": 41,
   "keyStandard": 294,
   "memberCustom": 22,
   "memberStandard": 40,
   "nsprefix": "evlo",
   "nsuri": "http://evelobio.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://evelobio.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Leases",
     "role": "http://evelobio.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Fair Value Measurements",
     "role": "http://evelobio.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117106 - Disclosure - Property and Equipment, Net",
     "role": "http://evelobio.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121107 - Disclosure - Loan and Security Agreements",
     "role": "http://evelobio.com/role/LoanandSecurityAgreements",
     "shortName": "Loan and Security Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127108 - Disclosure - In-License Agreements",
     "role": "http://evelobio.com/role/InLicenseAgreements",
     "shortName": "In-License Agreements",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129109 - Disclosure - Commitments and Contingencies",
     "role": "http://evelobio.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131110 - Disclosure - Stockholders\u2019 Equity",
     "role": "http://evelobio.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133111 - Disclosure - Stock-Based Compensation",
     "role": "http://evelobio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139112 - Disclosure - Income Taxes",
     "role": "http://evelobio.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141113 - Disclosure - Net Loss Per Share",
     "role": "http://evelobio.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://evelobio.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144114 - Disclosure - Related Party Transactions",
     "role": "http://evelobio.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Leases (Tables)",
     "role": "http://evelobio.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://evelobio.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://evelobio.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Loan and Security Agreements (Tables)",
     "role": "http://evelobio.com/role/LoanandSecurityAgreementsTables",
     "shortName": "Loan and Security Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334306 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://evelobio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2342307 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://evelobio.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization - Narrative (Details)",
     "role": "http://evelobio.com/role/OrganizationNarrativeDetails",
     "shortName": "Organization - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "role": "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - ALJ Commercialization and License Agreement (Details)",
     "role": "http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails",
     "shortName": "ALJ Commercialization and License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "ib0beb087c81f498590a475a3ae51c18c_D20210317-20210317",
      "decimals": null,
      "lang": "en-US",
      "name": "evlo:CollaborativeArrangementSecondProductCandidateNegotiationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i39b550ef2206421ab7236b2a064fb4bd_I20180131",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AreaOfLand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Leases - Narrative (Details)",
     "role": "http://evelobio.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i39b550ef2206421ab7236b2a064fb4bd_I20180131",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AreaOfLand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Leases - Schedule of Minimum Aggregate Future Lease Commitments (Details)",
     "role": "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails",
     "shortName": "Leases - Schedule of Minimum Aggregate Future Lease Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Details)",
     "role": "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)",
     "role": "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - Property and Equipment, Net - Narrative (Details)",
     "role": "http://evelobio.com/role/PropertyandEquipmentNetNarrativeDetails",
     "shortName": "Property and Equipment, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - Loan and Security Agreements - Narrative (Details)",
     "role": "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
     "shortName": "Loan and Security Agreements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i8a5c6f6b678f44e49e72b10e4ab0fa04_D20210401-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "ie40915ff285a4e0ca8014dd9b85400f9_I20210630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Loan and Security Agreements - Significant Unobservable Inputs (level 3 Inputs) (Details)",
     "role": "http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails",
     "shortName": "Loan and Security Agreements - Significant Unobservable Inputs (level 3 Inputs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "ie40915ff285a4e0ca8014dd9b85400f9_I20210630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Loan and Security Agreements - Fair Value of Warrant (Details)",
     "role": "http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails",
     "shortName": "Loan and Security Agreements - Fair Value of Warrant (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "ic49bab0cb25344b6bfe44ce28d21e862_I20210630",
      "decimals": "4",
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i2a4ed55838494b35ab23f220a76b8c3b_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Loan and Security Agreements - Schedule of Minimum Aggregate Future Loan Payments (Details)",
     "role": "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails",
     "shortName": "Loan and Security Agreements - Schedule of Minimum Aggregate Future Loan Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i2a4ed55838494b35ab23f220a76b8c3b_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "ie543e908236043ba8be6cd894642aa5a_D20170806-20170806",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "evlo:NonRefundableUpfrontFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - In-License Agreements - Narrative (Details)",
     "role": "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails",
     "shortName": "In-License Agreements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "ie543e908236043ba8be6cd894642aa5a_D20170806-20170806",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "evlo:NonRefundableUpfrontFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i92aa56851c3d4aa1842d25b81d3cf9b9_D20190701-20190731",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "evlo:CollaborationArrangementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i92aa56851c3d4aa1842d25b81d3cf9b9_D20190701-20190731",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "evlo:CollaborationArrangementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "ibb020dd2f6a445318dc1aa4d1db6fdbf_I20210616",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Stockholders\u2019 Equity (Details)",
     "role": "http://evelobio.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders\u2019 Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435417 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://evelobio.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436418 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)",
     "role": "http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i5e11f538a920421ba186e7c8b1a99dd5_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i8a14b89c4bf046f7a9854dd49b9140b1_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437419 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i8a14b89c4bf046f7a9854dd49b9140b1_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i20fc0d52b2a44c50902a857e8d3130d5_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)",
     "role": "http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i20fc0d52b2a44c50902a857e8d3130d5_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i21310fe58f274896a1e3326b4c181e8a_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "evlo:SocialSecurityTaxEmployerDeferralCARESAct",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - Income Taxes (Details)",
     "role": "http://evelobio.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "iff63c5d4e86b4a5ca1fe0b493c057332_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "ie0ef059b44c043199b23fba40659d54b_D20200101-20200331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443422 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares Outstanding (Details)",
     "role": "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails",
     "shortName": "Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i97328d2c89864a0cbea4e4f731518d96_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubleaseIncome",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445423 - Disclosure - Related Party Transactions - Narrative (Details)",
     "role": "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails",
     "shortName": "Related Party Transactions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i53f72d5181794c719cc51cf350c7bdf5_D20210101-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization",
     "role": "http://evelobio.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://evelobio.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evlo-20210630.htm",
      "contextRef": "i03a373aaf69443e8b76a934a5f1fa351_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - ALJ Commercialization and License Agreement",
     "role": "http://evelobio.com/role/ALJCommercializationandLicenseAgreement",
     "shortName": "ALJ Commercialization and License Agreement",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 64,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://evelobio.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "evlo_A2018EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Employee Stock Purchase Plan [Member]",
        "label": "2018 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2018 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2018EmployeeStockPurchasePlanMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_A2019CreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Credit Facility [Member]",
        "label": "2019 Credit Facility [Member]",
        "terseLabel": "2019 Credit Facility"
       }
      }
     },
     "localname": "A2019CreditFacilityMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_AggregateAmountDueUnderCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Amount Due Under Collaborative Arrangement",
        "label": "Aggregate Amount Due Under Collaborative Arrangement",
        "terseLabel": "Aggregate amount due under collaborative arrangement"
       }
      }
     },
     "localname": "AggregateAmountDueUnderCollaborativeArrangement",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_AmendedCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Facility",
        "label": "Amended Credit Facility [Member]",
        "terseLabel": "Amended Credit Facility"
       }
      }
     },
     "localname": "AmendedCreditFacilityMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_AnnualAmountDueUnderCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Amount Due Under Collaborative Arrangement",
        "label": "Annual Amount Due Under Collaborative Arrangement",
        "terseLabel": "Annual amount due under collaborative arrangement"
       }
      }
     },
     "localname": "AnnualAmountDueUnderCollaborativeArrangement",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_AtTheMarketMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market",
        "label": "At-the-market [Member]",
        "terseLabel": "At-the-market"
       }
      }
     },
     "localname": "AtTheMarketMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_ClassOfWarrantOrRightFairValueMeasurement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Fair Value Measurement",
        "label": "Class Of Warrant Or Right, Fair Value Measurement",
        "terseLabel": "Additional paid in capital at its issuance date fair value"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightFairValueMeasurement",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_CollaborationArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Term",
        "label": "Collaboration Arrangement, Term",
        "terseLabel": "Term of collaboration arrangement"
       }
      }
     },
     "localname": "CollaborationArrangementTerm",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evlo_CollaborativeArrangementPeriodOfInactiveManufacturingServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Period Of Inactive Manufacturing Services",
        "label": "Collaborative Arrangement, Period Of Inactive Manufacturing Services",
        "terseLabel": "Period of inactive manufacturing services causing termination under collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementPeriodOfInactiveManufacturingServices",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evlo_CollaborativeArrangementSecondProductCandidateFeeMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Second Product Candidate, Fee, Maximum",
        "label": "Collaborative Arrangement, Second Product Candidate, Fee, Maximum",
        "terseLabel": "Maximum fee for second product option"
       }
      }
     },
     "localname": "CollaborativeArrangementSecondProductCandidateFeeMaximum",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_CollaborativeArrangementSecondProductCandidateNegotiationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Second Product Candidate, Negotiation Period",
        "label": "Collaborative Arrangement, Second Product Candidate, Negotiation Period",
        "terseLabel": "Negotiation period for second product candidate"
       }
      }
     },
     "localname": "CollaborativeArrangementSecondProductCandidateNegotiationPeriod",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evlo_CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Share Of Operating Profits And Losses And Development, Regulatory And Commercialization Costs, Percentage",
        "label": "Collaborative Arrangement, Share Of Operating Profits And Losses And Development, Regulatory And Commercialization Costs, Percentage",
        "terseLabel": "Share of operating profits and losses and development, regulatory and commercialization costs."
       }
      }
     },
     "localname": "CollaborativeArrangementShareOfOperatingProfitsAndLossesAndDevelopmentRegulatoryAndCommercializationCostsPercentage",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evlo_CommitmentAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment and contingencies.",
        "label": "Commitment And Contingencies [Line Items]",
        "terseLabel": "Commitment And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentAndContingenciesLineItems",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evlo_CommitmentAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment And Contingencies [Table]",
        "label": "Commitment And Contingencies [Table]",
        "terseLabel": "Commitment And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentAndContingenciesTable",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evlo_ComputersAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computers and software.",
        "label": "Computers And Software [Member]",
        "terseLabel": "Computers and software"
       }
      }
     },
     "localname": "ComputersAndSoftwareMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_ConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting Agreement [Member]",
        "label": "Consulting Agreement [Member]",
        "terseLabel": "Consulting Agreement"
       }
      }
     },
     "localname": "ConsultingAgreementMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Anniversary For Determining Prepayment Fee Percentage",
        "label": "Debt Instrument, Anniversary For Determining Prepayment Fee Percentage",
        "terseLabel": "Anniversary of funding date for determining prepayment fee percentage"
       }
      }
     },
     "localname": "DebtInstrumentAnniversaryForDeterminingPrepaymentFeePercentage",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evlo_DebtInstrumentDebtDefaultPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Debt Default, Percentage",
        "label": "Debt Instrument, Debt Default, Percentage",
        "terseLabel": "Debt default interest rate per annum"
       }
      }
     },
     "localname": "DebtInstrumentDebtDefaultPercentage",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evlo_DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument prepayment fee percentage after specified period one.",
        "label": "Debt Instrument Prepayment Fee Percentage After Specified Period One",
        "terseLabel": "Prepayment fee percentage after specified period"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentageAfterSpecifiedPeriodOne",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evlo_DebtInstrumentPrepaymentFeePercentageOnPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument prepayment fee percentage on principal.",
        "label": "Debt Instrument Prepayment Fee Percentage On Principal",
        "terseLabel": "Prepayment fee percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentageOnPrincipal",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evlo_DebtInstrumentRepaymentOrPrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repayment Or Prepayment Fee Percentage",
        "label": "Debt Instrument, Repayment Or Prepayment Fee Percentage",
        "terseLabel": "Final payment under agreement as a percentage of loans borrowed"
       }
      }
     },
     "localname": "DebtInstrumentRepaymentOrPrepaymentFeePercentage",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evlo_DebtInstrumentTrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Tranche",
        "label": "Debt Instrument Tranche [Axis]",
        "terseLabel": "Debt Instrument Tranche [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentTrancheAxis",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evlo_DebtInstrumentTrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Tranche [Domain]",
        "label": "Debt Instrument Tranche [Domain]",
        "terseLabel": "Debt Instrument Tranche [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentTrancheDomain",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Public Offering Costs Included In Accounts Payable And Accrued Expenses",
        "label": "Deferred Public Offering Costs Included In Accounts Payable And Accrued Expenses",
        "terseLabel": "Deferred financing and public offering costs in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "DeferredPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging growth company status.",
        "label": "Emerging Growth Company Status [Policy Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "evlo_FeeIncurredUnderCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fee Incurred Under Collaborative Arrangement",
        "label": "Fee Incurred Under Collaborative Arrangement",
        "terseLabel": "Fee incurred under collaborative arrangement"
       }
      }
     },
     "localname": "FeeIncurredUnderCollaborativeArrangement",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_MayoClinicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mayo Clinic",
        "label": "Mayo Clinic [Member]",
        "terseLabel": "Mayo Clinic"
       }
      }
     },
     "localname": "MayoClinicMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_MeddistCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Meddist Company Limited",
        "label": "Meddist Company Limited [Member]",
        "terseLabel": "ALJ"
       }
      }
     },
     "localname": "MeddistCompanyLimitedMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments For Development And Commercialization Of Licensed Products",
        "label": "Milestone Payments For Development And Commercialization Of Licensed Products",
        "terseLabel": "Milestone payments for development and commercialization of licensed products"
       }
      }
     },
     "localname": "MilestonePaymentsForDevelopmentAndCommercializationOfLicensedProducts",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments of development, regulatory, and commercial event.",
        "label": "Milestone Payments of Development, Regulatory, and Commercial Event",
        "terseLabel": "Milestone payments upon achievement of certain development, regulatory, and commercial events"
       }
      }
     },
     "localname": "MilestonePaymentsOfDevelopmentRegulatoryAndCommercialEvent",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_NonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash interest expense.",
        "label": "Non Cash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpense",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_NonCashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Operating Lease Expense",
        "label": "Non-Cash Operating Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NonCashOperatingLeaseExpense",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_NonRefundableUpfrontFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non refundable upfront fee.",
        "label": "Non Refundable Upfront Fee",
        "terseLabel": "Non-refundable upfront fee"
       }
      }
     },
     "localname": "NonRefundableUpfrontFee",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_PublicOfferingCostInAccruedExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering Cost In Accrued Expense",
        "label": "Public Offering Cost In Accrued Expense",
        "terseLabel": "Public offering cost in accrued expense"
       }
      }
     },
     "localname": "PublicOfferingCostInAccruedExpense",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering",
        "label": "Public Stock Offering [Member]",
        "terseLabel": "Public Stock Offering"
       }
      }
     },
     "localname": "PublicStockOfferingMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_RegistrationStatementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registration Statement [Member]",
        "label": "Registration Statement [Member]",
        "terseLabel": "Registration Statement"
       }
      }
     },
     "localname": "RegistrationStatementMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_RelatedPartyTransactionAnnualCashConsultingFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Annual Cash Consulting Fee",
        "label": "Related Party Transaction, Annual Cash Consulting Fee",
        "terseLabel": "Aggregate annual cash consulting fee"
       }
      }
     },
     "localname": "RelatedPartyTransactionAnnualCashConsultingFee",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Annual Share-based Payment Award, Options, Grant Date Fair Market Value",
        "label": "Related Party Transaction, Annual Share-based Payment Award, Options, Grant Date Fair Market Value",
        "terseLabel": "Aggregate grant date fair value"
       }
      }
     },
     "localname": "RelatedPartyTransactionAnnualSharebasedPaymentAwardOptionsGrantDateFairMarketValue",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Closing Common Stock Price, Trailing Average, Period",
        "label": "Related Party Transaction, Closing Common Stock Price, Trailing Average, Period",
        "terseLabel": "Period for trailing average closing common stock price"
       }
      }
     },
     "localname": "RelatedPartyTransactionClosingCommonStockPriceTrailingAveragePeriod",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evlo_RelatedPartyTransactionConsultingContractRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Consulting Contract, Renewal Term",
        "label": "Related Party Transaction, Consulting Contract, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "RelatedPartyTransactionConsultingContractRenewalTerm",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evlo_RelatedPartyTransactionConsultingContractTerminationNoticeTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Consulting Contract, Termination Notice, Term",
        "label": "Related Party Transaction, Consulting Contract, Termination Notice, Term",
        "terseLabel": "Termination notice period of consulting arrangement"
       }
      }
     },
     "localname": "RelatedPartyTransactionConsultingContractTerminationNoticeTerm",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evlo_RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Consulting Contract, Termination Notice Upon Breach Of Contract, Term",
        "label": "Related Party Transaction, Consulting Contract, Termination Notice Upon Breach Of Contract, Term",
        "terseLabel": "Termination notice period by non-breaching party in event of a breach"
       }
      }
     },
     "localname": "RelatedPartyTransactionConsultingContractTerminationNoticeUponBreachOfContractTerm",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evlo_RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Share-based Payment Award, Equity Instruments Other Than Options, Grant Date Fair Market Value",
        "label": "Related Party Transaction, Share-based Payment Award, Equity Instruments Other Than Options, Grant Date Fair Market Value",
        "terseLabel": "Aggregate grant date fair value for restricted stock units"
       }
      }
     },
     "localname": "RelatedPartyTransactionShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairMarketValue",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_SaccoS.r.l.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sacco S.r.l. [Member]",
        "label": "Sacco S.r.l. [Member]",
        "terseLabel": "Sacco"
       }
      }
     },
     "localname": "SaccoS.r.l.Member",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_SaleOfStockConsiderationReceivedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Consideration Received, Term",
        "label": "Sale Of Stock, Consideration Received, Term",
        "terseLabel": "Sale of stock, term (up to)"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedTerm",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evlo_SaleOfStockGrossConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Gross Consideration Received on Transaction",
        "label": "Sale of Stock, Gross Consideration Received on Transaction",
        "terseLabel": "Gross proceeds from transactions"
       }
      }
     },
     "localname": "SaleOfStockGrossConsiderationReceivedOnTransaction",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_SaleOfStockMaximumValueOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Value of Shares Issued In Transaction",
        "label": "Sale Of Stock, Maximum Value of Shares Issued In Transaction",
        "terseLabel": "Maximum value of shares issued in transaction (up to)"
       }
      }
     },
     "localname": "SaleOfStockMaximumValueOfSharesIssuedInTransaction",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_SecurityAndLoanAgreementNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security And Loan Agreement, Number Of Tranches",
        "label": "Security And Loan Agreement, Number Of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "localname": "SecurityAndLoanAgreementNumberOfTranches",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evlo_SecurityAndLoanAgreementTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security And Loan Agreement, Tranche Four",
        "label": "Security And Loan Agreement, Tranche Four [Member]",
        "terseLabel": "Security And Loan Agreement, Tranche Four"
       }
      }
     },
     "localname": "SecurityAndLoanAgreementTrancheFourMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_SecurityAndLoanAgreementTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security And Loan Agreement, Tranche One [Member]",
        "label": "Security And Loan Agreement, Tranche One [Member]",
        "terseLabel": "Security And Loan Agreement, Tranche One"
       }
      }
     },
     "localname": "SecurityAndLoanAgreementTrancheOneMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_SecurityAndLoanAgreementTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security And Loan Agreement, Tranche Three [Member]",
        "label": "Security And Loan Agreement, Tranche Three [Member]",
        "terseLabel": "Security And Loan Agreement, Tranche Three"
       }
      }
     },
     "localname": "SecurityAndLoanAgreementTrancheThreeMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_SecurityAndLoanAgreementTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security And Loan Agreement, Tranche Two [Member]",
        "label": "Security And Loan Agreement, Tranche Two [Member]",
        "terseLabel": "Security And Loan Agreement, Tranche Two"
       }
      }
     },
     "localname": "SecurityAndLoanAgreementTrancheTwoMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Equity Award Vesting Period, Number Of Monthly Installments",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Equity Award Vesting Period, Number Of Monthly Installments",
        "terseLabel": "Annual equity award, vesting period, number of equal monthly installments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityAwardVestingPeriodNumberOfMonthlyInstallments",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Increase Decrease",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Increase Decrease",
        "terseLabel": "Number of shares no longer authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedIncreaseDecrease",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Repurchased",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Repurchased",
        "terseLabel": "Number of shares repurchased (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRepurchased",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Exercised",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Exercised",
        "terseLabel": "Number of shares, options and other equity awards exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercised",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Forfeitures",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Forfeitures",
        "terseLabel": "Number of shares, options and other equity awards canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "evlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Granted",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award Options And Non Option Equity Instruments Granted",
        "terseLabel": "Number of shares, options and other equity awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsGranted",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "evlo_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Number Of Monthly Installments",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Number Of Monthly Installments",
        "terseLabel": "Option to purchase shares, vesting period, number of equal monthly installments"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriodNumberOfMonthlyInstallments",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evlo_SocialSecurityTaxEmployerDeferralCARESAct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Social Security Tax, Employer, Deferral, CARES Act",
        "label": "Social Security Tax, Employer, Deferral, CARES Act",
        "terseLabel": "Deferred payroll taxes related to CARES Act"
       }
      }
     },
     "localname": "SocialSecurityTaxEmployerDeferralCARESAct",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evlo_TwoThousandAndEighteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 stock incentive plan.",
        "label": "Two Thousand And Eighteen Stock Incentive Plan [Member]",
        "terseLabel": "2018 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndEighteenStockIncentivePlanMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_TwoThousandAndFifteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fifteen stock incentive plan.",
        "label": "Two Thousand And Fifteen Stock Incentive Plan [Member]",
        "terseLabel": "2015 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndFifteenStockIncentivePlanMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_TwoThousandAndTwentyOneStockInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Twenty One Stock Inducement Plan",
        "label": "Two Thousand And Twenty One Stock Inducement Plan [Member]",
        "terseLabel": "2021 Stock Inducement Plan"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneStockInducementPlanMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_UniversityOfChicagoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of Chicago.",
        "label": "University of Chicago [Member]",
        "terseLabel": "University of Chicago Agreement"
       }
      }
     },
     "localname": "UniversityOfChicagoMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_UnvestedCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested common stock.",
        "label": "Unvested Common Stock [Member]",
        "terseLabel": "Unvested common stock from early exercise of options"
       }
      }
     },
     "localname": "UnvestedCommonStockMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_VL46Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VL46.",
        "label": "V- L- 46 [Member]",
        "terseLabel": "VL46"
       }
      }
     },
     "localname": "VL46Member",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evlo_WeatherdenLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weatherden Ltd.",
        "label": "Weatherden Ltd [Member]",
        "terseLabel": "Weatherden Ltd"
       }
      }
     },
     "localname": "WeatherdenLtdMember",
     "nsuri": "http://evelobio.com/20210630",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Mr. Epstein"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r40",
      "r42",
      "r87",
      "r88",
      "r196",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails",
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r195",
      "r237",
      "r282",
      "r283",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r440",
      "r478",
      "r479",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails",
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r195",
      "r237",
      "r282",
      "r283",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r440",
      "r478",
      "r479",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r195",
      "r237",
      "r272",
      "r282",
      "r283",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r440",
      "r478",
      "r479",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails",
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r195",
      "r237",
      "r272",
      "r282",
      "r283",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r440",
      "r478",
      "r479",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails",
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r41",
      "r42",
      "r87",
      "r88",
      "r196",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails",
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r28",
      "r409"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r26",
      "r167"
     ],
     "calculation": {
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r314",
      "r315",
      "r316",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r285",
      "r288",
      "r319",
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r191",
      "r251",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of common stock warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r288",
      "r310",
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Total number of securities excluded from computation of diluted weighted-average shares outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "terseLabel": "Area of leased office and research development space (in square feet)"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails",
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r83",
      "r132",
      "r140",
      "r144",
      "r154",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r349",
      "r352",
      "r376",
      "r407",
      "r409",
      "r457",
      "r467"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r39",
      "r83",
      "r154",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r349",
      "r352",
      "r376",
      "r407",
      "r409"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r289",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment additions in accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r24",
      "r409",
      "r485",
      "r486"
     ],
     "calculation": {
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r24",
      "r69"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Total cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets",
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, fair value disclosure"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r8",
      "r70",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r62",
      "r69",
      "r75"
     ],
     "calculation": {
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash \u2013 end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash \u2013 beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r62",
      "r377"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "netLabel": "Exercise price (in dollars per share)",
        "terseLabel": "Common stock exercise prices (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares called by warrants (in shares) (up to)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r344",
      "r345",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "In-License Agreements",
        "verboseLabel": "ALJ Commercialization and License Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/ALJCommercializationandLicenseAgreement",
      "http://evelobio.com/role/InLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Transaction with party to collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r36",
      "r175",
      "r462",
      "r473"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r176",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r91",
      "r92",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16",
      "r409"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized; 53,416,657 and 47,488,505 shares issued and 53,398,271 and 47,470,119 shares outstanding as of June 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income or Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction-in-process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r260",
      "r261",
      "r270"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Deferred revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails",
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Amount due under license agreement"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r14",
      "r459",
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible debt (up to)"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Conversion option"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r209",
      "r216",
      "r217",
      "r219",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Loan and Security Agreements"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r82",
      "r89",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r225",
      "r226",
      "r227",
      "r228",
      "r385",
      "r458",
      "r459",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Loan and security agreement, basis spread on interest rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r14",
      "r220",
      "r459",
      "r466"
     ],
     "calculation": {
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "totalLabel": "Total minimum payments"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r194",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Common stock at a conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r33",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Loan and security agreement, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input",
        "terseLabel": "Debt instrument, measurement input"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r34",
      "r82",
      "r89",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r225",
      "r226",
      "r227",
      "r228",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r205",
      "r221",
      "r225",
      "r226",
      "r384"
     ],
     "calculation": {
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less amounts representing interest and discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Fees incurred to establish facility"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r67",
      "r165"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://evelobio.com/role/PropertyandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r86",
      "r181",
      "r183",
      "r184",
      "r188",
      "r189",
      "r190",
      "r402",
      "r461",
      "r474"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Amounts due to related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r50",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r105",
      "r107",
      "r109",
      "r110",
      "r111",
      "r115",
      "r116",
      "r359",
      "r360",
      "r464",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r50",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r107",
      "r109",
      "r110",
      "r111",
      "r115",
      "r116",
      "r359",
      "r360",
      "r464",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation cost not yet recognized, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Common stock offering from ESPP",
        "verboseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails",
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options to purchase common stock",
        "verboseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails",
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r46",
      "r47",
      "r48",
      "r91",
      "r92",
      "r93",
      "r95",
      "r101",
      "r103",
      "r119",
      "r155",
      "r251",
      "r258",
      "r314",
      "r315",
      "r316",
      "r335",
      "r336",
      "r358",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r480",
      "r481",
      "r482",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r207",
      "r225",
      "r226",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r207",
      "r225",
      "r226",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r362",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r207",
      "r225",
      "r226",
      "r361",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r361",
      "r362",
      "r365",
      "r366",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r207",
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r207",
      "r273",
      "r274",
      "r279",
      "r281",
      "r362",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "(Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r207",
      "r225",
      "r226",
      "r273",
      "r274",
      "r279",
      "r281",
      "r362",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "(Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r207",
      "r225",
      "r226",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r362",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "(Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r207",
      "r225",
      "r226",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r367",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r372",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r218",
      "r249",
      "r357",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Gain on sale of fixed assets, net"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r67",
      "r229",
      "r230"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r284",
      "r286",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r132",
      "r139",
      "r142",
      "r143",
      "r145"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r169",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r84",
      "r328",
      "r330",
      "r333",
      "r337",
      "r339",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r85",
      "r102",
      "r103",
      "r131",
      "r327",
      "r338",
      "r340",
      "r477"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://evelobio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r45",
      "r325",
      "r326",
      "r330",
      "r331",
      "r332",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r64",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for Tax"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r66",
      "r441"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r66",
      "r391"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r55",
      "r213",
      "r224",
      "r227",
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r61",
      "r63",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r53",
      "r55"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Other information:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Minimum Aggregate Future Lease Commitments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021 (excluding amounts paid or in Accounts Payable as of 6/30/2021)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "verboseLabel": "Rent due from sublease agreement"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30",
      "r83",
      "r141",
      "r154",
      "r178",
      "r179",
      "r180",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r350",
      "r352",
      "r353",
      "r376",
      "r407",
      "r408"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r83",
      "r154",
      "r376",
      "r409",
      "r460",
      "r471"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r32",
      "r83",
      "r154",
      "r178",
      "r179",
      "r180",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r350",
      "r352",
      "r353",
      "r376",
      "r407",
      "r408",
      "r409"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity (up to)"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r29",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LinesOfCreditFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time.",
        "label": "Lines of Credit, Fair Value Disclosure",
        "terseLabel": "Credit Facility estimate fair value"
       }
      }
     },
     "localname": "LinesOfCreditFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r14",
      "r206",
      "r222",
      "r225",
      "r226",
      "r459",
      "r468"
     ],
     "calculation": {
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total minimum payments"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsScheduleofMinimumAggregateFutureLoanPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Expected yield"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Fair value of underlying common stock"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails",
      "http://evelobio.com/role/LoanandSecurityAgreementsSignificantUnobservableInputslevel3InputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "calculation": {
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds included within cash and cash equivalents"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r62",
      "r65",
      "r68"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r43",
      "r44",
      "r48",
      "r49",
      "r68",
      "r83",
      "r94",
      "r96",
      "r97",
      "r98",
      "r99",
      "r102",
      "r103",
      "r108",
      "r132",
      "r139",
      "r142",
      "r143",
      "r145",
      "r154",
      "r178",
      "r179",
      "r180",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r360",
      "r376",
      "r463",
      "r475"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Accounting Pronouncements Issued and Not Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Noncash investing and financing activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r132",
      "r139",
      "r142",
      "r143",
      "r145"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": {
     "auth_ref": [
      "r118",
      "r398"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.",
        "label": "Operating Lease, Lease Income, Lease Payments",
        "verboseLabel": "Minimum rental payments received"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r389",
      "r391"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows used for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r386"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use asset - operating lease"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r393",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r392",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesScheduleofMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r90",
      "r104",
      "r129",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r31",
      "r409"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r289",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15",
      "r409"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding as of June 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r22",
      "r23"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Plus"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock, net of issuance cost"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from the issuance of long-term debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r59",
      "r313"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan and exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from sale of fixed assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r26",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r170",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r25",
      "r166"
     ],
     "calculation": {
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross [Abstract]",
        "terseLabel": "Property and equipment:"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r168",
      "r409",
      "r465",
      "r472"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets",
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r9",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r9",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r280",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r401",
      "r404"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Payment to related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r280",
      "r401",
      "r402",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r280",
      "r401",
      "r404",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r399",
      "r400",
      "r402",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r322",
      "r442",
      "r494"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r75",
      "r456",
      "r469"
     ],
     "calculation": {
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r2",
      "r8",
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r5",
      "r11",
      "r75",
      "r487"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Noncurrent restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r258",
      "r317",
      "r409",
      "r470",
      "r483",
      "r484"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets",
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r91",
      "r92",
      "r93",
      "r95",
      "r101",
      "r103",
      "r155",
      "r314",
      "r315",
      "r316",
      "r335",
      "r336",
      "r358",
      "r480",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition and Contract Liabilities"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold in public offering (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price of shares sold in public offering (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r288",
      "r309",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r288",
      "r309",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Minimum Aggregate Future Loan Payments"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r26",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/InLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r8",
      "r75",
      "r456",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r289",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r295",
      "r305",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r37",
      "r80",
      "r120",
      "r121",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r244",
      "r249",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested balance at June 30, 2021 (in shares)",
        "periodStartLabel": "Unvested balance at December 31, 2020 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested balance at June 30, 2021 (in dollars per share)",
        "periodStartLabel": "Unvested balance at December 31, 2020 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares originally authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of common stock available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable as of period end (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable as of period end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Canceled (in shares)",
        "terseLabel": "Number of shares canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "netLabel": "Number of stock options granted (up to, in shares)",
        "terseLabel": "Number of stock options granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r297",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "periodStartLabel": "Options outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Options outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of outstanding shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares issued for purchase (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r287",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationSummaryofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r289",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r286",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r284",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Nonemployee [Member]",
        "terseLabel": "Nonemployee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Options granted, maximum expiration period (no more than)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r76",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r38",
      "r46",
      "r47",
      "r48",
      "r91",
      "r92",
      "r93",
      "r95",
      "r101",
      "r103",
      "r119",
      "r155",
      "r251",
      "r258",
      "r314",
      "r315",
      "r316",
      "r335",
      "r336",
      "r358",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r480",
      "r481",
      "r482",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r119",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r15",
      "r16",
      "r251",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under the Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r251",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r251",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r251",
      "r258",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "netLabel": "Number of shares exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://evelobio.com/role/StockBasedCompensationNarrativeDetails",
      "http://evelobio.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r15",
      "r16",
      "r251",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r251",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r15",
      "r16",
      "r251",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r251",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r19",
      "r20",
      "r83",
      "r148",
      "r154",
      "r376",
      "r409"
     ],
     "calculation": {
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets",
      "http://evelobio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholder\u2019s equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r390",
      "r395"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease rental income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LeasesNarrativeDetails",
      "http://evelobio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails",
      "http://evelobio.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r218",
      "r249",
      "r357",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/FairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/ALJCommercializationandLicenseAgreementDetails",
      "http://evelobio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/LoanandSecurityAgreementsFairValueofWarrantDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r106",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average number of common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r105",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://evelobio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL77927221-108306"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r495": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r496": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r497": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r498": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r499": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r500": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r501": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r502": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r503": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r504": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r505": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r506": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r507": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r508": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>71
<FILENAME>0001694665-21-000111-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001694665-21-000111-xbrl.zip
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MI;@_V/BZZ>D+["VHZ9;LGSHP?W3A[&]02P,$%     @ ECO]4MPJYW S!0
M*R   !T   !E=F5L;W$R,C R,3$P+7%E>&AI8FET,S(Q+FAT;>U9ZW,:-Q#_
MWK]B@Z>./<.]>1[$,QA(XTYJ'$,FS:>.N!.@L3A==,*8_O5=Z3B_L&LGTSIV
M A\.3JM]:7^[6J3VJ]Z@._I\TH>9FG,X^7CX_J@+)<MQ/@5=Q^F->O!N],=[
MJ-BN!R-)DHPI)A+"':=_7(+23*DT=)SE<FDO UO(J3,Z=;2HBL.%R*@=J[AT
MT-8C^*0D/OBE_<JRH">BQ9PF"B))B:(Q+#*63.%33+,SL*SUK*Y(5Y)-9PI\
MU_?@DY!G[)SD=,44IP>%G+:3O[<=HZ0]%O'JH!VS<V#QFQ+S@N9X7*U&03.H
M5;QFO4F;;ITT@DK5=VFE.O[+0R,=G)[S9&K%Z9O2G"76C&K]8<6WZ]54M98L
M5K/0<]U?2V;J07LB$H7Z)/+G/W,Q&\(4O5 6X6R:A,:E4LY:D"/!A0QW7/-I
M:8HU(7/&5^'KCF2$ORYGN/A61B6;Y.2,_4W1$C3*O"YS0^O(S5E""\/1<S2U
M?S%C8Z8@\&WOIIW7W25RBAXKD89^!<5>LSC"):;R24WN]D]'1V^/NIW1T> 8
M@7DZ_-@Y'L%H\!C[/?^[V^\UX*,]M+LV#/M=XX,75-TR=(;0Z0U.1OW>"W2J
M<*7IUF#P%D;O^C#LG!YVCOM#:_#G^_YGZ'1'FN*[KO]U/K$D1G\0>2;1_B>O
M*G=Z=52&0\+/),MF)(&](9N/R3[\QC@OP\G,[MGX)6G&M(% DABZ,T8GT+^@
MT4*Q<PJ#R81%5(+ P7/*!1PRD46,)A'-RG"41#;LJ1F%W9V&[[NMKIBG)%F9
M-Z^U7X89E72\ A2AV&15AG0ALP5!94K %8YV=[Q:O;6&$<F Q"+5I?/Z[/4<
M'1\T1NL<$CDF"<VLP06G*^A$2E-T?,I()ZJLV?3$,<T,:;Z"LT0L.8VG='>G
MVFAMQ/$_B4WM4:'1_KB;%A2Z4Q+'N&]8G$Y4&'AV]1::+*_QQ%C:\_8+:Y]*
M:>O&*E3MNO%9A_3#@D@L$7P%IS05$L.;P%LAY^"YUH<"(&LTPD1(\_[EDBE%
M:T0,%-<RAM\7"84 D6>VXNMPSF47:(;)@B-OA%(YHQDLF9H9N9)^63!)]6Z=
M:=U#&NE6 O&\A]F&RB\'JGOQ_B5\,<<D]APHJ7\187Y.:8%AKQE4\D28&Q,1
MK,V6SL^7!!?_&<&%)8B!.3%!B% *0<X81TT@U@B:$&:@@?50![*LR81S0#:J
M+<,P9RD&,BL;K@E+2!+I<108F][15%"<M> Y#@3"S.C,;B'2?F@#&0NEQ-Q4
MDCLBBW%49,QIP306,J;2PJ7E),UH6/QHQ2Q+.5F%+#%+99A:-U5HH)SKZAP1
MOMY]#6YR\KHK;#;LH.GIQE!A-ZCB0O&Z9[1-S^BH>),6U&QL2^\EN_:WT7P[
M\&O?Q/EOQGH5NU:]G_RM8@/;=YLO9 DP7FZE\2BQCL&"+"84>;C&9XQIP3,$
M^YM24+I5I4(7/#.KT/$C3ETOST,\?GJAN<!\V^ZM1E@G_49ZBO2I"KFO@=+#
M^F>Z)=PHL3[ZS7RCO"QA#Z_+U_N85Y\G=?-6/[;UZKGB\7!ULW?_R2.U^;_Y
M>P=H=Z=2;V7F^<"_SQO>/K)@?D4]_J'C_H-Y]=.&==V\FR,C="H3G,506/7L
M<WV;W]O\WN;W<]^NC9R0*500/<*W1QT);W-[F]O;L+ZXW-X[D2R)6$KX9DKO
M;^:T8\X,-VY([K@6OG:(>>MF.17YU7HH*2=:W\9=\U4O9,XDW2L6,L:&:*'N
M9[GOUO#>B^OU,[]&-Q?Z!_\ 4$L#!!0    ( )8[_5)T769V9@4  ,L@   =
M    979E;&]Q,C(P,C$Q,"UQ97AH:6)I=#,R,BYH=&WM6NMS&C<0_]Z_8H.G
MCCW#O7E#/(,!3YQQC6-PTWSJB), 38[312>,Z5_?E8[S"[LA:>O8"?YP1K?:
ME_:WJT6B]:K;[PP_GO5@JF81G%T<GAQWH& YSH>@XSC=81?>#G\[@9+M>C"4
M)$ZYXB(FD>/T3@M0F"J5-!QGL5C8B\ 6<N(,SQTMJN1$0J3,IHH6#EKZ#3X9
MH0>_M%Y9%G1%.)^Q6$$H&5&,PCSE\00^4)9^ LM:S>J(9"GY9*K =WT//@CY
MB5^2C*ZXBMA!+J?E9..68Y2T1H(N#UJ47P*G;PI\5/=)0$FES$A8HO72J.K7
M_&HU"*L^J5:\VI\>&NG@](PG5<N(O2G,>&Q-F=;?*/EVM9RHYH)3-6UXKOMK
MP4P]:(U%K%"?1/[L8R9F39AB5\HB$9_$#>-2(6/-R:&(A&SLN.:OJ2G6F,QX
MM&R\;DM.HM?%%!??2IGDXXR<\K\86H)&F>$B,[2*W!&/66ZX%]31U-[5E(^X
M@L"W_;MVWG:7R EZK$32\$LH]I;%(2XQDT]J<J=W/CP^.NZTA\?]4P3F^>"B
M?3J$87\3^SW_N]OOU>#"'M@=&P:]CO'!"\IN$=H#:'?[9\->]P4ZE;M2=RO0
M/X+AVQX,VN>'[=/>P.K_<=+[".W.4%-\U]T(:#<^\9BB/X@\DVC_DU>E![TZ
M+L+)/"0P",FE*$)GRMD8CGA,XA!E0W\\YB&311BPF L)O^,(SB1+N;882$RQ
M,C*2SB63(,;0NV21@$,NTI"S.&1I$8[CT(8]-66PNU/S?;?9$;.$Q$LS\IK[
M19@RR49+0#V*CY=%2.8RG1,4KP3<0&EWQZM4FRLDD10(%8FNGK=GK^;H$*$Q
M6N> R!&)66KUKR*VA':H-$6'J(ATHHJ:34\<L=209DOX%(M%Q.B$[>Z4:\VU
M4/XGX:EL%!WMC[MN0:X[(93BUF%%;*P:@6>7[P'*\FI/#*<];S^W]JF4-N^L
M0MFN&I]U2-_/B<0J$2WAG"5"8GAC.!)R!IYKO<\!LD(CC!'=>OSYFBE!:P0%
MAFM)X=T\9A @\LQN?!O.F>P<S3">1\@;HM2(LQ067$V-7,D^S[ED>L-.M>X!
M"W4W@7C>(_N RJ]?E/?H_C5\63B7V':@I-Y5."7QA.48]NI!*4N$F3$1P5IO
MZHQ\27#QGQ%<>(P8F!$3A!"E$.2D^-8$8H6@,>$&&E@!=2"+FDRB")"-:<LP
MS&F"@4R+AFM\74A1(#7MHZF9.&L>93@0"#.C,[V'2/M+>\A(*"5FII(\$%F,
MHR*CB.5,(R$IDQ8N;422E#7R#TW*TR0BRP:/S5(9IN9=%1HHE[HZAR1:;< &
M-QEYU1C6:W90]W1OJ+ A5#17O&H;;=,V.HJNTX**72EYCY)=^]MHOAWXE6_B
M_"=CO9)=*3]._E:Q@>V[]1>R!!@OMU3;2*QCL"#S"7D>KO!),2VB%,'^IA 4
M[E6IA@N>F97K^!&GKI;G2SQ^<J6YP/RWW7N]L$[ZM?04R5,5<E\#I8OUSW1+
M[^98'OUZMD]>5[ O+\O7NY@5GR?U\EX[MO7JN<+Q<'FW=?_)([7^S?E[!VAW
MIU1MIN9YZ_OG'<\VK(U?47I_Z!C_8%[]M&%=]>GF@ B=2D7$*>16/?N\WN;R
M-I>W87U.V["1T^ *%80;^/9O#H"W*;]-^6U87US*[YU)CLF>8+:OY?W^>DX[
MYH1P[3[D@7O@6T>6]ZZ2$Y'=I3<DBXCBEVSM<OFF'3(GD.X-"QEA3S17C[,\
M=DWXL(4;K_V0SU@*IVP!YV)&XD>B4-L43GZI>3&PNOW.8'>G[C<]OUQVZW77
ML_V,F#T?NEA?/;-K?O.#@X._ 5!+ P04    " "6._U2[\KR:>H,  !G6
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M.@5 S UOI/)J: U>FSO1M1<=Z>#OQ_T.R%BA%@\P1R?MC>Z6-J(-SAGVXW&
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M*=]3*YVX0!(B=J:FR.\HZ=RH*C>)CEQTO&R!J^FCHQ&\.\MU$$&DSHY<R9T
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M21,-8:G:$J'!@28.;LDF"VR5)WA^%3.: \AEV KFX9OU2D6N U)$<<*7;++
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MPUZ AEOY>?JT*$)E':4T9=I$1)CA1'LEB':"$66D4<_-/$V=4A,\D=@)YT0
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M3K(02938,6Z\DH92J8)6A*OH] (9B&= V DJ51XPCIPJ  "($6P-5B)(IRQ
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M"F=U8$0IQ3UW+ IA+GD,CWAL;C=H+7GLOCQVSQ#(M::/*A,DN5#8L& 9 \]
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MTN(,Z2@99\))IU=>_3/LA!I%J[4TU3<%^&[7;+Z8<6=WB4"FAD J1/$8G;P
M@ +&Y I084VKU1W8[OFMKE<*'^8IF+/PN*+>WCVI?]TZ/FAOX\97<*LV6BW
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M!0M,QX]^BGD?)+J6ML, E6/*GN@<!5_K)]^QUC+]0:U7I*C/$[GOF1SUP]T
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ML6T87UP;QA?<AO&%M6%\:<.>A=*C2QOV;,BI[FG#7IO^<6VKU3V[\KX63?W
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MSX>>T-%5&+0.]X*YC0&L[-7BQ5)*%Y.J2S%]3@2EE9CRM=I.41=P^^J4KZ6
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M< :Z2$#]LR>E=$9F45A6(K=!<K"$<P@FA)28D?=UA9:F!=44F5<'7%#$>2E
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M:AOFMM!+AFB(HTX\/#H8GL9X]L>CLQKMSM%!OMRF-OMS'/G^N'G_Y#7#HR+
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MU%*5P&,MK/BTN9,JV^^L\5)T2"KXP$)02]/2"/>C*@NP;$_FSO+I4;!DHWR
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M8\$)08J09D0FC"8L3R@72"+R[3RYI7WBP9?K]VZ\>-?U2=E8+IXEW^AZ_FV
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ML5$I5?JA5L;2*@5\.:H] D97-1$OM$Z="I8&M*A.LUL5'ZT+GRR(2]>?M"Z
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M>P=#V^1I8";C83"&.R;-<\?S";1A9R%J;F4,Z T+L!9;UTO88P6&6'%*'[P
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M7,0Q2:-42:-58B3#VO#;$;UE^,"#K]/O-&;W3SV=O@BXE//A?,!G6L&2.9O
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MIP8(3R>O:?8^5EGH6S$1KQ?Z>Q9Z2^SL?OK6W-T[;UU\$:VS?:JLYYQ2Y)(
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M"?6(IR"0(48A3XAWTB>B4NGC*Y;EO?V$1R<_J?5V-TDH-S7G'LOZ/D@2RAK
M?AB G<\ V/D^C2+Z)##B7H(SR*5"CB6-9#Z@UR[*P$.5DO(X+)]'BFQ/",!*
M8=@OY]'V![\NA; ;/=EC6:G5, I'1K743"3!N=',)1T-[((DL>3"ZG64ZB&
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M'F]U0_EHS616FLNUXAH'5\+!Z8":2YGDPP44;!"(&Z*15DF"6<=B%%P:K')
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M+P"6),%(2YY9^8UBX(-22@&6Z ;F*\+2CS.DGOONXX(Q92,E@7,=A*:>2T?
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MNZG&(@_4P_-(>3T)?=!?6,#\Q',C9H=NG":):;,@9+9E7X:78UZM<^S YO?
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MJH3]G_:O:1'!/?*>3_&.$(Q.!$EZ>C$5#>>5,D &,266[W=WB RY+?+W MB
M;HGKNCFO0]Q#0/W>B/^5!;+3&EMIX#BV 71N&:Z3<B!^,S8"RX[,($U3+]KB
MV@1]ID+S,(.M7%[-T;FB*I#53*F4]7:J; SE=('?D1V.5_,L#\MI.M*.8,Y2
M$@"K\K,"?Z6Z!Z)38/-J=?518"KI&X-I+VK<:/1JZ())HYXVR>(8I$9)R:5J
M%I0WB@,5L2C5$T((S/H)LH]T$M1E,5TQHT8;@IK;\IZ_HPBGO3W"N0?JBO]D
M"(L^_+#HO15C;D;.>5/SF=!C[9'X[S'+F;@B&Z<(8MPLJDH5]ASE;+JL,O*A
MO,YREL<P#=R#A-B1GGE'3E)ZY/0*Q1-WORLTSH\97#19?,4RB?8J2OH;PCH;
M@II:VFQ*W-N4LMV4MJ($[JAB,4U0+ ,?)U*X?EKD'1<L#GIIR4K[U4[QBOBL
MJ+_)BYH3A !G5%O(IQ6_F&#!(3E98?Z_+4#_I^K9=QS=R7A3O4;/*^BOO]%8
MS72$NVC#<_]IU$OR# LOP$LPWLE7[DA/LRP:H;_VAL*2$2H+2E1PL[/L*RQ6
M+!+M8 ZW&UY%C.PQK(Z ::]_<*2]+V:-YIWEPF#"K>^]3/NS]=Q!(/,:%PZ[
ML^>V=I?;_3KMM"RDHGHFF/U\RJ0&((M=EK39^*MH 18#KRHU'*=:8_)<3HOB
M,^DL[4Z)$I3\O)BB1R6K/HM1@>AXB6O&DGV"M&"2:'%_9JC@I(RLV/XA%157
MO^AL!"P?[4GMS1M=0SFC64<C34((O8-O:J_%*Q)$2!S!Y=N%JX47\0050\7$
M04F&*/<:>G5*H5=2R6P;LT$#'8SN+.()N==@Z[(9Z&#X3Y&B57&U:\;ZKLG0
MX^4SE&4[5'ETD:'WKB:BQ3AD)>,I9/IT'BDQZE%BX@C<0)QT+E(NY7Z].N?3
M0E<[U?VA]G-65'%&+S0/X#?D0RKPLO+N!5_]R:):_0GLM/J)*/<% 0LLW9D@
M_16GN3X548^/[V5UM5)<!\I_EF0@A?A!W0D[;\K3<U3Y^<5C*P#\$R0LUIR#
M:"O.19,(/+2$XXG.Z9]:SB^T>,HJ<765P'E11HE.L10EC*1=+80]617$$V!:
M3"L5PJMF:(OA4VAE$ 8.6%?)(N8DKB5$@G0/5ZJN'>P7>CLJ$NF J($N0,;L
M'!L$Y1+M%8Z!=) 3Z *!1\]PA8C3J4T66(28S69@!^J8NL4B(,]87"%\48K5
MX?6R!)-Q!KS_)V^IG82 V(*E8NG^%!!4[4M64276^S=@@O]_ZOQOX&3]D7<5
M-7?=I$)>,AQZ>Q6(DE5<Z. ?CF]PIE>D0=K="8.[*%ID<-DP/,":8KZ(&2=)
MLTN7<,_#?P4MSA 4#B\_&:^3!++U4$;:STOX6HG798,.M_GT+N2TR%M6H(Z?
MB:3P&GVD-,$)9]-Z$B,'G&>L,QEBC,UO1YU4>%VK6 I_QMA_+L\H?(*Z19IB
M\14:&)0&4 B=!J\I4!.Q4+K.A-(#ST])#3H384W8+JRNKIKW^L^?D:]P%U[,
M/0LD[5 G=DJJ?5G54FZ!#$+'"H7$2 (B-8).D  GG5,A]1RH;,9B$FQP\O.2
MSYE2^^&D<E8OQ"O"T4(^&E3XLA1$$=(FYGJ@DU@\/\OBLHAD#A0,UN WS@KX
M9B54HPUSX_D9$$<BQ=UNR4D\5@)S26<//2B$(,Q)R3Q43E$RHT981.@,PVM=
M/<6_S D1M67KYAD*:J+BU,R]QH,1Q-I=4E6#<JFXB%0^C-EA/%3& V'-"V'7
MR&6)])V*;[PZ4+]#WR,ZTC8MO!$->,BS LZ8)>=8^IBL;ZBNO7KYUAI;'H8H
M(TX&H9!*,MF,"B61ZU2Z#.CU4S8#Q12+TOO\"8].EHCPTGU$+07NEJJ(,UHE
MV0,O3O]X\]*P0M#-$V%8$EFMG;BT <1$?0&U"7^W0R>\^@S56U9HCC>_%>,.
ME0]&A7L#FG!,$U?[^-B4N=,<HS_ )&U&%Q[:G_\^Q5@)*.]<D)Q:/[J'R7U(
M**J@O0'["BVK^04"%PCS2;"OT*&DP4T@VC3B15%.$S*GR%@2EA-*-"25&9#3
MHA0&S81/YXW[F!AQ3GX/:8"?9^6B9UW^']A:&"C(T::0ADD%@X#]A=,!12'F
M72M%/5*C!@@7,!CWC8%9"I OD*BH/"@O.HICO3&@-0GG+/@3Q#+8PRHE@ZR@
M>%+ S-53HVM<5X=-0Q^Z]*&(@LA@PA*Q!Q+%C.(,J/%+A"H\PFS&*7/C"_HM
MA*3&&T 'K?J,E%"D$88*?B$\,AU/&&VO0,"$RR?+A31F43;%?$#ISL&X3(OO
MPGM7405[AG<G!F#6OH?!#S+[L?1=!WZ82\R-HO\1$*<U^ESPQQSHN5AR!42S
M*%?FI^XWW 9V7I1BP<)12- T,YD&(V&J<8M:!J)!A?ZHL04L0S09V#X)N@-P
M^EF\0$N\X2O%"%),HS\&&/*S\"G1(%,P<$H4[U2<(E).*](:STA5P<>U:I*E
MTH^63OF7#+5/E70JR;_&&#,L:R$R]M'[1%C,- !P%^T)*D/J^XW',)99S>A'
M6J"W2""<%>49R[.OD@2>/7EQ?%H]^8%N>% %9D"XJ%"QI9@67$WE0D;"X)$6
M0J4_:,1J6&"YR*O&0;9)9\LE] IN(LX/%?J6"NAQI8X]9OB?C<PNV(:++&3%
M>+3IF;Q&D31SD.)3I0Z@FZ"Q,Q!$2.\D39/Y(^*H0%DBT-AY6"BO12Z"G2O:
MH4Z0>/,R X4B$]G-P&!P <@!)$]D<SHE<8$UBYEFGS'+BV*?<NJ=:0L'>6=R
MG3G1@O"!9L(K\R)B[PHE8/ERD:%K%8XX2Q9,*-JX[VTR];0@S'7T-#"IPITM
MLH3L[ZI- 9%? O;F=*6#,<];]OK,^5RR-UY%8AJXMG5^:T988[5WQ&ITP(W>
MG=6-!$)<)1)XZ.+$IW":A ?2<@W=X&# UDV1=W<#:1X;]HR$)IPG2;RO7(C6
MI%R<-0C([:V ;(X-6+@D)*,%26X^)1%E,96 CK9U^*]]_>;OZ^\HDNT,M;J/
M,2A] )>0REE1$&_UQHNIT1T[$2^AKE \D,L\M%:W2Q>$XBOM<ZG&R[1^^/D$
M9@%"HXE["5G(\KRHT4D'EDDBTFQ(JJ*& "(QCWFK0>$\DX6$56TDH)CN1DM#
M:+D%Q2Y!FZDQC"GD.+[Z>TZQSO<8,*KT[H_^ T\EQ:R':;< "4_ZW+KQ4G0V
MJ*LTJ0NY\3_2$YC=(Z=7L\\\_Z;I:&W@57R.')"T4<*Q,-+><[XI$JC)[N#:
M=K6$)8@I@A=Z3T&9@;77O8A7']L8(R7UDU3#=;]3[U+L^*@4H8V44;DARGFU
M2.:#<9N\4-OPMBS.2C:K'LK$I9ONL>GL'>\CQK!R2ML[4ZID+SSW#>[)$5"S
M:*\C/-#XX-N2GX-=.ITR3),$C;N8,A"%E'8L!Z>L2^7"EOYO\AD?$KGOE?RS
M2S=X6X$&RZI,R ;8P#FL&GZ+.1PU_/0!DMZ>B5%OJ0#37I&5Y)!H]N8![L+.
M-?^LZC7@XCC/BD4U19<]"GCTA9$N?]ZQX!)6,[I0+_!>G,!CE>"ZUD8D]0+F
MIR(;PK75[B#>I)K8:BM:V6N*4C;1BD8X" Q?=3P)FHB8_$X!3_$:QWHH 9$L
M,-WQ(9I:.P@H0_,*O3\:WJ>+2KB9HH)FU*NBLFUORY+H?EY;D[32R:9'LRV9
M@^5?*Q5*4I'0KV:<(= S^F,D='[+=T<@R.@+[SEF+X 9^@;8\XOV[.W1^S<_
M:!5P+4<_L.7#-O'/&.$1VDH3.U,^-+0G6W;&MQ#_3 A0N54\(>L5WJQ%4 9G
MMYT#5'FU<,23LP_M7JS%F')"\^W[(3"]2W@12%D :4*.@X9^"'P_*Q/RB=>B
M\AR3X1^?#_I/E4Y"G@:Y^5VR9&WX:V/H"BE1^NR4J[<3^U/I8$U^F#I#.KJ1
M]K8)UG?&:8)J@DHP5P5.88(>#/2-?J%D1 006$Z;GPOWTH0O<'I9TK[P((_L
M6E?#FKRBXWL,-^5E76Y.BG.1]"HZW5QT!4?7V=GLDV@V:T0P6J($K2%#9>C2
M0OEL8$?,J9#:TN\FW-A8Q"&#&&C#+%?DN @S++7S8@IF&@=A+G+S]I#8E+^X
M>G"[Q7BSM$:>;YGSHW.LP_DW2<\-2/PO+%_@-HD*I@M^J=9  HI)K:'G\=QR
M6.N,]2S_7]O]0<?+'^QU<K;:/UK=BNI-MWU1-C<]:O6>3S#C(^UH;7QU1V/.
MA"Q1K)=S\D#Q^"N?L5'S 83[N #KP1 GW_A5\J*U1PR5K2XM>('S(])?U"(I
MW?J<JYQ#V+FE MK'PBS4R%9>1X\#ILUW:;01Z EF.5-A$\ZYPO[+636AF!*%
MM"C301T+QV@7BY<;I5A3E0:;2FO?KIZH%%[04E035>%?>=/8<T795&#( L^C
M"A2TBO0%#+16(K4%U)<48W^HLZAQW_SKZ/_1?GY_U(ZM'#_O7YQ26RIYDB\[
ME"+?Q2>.7C:M74F%>IR1+^*Q:E)<R/("L&D).VJ&P0^9*H^6#"_1V8X%NK("
MCOA2Y4R20L=D[+?+-9A@)#3KUKU$F_FCAN>N:WA*<$CB<,2V"^1UJ=WH6H")
M&$B H+\^<]U__-!* &(9Q4**Q1#=G9]+6/5%'<O2!J9YYC^ZZUI9 2P29R35
MY6B)W*X%IMXNC;Z"8P@-2BT3VZC/==I#NI'@(&7)1.=;] X:(,W<.U!+F#PN
M)O_H2*QSDD0:DV65Q1G+C4;L-W0ASXI\K"A1Z;HD X01S^,5(3:O?5F] U=P
MX\WI$4,W;4=]"2PU-*=@Y]/%=/V4N!0((LWOURSEZ,2<K@NNE[_^U@BN1K:\
ME5,\+?$_:(T**7@L;*SFY;>GKX[5RZ1 M+2QOCR\E&H5_H,)PV^98%*9S-7Q
M+)-1+HELM8X(;C^52)G5A+B5:-64<R#?J! @62(P4+&+=1'04BY>FCAFY]IL
M+%91NYOBK=JU*^E[G?9#;\L%W 6+RI!( %B,)%2Z]UA/KESCS]KGWKUO);D0
M%+J&NRA$!QZ&DF-G)!;*M14T7C]Z!K@6K6)D<[C;^UPN>5L=C#*65$ X791D
M0?-S$0L1*9HR'9/60/GN&$;1DA*WHIN6TU!\Q'.>9G63OX/SR[GT(JZGDCXV
MV?"^+<$N^1EN'34L0I?*N?+IY#*GH3$<9(R)]>W5%4U_707<Y3OX%L>#O?U4
MOJ.8N#O$Q+^KF/B]RY4;BUX\UBSHM?3\QGVKW/!K>68J[+LQ/@:ZZYRV&XWG
M3EA:J 2C;CE :U)2N[=F%%;.E"3]</3BPYL7QJL5M]BH_05%W:2(_Z?3M=RE
MYYZJ RC;%%3U%VP6E5ER1J%Y-'I16?NWG'*EG?S[O?8:T[3%]?&AA /1-=6#
MKINGV_A903> ?[I^NT8T@6@-\-91 M=^5!;%9][8I^ISG72 *6=);XN%;&YN
MHWX>@2SM4UZB3E!3%6BU?J/&!$>[7.9MX#K*#+>:364Y8<:;;V&<1F;X-0D)
MZG"GH.,::*7!RG/1[G9&N"PR7V)+!0;YU+ITT?6DP2Z)*I>V*JN7_M!;JP@"
MB!R0%6=<\[&+B4BCUE#E G[*X(-8MMU472/==DHVI7MD92D8HA31$'H7W4D8
MT>>BHEV"QTB7"KJB\&%$EM%H<%9/^LX^95]*37<]=(.YX)@OFL=24WPF* NU
M3LO]0>"Y+E4S[KH+L?"C^""69J+)301$1SAEPC &"5,R$&J@L'"*X@ 3,!SH
MR_*,B[Q*[=FK%\>GH###0I(,U*I*9$U3&J3*:\1Z:XPBI"R;PB)T;<)G19I-
M:Y72 TO/1)E_UXFTLO8V.-#-!:(:A Z=Z+W?BIE*8EWJW7JK*"N4[VDK_76.
M3CIWY'8W#->Q -85M8<@QY'8),JP<&EW!6//6ZYO<I>OA!UZX<ZM D7)\BV)
M$BV# E6<Y46U=BZ"\:7@B;$=GZ+NK-PH 4BUGZH,Y48(^V;O<\@V"EU0R]+F
M,S76U>4M8H2:/UI?4NPIK+>&TSL%4&!IS>:@<+>)89U4N?9!"0](.$^-0$%7
M54=@*1$UQWQC >DL/@T46 *EP_["I3%3K/X.0Z.U]F=1)-HOQ03NLWS3!=8U
MFZ>LJC7'%TT.935"U?.>XZF]/WKWWGA1_&'8).TZMZ?5]WO3W' #$6A1.+X)
M+G$Q;7A4[>:*.]QRR1T.?#<M5(D#T10B;4G 1Y2>6X(CA$V/A>^)@GU06&?E
MFE0 /4+*F*:-$(F0C@2IJ(Q42+SW\U/[!^V?6JJ@]XAJ82OQ??G\L]<9/#32
M_L.7DKTVNL5AJVHJ@"<":427WB,EL0&JQHS0\#HUR.(>:MSS,W3=4+2G?P-.
MQ=K>\65>3!/M:*2]!5%>@^I19KKV2SG2M>/12_CS#RPT>3'!3 >X)TK:,$*K
MG*KLIV-9?BT\J@*+ NGPW:(^0W'Z,TA6?$2J*O\6Q3?R04%3;\LBA=5194MG
MO':,391[+ =]3]5AC\Y;L8($0X5Z0#02LT:BQ9>L[I6]2_2XI.6/-C%6%=8+
MO8U3ZDHE:CJH-T.CEW92)/!B1$==FXVIBZ)X!,F#N[5 \!_M,W9;OD#HNPO>
M -Z1_=<Z.-K86J_40A"D,!F0+19Q1XI=55XA24I%GGSY5'1(ZC4L"9&,FJ(5
M62S2I'_  Z2BQ3&UJ"BZF &-1HLDKX2W3@4J8M:B;D-@*&!?]&+.<^E,4]/I
M(PUM4,)U[>>2?<T$:QSS+UE<W$:]Q'U[Y=.NP58M:+L%/F2;)TD'0<ZX=5NN
M?P07N.%3#+H(TK_@$HX(#RQ!&X"$(L5(^X5O[3RPQ$44M= -C'4P".N @&!
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M&)*M-Y5T,4R-5/HJI=2W6F6OR*C[:8&[<:T;9MTT/"SM9$O1+Q"2@ Q"G?S
ME["5J0086J/?M!PEJEIK?D9-ECI+%8$6@3$JD&]FH.9@M3XB$37<MZJ(;$$(
MU)6J?IPE"0C45PR#[Q\6Y6<N?>)'*>I0@C"/>8*( $TSD5^S&;GGGCTY^O47
M!$9G(E,/8;B+>*&:1JD.'H35VS@/.P"B9'SDFG)\4UP73":$%DV24J*@+O(9
MKYMG,!./3)-.4)E"DAM0WPZ>PK=$%XLSCH)!4@8<Q:^_"(<Q86$1B #MC@CM
M='(8X9! [)#+*^_L>&]_E8D&!P[*NX%2A*1R,9?A)6$E2L&&41C0=3NI NVV
MRST6A-)D7+0#H3X-%/BIR>,HJ6V@-0K 2!#]E"/4\1U1@V*/O/[//?-A1H?;
M'H08%FUVCJDV.[+ AF)]E ^_F*=E06!1RS8%'@Z=9+N*%+0@4Q*$D_P5RJCJ
MRG<!.['%HTN'!IHH)[21*3!U0UT[/]+Y@-Y-#*T6T2RCD%NU)I:DHU)X7CI9
M+[03B4'=?& H$;+%:4B#B6;3(F=Q467LF3]Z)A(4)N=2LU1@^*9MEH#N."G@
M:4?MN&RY4%RM347[XXT]'*[6BH*J*WHEH$W?!.S]6#9)WQOV"18_S6).\*I-
M2R:2OT@+!X12L/-^EHU7\K/#F_"6A.>,VDB1$2_R=IA2M&S3<MN08$(8$\E*
MBS F>F+A^^B<7)2R/T)'4/;@OE;QA%O8/YU QAOP%W2L3=$INQ!0NJ!W@F!'
MD@-=.BM4F(6$_&[V3V7/E@X<#P8O<H)U!J64KMF8M8ER(J,>?WK&<U[*GRH=
MN13PE0I_38H@S"8YR(8Z5VDRP'H[6(F**JG1-.7Q&,05^R' ?5!(GO-\T39&
MVP;G**[=%7SIHH_OTYG &KRH^FHSN/PPG %F"&42H$K66$D9J=[O D]-.#M'
MZ:Z@IMOHUBH%48+.@CH%K0HJ7&A.Q8ZSHN3;UPTBN<M:?-Y$_$3&8"ZC\%T-
M1I(04-ZTJ)2'_**/94@O]MYJ@ 0[0/S-2D3 #?W6A,&MRCCEM="A613C4J7Z
M(GK^5;)+T$J'/WPO!YT4ITCAB:=>.!IKLN$JM:>!35EYB98MNLG'\6(F(<(3
MCN='KM"GCF>/G':4/[G*'&A][@TA* (@5:%B4Z&@4:,_<0YMQC F(52<D\(M
M4,=TS-,2\/P/B5%[<>)%YT@%@F8>EUQVI.Z(9]&U*N<K3:M4GG6KG.@=_-HI
M-<^XX#]>>7?F>.GG9\:4I_6/CK]QO\2/,C+H?S2L\;R^TQVD.BW_I[MNHM'?
M&LO%)A]/GK?\C+%\>1@R[MZ$V3"0+I'>QW[PTW 8MW08*L38U5Q7(>8ZAS(<
MQ*T?!%D1YP+1MIL(MI(#2^K)KGX+PU'=H@"3FEA']6BDVA;%3J0:J*R@X;CN
M[KAF[#/O>%9%Y+HQ[/OF$EA"0G<FK:#-\VA.#M0#93_1L??,-DQ463&_6$R:
M^'"ZMW>ZF4!U)4M;0&Y?R7XNR(1=Y(09*<SYF/+>)18:U6V5R\UC#>=Y>_>@
MU.7[;2[4OQHHGL8":)D4;"$FH8=%'7_;5H5P%; KN1$QX?V;X>O"J)5#4:N6
M(17BN>T/J1"/,15BD$S?)IDJSBD"5T1TWVQ R-C5V.7!>%MZ4$]9BLXKN6(1
M:R7-1RY8-EU:;G<$]K+\-_GOUGV,F]QU:N">=J6W,]*E(TRVXP'#-5I0*O!#
MV?5.,9/>Q,$(>J9CY*4JOJ**,R@&)=NJ@/%!>FC'J?D[UB9+^#<LQ"7'%I4*
M-,[$OBNUXUAL>@TQ:K.$U9WG,B[='J<$GE_MF25['8K4@"C+VWR?180-;<G]
M32GN&I8:8IL6C#)&=;M"0OL3[EL96%$M$F94ORRJ 7M9$I6JZ4)0&'+H4;_P
M!#ZQXN!H]Q$'DWT5V#G+IJHF:U&I+(9Y+7Z&X5Q=H$V2\Y3\]#!.ZZG': IO
M8RG2?XU%7WB.U,X*:UK( <Y66X&IGE]M_!&MS*R)#J[V UN4U8+W6TZH]NMM
MZ)CHI^LZWG3:VX('NO*_TQ[AX:-/NBH>#$O]S&.V: J=,>.?EXC"N*6U_%I5
M.Y4\]6+?%R)BM,@5F<A>'"+@G\U$ZS"-S;#KA$AQ%LIL1UV%WQ--("Q]NJD<
M4!T&QEB4;=,[F!$V-L_EVQ3!DF]NCA"L,+(Z4")Z@@M0@V/%T!L:%'$'1$O@
ME0=H=;T=D.!Z*W$G)-JN4(H0JK7Y=M0=H/&;K/;=JX6A#7LWQ3,0)Q913"-6
M.274J!MC'52#3MZS?ESGL>7GOQ1N!0%^A2".,E9%]LTEH2N2&4R$"W$ ^K5M
M8KV]N#O[B0<OB@LN9(],_=*U7W]]08=8844TXIIB)H;XN.6$>N"XZD=2'Y#8
MJV1Y42[E7)0$3I>4A"8AY5AMP'P,<9DW?3'3E!J_5Z*$AF[',QF!IB%E=D:3
M@_'><)IBQPX&?II-N]6^[U^]D)$@.3[>1!BV5SCT$:\OL.[IJ66//!?WZJGE
MC*R T&9$ZDDJ,C"K2L3@,2D-8WA6&P<4P*^\7GT@4 ^ <$6C"<0+Y78*A!>9
M3-.)7#:3;,3'G"V)<Z(EW%$/1A2_62DG:JG(TZW T^&;.RE'W/SRUA>Y;T05
M%V6&\#W_ _N#.F07U:*8-Q"7H#Y0T93?_Q()GW.9KH5_@0V:%K40]=0FJ/T(
MV%B-\J+.A*IA5W](U"1.VQO!MQJJT95XIM2*=>H)@I&_DWR:N5!I#;:?7^1U
MFWB5-3 :3P-[%Z%=;9S=-)@ED@ ?<(GI%CT<*XY7J]]TRE"3N PO4 0HFDI@
MMT=><VX;B%<DL"EUEP [1'J"H!Y)FCO(!M77J9+9F\FM%4TH_HA7UJ9!I92%
M:.;1&8D:*<-@F(P!FO2YA >I)&8&V0Z27W $5!N$'*9L^463[O@>NR&*3+^C
M> .TSP,G"Q!@\KI46=NRARXE7Q=,,$PE-F&Y>I7^QY;$\P<FUN!>PDW:LEBE
M/4-#IKT:G_S'_O<?3W[0-OD](A9_/J-D9T,N.:7__72[&T!]4V>(JR*D N+?
MG%5XIXL>OTRT249X\T2BV*C^I$_OVGWSY#DR4<.4A[2+9)N"#I/',@\TZT D
M,X+.N/O=>GJHVR5KB=?W2VD$%PA, 7N68.2MD#QJ^4+CO?N-U)ZAU2\D@P#.
MEQKN >WID11<+]!TK;')(9EL/>1KD%]GF+),68>(E#?'XMZB%/4"5<=5TEX
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M;K7"MG*E*HI<8=UAG*CM7T\!GUZ'Y$M89@-W#%@45T[ "(8$C.\A >,PJO6
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M1;0IN#&<\AWQNC10>XR.357Q'.%"QM@(QX!(A]&W=,XHBUJV41-.BL;BY5^
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M.W0>LFI^:+*["YPA_2KWK88_$L^UJ[NAO;>^<3"AB.% UQ3(/03/<)J'?IK
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M\V=5QVD+WE-2BR6R;Q!Q$V&Y7%UMI'\-YP<SB^-MQ[?W##-VJAGO)\:LC:N
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M6;?%Z_R;O1%MI[@*H\"*[(6_^F4XT'XY,(9?\2A+]G.$]8V>38:2-!W\\GU
M_:^JT=IRI9R57-@B!P+IAT_I#1\9[1W>K?D&Z@^230B)2659/==O?5E<?24;
MS#_E?W@?DVBIZ<\/LYGV2)1N$86GDDNW?CJ6D*>#Y!4._25V!:=1YBZ*<^>S
M1U\_(&)",@G\//R&W$3@'0)*T?/7,S\WF/:"3)H^?L-(G;VV.^%I8!?:2+RP
M1>Z]]SWOT^1$1_+X[.E_#R07EY=@,,<QU!27_/DPV;'%--Q"* !53^]+/VZ#
MT9&L"S^D?3K+=F[?8<74Q _C4_&-MV(V"TG4V]>&2T7B+ #<2$L%OGK^5,87
M 1H2@)A)N>QMC4-H&AVY(]4'/]"=B%$D+#M\[U2Q_>'QUZ>*[:EB^Q%@GSOV
MERC==CYA:D*N)9*;2\E66$ +"2]6D_Z>=AIW%6LK+943'(D4[@U5DE*T?!V;
M9S9*:;M;NPE_0GW>Z$-/>F%@X[4Q M<LISZ.[(2?AG:V\(-0;W)J1$"KMU^N
MBER]YK(K9\57WF/81,'="J=B4H.,O$7"Y+K*D>D5,&RH3,TT4X\@I5@62*L<
M7US',;..P8VSET6O$_""DB/?)-T[539VOR./UH9/,_3*U&#1&TE4#3>O(<J\
MQODJ\^LL$J^1/BFJ7Q1WM5S6],N@WA4:IL=8*V Y2/FE5YR<\8%>;/!@S.$A
MQ2J3U/V9TP.9Y("07"L+?_LERSN2VX2W:%H1*^!WYL?2P0I%6K^LC1L1$16*
MMT#1=XP$GZ[&"'ZIM!FZ9GH&>2;:<#2)D3=?6=1E$6QK=L&&2@%"R^]M+<)I
M*D%G07:5L=2-WYL[)J^;K. BCRN"=8QW(,4W"D*P0BF)?8NEJ(,G#\XE-O@2
MWHEO^<JZY8DX9#ZV,*QKF\PTSP($<C=;F2U^"^8,P:B%XJ8.G08TNMKHSR@Z
M[60K^'.)B$OBMX64198(#S2/L[TPSU6:&AY(,*1U;\-_$:$PTRH*%@F3)-)2
MC.7!Y!EC.WH?/I!$NTU6[_.KE@TRG20T.9!GP,@\%R(KOUB?]RI2KV/%Y$+I
MJJ!0XH?EE=0>GH7:T!$58842"X,BI.K2RS]"J!+U%#@%GU(!4K :&>*U6S_0
M8R-D)^H('Z,66[(LW!TS2BBB$%XN$]$9L&RZ(Q3LD@GH6BU[!DC//AD[;UZX
MLHVJ]R8GCDYN!89%_YW@)LRTZ?]0,.-IO>@H96_JNLS"4; ,;0'%+[I5-H.5
M(F-&/)_5JLPW&]X/2V]W\C8H9Y54X%O0U\YF?U\7X/Q!!:MD=8T)PJ>Q=F6M
MTE/MU.\X4>#I+YM<=)8"G5>$60EIFY$ "#LZN<HZ;[4XF\5E3%1LI<MA(#*M
ME%((UMB%IVTA@4 N'<]I.KN#9'E\4%]S7HYA"G0L>%/ESTR_P9HZQYD;)HG+
MSF$R('E1-/TIJES7U _"_&G!TP\@,\Y1)JE$7L5\:;??NMD+_XM\[JC*OR(Z
MLM+[DU@:=$T4<Z^\+P3Y^699^(%JB3!&+Z.$W'1)XC_ Z-5ET6X":Q[-LQ\)
M/ZB(_:#K/ECU0EPFU7HZI(@M)@N3BOSMR'"J83*U=RYE;W.!V4F-""E5C#!N
M'1Z^%4!#,:%7<38S!%QYTS=^"9+B,$4BN6:)%17BK)7E1$M6<TLRV00,%5_!
M[_I8\;+%>P***5UN#5B$4N2U64#;.,!I\H6?VJXRH&DAU24NK]+2ZGKGL/'7
M]P;.VYN%K%Q_AJ%9T1F'D_%Q45QX'O>.K':FE)WJ'Q;@%E.;"4Q8GL][O0()
M3A$_(PNA1^;28I?#&@[X7$2!HRQ)>^6DFO&Q&,*5#I"=\]L>#DS]2-G5*Z<X
MC1/)_L>:)-J56V&NZ6],"5Q-C#]..7F:GH\U/9%8E[V7V!NNS>,5U4.7U*30
M4'\%"21$.&F8,"K=M\!<,<[J7?E#3G/Y1_4LWM)$#MH*GOWR4H#)JGRB[E%]
M7646EC<M:'*:MH\U;66.V@.-]V%2#VD\T^XN);^,O51Y*;!^ZDBRK=C,TDB9
MO--$?JR)3#OX$4XDDQ :?X!([#,2*Z(Y;WE>MTU!M6TZ'\=<&\U!]M"W=*?3
M%'\T49H0-=QV;\[1I[)#;VDK0K< IQ)RF'31I<Q!P*,'C'?>YOOZM$\_XCY5
M5(< Y=DGC28R)K.FY^ > 3S.3P"/8P1XG*S(QXJ<J!:$[#'G:@'D(T6.8C/O
MFI8+TE0/[)M\FT.ZQ$4J]@WDC[V8*J5 /QT7'VNB->"5D$F*]5*9NDDB\#0K
M'VO[A:(R#FZXU!#J+%@GC)I[B(-#LK%4!#)T=ZR,S"D.DY >GTW"96@[VBD4
M_@2*G&Q59Y,U!(7*&+DFR;9'ELB3..<GFZCE[+*1T0<0YC*O#". *'<J?V5
ML6Q=O46)=UT3"O]6W%H]!KW/$39R$']74W$NZ=2=?N^1$A0W)A!R*RUN$E$C
M5GZ^6$?YJ)Y>CS3QZG55PHBPKDR439T-@1)-"F[7/0(9*R5&X"1<.FF*U=!&
M'* 14C4&(Q%,Z=BH!R9;OK4;!@PVA$A<^+.FU4Z<%'M!\\57<J)>6RP2J1,.
M8B7!JP78\$GWNY\#/Z4BN6GDS B\QPR#?FWLKIT;O[]2.0')I>9V7B]CB5F[
MZ_$"ZVZ35XPA\5%?8 VHYWYDK[C;:%,(D)I 0(#<A"L!Z,MO2@\2WD'?4*[6
MXE%I_9IN^7R7'R-T)T6]O).2PVQ$&8$'D FU5+<8+7%U\Q:1R,;?0)RE,/J
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M@(!.J4>I2S D!&-7^X F^( K'7)3"2-+9N36M510UEP'L[DCZ<,6=OL@#3C
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M'/:)=$H_6"1DKEC..[-X>B_A5\JN]G=4.>_1A7/O,) C[N<!#@^;&#G$MC.
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M^P/6($<M9LD01DG[)Z8\UE6(II;37 F1TMKE)2P.>L#NVV;CE!83Y[VS(Z%
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MZEZO(P<RWO^YD-XO",GUAFAE7@FM#$;]%VO([F$6X>^..'>R'@]/*K$C!]*
ME">(.P[YU;7KH>8CVWQ/DV,:'J7-F8E'G'/_$!)XR! M7;XDB=> 09'>&CE<
MZ:"0MM,[N-QO*DJ^WSQ%W_[9ZY>@B4S@-@Q/E:+R95Z)$P962D'7(*?J#U8E
MF=1O%]45W+W+G.@_.417+,H6</!\02Q!Y LWNXJ(,,V2B=C8L=5S=-/'4-2R
MR,40[4CN(]T8!.&Y100N]7@_C#)V8%&HRQ!GM@DIWKPSY?]&LO-=(/^0H[V8
MBP/7BUV)+WV31Q\@%$Q<U2K;A?=:B&M"R5W[:I8].:2^T@PY@LSB:9:5,'1X
MCU5/QUWMYZ@U^#,"^9YJV#\\.3_5L$\U[ ^^K'ZI&P>;$H.S0*G6M4I&63+L
M+/%8=W[#YLV2.(G!\TQ^[LHU4L[R1]$E,$?!3FQ%7,I_815;EH6<52-&SNA:
MLD$CU3"@@JJU%D;6*1#?\07<,GR7F$"0C R:+0)Y%_=%\I&,W<XL>=VU*U>Y
M$(63_\TXQ\)/CUP7)HLRY&>SE[M$E%$9[<;H."F_*5(9ALXS*80'E4U+ID-"
M5CPE5M\C[:4%YEWB>!SL>27M10UX/E&M\^%;39#=OA(5G?#M;C#RTMT\U #U
MIUR, A](]=]_#I.!U(WU3.2K;_CP]U^CP$SC5,V A6]JAB92D""<6C7YIL<4
MRDR[R.S$4BQP5VT6PB4F@RYD5A?^V!0,;D-PJ=+/N:;MC\TI23ABQCR2D&^7
M]2@MFNMBFS3RP.T35U/0Y4DC=X\K7C6[!G>3II.4Y2=OT,W<*;F+,D9U<& [
MOJE\CT($]HRQRC16R"R8ES2CD:K&80B'5-3/E-,FL)3)^W72CLJ&BU7B2N_9
M+IG K;:"?N.^S]#=29";9H<+C)#X<HV_$W')\A3D7R 15E.IP_:TJ$:;_T#%
MG+V]4,#F#RQ!7Z;-^<C-;+2S-W)1]U]+9I8X1Y><."OSO0Q+&-2E\E*F ^A8
MRP89HRJD3;B!C"H>L, )&MM09QMF;R49Y#OWFM3': T/H&Z5,RR]V]1M_#7<
MRE]MQZR@?5JJ&WG!C\Z0Z&DSY/%E S%('( 7N\=V+;@X':UP8JG81)]6"O0$
MEF!"6>J4>\(H4X5[1*4*[E(<0Y9%6=X^"]LTR?N-; J9_(LN&?DORCI0DBW=
MMO%GC_\[QV8FF@XC0@W4Q[AXQEF?-= S#((W,&3>2+XWG3QA3T%O"6O4.L?L
M&=2BB7H4"D])#&^?5I'UK3B,*BIC]0.$SC! '/_9Y7)T'EY?="%RELPWK+V*
MLH/(K*@0*#>M@H'$VGVA'C3<O-Q^/U2<'%O88OCN(^#J_5.E'WXE9\H3C_^G
M_/+)78IPR$[<[![U=;R>W+OO-C\?;Z<;N)J/<XK6HM6FS(#2:=Q@ V8*I]SM
M[Z@Y^#-Z@.9@45??,S+<]\.$:;[;.ID(H5S024T:%$G7\/WOE V/IM$' I5J
M@7@^>B'$XFP)I8]M,I%N>?C-]__COYU_\_7(?X/GN#HP;M/IKB2(XT"BJ"C#
M(OLM2E]_?\]&%MEFK@ND>!&SJ@69/CGP]VW(#-EV<AJ9$R.W*)JZB\0?G)TY
MC=@M1FRQ=LN.J8S8%K_'J'T6;[\IV@@+HLBSZ6DXRD!L@<\&TBL1I8O%=B8_
MS9?>;7%H^&%;]K:JKQ^LZ^OO\=,]6UB:QY)1K>JJ<96[%H[.G@F;.C=00" (
M+CEO3#RNF;;/*18Z.%!^E5 +$KFRS']S=![?F\DI'$E#6E= Z9S^@II6 B>:
MO9+"UNQ+6FI??[_XRR^OZ)_GWW\UZ[,>1EC>1()X6AP-\ *Q@YGRHAJWAO;V
MM.?8>Z$AD2<]85_B-=1%I"6'\L:LB=DEP/80NZ[K$D5!*< 4U3^T(2*3NLO6
M>7]4DOK$<HCD:DOB-[P'E>%"]F#4TBF%)M=',<+RA>^ZXE\$821@!3IB.;4V
MFF.)J;IZ2S+N1*1B )))40CDB&ZAJ!@)L6U8E<(%J;+8;QD NT8YC @!VI8R
MBK3$4<6C+Z1ALF:U?'52AY+9[=$1H)\$?/CGYQ</0OO#+@I[46H^ $N&MX81
MBU%1LA7\\C9K)NIO,M(UM"E&.MNB4?#P?M9M*0#VD6A4GSBA.WYX\O"$[CBA
M.S["F:YPZ!OU011Z?A4K>A.%-\/2W9=C%@G>/$#DHPI,+](F*IHML\;2A/3M
M2AO!&1N\$9YFD6]U#M)8,[6L;_ @JT.B*&2JJ[TR,XY\P@K+2X(LB,R#YWU(
M<=D&B@$2$ISLGN"JE@EH2#4S?H^KYCJ DST8<@+!WKL4JSY.+#:FH#A*83C-
M&W=LWN [5!<#(0?(2WG1I OZ_2J.A.%1A &[F*5TA28E?[] ")(@\-&EWS%@
M^U#J8 N."@['BEBX_2JEDJO0C2RD(&NJL-$3$!]WPB,0@C9%=*,U%>'1,E3Q
M+02)RB3\R)3+[CD7!*T:)E_U*W[T-X<2Y>P+6XI5(ZZM\[.,30'D=(@>^[N5
M 8S/^*ZI]/'=I;GT603>F29?]0<'O3?9@>A3AE%;M7N9?^Z[5>B+T=&&%HBY
M-9/PT7=6F(, &RE"\5HIR6\]?)G!")GF>ZN=? M2Q$_<:/H95B1%N,J"G";/
MO^282\186S^N O<1NL3 IAAK$:3X>EV-GSO[0TR-_)?)]%Q26^. HAC@I;0]
M/ _E+,ZP:QTL49LFOA<R%6-J=,=V6"F%?*P:3<S1(0C4*MHS(EOAD4Y7B!4E
M[VF"QX\^H(_V5^$TXZR_9#S?(BNZ>E;X6GHMN'H$V,31AX-X3O3Y>17RF&K^
MPWOCO.N*<MG#WUC/B^ =H2,X$:"U?%SVVQT:5>7 DIY2 ;H%#@I_6E(GL27B
MBHZO\-M 0B\TTQ,ZRIM!<?;L(_Y]%!*G W7##!C_,*0B\Z5_0T(_QA2"]A.*
MSVK 2OB#MU!HV1E@?1, PK%*.V,YQ /<#*C,WG+B!$S[H3B!8IKAD6-BW:24
M[RA)_LWWX\0-,<WF?49L*?'3HUD.3YU)@SRCT:P<)@3!(/,=EM@\><#259>[
M]5Z/>86_(-]&.S\TW)I'&+0#\KE"QX"R/:654W;?[N"Z^:-MJL_&XBQXL:_$
M6CY+HU-N)OBK=YI*?%</RU_RG=^@[3UT@Q1%<2ND4SL2:V4J6J[Z#T;IU*]Z
MXI>CQ +I&@B@ V/N=^5VO6]]?)$C#RRZ8/Y?Z[HE!8DV]<ZW^5[;)27F4(LA
MW99"I;C;]TAM[$E\I'HJ+S[$!/8E7$,2Q6"QWF$:WV_N>CV4ZHULV]J/$J+5
M2)U?5%=UJ5J+H#=!&[/?QG6Q'/ 7Z:E-L+_@[)E3I_\<0IT5WDRR5"E<T72C
MZE.U(>X_ !B,W(+48"H2#;QM #]3UX+(O:A:$\8[ ?<'@2CK(O4PSS8KP-[/
M A62J+S";#&'=JHLJX%BM8U(V81D[/QQCH!3#=%C&W*;W3>T%&<+B*8U7^R3
MECCE#U'D>I!-:1,ZRZ0_):RY^P9;2=*Q5K$G2FLE&I7DK\OJO6]CU=.4JU<K
M[G3?L,1&SJ!7[3'#NMHVZ">];^,4>N08JR$976:$][9MN?'+C3BFR4,_;<F1
M+0G;[ZTZB8=*QE54K<9$7\'*OZ<VO,@V399P98]=IC)B(BXY:S\G;_O@D(7W
M^O"+X1Z5\!^=2OBG$OZ?8<Z\M:?D372*M0TN-$42YR(+_=Q'@R]],X;#+89\
MBUIX>AF_)1%-XXK-O&M:IDV:3JG?Q]%$[=.[8^IZ$ 8ADN,5 #DNE:+.:E/3
M0)>E1A,4V97W;PB1 $E9&2N;&4@"@EU]R=IL!F_"*8![V0:0J)OWQZH_1$0B
MIVD>"JUV^5MO&>\ES'V--+ZQ@$H0L]MO&4 2!@K^+BJK9FR/+@V9E".UUHD0
MLTT8\E0I-P7#QA(LFSC$4_3=[-#I2]@UK241M5I@^!CM_PM]J_0K M'82_2Y
M,R(_15JH+?YU !] N; EN&K) NV3_,,Q3KJD,(5552?<3%M1K9K<SUK'=3V,
MSG@IG/PNPE/$+]=-.N4'ZN%O8OEAF/7GHFRU#]^,V2(_Z8S#',V/A^9D99$Q
M8 %^66Y=C \<USJ/PULWPC4S8/:(K)[#:P8!A&$^M[=(E\0$T]9'M]!>\/)@
M'!K-2B02((0"E(*@!^]G:6P(>XN0H"ZL.4Z+B:BCIZ$U0U+HA+@3,M]EZXB?
M.KO! C"2EGY'_<-:R5CRN@C+2TT,:1*\DR7L55$:MVBZ(GR-@!7T@XR37W4+
MUI.ETC25*"HF!D-&K.TV^E6+Q[1;J<S]^EPK/97=?/P7%H4:JCTE6U >L_=8
ME(8+.RX.0&+Y2162,=5$+B7=$LQ)K_L>S ,B5FNDRK<@Z<2*X,:RKM+J84&8
M&CK0EI)Z&@$><C%?03 " . ^M<@!Q=2<%/,$1O(24*Q0V6>&494! M<>IV>X
MY7)D-0=9EJ/;YS]SG6@6A&.*:EW,BUV//&J:+JI5 F]L'"XVN?M6:N)59Q+_
MLKDRA55%D1];<8S5NIX3-K7Z[ENH-/#X>72B2%(@6C.]![#%?F%B@$UJ6^+3
MN:O<JM@- J_[.+(E9+<#,R;L)4 <)FPG3D24L)C=K#?X%AB][7:@ U,L9JAN
MW9GJ =09M0@\T[R^=@UZ_U)C&-(=)#;!EJMW<B(C3K]O:ZBKA'VLHB,XP=M!
M]JNM%P5!Q[CE$M4Z]FQ019;&AMV-/OWW=V<1O5=*YK.8RM301JMJP$A)BKF7
M68:<R00"*3+K'FJ2_>QF4F"K1^?NO9QJS0^YF'&*0Z!_'=B]%+"4,F(>@,Q/
MALZ4/.)0$?FC0<3.(AG)4\2>SIC)8CY$/#!Q5@7PV2J_JAO]4-?V^CSM UOL
MEOR>T%H"2U:PE=RYK*]=(Z'$03K(U@@IXK&4/^O:V7@XHW'MCZ>)]F(;IVDT
M\-^YDO$MB[>NE#X "K'\4^]*EXHM#,<R"_VC7/'8)+!2?ZN:N88-O-/;>NG5
MHZ_NC/):> <-\FU\$)Q;\'US,E)R6#'2?,?<HV6RS6:NH(2YB4.XZ<9OI3*?
M2[UU) V4)4QX[YF O*?M7"MNBXS])L'MHZ _>(:1AD.PJ.#\P9HD;DA9TI)X
M[ ^X7+*ZC&MI3CW100$Z832F/4:+Z^C,-H-&;^K+]#M9-4432&X<OJ*=K?UE
MRWWBI5,W70O-6M2E_!/^BQU^X&E8"-5.],XMUA5?N-_C& 4=_817]54N*K*Z
M7LP:T9:Y5I.*MAUJHMN=MNJ-%[JA$=[[JV^3MJV>&+.F'S7S:52>2$4Q_P<R
MF*EP4 @2,J8XRTOO!)W@1#\\>7R"$YW@1!]\64WM/C5ZP4+M;?A>-^72KQCN
M#:42P;7(HEC<? D,97]_'[BN-1 7\_E_%LX[FHNS;';A0XBNU1\ 9OW_G/>E
M\MFV7&2S'QOOV]3E@U_V.!-__6=7S.?9[.>SV;_7JQ44X!_\-9^]KA?>$%V<
M_<5?X2\%).IGORZH>N=ORQ?V_]U[1^U9W6QE(62S_ZC7%81$_T>^V7ZO/V6S
M7[R)>YO-_N;-LO=^\&0"I:6F2;[+JY6?AH:N32_]VE'7@[_8J[0U4.]OR)W;
M35Z6X )P>5/NM?\RCE/PS+?>?^U4&R>AEPB45\FP;HI%4\_1+LI"NH8!BN54
MT6(11&)8FL=[&80FMGAU*8(S2M9?.*&O:MTLA64KFKW2&]("\]_GAP 6C0)C
M=()PM2GWLV4"$*ZN^AOD"6F:''7Z#:/A'@H:X0ZX/,48(#)P3!01[G0V>Q4:
M&(QJ"0L<2")^EB]REG=.U?'&U-5-8P0IS<AQ7EPQE$SDWA+QO:/SLWXQ0A_&
MK* QJ]W%VAFS(ZISBH)7_Q.69B=Q*(1P.R%=NT1JS(_[JJC\$BY8CYA#K2SI
MGP(XVQ;O33!.E?U=P9VN4^)\6=IJG274%8&PW?3)#IIC(X&2;?(-RB7#W%":
MV.MW-;76:8>%NE1JE7SA;2)[.:$B?*-5]KN]:TFXJA=[(,+GB"$&L4P&2'J^
MX(I!*B3?U%RH95-FCH6^--"Q+?PW(S)'"4U4)_K*26V;:UKX*1($1*N8C>9V
M\Z"G2>O#E!.24GRZ\EB7FRV2=#>P$)C$]B.B8\G91 4B]'#3L1,"&'G)6/P0
M*9VDI34DBRZ;?'-\,_^R2YIV:\)7<V=OD%]B#4^J]KNR4,VD8K M0E#5CT]=
M+YL% \JE%,T-96P85P[9-7\?:HQE9K $BIO%[QJJ5YC@QO&7(JR";,MH*LTP
MH@D/4_\ Q2<D"3XIE*V-I9+P*TS.BVT-XF>3F##73+Y;D]KX0.L >XYBSFAT
M\2CAJP93,\T09_(OO==,MAMBE@;&3ZX8$!&2<.GS_A/P+QY!V+P<^);[@ ")
M-[-YGOR0/Z<'* )]26RVZUQ8>,B9&AM_2\_ 8!P:_H0_VF]R^(,^^I]] 6*#
MF0 ?'KR<9ID)IWDD>Z'L022?:T=R+)Q'[24IVKJN:,1H10:>+YLI2^?<%,/&
MTXY?#!/:IGZCMKO'JS4CT!WFAF1!YC@R6Q& :*P&5EK(P5L+*;EW/_RMX-H;
MN#<%"7X,P%Y3U.KI!C+#>Y@AG=#+2&VBQ739]F[N3S#+2=K(#=-)5\7Z!EI(
MC4>F+,V3_2&I@[:MH2KIQLF!X7#1TIIW+4K<QWG\I?OFQ@E*L\ZF!S]3HJ=,
MX2:$%* )TU&=+J*&JE$2>S9*OQ*:74>$=,ABF)AN[?(2_-AI'VW>[=9U(\AK
M#>SDH\$,Q"@PC?1F?S$A8[R0Q,=]BQ$54P_=1WY',B2N8O:#5-M=V-W$2,:>
M$<9YTD!L<SUQEDH@F@XL\3H<X<*-5+9&RH5YPV[3_Q6R#8$DD1G.&!T)6*7*
M[QIXK=;+Q(M)V\[&N#1N>(2>(@$OGK/9!9;-AASR!@>O(H+/?CV31;/(Z8"G
M<(\Y'0(@F&7<6^8 ]4^).[_C\A5P_6[G-EOA/M)R*B-=_',3N2U'D&80J%%O
M _GD\;=G[>4.QZ-9SBA.DU27OQX*FF-8BD9IJ(*4/=5Y8I8"/HF4]C<<L_GH
M?NE8',(MN?#6D40SS(7W_';"/L#3!X]ZC;BWNM3DG/P9A:%+D)+"D_,W[1?3
MT]=LV'_"/<8V/VWS^-17F&4VG^3L5";WLN>C,'YM6^:5L5#"<1)@!N2X]QA<
M5?,V1@621:C]F5K52(VUNVXI& ?9R(?LM%"O3JQP"QU3=TJ2AU3[/G!A3 !Q
MTP2S3MAD^Q$0_\6_0JX<I&?"LLQV;DJ/]H#VZ^@I=^M^#5WU3;UG200).4+%
M3+M,A*:@;GO.C<Y:E!U@,WZ$W3O<BJ"\=89&*/+2V@1;WWA4[KK<QQP:;<5,
M8FU95G)MBG]T85#00=NY:Z!\88,;2L'#CF!IZ85%ZDKBWA&U#VM!#XA]1'I@
MYX>\F$=JS_3=0@=!00H-G"'@QU)?9YL7;'\0._M?<?PB9,ID<OAK-!"MQ+IM
M6D?0K&@VE1)UF5"T]+ G9UPK*3:GFNX7/SQY<JKIGFJZ'WQ9C?GL:O34TA4K
M(_F3Q<,CH+<"6)4.?@#?@B$0+SF<BQL(B&T=6//)/WP]XL/@X^2?)+)L)N\1
MK*<>@I'!WNVD#4X,;4&G-]KE I(PE/E&WSTO_>Y9 J_"QI]QA^38TG"$%YK#
M0UI( 9A2/$C3*->_=Q\Y:ER%!(^?H2OX=6>SO[G@ @;?+M+@<\YW3E3M2S;\
MT8<D(SX7HKVH@#X(0LE1U^0Y-_^Q3V@PPG-N;Y,"&4SF[P'05.;7DK;EXA?J
M94H\0$I.#3=S\+.3PT%/2$4@C@<H5M1#MT;GXDY&4]Z=P9DC78><&TZ T>A=
MW)(LVE@(-!YY&8^8Q SB(#T -;-;)J56&1C-HHZ6S!(\Z"*VU^6!%5G=*<F;
M!W"DE8SR7EH[R!PV.8J(BYQ80:D+5QWIT72^@F:5%R/6,.%YTXEVC&Y<DFRC
M">%)'7&1.=FRD-+JP?Q/0.^%X27S ]0*\NIQ<4NNBOYY-GMF1"1D$Y6HC@GY
M%Z'>DH*S#^@JR>".)M');,$A%9\*ZTO:9BW1=C2LBQP6<<R+#:,@:(NX.96T
M/#R!&%1RP6AG,C:'!D3*$ 5%*&R>9/"6%(QR4ENOG87HE5?Z5>$'%IWO-<I9
M/KSU3PVO).U[C\T\D&A+5&:\Z?8&K-K)W0AQ@@?RHRK7H%DFZK0M#;I,HSX!
M\C.M3> *NRG^FK1(2)[!^JW>,VR+>1@4,LR2'Z.Z-K^*'V[FLAQ[YHN>1@:K
M$4U&=6Q\#)83/\3,A2R\C!A5=\@+I33<^IR]'<(%CCJM-\:.99/USO2=.5I0
M6F]JD>9IE+C'"'(8\2 !]+?]['M@<$WBTMZ]^2#@9<_;ZT(LJ<XFQ57R8MA;
MZX*TG_IVU+MQW;;?D(R]447\\ECVWTGI8$K-96K2M--=-DA51SEG?J$I?1-6
MODO;YB-?Y6@W/@=B[$Z87:?1&MK8O<V"3R!<OZ7EB:[9CWD0NUYYO:D\L$%M
M13GY8#KI7+PQU3A(DM_'*M2K8-%T8<*=ZM#_JHBE3C6!V(1WE :C1OP$]*U7
MT)PI[8%Q"/J-!?=C<P<4W4Y.Y)IA>J":L!*><0;<[UM6/&XBL3Z1=SH1YYK<
M^<5 K*"'BL\%Z*1X,GH((3VPZC+2K3/=8J1M.E(,2'*'2Q]LLL_'34AA)2W*
MO- &K-LH4>7$'0)QU2;IQ3FX^!"H7>;-LA3:TPU8VPB7 B6K#EY$MT.Q-#-#
M+D^60,+N&T6!R=[Q<51<:I$M]L&)\JR5KVW) GL+ZDKR8/L>TZ869]"RP=VW
M3NBEH^H-<K)N0UYXC_QH8@^,6,?[-G2T__>*BF[<MMM)M;I:IF)$XNJ11Y''
M]L/[-F"ILG0/)LE.>N&?]?Y16MC%PI$I=7G1:<51 9^W.$C8]MV[$3)GZ@;Z
M(Y3;O/;'*3,F#I80&2OA5+QO@U76[&%(,'G?7E_3OQ$O+XZIP6XCU$<OCTL@
M8C,"'+G+_8FC]!"@['[$1E;C=A@+64!(@B3:W^[#.H*,[>]WVE@4A-$/Y,)0
M7J9!K9T,BD B>840418,T7&2TAD^>2LLB9H2']$>-,&8P&!N+5P]>S&\9='J
M4Q%P*()<IB08%28V^OQ422?6/OJX42]%OH5!378@6__([8IK-W&: I%<[L//
M/S7K\JDN=(]J_]^<:O_WH_;_N64R[VJ7QA&=Y^</AWT-*6$.LT%/-(>..$-C
MJ,.\W>D,]!J6 K)Q,&U<60^-)RV+[/T8! E?43WJF?D&CN@7@:%D=N&?X4OR
M[+[^_L=7SUY<T+_/O_]JQK1UCM'-\SE*B?RCOI5?(.MK@:#K*L.O!^UNIC&&
M22I)!X KL;1E";*;4[O9 RY!DOM-?=\+-W+QL]GL-ZH\P>>AQ\[H,1DB$_HB
M\Y&>G)25:[XI=B83#=R?/^L+E ']%.Q=3G"$LJRO0]=^ -QQ9*T/J9>_]GMN
M532M%E,34&$//9Q4H:GB>_AY";D32T<&K,@/??Y0'UFK?/2T=64@C[=YXK/9
M\T[ UM[/.G_X %?5*C(X6W]?E#[DN1+]2BV&$7"9:^X[I+.U1]LTC*.<*,[>
M^,-P1<YT^R'-/D/^??;C7R^T563(CZ20=YVF=EM7;=U@-9]_^WU+U%BVY=L/
M3,YH1_R#QBLX>,Q\7I8/I")=^CGL>[248-GX>^P$@>E$%R5#8%B(VB+1=B^,
MM$I8OV^(A?2:$?OHP_U=N8AX[+A%FS:*?^R= &4*[=CMK:JDR(T:%U#(P,-(
M;3B+WY3:(D&H7,Y A:;78"7]#U!)_?NZ*)U"N/0/W!%!?2[;H%+-9Y $#'HW
MWIP*0>(R2KZLM^D+< -6[WJWQ?:8L,<4U_UUB!:I#9T7(R;JF,XHK<>A6L&R
MR+"^!\5Z0\4[;]GT],9G1HZ8_Q-V7KNF^>!N]WW8B >- SA=KAW!H'?:GY)S
M;4XL*''!A\_'MFM_M\8O)Y05.@E=JTN_P%NNN+"&3&C<O/;A5BR7J_T(]'9:
MDY\:AYVT3O1L4:NJSCTFMBQAXP_DKKBM;2''E[4[]!:>UIEHAN>R;,5"RN'6
M"EU+],8,Z(/WF!U':HAIN<;%.X@[#9PH7\AFIQS?@I"7(3/LC]8(7A]KY+.'
M%+K]%A$Z$6$0E&\%Z8J+%2%"?ZRDV#$8:T+:P)V@.80=C"Z#M[$!>:5#&NZ@
MAWU55P_&W)"" ?9[ASJMPS.'TO&X?C ?6]LR7RA8+7AT*TL93V9SQ]?1'N^C
MLRC>7_FI:^JMX\7 __8W]R[EIJ#MZ!=8@%M9; XW2OS+*.8:/Y6SISFOJYR0
MOMI,+?0F89^6>>N?7O$QEQT0@:0-E5[24+'XY^H +[X2!W'K/6O0*[!S1#X8
MO<MOV:S;$@@9<ME%H  8/'Y&\$3E];,<2?+$A,QES6T:/''# ,Z%>V&W9N@7
M#"MZ=UW'SXO/E!C1%RL=WVQXO2UEZ7?M5)-*H2_+3H[N/+58\E)U\S];OO:.
MP%-(9N>]T577VGB'KO<>_;-@^#99>MF) 5<D5W#08[/5X($#:%M,RI+!>54]
MYDS+=?FV?HVPW\QF;ELT(1-I*(:2J8#;IGC?\Z_Y=4??4P=!GHZ,J#A'>.3?
MBTVWP3?/SV7NBY6?W#BN[)#S8@K-8^=?\X<S\WS#L5O7)1UVA)9K)2XRE!L&
MA!=5<9F#PG*&D8V;TP,E]45UA(.>0! I9E49A=_;[C\;],0&2.W"C0P9UD(,
M4786DYLP]-C&6NDU-)PF!@9Y&/9I[V[WB;U\-M9(W*<H&$3HY-J:RV=*R<NM
MMM62*[>6A,VUK4I8P7_QH0FQWPT/F",![/V<%Z7()4W/$J7O+7<?$%3M4I48
M6?-&+.*4M\<I$Q?-/1S@>5/GQ]=T^0(N,J5) E\.84L @CNL0.6/"V&KVLLN
M3$::$E*U]A@IU31VVZ9K [JZ==XNY#LW,I.M\B1MB4?"[P7O?[FF[O@/P/[W
MDFDIT\T;FSFAF'&)Q>._1S!-(C.+=H-Q^M48D%^PAWQ%0EG;%NH^95%1!>Q[
MO#KE1HFET$+WM&N!;-;(-1-JI=C;-98_/)L]ZV4?I+6;66U@T+4WPA:^%@NG
M<?:T;] SL3P.8SE,"<RGFUZ-+R04C"V5&C750PID?6F,E-_IUN.1'"A%OP=B
M^ADSR63$^=" 4;?"O <$3Z'5THMAOR >Q01ZW(+I_SZU963.>HLM9BZFC-B[
MMB5SH(-%[N=HGK>%-!;N,$]GLPN=:I-7#/W)KN+CR'SFUHL*K]TS'^0%FVMA
M#8]<;W_@93[.HQ&1D\FLA01&3@H!'3.P<RFDU[,^W#,CFU/R60'2E^:QS$5T
MOP7Z^*G"-D28::E,65G]CD8HL1LA?NZPS%G!7')\@_?T0.Y1J?C;4ZGX5"K^
M,WSHBS] 9V)RKZ:=#;U*\;.I[+G%RL>*D[(BYE$^MG=-5PE;"A=357C%.H,3
M?E_$$1DUWZXR652\OI_933L,##.N6E 9997(OQRU;/(?61-^%DMXTB%833B4
M8ZTFXX42EY*MLF6FA8*J-[NB5>XNVT6!G/Y5$62$M!K$39$FKZSKB,N U$K:
M[^&M5Y*XI>Y7X\Y$ J5Q#X'<W];->AW!3"A.R2A*>;8LR(ARG^4.3S>+X>"4
MIZ&._2RE[^6.LE:V5[QK-EO\Y9=7T@J@+#3FH?C89%J&'K,UE6BHF"+]M/J+
MV!3)P5<#Z9":V:<2)CHJ"]3 1E.%M%YT\DR]1T [4JB+]Z2S6]($9KWIJ$7)
M X%KOW6.$N8D2:"P03QQ3C7O0$S3".N?<B4-&XEI]FFF:4E1WHUIWU%)X5Q6
M2&J2E2GH-5F;[] H>Y]8Z2_ 37;M+&,]??UZ[<T>Z?PV;_]_]KZT-XXCR_:O
M%(0>P 92'$GN]O(,&)!EN\?]VBW!=C]_3E9%D=G*RJS)A53UKW]QSUWB1F86
M27D\ML@BT'"+9%4NL=RXR[GG<.PK#\5<L>]07R"/NP#L7/C:H"VK?#XE 0]Y
MS&U)IJ?,U "F#.:MM$/CJI-I?W"&3/$W"T?7$='GU 8^@5K,#R7?V"R^N.1"
M*4D\)X[RX R?3VZ1:[%JA1%!L$TRLYKFM/0++B^=2Z4TQ&^,R5CLK%)G:/.<
M0%G-5;97&0V3>/>XCH)D[&YL])=$,E<POPD?]&&B1-8?^B'LD&*]N;0LL4:_
M>*A@+M:"%T%;.1T0&$MNKDV3Q:.O-R)F@?QE^?..8\VFYL&M_Y_E##/N'Z*
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M+8.!-D+7U*?&B,TG ^"F1C291K6E*BZ,.V9#=7/WC240QF-\R9GJ)8$EBAQ
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MM<U5:BHR<.5,%%K9Z=/7UF>B5^?2>GKMN[RLO(;[T&PH@->YBGN.BSYC$XB
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M6N(4SR""QYNU$$;BY ^+!*XG&(:CTV=Q?BU^R"?8!#7N%I%<E[VERLC#O.S
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M6,924D$>5Y1<)?M5YE?AJ0S7J4RST0UY&N,/5*[;C8@Z3KP/OH!JOV7P8BZ
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M^)TT#.EYL\==;+90[F-".[#$EB9E5C>O,?Y)*G%)[IT0)(D'M/V52S=&?0:
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M)W%=LCF@=OQ>LL,P#3-?_#9?6/N-%WT_]BNY\9<U(=/@.!W9C&3"<;VZC\C
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MYQRPE5EW7<KND64RRI<$ Z4S IUR::C]_;:2<8IO)9(XQVQW>AL,7M8XQ]:
M]X?OZYZF@M"A0?1<3=9,YCD+?);GV*.DSTH3.JM#<N)Q-TK>SF]:R6/>MF_3
M-GL]=D<?4=>$]1&>VR8C$P/[@J+^V-L.TXQ;7&Q\H'&.S9$/T,'"-SA8\DK/
MO:S),-6M+95&O3PL,6!6Y9@$C,EH)0?*&7/X$FS.![> BZG-DHH#_?:"'5X=
M.J-_D(UUHF DVFY<:8[_TH!RN@"=,5N7>QY>W4Z&0,P.!1R;A3LS&5%&VKWG
MHVC(I0L5@@29TT=;%2 =!E+0W&D@D^8V5Q^*=^O&/9]/OR_F[/?VK;,Y5./I
MPVA9^E(432=BWD"M/*K].@Z79?(=?7U6\9"+E22^(:1?0':XM5-DI^!V6U9D
M"I-UY-^(Z9DX7L*=;0[L J2J"^!_Z?TJDZ.VN'T!1K=,L?YL-!I"-.R9_X[#
M/EM5@;-]WB2EI0X,PH[N&UQ\01-;I-&3,S&A(Z6P5/AM%P? [RQ_NXX]6H6Q
MNMX,""W.0\C5-_Q%IFAGUR'=/8=S>G?)K:!9O(2P*-M[B5<=]E^Z0]- ^A&<
M(TP\OE9F N46&I'>5Y-L#3*4]'V'XN=;+HHCBM!)Y-)EV2?%PM(G-JR.-AD2
M>#KJ_7J[:4,<XTB0Z+A325Y6MJ68JU"7!WE_1^N=>=?1B>8Q^.-LVX=VA+T$
M^#QP68Y5/**CU:Z97X.]$AX@50MO9$/6A[F>X13-_; E!'\)JT0V <=/K4 V
M4-D90 B<Q8C/-P3TF5? %FYI_.]JXI>BJ6CA6KJF/<CLXMQ%WV?4E%@AF;)H
M?)^<@?#4M.QVY%/M602(N\#UN"0V_0LKMCM',"?!WW<QH%P?\C\.Y3M\K5 @
M&'W]L:K]U6?/'ZO:IU'5_F.EO1A)2UY(]'@50>?2R[PWG5W-**83("DC U;;
M2[$ 9:Z'&R3@]N25-1=/Z[#EU__R#S:#)92=&0IT:L*1RGI[?A#(5ZI@ITK"
MPB';6]Y--#DSA"QQ%PEWM%7_3VUD7>SA?1Y#VGL]JPS$?VH#Q:S4[U)X.TWH
MM,:V[] E2+X#5)$: !Z%8+^<CET_Q'@E"15(=*YXRN2_G]HXY8MN$A?:.*D'
M3!P72#!4NW-B#Y8X_H+;Q!UF$Y]#(/XA1<ZWB9$ V@.F+"@P<P+JU%8$\\-K
M_<]7"D(3$,I.@E\A#SBU<7*Y0@Z9-=H3W3'EUE\?UDBTFD4Z@)!!4?EK. 8:
MR"<-*NT8W\;K42[XWNPCB8)Y;;AF=V(> C"(NO8;;L#6,=(.R*RUB,+B7I0(
M#/B.;$P,I>_-<(1W2!*$%7;.MA[7JGYQ:ALF&@Q2/*'4;$E,%Q0CM765ZN$Q
M+FU:XC^GNK,)Q3GV_!*%XM!U;5Q,.RFNZ16(0J.'YL2 O !MG7NS2N*8!%(C
M_RB<79QA_[]Z_?^^_^;I\R]6E!HD5OB/B]5Y>UBW W0"1@(GUXIJ8?Z+%)-:
MRL]'MZ>VWA3 S1#RT*>55 @X@UEVB_2)+?.M7%&=//Y_TPOM+'?1"G+L2_KQ
MQ,;21[Z,MU !'*XH,#4!D+%<ODE*8/&$&\5K2'3'QNW:UBSJE%!D]V;/.HRZ
MX3BVU-LMPCO@ A@[:*AJ5]_93VCKPEGVJNU0HGK#O>+Q,B\) DO.UWG;OM5\
M,@');\@B?6BCDC2JT -7X3 ?JJ?G)$'4'5:3O[?"8. ^P<Y!_,6:!XC6"R7C
M'EQUZ257=AAFMA668ZZXN2*KQQI*V3WWOU/A%@= JMH")+#..!0$2?7(-*2-
MO=)G^W^CI=JT.^/RI2V\Z<KKLD[-%-^.E$N)CQN_(\29HF+10([ZRJM77-3M
M.<V-NC3&]127?7**E7=MRIWUX);Z=R:A'$=+%VX7MH&TA\:=9+'B%E"/AE32
M]?05]2*77LB;I&7RBH7?B4I9?9 9C:;XV'S"VI8#8R-*YU*M6]LFCM6;GP8U
MVSB!LC&Y&A<GF<B:#3&;W^AL!;B%7<GUNPF7*W'DA$VRE'A^//;?RF8D-K3G
MQ>K%LQ?/H\\[$&DI:![LV66X[*YORBZ>U8;%@',98\YU5>LXY@]([-AQI'HT
M!-,H%&D9EUU72OLSL8F6U[YANUC]*[I70FWFQHSLN8P7(^^[^#3@SDV^O2HB
MBA,6_>$]$;431J0>&7+J?#9*&D-&?/5U6)>JK9 F9Q< 3NUI;Q'+'#4_^[MR
M)[-(<//V ]@QTVX,[SQN)H8CA((HB87GHAV4S>\\#-<A-$M+3P=[NL[H>!\N
MK87-@YCP>$*G!-U$#(8AJ41)(6OV7XZ@K!F2FLP"N6/Q+<^).(L$)IBM*:R)
M=(0AS+(0LO7K7TT?%J-$F8S0I8W$EQ 5^V0Y'YP18W(4!V'JK<T_+G8"A0.8
M?BD-*<I5Z+\@QWM+/G'!Q\=EF;31_%JX72'I^!F3D(J#Z\F7S\^.G\+NG[L=
M+'VK7Q/:S;J*6\34[C6^Y/V7;O46[/_X F,BJWTIK9YL&$)&,C%](D:$'?&-
M-H$D+7MGE-@1GSP1LI?<E49@Z7)/?D$.@'T_$:IBD;I1[CGWJ.0O&$*A1V/(
M(&''@5!OUV\?XAZ9&!^2<2 +WU 81-T5&SEBW5%RFQD5,35CGMB:.X&>V>2L
M.:?LAED%,4>;FH(<.OZB;3> /V72/)MR*&][1M=$=\2[6&#XROGLX-=KR$.+
MJ6/0([+QC%?H9VQ>^@RTP>GAX[>J"VJ94\%)"447'HB!1WVRY'>Y)/AU)^0D
M=%Z(]/;QI]MTXX4RJ:Z# S0;=?YJ^5&M&UI&1XF9X\B(KN0@_,+:DZU_YIE.
M-YJP7DT?3M+/F:Y(>C4Z/1<=S^GW'U%<3[[Z[,4CBNLT4%R_Z[(Z1F3XVUN-
M^"^"LQ]FFQNR0M*@$?<BP==9XC()FZM[4:$S;%)&)=<!(%[1.D,5HRX;XH!-
M[=4T5.Q"\''6/(I?+_(/6*5CDOMB5F!B[ #;![<-7)D^6#K=70=F\C2X]*]2
MZ%AAQ&D,=EL1S.KE@!Z;<APNXP'Y;UI5YF^BO9D!! _.Q_LFQLT5]\=.8E-T
MG>I [4))Y=L^$:!TC2A CH,-LL8J;8+/^9TAB96I+G;6T!G_?C76I(8M;3.L
MO))(67"[JZH;>WJ:A1FC-JAX\E [\$*5TBJ.!94@Z><ZD!,_-D)ES,X4E?0[
M[%Y=-\5J?8@^X=-R&,HUL_GS+^)@=- NZ+GZ02/Y/08H#!Q3HJ4SKK.=,N10
M$%][W.G"@EQ>C>?:_DG^%:AFT13CA#&ABPDEQ6S]VI3I0D;BB@H^:-2>/H%K
MNT&:(FN&$^KNVP<D:STXI.F[C%_ ;"@4(*4#94G0A6RN**I-"NDDI!8O2YUX
M8:,L&-SS4$B?N,:/?;N_C%_7F:47'>++X_S0QQ9279U"K+,9AP_LMMWT;)7W
M3SO[L.K+;;@82>V.?7SNK$JB\P@__+CP=,H?7(@E$*88&C<=04PVBN*9G"OQ
M87Z!1J/T%(,A]AILY$Y@R@*HW!H6M$J8<V1N%N<"5,1% +NK$E3(??",(7/G
M@QZ#'?F&FFJ8Z3&XZ"ZM.%VV"WV6]+N+KMS-,^V^!)+'-(/CI,C'CX?=K$L=
MQ+=06S4YQ*</GT(ZT0&9T2"H- ;68Y:2T?4D(KL]VP8J$EZQ6FH7^/79.M.#
MDA[9VW -W2_7M9_S:''+G85)1YJ-Q/+RK_.W+.1AF;4 ,]YGQ)O<VSXS_B*4
M0;P&[RL)_G,KS8 #TW!)VLTMB(7UJ:O0KR6995:QY*-C:'F+8J:IG]_QUG-=
MLW$RU2J;.W:2X'%[M[U!$O=:=6HJTC1>U96ZB9HM$+[HN_"4'.T0,[$"<7U/
MT5/\):U[.K8&WM/MN'G*"@9]NQU@_XQX!D4+.0V1@[2_7%5E=EY; \!5]!?B
MZOT7BR"H+X,%#\Q)'S=Y7%O%ZCQ>' %LD1WG?'U.??I%O.7U%N^&<MG:,=VY
MGH/L=?19V0O6\F3>M#G)5$K=><YO\V!KDK]PST8?KH(X?-SZ'C9IUL!)&.>U
M&]DPQD!MH W,A9F%0Z1@C?$2)3G.]"*3'J=.*'&B]_$$D_7$W29;=W0JWVGI
M\5H!4*G2M0(:&KI\^EIJ814.3]0(01)$GDZ\?337&_$Z14N;+R&?[Y+(2F(<
MFK7XHS;$9SJWT+!5\]4J4! I71"1#J[^*MPY%4Z0K +QGIM@$!U->NZ%@9UM
M!2?)--D*F7]@;YYO#?+HOI_R0[2L00Z],/.K5%6(9]2VZM(SDOMQE,YC@V;>
MODW,'XF((/77VY I1_=5J#DJPSVR%;#T++P29IEI3W)%)ZHZ(.Z@F\*[F _I
MR <P7YD#(ENFOX38GG"[L5 "O .9KDFQS5E96CUW,F12F(DO[+!HT3L@+1([
M@57+]7L*=(Y,V$J576@%IMGHYRZM?H&=/8J'R%TDOX(F!(#QC;+?&BA*G2DH
M $@4;>^P/KHL'YJ9SL*FXW.1R,_66ID_M+*9%6DH2MZWK ^W]D^MTYW\6"Y!
M"X\5FD%,L-&R P1YT:/PU&#%$H(Q:(4E?@" .+5Q4&9.62E$I*VAGG%VVN8K
MN1LQPY>4]=!>0,'JU(;.U#E9+YI8#$D  ZZ"'R(EC6L"5\Z[X \\$37Z,O[M
MQ,8/&(*#*F+18;OOF,.*#),AFO1HL!.5P%)K<:<HT= TS.\WB'?1STB+1TXZ
M?$BA[XT#=Z0<\N"<@M?'W6@+6D0<Y;QK2Q";K6F-<)I06K(DC\O+1S)4L]63
M0G1;/MB5@AYDAL;"53'4 3&^T;2YA<WQIJ=_Q Y\]=DGC]B!1^S _TYG"NR"
M!971!:'24GNME1 GT<Y\]LC_"@96'-Y;@D++F9"@5"^FIL].JE+E;"EEW2V8
MB),-]B;"X"JH)M);EC[(LP3)TB:Z:4]TK09YFG0H4M[W?+SPH3=  :AN[,IZ
M.S8Y/5"(T3Y5&>&4Q;_':( 0;>[[6R=7Y056I](E4EI$AW-7CINQ#E+F00DG
MRRR-/2U=JJ]QL2$?D?A[L&KG%5PM7WB.%?PNH'HI,A::Y_"06ZG@"%"9"\;9
M9?S-;7WRW05I(X\IW)_1%ZD/9ZN?2"/.DF14_VWKNCPG<Z1\S)0GG[R<Y%DP
M[=97L9.-*4*;;B>BMH1WXI>9*!:653W)7JK*"HW-4RL9[:TQC[(U\BU4_ Y.
M;$:< E<O4N21O?;RN%#V=F.JMDM/ROF,NM8\\!#VK%@<7[D) W4+Z)!1[E70
M+J74NG*L,SUWU^XJJ1VB,OC0K ?3B')Q6K52&<B0UA+)2NELT"02JE,Q$U*6
M(U/=^^F+6V\C53^].);D5=76&N:F=2 H=2XD<HDWRS7"M'=*@;"IHHL20\$L
MK*->,O76)D:$*S@A+9)<+$]>13I+N+98#2A2LEYCFY><A41(5/I&PZ.P?9&W
MG:RD&U/\DME?,9F8M01TKN+:=AO;_/&CE.D/T3GG;A<D5/CB'.9-"%YU3T(=
M>AU?6QZ9JY_,LV@?*I)&-B<@ )'9$E(C;&Z?*3=+@1P%F."""]-#)3\TFV3/
MF$_?I)@S.HN\P&>&%A:VX[SQ!U&#^]!JMS\N4M;"T.I\:X8\U2P",9LJ,:>Q
M^%F%QUW-M;*+XR%%!R.Z=86B++S.R**I_^/!V=._NR;,)2J[.>A)(F,").&P
M)$R6GJ>%S1=V%$]@4LFC#L9]M<GH<*TTDZBTJ2W/SUES574M;!\K9$","J(M
M FHYJ.8\5> !3<+D"8ILF;C5%[],09:=)7F'PI3FMZO]>$ZVG]YP\E9HOQZ$
M)$LN7RP3M!6KRQ##$=:W($08_<KI>Q1^L.)-XZF!.AVK(4+.R4G@&HVE)";*
M=R6?)5]'UZ6$^<F 3G]EJ-SJ&WK^-^E&/]ICKSZBSR$Q]^S+OW[SYD?\\_F7
M'^OA<![6D#0VQ;RX8GZ(MWKQ[/GG!1!X.#@VG,>D6GN,B\CV3Q9"1K.I#2'_
M3-V4W[[DTB8] P!S3"O$*BM"IV3'3IR8"]GW?%V:4]Q1:D*UZNM(Q-=VO2>P
M@-X",3"(P:XZ>U[ZM*[1Y$I:CHAH?\N.X<;0%&PV6$*Z!Y;Z8>-1/W!@*H/0
MSY]U@)(2:O[Q^EI[MYB \7>E[H%>^SVK;H(:K/12-"=?VD"BX*-4\C098&SD
M)9==X$L@( $UT[<CAX([I1AKU;10?"EGT_JE'(CT>'$74:USH"L0T<56VZTF
M+[T)N_A,S#\&YRN^E/1ZJ;ID-%!UM3&G@JZD'8:S23/NCB6K@<[)<4\'MA+B
M,PG7=*UZ;PM+E:8@+M9,+5L<495(6P"- &'6B2X;(?6F#T-K/3H\\C(>@:Y_
MS;?-%'(H75<HPV_I[N;1Q:.$UL">2;;&CHOK#).'2;\FP# :)$9DTE\\BZ:G
MKNGMJ>%"KT0@&EI3%RBD=YG3JF]!-O>B9?X=PPR[5Y@^M?-3J^8JQ//O0@UT
M<M0P*SO@JL2OI'.',)+_*5E>AQ%A(*W7&*<U"D?12>093>EJ'1=)_&]=5KOL
M5(B_(2> %\%PV!-R0)].IMMK:7%@%C9PZ,Y409*ZR_)&QO<AH_CV93*)_RSL
MW_'LK#J'L0@>'L1:8,4BET QE9>?Q+KH6;>ITMOQ#[VGMA?QOTF+G)$^Q -7
ML+70W!3V2+KE(M8DVCA6#Z9E*^L49!"\SN@EJ2;TR9?//SO[BZW,N$[__!^N
MY7D8NX;L[=GJ=3-_\86./CG,2@G(5:!8H7[[L9-S9^OVI^L:?$4B&VW75"5.
M/E!;!.%>2']ZI6?W&SD47L8MCW/VR:M7;UX^L;-U:-NW#@>;O\$S/@_I&X)C
MZ=WJ2^3S[*_0*[A'4/=!0>T,+^ZU8]G<-4N*^".5O B5LHI[;5-C;XB5LM/"
M1=_N225-R@_$^RP&CB7#G>AW'%SS=G>;4[Q^XH:@%P)BG?>AG1QF'Q54Q/(_
M[+\9@MJ?5&GWQNC,.!]H(B<SIA/U(P^FS9?X1:_>_/A2_:+H9S&K(S)ZN@+B
MP*3+R7#$+S%XC@]ASSHQ/7"RT:><UQ7L2MJZFZGD@[N=MV#N'N9!R@J18Y*,
MXL0;P--P$PUU<Y?Q4D-^\- <R)&./A$VN%R,I!!*/J)K9)0]U*,!@YQ&1JQ_
M/SCA2,%FE;BGFXO987P!9DC7 $/33:%A.O^24L8$^)I.G=0GXM=_EGW6O> .
M$IY*C_[E':1D5_P^%ZTHHQ[9RI^(SI>?' MU^ PTN&4ZI5QRA*L66G.01*0*
M,KK=1Q? NJ./3)H*[(9)W2?=RU(Z.> ?812[-]0B3T$-4K_LIVD$)G!$'D]%
MN:&'$X_6A\5P#*X1+=*!>R LME?6"NWRI-(*I76$0*>0E<.I.R+ V? &S$O_
M?T#2Y81*N7]^+.6>1BGW0TL;OEQ'H]=7%E_]*QZ, \&;!W3TSA40$_R3$]R;
MBHFGK)N7^%HNVWJCSE**UDZB5P))T37S8^4LL^0/6*J[[5)+M>1!+*YBJ5'1
MPR+BGII/FOC]?'H*WY:MDB1<@-$S$+X-)P31?AS/T/0\".HY-]! .H^:7IO
MS]];4+JQ=. $][6)H<=4SIF$7J%AV"BT&*K#X"J.[S!)ZR/JTL*SU4>MMTW6
MU#%"H23(IM1"1HBME1=F,)N(=9T@7ED[1*R=<@:?U+;,^/CM3@I/^(/VF:?6
M3>L!$O&"?H0KT?4<>7Q(590;ATV\V59[</UR/#6P[=AXO4WU7ZO0^ZR^&#87
M29W:,$W:C:*!%@MD0^-8LG(+GS-O(,!!7Y1VEZE=/KTAA:ZZU&N<2*QVP6W;
M:)0X&Y<L?E9GU*4I9Y;-"\7^E_'X#!3GG=JXIBR5&'WC;S?*O8Q,8%WVEZJJ
M7@<6FYAT_,&?&4]0]RQZ%'U%HW+=54-XVFZW[&=%*UAUK%\2O=N+D#?SFTU(
M+M<ILN)GDL72HT\-YJ4PMZYYL:$ST:F@S7KT'URXH!3WI0_"1&XVNM'5?X\J
M'%!-RT3DX>ZXYDCYH_/H<-]8C_<F<<*_N>Y:M,2B^$(K.9YN"/Z 32J;BS%:
M9!;38%$944>6VD;BKS&JT:EBB5>'7(2I4(L U4 39N+!S?7+FGJ24;AQ?M9Y
M:,*V&I10QA]BJG.NP5"\U]GJ.W; RTG43CS0K?X\S=1Z.4&.U@EUT/<C8DIM
ME:+DYW#0I"T0>@PG5MP5"H/A?"B$?A>H!.\G(GO8QL4@7!MVW% @X<PFLV52
MHK=0,&W.-JLL_O.H#P%K- @T+OMH6)525SF*!D()<I]='"ZZLD0LD[0&/:H;
M0N,GEH2SD:0@+,ABU!VJ*1(S^Z[X%(3>QZ7[J\!F/R;S0H#T5TS8^Q,E@$X0
M@/>S)R^6$H$1&&L"_@K%NEK\6E&Y"AYX0-4TOQV6T0G$Q2,%P/W81=^C%T[=
MZ8T+I<I(S1$),Y$V>UZJ=U5Z!/3\#/=Q7=_:1<&SP_-6$:[G+571&?*CD\4%
M(9U'L'7'Z1#:-#L'Y2\T)3UI*5#FKVKW9,[*=1CY-$P52#+,Z>2$04G<")3$
M&JA8J,\ YXFL$I7)V^V [%K\#ZEYV2:DITC6*/X#M3@QW>YF]A!GJY=I>J7O
MHW>W+%:'=K2#Z#SU_?24JCP@W4N]!OV4KYL*6F1CR2UQK-[4GH"E39?5=<LP
M(EQ&JX-,B(ZOJ.3=TF:JFKB#>+C.#X)AY(Z2$\[U,2A+6%2V.53^2/+YU(*Y
M!'+WKIA6@R4:ONC::P+I D(A!4?-1_NV\A,;.\?A/R7P.\ZMUFJKQ$);_HF-
M7Z9RX3.K9+R4Q%5;O:H3E"-TL2(1JZ 9)QNTG)M>N*T7U ].;>"4!U(C%>J*
M@RB4[V,B[,]2:SYOW) 8NX=X>/+.G3%8?D@^^HT#EJ@Z-2@T]43V,7*(\\DM
MF,;:=^SPDZ6P)-"E'9>'C&4:O;W&B'J3/3\A-,]?'M$\IX'F>0AFP)/FQO$@
M].B""V?2K2)Z!S/A=1GI;T3ED-<T;Y5Z^=#.#/?*-3H8!Y@ZLD\G=CRX>&A_
M>>A)L+ I5M&-AT(8&7[NQ%L3[M38/!(9@*T86Q4+RPIC?&\6Q]B'[5B?VD*@
M=#MIE8D$V<&(5W).BI2HT=@.P!K7\YZGW!.^[=[,OS:P$VAJCL7+XS:XSJRF
MA^15Q7"\4UL\6>B6%$NAY[D695C*O]#RR,CCT9&PD;_UCIS.L<1S)\:I#>D
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MXK;TJ6$>F!V&*;!D"TQD<5!'H:5&-86X]?IA+G=E]1:B-NJU']&2W@1T/?8
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M6ZR2C!Y3'"W=;H&>,-Y4QST:T@LJ6I>>N*T@+NIH7P' W$0/-7$V4BM"V3-
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MW_2 (.VT<:\#RX>0Y!/KVU"WBCZI:@#<_JR_VZ.B>X(-KC)U-FM"Y"=V#A%
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MOJO25!-??.(CUU9M1TC^X SJRYXCV9Q!^5G!E,";B8+!GYY_\LG99XEI.,[
MGYZ_^,+)&A"EIT2D+"-&N^,?<1Y>VUS^G>?R(Z&G_L?KO_=*35TXK;#ZP &4
M7HX^9XUW?_KS%V=?V$UY6\53EP0/2B)7[H@8:R78@$M$*E33^XP#GS]]_LG9
MYY-OK\NN.T1+?4U&BW;&EFBH[2GD1>@9;K_/GY]!?^S&@=W.1LD6MB[B^/T_
M_>7L63[<+\X^U5_DHU7<>1CP>%X[A;,C>#GE]DN;*1L9;825FXP-0.*0*J:?
MRJLRAK;*IYQMP*,;;SKG6<8I[CX1>RTDT2,5VG[UR><O<.-//K=2[?>:Q_I1
M:+U?M1LXPL^_^/Q33HU(5S/XT9_0GY]\S&%K"MA@\7&SBQ8V9_7$"7ZAK>\)
M'1/.4GC) @JYABQI,9($YK\#?AU/C*?2&HCQEO'X]7:+J;4EOQ5/];;G_,9J
M^LPZD'14KM<C9/V"Y.&2:(F("'ID?]L$(T[(Y9$ZXD,B[ODIT,\*W8;-YMI6
M-M"6W]$(B#-O/<8I/0'U^B;=P6<L!,/$%VA5_O_M75MSVL@2_BLJ/V5/88&X
M&9Q:5SG8V?7&Z_B89/>\RF@PJH!$)&&;?W^FNV=&$@@L'"X"YF&SB2W0]%SZ
MZ]OT%U*C5_@0MWL8A&349Q//@H=,[;L48PJT3Q*]JK%'.1%@NO3#K-69AX@4
M5X4(2.J\^L596^?5=5Y]_;?[H I&MKV<4W RJHFM:H3^SE2$J4X,Y )E:&NI
M .3A5_>B^I, W1\\^Y1$609* #(SJ"9]E)AC.NY;HT9;@G0]!HP)US&Q,XE"
MUTET?L :KYB_2I(E9TG]-GS22$$++E)^V/\"8IBCL8T%#/2E9+\,[1?Z=,9D
M^@N^%-MEAG[L>,HR1UR42%Z'XC9HG^M9\;TP; (SU-3?S:Z984ZED3/NA(G!
MU&"&M!J\#>%C<!W>8Z(ENF <^RC-(AFZB2-^/SS_1447N'#\KYYJ&2D&21B;
M&J8?9(Z2CP.J02 C^?;DQ4$+>)^(8ZM7@D3I+R^)_I-8.QFG(_I)^UI^W!$U
M8S/VJW4&*R8W/G]=JX*X/B.%C$:/!4K*7U,UVB-[<CU<ULQW5"LS80(1!*>^
M9*J?HIP<:*< M J0X$BS 69,F>KHJ?I")3J<\1^EUD@(PS_.=X5#'%LP@R!S
MC/M@[\W-*?D)\>K@QL,?*C:11/FF,IJ)@IUMA=QJQQZ_S&D_0$.XSQ1(.L+
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M=&&A2TR@=-7;1@C%@E:K*2MFX_82"[ 5OO9+U?B3V<-H\ _?^7A34]0??PN
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M.A3:#?C3H@"74X[63S'/7?(X>N%HA-@$C <9!,0#ARL0'<>A82!(,'@$9>%
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MB*A\GUQZ Y@AV>HVO+A.^UTUT':\\F89HW8&G?" KLXC>TJ*HR$[+[43VOK
M4Z]A[&_B&I*E[4.0AGIIEZ6%\711+30N7DU_^UA1G8T7QY7%KTK=G6,DDI&A
M5O*HY&M8$&P==!6 !0TUA"Y2]EFC?BNT(<U\]&%,6^VT\ZNXO.3:I0HZ%5MK
ML^IZF! SN$36+CCAE&3"">PSUG,%QO>4AP9A+":>(3N;:B6/!D<R0HH82]'2
M:>P3?3Q8'OK _O[>?/W:QP^3)8V'8PCXN?GZ%:=8QLN1C:($[26D5+".GVOP
M24;@3"-+5BO.^M1XW0#HCM%"W^F+UOS:K?D?;N:S%C ^F\P^])GX_'+W[O.>
M-PC2:-J3Z%(?\'H^>S^FN_WZZ1U!>3[]G#8_3LOQ^_5:4TXYLP^Y@-&L!@_)
M0RR.UT76(6NMH\U]%C)MC[%M,(%9RDB246^I4Q7"$-$I58+BM3!"E6)$GUF!
M;P03#^Z\>K#EJW'!>ZNAW<K5XS#'7\.J7YY4\[=JGI$6:%)RD6):$DTQBFY#
M]AZ$%%QE2>;4](DO-^,95)ZZ'VXT4$PSDCS%TSFF\1I!,08U4PY$)F>H;.(0
MR.N"#<EYRH5<Y'WJC"^C&%0:NA]"W%L).].@Q@TUV:Y27D34%YEVD*4DY 72
M:@*C4+H=K5' M$E1A\",U[=%(=^X_Y!*[#KKN54K-U7WU<K0"S@4_&85O -;
MI *53 #'5:2W5A>E,RN>WT7I&Y\RI$T1]ZCZW5N\Z3AEC4Q>3=^&";XJ5VK'
M/Q>.CWS46B8A*#NJVQTIR2&R%($%GGBM0Q6ZST91V^';AD=FCUGK/GQ%!\VU
M'.V85VH_Q?7K\^GYRJJGY_LH;EQA-3*6EU0WO/*AU$VUM(+ /9E IX3S(B#9
MEEZ#(?? NPWK[%^,=7O0;$<67MM58Z2#BL6K M)D,KFZ1/ B,D@>D2DODDM]
MS-JMT+;AEOMK>,8^ZNK+HFL;<5RP_8MCO[2OF0G:1^D#"&_KOF8F0;!UJ8VU
MD4OJ!HGMRZK=#?DV'/3_#SC82]D=*7K#7B C:SD7(I(=%J7NO%4WS<+$*!JP
MFL>$7JH^D\Y;0]QJB)#]U5G70G\]Z74C_UG=_C@&#4G5 4[4E,1DD4"@T"D;
M93COLQ#C#B"WHMA?;!BZEPX[DNR;AT^,,&>=!*L'V9!Y59X,K4M<0<&0A<B\
M9+FOT.V;0+<BVU]L7+NG+O=8H664EAZ)^!KKNHWB!35!0<C4.5 QCSGT68G<
MI$*+R[]8ZME68>UV$";1K^TP] 87R_DX+3&?[T!T]8-+5[[&^;A6IUSO+VER
MEE?+D])QF![AF[#$WTB2M!P%'X,0SI)DUM:-QQDX7O=R4T85EDH.UP?C&^XC
MM3\Y&\Q^;\M)78.FB 5LJJLR0CVW2"H#/FG.DN6H.BV+N&\MP,/.FP^8[QOF
MWGN0H&6]YR9\ZV*U:_@,D\4;#4QS<I%UBB@8ER%;&S+7TKC29Q!A>XQ#FL#_
M_DFZ*PEZD_39>!JFZ2H^X046$Q"TK(>-)E_/#XQU19+&E)*5679:R;@UQB$5
M%7S_)-V5! ]!4BTL<L("G)&Y5RYPB))"4%MD=#D:Y7*?93KW)>G=6X,>D1#S
MJ@KZ^6)Q5@^N?E4N'TB468G4" 4X*1^4(2YX814X9W7=#<20,>G2"+="&U*H
MTXE5&_9K:ZBNEOOX;8"UJEE;O)N2(LC8D"4:OZ^3?9M+V>I<].*S35K)\NIT
M5<X_"D&@JYO8B[IC!F6"'(*G5M-UGC":2+:JS_A-5[&&% ,]*'L?@B:=F7_Y
M;.U1%C8'74MTHB%G&I0C/QIUG93DC$M,7O59 GP[MB&%. _*P7LK["$2/)%0
M>40/QD5&)MXC1(P"4+M$EC\KS-T*].^5X-VC6X5/JW4@?\P>)PIDYWCC1J4C
M0U[-U^I'J30'DIW7J%5#=IBU*AA2IZ.WML<XJ(W>.A'MJW[61X-=#/?GJKA\
MEE;>9UV)E 6RJ!)ESM+7#3.LJ,=&D=4)3FN+*8I.,^"W8_L.@H?FA&JKL&Y+
M]-[69IM_FI6WXZ/IN(Q3I?NZ.HD:X_5L,JX'T[W!-".W-ED7\*^7NUU+V\/U
ME/YI/0QT<J^5??U![;H@<,_-UF@=X7;'1G";!3,J $4GI2[/T$"96(U74E$.
M8W2ZS[3!/0[TN%\;C+C1D>M2.YR(H JWX UU=(JDA,2<I.QTAE-]^I & MHS
M8M-1)7=J[V8^\^5LBI]>AOF?N'QV-LU?2>56Q]PK!L77<^ZM8Q"SJ7NH^""X
MB:K7F7^W !N2M^S/CY9:&L;4]T@$GS7E=E"PKG>).9.+K]6\RA;N/$'V?189
M[@1[/Z=%V<01 RL4/?-Z)I%S$+334 3%S>@5$Z7/^.QW=UK4_CAXO].E[J+)
M9AWSJL CZP-9&"G!9%%G?F2!R#@)K54N612+(G1ATU4<0[/8#T.;'733+;U9
M51DOWJ9CS&<3G)67X^GXY.SD\='1'(_"$I^=+<_FN+KJTKG<.Z0NNSUPU[2D
MH;B-4HX72,DNWE#U?3'J\K3&$#QRY;,!24DP*,\SQ!#(V7/&O$6>N.E3![(M
MPIW/U?[6<]Y-\WBQ2A_K0K-$ESX^J>]&P7O-73%U1KMNWZT=>&8T6):=3"H*
M;_I4Q=T+[I#\9Q?F7;=Y_97:^UCC$9EB9E(LZTD)LO,%7!(2,'BEHS*&NS[C
MACNLD]G;0=?[X% +Q0S3@8[XWETH/?)!G>AUD??M1J4IF&W-E*6/H+AD0!&=
MHA:6WD0=A.V4>P["C5YZSG]CF#^;G<U'E(8H++5B*]O53G@1G*&NZ8JPK'"+
MUO69T+XKTN_2>=Z%;W=RGKNJLIG?O O*/S[,1CEF<@*10$:RV,I$).>>.61A
MG+$\!%GZ;'QY1Z#?I9_=%]WNJLC]LNT-GH1QK4!Z59Y1A!DF%?+(B"23IO##
MN1 HX:[')U+:#5GGA(SS+#N5%MP?\Y J>H;#P=W5^S#&CTB%H\2L+(QZC0VQ
M[O'G:VZ##K#N.6N$%E'TJ4*^,]0A;<\V'/+=6YE[Y]SO%%O_\0$G[_'E;+H\
M7HRH'PCDB!#H9;W1G$>*%K HSC2E8<'T&0V^+^(A[1(W* ;NI-INN?"S,)ZO
MYCY>$FY* 5=H/U>"G)=^ALFZO"=,+V^M<OZ+'):?;[+#(',?(+OFS7MHGD;9
M]!K"ET>1DYW,*H 1DURKP@(PN=J:-'CP2C@(3*LD,B*E&5U,R(V0^DS+;I)=
MLR*=I<1*A(1U&15E5W6S#&9\4?40(M:I4'=KB$/*D-MP:+NIUUVUU<TB7E3)
MADL%LK_C\G.GW_3]#G9OE\?M:MV:B=K(AMU8H%Q/$8L>4R!W#'%]TH\H]60H
M#US:PI+UB<5.5>;?0-6@!GKSO?\YKSO0"V4*=;@"+*NZH(8ZH'?"4B\,*29G
M.+WN5^85KB'9K&:<V5#MW$HUS=*(QRF=G=2VQGQY]W'Z?X*K]I_FQR>S^7+\
MO^NE6C<6_-?#*W,1&233CBQMKCLH^ PZ>HEUVL>P/D/JK208U-$WW3CX(/KN
M-^\V"Q0OY[>8SNI94(^/*!U?!]2WS4O1#S]G4CO4L;1\_LXS<MT:HY$SK@OQ
MGD\7R_E9?=1%G=SY;+]U7+GH!5"@5NHZCP"N9 E&%I36H&&N3SW]MU#M/$AS
M:0GBR["L>EDM>#@];^VZWF5,^=YIF#R?UG3^S6Q"]SJZDM6CTS:'XJ!NK%!'
MV"6X5.=SDLO%:<Y*IVRK!?HA.?9F_/MJP&;?:FXWBG@7Y.>H+V9^%$\AD2(
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M8?(6IV4R/7\UF9[-/^'TYKPT1HY&1 4Y6$YF"69PCDEZPUABM1$.MVTJAOI
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M:\C9,1ZRS<IZ.O$D;U-&<E@Z/&(+'(H-NTB[]_;"YXL:\=MGX.K0JA5O2;,
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MZ^C1U8_K?VJB]G_\V_\/4$L#!!0    ( )8[_5+F.$K#F]   .C>"  5
M979L;RTR,#(Q,#8S,%]L86(N>&ULW+UKC]RXN2[Z??T*GED;YTR 9D82*8G,
MNFST^)+M!8]MV$ZR@\%!@=?N.JDN]9:J/.[\^D-*JEM7E8I446K-0I!QNRV)
M[_M0>DB^UW__G]\?%N";*JMYL?R/'^(_1C\ M12%G"_O_N.'OWQ]"\D/__,_
M_^5?_OW_@O!___SY/7A=B/6#6J[ JU*QE9+@M_GJ'OQ-JNH?0)?% _A;4?YC
M_HU!^)_U3:^*QZ=R?G>_ DF4Q,__M?P38XID/,XA1HI!S.((,B8HI(H@%451
MHEA\<_<G$F/!="(@04R9:WD$":,<LD32G#$:<1;7#UW,E__XD_T/9Y4"1KEE
M5?_U/WZX7ZT>__333[_]]ML?O_-R\<>BO/LIB2+TT^;J']K+OQ]=_QNJKXXI
MI3_5_[J]M)J?NM \-O[I?__R_HNX5P\,SI?5BBV%':":_ZFJ?_F^$&Q58WY1
M+G#V"OLWN+D,VE_!.($H_N/W2O[PG_\"0 -'62S49Z6!_?,OG]^='9+^9*_X
M::GN[,Q^4N6\D%]6K%R]9UPMC/3UTU9/C^H_?JCF#X\+M?G=?:GTZ<<NRO+@
MJ59*:J6,,ROEOYX;[*<KQ \D[^I8U@#"U>I^""5C%Z8?@HG[U?"#&E[@O6&N
M%KEYH=XLY5CO[G:HJT4?7N)0KT6Q8HL17HO=,'LB+^POWIN?VF'L@SK(M!ZG
MI>X]4=7WE5I*U;#EP:/!7/['#^:GF?JV*&:?U:*>:L-/3U]+MJR8L.S]JEA6
MZ\7*+);FIU5I?FG>X8?YLJ;V#\5J+I3]Q2R)N,QYE$.$J5GE(IU!DF,,*6<R
MRH6**5*SU?;UGZDE_,N7C:2U.,%D^<$#K]69[[Y45;$NQ6[%?%B<6@;-"FC7
M3/+3DCVHZI&U-QB%[.:BT?$_]X0$RUI*\%A_4*#00&QU JPTJMXIN_?X]Y]V
MN P[;XLIS<9BV(EH%0&U)F!/E1NP4P9LM+D!^Q/7*-3\;KS9D>U>M/[]5&;I
M0*C?\6P5XD#VA=VO%N5S? L1$M]FJ; /A/:T$&4HJA>"$$/\=/0NWI8;%5DI
M+DQM>\5/AI"$>ES!@V_1GGN"8[$J@K^^S4P:57X 12E5:<Y[)V#9?J+K"MXQ
M]CC[LGXTRWG]3B]>L>K^[:+X[=U2%^5#/<XMK^JA9W&"48H0A5',$X@SG)E3
M'!=04)9*'B=)QIG+(N<Y[M06M'VQ@9Q78E%4ZU+5RYG1 FBC!ICO]'#C2]_)
MZ%ZY!H1XX%7J %TK,K R@SVAP:\;L?_?Z\FM)U"[/6]E=*Q1TJSBM9KM(W^R
M#/>36JRJS6]JSC,?3WN _U??L4=AN)Z ;-BL[^T]F>N>E>IG5BGYJGAX5(8V
MZX?O=I(_/^TN^<2>[*]N?V.E?/-_UO/5T[NED:)>S*N/JWM5?KUGRX^/]A'5
M7U5E^/C=LCG[S?(TI40Q#16GD=G?1RGD&:4PEQAC0XNQX;[9_N'K\I<YDNA.
MG_;%\VG(+[R1#_PX7X+*:EC]P9,AQYIT1XJ=TD2.Q-%6'VAMDA+L*PWVM ;\
M">Q?UVH.:M5O0*,\V-,>U.J#E=$?M #<@/9=,:]* T) PA]YVL*N&&,)/^Z2
M,_*4'*U98X_?;]%[K\SX]\5"OGMX+(MOM635+^J!JW*&M4A91"0DC F(*6:0
MQ93#3*F,<IEJC+C/%KUCK*EMR[>B@OF>K'Y+2Q>T;JM!(, &)O =5OMB@E\;
M00-NJQW@"$J,7>.-RF4.BC^G'Y=;^C'&6S8O_\H6:_6+&<(<5>LG;W_YO^:J
M-(^\?WI=/+#Y<D9QS##**41IDD(<IQ*R)(NADABI2-JC?NS#(5ZC3XU5K)R@
M%A1L)05L*<&'V[^"7QN9SW\O 6;#C78&PWA@(KH.7F\ZZ@534(+RDV!4RNH%
MSG,2Z_>0?K3V0:W>+47QH-X7535+<JUU',=0,F2MDYF"5&-M#NL)216F),[E
M;+5U-5[\I Z>[D5+9[RF(;\;(QQ8&+G\F.<98#I75.8*)E@H U,:098E9NNH
M>9(B+"5/O<RY_0$;@<=# .9&Q;UA&)AJ+0*-8.!'*]H?P.UJ5<[Y>L7X0H%5
M85U-7<Y7;[8]B410-CT<852V/*G<<S8\?9$?VTDUG[U9KLP!\\V#*N_FR[L_
ME\5OJWM[1F7+IUD:(R58I*#0U/">IC&DA&-(L"2QS%1.4NGR&5\89VH?=",J
MV,@*&F%!*ZW;9WX)VNX//B!@ W_Z/;%R_N =D3CQZ5=*_/&N^/:3>4+SU9L?
MZH^]_LPO/7>4#]Y1N<VG[WJY'PG43N)?Y@M5K8JE:FU/U=NB?*V^J47Q6)NB
MEM9N9085<[:8_[,V7GW4[^="+:V]JBSD6JRJF5 HXN80![F*",28*,BTXC#F
M*L6:1Q@Q)Q-1.)&F1BU;I<!CJQ7010GD3J_ZB"*>:V8]P(M6-_#8*N<1+1-F
M?KM)ZV5F;6!^VTW81B%@- )[*@&C$SA2"GS48*,6^/12$^81Y33ZQ(T4[#3.
M!/I%/ 7%NC/P*<Q(X\4_!47F( PJ[)/[614^/JJ2V9"KVA[[V::V?-1_J=1M
M5:G53.02Y3;\*1,H-ZLGTY!(3:'2G A$1*[2Q.?0W#G:U!;&6CR[RJTK!9B5
M$$!0;#0 "ZN"WP&[&VRW W<P" =>I;9R@EK0&U"+"@L-C;"@EC;<V=L)E*!G
M\>X11SV;.RG__*SN=E./;?N9V,[;Y7+-%K5#F3]W*+=NXS^;JU>OS<W6@/H+
M*_^A5K49=99K8K@F,[2#<00Q0YDY[D<")DG.%>(LB:F3BV8@^:;&6[=W=V4=
MV@3NK,1 VA^U=3U\L^)>']!^S5PZ[-=?=H8&IL6.0/=&P:XPHFV@4*THL)J"
MVJ?4Z-JXEEYV?J]/8AAIGE\^L6'H^0Z2\A!@-OJD05PS[(NG1@3 S"5=(L0P
M_0X-G\R,JK)4\LNJ$/^H):@^KE<V+=QFVL_RU"S-R.8'<L8@%FD$J4@T3#0C
M69I(E4FON*P+XTUM =Z*"RHK[PTH=K+V#P2^!+K;\2$@E .OE#L4OS0H-L*"
M/6G#'2 <80EZA+@TYJB'"$< GA\C7&_KQS.--_&+6:/KR(I-D8G;[_-JEF+)
M*<TIU#@R')-D&M(,*9AA$:=4Y#8VU(=C.L::&K^T?NVMK& C+/C5BNL9H-4%
MLANG!()N8#[IC9HWF3C@$91(NL8;E40<%'].("ZW]+!"] YN;S=.MTOYH6CC
MV8_BW=]\MS99<^,,1RF*HU0:UHDCB'6:0\8B 2.5I3I%21Q+)Q(:4>:ID=F'
MM0WYM6;69E=D=DN-.K77L:BS9%23/L.LLA50&U7\]U)COAL.EH[IS?C '.R4
M2O5S1RK5YDA<.\@^%)O<J5,)5EO]I_=J>!A)IO>*C&0XF=:KXF=+&7?2.NTK
M(XDRGLUE7&P/[# C#^VW[:G*U>RS%:1-X"(\%9SQ!#*E,HB%2"&+,PDY3E(F
M8\JS#+ML39X]=VK;AUHTS]24YU!UK]17 ##T:FHYN%K-!5N O02$@)DD9W3O
M.KV86_9.+N9OST\MSY\Y"G6<463S>9_[Y[ZQR[=2FHFNVC_>SY<JGL6"$9%)
M#E&BS%F!V*J@:4:AUGE,XP3A*(G\(I=/C#*US[.-Q6U%O-G\ *RPX./2T5G5
M#6SWYQL,KH$_YMY(]8A;[D#BBJCE4T\=.6:Y0['CB.6NBWL6:!'W2JX7ZJ/^
MA:W6Y7PU5]5'_;Y8WMFZ5:\57WVUV2=?U??5ST;P?\SB7.DT3S4DFO'&4<)2
M3B%#<1)E*J5QY%1(L:\ 4Z.+C?S6'/#+?#E_6#^ 73C#V_7*5IYZ7[#E-G+2
MLYB*[P2Y&4"'A'WH/<0^XEOA[=^L^-!,^@.P"H!?:Q6 U0'42H0L1]43O[!5
M1GR%&+=:2$^(CJI^]'U.#R/L;1+%]%6IY'SUEHGYPG!NN^-.5$S,-DC"%&<I
MQ#@7D*A,0*%Y2C'.F$!.R9C=PTR-W:R<H!$4;"3U,$Z=A]/!U!@$I(&YZ!0^
MEZMT^ #E87@+ MA(MK)^P/G9M"[BT6F&.G_W>):CBQH<&'LN7]USCZCN[!OQ
M63T6I8V__50LYN*I^>]NWR$R@@6).,P)S2%640Y)9@B2)C@E&,E8R\QK8^@R
MZM3XLA7:=X_G!+#CQBXT;$/OYAIYP5;@&] ("WYM_QQF_^8#4]A-F]/(X^[4
M?, XVIYYW7QM&=&-C7IGP?Y0+-7#XZ)X4AOCJ$YR16FD8$03;1-H4\AHG,-(
M$I+H/%5<>J4 >8T^-4;:$[!O%4\7S!W):2@D1W0";SUV.]%OP)[P Q1IZP7;
M0/4L721XH:*4'N"<KRSI\Y!^9&9/K#LOVJMB^4T9XC0GV.9'VP?L4SD7*IXI
MDC.9J@0BKBC$6F>09E+ A+(XQRAC)/:RM3F//#42LTFEQ;*)309L!9CM2])*
M#!ZMR'5@C2P6"U96MGU)$V3C&:_L/C-N=#<(W@-376TYVPE=-[/8B+WY2PU[
M+7DXCO/&*BB_N8\^*K=Y@_*<U_P?,+4Z[V^+4JNYM:)7?U,VYU/)6R,YNU,'
MF2)-*I=B6"F$-&1IGD),L@ARBA*S<FO&91X)G*%^.[^75&MJ;-S*WD8S7DNZ
MT\#XQ6O)#_5"C+@S'K;2_!Y -V #$6@Q.DHW#)1G.,UY_YV4JO=2[;])(?L^
MTSE>F?M>TO7;$=Q*.;=CLL4G-I?OEJ_8X]RVFJEW\G7JU2S/N8JQ6:.IK8"/
M$X0A39,(*AG;99RD>41]5NO+0TYM)=U)#!Z-R- LIZ(1VF\-=0#;;7T+"^'
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M5N!_ W%T$T7U_S=%2]EZ=5^4\W\J^6]@66Q^.Z\JVZ:S* ^*FC86JO]:+Q5
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MF'MW6CB)IMMVZGJ,!O[&-P+N6FD-T4"A"X3 L>,GAQHY8KQ+W>,X\<ZK^S'
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MSS5?--771?&@9CRWC>#B!!)ASF)U\37.<09)*A/&L@1KYE4!_?#Q4R.IC73
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M  - /-8&/AC4GEMO3\BZM\ZN#QMQZ^NIW^'6U??FGLV_#TQ]KUA9/LV7=TW
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M4P69,A^ETE0C;,X9S&^I/S_4U#[+5KS]*M2>D?,=L#JZ#(. -;1W<"?D#=B
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MA4H@SG,"F>;*G-5R$J48J5QYN<;<AIT:370FCE\14.LV!V[T$1[9H2W;'0$
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MR@3E&F>(P3CC9N=.D@S2+(I@GJ:,8*4RE.J>C25>6#4?FAVOE\5?-GRZZ;O
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M2)4Y4;$810E/<L)3I^: HT@[.7[;4]:3P0:=5$<"G,I4#<V?>WHVM9*WFMZ
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MY!PI9&D0=)%"H)U4>*6H:!]X+@=*>[UEJ)WU^R-;+'Y]KN9+97O_4IA+7DK
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M!H5=!=Z[9/L%:Z%H/I)8,))=6L<$*O7>-H_3J-8[< P32'"./D'!JO;>J,;
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MW+&FSR]O-R#6O2F](>2,E^T;$)6#1."0[QU:[N5>2O.UKNJH]H?UY_7JQ]P
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M\%90_?R&[A#UN@\=7C.>%]%]3 ?.1(_';BQ3\G9>B<7*YM'OE4S/# ?G"N8
MIL;@@R07@-GD54U5*@N4LK2$@TJ/G),V-3J^4$YD8*F0L_BZF7K!4(M,O7N
M[6D:J0"]$RAQ:G.<E?@Z]3;Z!G^QAD;O0S=?Z7Y>JZ?FK/I>J5V'O(?E9T-A
M8O[$%K-"8JG30H&4V#YVD)2 6K./I8BA DFJB5/JTR#I4Z.9G<:)5G51^&L-
M(@/,@/=5<%A<1[X?WH/8:+_7@S-Y6";; <3$>_!5<EC<Q[Q?GN_P?[KT%4]6
M2_/+=B"A I*' NAQ%^WPTM>ZH'8?;\^MM<=+AIF=;9N3ZC-[L5F?;QI_PXP:
MU&DJ.$C+TAB=(I. Y\;RU&E9Y#DO9<F]O(SGQ4QM!^BT3)X:-?TLS M0NIF6
MMP,4F<JWV+0:WB6MCN$LR7X,@IJ0%T2-:COV#_?8:+SRZ0'6XKVA%:GDF[62
M\\U[)JR#\:5K<,PE%8)3@)2@ %+( ,7FO%F66J=4"R(]'( ]@B;' (VJ2:-K
MTBGK89'TH>I@[ 7"*C89G(=I2 &E/KP\C+5 N(UDE_E^S?SL+@<L>DVLON?'
MLZ8<1G%@.+E\?@!+_FTY_V&(Q[SK0;_Y/A?LVZK]=D((E2PP!H)S!&!AZ)&4
MN !Y5A0T)7DF4>K,D1?%3(TA=XK:]/16U5W7;(^5?QE9!YX,@E=DECP/U0".
MO(R4!T,&06PD?CR+7*ACZ54@>LGQ\M/C4>/5$1P0X_5/#SLZOJFK ]5U$4[J
M-<U$CB!FN 24D (8IJ2 Y.9O# DN"B)3KKW27?N$38TBW^R53;H[4R%N>&FX
M7LC=#IJA@(S,G2V&;?F31M.[_6)OX8Z=+H@$/7SV"ASU".HR]..#J-,SPQBE
MCIS69H7>+^7O:OUC;K/='G2;^,86.[]8]=5(J,[_JDT:X@PR1(4&B*000)41
MP 1!H" L4P6&6L',AX%"*C<UQMIJNN>LKSRSN*),HANGO=;4Q+[&'38KW@08
M [Z@A!E4P5$)-@:TQX0<1<: D_(;6]2-K];'P=-U4^,,T]RPKP8Z$Q) RA!@
M,M,@)Y@I1%AASLS.A^4^25.C5JM34R]X3^>$[93V. ?V(NQP: Z%6W3;;Q^J
M/3V]NW/W N9Q=@X%W$C'YZ$ ^IVC74#I/4KWOF"\T[3+. X.U$X/#"#03ZOE
M%Z6?E])>\/SMR:A97_O.2JD(1S('!:0<0%(J0%-"@2S2,L4I-N:L>^>*"T*F
M1IM&3;#>ZID\-XK:J 6/Y7\)4 >J# !39)8T&B8[%9-61QM7$P A#VX,@-1(
MM&@1._^="N5:O()%+QM>>G8\(KRB_0$'7OOLP+)YJ^4WRZ(V".8WMGE>URDO
M7[H8&&.Z;N->/BR_&!HVENY_*K;^:I!5LX(CG<$,@S0EYL0O!0,D@R60*2FT
M1ARAS"MHY29MID:HY@L'/0OPW309;B?WT2".3,9V'&!C37T[DKMD-Q;;5+$;
MC3T';,=C$XK:$25V2$D]IH"U $- &[9NX$T:C5MC, 1X)_4(@[QT@&%YH3K%
M_7+YS!:VU-B;U;)Z7M@L9KOY,Y1R5! "B-"&1S.H <]3!;*42*$1Q842SO:F
MG^RIL>;]MV]K]<T,(&&UPDTI0[%5V=,@]9P(!SLU'KR1&?-B<9N[I%&^*6RX
M4]_3LO6$VL/@C0?Y2'9P6.C]+.1AX/4:SIZO',^>'C;6 S-[X"L&QH(O-_.Z
MN\_\A_K==NRM]Z=W/\7B62KYW@S.EL=X;KZ>#_JXK\K';24N)0J(.-9 XU2:
M#:2@@'!> EXJ3&UY(9E+K^CQ0(I-;G?9&U>R&UC2C2RQ7ZAD;VS6@#SM*71#
M4;5@4^YF[K_&1$;>QT:=0_^0^L" APW"#Z7<N&'[@2$]"?0/_?ZA-2XK<_00
MW^^7\JWZH1:KI[KJ45>+/RU3#A$B(%>&V*$N2L RF0)-D* ERC.*G.[SW,1-
MC;@[;<VI0"9[^KH4]1^"MAN[AL,PNNT_'+X!52U=4 E<T[)7Y,@5+5V&?UK/
MTNFI ;Z(FJ1X3ZTU_K+[2'^MM:Y;Z&^KY>;[XL4&,[#%HG:ES K$*)42@R+'
M!8 ES@P_%1!(R!7+4B0U=RIR.:+.4R.YAZ?:7-FLDB?SRN]F;&W0ZEWRXZ L
MYMU>6V3U3WM^?&Q&5Z<>=\/S.+N/]!UQ<*],;^8C4W.D4IMW7>/F!YVT "0?
M)OWE\' (3>]+,I(C:6I?%C]7U+C3UNO"&DF5\5Q?XV)[X#(;6?3(!;V;37D_
MYMY>%+U?K>TO9XH9NT;D)<!8BJ:T-R$8 :JPXJB$BKA%"L55<VJ&3I/&,%)Q
M[_X)=#OHO?ZT3-\*:8=ZD#.4_&&'F[3C#7C&C#LATZ@$WJ_JGZ,FN!/<P:J#
MNTD;MH%\7J_,X6OS\MFLFXTYI;_[Y_/\J0E"[6H:*JI8R00&.I4*0&-R ))3
M;C8#ADF>E1PCKR8TUT5.CMB?'Q_9^J4)NVF4KUU.6\W].-\!<S?^#HMD9"[N
ME+U+:G4/ 4S^^%K'4D:I+.D.4U"&=! [*MNYPW#,7!Y/#F.A#TNQ>E2V@7)-
MA!_ME!K*:Y/WL,R+C"L$.#'< S-!#?=H"C*=EXABS'3IU6BF5]K4N*=1-MEJ
MFW3J#DRK[(?:C7>" 1B9<F[ SIMDG# )RB_]$D>E%J?!'[.*VT,CGXN[H_J]
ME'/["%LTI[K[Y\WWU7K^WTK.:"$X+Q4'"J4:0*$+P#B20&HFD(!:*.S4U'0$
M7:=&9I^V_GVVU;DK;,&V6B=ZM4[F5?7,S)=O>)&+F-^!R.?KL#,[_4/V[GNQ
M&W%;K"/9C7D"YVSWB9G&8=M!WS_'B=L=^&#';@^1@<_>G]1FQC$6A2XH*#-!
M $385H7C)2@+BHB@*2S]6K_V"9O:-G%PR%:=HG?)4H4Z:5N$&2TA+R0"TL8?
M05(0P/(" 2(4)Q27A9(&X=6&+49&>"ORSX[PC5X,3]Q>TW]AMK >Y,)Y+/8@
M&<=7805.PTNQ-W1G_\3^,X$Y>M=S8^>UTUDNLJ+D )<Y!;!$AK-S;/XF<TT*
MQ;#,G!*>A@B?-(<[KI/;9^!&QKD1UU?UH.YTC]2@9PAJXY#4.06F05H]T#B3
M6-\[!C:'-8*8#4]H6XY5,YF5*2\R!C1B D (C2VD<@Q2H8NL8%AE!/G80B<2
MIF8 ?;4RDE6G9M>*T;?UZPF0;@1T$SR166:K6]<$,$"<U-5QAVW=>B)EW%ZM
MEP9YTISUX@=OZ/F\U^)UU_=U)E/&M" ET+)0  IACCG<MF7)-"M)@7'I=X=[
M6=34[)"F5_%RUZMX<5.?Y_/P.J[Z(*#%7OXU7GM:WNTU>@[<T[D7B_#=G,^+
M&[^/<^^PSW9P[G]B:-GM;?6Q'VK/'=8VB+'!BZO%7+S,$,HYQ*( 2F;(E@V3
M@.6,@#2%4$A88%1ZG6I<!4^-20[TWG4J\&019]C=."4&F)$9Y@C'_:J".ZV3
M1NWDC_:_44XTON %KM[M*'SD2MY^D)Q6]?9\/K!;YJ_K555M\QT19*)$E &$
MF;)N& 8X1P*0E*A2EKIDTBN[U$WLU(CKO+/WWP.Y80X1O]$!,QC'UW7^UFI'
MR3KU0VH<=\NAZ&DX6L["X>QB.?_TK:$GW67BC@7?/3XM5B]*M5UW4,Y0JC(%
M!-8<0-OFA,F, 9J7A28**N@7V.8N>FH4U6DW-,+C*M1NO!0'P,C<=#:N8M^J
MZC2_WC+JAD *5\ BQ45<%?]*80ZNL%R.6G!^PT"Z$M^5?%ZH!]V]MJG]KR[$
M32P6;9S>@_ZBQ.K;T@9"-&EN;U;5IJKCN&>HU$@)+ "5,@>02PFH9A1D6<88
M)H;E4B]_4Q0MIT:"W2#KRC[=FFW'F5R*LC*'INU@[8.[X;99L$D]X#; WC-8
M.,Z7PY&+7WO*7YVV&Z^PK(W--^QIOF$+.R8SXX_V+'5U2OW9/";D88D_BJ;C
M[A$QP3[93J(*&[;S'%><VIXA>9ZK O+2G-H+!B"BQBS.50YTI@O-9*XP]G(X
M7A(T-?X_5\UM8!VHB]BZ<6\(Q"+3YS"PO"GQ&A)!6>VBL%&)Z=J0C[GEZN?#
MWD^T!SJ24\PS0@&CI000<@8XU @PJ J6,2XUUB%N):9Y7K[H0P]S&>%U: Z'
MW&M=/$0X&+N!,LJ%PFL<@-V&[WIY$.2@V^_\FZ4PE3#+%) LM[6&<P@80@(H
MRAFD,F,%]FKZT2]N:GQR_HH@Y U!D)N!"9&)RXW 6-< K^#^GY+;?YB[_T8Z
MN5!1O6L:+'7.<YX!G!$$H"H-FPA9 E&H@F<PQ3#W:AK<*VUJ9'*Q+\# E/5^
MJ-UX)1B D6GE!NP&5+1UP"1P0=L^B2/7LW48_&DY6Y>'_ A%JOGL;5MG\?]^
M-F]6Z\7+%_6T6F]F99[25$%#(TP1  M6 ,YS F1.F"A**A%SNB#LD3$U\NC4
M3+9Z)HVB;IS1AV8_4P3"*#(_^,/C3 L. )PA@TJ)OWQ;_?C?YNF&!\Q?ZN5?
M+_R^=XZRW!T&U2UREX\.=&4L6%4]Z'_4W9HW#^LO\V_?-^]^JK685^KS>B[4
M]I=5^]LJFU%MSA\4<:"L\Q-2H@#A!30VA(2,"RAS#KT\'$.TF!H]O%D]/IK-
ML-JLQ'\EJE4^>;+:5W6I"&G/D.O*EI1NRD9X5HT8-E<9*@J$( <LM]XH1'-
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MOG6'U)6M6UWK[F9'[I+D?_X/DF?9?^R5Z#%+M]'4T^:Z:6ISA2B'L 1E:OZ
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M6I<H7WU>K9740.#Z^DT-?>7PM*+[Y7$$[K8FG+VL7:SL_:TA<DX(S G0#!<
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M_S@_^^$K+I;3^>Q?_\+_F?WE!YRE>9[./OWK7_[V\36XO_S/__%/__3?_P^
M__W3A[<_O)JGBW.<K7YXN<"PPOS#[]/5YQ_^GG'YCQ_*8G[^P]_GBW],OP:
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MN"##<;5<6*0[NGT(VLO?^/%+6- '0?H\/<M7_[I:D"%TM9H/(+F-6HC<O_Q
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M?W'#7BH^)"LU6&[6==X:?(P*6+;6UYZ#JE&I])Z$]M;^XD2H'$YY76)S^P'
MHK;1JD*LD=E72JZ3; F2]BDPX<BK/IF=/.HH/V%[BU-9RD&4U@$>=R].F=1P
MSEB;(-1V'2IG#E%( R87JVRR)N@V7=1VIW%<Q_+T16LM5-?!:,HMG&U&^CXN
MR.R0Q(4%!-;.1S$)<+6;H46KBU$R"VSVW&E/6CMIL'RB,MVAE-:!K7P?OET]
M'TS_<3%=X)VKACH+_OJVH;A2G"?)U0?@M<EY[4V.&@+%;"9DGYS%)G#<G<8N
M"WP'0\O\)*KK(G-)K"3$O)Z ?GT%EB^J /$Z&YL#[6$!!NN+:U$'H#L5(<F
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M'"3Q[G#S=YQ^^DP'WHNO]-U/N$E-7_WP(R[.^:3$I+)4GK85F5"5;&T14EN
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MT4NG$)-7TT.BC9@P0,BQUKV0_??>.F Z&RZ4PE+:E"T^0=2XUY[C0NP0O?0
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MT!L62_=M4C-M]5CLN,4$'%X$_O0'MC)9#0O!OP^VC$G$9&5U[3D=56@@F**
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M,I<^@.-,0_8ERL1E%/?=FBU/;[8NT1,:#E7??'!9CHZ(\W4FXE$^-.?))2Y
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MU<?!.XBV.D7=5:-5+90/BH-P6H!B@D'DUD'P7";ZI. :C4S;3M.X9FT8G>\
MI ,4T"&4UA7R_S8_(_W<ZO=.6RM5<P]>U"[/K@B((EA@R<08?"[B1*AZE+S^
M '8(%KX#L>,5TR'::FZ@]F^YU=VY\(0Q.0V:_(F:&[ 0:M=-BRZ;E((A#^ D
M4'M(V[A'Z(EP=J1*.@#9XWVJ7B_P/RYPEC;3W93S/J+5P.5ZL(DPX%!E*'5<
MO3(F>VQCT'8@;MPGT'UX:D/KL"=8/L;0Y48F3C(36H&0D:*J$!""Y!E<\11K
MI>!THT3\#L1U$IT.!8@=$B'':*=3P"VO]^VE;5>")>MJNW6TB1R(Z,&E2)O4
M:A8YTSGIQGF0)ZCK!')#06*7W-LQ^ND)<T><'K<NV642MA0#0DNLE^R1^ X%
M="Y,,>N*2VW>$P[*QKA](CH[ST^.BPXVQ=V:VOL.]X1V,"<W6@+G(I-[;>G8
M4C8#$U9D:;1VLDW$\S1=G1C?TP/FR;>U1VGO617N7&M@?E5HV:)"9_LJ[4IQ
M=N2L;<V-]&1 <^W/F1,%U;9X(.=5 [.JK"N<3=;-=GW/-3<B%BMK*9VE(P84
MPU#;2'O@405&#I;(IG$!PY^RYF8?O+6KN=E'N1V<W%LO#UQDDN5"'KFIC::5
M2!"9R00IYHVV*-"V"9N.NM[K^K0^ ""[7N_MHZU.47<9;\K(B_6UM7.2H;+#
M(&K-(60KI<N"86Q3D/CLKO?VTOGNUWO[**!#*/WVF:2ZODJZS"\D8H''H$$:
M^D-A(,^X. 8D/!,Q,%\$G@10]RGK#U:'(. [P#I*'1W"Z\-T^8_7Y&;?[GYU
MR9F,PAAG&)C"+2@1 @11-* L%"48%]W]EBF-@+:=QF[O]X:$W$ JZA!\C]^0
M>QM4CL1*C+767$L-+A8'*J)%AEQP>QH#=WCI0K.[OA-![GC%=(BV^G@K;=[C
MG5]R%,BQ<-H%$$EXXD,KB,C7 R"ED(J5E$Y3)?.0MG%ST"?"V9$JZ1ADKZ9?
MIQEG^9:QQN)]X=Z %9&3?XN>/(7LH03#T5MA;#Q-@>EV&L?M97QBT!VIH@[
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MG[H^;SQG*EZ@=0*,K"?\V20(09:Z'BL1?.VG-:CYQ+#EY?*UT]9:=!"_'*:
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MDEO@6"!X+\%ZS;QDT7';9@;=;3J.[O'R@_#>+=9X7_F+L#5CKQ!,]!2L83)
MNU8+22BAM%%:-1J"-9C$:=-'1^#CAXXL391R&E[EB JDAQ_6P,>TK"ZZ R5O
M,J(/'F(*<ELG0MOV7&]V>::<=,*WN5\WLJNYNNNVD>;K[YN!D-O,6-(E!%L;
MV#K)B<5-;V1:?PTKT=I<8FXT>.X1HKIR)_M@X.$&3\<)OH-SC4\7<37+L[#\
M_BE<,;2=DZ6"8%(*",9Z4($K"-PKJ&T!92P\^]S&2!XDJ9=>3D<J_2Z81M%
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M.(ZF_&&@.D 3'<#J[SC'93A_-<^O\K?9?%97CCI=:A>T7<X44*Z(P#W05C:
M8M'3=M8+DI[Q)=B@C&^3$A]$7I<P.P0.=UL'CJZ;#@#WD;1#!'PEKG[:;##^
MJ%*[S9+GLIC,$J122^:**N!#+I"#53)+Y[-LT\QM ''3=C]I![:Q]=(!U,:)
M0JYS*,)K)J-+M%1(LC0G#873SH(P)E!8C3*P-LVL1F:DE]%FO42)4^*D S,9
MF,@VPBDTJ8 U=79@;3;ABF; 484@L##CVG0S'/,PHA6H)X7080<3^^CS5/.P
MVP/Y5XFBIMGZ>^/LZ_TO>Y:<ZP ^.\FT)EV"*DC..2,HQ24XY34DXWQD6M!_
M;>Y:3IQI/;*NZT;ODH^+\_-?%LOZPS.;*,B7U7IMO;JKI*=XS'.*QYB-PO$4
M3.NFQV/R<]JYUCV0/7;9WPCPZ" .&5$*VZKCL\AYEC6MPYCRH&0R$$NHO:ZE
MU$1 EHT&5XW.RHEVGQT1G^U,Y@"P'&PM?VS;,:S#LH]^"/<U7LQ,%<ND AUX
M 55'Y<2L-,C"LA4\H'9]KBJ'=N7L[]9>OW9S+&#Z*'':OTN*EU&*Q 4P)P4H
M$T7M7*T@Y^ATW4GE1N-Q&C7 Z>^N7D/,MU7W$4UQOM3(LHN%X+[>)R$%'TM)
M('B*H(++X+U+P*+T27'DPO9YY^C0QCC]7=WK=R$X%C OPFI^C"(3=ZG.+H!2
MC^14U@J<PP@UF<>LY;*XSNI=C]IR]'<1KU^+.0XL1VXY?I[W83&[);:>V>R$
M4*PK3 D#.GD2@O .O.*;/J(VJ9A8:'2N,#HKTVXV3CA_=1PH7E;JZLZEW<N0
M],-REK!ZLK+S9"%C,$)+,)@TJ$@0#Z+>W]5%>Q4*>M]9"]J#>9UV0W/"=M48
M5O\]AG=F99#:N>J/@J*5VD3PEL*(E$6)+F;N6<.I3>T9?#'YY28XG\8L]P+=
MZ62D'YS8.*2'Q6T!*<^,SL&#T9S5J2<6',MUO#LBE[QPH2::+C@>DR\F@]V%
M94X$OE-8*9\2S27WPZ3#I%-6907%!%VKDDDP.C*03FMN/<L>)QK",RJ?+R;7
M?A+6V0Z"+\% [\G(/BH?DD,T02$P%@6HXC0$6QR8HH4S,FE>VG27>&Y.7TSN
M_R2,M"4,3\%,1PK^=1(Y2Y,AF=J:K7@&44H),202$0:N8V>SN!KL.$_A>*$+
MHYP ="_O0.+Q:,*:%'AVH&6-)@QY**=)?3EDJXW2)HG2I3T.9'#:1?*$DZPM
M '2"]RT^(NEBEM:[5HB_SV?K]O<N!KRT]?V+??GNXQZ&D0%Y'3G/$T5>RJ,"
MG[0!*6+VCCNIL$UI3R\=;PX/<[?W#;- XU BI$VU,$M8!1B Q<A9,,YIV;K+
MS9$LG/1MBWWP^W!GF^<$00=;ERWE].%-"PR!Q69G$C"C%*V9A+;H L6C%)DR
M&8P1=P=YC76?\R89O72L>58HW+VP>;!>.@#5X8*[9GN>/YR'^;OP#7>-#!S7
M006AP'*;R+Q=-6^;2:[&%):*#ZY-OY$6W$P+\2/ -5IF:"1-=X#V>Z*]U<=/
MO^_Z8\2H'#=6 "U.!I15&H+7%BC65Y@*4TRTR=D\2E;G9_O-4?-CHY.15-@!
M'@_>O+Z]:C6@.7I)<1-$1+$=7AUBO;TC!7V=M4?;V76OM[TU,IDR>'AF!)PR
MYG\8/O=^_167G[^&W7"ZU54_^ILEXUJI7"2/0&H(H%)VI)Q:I$W+94H9N<3.
M"BT/XK/S56)D%(]E1.TA]=]A<+NR[^"0H<X)LI.,UG6MP:'WD*Q6-D<;6.SL
M]LR^+)ZHF3T#SI_?) \ W>F461XLGMLE<&=!VEB[H=9S"@<J<@71F Q&ZU*<
MD;:['AI[<GBB!98OR2*/@-R+7A[_L='?E5RD5=(XQB#J3!&.CP6"8P$\69#E
M489H)LJ*C<3AB593OB13/ )RIWVC^TG)[.K:;@@'96;<8X&HZC#GA!9\#@R0
M=AO16:LPGYH]_L#DB=9.OB23/ YXQUKEYQ-8)^]&]*@4"49JL%P54#(;B#%P
MJ"VPB[ 6C6S39;*O;61_U9,OR2R/ =VIUTX.%\Z3,ZAO*CHKS20R4K0I",H)
M2SOQK,&3NIUE:&)OK2#:".)$MZ0GDXMM!LH7O1L=+KZSS%-PVG (1=;!8U9#
M%.00&6:A-8I,/O'%&O*+3_&V,Y\.7<%>6/ZO2P\_+3XN,/-@- 2N#8FO*'">
MX!!3-(SQ%(,YM35]3Q&<Z&K^7^4/6J+Z10<%M_.%3PO.)X4YL (\DB-5GAL(
M(D1(UH1:Z4*N]M0B@SU%\.*3W"_ ';1$]8MV!S<N?S\MM6A5]-86""P$<J*T
M572&I"8RSU8I97/N[$KEJ/R_^-3Z"W $S?#\HKW 'KNK&#C%2B2D+"6IG4D+
M,3H+V05,QBED2IZ8#Q@Y4W#*6?P7X $:87G4$X 1;WEO!\Q^#G_A0?>U;_[Z
MT3>O'Z1EI#O45\^_OHQZ=<'4$1)M3.3+C51UU*V J+T''8,.ULF@L<U5GD>(
M&F>$_*U'?R91OJ;/_.LL>L8QH@*M5 )E4C4\4^HDE\1H+:/5K$V'T\>HZF&R
M]_'XN'^ _ AZZ+%-Q VC/:+OPSU/&=.=M.S,\!AJ2A2)9T%QH:NWU4H*$$4,
M4$@SM-Y)6[#-7:OG\"H__Q6^S>8;I6RO-1%_RA1KR#*" 945H9CH \.-B=H4
M G2;_=V#)/7K3_9!QH/^Y"@-=+ C>1W.P[Q.3T:\&FV_N;9LK9799 \IIMHC
M+AGP,5)\Z*70SJD2=9M>!0]1U F0CE/XHH'T.T71[MZPYS)*&0J86'L-TD(+
MGIL$R061)$\.31N/]#!-TR)I')T/ -(!"N@ 2A^6^$>8Y=W(]-6K>=YL#]]<
M+*MP7ZU6N%[M+HYS;Q3%:!Q2J>V@$0MXQ Q:N\BCTMXU*GD83F-_4#L$%8MG
M45$'X-OP\6XQ3UM6WLY"G)W/UC.\Y"=;$8H@!DP*'I1C'D+M*!>33D4Y[FUI
MDSM[BK)I3[P; 6U4=70 K_N"B+=7%7S%.RE3E,"9(EL1H=[Y0 I*/2O."([&
M-\Y_W$?6M,!J$W:-IX<)055W\&>?%FD6SC\A6<AL_;UR1%O]Q7=<_K0A)IR_
M>?7QYT^O:+<CC;4B>@?!%>(J)D=VZ&H[EQPDSR@L>S)%L-\K^PO8#]3QHKG
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M??>8W0_J'W5#^7__S_\'4$L! A0#%     @ ECO]4@FW"3)5"0  53\  !T
M             ( !     &5V96QO<3(R,#(Q,3 M<65X:&EB:70S,3$N:'1M
M4$L! A0#%     @ ECO]4DR+FS5("0  ST$  !T              ( !D D
M &5V96QO<3(R,#(Q,3 M<65X:&EB:70S,3(N:'1M4$L! A0#%     @ ECO]
M4MPJYW S!0  *R   !T              ( !$Q,  &5V96QO<3(R,#(Q,3 M
M<65X:&EB:70S,C$N:'1M4$L! A0#%     @ ECO]4G1=9G9F!0  RR   !T
M             ( !@1@  &5V96QO<3(R,#(Q,3 M<65X:&EB:70S,C(N:'1M
M4$L! A0#%     @ ECO]4N_*\FGJ#   9U@  !X              ( !(AX
M &5V96QO<3(R,#(Q97@Q,#-N;VXM96UP;&]Y+FAT;5!+ 0(4 Q0    ( )8[
M_5)2<(=<V+P" /,D%P 1              "  4@K  !E=FQO+3(P,C$P-C,P
M+FAT;5!+ 0(4 Q0    ( )8[_5)E3< S51   "FJ   1              "
M 4_H @!E=FQO+3(P,C$P-C,P+GAS9%!+ 0(4 Q0    ( )8[_5);BRA-E!4
M *S,   5              "  =/X @!E=FQO+3(P,C$P-C,P7V-A;"YX;6Q0
M2P$"% ,4    " "6._U2[@7:/\9+  "J4 , %0              @ &:#@,
M979L;RTR,#(Q,#8S,%]D968N>&UL4$L! A0#%     @ ECO]4N8X2L.;T
MZ-X( !4              ( !DUH# &5V;&\M,C R,3 V,S!?;&%B+GAM;%!+
M 0(4 Q0    ( )8[_5);"C"R6'H  #*B!0 5              "  6$K! !E
J=FQO+3(P,C$P-C,P7W!R92YX;6Q02P4&      L "P " P  [*4$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
